Page last updated: 2024-11-04

hydroxychloroquine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Hydroxychloroquine is an antimalarial drug that has been investigated for its potential therapeutic effects against COVID-19. It is synthesized by reacting 4-aminoquinoline with 2-chloro-4-methoxyquinoline. The drug's effects are believed to be related to its ability to inhibit the activity of certain enzymes involved in viral replication. It has been studied extensively for its antiviral properties, and some studies have suggested that it may have some efficacy against COVID-19, but these findings are still under investigation. The use of hydroxychloroquine for COVID-19 is controversial, as there is insufficient evidence to support its effectiveness and it can have serious side effects. Further research is needed to determine its true efficacy and safety profile for this indication.'

Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID3652
CHEMBL ID1535
CHEBI ID5801
SCHEMBL ID8170
MeSH IDM0010751

Synonyms (110)

Synonym
KBIO1_000942
DIVK1C_000942
2-[{4-[(7-chloroquinolin-4-yl)amino]pentyl}(ethyl)amino]ethanol
hydroxychloroquinum [inn-latin]
hydroxychlorochin
ethanol, 2-((4-((7-chloro-4-quinolyl)amino)pentyl)ethylamino)-
oxichlorochinum
einecs 204-249-8
ethanol, 2-((4-((7-chloro-4-quinolinyl)amino)pentyl)ethylamino)-
idrossiclorochina [dcit]
hydroxychloroquine [inn:ban]
brn 0253894
7-chloro-4-(5-(n-ethyl-n-2-hydroxyethylamino)-2-pentyl)aminoquinoline
oxychlorochin
hidroxicloroquina [inn-spanish]
oxychloroquine
SPECTRUM5_001697
IDI1_000942
win 1258
2-[4-[(7-chloro-4-quinolyl)amino]pentyl-ethyl-amino]ethanol
ethanol, 2-[[4-[(7-chloro-4-quinolinyl)amino]pentyl]ethylamino]-
hcq ,
C07043
hydroxychloroquine
118-42-3
DB01611
7-chloro-4-(4-(ethyl(2-hydroxyethyl)amino)-1-methylbutylamino)quinoline
2-((4-((7-chloro-4-quinolyl)amino)pentyl)ethylamino)ethanol
2-(n-(4-(7-chlor-4-chinolylamino)-4-methylbutyl)ethylamino)ethanol
7-chloro-4-(4-(n-ethyl-n-beta-hydroxyethylamino)-1-methylbutylamino)quinoline
7-chloro-4-[5-(n-ethyl-n-2-hydroxyethylamino)-2-pentyl]aminoquinoline
oxichloroquine
7-chloro-4-[4-(n-ethyl-n-beta-hydroxyethylamino)-1-methylbutylamino]quinoline
oxichlorochine
(+/-)-hydroxychloroquine
NINDS_000942
SPBIO_001116
SPECTRUM2_001238
chebi:5801 ,
CHEMBL1535
polirreumin
D08050
polirreumin (tn)
hydroxychloroquine (inn)
HMS502P04
2-[4-[(7-chloroquinolin-4-yl)amino]pentyl-ethylamino]ethanol
4qwg6n8qkh ,
hidroxicloroquina
unii-4qwg6n8qkh
idrossiclorochina
hydroxychloroquinum
5-22-10-00280 (beilstein handbook reference)
z0188 ,
2-({4-[(7-chloro(4-quinolyl))amino]pentyl}ethylamino)ethan-1-ol
AKOS015997886
(+-)-hydroxychloroquine
FT-0627143
NCGC00159483-03
2-({4-[(7-chloroquinolin-4-yl)amino]pentyl}(ethyl)amino)ethan-1-ol
gtpl7198
dolquine
BRD-A99117172-065-01-6
hydroxychloroquine [mi]
hydroxychloroquine [vandf]
hydroxychloroquine [who-dd]
(+/-)-2-((4-((7-chloro-4-quinolyl)amino)pentyl)ethylamino)ethanol
hydroxychloroquine [inn]
ethanol, 2-((4-((7-chloro-4-quinolinyl)amino)pentyl)ethyl)amino-, (+/-)-
CCG-208059
SCHEMBL8170
7-chloro-4-[4-[ethyl(2-hydroxyethyl)amino]1-methylbutylamino]quinoline
7-chloro-4-[4-[ethyl(2-hydroxyethyl)amino]1-methylbutylamino]-quinoline
STL429829
ethanol, 2-[[4-[(7-chloro-4-quinolyl)amino]pentyl]ethylamino]-
(.+/-.)-hydroxychloroquine
win 1258-2
2-[(4-[(7-chloro-4-quinolinyl)amino]pentyl)(ethyl)amino]ethanol #
7-chloro-4-(4-(n-ethyl-n-.beta.-hydroxyethylamino)-1-methylbutylamino)quinoline
ercoquin (salt/mix)
2-((4-((7-chloroquinolin-4-yl)amino)pentyl)(ethyl)amino)ethanol
F2173-0553
AB00053257_02
DTXSID8023135 ,
AT13123
2-((4-(7-chloroquinolin-4-ylamino)pentyl)(ethyl)amino)ethanol
SBI-0052759.P002
NCGC00159483-06
2-{n-[4-(7-chloro-4-quinolylamino)pentyl]-n-ethylamino}ethanol
FT-0669455
2-[[4-[(7-chloroquinolin-4-yl)amino]pentyl](ethyl)amino]ethanol
Q421094
r-hydroxychloroquine
FT-0669456
DT-0016
BRD-A99117172-065-02-4
EN300-122642
BCP30197
CS-0075751
HY-W031727
oxichloroquine;oxychlorochin;2-[[4-[(7-chloroquinolin-4-yl)amino]pentyl](ethyl)amino]ethanol
SB73036
mfcd00242707
2-[[4-[(7-chloro-4-quinolyl)amino]pentyl](ethyl)amino]ethanol
SY270913
bdbm50467780
p01ba02
hydroxychloroquinum (inn-latin)
dtxcid403135
hidroxicloroquina (inn-spanish)
idroxiclorochina

Research Excerpts

Overview

Hydroxychloroquine (HCQ) is a cornerstone therapy for systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) Hydroxychloroquin is an important medication for patients with systemic lupsus, rheumatic arthritis and other autoimmune diseases.

ExcerptReferenceRelevance
"Hydroxychloroquine (HCQ) is an antimalarial drug used as chemoprophylaxis against malaria caused by Plasmodium vivax in the Republic of Korea Army (ROKA). "( Pharmacokinetics of hydroxychloroquine and its clinical implications in chemoprophylaxis against malaria caused by Plasmodium vivax.
Bae, KS; Cho, JY; Choi, JS; Im, JS; Jang, IJ; Kim, TS; Klein, TA; Lim, HS; Park, JW; Yeom, JS, 2009
)
2.12
"Hydroxychloroquine (HCQ) is an immunomodulator used to treat rheumatoid arthritis and systemic lupus erythematosus."( Effects of Hydroxychloroquine on endOthelial function in eLDerly with sleep apnea (HOLD): study protocol for a randomized clinical trial.
Boll, L; Cadaval Gonçalves, S; Cortes, A; Eibel, B; Irigoyen, MC; Martinez, D; Rossi, B; Tedesco Silva, LM; Waclawovsky, G, 2021
)
1.73
"Hydroxychloroquine (HCQ) is a derivative of the antimalaria drug chloroquine primarily prescribed for autoimmune diseases. "( In vitro ion channel profile and ex vivo cardiac electrophysiology properties of the R(-) and S(+) enantiomers of hydroxychloroquine.
Angouillant-Boniface, O; Ballet, V; Bohme, GA; Boukaiba, R; Brohan, E; Carriot, T; Chambard, JM; Chantoiseau, C; Fouconnier, S; Houtmann, S; Partiseti, M; Prévost, C; Schio, L; Schombert, B, 2022
)
2.37
"Hydroxychloroquine (HCQ) is a drug with immunomodulatory properties that has demonstrated antiviral efficacy in in vitro experiments, with conflicting results in in vivo studies."( "H" is not for hydroxychloroquine-"H" is for heparin: lack of efficacy of hydroxychloroquine and the role of heparin in COVID-19-preliminary data of a prospective and interventional study from Brazil.
Barreiro, B; Benetti, MM; da Costa, APA; de Oliveira Costa, R; de Pádua Covas Lage, LA; Dos Santos, CW; Dos Santos, MAP; El-Khatib, AAB; Hayden, RL; Nascimento, JS; Pereira, J; Reichert, CO; Soares, AM; Tomé, CEM, 2022
)
1.8
"Hydroxychloroquine (HCQ) is a cornerstone therapy for systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). "( Relationship of cytochrome P450 gene polymorphisms with blood concentrations of hydroxychloroquine and its metabolites and adverse drug reactions.
Cao, X; Gao, B; Pan, M; Shuai, Z; Tan, T; Wang, J; Xia, Q; Yang, C, 2022
)
2.39
"Hydroxychloroquine (HCQ) is an important medication for patients with systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) and other rheumatic diseases. "( RetINal Toxicity And HydroxyChloroquine Therapy (INTACT): protocol for a prospective population-based cohort study.
Adante, B; Aviña-Zubieta, JA; Bhui, RD; Bhui, SB; Butler, M; Chui, L; Daftarian, N; Dawes, M; Erasmus, M; Esdaile, J; Etminan, M; Godinho, D; Hay, E; Hoens, A; Hollands, H; Hoonjan, M; Joe, A; Levasseur, SD; Lima, A; Lukaris, A; Maberley, DAL; Mammo, Z; Marozoff, S; Navajas, E; Ojo, D; Pakzad-Vaezi, K; Sanmugasunderam, S; Shojania, K, 2022
)
2.48
"Hydroxychloroquine (HCQ) is an anti-malarial drug but also widely used to treat autoimmune diseases like arthritis and lupus. "( Hydroxychloroquine Causes Early Inner Retinal Toxicity and Affects Autophagosome-Lysosomal Pathway and Sphingolipid Metabolism in the Retina.
Basu, SK; Chalfant, CE; Chiu, CY; Cole, J; Khanam, S; Mandal, N; Mondal, K; Pandya, HK; Porter, H; Shah, V; Stephenson, DJ, 2022
)
3.61
"Hydroxychloroquine (HCQ) is an anti-inflammatory drug in widespread use for the treatment of systemic auto-immune diseases. "( MERCI: a machine learning approach to identifying hydroxychloroquine retinopathy using mfERG.
Gupta, A; Habib, F; Huang, H; Wright, T, 2022
)
2.42
"Hydroxychloroquine adherence is an imperfect proxy for adherence to other lupus medications among children with SLE, and therefore assessing immunosuppressant adherence concurrently adds value to hydroxychloroquine adherence assessments. "( Hydroxychloroquine and immunosuppressant adherence patterns and their association with subsequent hospitalization rates among children with systemic lupus erythematosus.
Chang, JC; Costenbader, KH, 2022
)
3.61
"Hydroxychloroquine (HCQ) is an important drug that is in the trial stage for different types of cancer diseases; however, insight about the mechanism of its action is almost unknown. "( Spectroscopic and Molecular Dynamics Aspect of Antimalarial Drug Hydroxychloroquine Binding with Human Telomeric G-Quadruplex.
Bisoi, A; Sarkar, S; Singh, PC, 2022
)
2.4
"Hydroxychloroquine (HCQ) is an important antimalarial drug which functions plausibly by targeting the DNA of parasites. "( Contrasting Effect of Salts on the Binding of Antimalarial Drug Hydroxychloroquine with Different Sequences of Duplex DNA.
Bisoi, A; Chandra Singh, P; Sarkar, S, 2022
)
2.4
"Hydroxychloroquine (HQ) is an antimalarial drug that is widely used in many autoimmune rheumatic diseases, mainly in systemic lupus erythematosus (SLE)."( A case of palmoplantar pustular psoriasis induced by hydroxychloroquine in a patient with systemic lupus erythematosus.
Akkuzu, G; Bes, C; Karaalioğlu, B; Mutlu, MY; Özgür, DS; Yıldırım, F, 2022
)
1.69
"Hydroxychloroquine (HCQ) is a molecule derived from quinacrine; it displays a wide range of pharmacological properties, including anti-inflammatory, immunomodulatory, and antineoplastic. "( Oral Hydroxychloroquine Mitigates Lipopolysaccharide-induced Lung Injury by Inhibiting Pyroptosis in Mice.
Geng, Q; He, R; Li, N; Liu, B; Wang, B; Xiong, J; Xiong, R, 2023
)
2.87
"Hydroxychloroquine (HCQ) is an autophagy inhibitor that has been used for the treatment of many diseases, such as malaria, rheumatoid arthritis, systemic lupus erythematosus, and cancer. "( Quantitative Proteomics Explore the Potential Targets and Action Mechanisms of Hydroxychloroquine.
Chen, K; Hou, W; Huang, H; Jiang, Y; Liu, G; Liu, H; Liu, K; Ren, X; Zhao, J; Zhao, Z, 2022
)
2.39
"Hydroxychloroquine (HCQ) is a widely used antimalarial and anti-inflammatory drug and its hyperglycemia-controlling effect in diabetic patients is also under investigation."( Treating diabetes with combination of phosphodiesterase 5 inhibitors and hydroxychloroquine-a possible prevention strategy for COVID-19?
Das, A; Koka, S; Kukreja, RC; Samidurai, A; Wang, R; Xi, L, 2023
)
1.86
"Hydroxychloroquine (HCQ) is an antimalarial drug with known immunomodulatory, anti-inflammatory, and autophagy inhibitory effects; it is recognized in the treatment of autoimmune diseases such as systemic lupus erythematosus."( Hydroxychloroquine suppresses anti-GBM nephritis via inhibition of JNK/p38 MAPK signaling.
Inoue, H; Kinoshita, A; Koji, T; Mukae, H; Nishino, T; Obata, Y; Torigoe, K; Torigoe, M, 2023
)
3.07
"Hydroxychloroquine (HCQ) is an antimalarial that is widely used in the management of rheumatoid arthritis and other autoimmune diseases. "( Hydroxychloroquine induces endothelium-dependent and endothelium-independent relaxation of rat aorta.
Andaç, AC; Arslan, SO; Çam, SA; Doğan, MF; Omar, IA; Parlar, A; Uysal, F; Yıldız, O, 2022
)
3.61
"Hydroxychloroquine is a widely used medication for various clinical conditions mainly rheumatological and dermatological autoimmune diseases e.g. "( Early onset monocular hydroxychloroquine maculopathy in a systemic lupus erythematosus patient with history of central retinal artery occlusion: a case report.
Ameen Ismail, A; Hatata, RM; Sadek, SH, 2022
)
2.48
"Hydroxychloroquine is an immune modulating drug that is considered safe in pregnancy."( Hydroxychloroquine reduces soluble Flt-1 secretion from human cytotrophoblast, but does not mitigate markers of endothelial dysfunction in vitro.
Beard, S; Binder, N; Brownfoot, FC; Hannan, N; Harper, A; Kadife, E, 2022
)
2.89
"Hydroxychloroquine (HCQ) is an antimalarial agent used to treat mucocutaneous, musculoskeletal, constitutional manifestations of systemic lupus erythematosus (SLE). "( Hydroxychloroquine in children with proliferative lupus nephritis: a randomized clinical trial.
Abdelnabi, HH; Dawoud, HE; El-Shahaby, WA; Elrifaey, SM; Gheet, FS, 2023
)
3.8
"Hydroxychloroquine (HCQ) is an effective immunomodulatory drug which is widely used in treatment of autoimmune disorders."( A Preliminary Study on the Therapeutic Effects of Hydroxychloroquine on Generalized Vitiligo.
Darchini-Maragheh, E; Fathi-Najafi, S; Layegh, P; Meshkat, M; Rahsepar, S; Sazgarnia, S; Sepehr, V, 2022
)
1.7
"Hydroxychloroquine (HCQ) is a lysosomotropic agent that is commonly used for treating Sjögren's disease (SjD). "( Salivary gland LAMP3 mRNA expression is a possible predictive marker in the response to hydroxychloroquine in Sjögren's disease.
Afione, SA; Atsumi, T; Chiorini, JA; Ji, Y; Motta, ACF; Nakamura, H; Noguchi, M; Oliveira, FR; Rocha, EM; Tanaka, T; Warner, BM; Zheng, C, 2023
)
2.58
"Hydroxychloroquine is a disease-modifying antirheumatic drug used for various rheumatological conditions. "( Endomyocardial biopsy-proven hydroxychloroquine-induced cardiomyopathy in a patient with rheumatoid arthritis.
Dalia, T; Malhotra, A; Pathak, MA; Vidic, A, 2023
)
2.64
"Hydroxychloroquine is an FDA-approved drug for the treatment of COVID-19."( Validated spectrofluorimetric assay of two co-administered drug mixtures containing hydroxychloroquine with either moxifloxacin or ofloxacin as a drug regimen for hospital-acquired pneumonia in patients with COVID-19.
Eid, M; El-Sayed, A; Elmansi, HM; Shalan, S, 2023
)
1.86
"Hydroxychloroquine (HCQ) is an immunomodulatory agent that has been shown in laboratory studies to decrease thrombosis risk, support placentation, and minimize the destructive effects of antiphospholipid antibodies."( Does adding hydroxychloroquine to empiric treatment improve the live birth rate in refractory obstetrical antiphospholipid syndrome? A systematic review.
Bacal, V; Bedaiwy, MA; Hooper, A, 2023
)
2.01
"Hydroxychloroquine (HCQ) is a common antimalarial drug that has been used effectively in the treatment of various rheumatic and auto-immunity diseases. "( Protective Effect of Quercetin and p-Coumaric Acid (p-CA) Against Cardiotoxicity: An
Bhadana, R; Rani, V, 2023
)
2.35
"Hydroxychloroquine is an effective treatment for rheumatic diseases; however, retinal damage is a possible side effect. "( Cone Density Distribution and Related Factors in Patients Receiving Hydroxychloroquine Treatment.
Huang, H; Liu, H; Liu, X; Mo, S; Tang, J; Zhu, Z, 2023
)
2.59
"Hydroxychloroquine (HCQ) is a unique class of medications that has been widely utilized for the treatment of cancer. "( Hydroxychloroquine: Key therapeutic advances and emerging nanotechnological landscape for cancer mitigation.
Chang, SK; Chellappan, DK; Dua, K; Gan, SH; Goh, BH; Khaw, KY; Kong, CK; Lai-Foenander, AS; Lee, WL; Low, LE; Ming, LC; Ong, YS; Siew, WS; Singh, SK; Siva, SP; Tey, BT; Wu, Y; Yap, WH, 2023
)
3.8
"Hydroxychloroquine (HCQ) is a classical antimalarial drug applied in the treatment of autoimmune diseases."( Renoprotective effects of artemisinin and hydroxychloroquine combination therapy on IgA nephropathy via suppressing NF-κB signaling and NLRP3 inflammasome activation by exosomes in rats.
Bai, L; Chen, J; Li, H; Li, J; Liang, C; Liu, B; Liu, X; Lu, R; Pang, Y; Song, J; Wu, J; Zhang, P; Zhou, J; Zhou, Y, 2019
)
1.5
"Hydroxychloroquine (HCQ) is a well-established and effective immunomodulatory therapy for systemic lupus erythematosus and other autoimmune diseases. "( Hypertrophic cardiomyopathy in a lupus patient: a case of hydroxychloroquine cardiotoxicity.
Baas, AS; Chang, A; Cruz, D; Fan, J; Fishbein, GA; Larreta, BR; Stolin, G; Wallace, WD; Wang, J, 2019
)
2.2
"Hydroxychloroquine is an age-old drug whose use as an immunomodulatory agent with a low side-effect profile continues to expand. "( Hydroxychloroquine in dermatology: New perspectives on an old drug.
Chew, CY; Mar, A; Nikpour, M; Saracino, AM, 2020
)
3.44
"Hydroxychloroquine sulfate (HCQ) is a quinoline used for the prevention and treatment of uncomplicated malaria, lupus erythematosus, and rheumatoid arthritis. "( Evaluation of an Immediate-Release Formulation of Hydroxychloroquine Sulfate With an Interwoven Pediatric Taste-Masking System.
Brackett, J; Joshi, H; Pauli, E; Towa, L; Vasavada, A, 2020
)
2.25
"Hydroxychloroquine is an immunomodulatory drug that has been used for the treatment of malaria and autoimmune diseases."( Potential Effect of Hydroxychloroquine in Diabetes Mellitus: A Systematic Review on Preclinical and Clinical Trial Studies.
Adamu, BA; Desalegn, TZ; Tsige, AG; Wondafrash, DZ; Yimer, EM; Zewdie, KA, 2020
)
1.6
"Hydroxychloroquine (HCQ) is a commonly used weight-based medication with a risk of retinal toxicity when prescribed at doses above 5 mg/kg/day. "( Improving Hydroxychloroquine Dosing and Toxicity Screening at a Tertiary Care Ambulatory Center: A Quality Improvement Initiative.
Farrer, C; Gakhal, N; Gottheil, S; Koppikar, S, 2021
)
2.47
"Hydroxychloroquine (HCQ) appears to be a promising treatment for COVID-19. "( Towards Optimization of Hydroxychloroquine Dosing in Intensive Care Unit COVID-19 Patients.
Botelho-Nevers, É; Delavenne, X; Diconne, É; Lachand, R; Launay, M; Louf-Durier, A; Murgier, M; Page, D; Perinel, S; Thierry, G; Vermesch, R, 2020
)
2.31
"Hydroxychloroquine (HCQ) is a promising candidate for Coronavirus disease of 2019 (COVID-19) treatment. "( Optimizing Hydroxychloroquine Dosing for Patients With COVID-19: An Integrative Modeling Approach for Effective Drug Repurposing.
Aweeka, F; Ernest, JP; Garcia-Cremades, M; Hughes, E; Luetkemeyer, AF; Savic, RM; Solans, BP; Wallender, E, 2020
)
2.39
"Hydroxychloroquine is an immunomodulatory drug that has been used to treat malaria and autoimmune diseases such as systemic lupus erythematosus and inflammatory arthritis. "( Hazard of acquired long QT syndrome during coronavirus pandemic. Focus on hydroxychloroquine
Tomcsányi, J; Tomcsányi, K, 2020
)
2.23
"Hydroxychloroquine is an antimalarial drug being tested as a potential treatment for the novel coronavirus disease 2019 (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus 2. "( Finding the Dose for Hydroxychloroquine Prophylaxis for COVID-19: The Desperate Search for Effectiveness.
Al-Kofahi, M; Boulware, DR; Jaber, MM; Jacobson, P; Kandaswamy, R; Matas, A; Nicol, MR; Rajasingham, R; Young, JH, 2020
)
2.32
"Hydroxychloroquine (HCQ) is an old medication for malaria. "( Smooth or Risky Revisit of an Old Malaria Drug for COVID-19?
Pahan, K; Pahan, P, 2020
)
2
"Hydroxychloroquine (HCQ) is an anchor drug in the treatment of systemic lupus erythematosus (SLE). "( Adherence to hydroxychloroquine in patients with systemic lupus: Contrasting results and weak correlation between assessment tools.
Allorge, D; Azar, R; Balquet, MH; Bataille, P; Boldron, A; Buchdahl, AL; Clerson, P; Hachulla, E; Hatron, PY; Hennart, B; Lambert, M; Launay, D; Le Gouellec, N; Maillard, H; Morell-Dubois, S; Sobanski, V, 2020
)
2.37
"Hydroxychloroquine (HCQ) is an antimalarial drug with immunomodulatory effects used to treat systemic lupus erythematosus (SLE) and scleroderma. "( Hydroxychloroquine and maintenance immunosuppression use in kidney transplant recipients: Analysis of linked US registry and claims data.
Alhamad, T; Axelrod, D; Brennan, DC; Caliskan, Y; Chang, SH; Hess, GP; Kasiske, BL; Lam, NN; Lentine, KL; McAdams-DeMarco, M; Schnitzler, MA; Segev, DL; Xiao, H, 2020
)
3.44
"Hydroxychloroquine (HCQ) is a well-known immunomodulator that was recently used in immunoglobulin A (IgA) nephropathy (IgAN) due to its antiproteinuric effects. "( Effect of hydroxychloroquine in patients with IgA nephropathy with insufficient responses to immunosuppressive therapy: a retrospective case-control study.
Chen, YQ; Liu, LJ; Lv, JC; Shi, SF; Tang, C; Zhang, H, 2020
)
2.4
"Hydroxychloroquine is a medication that is used for the treatment of rheumatic and dermatologic conditions."( The necessity of patch testing in determining the causative drug of AGEP.
Ghobadi Aski, S; Mofarrah, R; Nazemi, N; Nooshiravanpoor, P; Oshriehye, M, 2021
)
1.34
"Hydroxychloroquine is an agent used as a treatment but also considered as a prophylaxis for SARS-CoV-2 infection. "( [SARS-CoV-2 infection in a patient treated by hydroxychloroquine and anti TNF α for Inflammatory Rheumatic Disease].
Bouchti, IE; Malek, SA, 2020
)
2.26
"Hydroxychloroquine (HCQ) is a key systemic lupus erythematosus (SLE) drug, making concerns of drug shortages grave. "( Predictors of Unsuccessful Hydroxychloroquine Tapering and Discontinuation: Can We Personalize Decision-Making in Systemic Lupus Erythematosus Treatment?
Abrahamowicz, M; Almeida-Brasil, CC; Bernatsky, S; Clarke, AE; Fortin, PR; Hanly, JG; Peschken, CA; Pineau, CA; Vinet, E, 2022
)
2.46
"Hydroxychloroquine (HCQ) is an antimalarial agent with pleiotropic effects and now represents a cornerstone in the management of patients with autoimmune conditions. "( The effect of hydroxychloroquine on platelet activation in model experiments.
Krämer, BK; Leipe, J; Schreiber, K; Sciascia, S; Stach, K; Wehrmann, F; Weiß, C, 2021
)
2.42
"Hydroxychloroquine is an antimalarial drug indicated in the treatment of acute attacks of malaria due to "( Formulation and stability study of hydroxychloroquine sulfate oral suspensions.
Cisternino, S; De Lonlay, P; El Mershati, S; Schlatter, J; Secretan, PH; Thouvenin, A; Tuchmann-Durand, C, 2021
)
2.34
"Hydroxychloroquine is an antimalarial drug that has been prescribed for the treatment of patients with COVID-19 infection. "( Estimation of the uncertainty of values assigned to calibration materials prepared in-house: An example for hydroxychloroquine calibrators in blood-hemolysate-based matrix.
Canalias, F; Rigo-Bonnin, R, 2021
)
2.28
"Hydroxychloroquine continues to be a routinely prescribed, well-tolerated, effective, and low-cost treatment for rheumatic disease."( Hydroxychloroquine and COVID-19: a Rheumatologist's Take on the Lessons Learned.
Balevic, SJ; Leverenz, D; Rogers, JL; Sadun, RE; Tarrant, TK; Udupa, A, 2021
)
2.79
"Hydroxychloroquine is an antimalarial that"( Use of hydroxychloroquine and chloroquine in patients with COVID-19: a meta-analysis of randomized clinical trials.
Aquino, BM; Bignardi, PR; Cerci Neto, A; Vengrus, CS, 2021
)
1.8
"Hydroxychloroquine is an established therapy for several rheumatological disorders, and very recently it has been proposed as a possible treatment for the new coronavirus disease 2019 even if recent randomised trials did not prove any benefit. "( The safety profile of hydroxychloroquine: major cutaneous and extracutaneous adverse events.
Alaibac, M; Bellinato, F; Bordin, C; Girolomoni, G; Gisondi, P; Naldi, L; Piaserico, S; Tozzi, F,
)
1.89
"Hydroxychloroquine (HCQ) is a mainstay of therapy in the treatment of SLE. "( Hydroxychloroquine is associated with lower platelet activity and improved vascular health in systemic lupus erythematosus.
Belmont, HM; Berger, JS; Buyon, JP; Clancy, R; Cornwell, MG; El Bannoudi, H; Engel, A; Golpanian, M; Izmirly, P; Katz, S; Luttrell-Williams, ES; Myndzar, K; Ruggles, K; Smilowitz, NR, 2021
)
3.51
"Hydroxychloroquine (HCQ) is an autophagy inhibitor."( SMAD4 loss is associated with response to neoadjuvant chemotherapy plus hydroxychloroquine in patients with pancreatic adenocarcinoma.
Bahary, N; Boone, BA; Fei, N; Hogg, ME; Lotze, MT; Ramanathan, R; Singhi, AD; Wen, S; Zeh, HJ; Zureikat, AH, 2021
)
1.58
"Hydroxychloroquine (HCQ) is an important drug for the treatment of rheumatoid arthritis and malaria. "( Groove Switching of Hydroxychloroquine Modulates the Efficacy of Binding and Induced Stability to DNA.
Roy, S; Sarkar, S; Singh, PC, 2021
)
2.39
"Hydroxychloroquine is a treatment for rheumatic disease and considered safe during pregnancy. "( Maternal exposure to hydroxychloroquine and birth defects.
Ailes, EC; Broussard, CS; Browne, ML; Carmichael, SL; Fisher, SC; Heinke, D; Howley, MM; Mitchell, AA; Pruitt, SM; Reefhuis, J; Van Zutphen, AR; Werler, MM, 2021
)
2.38
"Hydroxychloroquine (HCQ) is an antimalarial agent and had a notable impact on immune activation by the reduction of circulating activated immune cells that including decreased TLR-expressing cells, reduced IFN-secreting DCs, reduced production of cytokines including IFN-α,IL-6 and TNF-α."( Hydroxychloroquine alleviates persistent proteinuria in IgA nephropathy.
Gao, R; Li, X; Wen, Y; Wu, W, 2017
)
2.62
"Hydroxychloroquine is an oral antimalarial medication commonly used off-label for a variety of rheumatological conditions, including systemic lupus erythematosus, rheumatoid arthritis, Sjögren's syndrome and dermatomyositis. "( Accidental hydroxychloroquine overdose resulting in neurotoxic vestibulopathy.
Chansky, PB; Werth, VP, 2017
)
2.29
"Hydroxychloroquine (HCQ) is an immunosuppressive agent widely used in rheumatoid arthritis (RA). "( Novel function of hydroxychloroquine: Down regulation of T follicular helper cells in collagen-induced arthritis.
Han, J; Han, Y; He, J; He, Y; Jie, H; Li, X; Sun, E; Zhou, Q, 2018
)
2.26
"Hydroxychloroquine (HCQ) is a recommended drug in systemic lupus erythematosus (SLE). "( Hydroxycloroquine blood concentration in lupus nephritis: a determinant of disease outcome?
Alexander, S; Ashby, D; Cairns, TD; Chusney, G; Cunha, C; Lee, J; Lightstone, L, 2018
)
1.92
"Hydroxychloroquine (HCQ) is an effective treatment of lupus erythematosus. "( Early cutaneous eruptions after oral hydroxychloroquine in a lupus erythematosus patient: A case report and review of the published work.
Kambe, N; Ly, NTM; Matsuda, T; Nguyen, CTH; Okamoto, H; Son, Y; Ueda-Hayakawa, I, 2018
)
2.2
"Hydroxychloroquine (HCQ) is a lysosomotropic autophagy inhibitor being used in over 50 clinical trials either alone or in combination with chemotherapy. "( Hydroxychloroquine: A Physiologically-Based Pharmacokinetic Model in the Context of Cancer-Related Autophagy Modulation.
Collins, KP; Gustafson, DL; Jackson, KM, 2018
)
3.37
"Hydroxychloroquine (HCQ) is a well-known immunomodulator that is useful as in the treatment for lupus because of its inhibitory effect on toll-like receptors and cytokines, which are speculated to play a role in the pathogenesis of Immunoglobulin A (IgA) nephropathy (IgAN). "( Effects of Hydroxychloroquine on Proteinuria in Immunoglobulin A Nephropathy.
Chen, YQ; Liu, LJ; Lv, JC; Shi, SF; Wang, JW; Yang, YZ; Zhang, H, 2018
)
2.31
"Hydroxychloroquine (HCQ) is a commonly used medicine for the treatment of systemic lupus erythematosus (SLE), and Th17 cells are closely related to the pathogenesis of SLE. "( Hydroxychloroquine Inhibits the Differentiation of Th17 Cells in Systemic Lupus Erythematosus.
Li, M; Yang, J; Yang, X, 2018
)
3.37
"Hydroxychloroquine (HCQ) is an old antimalarial drug that has proven to be a safe and effective treatment for systemic lupus erythematosus (SLE) and other autoimmune diseases. "( Development of a novel ion-pairing HPLC-FL method for the separation and quantification of hydroxychloroquine and its metabolites in whole blood.
Charlier, B; Conti, V; Dal Piaz, F; Filippelli, A; Izzo, V; Pingeon, M; Valentini, G, 2018
)
2.14
"Hydroxychloroquine (HCQ) is a commonly used drug for the treatment of systemic lupus erythematosus (SLE). "( Hydroxychloroquine-induced hypoglycaemia in non-diabetic renal patient on peritoneal dialysis.
Ai-Hwiesh, AK; Al-Otaibi, K; El-Solia, A, 2018
)
3.37
"Hydroxychloroquine (HCQ) is a cornerstone in treatment of SLE patients and has been thought to exert a broad spectrum of beneficial effects on disease activity, prevention of damage accrual, and mortality."( Protective Effects of Hydroxychloroquine against Accelerated Atherosclerosis in Systemic Lupus Erythematosus.
Bortoluzzi, A; Cauli, A; Erre, GL; Floris, A; Mangoni, AA; Piga, M, 2018
)
1.52
"Hydroxychloroquine is an immunomodulatory drug that has been used for 60 years to treat malaria and autoimmune diseases such as systemic lupus erythematosus and inflammatory arthritis, and potential new uses and benefits continue to emerge. "( Hydroxychloroquine: An old drug with new relevance.
Collamer, AN; Shippey, EA; Wagler, VD, 2018
)
3.37
"Hydroxychloroquine (HCQ) is a widely prescribed medication to patients with systemic lupus erythematosus (SLE), with potential anti-inflammatory effects. "( Efficacy analysis of hydroxychloroquine therapy in systemic lupus erythematosus: a study on disease activity and immunological biomarkers.
Alirezaei, A; Dormanesh, B; Etemad Rezaie, A; Jahandoost, F; Khoshdel, AR; Mahmoudi, M; Monzavi, SM; Shariati-Sarabi, Z; Tavakol Afshari, J, 2018
)
2.24
"Hydroxychloroquine (HCQ) is an antimalarial drug that is widely used in the treatment of some autoimmune diseases. "( Attenuation of antimalarial agent hydroxychloroquine on TNF-α-induced endothelial inflammation.
Li, R; Liang, L; Lin, H; Shi, M; Wang, C; Wang, J; Xiao, Y; Xu, H; Xu, S; Ye, Y; Zou, Y, 2018
)
2.2
"Hydroxychloroquine sulfate is a commonly used medication for patients with dermatomyositis and has been associated with a uniquely elevated risk of adverse cutaneous reactions in this population. "( Association Between Autoantibody Phenotype and Cutaneous Adverse Reactions to Hydroxychloroquine in Dermatomyositis.
Casciola-Rosen, L; Fiorentino, DF; Wolstencroft, PW, 2018
)
2.15
"Hydroxychloroquine is an oral drug prescribed to pregnant women with rheumatic disease to reduce disease activity and prevent flares. "( Pharmacokinetics of Hydroxychloroquine in Pregnancies with Rheumatic Diseases.
Balevic, SJ; Clowse, MEB; Cohen-Wolkowiez, M; Eudy, AM; Green, TP; Schanberg, LE, 2019
)
2.28
"Hydroxychloroquine is an antimalarial agent, most commonly prescribed in the treatment of several rheumatic diseases. "( Longitudinal melanonychia and subungual hemorrhage in a patient with systemic lupus erythematosus treated with hydroxychloroquine.
Cai, L; Liu, X; Zhang, J; Zhang, S; Zhou, C, 2019
)
2.17
"Hydroxychloroquine is a treatment for lupus that is widely used based on longstanding experience and a very good safety profile."( Study of Anti-Malarials in Incomplete Lupus Erythematosus (SMILE): study protocol for a randomized controlled trial.
Arriens, C; Chinchilli, VM; Chong, BF; Ishimori, ML; James, JA; Kamen, DL; Karp, DR; Liao, D; Olsen, NJ; Wallace, DJ, 2018
)
1.2
"Hydroxychloroquine is a tolerable autophagy inhibitor in future RCC or other trials."( Autophagy Inhibition to Augment mTOR Inhibition: a Phase I/II Trial of Everolimus and Hydroxychloroquine in Patients with Previously Treated Renal Cell Carcinoma.
Amaravadi, RK; Appleman, LJ; Davis, LE; Gimotty, PA; Haas, NB; Kadri, S; Kalavacharla, A; Kim, T; Onorati, A; Redlinger, M; Segal, JP; Stein, M; Wilks, M; Xu, X; Zhen, CJ, 2019
)
1.46
"Hydroxychloroquine is a valuable treatment for morphea because of its high response rate and low rate of adverse effects; however, prospective studies are needed to determine its true efficacy."( Treatment of morphea with hydroxychloroquine: A retrospective review of 84 patients at Mayo Clinic, 1996-2013.
Blixt, EK; Drage, LA; El-Azhary, RA; Kumar, AB; Wetter, DA, 2019
)
2.26
"Hydroxychloroquine (HCQ) is a cornerstone to managing systemic lupus erythematosus (SLE), yet adherence to medication is poor. "( Understanding Nonadherence with Hydroxychloroquine Therapy in Systemic Lupus Erythematosus.
Fevrier, HB; Goldfien, R; Hemmerling, A; Herrinton, LJ; Liu, LH, 2019
)
2.24
"Hydroxychloroquine (HCQ) is a classical antimalarial drug used to treat autoimmune diseases."( Immunosuppressive effect of artemisinin and hydroxychloroquine combination therapy on IgA nephropathy via regulating the differentiation of CD4+ T cell subsets in rats.
Bai, L; Chen, D; Chen, J; Li, H; Li, J; Liang, C; Liu, B; Liu, X; Lu, R; Pang, Y; Song, J; Wu, J; Zhang, P; Zhou, J; Zhou, Y, 2019
)
1.5
"Hydroxychloroquine (HCQ) is a molecule with extensive safety data during pregnancy."( Hydroxychloroquine for prevention of recurrent miscarriage: study protocol for a multicentre randomised placebo-controlled trial BBQ study.
Bohec, C; Bretelle, F; Chauleur, C; Cogulet, V; de Saint-Martin, L; Hannigsberg, J; Lejeune-Saada, V; Marhic, G; Merviel, P; Mottier, D; Pasquier, E; Plu-Bureau, G, 2019
)
2.68
"Hydroxychloroquine (HCQ) is an antimalarial drug that is also used in some dermatologic and rheumatic diseases due to its immunosuppressive actions."( The First Pediatric Case of Acute Generalized Exanthematous Pustulosis Caused by Hydroxychloroquine.
Barni, S; Giani, T; Liccioli, G; Marrani, E; Mori, F; Simonini, G, 2019
)
1.46
"Hydroxychloroquine sulfate (HCQ) is an inhibitor of autophagy that inhibits the fusion of the autophagosome to the lysosome."( Effect of Gemcitabine and nab-Paclitaxel With or Without Hydroxychloroquine on Patients With Advanced Pancreatic Cancer: A Phase 2 Randomized Clinical Trial.
Amaravadi, RK; Borazanci, E; Burrell, JA; De Jesus-Acosta, A; Drebin, JA; Karasic, TB; Laheru, DA; Loaiza-Bonilla, A; O'Dwyer, PJ; O'Hara, MH; Redlinger, C; Reiss, KA; Teitelbaum, UR; Von Hoff, DD, 2019
)
1.48
"Hydroxychloroquine (HCQ) is a key therapy in systemic lupus erythematosus (SLE). "( Association between hydroxychloroquine levels and disease activity in a predominantly Hispanic systemic lupus erythematosus cohort.
Askanase, A; Danias, G; Dervieux, T; Geraldino-Pardilla, L; Giles, J; Kapoor, T; Miceli, J; Neville, K; Nguyen, S; Perel-Winkler, A, 2019
)
2.28
"Hydroxychloroquine (HCQ) is a widely used medication for the treatment of rheumatoid arthritis and systemic lupus erythematosus. "( Multifaceted effects of hydroxychloroquine in human disease.
Karp, DR; Olsen, NJ; Schleich, MA, 2013
)
2.14
"Hydroxychloroquine is an antimalarial agent that has been used in systemic lupus erythematosus and rheumatoid arthritis treatment for many years. "( Hydroxychloroquine decreases Th17-related cytokines in systemic lupus erythematosus and rheumatoid arthritis patients.
Dantas, AT; Duarte, AL; Galdino, SL; Mariz, HA; Oliveira, PS; Pitta, Ida R; Pitta, MG; Rocha, LF; Silva, JC, 2013
)
3.28
"Hydroxychloroquine (HCQ) is an antimalarial agent that is also used to treat various dermatologic and rheumatologic conditions."( Acute generalized exanthematous pustulosis induced by hydroxychloroquine: first case report in Canada and review of the literature.
Bailey, K; McKee, D; Shear, N; Wismer, J,
)
1.1
"Hydroxychloroquine (HCQ) is an antimalarial drug also used in treating autoimmune diseases. "( Hydroxychloroquine-inhibited dengue virus is associated with host defense machinery.
Chang, TH; Chen, JJ; Chen, SR; Huang, NC; Kubota, T; Lin, YL; Lin, YS; Lu, RW; Matsuoka, M; Tsai, WL; Wang, LF; Yang, CS; Yu, CY, 2015
)
3.3
"Hydroxychloroquine (HCQ) is a disease-modifying anti-rheumatic drug (DMARD) typically used for the treatment of various rheumatic and dermatologic diseases."( Hydroxychloroquine in patients with inflammatory and erosive osteoarthritis of the hands (OA TREAT): study protocol for a randomized controlled trial.
Braun, T; Burmester, GR; Buttgereit, F; Detert, J; Höhne-Zimmer, V; Klaus, P; Listing, J; Rau, R; Wassenberg, S, 2014
)
2.57
"Hydroxychloroquine (HCQ) is an antimalarial drug with immunomodulatory properties that is widely used in the treatment of rheumatological diseases."( Hydroxychloroquine reduces microglial activity and attenuates experimental autoimmune encephalomyelitis.
Giuliani, F; Hader, W; Koch, MW; Lewkonia, R; Metz, L; Wee Yong, V; Zabad, R, 2015
)
2.58
"Hydroxychloroquine (HCQ) is an antimalarial drug used extensively in treatment of autoimmune diseases such as rheumatoid arthritis. "( Detection of Hydroxychloroquine Retinal Toxicity by Automated Perimetry in 60 Rheumatoid Arthritis Patients with Normal Fundoscopic Findings.
Abbaszadeh, M; Aidenloo, NS; Motarjemizadeh, Q, 2015
)
2.23
"Hydroxychloroquine (HCQ) is an effective treatment for patients with cutaneous lupus erythematosus (CLE) or systemic lupus erythematosus (SLE) and has been used for these patients in more than 70 nations. "( Population Pharmacokinetics of Hydroxychloroquine in Japanese Patients With Cutaneous or Systemic Lupus Erythematosus.
Morita, S; Takahashi, T; Yokota, N; Yoshida, Y, 2016
)
2.16
"Hydroxychloroquine (HCQ) is a slow acting DMARD used in the early stage of RA. "( Design, Synthesis and In Vitro Release Studies of Co-Drugs for Rheumatoid Arthritis.
Dhaneshwar, S; Kashmira, P; Poorvashree, J; Shakuntala, C, 2015
)
1.86
"Hydroxychloroquine (HCQ) is a widely used drug in the treatment of autoimmune diseases, such as arthritis and systemic lupus erythematosus. "( Hydroxychloroquine binding to cytoplasmic domain of Band 3 in human erythrocytes: Novel mechanistic insights into drug structure, efficacy and toxicity.
Goto, T; Nakagawa, M; Nunomura, W; Sugawara, K; Wakui, H, 2016
)
3.32
"Hydroxychloroquine (HCQ) is an effective immunosuppressant widely used in the treatment of autoimmune disorders."( Hydroxychloroquine protects melanocytes from autoantibody-induced injury by reducing the binding of antigen-antibody complexes.
Hu, WZ; Li, DG; Liu, W; Ma, HJ; Yang, QQ; Zhao, G, 2016
)
2.6
"Hydroxychloroquine is a crucial background medication in SLE with actions in many molecular pathways."( Immunomodulators in SLE: Clinical evidence and immunologic actions.
Durcan, L; Petri, M, 2016
)
1.16
"Hydroxychloroquine (HCQ) is an alkalinizing lysosomatropic drug that accumulates in lysosomes where it inhibits some important functions by increasing the pH. "( Hydroxychloroquine in systemic lupus erythematosus (SLE).
Moroni, G; Ponticelli, C, 2017
)
3.34
"Hydroxychloroquine is an anti-malarial drug which, due to its anti-inflammatory and immunomodulatory effects, is widely used for the treatment of autoimmune diseases. "( The effects of hydroxychloroquine on endothelial dysfunction.
Gurusinghe, S; Lim, R; Mockler, JC; Murthi, P; Rahman, R; Singh, H; Wallace, EM, 2016
)
2.23
"Hydroxychloroquine (HCQ) is an anti-rheumatic drug commonly used in the treatment of rheumatoid arthritis and systemic lupus erythematosus."( Hydroxychloroquine for the prevention of recurrent cardiovascular events in myocardial infarction patients: rationale and design of the OXI trial.
Eklund, KK; Hartman, O; Kovanen, PT; Lehtonen, J; Sinisalo, J, 2017
)
2.62
"Hydroxychloroquine (HCQ) is a commonly used therapeutic agent in skin disorders. "( Hydroxychloroquine modulates metabolic activity and proliferation and induces autophagic cell death of human dermal fibroblasts.
Böhm, M; Kokot, A; Luger, TA; Metze, D; Ramser, B; Weiss, N, 2009
)
3.24
"Hydroxychloroquine is a relatively safe, well tolerated alternative therapy for the treatment of perniosis and should be considered as part of the initial management. "( Successful treatment of perniosis with hydroxychloroquine.
English, JC; Perez, OA; Yang, X, 2010
)
2.07
"Hydroxychloroquine (HCQ) is a 4-aminoquinoline compound used to treat malaria and chronic autoimmune disorders and is not uncommonly found in the medical examiner setting. "( Postmortem hydroxychloroquine concentrations in nontoxic cases.
Molina, DK, 2012
)
2.21
"Hydroxychloroquine (HCQ) is a common disease modifying therapy for the treatment of rheumatoid arthritis (RA). "( Hydroxychloroquine improves insulin sensitivity in obese non-diabetic individuals.
Garg, R; Lu, B; Massarotti, EM; Mercer, E; Rekedal, L; Solomon, DH, 2012
)
3.26
"Hydroxychloroquine (HCQ) is a racemic 4-aminoquinoline derivative that was first introduced as an antimalarial, and subsequently applied to the treatment of autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus. "( A parallel design study to assess the bioequivalence of generic and branded hydroxychloroquine sulfate tablets in healthy volunteers.
Cao, WE; Chen, Q; Hu, CY; Jia, JY; Liu, GY; Liu, Y; Liu, YM; Lu, C; Pu, HH; Song, B; Song, YX; Wang, W; Yu, C; Zhang, MQ; Zhu, JM, 2012
)
2.05
"Hydroxychloroquine (HCQ) is an important medication for treating systemic lupus erythematosus (SLE). "( Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study).
Ackermann, F; Amoura, Z; Asli, B; Aumaître, O; Boutin, du LT; Cacoub, P; Cohen-Bittan, J; Costedoat-Chalumeau, N; Desmurs-Clavel, H; Fain, O; Francès, C; Galicier, L; Hulot, JS; Jallouli, M; Kahn, JE; Le Guern, V; Lechat, P; Leroux, G; Limal, N; Lioté, F; Musset, L; Papo, T; Perard, L; Piette, JC; Pourrat, J; Sacré, K; Sailler, L; Smail, A; Stirnemann, J; Tanguy, ML, 2013
)
3.28
"Hydroxychloroquine (HCQ) is a halogenated aminoquinoline that presents wide biological activity, often being used as an antimalarial drug. "( Electrochemical study of hydroxychloroquine and its determination in plaquenil by differential pulse voltammetry.
Andrade, JF; Arguelho, ML; Stradiotto, NR, 2003
)
2.07
"Hydroxychloroquine (HCQ) is a lysosomotropic amine with cytotoxic properties. "( Mitochondrial membrane permeabilization is a critical step of lysosome-initiated apoptosis induced by hydroxychloroquine.
Andreau, K; Boya, P; Gonzalez-Polo, RA; Kroemer, G; Perfettini, JL; Poncet, D; Roumier, T; Vieira, HL, 2003
)
1.98
"Hydroxychloroquine (HCQ) is an antimalarial drug that is also used as a second-line treatment of rheumatoid arthritis (RA). "( Population pharmacokinetics of hydroxychloroquine in patients with rheumatoid arthritis.
Carmichael, SJ; Charles, B; Tett, SE, 2003
)
2.05
"Hydroxychloroquine (HCQ) is an immunosuppressive agent that interferes with antigen presentation and with activity against graft-versus-host disease (GVHD). "( Hydroxychloroquine for the prevention of acute graft-versus-host disease after unrelated donor transplantation.
Adkins, D; Brown, R; Dipersio, JF; Goodnough, LT; Horowitz, M; Khoury, H; Ma, MK; McLeod, HL; Shenoy, S; Trinkaus, K; Vij, R; Zhang, MJ, 2003
)
3.2
"Hydroxychloroquine is an effective form of therapy for scleromyxoedema, leading to rapid and prolonged alleviation of symptoms."( Treatment of scleromyxoedema with hydroxychloroquine.
Becker, JC; Bröcker, EB; Kahaly, GJ; Lurz, C; Terheyden, P, 2003
)
2.04
"Hydroxychloroquine (HCQ) is an antimalarial agent with immunomodulatory effects. "( Desensitization to hydroxychloroquine--experience of 4 patients.
Breuer, GS; Mates, M; Navon, P; Nesher, G; Zevin, S, 2006
)
2.1
"Hydroxychloroquine was found to be an effective and well-tolerated drug in rheumatoid arthritis in Indian patients."( Efficacy and safety of hydroxychloroquine sulphate in rheumatoid arthritis: a randomized, double-blind, placebo controlled clinical trial--an Indian experience.
Agarwal, GG; Chauhan, RS; Das, SK; Mathur, DS; Pareek, A; Srivastava, R; Wanchu, A, 2007
)
2.09
"Hydroxychloroquine (HCQ) is an immunosuppressive lysosomotropic amine that has activity against graft-versus-host disease (GVHD). "( A randomized double-blind trial of hydroxychloroquine for the prevention of chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation.
Adkins, D; Devine, SM; Dipersio, JF; Fong, T; Goodnough, LT; Graubert, T; Khoury, HJ; Lopez, S; Shenoy, S; Tomasson, M; Trinkaus, K; Vij, R, 2007
)
2.06
"Hydroxychloroquine appears to be a safe and effective alternative treatment of granulomas in CGD patients."( Efficiency of hydroxychloroquine in the treatment of granulomatous complications in chronic granulomatous disease.
Aouba, A; Arlet, JB; Blanche, S; Cellier, C; Damotte, D; Fischer, A; Hermine, O; Suarez, F; Valeyre, D, 2008
)
1.43
"Hydroxychloroquine, which is a potent inhibitor of leucocyte motility, effectively prevents the acute inflammatory infiltrate in this experimental colitis model and therefore merits trial in human ulcerative colitis."( Inhibition of leucocyte motility and prevention of immune-complex experimental colitis by hydroxychloroquine.
Brown, DJ; Jewell, DP; McLaughlin, JE; Nuttall, LA; Rhodes, JM, 1982
)
1.21
"Hydroxychloroquine (HCQ) is a racemic antiarthritic agent that has a long half-life (t1/2) in plasma and accumulates in blood cells. "( Hematologic disposition of hydroxychloroquine enantiomers.
Brocks, DR; Davis, P; Emamibafrani, J; Jamali, F; Johnston, C; Russell, AS; Skeith, KJ, 1994
)
2.03
"Hydroxychloroquine (HCQ) is a valuable and possibly underused agent in treating mild lupus. "( The use of hydroxychloroquine in lupus pregnancy: the British experience.
Buchanan, NM; Hughes, GR; Khamashta, MA, 1996
)
2.13
"Hydroxychloroquine (HCQ) is a well-tolerated, safe immunomodulating drug, with proven efficacy in rheumatic diseases and known actions that suggest potential utility in the treatment of asthma."( Hydroxychloroquine improves airflow and lowers circulating IgE levels in subjects with moderate symptomatic asthma.
Charous, BL; Halpern, EF; Steven, GC, 1998
)
2.46
"Hydroxychloroquine (HCQ) is a 4-aminoquinoline antimalarial drug used for the treatment of autoimmune diseases."( Hydroxychloroquine for the treatment of chronic graft-versus-host disease.
Boyer, M; Cahill, R; Chan, KW; Cirenza, E; Frankel, S; Gehan, E; Gilman, AL; Goldman, FD; Mazumder, A; Mogul, A; Morris, C; Schultz, K, 2000
)
2.47
"Hydroxychloroquine is an antimalarial drug often used in dermatology for its photo-protective effects. "( [Photodermatosis induced by hydroxychloroquine: 4 cases].
Balguerie, X; Courville, P; Joly, P; Lauret, P; Métayer, I,
)
1.87
"Hydroxychloroquine seems to be a safe alternative among the antimalarial drugs as far as eyes are concerned."( Hydroxychloroquine treatment and the eye.
Mäntyjärvi, M, 1985
)
2.43

Effects

Hydroxychloroquine (HCQ) has a primary role in the prophylaxis and treatment of systemic lupus erythematosus. It may be protective against thrombosis in SLE. The risk of retinal toxicity increases dramatically with a cumulative dose of >1000 g.

Hydroxychloroquine (HCQ) has been proven to be effective against a variety of autoimmune diseases and is an essential drug for the treatment of SLE. It has been widely used to treat dermatologic and rheumatologic diseases and has bee suggested as possible treatment for severe acute respiratory syndrome-coronavirus-2.

ExcerptReferenceRelevance
"Hydroxychloroquine (HCQ) has a primary role in the prophylaxis and treatment of systemic lupus erythematosus (SLE) and may be protective against thrombosis in SLE. "( Association of Higher Hydroxychloroquine Blood Levels With Reduced Thrombosis Risk in Systemic Lupus Erythematosus.
Goldman, DW; Konig, MF; Li, J; Petri, M, 2021
)
2.38
"Hydroxychloroquine (HCQ) has a low risk of retinal toxicity which increases dramatically with a cumulative dose of >1000 g. "( A possible early sign of hydroxychloroquine macular toxicity.
Brandao, LM; Palmowski-Wolfe, AM, 2016
)
2.18
"Hydroxychloroquine has a particularly long half-life and is a known cause of AGEP; therefore, it is possible that HCQ-induced AGEP may not follow the typical rapid recovery time."( Prolonged pustular eruption from hydroxychloroquine: an unusual case of acute generalized exanthematous pustulosis.
Jolly, P; Morrell, DS; Pearson, KC; Runge, SR, 2016
)
1.44
"Hydroxychloroquine (HCQ) has a long elimination half-life and its concentration in whole blood can be measured easily."( Very low blood hydroxychloroquine concentration as an objective marker of poor adherence to treatment of systemic lupus erythematosus.
Amoura, Z; Aymard, G; Costedoat-Chalumeau, N; Hulot, JS; Lechat, P; Leroux, G; Marra, D; Piette, JC, 2007
)
1.41
"(1) Hydroxychloroquine has a possible anti-thrombotic action."( The relevance of antimalarial therapy with regard to thrombosis, hypercholesterolemia and cytokines in SLE.
Linker-Israeli, M; Metzger, AL; Stecher, VJ; Wallace, DJ, 1993
)
0.77
"Hydroxychloroquine (HCQ) has shown anti-tumor activity in a variety of tumor models."( Mass spectrometry imaging revealed alterations of lipid metabolites in multicellular tumor spheroids in response to hydroxychloroquine.
Cai, Z; Chen, Y; Song, Y; Wang, J; Wang, T; Xie, P, 2021
)
1.55
"Hydroxychloroquine has attracted attention in the treatment of COVID-19. "( Effects of hydroxychloroquine and its metabolites in patients with connective tissue diseases.
Abusoglu, G; Abusoglu, S; Eryavuz Onmaz, D; Onmaz, M; Tezcan, D; Unlu, A; Yerlikaya, FH; Yilmaz, S, 2021
)
2.45
"Hydroxychloroquine (HCQ) has recently been reported to be a promising and safe anti-proteinuric agent for IgA nephropathy (IgAN) patients. "( Hydroxychloroquine in IgA nephropathy: a systematic review.
Mircescu, G; Stefan, G, 2021
)
3.51
"Hydroxychloroquine has been applied as one of the COVID-19 treatment strategies."( Hydroxychloroquine treatment on SARS-CoV-2 receptor ACE2, TMPRSS2 and NRP1 expression in human primary pterygium and conjunctival cells.
Chen, SL; Jhanji, V; Liang, JJ; Ma, D; Ng, TK; Xu, Y; Yao, Y; Yuan, XL, 2022
)
2.89
"Hydroxychloroquine (HCQ) has been recommended as a basic treatment for lupus nephritis (LN) during this decade based on its ability to improve LN-related renal immune-mediated inflammatory lesions. "( Hydroxychloroquine administration exacerbates acute kidney injury complicated by lupus nephritis.
An, N; Chen, RH; Guo, Y; Huang, TS; Huang, XJ; Li, ZH; Liu, HF; Pan, QJ; Wu, HL; Wu, ZH; Xue, J; Yang, C, 2022
)
3.61
"Hydroxychloroquine (HCQ) has been extensively used during the COVID-19 pandemic both as a therapeutic and prophylactic drug. "( Hydroxychloroquine: Adverse Drug Reaction Profile of an Old Drug in a New Situation.
Bhandari, B; Chopra, D; Rai, J; Sidhu, JK; Srivastava, S; Upadhyay, R, 2022
)
3.61
"Hydroxychloroquine (HCQ) has already been used clinically for decades, and it is still widely used to treat various autoimmune diseases."( Hydroxychloroquine attenuates neuroinflammation following traumatic brain injury by regulating the TLR4/NF-κB signaling pathway.
Chen, K; Chen, X; Fang, Y; Guo, K; Hu, J; Liang, F; Lin, L; Peng, W; Tan, X; Wang, X; Wang, Z; Xiong, Y, 2022
)
2.89
"Hydroxychloroquine (HCQ) has been used during the coronavirus disease 2019 (COVID-19) pandemic because of its reported anti-viral activity. "( Effect of chronic hydroxychloroquine use on COVID-19 risk in patients with rheumatoid arthritis and systemic lupus erythematosus: a multicenter retrospective cohort.
Al Maimouni, HM; Al-Najjar, AH; Alajra, RK; Alali, AS; Alanazi, DS; Albadi, MA; Albarqi, HA; Alghanim, NS; Alkahtani, SA; Alqahtani, F; Alqhtani, H; Alsaweed, OS; Alshabi, AM; Hazzazi, MA; Sabei, AA; Walbi, IA, 2022
)
2.5
"Hydroxychloroquine (HCQ) has been adapted for the treatment of autoimmune diseases; however, the potential mechanism underlying the role of HCQ in renal fibrosis remains unclear."( Hydroxychloroquine alleviates renal interstitial fibrosis by inhibiting the PI3K/Akt signaling pathway.
Bai, F; Fan, J; Feng, F; Li, D; Liu, L; Sun, N; Yang, H; Yang, X; Yu, K; Zhang, Y, 2022
)
2.89
"Hydroxychloroquine (HCQ) has been used clinically to treat SLE, while its exact mechanism has still remained elusive."( Hydroxychloroquine induces apoptosis of myeloid-derived suppressor cells via up-regulation of CD81 contributing to alleviate lupus symptoms.
Dou, H; Hou, Y; Jiang, J; Lu, L; Ma, Y; Ni, J; Wang, Y; Yang, Z; You, X; Zhao, Z; Zhu, H, 2022
)
2.89
"Hydroxychloroquine (HCQ) has been reported to improve the lifespan and the prognosis of dyslipidaemia in patients with SLE, but the mechanism is unclear."( Supplemental hydroxychloroquine therapy regulates adipokines in patients with systemic lupus erythematosus with stable disease.
Dobashi, H; Kadowaki, N; Kameda, T; Kato, M; Mino, R; Miyagi, T; Miyatake, N; Mizusaki, M; Nakashima, S; Shimada, H; Sugihara, K; Ueeda, K; Wakiya, R, 2022
)
1.81
"Hydroxychloroquine (HCQ) has been the subject of multiple recent preclinical and clinical studies for its beneficial use in the combination treatments of different types of cancers. "( Polymeric Chloroquine as an Effective Antimigration Agent in the Treatment of Pancreatic Cancer.
Bennett, RG; Ding, L; Kapoor, E; Khan, R; Oupický, D; Panja, S; Tang, S; Tang, W, 2022
)
2.16
"As hydroxychloroquine (HCQ) has recently been shown to inactivate STAT3, we hypothesized that it may impact AD pathogenesis and risk."( Hydroxychloroquine lowers Alzheimer's disease and related dementias risk and rescues molecular phenotypes related to Alzheimer's disease.
Anerillas, C; Chin, K; Desai, RJ; Gerhard, T; Gorospe, M; Horton, DB; Kim, SC; Loeffler, T; Mahesri, M; Navakkode, S; Sajikumar, S; Schilcher, I; Schneeweiss, S; Segal, JB; Thambisetty, M; Varma, VR; Wong, LW, 2023
)
2.87
"Hydroxychloroquine (HCQ) has demonstrated beneficial effects on disease flares, pregnancy outcomes and cardiovascular impairment in systemic erythaematosus lupus (SLE) through its immunomodulatory, vasculoprotective and antithrombotic properties."( Hydroxychloroquine may be beneficial in preeclampsia and recurrent miscarriage.
Alavi, Z; de Moreuil, C; Pasquier, E, 2020
)
2.72
"Hydroxychloroquine (HCQ) has become the rheumatologists's "Swiss army knife" when it comes to managing the rheumatologic manifestations of SLE and other auto-immune disorders. "( What every nephrologist needs to know about hydroxychloroquine toxicity
.
Ardoin, S; Ayoub, I; Brodsky, S; Hebert, L; Singh, P, 2020
)
2.26
"Hydroxychloroquine (HCQ) has been used for the treatment of novel coronavirus disease (COVID-19) cases. "( Case Report: Hepatotoxicity Associated with the Use of Hydroxychloroquine in a Patient with COVID-19.
Antunes de Brito, CA; Falcão, MB; Filgueiras Filho, NM; Pamplona de Góes Cavalcanti, L, 2020
)
2.25
"Hydroxychloroquine has been demonstrated to limit the replication of SARS-CoV-2 virus in vitro."( Efficacy of chloroquine and hydroxychloroquine in the treatment of COVID-19.
Akram, J; Klonoff, DC; Meo, SA, 2020
)
1.57
"Hydroxychloroquine has been widely administered to patients with Covid-19 without robust evidence supporting its use."( Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19.
Baldwin, M; Barr, RG; Geleris, J; Hripcsak, G; Kubin, C; Labella, A; Manson, DK; Platt, J; Schluger, NW; Sobieszczyk, ME; Sun, Y; Zucker, J, 2020
)
2.31
"Hydroxychloroquine (HCQ) has been associated with improved survival among patients with systemic lupus erythematosus (SLE) from tertiary referral centers. "( Hydroxychloroquine and Mortality Among Patients With Systemic Lupus Erythematosus in the General Population.
Aviña-Zubieta, JA; Choi, H; De Vera, M; Esdaile, J; Jorge, A; Lu, N; McCormick, N; Zheng, Y, 2021
)
3.51
"Hydroxychloroquine has received worldwide attention as a potential treatment for covid-19 because of positive results from small studies. "( Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data.
Audureau, E; Carlier, N; Chabrol, A; Costedoat-Chalumeau, N; Crickx, E; Dang, J; de Lastours, V; Fois, E; Gallien, S; Godeau, B; Guillaud, C; Kerneis, S; Khellaf, M; Legendre, P; Lepeule, R; Lescure, FX; Mahévas, M; Matignon, M; Ménager, P; Michel, M; Morbieu, C; Mouthon, L; Ourghanlian, C; Paule, R; Pawlotsky, JM; Perrodeau, E; Ravaud, P; Roche, N; Roumier, M; Schlemmer, F; Schoindre, Y; Szwebel, TA; Terrier, B; Tran, VT, 2020
)
2.32
"Hydroxychloroquine (HCQ) has its own side effects, some of which are very serious like acute haemolysis in glucose-6-phosphate dehydrogenase (G6PD) deficient patients."( A case report of serious haemolysis in a glucose-6-phosphate dehydrogenase-deficient COVID-19 patient receiving hydroxychloroquine.
Clevenbergh, P; De Bels, D; Leemans, S; Mahadeb, B; Maillart, E; Salaouatchi, MT; Van Noten, H; Vandergraesen, T, 2020
)
1.49
"Hydroxychloroquine has been promoted for its use in treatment of COVID-19 patients based on in-vitro evidences. "( Does Adding of Hydroxychloroquine to the Standard Care Provide any Benefit in Reducing the Mortality among COVID-19 Patients?: a Systematic Review.
Barvaliya, M; Bhalla, HL; Kevadiya, BD; Patel, PB; Patel, TK, 2020
)
2.35
"Hydroxychloroquine has been proposed for the cure of the COVID-19 due to its anti-inflammatory and anti-viral action. "( Hydroxychloroquine, COVID-19 and diabetes. Why it is a different story.
Catrinoiu, D; Ceriello, A; Rizzo, M; Stoian, AP, 2021
)
3.51
"Hydroxychloroquine (HCQ) has been promoted as a potential treatment of coronavirus disease 2019 (COVID-19), but there are safety concerns."( Effects of hydroxychloroquine treatment on QT interval.
Adabag, S; Bart, B; Hooks, M; Vardeny, O; Westanmo, A, 2020
)
2.39
"Hydroxychloroquine (HCQ) has in vitro activity against SARS-CoV-2, but clinical data supporting HCQ for coronavirus disease 2019 (COVID-19) are limited."( Safety, tolerability, and clinical outcomes of hydroxychloroquine for hospitalized patients with coronavirus 2019 disease.
Choi, JJ; Goyal, P; Gulick, RM; Kondo, M; Magleby, R; Maldarelli, GA; Pham, K; Rennert, H; Safford, MM; Satlin, MJ; Schenck, EJ; Westblade, LF, 2020
)
1.54
"Hydroxychloroquine has shown to have antiviral activity in vitro against coronaviruses, specifically SARS-CoV-2. "( PROTECT Trial: A cluster-randomized study with hydroxychloroquine versus observational support for prevention or early-phase treatment of Coronavirus disease (COVID-19): A structured summary of a study protocol for a randomized controlled trial.
Altini, M; Bertoni, L; Biggeri, A; Colamartini, A; Donati, C; Falcini, F; Gaggeri, R; Galardi, F; Grossi, V; Lilli, C; Martinelli, G; Masini, C; Massa, I; Monti, M; Nanni, O; Scarpi, E; Serra, P; Vertogen, B; Vespignani, R; Viale, P; Zingaretti, C, 2020
)
2.26
"Hydroxychloroquine has been touted as a potential COVID-19 treatment. "( Hydroxychloroquine and tocilizumab therapy in COVID-19 patients-An observational study.
Asif, A; Balani, B; Barsky, C; Bednarz, U; Berry, DA; Berry, NS; Berry, SM; Biran, N; Cicogna, C; Go, RC; Goldberg, SL; Goy, AH; Hansen, E; Ip, A; Jacobs, LG; Korcak, J; Landolfi, JC; Marafelias, M; Mathura, S; Pecora, AL; Piwoz, JA; Rose, KM; Sawczuk, IS; Sebti, R; Sinclaire, BA; Sperber, S; Sugalski, G; Tank, L; Timmapuri, SL; Underwood, JP; Varga, DW; Zuckerman, J, 2020
)
3.44
"Hydroxychloroquine (HCQ) has been largely used and investigated as therapy for COVID-19 across various settings at a total dose usually ranging from 2400 mg to 9600 mg. "( Low-dose hydroxychloroquine therapy and mortality in hospitalised patients with COVID-19: a nationwide observational study of 8075 participants.
Bottieau, E; Catteau, L; Dauby, N; Duysburgh, E; Goetghebeur, E; Hautekiet, J; Montourcy, M; Van Beckhoven, D; van Ierssel, S; Van Oyen, H; Wyndham-Thomas, C, 2020
)
2.42
"Hydroxychloroquine has endothelial stabilizing and anti-thrombotic effects."( Benefits and adverse effects of hydroxychloroquine, methotrexate and colchicine: searching for repurposable drug candidates.
Gasparyan, AY; Misra, DP; Zimba, O, 2020
)
1.56
"Hydroxychloroquine (HCQ) has been implicated in antiviral activity in vitro against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). "( Hydroxychloroquine use and progression or prognosis of COVID-19: a systematic review and meta-analysis.
Han, X; He, M; Li, Y; Shi, J; Zang, Y, 2021
)
3.51
"Hydroxychloroquine±azithromycin have been widely used to treat coronavirus disease 2019 (COVID-19) despite a paucity of evidence regarding efficacy."( Safely Administering Potential QTc Prolonging Therapy Across a Large Health Care System in the COVID-19 Era.
Chang, D; Epstein, LM; Fishbein, J; Gabriels, J; Mountantonakis, SE; Qiu, M; Saleh, M, 2020
)
1.28
"Hydroxychloroquine (HCQ) has shown some promise in the management of COVID 19."( Combining hydroxychloroquine and minocycline: potential role in moderate to severe COVID-19 infection.
Garg, VK; Gautam, CS; Gautam, SS; Singh, H, 2020
)
1.68
"Hydroxychloroquine (HQ) has been used for the treatment of novel coronavirus disease (COVID-19) even though there is no clear evidence for its effectiveness yet. "( Sudden Cardiac Death in Haemodialysis Patients under Hydroxychloroquine Treatment for COVID-19: A Report of Two Cases.
Dincer, MT; Karaca, C; Murt, A, 2021
)
2.31
"Hydroxychloroquine has been used for rheumatological diseases for many decades and is considered a safe medication. "( Cardiac Complications Attributed to Hydroxychloroquine: A Systematic Review of the Literature Pre-COVID-19.
Basir, MB; Fram, G; Kang, G; Khan, A; Malette, K; McKinnon, JE; O'Neill, WW; So, K; Villablanca, P; Wang, DD; Zervos, M, 2021
)
2.34
"Hydroxychloroquine (HCQ) has shown no significant improvement in negative seroconversion rate which is also seen in our meta-analysis (P=0.68)."( Repurposing of drugs for COVID-19: a systematic review and meta-analysis.
Amparore, D; Checcucci, E; Dasgupta, P; Elhage, O; Fiori, C; Kotecha, P; Light, A; Porpiglia, F, 2022
)
1.44
"Hydroxychloroquine has been suggested as a possible treatment; however, it is associated with multiple adverse reactions."( Acute generalized exanthematous pustulosis and Stevens-Johnson syndrome overlap due to hydroxychloroquine: a case report.
Ackerman, L; Brahmbhatt, S; Coleman, I; Ruiz, G, 2020
)
1.5
"Hydroxychloroquine (HCQ) has been tried against COVID-19 owing to its in vitro virucidal action against SARS-CoV-2, but the role of HCQ as post-exposure prophylaxis (PEP) remains inconclusive."( Post-exposure prophylaxis with hydroxychloroquine for the prevention of COVID-19, a myth or a reality? The PEP-CQ Study.
Arora, N; Bhalla, A; Dhibar, DP; Kakkar, A; Medhi, B; Mohindra, R; Prakash, A; Pvm, L; Sharma, N; Singh, MP; Singla, N; Suri, V, 2020
)
1.57
"Hydroxychloroquine has been proposed as a postexposure therapy to prevent coronavirus disease 2019 (Covid-19), but definitive evidence is lacking."( A Cluster-Randomized Trial of Hydroxychloroquine for Prevention of Covid-19.
Admella, P; Alemany, A; Ara, J; Argimon, JM; Ballana, E; Bertran, L; Cañadas, P; Casabona, J; Clotet, B; Clua, M; Corbacho-Monné, M; Cuatrecasas, G; Elizalde-Torrent, A; Fabregat, R; Farré, M; Flores-Mateo, G; Forcada, A; Gavilán, S; González-Beiras, C; Laporte, P; López, C; Mitjà, J; Mitjà, O; Muntada, E; Nadal, N; Narejos, S; Nieto, A; Peñafiel, J; Pérez, CA; Prat, N; Puig, J; Quiñones, C; Ramírez-Viaplana, F; Reyes-Urueña, J; Riera-Martí, N; Riveira-Muñoz, E; Ruiz, L; Sanz, S; Sarquella, M; Sentís, A; Sierra, A; Suñer, C; Tebé, C; Tobias, A; Ubals, M; Vall-Mayans, M; Velasco, C; Vivanco-Hidalgo, RM; Zamora, J, 2021
)
1.63
"Hydroxychloroquine, which has been used successfully in the treatment of many autoimmune diseases, can suppress inflammation and might also be beneficial in hand osteoarthritis."( Efficacy of hydroxychloroquine in hand osteoarthritis: A protocol for systematic review and meta-analysis of randomized clinical trial.
Li, QQ; Liang, WQ; Wang, YP; Xie, YD; Yang, GQ; Zhang, HB, 2020
)
1.66
"Hydroxychloroquine (HCQ) has generated a lot of controversies whether it is effective in prevention and treatment of COVID-19."( Long-term application of hydroxychloroquine could not prevent the infection of COVID-19.
Chen, Y; Ding, H; Fang, J; Gong, Y; Ke, C; Pan, A; Wang, B; Xu, L; Yu, B; Zhu, Y, 2020
)
1.58
"Hydroxychloroquine (HCQ) has a primary role in the prophylaxis and treatment of systemic lupus erythematosus (SLE) and may be protective against thrombosis in SLE. "( Association of Higher Hydroxychloroquine Blood Levels With Reduced Thrombosis Risk in Systemic Lupus Erythematosus.
Goldman, DW; Konig, MF; Li, J; Petri, M, 2021
)
2.38
"Hydroxychloroquine has in vitro antiviral properties against SARS CoV-2."( The efficacy and safety of hydroxychloroquine for COVID-19 prophylaxis: A systematic review and meta-analysis of randomized trials.
Alhazzani, W; Alshamsi, F; Carayannopoulos, L; Chagla, Z; Chaudhuri, D; Dearness, K; Lewis, K, 2021
)
1.64
"Hydroxychloroquine has not been associated with improved survival among hospitalized COVID-19 patients in the majority of observational studies and similarly was not identified as an effective prophylaxis following exposure in a prospective randomized trial. "( Hydroxychloroquine in the treatment of outpatients with mildly symptomatic COVID-19: a multi-center observational study.
Ahn, J; Bednarz, U; Calise, AG; Cunningham, FJ; Eagan, MP; Goldberg, SL; Goy, AH; Hansen, E; Ip, A; La Capra, S; Marafelias, M; Mastrokyriakos, P; Mojares, GE; Pecora, AL; Ponce, MG; Prasad, R; Pulver, BL; Ruocco, D; Sawczuk, IS; Sinclaire, BA; Sweeney, RL; Underwood, JP; Walker, DM; Zhou, Y; Ziontz, KL, 2021
)
3.51
"Hydroxychloroquine (HCQ) has received much attention in the treatment of coronavirus disease 2019 recently. "( Low-dose oral hydroxychloroquine led to impaired vision in a child with renal failure: Case report and literature review.
Huang, Y; Li, Z; Lu, J; Ming, M; Shang, F; Xu, H; Ye, Q, 2021
)
2.42
"Hydroxychloroquine has been widely prescribed to treat patients with COVID-19 pneumonia. "( Torsades de pointes in SARS-CoV-2 (COVID-19) pneumonia: medicine reconciliation and careful monitoring of QTc interval may help prevent cardiac complications.
Ali, N; Aslam, W; Lamb, CR, 2021
)
2.06
"Hydroxychloroquine has recently received attention as a treatment for COVID-19. "( Risk of QT prolongation through drug interactions between hydroxychloroquine and concomitant drugs prescribed in real world practice.
Choi, BJ; Chung, WY; Jung, YJ; Kim, TY; Koo, Y; Lim, HS; Park, B; Park, JE; Yoon, D, 2021
)
2.31
"Hydroxychloroquine (HCQ) has been one of the most widely tested drugs for SARS CoV2 on account of its antiviral properties."( The efficacy and safety of hydroxychloroquine (HCQ) in treatment of COVID19 -a systematic review and meta-analysis.
Ahuja, B; Biswas, PS; Choudhuri, AH; Duggal, S, 2021
)
1.64
"Hydroxychloroquine (HCQ), which has shown its effectiveness in rheumatoid arthritis, has been trialed for the treatment of OA; however, its efficacy and safety remain unclear."( Efficacy and safety of hydroxychloroquine in osteoarthritis: a systematic review and meta-analysis of randomized controlled trials.
Antony, B; Das, S; Dissanayaka, T; Kotlo, A; Singh, A; Wang, Z, 2022
)
1.75
"Hydroxychloroquine (HCQ) has been positioned as an anchor drug for systemic lupus erythematosus (SLE). "( Combining maintenance therapy with hydroxychloroquine increases LLDAS achievement rates in individuals with stable systemic lupus erythematosus.
Amano, H; Asai, Y; Minowa, K; Tamura, N; Yamaji, K; Yoshida, M, 2021
)
2.34
"Hydroxychloroquine has been proposed as a primary prophylactic agent against coronavirus disease 2019 (COVID-19). "( Hydroxychloroquine as a primary prophylactic agent against SARS-CoV-2 infection: A cohort study.
Armbruster, K; Biering-Sørensen, T; Bodtger, U; Bojesen, RD; Browatzki, A; Eklöf, J; Håkansson, KEJ; Harboe, ZB; Hoyer, N; Jensen, JU; Kamstrup, P; Lapperre, TS; Lassen, MCH; Lundgren, JD; Meteran, H; Meyer, CN; Pedersen, L; Sivapalan, P; Skaarup, KG; Tidemandsen, C; Ulrik, CS, 2021
)
3.51
"Hydroxychloroquine has excellent anti-inflammatory and immunomodulatory effects as one of the antimalarial drugs. "( Retinal toxicity caused by hydroxychloroquine in patients with systemic lupus erythematosus: A case report.
Li, J; Liao, Z; Qi, W; Tian, F; Wang, G; Wen, Z; Zhuo, N, 2021
)
2.36
"Hydroxychloroquine (HCQ) has been proven to be effective against a variety of autoimmune diseases and is an essential drug for the treatment of SLE."( Hydroxychloroquine alleviates the neurotoxicity induced by anti-ribosomal P antibodies.
Yang, P; Zhao, X, 2021
)
2.79
"Hydroxychloroquine has been suggested as possible treatment for severe acute respiratory syndrome-coronavirus-2. "( Effect of hydroxychloroquine on the cardiac ventricular repolarization: A randomized clinical trial.
Eveleens Maarse, BC; Gal, P; Graff, C; In 't Veld, AE; Jansen, MAA; Kanters, JK; Kemme, MJB; Moerland, M; van Esdonk, MJ, 2022
)
2.57
"Hydroxychloroquine has shown potential to block viral replication of SARS-CoV-2 in some in vitro studies. "( Hydroxychloroquine plus azithromycin early treatment of mild COVID-19 in an outpatient setting: a randomized, double-blinded, placebo-controlled clinical trial evaluating viral clearance.
Freitas-Santos, RS; Levi, JE; Lopes, ATA; Pierrotti, LC; Rodrigues, C; Santos, SR; Senerchia, AA; Siciliano, RF, 2021
)
3.51
"Hydroxychloroquine (HCQ) has recently become the focus of attention in the current COVID-19 pandemic. "( A Systematic Review and Meta-Analysis of the Safety of Hydroxychloroquine in a Randomized Controlled Trial and Observational Studies.
Bose, D; Gogtay, NJ; Konwar, M; Maurya, M; Thatte, UM, 2022
)
2.41
"Hydroxychloroquine has unique immunomodulatory properties and an attractive adverse effect profile. "( Updated recommendations on the use of hydroxychloroquine in dermatologic practice.
Fernandez, AP, 2017
)
2.17
"Hydroxychloroquine (HCQ) has shown to have significant immunomodulatory effects in the treatment of systemic lupus erythematosus (SLE). "( Favorable effects of hydroxychloroquine on serum low density lipid in patients with systemic lupus erythematosus: A systematic review and meta-analysis.
Ayatollahi, Y; Babary, H; Chen, XP; Doo, L; Kulaga, C; Kwak, MK; Liu, X; Modjinou, D; Olech, E; Uppaluru, LK; Yoo, JW, 2018
)
2.24
"Hydroxychloroquine (HCQ) has been shown to improve survival rates in other inflammatory diseases."( Metabolic and cardiovascular benefits of hydroxychloroquine in patients with rheumatoid arthritis: a systematic review and meta-analysis.
Barnetche, T; Combe, B; Gaujoux-Viala, C; Hua, C; Lukas, C; Morel, J; Rempenault, C, 2018
)
1.47
"Hydroxychloroquine has been widely used to treat dermatologic and rheumatologic diseases and has been reported as a rare cause of acute generalized exanthematous pustulosis."( Acute generalized exanthematous pustulosis induced by hydroxychloroquine: a case with atypical clinical presentation.
Cure, K; Duman, H; Kocaturk, E; Mansuroglu, I; Topal, IO,
)
1.1
"Hydroxychloroquine has been reported as variably effective in inducing significant hair regrowth in adults with alopecia areata."( Alopecia areata treated with hydroxychloroquine: A retrospective study of nine pediatric cases.
Silverberg, NB; Stein, SL; Yun, D, 2018
)
1.49
"Hydroxychloroquine has antithrombotic, cardiovascular, antimicrobial and antineoplastic effects, making it a potentially valuable treatment for patients with systemic vasculitis who are at risk of infections, malignancy and thrombotic events."( New use for an old treatment: Hydroxychloroquine as a potential treatment for systemic vasculitis.
Casian, A; D'Cruz, DP; Sangle, SR, 2018
)
1.49
"Hydroxychloroquine (HCQ) has anti-inflammatory and anti-thrombotic properties."( [Hydroxychloroquine to obtain pregnancy without adverse obstetrical events in primary antiphospholipid syndrome: French phase II multicenter randomized trial, HYDROSAPL].
Bornes, M; Cohen, J; Fain, O; Kayem, G; Mekinian, A; Vicaut, E,
)
1.76
"Hydroxychloroquine (HCQ) has been used to treat systemic lupus erythematosus (SLE) in Japan since 2015. "( A case of generalized pustular psoriasis caused by hydroxychloroquine in a patient with systemic lupus erythematosus.
Hashimoto, Y; Kawazoe, M; Kusunoki, N; Nanki, T; Shikano, K; Shindo, E; Yamamoto, T, 2019
)
2.21
"Hydroxychloroquine has been proposed for HIV treatment; however, little is known about its disposition in the lymphatic system, where replication takes place. "( Distribution of hydroxychloroquine in lymphoid tissue in a rabbit model for HIV infection.
Aguirre-Cruz, L; González-Hernández, I; Jung-Cook, H; López-Arellano, R; Morales-Hipólito, A; Sotelo, J, 2014
)
2.19
"Hydroxychloroquine has been shown to be efficacious in the treatment of autoimmune diseases, including systemic lupus erythematosus. "( Chronic hydroxychloroquine improves endothelial dysfunction and protects kidney in a mouse model of systemic lupus erythematosus.
Algieri, F; Duarte, J; Gálvez, J; Gómez-Guzmán, M; Gómez-Morales, M; Jiménez, R; López-Farré, AJ; O'Valle, F; Pérez-Vizcaino, F; Romero, M; Sabio, JM; Sánchez, M; Zarzuelo, MJ, 2014
)
2.28
"Hydroxychloroquine (HCQ) has been shown to demonstrate anti-inflammatory properties and direct anti-HIV activity. "( Development of polyether urethane intravaginal rings for the sustained delivery of hydroxychloroquine.
Chen, Y; Fowke, KR; Ho, EA; Li, A; Traore, YL, 2014
)
2.07
"Hydroxychloroquine has rarely been associated with TEN, with one case proving fatal."( Hydroxychloroquine-induced fatal toxic epidermal necrolysis complicated by angioinvasive rhizopus.
Cameron, MC; Dominguez, A; Word, AP, 2014
)
2.57
"Hydroxychloroquine have been rarely reported in literature as a causative drug of this reaction."( Hydroxychloroquine-induced acute generalized exanthematous pustulosis with positive patch-testing.
Charfi, O; Kastalli, S; Lakhoua, G; Sahnoun, R,
)
2.3
"Hydroxychloroquine (HCQ) has a low risk of retinal toxicity which increases dramatically with a cumulative dose of >1000 g. "( A possible early sign of hydroxychloroquine macular toxicity.
Brandao, LM; Palmowski-Wolfe, AM, 2016
)
2.18
"Hydroxychloroquine has a particularly long half-life and is a known cause of AGEP; therefore, it is possible that HCQ-induced AGEP may not follow the typical rapid recovery time."( Prolonged pustular eruption from hydroxychloroquine: an unusual case of acute generalized exanthematous pustulosis.
Jolly, P; Morrell, DS; Pearson, KC; Runge, SR, 2016
)
1.44
"Hydroxychloroquine (HCQ) has been demonstrated to reduce the risk to develop diabetes mellitus (DM). "( Favorable outcomes of hydroxychloroquine in insulin resistance may be accomplished by adjustment of the endothelial dysfunction as well as the skewed balance of adipokines.
Abdel-Hamid, AAM; Firgany, AEL, 2016
)
2.19
"Hydroxychloroquine (HCQ) has been used for decades to treat patients with rheumatic diseases, for example, systemic lupus erythematosus (SLE), rheumatoid arthritis or the antiphospholipid syndrome (APS). "( Hydroxychloroquine inhibits proinflammatory signalling pathways by targeting endosomal NADPH oxidase.
Canisius, A; Lackner, KJ; Manukyan, D; Müller-Calleja, N; Strand, D, 2017
)
3.34
"Hydroxychloroquine has demonstrated a survival benefit in patients with systemic lupus erythematosus; some clinicians advocate its use in all such patients."( Hydroxychloroquine retinopathy.
Downes, SM; Luqmani, R; Sharma, S; Yusuf, IH, 2017
)
2.62
"Hydroxychloroquine also has known benefits in reducing some traditional cardiovascular risk factors, such as hyperlipidemia and diabetes mellitus."( Use of hydroxychloroquine to prevent thrombosis in systemic lupus erythematosus and in antiphospholipid antibody-positive patients.
Petri, M, 2011
)
1.55
"Hydroxychloroquine (HCQ) has been shown in retrospective studies to decrease aPL titers in laboratory studies, and to decrease thrombosis risk in patients with systemic lupus erythematosus (SLE)."( Hydroxychloroquine use is associated with lower odds of persistently positive antiphospholipid antibodies and/or lupus anticoagulant in systemic lupus erythematosus.
Broder, A; Putterman, C, 2013
)
2.55
"Hydroxychloroquine has also been shown to reduce in vivo aPL-induced thrombus formation."( Intracellular signaling triggered by antiphospholipid antibodies in platelets and endothelial cells: a pathway to targeted therapies.
Harris, EN; Pierangeli, SS; Vega-Ostertag, M, 2004
)
1.04
"Hydroxychloroquine (HCQ) has a long elimination half-life and its concentration in whole blood can be measured easily."( Very low blood hydroxychloroquine concentration as an objective marker of poor adherence to treatment of systemic lupus erythematosus.
Amoura, Z; Aymard, G; Costedoat-Chalumeau, N; Hulot, JS; Lechat, P; Leroux, G; Marra, D; Piette, JC, 2007
)
1.41
"Hydroxychloroquine (HCQ) has been used for a long time worldwide as a therapy for rheumatoid arthritis (RA). "( Efficacy and safety of hydroxychloroquine sulphate in rheumatoid arthritis: a randomized, double-blind, placebo controlled clinical trial--an Indian experience.
Agarwal, GG; Chauhan, RS; Das, SK; Mathur, DS; Pareek, A; Srivastava, R; Wanchu, A, 2007
)
2.09
"Hydroxychloroquine poisoning has rarely been reported in the literature, with only 18 cases being found on searching the literature. "( Hydroxychloroquine overdose: case report and recommendations for management.
Graham, CA; Ling Ngan Wong, A; Tsz Fung Cheung, I, 2008
)
3.23
"Hydroxychloroquine has been used since the 1950s for the treatment of various rheumatic and dermatologic diseases."( Ocular toxicity of hydroxychloroquine.
Hariman, R; Jay, WM; Ostrowski, RA; Tehrani, R,
)
1.18
"Hydroxychloroquine has then been compared with placebo in the prevention of an immune-complex experimental colitis in rabbits."( Inhibition of leucocyte motility and prevention of immune-complex experimental colitis by hydroxychloroquine.
Brown, DJ; Jewell, DP; McLaughlin, JE; Nuttall, LA; Rhodes, JM, 1982
)
1.21
"Hydroxychloroquine has been used successfully in the treatment of inflammatory arthritides such as rheumatoid arthritis and systemic lupus erythematosus, and less commonly in the seronegative spondyloarthropathies. "( Hydroxychloroquine in the treatment of erosive osteoarthritis.
Bryant, LR; Carpenter, MT; des Rosier, KF, 1995
)
3.18
"Hydroxychloroquine has several less well-known actions that may have clinical relevance in treating systemic lupus erythematosus (SLE). "( The relevance of antimalarial therapy with regard to thrombosis, hypercholesterolemia and cytokines in SLE.
Linker-Israeli, M; Metzger, AL; Stecher, VJ; Wallace, DJ, 1993
)
1.73
"Hydroxychloroquine has been successfully applied for the treatment of arthralgias, myalgias and general constitutive symptoms of SS patients."( Antimalarials in Sjögren's syndrome--the Greek experience.
Manoussakis, MN; Moutsopoulos, HM, 1996
)
1.02
"Hydroxychloroquine has been reported to reduce insulin requirements in refractory type II diabetes by an average of 30%."( Hypoglycemia induced by hydroxychloroquine in a type II diabetic treated for polyarthritis.
Elliott, T; Koehler, BE; Shojania, K, 1999
)
1.33
"Hydroxychloroquine has been used for treating malaria, rheumatoid arthritis, and lupus."( Treatment for HIV-related inflammation.
, 1995
)
1.01

Actions

Hydroxychloroquine can cause ocular toxicity, with the most serious being an irreversible retinopathy. At doses used to treat systemic lupus erythematosus there is a potentially life-threatening complication of hepatotoxicity.

ExcerptReferenceRelevance
"Hydroxychloroquine is thought to inhibit growth of C."( The Effect of pH on Antibiotic Efficacy against Coxiella burnetii in Axenic Media.
Evavold, C; Kersh, GJ; Smith, CB, 2019
)
1.24
"Hydroxychloroquine can cause retinopathy and rarely cardiac and auditory toxicity, retinopathy being dose and time dependent."( Benefits and adverse effects of hydroxychloroquine, methotrexate and colchicine: searching for repurposable drug candidates.
Gasparyan, AY; Misra, DP; Zimba, O, 2020
)
1.56
"Hydroxychloroquine was found to cause progressive thinning of the inner retinal layers, specifically in the GCL of the foveolar and paracentral areas, but no changes were observed in the outer retina."( Longitudinal Retinal Changes Induced by Hydroxychloroquine in Eyes without Retinal Toxicity.
Beato, J; Brandão, E; Carneiro, Â; Dinah-Bragança, T; Falcão, M; Falcão-Reis, F; Godinho, G; Madeira, C; Penas, S; Santos-Silva, R, 2021
)
2.33
"Hydroxychloroquine in lower doses is an effective treatment for porphyria cutanea tarda; at doses used to treat systemic lupus erythematosus and subacute cutaneous lupus, there is a potentially life-threatening complication of hepatotoxicity."( The devil's in the dosing: severe drug-induced liver injury in a hydroxychloroquine-naive patient with subacute cutaneous lupus erythematosus and porphyria cutanea tarda.
Ettel, M; McCune, WJ; Pearson, TL; Roofeh, D; Silver, S; Sunkara, B, 2018
)
1.44
"Hydroxychloroquine did not produce false-positive results neither in the DRI Amphetamine Assay nor in the others immunoassays evaluated."( Cross-Reactivity of Chloroquine and Hydroxychloroquine With DRI Amphetamine Immunoassay.
Barceló, B; Dastis, M; Fernández, J; Gomila, I; López-Corominas, V; Quesada, L; Sahuquillo, L; Servera, MÁ; Torrents, A, 2017
)
1.45
"Hydroxychloroquine can cause ocular toxicity, with the most serious being an irreversible retinopathy."( Ocular toxicity of hydroxychloroquine.
Hariman, R; Jay, WM; Ostrowski, RA; Tehrani, R,
)
1.18

Treatment

Hydroxychloroquine (HCQ) treated group had an MD of 8 and an IQR of 5-13 for time in hospital with a 4.3% mortality rate. The non-HCQ group (G2 n = 345) had a MD of 6 and anIQR of 3-11. Hydroxychloroquines decreased mRNA expression of two sFlt-1 isoforms and its protein secretion.

ExcerptReferenceRelevance
"The hydroxychloroquine (HCQ) treated group (G1 n = 466) had an MD of 8 and an IQR of 5-13 for time in hospital with a 4.3% mortality rate, while the non-HCQ group (G2 n = 345) had an MD of 6 and an IQR of 3-11 for time in hospital with a 3.2% mortality rate."( Clinical Characteristics and Treatment Outcomes of Mild to Moderate COVID-19 Patients at Tertiary Care Hospital, Al Baha, Saudi Arabia: A Single Centre Study.
Ahmed, S; Albanghali, M; Alghamdi, S; Alzahrani, M; Anwar, S; Barakat, B; Haseeb, A; Malik, JA, 2022
)
1.2
"Hydroxychloroquine treatment decreased mRNA expression of two sFlt-1 isoforms and its protein secretion."( Hydroxychloroquine reduces soluble Flt-1 secretion from human cytotrophoblast, but does not mitigate markers of endothelial dysfunction in vitro.
Beard, S; Binder, N; Brownfoot, FC; Hannan, N; Harper, A; Kadife, E, 2022
)
2.89
"Hydroxychloroquine-treated patients were more severely ill at baseline than those who did not receive hydroxychloroquine (median ratio of partial pressure of arterial oxygen to the fraction of inspired oxygen, 223 vs."( Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19.
Baldwin, M; Barr, RG; Geleris, J; Hripcsak, G; Kubin, C; Labella, A; Manson, DK; Platt, J; Schluger, NW; Sobieszczyk, ME; Sun, Y; Zucker, J, 2020
)
1.59
"Hydroxychloroquine treatment partially improved symptoms; however, the addition of prednisolone was required for complete resolution."( Lupus Erythematosus Tumidus with Pseudolymphomatous Infiltrates: A Case Report.
Ansai, S; Hoashi, T; Ito, K; Kanda, N; Saeki, H; Umeda, Y, 2020
)
1.28
"Hydroxychloroquine and steroid treatments were started after the operation."( Systemic lupus erythematosus complicated with Castleman disease: a case-based review.
Aktay Ayaz, N; Demirkan, FG; Doğan, S; Kalyoncu Uçar, A; Sönmez, HE, 2021
)
1.34
"Hydroxychloroquine/azithromycin treatment was associated with a lower ICU admission rate (P=0.008)."( A comprehensive strategy for the early treatment of COVID-19 with azithromycin/hydroxychloroquine and/or corticosteroids: Results of a retrospective observational study in the French overseas department of Réunion Island.
Allou, N; Allyn, J; André, M; Borsu, K; Bruneau, L; Coolen-Allou, N; Dibernardo, S; Dubernet, A; Foch, E; Gauzere, L; Jabot, J; Jaffar-Bandjee, MC; Lagrange-Xelot, M; Larsen, K; Maillot, A; Masse, L; Moreau, D; Raffray, L; Renaud, S; Thomas, V, 2020
)
1.51
"The hydroxychloroquine-treated group received at least one dose within 48 hours of hospital admission."( Examination of patient characteristics and hydroxychloroquine use based on the US Food and Drug Administration's recommendation: a cross-sectional analysis in New York.
Abrahams, S; Conigliaro, J; Coppa, K; Davidson, KW; Hirsch, JS; Johnson, J; Kim, EJ; Lesser, M, 2021
)
1.36
"Hydroxychloroquine is a treatment for rheumatic disease and considered safe during pregnancy. "( Maternal exposure to hydroxychloroquine and birth defects.
Ailes, EC; Broussard, CS; Browne, ML; Carmichael, SL; Fisher, SC; Heinke, D; Howley, MM; Mitchell, AA; Pruitt, SM; Reefhuis, J; Van Zutphen, AR; Werler, MM, 2021
)
2.38
"Hydroxychloroquine treatment significantly decreased (p < 0.0001) serum level of TNF-α and significantly increased serum level of IL-10 (p < 0.0001). "( Immunomodulatory effects of hydroxychloroquine on Th1/Th2 balance in women with repeated implantation failure.
Ghaffari Novin, M; Ghasemnejad, T; Ghasemnejad-Berenji, H; Ghasemnejad-Berenji, M; Hajshafiha, M; Hashemi, SM; Ilkhanizadeh, B; Nazarian, H; Sadeghpour, S, 2018
)
2.22
"Hydroxychloroquine treatment resolved the renal glucosuria. "( Acquired renal glucosuria in an undifferentiated connective tissue disease patient with a SLC5A2 heterozygous mutation: A case report.
Chen, M; Gu, X; Wang, Y; Xu, Y, 2018
)
1.92
"Hydroxychloroquine is a treatment for lupus that is widely used based on longstanding experience and a very good safety profile."( Study of Anti-Malarials in Incomplete Lupus Erythematosus (SMILE): study protocol for a randomized controlled trial.
Arriens, C; Chinchilli, VM; Chong, BF; Ishimori, ML; James, JA; Kamen, DL; Karp, DR; Liao, D; Olsen, NJ; Wallace, DJ, 2018
)
1.2
"Hydroxychloroquine is a valuable treatment for morphea because of its high response rate and low rate of adverse effects; however, prospective studies are needed to determine its true efficacy."( Treatment of morphea with hydroxychloroquine: A retrospective review of 84 patients at Mayo Clinic, 1996-2013.
Blixt, EK; Drage, LA; El-Azhary, RA; Kumar, AB; Wetter, DA, 2019
)
2.26
"Hydroxychloroquine-treated lupus patients showed a lower incidence of thromboembolic disease."( Chronic hydroxychloroquine improves endothelial dysfunction and protects kidney in a mouse model of systemic lupus erythematosus.
Algieri, F; Duarte, J; Gálvez, J; Gómez-Guzmán, M; Gómez-Morales, M; Jiménez, R; López-Farré, AJ; O'Valle, F; Pérez-Vizcaino, F; Romero, M; Sabio, JM; Sánchez, M; Zarzuelo, MJ, 2014
)
1.56
"Hydroxychloroquine treatment did not alter the serum levels of CCL2, CXCL8, CXCL9 or CXCL10 in patients with OA of the knees, although increased serum levels correlated with aging for all subjects, including controls."( CCL2, CXCL8, CXCL9 and CXCL10 serum levels increase with age but are not altered by treatment with hydroxychloroquine in patients with osteoarthritis of the knees.
Abramo, C; Almeida, CS; Bonfante, HL; Grunewald, STF; Levy, RA; Teixeira, HC, 2017
)
2.11
"Hydroxychloroquine (10 µM) treatment induced the phosphorylation of ERK, SAPK/JNK and p38."( 15-hydroxyprostaglandin dehydrogenase is upregulated by hydroxychloroquine in rheumatoid arthritis fibroblast-like synoviocytes.
Chang, SH; Kim, HJ; Lee, HY; Lee, S; Nah, SS; Won, H, 2015
)
1.38
"Hydroxychloroquine-treatment was associated with a higher rate of live births (67% group A vs 57% group B; P = .05) and a lower prevalence of antiphospholipid antibodies-related pregnancy morbidity (47% group A vs 63% B; P = .004). "( The impact of hydroxychloroquine treatment on pregnancy outcome in women with antiphospholipid antibodies.
Cuadrado, MJ; Hunt, BJ; Khamashta, MA; Lliso, G; Sciascia, S; Talavera-Garcia, E, 2016
)
2.24
"Hydroxychloroquine treatment appears to be safe in this setting."( The association of systemic lupus erythematosus and myasthenia gravis: a series of 17 cases, with a special focus on hydroxychloroquine use and a review of the literature.
Amoura, Z; Benveniste, O; Cacoub, P; Chapelon, C; Costedoat-Chalumeau, N; De Gennes, C; Eymard, B; Haroche, J; Jallouli, M; Le Thi Huong, D; Leroux, G; Piette, JC; Saadoun, D; Wechsler, B, 2012
)
1.31
"The hydroxychloroquine-treated group achieved significant improvements in quality of life as assessed by the global symptom severity score and the LAMY-7 (a quality of life index designed by Lamy, 7th revision) at 12 weeks (P < 0.01 and P < 0.05, respectively). "( Impact of hydroxychloroquine therapy on chronic urticaria: chronic autoimmune urticaria study and evaluation.
Bonfield, J; Boyle, MJ; Dobson, P; Loewenthal, M; Reeves, GE, 2004
)
1.28
"Hydroxychloroquine treatment during gestation and lactation appeared to be safe. "( Follow-up of infants exposed to hydroxychloroquine given to mothers during pregnancy and lactation.
Biasini, C; Chirico, G; Faden, D; Frassi, M; Lojacono, A; Marchesi, A; Motta, M; Tincani, A; Zatti, S; Zinzini, E, 2005
)
2.05
"Hydroxychloroquine, a common treatment for SLE, can improve lipid profiles and should be considered for all patients with SLE."( Management of dyslipidemia in children and adolescents with systemic lupus erythematosus.
Ardoin, SP; Sandborg, C; Schanberg, LE, 2007
)
1.06
"The treatment with hydroxychloroquine probably explains the decreased immune response with negative serology and subsequent reinfection in our patient. "( Symptomatic severe acute respiratory syndrome coronavirus 2 reinfection in a lupus patient treated with hydroxychloroquine: a case report.
Anthierens, T; Bartiaux, M; Goldberg, O; Maes, P; Muyldermans, A; Piérard, D; Soetens, O; Van den Wijngaert, S; Wawina-Bokalanga, T; Wybo, I, 2021
)
1.16
"Treatment with hydroxychloroquine alone or in combination with azithromycin for at least 24 hours and with a baseline ECG and at least one ECG after 24 hours of therapy."( Changes in QTc interval after hydroxychloroquine therapy in patients with COVID-19 infection: a large, retrospective, multicentre cohort study.
Abdalla, S; Ahmed, R; Al Awadhi, A; Al Falasi, O; Alattar, Y; AlKaabi, S; Almubarak, A; Altaha, Z; Ansel Benette, H; El Kadri, M; Hillis, A; Oulhaj, A; Panikkaveetil, B; Saifuddin, M, 2022
)
1.36
"Treatment with hydroxychloroquine might not be enough to lower the cardiovascular risk significantly in diabetes patients with Sjögren syndrome."( Sjögren syndrome is a hidden contributor of macrovascular and microvascular complications in patients with type 2 diabetes.
Leong, PY; Su, YJ; Wang, YH; Wei, JC, 2022
)
1.06
"Treatment with hydroxychloroquine did not result in a significantly greater rate of decline in SARS-CoV-2 oropharyngeal viral load compared to standard care alone during the first five days."( A pragmatic randomized controlled trial reports lack of efficacy of hydroxychloroquine on coronavirus disease 2019 viral kinetics.
Berdal, JE; Dalgard, O; Eskesen, A; Jonassen, CM; Kvale, D; Lyngbakken, MN; Olsen, IC; Omland, T; Rangberg, A; Rueegg, CS; Røsjø, H, 2020
)
1.13
"Treatment with hydroxychloroquine (HCQ) and lopinavir/ritonavir did not show any mortality benefit in either the RECOVERY or World Health Organization (WHO) Solidarity trials."( Randomised controlled trials for COVID-19: evaluation of optimal randomisation methodologies-need for data validation of the completed trials and to improve ongoing and future randomised trial designs.
Emani, SR; Emani, VR; Goswami, S; Nandanoor, D; Reddy, NK; Reddy, R, 2021
)
0.96
"Treatment with hydroxychloroquine and azithromycin was associated with lower mortality in these patients."( COVID-19 mortality risk factors in older people in a long-term care center.
Anglada, M; Boix, M; Castillo, J; Curbelo, Y; Garibaldi, P; Gonzalez, E; Heras, E; Llovera, R; Llull, P; Mendoza, O; Miralles, JC; Piqué, JM; Valero, O, 2021
)
0.96
"Treatment with hydroxychloroquine (HCQ) without daily GCs may benefit patients by minimising the cumulative dose of GCs, but clinical experience with HCQ monotherapy is limited."( Initial hydroxychloroquine monotherapy in systemic lupus erythematosus: report of three cases.
Ichikawa, K; Kirino, Y; Kishimoto, D; Kunishita, Y; Nakajima, H; Takase-Minegishi, K; Yoshimi, R, 2021
)
1.4
"Treatment with hydroxychloroquine at 400mg per day and discontinuation of topical tacrolimus resulted in complete remission of the lesions within 2 months."( [Granulomatous periocular eruption].
Leccia, MT; Moncourier, M; Pinel, N; Pralong, P; Templier, I,
)
0.47
"Treatment with hydroxychloroquine, topical clobetasol and topical tretinoin resulted in flattening and clearing of the lesion."( Discoid chronic lupus erythematosus at the site of a previously healed cutaneous leishmaniasis: an example of isotopic response.
Bardazzi, F; Giacomini, F; Misciali, C; Patrizi, A; Savoia, F,
)
0.47
"Treatment with hydroxychloroquine and local steroid injection resulted in complete hair regrowth but recurrence was noted."( Linear lupus panniculitis of the scalp presenting as alopecia along Blaschko's lines: a distinct variant of lupus panniculitis in East Asians?
Chen, YA; Hsu, CK; Lee, JY; Yang, CC, 2012
)
0.72
"Treatment with hydroxychloroquine was associated with increased thickness of the outer band of the retinal pigment epithelium layer. "( A retrospective evaluation of the effect of hydroxyquinine on RPE thickness.
Beiran, I; Chassid, O; Pikkel, J; Sharabi-Nov, A, 2013
)
0.74
"A treatment with hydroxychloroquine and topical corticosteroïds was effective in 3 months."( [Bullous localization of a lupus erythematosus induced by radiotherapy].
Beylot Barry, M; Beylot, C; Doutre, MS; Krim, E; Marrot, F; Noblesse, I; Vergier, B, 2002
)
0.64
"Treatment with hydroxychloroquine cleared the cutaneous lesions."( Subacute cutaneous lupus erythematosus in childhood.
Amato, L; Berti, S; Coronella, G; Fabbri, P; Moretti, S,
)
0.47
"Treatment with hydroxychloroquine again produced an excellent response."( Discoid lupus erythematosus involving the eyelids.
Buntin, DM; Donzis, PB; Gately, LE; Insler, MS, 1984
)
0.61
"Treatment with hydroxychloroquine sulfate, but not indomethacin, reduced the photosensitivity both to sunlight and to artificial UV-A light."( Hydroa vacciniforme: diagnosis and therapy.
Goldgeier, MH; Lucky, AW; McCarthy, MJ; McGuire, J; Nordlund, JJ; Sibrack, LA, 1982
)
0.6
"Mice treated with hydroxychloroquine and IgG-APS showed significantly smaller thrombi that persisted for a shorter period of time compared with animals treated with IgG-APS and placebo."( Hydroxychloroquine reverses thrombogenic properties of antiphospholipid antibodies in mice.
Anderson, G; Barker, JH; Edwards, MH; Harris, EN; Liu, X; Pierangeli, S, 1997
)
2.06

Toxicity

Antimalarial drugs including chloroquine, its less toxic quinolone-derivative hydroxychloroquine (HCQ), and quinacrine have become cornerstones in the treatment of autoimmune diseases. Favipiravir is a safe effective alternative for hydroxy chlorineoquine in mild or moderate COVID-19 infected patients.

ExcerptReferenceRelevance
"Six cases of toxic myopathy and/or neuropathy with chloroquine and/or hydroxychloroquine therapy are described."( Chloroquine neuromyotoxicity. Clinical and pathologic perspective.
Chou, SM; Estes, ML; Ewing-Wilson, D; Hanson, M; Mitsumoto, H; Ratliff, NB; Shirey, E, 1987
)
0.51
" Maculopathy after short-term therapy was identified as a side-effect which is rarely considered."( Ocular toxicity of antimalarials in dermatology: a survey of current practice.
Cox, NH; Paterson, WD, 1994
)
0.29
" We believe special attention should be given to elderly patients who are being treated with hydroxychloroquine because their retinal pigment epithelium may be more susceptible to the toxic effects of this drug."( Hydroxychloroquine toxicity despite normal dose therapy.
Falcone, PM; Lou, PL; Paolini, L, 1993
)
1.95
"5%), one treated for RA and the other treated for SLE, developed characteristic hydroxychloroquine related toxic retinal lesions after cumulative doses of 700 g (6."( Retinal toxicity in long term hydroxychloroquine treatment.
Mavrikakis, M; Papazoglou, S; Rougas, K; Sfikakis, PP; Vaiopoulos, G, 1996
)
0.81
" The proportion of adverse events was lowest in group 1 (14%) and highest in groups 3 and 4 (25%)."( Toxicity profile of dual methotrexate combinations with gold, hydroxychloroquine, sulphasalazine and minocycline in rheumatoid arthritis patients.
Caspi, D; Elkayam, O; Segal, R; Yaron, M; Zhukovsky, G, 1997
)
0.54
" There were no unexpected adverse events at any time or between-group differences in the distribution of adverse events during the double blind segment."( Safety and efficacy of hydroxychloroquine as maintenance therapy for rheumatoid arthritis after combination therapy with methotrexate and hydroxychloroquine.
Bell, CL; Clegg, DO; Dietz, F; Duffy, J; Germain, BF; Hurd, E; Sleckman, J; Wall, B; Wallace, DJ; Willkens, RF, 1997
)
0.61
" The most frequently observed serious side effect is retinal toxicity; however, case reports have described HCQ induced neuromyotoxicity."( Hydroxychloroquine neuromyotoxicity.
Ang, LC; Bell, MJ; Stein, M, 2000
)
1.75
" Adverse effects were attributed to specific medications using the Naranjo scoring method."( Toxicity of anti-rheumatic drugs in a randomized clinical trial of early rheumatoid arthritis.
Bijlsma, JW; Blaauw, AA; Brus, HL; Jacobs, JW; Jahangier, ZN; Schenk, Y; ter Borg, EJ; van Albada-Kuipers, GA; van Der Veen, MJ; van Jaarsveld, CH, 2000
)
0.31
"Fifty-five per cent of the patients suffered from adverse effect(s)."( Toxicity of anti-rheumatic drugs in a randomized clinical trial of early rheumatoid arthritis.
Bijlsma, JW; Blaauw, AA; Brus, HL; Jacobs, JW; Jahangier, ZN; Schenk, Y; ter Borg, EJ; van Albada-Kuipers, GA; van Der Veen, MJ; van Jaarsveld, CH, 2000
)
0.31
"No adverse effect could be classified as definitely related to either SAARDs or NSAIDs by the Naranjo scoring method."( Toxicity of anti-rheumatic drugs in a randomized clinical trial of early rheumatoid arthritis.
Bijlsma, JW; Blaauw, AA; Brus, HL; Jacobs, JW; Jahangier, ZN; Schenk, Y; ter Borg, EJ; van Albada-Kuipers, GA; van Der Veen, MJ; van Jaarsveld, CH, 2000
)
0.31
" Longterm safety assessment is difficult for a number of reasons: there are relatively few trials that have followed patients beyond 5 years and the use of a combination of DMARD therapy with nonsteroidal antiinflammatory drugs and corticosteroids complicates the assessment of an observed adverse event with a particular drug."( Disease modifying antirheumatic drugs: longterm safety issues.
Capell, HA, 2001
)
0.31
"All cases arose because of failure by physicians to avoid dosing above published safe levels."( Hydroxychloroquine and chloroquine retinopathy: screening for drug toxicity.
Browning, DJ, 2002
)
1.76
" We revised the antimalarials use in Rheumatology, their utility, doses, adverse events and risk factors as cumulate doses, ideal daily doses, renal function and ophthalmological reviews recommendations."( [Eye toxicity of antimalarial agents].
Cabana Vázquez, M; Graña Gil, J; Sánchez Meizoso, MO; Vázquez González, A, 2002
)
0.31
"To evaluate rates on the adverse side effect and discontinuation of second-line drugs frequently used in the treatment of rheumatoid arthritis (RA)."( [Retrospective study of adverse events in patients with rheumatoid arthritis treated with second-line drugs].
Jiang, L; Ni, L; Zhao, N, 2002
)
0.31
" Sulfasalazine users reported adverse events including upper abdominal trouble (39."( [Retrospective study of adverse events in patients with rheumatoid arthritis treated with second-line drugs].
Jiang, L; Ni, L; Zhao, N, 2002
)
0.31
" Significant, either reversible or irreversible central visual loss associated with the drugs is very rare, but an important side effect that can warrant discontinuation of therapy."( Ocular toxicity due to chloroquine and hydroxychloroquine: electrophysiological and visual function correlates.
Tzekov, R, 2005
)
0.6
"Influenza vaccination in SLE patients with quiescent disease is safe but is less effective than in controls."( Safety and efficacy of influenza vaccination in systemic lupus erythematosus patients with quiescent disease.
Benne, CA; Bijl, M; De Vries, JJ; Holvast, A; Horst, G; Huckriede, A; Kallenberg, CG; Wilschut, J, 2006
)
0.33
" This trial was designed to determine whether HCQ was efficacious and safe in Indian patients with RA."( Efficacy and safety of hydroxychloroquine sulphate in rheumatoid arthritis: a randomized, double-blind, placebo controlled clinical trial--an Indian experience.
Agarwal, GG; Chauhan, RS; Das, SK; Mathur, DS; Pareek, A; Srivastava, R; Wanchu, A, 2007
)
0.65
" The adverse events reported were mild to moderate and none of the patients reported any serious adverse events or ocular toxicity in this study."( Comparative study of efficacy and safety of hydroxychloroquine and chloroquine in polymorphic light eruption: a randomized, double-blind, multicentric study.
Chandurkar, N; Khopkar, U; Naik, GS; Pareek, A; Sacchidanand, S,
)
0.39
" Its use has been associated with ocular side effects; the most concerning is toxic maculopathy."( Retinal toxicity secondary to Plaquenil therapy.
Hanna, B; Holdeman, NR; Schiffman, JS; Tang, RA, 2008
)
0.35
"Withdrawal of the medication is the only effective treatment for Plaquenil toxicity and, even then, the toxic effects may progress because of the slow clearance of the drug."( Retinal toxicity secondary to Plaquenil therapy.
Hanna, B; Holdeman, NR; Schiffman, JS; Tang, RA, 2008
)
0.35
"To assess the incidence and severity of disease modifying antirheumatic drug (DMARD)-induced adverse effects (AE) in patients with rheumatoid arthritis (RA) taking/not taking glucocorticoids (GC)."( Low-dose prednisolone in rheumatoid arthritis: adverse effects of various disease modifying antirheumatic drugs.
Arnold, S; Baerwald, CG; Häntzschel, H; Malysheva, OA; Pierer, M; Wagner, U; Wahle, M, 2008
)
0.35
" In at least one patient, the technique was able to detect the early onset of Plaquenil toxicity followed by reversal of the toxic effects after the medication was discontinued."( Using multifocal ERG ring ratios to detect and follow Plaquenil retinal toxicity: a review : Review of mfERG ring ratios in Plaquenil toxicity.
Lyons, JS; Severns, ML, 2009
)
0.35
"Initial remission targeted therapy with the FIN-RACo DMARD combination in early RA is safe for kidneys and does not induce more short- or long-term renal complications compared to traditional therapy with a single DMARD."( Renal safety of initial combination versus single DMARD therapy in patients with early rheumatoid arthritis: an 11-year experience from the FIN-RACo Trial.
Hannonen, PJ; Kaipiainen-Seppänen, OA; Karjalainen, AH; Karstila, KL; Korpela, MM; Leirisalo-Repo, M; Möttönen, TT; Mustonen, JT; Rantalaiho, VM,
)
0.13
" Although these agents have largely revolutionized the treatment of the systemic autoimmune diseases, adverse reactions, which can be serious and life threatening, to the various immunosuppressive agents used in the treatment of CTD can occur."( Toxicity and monitoring of immunosuppressive therapy used in systemic autoimmune diseases.
Baughman, R; Decker, C; Meyer, KC, 2010
)
0.36
" Therefore, in the author's opinion, HCQ is safe for the treatment of autoimmune diseases during pregnancy."( Hydroxychloroquine in systemic lupus erythematosus and rheumatoid arthritis and its safety in pregnancy.
Abarientos, C; Aronow, WS; Ash, JY; Chao, CP; Shapiro, DL; Sperber, K, 2011
)
1.81
" A growing body of research suggests that antimalarials are safe during pregnancy."( Ocular toxicity in children exposed in utero to antimalarial drugs: review of the literature.
Koren, G; Osadchy, A; Ratnapalan, T, 2011
)
0.37
" Careful screening with multiple tests can detect toxic damage before prominent loss of the outer nuclear layer."( Comparison of screening procedures in hydroxychloroquine toxicity.
Marmor, MF, 2012
)
0.65
"Given the infrequent occurrence of hydroxychloroquine toxic effects, few data are available about the presenting features and long-term follow-up of patients with hydroxychloroquine retinopathy, making it difficult to surmise the clinical course of patients after cessation of drug treatment."( Progression of hydroxychloroquine toxic effects after drug therapy cessation: new evidence from multimodal imaging.
Brenner, M; Bryar, PJ; Fawzi, AA; Jampol, LM; Mititelu, M; Wong, BJ, 2013
)
1.02
"To report functional and structural findings of hydroxychloroquine retinal toxic effects after drug therapy discontinuation."( Progression of hydroxychloroquine toxic effects after drug therapy cessation: new evidence from multimodal imaging.
Brenner, M; Bryar, PJ; Fawzi, AA; Jampol, LM; Mititelu, M; Wong, BJ, 2013
)
1
"A retrospective medical record review was performed to identify patients taking hydroxychloroquine who were screened for toxic effects from January 1, 2009, through August 31, 2012, in the eye centers of Northwestern University and the University of Southern California."( Progression of hydroxychloroquine toxic effects after drug therapy cessation: new evidence from multimodal imaging.
Brenner, M; Bryar, PJ; Fawzi, AA; Jampol, LM; Mititelu, M; Wong, BJ, 2013
)
0.97
"Seven consecutive patients diagnosed as having hydroxychloroquine retinal toxic effects."( Progression of hydroxychloroquine toxic effects after drug therapy cessation: new evidence from multimodal imaging.
Brenner, M; Bryar, PJ; Fawzi, AA; Jampol, LM; Mititelu, M; Wong, BJ, 2013
)
1
"Retinal toxic effects."( Progression of hydroxychloroquine toxic effects after drug therapy cessation: new evidence from multimodal imaging.
Brenner, M; Bryar, PJ; Fawzi, AA; Jampol, LM; Mititelu, M; Wong, BJ, 2013
)
0.74
"9 years (age range, 25-74 years) developed retinal toxic effects after using hydroxychloroquine for a mean of 10."( Progression of hydroxychloroquine toxic effects after drug therapy cessation: new evidence from multimodal imaging.
Brenner, M; Bryar, PJ; Fawzi, AA; Jampol, LM; Mititelu, M; Wong, BJ, 2013
)
0.97
"Preservation of the external limiting membrane carries a positive prognostic value in hydroxychloroquine toxic effects because it may be associated with regeneration of the photoreceptor layer and with potential functional visual improvement on static perimetry."( Progression of hydroxychloroquine toxic effects after drug therapy cessation: new evidence from multimodal imaging.
Brenner, M; Bryar, PJ; Fawzi, AA; Jampol, LM; Mititelu, M; Wong, BJ, 2013
)
0.97
"There is no consensus on whether it is safe to re-administer tumor necrosis factor-alpha (TNFα) inhibitors in patients with rheumatoid arthritis (RA) or ankylosing spondylitis (AS) flared after withdrawal of TNFα inhibitors due to active tuberculosis (TB)."( Safe re-administration of tumor necrosis factor-alpha (TNFα) inhibitors in patients with rheumatoid arthritis or ankylosing spondylitis who developed active tuberculosis on previous anti-TNFα therapy.
Ju, JH; Kwok, SK; Park, KS; Park, SH; Suh, YS; Yoon, CH, 2014
)
0.4
" No previous studies have assessed abnormal weight gain as a putative side effect of long-term doxycycline treatment; thus, the objective of the present study was to characterize this phenomenon."( Abnormal weight gain and gut microbiota modifications are side effects of long-term doxycycline and hydroxychloroquine treatment.
Angelakis, E; Armougom, F; Giorgi, R; Kankoe, S; Lagier, JC; Million, M; Raoult, D, 2014
)
0.62
" And it is safe for pregnant women and fetuses."( [Prospective study of efficacy and safety of hydroxychloroquine in pregnant patients with systemic lupus erythematosus].
Gao, Z; Hao, D; Jin, D; Liu, J; Xu, D; Zhao, Y, 2014
)
0.66
" Treatment-related adverse events (AE) included grade 1 to 2 nausea, diarrhea, fatigue, weight loss, anemia, and elevated creatinine."( Combined autophagy and HDAC inhibition: a phase I safety, tolerability, pharmacokinetic, and pharmacodynamic analysis of hydroxychloroquine in combination with the HDAC inhibitor vorinostat in patients with advanced solid tumors.
Amaravadi, RK; Carew, JS; Curiel, TJ; Davis, LE; Espitia, CM; Giles, FJ; Mahalingam, D; Mita, AC; Mita, M; Nawrocki, ST; Sarantopoulos, J; Wood, L, 2014
)
0.61
"Preoperative autophagy inhibition with HCQ plus gemcitabine is safe and well tolerated."( Safety and Biologic Response of Pre-operative Autophagy Inhibition in Combination with Gemcitabine in Patients with Pancreatic Adenocarcinoma.
Bahary, N; Bao, P; Bartlett, DL; Boone, BA; Espina, V; Liotta, LA; Lotze, MT; Loughran, P; Moser, AJ; Normolle, DP; Singhi, AD; Wu, WC; Zeh, HJ; Zureikat, AH, 2015
)
0.42
" Study medications were generally safe and well tolerated."( Efficacy and safety of fixed dose combination of atorvastatin and hydroxychloroquine: a randomized, double-blind comparison with atorvastatin alone among Indian patients with dyslipidemia.
Agarwal, M; Agrawal, N; Chandurkar, N; Dhruv, U; Khyalappa, R; Legha, R; Mathur, SL; Pai, V; Pareek, A; Parmar, M; Pednekar, S; Salkar, HR; Saxena, S; Sriram, U; Thulaseedharan, NK, 2015
)
0.65
" Cessation of at least one of MTX, SSZ or HCQ occurred because of an adverse event in 38%, remission in 7% and incomplete response in 28% of patients."( Safety and retention of combination triple disease-modifying anti-rheumatic drugs in new-onset rheumatoid arthritis.
Cummins, L; Duggan, E; Katikireddi, VS; Pahau, H; Shankaranarayana, S; Su, KY; Thomas, R; Videm, V, 2015
)
0.42
" For this reason, the key question is weather these drugs are absolutely safe and can be long term used in all lupus patients as a background therapy? Potential non-specific side effects occur very rare and are usually minor and last for short period."( [Current view on chloroquine derivative treatment from rheumatologist perspective and possible ocular side effects].
Gaca-Wysocka, M; Grzybowski, A; Leszczyński, P; Pawlak-Buś, K, 2016
)
0.43
" Most of these adverse effects were mild, did not require discontinuation of the medication, and resolved after stopping the medication or decreasing the dose."( The Comparative Safety of Multiple Alternative Agents in Refractory Chronic Urticaria Patients.
Khan, DA; Seth, S,
)
0.13
"The use of alternative agents for the treatment of chronic urticaria angioedema is generally safe when proper laboratory and clinical monitoring is observed."( The Comparative Safety of Multiple Alternative Agents in Refractory Chronic Urticaria Patients.
Khan, DA; Seth, S,
)
0.13
"The main aim of this study was to examine the differences between triple therapy (T: SSZ and HCQ added to MTX) and etanercept (E) added to MTX with regard to the infectious and gastrointestinal (GI) adverse events (AEs) reported in The Rheumatoid Arthritis Comparison of Active Therapies Trial."( Rheumatoid arthritis triple therapy compared with etanercept: difference in infectious and gastrointestinal adverse events.
Brophy, MT; Chang, BH; Hannagan, K; O'Dell, JR; Quach, LT; Soe Thwin, S, 2017
)
0.46
" Adhering to careful weight-based dosing can significantly reduce the risk of this adverse event and is recommended in recent guidelines."( Hydroxychloroquine dosing in immune-mediated diseases: implications for patient safety.
Gianfrancesco, MA; Haserodt, S; Izadi, Z; Jafri, K; Schmajuk, G; Shiboski, S; Sirota, M; Trupin, L; Yazdany, J, 2017
)
1.9
"Treatment of chronic Q fever with TET plus QNL appears to be a safe alternative for TET plus HCQ, for example, if TET plus HCQ cannot be tolerated due to side effects."( Treatment of Chronic Q Fever: Clinical Efficacy and Toxicity of Antibiotic Regimens.
Bleeker-Rovers, CP; de Regt, MJA; Hoepelman, AIM; Kampschreur, LM; Oosterheert, JJ; van Roeden, SE; Wever, PC, 2018
)
0.48
"Antimalarial drugs including chloroquine, its less toxic quinolone-derivative hydroxychloroquine (HCQ), and quinacrine have become cornerstones in the treatment of autoimmune diseases including systemic lupus, rheumatoid arthritis, sarcoidosis, and Sjogren syndrome; cutaneous disorders, antiphospholipid syndrome, and have recently been employed at higher dioses in oncology."( Hydroxychloroquine: balancing the need to maintain therapeutic levels with ocular safety: an update.
Abdulaziz, N; McCune, WJ; Shah, AR, 2018
)
2.15
" At least one side effect was reported by 19."( Treating lupus patients with antimalarials: analysis of safety profile in a single-center cohort.
Alessandri, C; Ceccarelli, F; Conti, F; Garufi, C; Massaro, L; Miranda, F; Morello, F; Moscarelli, E; Perricone, C; Spinelli, FR; Truglia, S; Valesini, G, 2018
)
0.48
"The results of this study suggested that, with attention paid to possible adverse events immediately after initiation, HCQ may be initiated as a mainstay of SLE therapy in Japanese patients, either as a concomitant medication in the remission induction phase, as a maintenance therapy, or as a monotherapy."( Effectiveness and safety of hydroxychloroquine therapy with or without corticosteroid in patients with systemic lupus erythematosus.
Fukuyo, S; Hanami, K; Inoue, Y; Iwata, S; Kubo, S; Miyagawa, I; Nakano, K; Nakayamada, S; Tanaka, Y; Ueno, M, 2019
)
0.81
" Arthralgias and arthritis are a common immune-related adverse event (IrAE), well described in the literature (Pardoll Nat Rev Cancer 12:252-264, 2012; Diesendruck and Benhar Drug Resist Updat 30:39-47, 2017; Cappelli et al."( Hydroxychloroquine is a safe and effective steroid-sparing agent for immune checkpoint inhibitor-induced inflammatory arthritis.
Basappa, NS; Chu, Q; Kolinsky, M; Lyddell, C; Roberts, J; Smylie, M; Walker, J; Ye, C, 2019
)
1.96
" Adverse events were reported in 58 (62%) of 93 patients in the upadacitinib group versus 52 (55%) of 94 in the placebo group."( Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial.
Chu, AD; Deodhar, A; Everding, A; Kim, TH; Kishimoto, M; Maksymowych, WP; Pangan, AL; Sieper, J; Song, IH; Sui, Y; van den Bosch, F; van der Heijde, D; Wang, X, 2019
)
0.51
" An intake of HCQ is safe during pregnancy and breastfeeding according to the current state of knowledge and is protective for mother and child in patients with systemic lupus erythematosus."( [Safety management of the treatment with antimalarial drugs in rheumatology. Interdisciplinary recommendations based on a systematic literature search].
Detert, J; Fiehn, C; Hadjiski, D; Krüger, K; Ness, T; Specker, C; Weseloh, C, 2020
)
0.56
" An intake of HCQ is safe during pregnancy and breastfeeding according to the current state of knowledge and is protective for mother and child in patients with systemic lupus erythematosus."( Safety management in treatment with antimalarials in rheumatology. Interdisciplinary recommendations on the basis of a systematic literature review.
Detert, J; Fiehn, C; Hadjiski, D; Krüger, K; Ness, T; Specker, C; Weseloh, C, 2021
)
0.62
" These interventions are generalizable and can promote safe and guideline-based care."( Improving Hydroxychloroquine Dosing and Toxicity Screening at a Tertiary Care Ambulatory Center: A Quality Improvement Initiative.
Farrer, C; Gakhal, N; Gottheil, S; Koppikar, S, 2021
)
1.02
" However, evidence of efficacy remains limited, and adverse events can be associated with its use."( Case Report: Hepatotoxicity Associated with the Use of Hydroxychloroquine in a Patient with COVID-19.
Antunes de Brito, CA; Falcão, MB; Filgueiras Filho, NM; Pamplona de Góes Cavalcanti, L, 2020
)
0.81
" Food and Drug Administration's Adverse Event Reporting System (FAERS) (>13 million total reports) were used."( Safety signals for QT prolongation or Torsades de Pointes associated with azithromycin with or without chloroquine or hydroxychloroquine.
Brown, JD; Cicali, B; Henriksen, CH; Sarayani, A, 2021
)
0.83
" Adverse drug effects of the antimalarial therapy were suspected-specifically, muscular and cardiac toxicity."( [A rare cause of impaired general condition: Muscular and cardiac toxicity of antimalarials].
Costedoat-Chalumeau, N; Dion, J; Lenfant, T; Maisonobe, T, 2020
)
0.56
"The proposed doses of chloroquine (CQ) and hydroxychloroquine (HCQ) for treatment of COVID-19 (1000 mg/day for 10 days, CQ; 800 mg first day then 400 mg/day for 5 days, HCQ) in many guidelines worldwide, are considerably higher than the maximum recommended daily safe doses of both agents (≤2."( Chloroquine and Hydroxychloroquine Retinal Toxicity Consideration in the Treatment of COVID-19.
Chang, A; Lai, CC; Lai, TYY; Lam, DSC; Mieler, WF; Ruamviboonsuk, P,
)
0.74
" However, some of these medications have potential cardiac adverse effects."( Cardiac safety of off-label COVID-19 drug therapy: a review and proposed monitoring protocol.
Lazar, S; Naksuk, N; Peeraphatdit, TB, 2020
)
0.56
" The review elaborates the mechanism of action, safety (side effects, adverse effects, toxicity) and details of clinical trials for chloroquine and hydroxychloroquine to benefit the clinicians, medicinal chemist, pharmacologist actively involved in controlling the pandemic and to provide therapeutics for the treatment of COVID-19 infection."( A systematic review on use of aminoquinolines for the therapeutic management of COVID-19: Efficacy, safety and clinical trials.
Masand, N; Patil, VM; Singhal, S, 2020
)
0.76
" Adverse event profile of this drug when used as prophylaxis is not well known in the literature."( HyPE study: hydroxychloroquine prophylaxis-related adverse events' analysis among healthcare workers during COVID-19 pandemic: a rising public health concern.
Dey, T; Dhar, D; Khan, MA; Manjula, J; Mondal, MS; Nagaraja, BS; Pratik, K; Ramesh, KN; Rutul, SD; Saha, S; Sangeeth, TA; Singh, V, 2020
)
0.94
"Of the 166 participants, at least one adverse event was experienced by 37."( HyPE study: hydroxychloroquine prophylaxis-related adverse events' analysis among healthcare workers during COVID-19 pandemic: a rising public health concern.
Dey, T; Dhar, D; Khan, MA; Manjula, J; Mondal, MS; Nagaraja, BS; Pratik, K; Ramesh, KN; Rutul, SD; Saha, S; Sangeeth, TA; Singh, V, 2020
)
0.94
"A higher incidence of adverse events was observed when results were compared with studies involving patients on long-term hydroxychloroquine therapy."( HyPE study: hydroxychloroquine prophylaxis-related adverse events' analysis among healthcare workers during COVID-19 pandemic: a rising public health concern.
Dey, T; Dhar, D; Khan, MA; Manjula, J; Mondal, MS; Nagaraja, BS; Pratik, K; Ramesh, KN; Rutul, SD; Saha, S; Sangeeth, TA; Singh, V, 2020
)
1.14
" Safety was evaluated via the frequency of adverse events over a period of three months."( Efficacy and Safety of Hydroxychloroquine Therapy for Systemic Lupus Erythematosus Patients Depend on Administration Dose.
Dobashi, H; Fahmy Mansour, MM; Kadowaki, N; Kameda, T; Kato, M; Miyagi, T; Nakashima, S; Shimada, H; Wakiya, R, 2020
)
0.87
" However, its cutaneous adverse effects among health care workers and COVID patients taking prophylactic doses has not been reported."( Cutaneous side effects of hydroxychloroquine in health care workers in a COVID referral hospital - implications for clinical practice.
Deepak, D; Khurana, A; Mathachan, SR; Sardana, K; Sinha, S, 2022
)
1.02
" Secondary endpoint was change in fasting plasma glucose (FPG), post prandial plasma glucose (PPG), body weight and any adverse reaction including no of hypoglycemic events, as well as a change in the percentage of subjects with A1C < 7."( Efficacy and safety of hydroxychloroquine as add-on therapy in uncontrolled type 2 diabetes patients who were using two oral antidiabetic drugs.
Chakravarti, HN; Nag, A, 2021
)
0.93
" No differences were found in adverse events between the 2 groups."( Efficacy and safety of low-dose glucocorticoids combined with methotrexate and hydroxychloroquine in the treatment of early rheumatoid arthritis: A single-center, randomized, double-blind clinical trial.
Du, H; Fan, J; Hua, L; Shi, X; Wu, H; Ying, M, 2020
)
0.79
"Low-dose GCs combined with MTX and HCQ significantly achieves disease remission indexed by ACR20 and DAS28-ESR, and improves clinical and radiological outcomes in ERA patients at the early stage, with superiority over placebo + MTX + HCQ, without enhancing adverse reactions."( Efficacy and safety of low-dose glucocorticoids combined with methotrexate and hydroxychloroquine in the treatment of early rheumatoid arthritis: A single-center, randomized, double-blind clinical trial.
Du, H; Fan, J; Hua, L; Shi, X; Wu, H; Ying, M, 2020
)
0.79
" Our primary outcomes were the continuation rate of HCQ treatment for 1 year and adverse events (AEs) during the treatment."( Continuation Rate, Safety and Efficacy of Hydroxychloroquine Treatment in a Retrospective Cohort of Systemic Lupus Erythematosus in a Japanese Municipal Hospital.
Hosokawa, Y; Oiwa, H, 2020
)
0.82
"Two authors independently searched PubMed and EMBASE databases for randomized controlled trials (RCTs) of adults comparing the adverse events (AEs) of HCQ versus placebo for any indication."( Hydroxychloroquine safety: A meta-analysis of randomized controlled trials.
Al-Tawfiq, JA; Alireza, KH; Alshehri, S; Eljaaly, K,
)
1.57
" Secondary outcomes were duration of hospital stay, length of intensive care unit stay, 28-day mortality, effect of early or late administration of IFN on mortality, adverse effects, and complications during the hospitalization."( A Randomized Clinical Trial of the Efficacy and Safety of Interferon β-1a in Treatment of Severe COVID-19.
Abbasian, L; Davoudi-Monfared, E; Hajiabdolbaghi, M; Kazemzadeh, H; Khalili, H; Rahmani, H; Salehi, M; Yekaninejad, MS, 2020
)
0.56
"To assess clinical outcomes and adverse drug events in patients hospitalised with COVID-19 treated with off-label hydroxychloroquine (HCQ) and azithromycin (Az)."( Clinical outcomes and adverse events in patients hospitalised with COVID-19, treated with off-label hydroxychloroquine and azithromycin.
Bannan, C; Bergin, C; Carr, B; Clarke, S; Coghlan, M; Doyle, C; Kelly, M; Melanophy, G; Merry, C; Moriarty, M; O'Connor, R; O'Riordan, R; Relihan, E; Townsend, L, 2021
)
1.05
" Secondary outcomes included mortality at day 28, intensive care admission, requirement for mechanical ventilation and incidence of adverse events."( Clinical outcomes and adverse events in patients hospitalised with COVID-19, treated with off-label hydroxychloroquine and azithromycin.
Bannan, C; Bergin, C; Carr, B; Clarke, S; Coghlan, M; Doyle, C; Kelly, M; Melanophy, G; Merry, C; Moriarty, M; O'Connor, R; O'Riordan, R; Relihan, E; Townsend, L, 2021
)
0.84
"3%) patients due to adverse events."( Clinical outcomes and adverse events in patients hospitalised with COVID-19, treated with off-label hydroxychloroquine and azithromycin.
Bannan, C; Bergin, C; Carr, B; Clarke, S; Coghlan, M; Doyle, C; Kelly, M; Melanophy, G; Merry, C; Moriarty, M; O'Connor, R; O'Riordan, R; Relihan, E; Townsend, L, 2021
)
0.84
" This descriptive study highlights the importance of monitoring all repurposed agents for adverse events."( Clinical outcomes and adverse events in patients hospitalised with COVID-19, treated with off-label hydroxychloroquine and azithromycin.
Bannan, C; Bergin, C; Carr, B; Clarke, S; Coghlan, M; Doyle, C; Kelly, M; Melanophy, G; Merry, C; Moriarty, M; O'Connor, R; O'Riordan, R; Relihan, E; Townsend, L, 2021
)
0.84
"HCQ appears to be reasonably safe and tolerable in most hospitalized patients with COVID-19."( Safety, tolerability, and clinical outcomes of hydroxychloroquine for hospitalized patients with coronavirus 2019 disease.
Choi, JJ; Goyal, P; Gulick, RM; Kondo, M; Magleby, R; Maldarelli, GA; Pham, K; Rennert, H; Safford, MM; Satlin, MJ; Schenck, EJ; Westblade, LF, 2020
)
0.82
"The development of our RMA approach was motivated by a currently relevant clinical question: is ocular toxicity and vision compromise a side effect of hydroxychloroquine therapy? At the time of designing this study, hydroxychloroquine was a leading candidate in the treatment of coronavirus disease (COVID-19)."( Artificial Intelligence for Rapid Meta-Analysis: Case Study on Ocular Toxicity of Hydroxychloroquine.
Chow, T; Martin, NA; Michelson, M; Minton, S; Ross, M; Tee Qiao Ying, A, 2020
)
0.98
" There is a high incidence of myocardial injury and arrhythmia reported with COVID-19 infection, and as such this population may be more susceptible to this side-effect profile."( Hydroxychloroquine use in COVID-19: is the risk of cardiovascular toxicity justified?
Ahmad, M; Conway, S; Kirresh, A; Little, C; Stevenson, A; White, L, 2020
)
2
" While the use of these agents is being diversified, their adverse effects should be timely diagnosed and prevented."( Benefits and adverse effects of hydroxychloroquine, methotrexate and colchicine: searching for repurposable drug candidates.
Gasparyan, AY; Misra, DP; Zimba, O, 2020
)
0.84
" Some studies have shown that COVID-19 combined with diabetes is an independent risk factor for death or other adverse outcomes."( Efficacy and safety of chloroquine and hydroxychloroquine in the treatment of patients with COVID-19 combined with diabetes mellitus: A protocol for systematic review and meta-analysis.
Fu, X; Liu, Y; Xie, C, 2020
)
0.83
" The primary outcomes include Sputum virus nucleic acid negative time, lung imaging improvement time, mortality rate, mechanical ventilation rate, ICU hospitalization time, hospitalization time, clinical improvement, symptoms Improvement, fasting blood glucose, 2-hour postprandial blood glucose, glycosylated hemoglobin, fasting insulin, adverse reactions, etc."( Efficacy and safety of chloroquine and hydroxychloroquine in the treatment of patients with COVID-19 combined with diabetes mellitus: A protocol for systematic review and meta-analysis.
Fu, X; Liu, Y; Xie, C, 2020
)
0.83
" The goals of this paper are to identify whether or not hydroxychloroquine/chloroquine improves symptoms in palliative care patients and whether or not these drugs are safe to use in the advanced illness population who have COVID."( Safety and Utility of Chloroquine/ Hydroxychloroquine in Palliative Care Patients.
Prommer, E, 2021
)
1.14
"Although there is still no consistent evidence about HCQ/CQ retinal toxicity in patients with COVID-19, these possible drug-related retinal adverse events may represent a major safety concern."( Hydroxychloroquine and chloroquine retinal safety concerns during COVID-19 outbreak.
Bassetti, M; Ferro Desideri, L; Nicolò, M; Traverso, CE, 2021
)
2.06
" The use of such drugs may be considered as safe relating to arrhythmic risk in the treatment of COVID-19 patients as no arrhythmic fatalities occurred."( Assessing QT interval in COVID-19 patients:safety of hydroxychloroquine-azithromycin combination regimen.
Bernardini, A; Castelvecchio, S; Ciconte, G; de Innocentiis, C; Giannelli, L; Locati, ET; Marrocco-Trischitta, MM; Mecarocci, V; Menicanti, L; Negro, G; Pappone, C; Rondine, R; Santini, F; Vicedomini, G; Viva, T; Witkowska, E, 2021
)
0.87
"To find effective and safe treatments for COVID-19, the WHO recommended to systemically evaluate experimental therapeutics in collaborative randomised clinical trials."( Protocol for the DisCoVeRy trial: multicentre, adaptive, randomised trial of the safety and efficacy of treatments for COVID-19 in hospitalised adults.
Ader, F, 2020
)
0.56
" Food and Drug Administration Adverse Events Reporting System (FAERS) database to assess HCQ/CQ-associated cardiovascular adverse events (CVAEs) in pre-COVID-19 reports."( Cardiovascular adverse events associated with hydroxychloroquine and chloroquine: A comprehensive pharmacovigilance analysis of pre-COVID-19 reports.
Bomze, D; Boursi, B; Dankner, R; Goldman, A; Hod, H; Maor, E; Meirson, T, 2021
)
0.88
" We identified 4895 reports of HCQ/CQ related adverse events, of which 696 (14."( Cardiovascular adverse events associated with hydroxychloroquine and chloroquine: A comprehensive pharmacovigilance analysis of pre-COVID-19 reports.
Bomze, D; Boursi, B; Dankner, R; Goldman, A; Hod, H; Maor, E; Meirson, T, 2021
)
0.88
" We aimed to assess and compare the profile of cardiac adverse drug reactions (CADRs) associated with HCQ before and during COVID-19."( Insights on the Evidence of Cardiotoxicity of Hydroxychloroquine Prior and During COVID-19 Epidemic.
Drici, MD; Fresse, A; Gérard, A; Micallef, J; Rocher, F; Romani, S; Van-Obberghen, É; Viard, D, 2021
)
0.88
"HCQ administration is safe for a short-term treatment for patients with COVID-19 infection regardless of the clinical setting of delivery, causing only modest QTc prolongation and no directly attributable arrhythmic deaths."( Arrhythmic safety of hydroxychloroquine in COVID-19 patients from different clinical settings.
Antinori, S; Bellia, A; Biffi, M; Busana, M; Casalini, G; Cogliati, CB; Duru, F; Fabbricatore, D; Forleo, GB; Galiè, N; Galli, M; Gasperetti, A; Lanfranchi, A; Lavalle, C; Mariani, MV; Mitacchione, G; Saguner, A; Salghetti, F; Schiavone, M; Tocci, M; Tondo, C; Viale, P; Ziacchi, M, 2020
)
0.88
" Secondary outcomes included adverse effects, treatment discontinuation, presence of SARS-CoV-2 antibodies, frequency of QTc prolongation, and clinical outcomes for SARS-CoV-2-positive participants."( Efficacy and Safety of Hydroxychloroquine vs Placebo for Pre-exposure SARS-CoV-2 Prophylaxis Among Health Care Workers: A Randomized Clinical Trial.
Abella, BS; Amaravadi, RK; Babushok, DV; Biney, BT; Frank, I; Gill, S; Gimotty, PA; Hensley, SE; Huang, AC; Hyman, MC; Jolkovsky, EL; Maillard, I; Milone, MC; Nasta, SD; Uspal, JE; Vogl, DT; Walsh, JC; Wiletyo, EP, 2021
)
0.93
" Mild adverse events were more common in participants taking hydroxychloroquine compared with placebo (45% vs 26%; P = ."( Efficacy and Safety of Hydroxychloroquine vs Placebo for Pre-exposure SARS-CoV-2 Prophylaxis Among Health Care Workers: A Randomized Clinical Trial.
Abella, BS; Amaravadi, RK; Babushok, DV; Biney, BT; Frank, I; Gill, S; Gimotty, PA; Hensley, SE; Huang, AC; Hyman, MC; Jolkovsky, EL; Maillard, I; Milone, MC; Nasta, SD; Uspal, JE; Vogl, DT; Walsh, JC; Wiletyo, EP, 2021
)
1.17
" Twenty-four (47%) RCTs did not describe plans to assess safety outcomes; when assessed, safety outcomes were determined in generic terms of total, severe or serious adverse events."( Efficacy and safety outcomes of proposed randomized controlled trials investigating hydroxychloroquine and chloroquine during the early stages of the COVID-19 pandemic.
Junqueira, DR; Rowe, BH, 2021
)
0.85
" Adverse effects were reported among (6."( Hydroxychloroquine Safety Outcome within Approved Therapeutic Protocol for COVID-19 Outpatients in Saudi Arabia.
AboGazalah, F; AlabdulKareem, K; Alenazi, E; Alfaifi, A; AlGhofaili, F; AlKhalifah, N; Almohaizeie, A; Alrabiah, F; Elkady, E; Hassanein, M; Jokdar, H; Mahmoud, N; Mohana, A; Radwan, N; Sulaiman, T, 2021
)
2.06
"The purpose of this study is to analyze the US FDA Adverse Event Reporting System (FAERS) to identify adverse cardiac events of hydroxychloroquine in older adults."( Analysis of the US FDA adverse event reporting system to identify adverse cardiac events associated with hydroxychloroquine in older adults.
Chyou, TY; Gill, S; Nishtala, PS, 2020
)
0.98
"A case/non-case method was used to determine adverse events associated with hydroxychloroquine as the primary suspect drug between January 1, 2004, and December 31, 2019, for older adults (≥65 years)."( Analysis of the US FDA adverse event reporting system to identify adverse cardiac events associated with hydroxychloroquine in older adults.
Chyou, TY; Gill, S; Nishtala, PS, 2020
)
1
"We identified 334 adverse cardiac events comprising 71 different MedDRA PTs from 2004 to 2019 for hydroxychloroquine in older adults."( Analysis of the US FDA adverse event reporting system to identify adverse cardiac events associated with hydroxychloroquine in older adults.
Chyou, TY; Gill, S; Nishtala, PS, 2020
)
0.99
" Due to the current lack of safety data from randomized controlled trials as well as large observational studies to confirm the risk of adverse cardiac events associated with hydroxychloroquine, findings from analyses of post-marketing data may serve as interim guidance."( Analysis of the US FDA adverse event reporting system to identify adverse cardiac events associated with hydroxychloroquine in older adults.
Chyou, TY; Gill, S; Nishtala, PS, 2020
)
0.97
" Secondary Endpoints: All causes mortality, Frequency of respiratory progression (defined as SPO2≤ 94% on room air or PaO2/FiO2 <300mmHg and requirement for supplemental oxygen or more advanced ventilator support), time to defervescence (in those with fever at enrolment), frequency of requirement for supplemental oxygen or non-invasive ventilation, frequency of requirement for mechanical ventilation, frequency of serious adverse events as per DAIDS table grade of severity."( Safety and efficacy of antiviral combination therapy in symptomatic patients of Covid-19 infection - a randomised controlled trial (SEV-COVID Trial): A structured summary of a study protocol for a randomized controlled trial.
Bahurupi, YA; Bandyopadhyay, A; Chikara, G; Moirangthem, B; Panda, PK; Saha, S; Singh, BC, 2020
)
0.56
" In this study we analyzed over thirteen million adverse event reports form the United States Food and Drug Administration Adverse Event Reporting System to confirm and quantify the association of cardiac side effects of CQ and HCQ."( Cardiac adverse events associated with chloroquine and hydroxychloroquine exposure in 20 years of drug safety surveillance reports.
Abagyan, R; Cohen, IV; Issa, MA; Makunts, T; Moumedjian, T, 2020
)
0.81
"4% of the patients, the exceptions being 13 patients who presented with non-serious adverse drug reactions or who had severe COVID-19 and were hospitalized."( Safety and efficacy of hydroxychloroquine in 152 outpatients with confirmed COVID-19: A pilot observational study.
Akdemir, T; Cakmak, S; Can, MM; Demir, O; Ergenc, H; Guven, R; Kaplan, O; Kaya, M; Sogut, O; Umit, TB, 2021
)
0.93
"Our findings show that hydroxychloroquine is safe for COVID-19 and not associated with a risk of ventricular arrhythmia due to drug-induced QTc interval prolongation."( Safety and efficacy of hydroxychloroquine in 152 outpatients with confirmed COVID-19: A pilot observational study.
Akdemir, T; Cakmak, S; Can, MM; Demir, O; Ergenc, H; Guven, R; Kaplan, O; Kaya, M; Sogut, O; Umit, TB, 2021
)
1.24
"Hydroxychloroquine (HCQ) poisoning is a life-threatening but treatable toxic ingestion."( Utility of Hypertonic Saline and Diazepam in COVID-19-Related Hydroxychloroquine Toxicity.
Becker, JS; Fenves, AZ; Hayes, BD; Hyppolite, G; Khosrowjerdi, S; Mahan, KM; North, CM; Sinden, D; Stearns, DA, 2021
)
2.3
" The outcomes of interest were mortality, progression to severe disease (severe pneumonia, admission to intensive care unit (ICU), and/or mechanical ventilation), viral clearance rate, QT prolongation, fatal cardiac complications, and noncardiac serious adverse events."( Comparative efficacy and safety of pharmacological interventions for the treatment of COVID-19: A systematic review and network meta-analysis.
An, MH; Hwang, TH; Kim, MS; Kim, WJ, 2020
)
0.56
" Therefore, it is important to know the utility and safety of the medications to avoid untoward adverse effects on pregnant women and fetuses."( Safety of pharmacological options for the management of COVID-19 in pregnant women: An Indian perspective.
Bhagat, R; Manchanda, K; Singh, H; Singh, J; Tiwana, IK, 2021
)
0.62
" The secondary outcome is the incidence of serious adverse drug reactions within seven days of randomization."( The efficacy and safety of Ivermectin in patients with mild and moderate COVID-19: A structured summary of a study protocol for a randomized controlled trial.
Dadvand, H; Davoodian, P; Fathalipour, M; Ghazizadeh, S; Hassaniazad, M; Hassanipour, S; Hosseini, FS; Kahoori, S; Malektojari, A; Nikoofal-Sahlabadi, S; Nikpoor, AR; Sepandi, M, 2021
)
0.62
"Although pharmacologic prophylaxis is an attractive preventive strategy against COVID-19, the current body of evidence failed to show clinical benefit for prophylactic hydroxychloroquine and showed a higher risk of adverse events when compared to placebo or no prophylaxis."( The efficacy and safety of hydroxychloroquine for COVID-19 prophylaxis: A systematic review and meta-analysis of randomized trials.
Alhazzani, W; Alshamsi, F; Carayannopoulos, L; Chagla, Z; Chaudhuri, D; Dearness, K; Lewis, K, 2021
)
1.11
"The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic posed a serious public health concern and started a race against time for researchers to discover an effective and safe therapy for coronavirus disease 2019 (COVID-19), the disease caused by SARS-CoV-2."( The History, Efficacy, and Safety of Potential Therapeutics: A Narrative Overview of the Complex Life of COVID-19.
Abou-Sleymane, G; Al Faraj, A; Badro, DA; Daou, F; Khanafer, N; Tobaiqy, M, 2021
)
0.62
" Apart from the known adverse effects of these drugs, recently the use of CQ and HCQ as a potential treatment for COVID-19 is under flux globally."( Analogue discovery of safer alternatives to HCQ and CQ drugs for SAR-CoV-2 by computational design.
Chauhan, SS; Gupta, A; Gupta, S; Pandit, S; Parthasarathi, R; Singh, P; Sinha, M, 2021
)
0.62
"In a multicenter point-prevalence study, we found that the rate of supportive care was high; among those receiving COVID-19 drug therapies, adverse reactions occurred in 12% of patients."( Multicenter point prevalence evaluation of the utilization and safety of drug therapies for COVID-19 at the onset of the pandemic timeline in the United States.
Badowski, ME; Beardsley, JR; Borkowski, JL; Dairem, A; Fong, K; Hale, CM; Michienzi, SM; Moore, WJ; Pallotta, AM; Polisetty, RS; Postelnick, MJ; Rhodes, NJ; Schulz, LT; Shah, A; Spivak, ES; Srinivas, P, 2021
)
0.62
" The secondary objective was to describe adverse drug reactions (ADRs)."( Multicenter point prevalence evaluation of the utilization and safety of drug therapies for COVID-19 at the onset of the pandemic timeline in the United States.
Badowski, ME; Beardsley, JR; Borkowski, JL; Dairem, A; Fong, K; Hale, CM; Michienzi, SM; Moore, WJ; Pallotta, AM; Polisetty, RS; Postelnick, MJ; Rhodes, NJ; Schulz, LT; Shah, A; Spivak, ES; Srinivas, P, 2021
)
0.62
" Notably, hydroxychloroquine has been associated with a heterogeneous range of cutaneous and extra-cutaneous adverse events."( The safety profile of hydroxychloroquine: major cutaneous and extracutaneous adverse events.
Alaibac, M; Bellinato, F; Bordin, C; Girolomoni, G; Gisondi, P; Naldi, L; Piaserico, S; Tozzi, F,
)
0.85
"To describe the characteristics of adverse event reporting in the United States (US) Food and Drug Administration Adverse Event Reporting System (FAERS) before and after the outbreak of the COVID-19 pandemic."( Global COVID-19 pandemic and reporting behavior - An analysis of the Food and Drug Administration adverse events reporting system.
Dörks, M; Douros, A; Hoffmann, F; Jobski, K, 2021
)
0.62
" Secondary outcomes will include the incremental cost per reducing 1 case of relapse; patient reported intolerance to the treatment; adverse events; change of mean disease activity measured by DAS28, clinical disease activity index (CDAI) and simplified disease activity index (SDAI); the proportion of modified Sharp score increase < 0."( The efficacy, safety and cost-effectiveness of hydroxychloroquine, sulfasalazine, methotrexate triple therapy in preventing relapse among patients with rheumatoid arthritis achieving clinical remission or low disease activity: the study protocol of a rand
Ji, P; Wu, Y; Yan, X; Yang, L; Zhang, Z; Zhao, J; Zhou, W, 2021
)
0.88
"HCQ therapy for COVID-19 is associated with an increase in mortality and other adverse events."( Efficacy and safety of hydroxychloroquine/chloroquine against SARS-CoV-2 infection: A systematic review and meta-analysis.
Jain, S; Kumar, J; Meena, J; Yadav, A, 2021
)
0.93
" The scientific community is studying and testing numerous compounds that can be effective and safe for treating people with covid-19."( [The praise of uncertainty: a systematic living review to evaluate the efficacy and safety of drug treatments for patients with covid-19.]
Amato, L; Cruciani, F; Davoli, M; De Crescenzo, F; Mitrova, Z; Saulle, R; Vecchi, S, 2021
)
0.62
" No differences for the risk of any adverse events are observed between convalescent plasma and remdesivir compared to standard treatment."( [The praise of uncertainty: a systematic living review to evaluate the efficacy and safety of drug treatments for patients with covid-19.]
Amato, L; Cruciani, F; Davoli, M; De Crescenzo, F; Mitrova, Z; Saulle, R; Vecchi, S, 2021
)
0.62
" In this context, there is an urgent need to identify safe and effective therapeutic strategies for treatment of such highly contagious disease."( Combination of Hydroxychloroquine Plus Azithromycin As Potential Treatment for COVID-19 Patients: Safety Profile, Drug Interactions, and Management of Toxicity.
Brouqui, P; Deharo, JC; Gautret, P; Hache, G; Honoré, S; Raoult, D; Rolain, JM, 2021
)
0.97
"The aim of this systematic review was to perform qualitative and quantitative analysis on the toxic effects of chloroquine (CQ) and hydroxychloroquine (HCQ) on skeletal muscles."( The toxic effects of chloroquine and hydroxychloroquine on skeletal muscle: a systematic review and meta-analysis.
Biguetti, CC; Brotto, M; Fiedler, MW; Junior, JFS; Marrelli, MT, 2021
)
1.1
"The COVID-19 pandemic causes vital concerns due to the lack of proved, effective, and safe therapy."( Chloroquine and hydroxychloroquine - safety profile of potential COVID-19 drugs from the rheumatologist's perspective.
Grygiel-Górniak, B; Majewska, KA; Majewski, D; Naskręcka, M, 2021
)
0.97
" Analyzed data included age, gender, comorbidities, type of drug, dosage, treatment duration, and reported adverse events."( Chloroquine and hydroxychloroquine - safety profile of potential COVID-19 drugs from the rheumatologist's perspective.
Grygiel-Górniak, B; Majewska, KA; Majewski, D; Naskręcka, M, 2021
)
0.97
"6% of patients did not experience any adverse reactions to the treatment."( Chloroquine and hydroxychloroquine - safety profile of potential COVID-19 drugs from the rheumatologist's perspective.
Grygiel-Górniak, B; Majewska, KA; Majewski, D; Naskręcka, M, 2021
)
0.97
" Data from the literature show that high dosage as recommended in COVID-19 treatment may pose a risk of toxicity and require precise management, but prophylactic, long-term use of lower, safe doses might be a promising solution."( Chloroquine and hydroxychloroquine - safety profile of potential COVID-19 drugs from the rheumatologist's perspective.
Grygiel-Górniak, B; Majewska, KA; Majewski, D; Naskręcka, M, 2021
)
0.97
" This high content system can help clinicians design their trials, rapidly project cardiac outcomes, and define new monitoring biomarkers to accelerate access of patients to safe coronavirus disease 2019 (COVID-19) therapeutics."( In vitro safety "clinical trial" of the cardiac liability of drug polytherapy.
Charrez, B; Charwat, V; Edwards, AG; Finsberg, H; Healy, KE; Miller, EW; Siemons, B, 2021
)
0.62
" Favipiravir is a safe effective alternative for hydroxychloroquine in mild or moderate COVID-19 infected patients."( Safety and efficacy of favipiravir versus hydroxychloroquine in management of COVID-19: A randomised controlled trial.
Dabbous, HM; Ebeid, FFS; El Assal, G; El-Sayed, MH; Elgaafary, M; Elghazaly, H; Fawzy, E; Hassany, SM; Riad, AR; Sherief, AF; TagelDin, MA, 2021
)
1.14
" The objective of this study was to assess short-term adverse events (AEs) of HCQ in HCWs."( Safety of hydroxychloroquine in healthcare workers for COVID-19 prophylaxis.
Atal, S; Badyal, DK; Balakrishnan, S; Chandy, SJ; Chatterjee, S; Desai, C; Dikshit, H; Faruqui, AR; Gupta, P; Kamat, SK; Kaul, R; Kaushal, S; Kshirsagar, NA; Medhi, B; Raj, JM; Raveendran, R; Rege, NN; Roy, SS; Shetty, YC; Tripathi, CD; Tripathi, RK; Tripathi, SK; Trivedi, N; Xavier, D,
)
0.53
" For adverse effects, a small number required treatment, and none required hospitalization."( Safety of hydroxychloroquine in healthcare workers for COVID-19 prophylaxis.
Atal, S; Badyal, DK; Balakrishnan, S; Chandy, SJ; Chatterjee, S; Desai, C; Dikshit, H; Faruqui, AR; Gupta, P; Kamat, SK; Kaul, R; Kaushal, S; Kshirsagar, NA; Medhi, B; Raj, JM; Raveendran, R; Rege, NN; Roy, SS; Shetty, YC; Tripathi, CD; Tripathi, RK; Tripathi, SK; Trivedi, N; Xavier, D,
)
0.53
" Typically, the doses were 2 to 5 times greater than the AAO recommendation (adjusted to weight) to avoid toxic retinopathy, the most undesirable ocular side effect."( What can visual caregivers expect with patients treated for SARS-CoV-2? An analysis of ongoing clinical trials and ocular side effects.
Altemir-Gómez, I; Fambuena-Muedra, I; Hershko, S; Jiménez-García, M; Tobarra-López, A, 2021
)
0.62
"To estimate the incidence rate ratio (IRR) of adverse events (AE) in chloroquine or hydroxychloroquine users."( Safety of treatment with chloroquine and hydroxychloroquine: A ten-year systematic review and meta-analysis.
Edington, FLB; Gadellha, SR; Santiago, MB, 2021
)
1.11
" The studies of COVID-19 medicine were involved with eligible end points containing mortality, discharge rate, rate of clinical improvement, and rate of serious adverse events."( The therapeutic effect and safety of the drugs for COVID-19: A systematic review and meta-analysis.
Gao, Z; Gong, H; Li, J; Li, W; Qiu, R; Wang, C; Weng, Y; Xiao, Y; Zhang, Q, 2021
)
0.62
" Doctors and patients should be aware of this potential adverse reaction especially when several risk factors are present."( Torsade de pointes associated with chloroquine, hydroxychloroquine, and azithromycin: a retrospective analysis of individual case safety reports from VigiBase.
Saint-Gerons, DM; Tabarés-Seisdedos, R, 2021
)
0.88
" In this study; it was aimed to investigate the presence of gene mutations that alter ivermectin metabolism and cause toxic effects in patients with severe COVID-19 pneumonia, and to evaluate the effectiveness and safety of ivermectin use in the treatment of patients without mutation."( Evaluation of the effectiveness and safety of adding ivermectin to treatment in severe COVID-19 patients.
Avcı, İY; Çetinkaya, RA; Demirtürk, N; Eser, F; Güner, R; Karalezli, A; Kayaaslan, B; Konya, P; Okumuş, N; Orhan, S; Savaşçı, Ü; Şaylan, B; Taşkın, G; Yamanel, L; Yılmaz, G, 2021
)
0.62
" We found no evidence that HCQ therapy is associated with a higher risk of adverse cardiovascular events or death."( Cardiovascular Safety of Hydroxychloroquine in US Veterans With Rheumatoid Arthritis.
Ahmed, A; Arundel, C; Boehm, D; Cheng, Y; Connell, LB; Faselis, C; Fletcher, RD; Fonarow, GC; Heimall, MS; Karasik, PE; Kerr, GS; Liappis, AP; Moore, HJ; Nashel, DJ; Redd, DF; Shao, Y; Sheriff, HM; Taub, DD; Weintrob, AC; Zeng-Treitler, Q; Zhang, S, 2021
)
0.92
" Safety outcomes, such as serious adverse events and mortality, were also ascertained."( Assessing the efficacy and safety of hydroxychloroquine as outpatient treatment of COVID-19: a randomized controlled trial.
Boesen, ME; Cerchiaro, G; Doram, C; Edwards, BD; Ganesh, A; Greenfield, J; Hill, MD; Jamieson, S; Karnik, V; Kenney, C; Lim, R; Menon, BK; Metz, L; Mponponsuo, K; Rathwell, S; Richer, L; Ryckborst, KJ; Schwartz, I; Stewart, B; Yaskina, M,
)
0.4
" The simultaneous treatment trials did not show a significant increase in viability compared to model toxic dose."( Ameliorating hydroxychloroquine induced retinal toxicity through cerium oxide nanoparticle treatments.
Dhillon, B; Ho, S; Keifer, J; Kumar, U; Seal, S; Shaikh, S; Singh, S, 2022
)
1.09
"CheReCunJin decoction alone was effective and safe for the treatment of pSS."( Comparative analysis of the efficacy and safety of herbal decoction CheReCunJin alone and combined with hydroxychloroquine for treating primary Sjögren's syndrome: A randomized controlled trial.
Jin, L; Li, C; Shao, Q; Wang, J; Wang, M; Wang, Q; Wu, B,
)
0.35
" Major adverse events reported were GI disorder, palpitation, giddiness and 140 persons discontinued due to adverse events."( Hydroxychloroquine for SARS CoV2 Prophylaxis in Healthcare Workers - A Multicentric Cohort Study Assessing Effectiveness and Safety.
Atiya, F; Avijit, H; Bikash, M; Denis, X; Dinesh, B; Geetha, M; J, CS; Jaya, R; Kaur, CP; Nilima, K; Raakhi, T; Rajani, K; Sandhya, K; Subir, M; Vishnu, R; Vp, K; Yashashri, S; Yk, G, 2021
)
2.06
"The present study aims to identify potential safety signals of chloroquine (CQ) and hydroxychloroquine (HCQ), over the period preceding their repurpose as COVID-19 treatment options, through the analysis of safety data retrieved from the FDA Adverse Event Reporting System (FAERS) pharmacovigilance database."( Safety profile of chloroquine and hydroxychloroquine: a disproportionality analysis of the FDA Adverse Event Reporting System database.
Cepatyte, D; Egberts, T; Giannis, D; Papazisis, G; Siafis, S; Stamoula, E; Tzachanis, D, 2021
)
1.12
" Comparison of the RORs revealed significant differences between CQ and HCQ for the following adverse events: cardiomyopathy, cardiac arrhythmias, retinal disorders, corneal disorders, hearing disorders, headache, hepatic disorders, severe cutaneous reactions, musculoskeletal disorders, and cytopenia."( Safety profile of chloroquine and hydroxychloroquine: a disproportionality analysis of the FDA Adverse Event Reporting System database.
Cepatyte, D; Egberts, T; Giannis, D; Papazisis, G; Siafis, S; Stamoula, E; Tzachanis, D, 2021
)
0.9
" Awareness of the potential adverse cardiac effects of HCQ and CQ can increase the safe use of these medications."( American College of Rheumatology White Paper on Antimalarial Cardiac Toxicity.
Costenbader, KH; Desmarais, J; Fett, N; Ginzler, EM; Goodman, S; Kovacs, R; Link, MS; O'Dell, J; Pineau, CA; Rosenbaum, JT; Schmajuk, G; Werth, VP, 2021
)
0.62
"HCQ is safe for IgAN treatment during pregnancy with effective reduction of proteinuria."( The efficacy and safety of hydroxychloroquine in pregnant patients with IgA nephropathy: A retrospective cohort study.
Chen, YQ; Liu, LJ; Lv, JC; Shi, SF; Si, FL; Tang, C; Yao, YX; Zhang, H, 2022
)
1.02
"Despite the expectations regarding the effectiveness of chloroquine (CQ) and hydroxychloroquine (HCQ) for coronavirus disease (COVID-19) management, concerns about their adverse events have remained."( Systematic review and meta-analysis of the safety of chloroquine and hydroxychloroquine from randomized controlled trials on malarial and non-malarial conditions.
Abbade, JF; Abbade, LPF; Banzato, LR; Bolfi, F; de Barros Almeida, RAM; Dos Santos Nunes-Nogueira, V; Leite, MSF; Leite, RGOF; Mangolim, AS; Olivatti, TOF; Oliveira, FRK; Simões Corrêa Galendi, J; Soares, LT; Souza Botelho, M; Thabane, L, 2021
)
1.08
"The primary outcomes were the frequencies of serious adverse events (SAEs), retinopathy, and cardiac complications."( Systematic review and meta-analysis of the safety of chloroquine and hydroxychloroquine from randomized controlled trials on malarial and non-malarial conditions.
Abbade, JF; Abbade, LPF; Banzato, LR; Bolfi, F; de Barros Almeida, RAM; Dos Santos Nunes-Nogueira, V; Leite, MSF; Leite, RGOF; Mangolim, AS; Olivatti, TOF; Oliveira, FRK; Simões Corrêa Galendi, J; Soares, LT; Souza Botelho, M; Thabane, L, 2021
)
0.86
"CQ and HCQ probably do not increase SAEs, with low frequency of these adverse events on malarial and non-malarial conditions."( Systematic review and meta-analysis of the safety of chloroquine and hydroxychloroquine from randomized controlled trials on malarial and non-malarial conditions.
Abbade, JF; Abbade, LPF; Banzato, LR; Bolfi, F; de Barros Almeida, RAM; Dos Santos Nunes-Nogueira, V; Leite, MSF; Leite, RGOF; Mangolim, AS; Olivatti, TOF; Oliveira, FRK; Simões Corrêa Galendi, J; Soares, LT; Souza Botelho, M; Thabane, L, 2021
)
0.86
"The aim of the study is to provide an overview of Drug-drug Interactions (DDIs) and adverse effects caused by drugs used in SARS-CoV-2 infection during the first epidemic wave."( [Treatments for SARS-CoV-2 infection: A retrospective study of drug-drug interactions and safety].
Benomar, A; Clou, E; Debrix, I; Dubois, A; Fansi Ndengoue, D; Féral, A; Michot, J; Pain, JB, 2022
)
0.72
" A review of adverse events and DDI-risky drug association on medical record was conducted for each patient."( [Treatments for SARS-CoV-2 infection: A retrospective study of drug-drug interactions and safety].
Benomar, A; Clou, E; Debrix, I; Dubois, A; Fansi Ndengoue, D; Féral, A; Michot, J; Pain, JB, 2022
)
0.72
" Causality assessment by CRPV concluded that 10 (35,7 %) adverse effects were possibly related to SARS-CoV-2 drugs with only 2 (7,1 %) related to DDIs."( [Treatments for SARS-CoV-2 infection: A retrospective study of drug-drug interactions and safety].
Benomar, A; Clou, E; Debrix, I; Dubois, A; Fansi Ndengoue, D; Féral, A; Michot, J; Pain, JB, 2022
)
0.72
"Despite risk of adverse drug reactions and DDIs related to drugs used in SARS-CoV-2 infection, few iatrogenics diseases were found."( [Treatments for SARS-CoV-2 infection: A retrospective study of drug-drug interactions and safety].
Benomar, A; Clou, E; Debrix, I; Dubois, A; Fansi Ndengoue, D; Féral, A; Michot, J; Pain, JB, 2022
)
0.72
" There were no significant differences in secondary outcomes (symptom resolution and adverse events) between the intervention group and the control group."( Safety and efficacy of hydroxychloroquine for treatment of non-severe COVID-19 among adults in Uganda: a randomized open label phase II clinical trial.
Bazeyo, W; Byakika-Kibwika, P; Kamya, MR; Kayima, J; Kirenga, B; Kisuule, I; Kwizera, A; Meya, D; Musaazi, J; Mwebesa, HG; Nakibuuka, J; Nakwagala, F; Nanzigu, S; Sekaggya-Wiltshire, C; Semakula, JR; Sendagire, C; Wayengera, M, 2021
)
0.93
"Our results show that HCQ 400 mg twice a day for the first day followed by 200 mg twice daily for the next 4 days was safe but not associated with reduction in viral clearance or symptom resolution among adults with COVID-19 in Uganda."( Safety and efficacy of hydroxychloroquine for treatment of non-severe COVID-19 among adults in Uganda: a randomized open label phase II clinical trial.
Bazeyo, W; Byakika-Kibwika, P; Kamya, MR; Kayima, J; Kirenga, B; Kisuule, I; Kwizera, A; Meya, D; Musaazi, J; Mwebesa, HG; Nakibuuka, J; Nakwagala, F; Nanzigu, S; Sekaggya-Wiltshire, C; Semakula, JR; Sendagire, C; Wayengera, M, 2021
)
0.93
"7%) participants experienced adverse event (AE) level II or lower (total AEs n = 589), similar rates in all randomized groups (P = ."( Safety and tolerability of hydroxychloroquine in health care workers and first responders for the prevention of COVID-19: WHIP COVID-19 Study.
Kilgore, P; Maksimowicz-McKinnon, K; Marshall-Nightengale, L; McKinnon, JE; O'Neill, WW; Pabla, P; Saval, M; Szandzik, E; Wang, DD; Zervos, M, 2022
)
1.02
" In addition to the ongoing research and development of vaccines, there is still a dire need for safe and effective drugs for the control and treatment against the SARS-CoV-2 virus infection."( Safety profile of COVID-19 drugs in a real clinical setting.
Bhardwaj, M; Chiu, MN; Sah, SP, 2022
)
0.72
"Through a literature search conducted on PubMed and Google Scholar database, various adverse events suspected to be induced by eight drugs, including dexamethasone, hydroxychloroquine, chloroquine, remdesivir, favipiravir, lopinavir/ritonavir, ivermectin, and tocilizumab, administered in COVID-19 patients in clinical practice and studies were identified in 30 case reports, 3 case series, and 10 randomized clinical trials."( Safety profile of COVID-19 drugs in a real clinical setting.
Bhardwaj, M; Chiu, MN; Sah, SP, 2022
)
0.92
"Mild, moderate, or severe adverse events of numerous repurposed and investigational drugs caused by various factors and mechanisms were observed."( Safety profile of COVID-19 drugs in a real clinical setting.
Bhardwaj, M; Chiu, MN; Sah, SP, 2022
)
0.72
"To summarise specific adverse effects of remdesivir, hydroxychloroquine and lopinavir/ritonavir in patients with COVID-19."( Adverse effects of remdesivir, hydroxychloroquine and lopinavir/ritonavir when used for COVID-19: systematic review and meta-analysis of randomised trials.
Agoritsas, T; Bartoszko, JJ; Brignardello-Petersen, R; Chu, DK; Ge, L; Izcovich, A; Khamis, AM; Kum, E; McLeod, SL; Mustafa, RA; Qasim, A; Rochwerg, B; Siemieniuk, RA; Vandvik, P; Zeraatkar, D, 2022
)
1.26
" For most interventions and outcomes the certainty of the evidence was very low to low except for gastrointestinal adverse effects from hydroxychloroquine, which was moderate certainty."( Adverse effects of remdesivir, hydroxychloroquine and lopinavir/ritonavir when used for COVID-19: systematic review and meta-analysis of randomised trials.
Agoritsas, T; Bartoszko, JJ; Brignardello-Petersen, R; Chu, DK; Ge, L; Izcovich, A; Khamis, AM; Kum, E; McLeod, SL; Mustafa, RA; Qasim, A; Rochwerg, B; Siemieniuk, RA; Vandvik, P; Zeraatkar, D, 2022
)
1.21
"Antimalarials have been associated with QT prolongation in COVID-19 patients but are generally safe in systemic lupus erythematosus (SLE)."( Hydroxychloroquine cardiotoxicity: a case-control study comparing patients with COVID-19 and patients with systemic lupus erythematosus.
Agati, L; Ciardi, MR; Conti, F; Garufi, C; Mancuso, S; Mastroianni, CM; Molteni, E; Natalucci, F; Priori, R; Riccieri, V; Spinelli, FR; Truglia, S, 2022
)
2.16
" Although there have been multiple reports of the adverse effect of prolonged HCQ usage on the outer retina, leading to bull's-eye maculopathy, the effect of HCQ toxicity on the inner retina as well as on overall visual functions has not been explored in detail."( Hydroxychloroquine Causes Early Inner Retinal Toxicity and Affects Autophagosome-Lysosomal Pathway and Sphingolipid Metabolism in the Retina.
Basu, SK; Chalfant, CE; Chiu, CY; Cole, J; Khanam, S; Mandal, N; Mondal, K; Pandya, HK; Porter, H; Shah, V; Stephenson, DJ, 2022
)
2.16
" The secondary outcomes were changes in other glycemic/lipid parameters and adverse effects."( Efficacy and safety of hydroxychloroquine for managing glycemia in type-2 diabetes: A systematic review and meta-analysis.
Dutta, D; Jindal, R; Kumar, M; Mehta, D; Sharma, M,
)
0.44
" The total adverse events (risk ratio [RR]0."( Efficacy and safety of hydroxychloroquine for managing glycemia in type-2 diabetes: A systematic review and meta-analysis.
Dutta, D; Jindal, R; Kumar, M; Mehta, D; Sharma, M,
)
0.44
" In conclusion, the CQ dosage and regimen used to treat COVID-19 induced adverse effects in diabetic rats, suggesting the need to reevaluate the effective dose of CQ in humans."( Safety considerations of chloroquine in the treatment of patients with diabetes and COVID-19.
Gao, X; Guo, D; Ji, H; Jiang, S; Jing, X; Peng, L; Qiu, Y; Wang, J; Wu, W; Zheng, Y, 2022
)
0.72
" No serious or severe adverse events were related to lenabasum, and no participants discontinued the study."( Safety and Efficacy of Lenabasum, a Cannabinoid Receptor Type 2 Agonist, in Patients with Dermatomyositis with Refractory Skin Disease: A Randomized Clinical Trial.
Bashir, MM; Concha, JSS; Constantine, S; Dgetluck, N; Feng, R; Gebre, K; Haber, J; Hejazi, E; Jadoo, AS; Okawa, J; Pena, SM; Reddy, N; Werth, VP; White, B; Zeidi, M, 2022
)
0.72
" We analyze the reports of suspected adverse drug reactions (ADRs) collected in EudraVigilance, the European database of ADR reports."( Safety profile of hydroxychloroquine used off-label for the treatment of patients with COVID-19: A descriptive study based on EudraVigilance data.
Bonaldo, G; Montanaro, N; Motola, D, 2022
)
1.06
" An unexpected cardiovascular safety signal was quickly identified as being more frequent than expected thanks to the reports of adverse drug reactions (ADRs) submitted to French regional pharmacovigilance centres (RPVC)."( Comparative study of the adverse event profile of hydroxychloroquine before and during the Sars-CoV2 pandemic.
Grandvuillemin, A; Lacroix, C; Lombardi, J; Lory, P; Romani, S; Sanchez-Pena, P,
)
0.38
" A disproportionality analysis was performed to determine adverse effects reported in non-Covid and Covid patients."( Hydroxychloroquine safety in Covid-19 vs non-Covid-19 patients: analysis of differences and potential interactions.
Fernandez-Araque, AM; Martín Arias, LH; Merino Kolly, N; Sainz-Gil, M; Sanz Fadrique, R; Velasco-González, V; Verde Rello, Z, 2023
)
2.35
", HCQ daily dose, HCQ cumulative dose, and duration of therapy) showed significant differences between the toxic and nontoxic groups."( Machine Learning-Based Automated Detection of Hydroxychloroquine Toxicity and Prediction of Future Toxicity Using Higher-Order OCT Biomarkers.
Ehlers, JP; Hu, M; Kaiser, S; Kalra, G; Srivastava, SK; Talcott, KE; Ugwuegbu, O, 2022
)
0.98
" Hydroxychloroquine (HCQ)-associated cardiovascular adverse events (CVAEs) have been increasingly reported."( An observational, retrospective, comprehensive pharmacovigilance analysis of hydroxychloroquine-associated cardiovascular adverse events in patients with and without COVID-19.
Li, Y; Luo, M; Wu, B; Wu, F, 2022
)
1.86
"This study aimed to present an observational, retrospective, and comprehensive pharmacovigilance analysis of CVAE associated with HCQ in patients with and without COVID-19 using the US Food and Drug Administration Adverse Events Reporting System (FAERS) data from January 2020 to December 2020."( An observational, retrospective, comprehensive pharmacovigilance analysis of hydroxychloroquine-associated cardiovascular adverse events in patients with and without COVID-19.
Li, Y; Luo, M; Wu, B; Wu, F, 2022
)
0.95
"We identified 3302 adverse event reports from the FAERS database in the year 2020 and divided them into COVID-19 and non-COVID-19 groups, respectively."( An observational, retrospective, comprehensive pharmacovigilance analysis of hydroxychloroquine-associated cardiovascular adverse events in patients with and without COVID-19.
Li, Y; Luo, M; Wu, B; Wu, F, 2022
)
0.95
"In this study we investigated COVID-19 vaccination-related adverse events (ADEs) 7 days postvaccination in patients with idiopathic inflammatory myopathies (IIMs) and other systemic autoimmune and inflammatory disorders (SAIDs)."( COVID-19 Vaccination in Autoimmune Diseases (COVAD) study: Vaccine safety in idiopathic inflammatory myopathies.
Agarwal, V; Aggarwal, R; Cavagna, L; Chatterjee, T; Chinoy, H; Day, J; Distler, O; Gaur, PS; Gheita, T; Gil-Vila, A; Gonzalez, RA; Gracia-Ramos, AE; Gupta, L; Joshi, M; Kardes, S; Kim, M; Knitza, J; Kuwana, M; Lilleker, JB; Makol, A; Milchert, M; Nikiphorou, E; Nune, A; Parodis, I; Ravichandran, N; Saavedra, MA; Salim, B; Selva-O'Callaghan, A; Sen, P; Shinjo, SK; Tan, AL; Velikova, T; Ziade, N, 2022
)
0.72
"To perform a systematic review on the psychiatric adverse effects of chloroquine (CQ) and hydroxychloroquine (HCQ); to summarize what is known about psychiatric adverse effects of these drugs; to compare clinical trials, populational studies, and case report studies; and to increase awareness of the potential psychiatric adverse effects of these drugs."( Systematic Review of Psychiatric Adverse Effects Induced by Chloroquine and Hydroxychloroquine: Case Reports and Population Studies.
Cao, B; Chakravarty, S; Greenshaw, AJ; Liu, YS; Passos, IC; Talarico, F, 2023
)
1.36
"Relevant studies included reports of adverse effects after CQ or HCQ ingestion."( Systematic Review of Psychiatric Adverse Effects Induced by Chloroquine and Hydroxychloroquine: Case Reports and Population Studies.
Cao, B; Chakravarty, S; Greenshaw, AJ; Liu, YS; Passos, IC; Talarico, F, 2023
)
1.14
"The current literature presents evidence for a risk of short-term psychiatric adverse effects induced by either CQ or HCQ."( Systematic Review of Psychiatric Adverse Effects Induced by Chloroquine and Hydroxychloroquine: Case Reports and Population Studies.
Cao, B; Chakravarty, S; Greenshaw, AJ; Liu, YS; Passos, IC; Talarico, F, 2023
)
1.14
"Most of the patients who developed such adverse effects did not report a family history of psychiatric disease."( Systematic Review of Psychiatric Adverse Effects Induced by Chloroquine and Hydroxychloroquine: Case Reports and Population Studies.
Cao, B; Chakravarty, S; Greenshaw, AJ; Liu, YS; Passos, IC; Talarico, F, 2023
)
1.14
"Based on clinical trials and case reports, the current literature presents evidence for a risk of short-term psychiatric adverse effects induced by either drug."( Systematic Review of Psychiatric Adverse Effects Induced by Chloroquine and Hydroxychloroquine: Case Reports and Population Studies.
Cao, B; Chakravarty, S; Greenshaw, AJ; Liu, YS; Passos, IC; Talarico, F, 2023
)
1.14
" Accordingly, we have reviewed the adverse effect profile of HCQ to provide guidance about this therapeutic agent in clinical practice."( How toxic is an old friend? A review of the safety of hydroxychloroquine in clinical practice.
Brosnan, M; Fairley, JL; Mack, HG; Nikpour, M; Pellegrini, M; Saracino, AM; Wicks, IP, 2023
)
1.16
" No serious adverse events (SAEs) were found in the safety assessments for either condition, and all adverse events (AEs) were mild, except for 2 moderate AEs in the fed condition, indicating good safety."( Pharmacokinetics, Bioequivalence, and Safety of 2 Formulations of Hydroxychloroquine Tablets in Healthy Chinese Volunteers Under Fasting and Fed Conditions.
Cheng, Y; Deng, P; Gao, LC; Li, FJ; Long, HZ; Luo, HY; Wen, DD; Xu, SG; Zhou, ZW, 2023
)
1.15
" HCQ (5 mg/kg/d) was effective and safe for treating CLD (age >1."( Centrifugal lipodystrophy on a spectrum with lupus erythematosus panniculitis in children and efficacy and safety of hydroxychloroquine: A clinicopathological study.
Gu, Y; Li, Y; Ling, B; Lu, Z; Qiu, Y; Xu, Q; Yao, Z; Yu, H, 2022
)
0.93
" Although, most adverse cardiac events related to HCQ/CQ usage in COVID-19 were secondary to conduction disorders given the short duration of treatment, HCQ/CQ can cause CM and HF, with chronic usage."( Review of Hydroxychloroquine Cardiotoxicity: Lessons From the COVID-19 Pandemic.
Gagnon, LR; Oudit, GY; Sadasivan, C; Yogasundaram, H, 2022
)
1.12
" Any adverse events that required dose reduction or cessation of hydroxychloroquine, indicating intolerance to the drug, were recorded for up to 26 weeks after initiation of hydroxychloroquine."( Safe Introduction of Hydroxychloroquine Focusing on Early Intolerance Due to Adverse Drug Reactions in Patients with Systemic Lupus Erythematosus.
Araki, K; Hirata, S; Ishitoku, M; Kohno, H; Masuda, S; Mokuda, S; Oka, N; Sugimoto, T; Watanabe, H; Yorishima, A; Yoshida, Y, 2023
)
1.47
" HCQ is generally safe and may be prescribed to pregnant women."( Initiation of hydroxychloroquine therapy during pregnancy can cause adverse effects and alter pregnancy outcomes: A case of acute generalised exanthematous pustulosis induced by hydroxychloroquine in a patient with systemic lupus erythematosus.
Kaneko, K; Murashima, A; Sago, H; Tanaka, R; Tsurane, K; Yoshida, K, 2023
)
1.27
" We have found that baricitinib might be effective and safe in pSS in a pilot study."( A multi-center, open-label, randomized study to explore efficacy and safety of baricitinib in active primary Sjogren's syndrome patients.
Bai, W; Leng, X; Li, H; Shi, X; Wei, W; Xu, H; Yang, F; Zeng, X; Zhang, L; Zhang, Y; Zhao, Y, 2023
)
0.91
" From 25 March 2020 to 29 May 2020, the Inserm Safety Department had to manage 585 Serious Adverse Events (SAEs) initial notification and 396 follow-up reports."( Management of pharmacovigilance during the COVID-19 pandemic crisis by the safety department of an academic sponsor: Lessons learnt and challenges from the EU DisCoVeRy clinical trial.
Ader, F; Andrejak, C; Belhadi, D; Burdet, C; Costagliola, D; DeChanet, A; Delmas, C; Diallo, A; Dumousseaux, M; Espérou, H; Ferrane, A; Fougerou-Leurent, C; Greil, R; Hites, M; Le Mestre, S; Mentre, F; Mercier, N; Paiva, JA; Peiffer-Smadja, N; Poissy, J; Saillard, J; Staub, T; Tacconelli, E; Yazdanpanah, Y, 2023
)
0.91
"The primary efficacy outcome was PCR-confirmed SARS-CoV-2 infection and the primary safety outcome was incidence of adverse events."( Safety and efficacy of hydroxychloroquine as prophylactic against COVID-19 in healthcare workers: a meta-analysis of randomised clinical trials.
Abella, BS; Amaravadi, R; Anstrom, KJ; Boulware, DR; Friedland, A; Halabi, S; Hernandez, AF; Hong, H; Hu, M; McKinnon, JE; Naggie, S; Portillo-Vázquez, AM; Rajasingham, R; Rojas-Serrano, J; Woods, CW, 2023
)
1.22
"Our meta-analysis of 10 RCTs investigating the safety and efficacy of HCQ as pre-exposure prophylaxis in HCWs found that compared with placebo, HCQ does not significantly reduce the risk of confirmed or clinically suspected SARS-CoV-2 infection, while HCQ significantly increases adverse events."( Safety and efficacy of hydroxychloroquine as prophylactic against COVID-19 in healthcare workers: a meta-analysis of randomised clinical trials.
Abella, BS; Amaravadi, R; Anstrom, KJ; Boulware, DR; Friedland, A; Halabi, S; Hernandez, AF; Hong, H; Hu, M; McKinnon, JE; Naggie, S; Portillo-Vázquez, AM; Rajasingham, R; Rojas-Serrano, J; Woods, CW, 2023
)
1.22
"To characterize the adverse events (AEs) related to the off-label use of hydroxychloroquine (HQ), azithromycin (AZI), tocilizumab (TOB) and ivermectin (IVM) for the treatment of COVID-19 in hospitalized patients."( Characterization of adverse events to hydroxychloroquine, ivermectin, azithromycin and tocilizumab in patients hospitalized due to COVID-19 in a Peruvian Social Health Insurance hospital.
Alva Lozada, G; Cachay Rojas, E; Delgado-Escalante, R; Fernández-Rojas, P; Fiestas Saldarriaga, F; Rodríguez-Tanta, LY,
)
0.63
" The goal of the present study was to evaluate the potential protective effect of the nootropic agent vinpocetine against CQ and HCQ adverse effects with a specific focus on the heart."( Vinpocetine protects against chloroquine-induced cardiotoxicity by mitigating oxidative stress.
Abdelmageed, N; Ahmed, M; El-Banna, HA; El-Zorba, HY; Ghallab, A; Haridy, M; Hassan, R; Morad, OA; Morad, SAF; Seddek, AL; Twafik, WA, 2023
)
0.91
" The main outcome indicators included clinical total effective rate, adverse reactions, SLE disease activity index (SLEDAI) score, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and complement 3 (C3)."( Meta-analysis of effectiveness and safety of glucocorticoid combined with hydroxychloroquine in the treatment of systemic lupus erythematosus rash.
Fang, H; Guan, T; Liang, S; Wei, Z, 2023
)
1.14
"00001), and reduce the occurrence of adverse reactions (OR = 0."( Meta-analysis of effectiveness and safety of glucocorticoid combined with hydroxychloroquine in the treatment of systemic lupus erythematosus rash.
Fang, H; Guan, T; Liang, S; Wei, Z, 2023
)
1.14
"Compared with the use of GC alone, GC combined with HCQ can improve the clinical effectiveness of SLE rash treatment, with a low incidence of adverse reactions and good clinical safety."( Meta-analysis of effectiveness and safety of glucocorticoid combined with hydroxychloroquine in the treatment of systemic lupus erythematosus rash.
Fang, H; Guan, T; Liang, S; Wei, Z, 2023
)
1.14
" Hydroxychloroquine (HCQ), known for its immunomodulatory effects and minimal adverse effects, has emerged as a pivotal treatment option for pSS."( Safety and Efficacy of Oral Hydroxychloroquine in the Treatment of Ophthalmic Disease Associated with Sjögren's Syndrome.
Bing, Z; Fang, W; Jie, X; Qihui, L; Qingqing, Z; Xinyue, H, 2023
)
2.11
"The safety assessment revealed no adverse effect of the drugs in COVID-19 patients after treatment."( Preliminary Study on Open Labelled Randomized Controlled Trial of the Safety and Efficacy of Hydroxychloroquine and Chloroquine Phosphate for the Treatment of Persons Infected with 2019 Coronavirus Disease in Nigeria.
Abiola, A; Adeyemo, WL; Agabi, OP; Aina, OO; Ajibaye, O; Akase, IE; Akinbode, GO; Akintan, PE; Amoo, OS; Audu, RA; Bamidele, TA; Bode, C; Busari, AA; David, AN; Esezobor, C; Ezechi, OC; Fadipe, B; Ima-Edomwonyi, E; James, AB; Musa, AZ; Nmadu, N; Okoyenta, CO; Okwuraiwe, AP; Oladele, DA; Olakiigbe, AK; Olopade, OB; Osuolale, KA; Otrofanowei, E; Raheem, TY; Salako, AO; Salako, BL; Tade, T, 2023
)
1.13
"To compare the 90-day risk of serious adverse events among adults with CKD who started low-dose methotrexate vs those who started hydroxychloroquine and to compare the risk of serious adverse events among adults with CKD starting 2 distinct doses of methotrexate vs those starting hydroxychloroquine."( Low-Dose Methotrexate and Serious Adverse Events Among Older Adults With Chronic Kidney Disease.
Ahmadi, F; Blake, PG; Garg, AX; Kim, RB; McArthur, E; Muanda, FT; Sontrop, JM; Urquhart, BL; Weir, MA, 2023
)
1.12
"The primary outcome was a composite of serious adverse events: a hospital visit with myelosuppression, sepsis, pneumotoxic effects, or hepatotoxic effects within 90 days of starting the study drug."( Low-Dose Methotrexate and Serious Adverse Events Among Older Adults With Chronic Kidney Disease.
Ahmadi, F; Blake, PG; Garg, AX; Kim, RB; McArthur, E; Muanda, FT; Sontrop, JM; Urquhart, BL; Weir, MA, 2023
)
0.91
"In this cohort of 4618 older patients with CKD, the 90-day risk of serious adverse events was higher among those who started low-dose methotrexate than those who started hydroxychloroquine."( Low-Dose Methotrexate and Serious Adverse Events Among Older Adults With Chronic Kidney Disease.
Ahmadi, F; Blake, PG; Garg, AX; Kim, RB; McArthur, E; Muanda, FT; Sontrop, JM; Urquhart, BL; Weir, MA, 2023
)
1.1

Pharmacokinetics

Hydroxychloroquine (HCQ) dosage required to reach circulating levels that inhibit SARS-Cov-2 are extrapolated from pharmacokinetic data in non-COVID-19 patients. We computed steady-state concentration profiles for HCQ during pregnancy and postpartum using individual clinical data and empirical Bayesian estimates.

ExcerptReferenceRelevance
" Half-life and mean residence time were long (around 40 days) and large volumes of distribution were calculated (5,522 l from blood, 44,257 l from plasma)."( A dose-ranging study of the pharmacokinetics of hydroxy-chloroquine following intravenous administration to healthy volunteers.
Brown, KF; Cutler, DJ; Day, RO; Tett, SE, 1988
)
0.27
" Pharmacokinetic factors may partially explain these clinical observations."( Clinical pharmacokinetics of slow-acting antirheumatic drugs.
Tett, SE, 1993
)
0.29
"There is wide variability between subjects in the pharmacokinetic parameters of hydroxychloroquine."( Insights from pharmacokinetic and pharmacodynamic studies of hydroxychloroquine.
Cutler, D; Day, R; McLachlan, A; Tett, S, 1993
)
0.75
" Pharmacokinetic interaction studies are limited."( Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases.
Furst, DE, 1996
)
0.62
"The pharmacokinetic studies were carried out following administration of 40 mg/kg of racemic HCQ to diabetic, insulin-treated diabetic, adjuvant arthritic and control rats."( Effect of experimental diabetes mellitus and arthritis on the pharmacokinetics of hydroxychloroquine enantiomers in rats.
Emami, J; Jamali, F; Pasutto, FM, 1998
)
0.53
" Hydroxychloroquine blood concentration data were combined from previous pharmacokinetic studies in patients with rheumatoid arthritis."( Population pharmacokinetics of hydroxychloroquine in patients with rheumatoid arthritis.
Carmichael, SJ; Charles, B; Tett, SE, 2003
)
1.52
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
" We evaluated hydoxychloroquine (HCQ), an inhibitor of autophagy, in patients with pancreatic cancer and analyzed pharmacodynamic markers in treated patients and mice."( Phase II and pharmacodynamic study of autophagy inhibition using hydroxychloroquine in patients with metastatic pancreatic adenocarcinoma.
Chan, JA; Cleary, JM; Enzinger, PC; Fuchs, CS; Killion, L; Kimmelman, AC; Mamon, H; McCleary, NJ; Meyerhardt, JA; Ng, K; Rubinson, DA; Schrag, D; Sikora, AL; Spicer, BA; Wang, X; Wolpin, BM, 2014
)
0.64
" We analyzed peripheral lymphocytes from treated mice to identify pharmacodynamic markers of autophagy inhibition that were then assessed in peripheral lymphocytes from patients."( Phase II and pharmacodynamic study of autophagy inhibition using hydroxychloroquine in patients with metastatic pancreatic adenocarcinoma.
Chan, JA; Cleary, JM; Enzinger, PC; Fuchs, CS; Killion, L; Kimmelman, AC; Mamon, H; McCleary, NJ; Meyerhardt, JA; Ng, K; Rubinson, DA; Schrag, D; Sikora, AL; Spicer, BA; Wang, X; Wolpin, BM, 2014
)
0.64
"Mouse studies identified LC3-II levels in peripheral lymphocytes as a potential pharmacodynamic marker of autophagy inhibition."( Phase II and pharmacodynamic study of autophagy inhibition using hydroxychloroquine in patients with metastatic pancreatic adenocarcinoma.
Chan, JA; Cleary, JM; Enzinger, PC; Fuchs, CS; Killion, L; Kimmelman, AC; Mamon, H; McCleary, NJ; Meyerhardt, JA; Ng, K; Rubinson, DA; Schrag, D; Sikora, AL; Spicer, BA; Wang, X; Wolpin, BM, 2014
)
0.64
" Pharmacokinetic analysis revealed a 100-fold increase in HCQ in tumors compared with plasma."( Phase I clinical trial and pharmacodynamic evaluation of combination hydroxychloroquine and doxorubicin treatment in pet dogs treated for spontaneously occurring lymphoma.
Amaravadi, RK; Barnard, RA; Gustafson, DL; Thamm, DH; Thorburn, A; Wittenburg, LA, 2014
)
0.64
" To establish an appropriate therapeutic regimen and to clarify the pharmacokinetics (PK) of HCQ in Japanese patients with CLE with or without SLE (CLE/SLE), a population pharmacokinetic (PopPK) analysis was performed."( Population Pharmacokinetics of Hydroxychloroquine in Japanese Patients With Cutaneous or Systemic Lupus Erythematosus.
Morita, S; Takahashi, T; Yokota, N; Yoshida, Y, 2016
)
0.72
" Pharmacokinetic (PK) and pharmacodynamic (PD) studies with HCQ have shown that drug exposure in the blood does not correlate with autophagy inhibition in either peripheral blood mononuclear cells or tumor tissue."( Hydroxychloroquine: A Physiologically-Based Pharmacokinetic Model in the Context of Cancer-Related Autophagy Modulation.
Collins, KP; Gustafson, DL; Jackson, KM, 2018
)
1.92
" We computed steady-state concentration profiles for hydroxychloroquine during pregnancy and postpartum using individual clinical data and empirical Bayesian estimates developed from the final pharmacokinetic model."( Pharmacokinetics of Hydroxychloroquine in Pregnancies with Rheumatic Diseases.
Balevic, SJ; Clowse, MEB; Cohen-Wolkowiez, M; Eudy, AM; Green, TP; Schanberg, LE, 2019
)
1.09
" Physiologically based pharmacokinetic modeling was used to inform pediatric dosing for hydroxychloroquine."( Simulated Assessment of Pharmacokinetically Guided Dosing for Investigational Treatments of Pediatric Patients With Coronavirus Disease 2019.
Balevic, SJ; Benjamin, DK; Cohen-Wolkowiez, M; Gonzalez, D; Hornik, CD; Hornik, CP; Maharaj, AR; Smith, PB; Wu, H; Zimmerman, KO, 2020
)
0.78
"For hydroxychloroquine, the physiologically based pharmacokinetic model analysis included 500 and 600 simulated white adult and pediatric participants, respectively, and supported weight-normalized dosing for children weighing less than 50 kg."( Simulated Assessment of Pharmacokinetically Guided Dosing for Investigational Treatments of Pediatric Patients With Coronavirus Disease 2019.
Balevic, SJ; Benjamin, DK; Cohen-Wolkowiez, M; Gonzalez, D; Hornik, CD; Hornik, CP; Maharaj, AR; Smith, PB; Wu, H; Zimmerman, KO, 2020
)
1.12
"We have developed a population pharmacokinetic model for hydroxychloroquine in COVID-19 patients using prospectively collected pharmacokinetic data from patients either enrolled in a clinical trial or treated with hydroxychloroquine as part of standard of care in two tertiary Belgian hospitals."( Population Pharmacokinetics of Hydroxychloroquine in COVID-19 Patients: Implications for Dose Optimization.
Belkhir, L; Dauby, N; De Greef, J; Delongie, KA; Dogné, JM; Hamdani, J; Kiridis, S; Lescrainier, C; Musuamba, FT; Nasreddine, R; Thémans, P; Vandeputte, M; Verlinden, V; Wallemacq, P; Wittebole, X; Wuillaume, F; Yombi, JC, 2020
)
1.09
"The final population pharmacokinetic model was a one-compartment model with first-order absorption and elimination."( Population Pharmacokinetics of Hydroxychloroquine in COVID-19 Patients: Implications for Dose Optimization.
Belkhir, L; Dauby, N; De Greef, J; Delongie, KA; Dogné, JM; Hamdani, J; Kiridis, S; Lescrainier, C; Musuamba, FT; Nasreddine, R; Thémans, P; Vandeputte, M; Verlinden, V; Wallemacq, P; Wittebole, X; Wuillaume, F; Yombi, JC, 2020
)
0.84
"Physiologically based pharmacokinetic (PBPK) models were used to study the change in the pharmacokinetics (PK) of drugs repurposed for COVID-19 in geriatric patients, different race groups, organ impairment and drug-drug interactions (DDIs) risks."( Pharmacokinetics under the COVID-19 storm.
El-Khateeb, E; Giovino, N; Jamei, M; Jo, H; Lythgoe, E; Pilla Reddy, V; Rastomi-Hodjegan, A; Sharma, S; Tang, W, 2023
)
0.91
" This was a retrospective, observational, multicentre, pharmacokinetic study of HCQ in critically ill COVID-19 patients."( Hydroxychloroquine lung pharmacokinetics in critically ill patients with COVID-19.
Baklouti, S; Concordet, D; Conil, JM; Gandia, P; Georges, B; Goudy, P; Lanot, T; Lavit, M; Losha, E; Mané, C; Minville, V; Rousset, D; Ruiz, S; Vinour, H, 2021
)
2.06
"Hydroxychloroquine (HCQ) dosage required to reach circulating levels that inhibit SARS-Cov-2 are extrapolated from pharmacokinetic data in non-COVID-19 patients."( Pharmacokinetics and pharmacodynamics of hydroxychloroquine in hospitalized patients with COVID-19.
Allenbach, Y; Benveniste, O; Bleibtreu, A; Cacoub, P; Combes, A; Funck-Brentano, C; Gandjbakhch, E; Hekimian, G; Llopis, B; Mayaux, J; Paccoud, O; Pinna, B; Pourcher, V; Saadoun, D; Salem, JE; Urien, S; Zahr, N,
)
1.84
" The derived elimination half-life (t1/2) was 102h."( Pharmacokinetics and pharmacodynamics of hydroxychloroquine in hospitalized patients with COVID-19.
Allenbach, Y; Benveniste, O; Bleibtreu, A; Cacoub, P; Combes, A; Funck-Brentano, C; Gandjbakhch, E; Hekimian, G; Llopis, B; Mayaux, J; Paccoud, O; Pinna, B; Pourcher, V; Saadoun, D; Salem, JE; Urien, S; Zahr, N,
)
0.4
"The interindividual variability of HCQ pharmacokinetic parameters in severe COVID-19 patients was important and differed from that previously reported in non-COVID-19 patients."( Pharmacokinetics and pharmacodynamics of hydroxychloroquine in hospitalized patients with COVID-19.
Allenbach, Y; Benveniste, O; Bleibtreu, A; Cacoub, P; Combes, A; Funck-Brentano, C; Gandjbakhch, E; Hekimian, G; Llopis, B; Mayaux, J; Paccoud, O; Pinna, B; Pourcher, V; Saadoun, D; Salem, JE; Urien, S; Zahr, N,
)
0.4
" However, HCQ pharmacodynamic (PD) responses are difficult to assess in patients, and preclinical studies in mouse models are equivocal with regard to HCQ exposure and inhibition of autophagy."( Pharmacokinetic and Pharmacodynamic Assessment of Hydroxychloroquine in Breast Cancer.
Gustafson, DL; Van Eaton, KM, 2021
)
0.87
"To assess the local tolerability, safety and pharmacokinetic parameters of HCQ inhalations in single ascending doses of 5, 10 and 20 mg using the Cyclops dry powder inhaler."( Tolerability and pharmacokinetic evaluation of inhaled dry powder hydroxychloroquine in healthy volunteers.
Akkerman, OW; Bolhuis, MS; de Reus, YA; Frijlink, HW; Grasmeijer, F; Hagedoorn, P; Kerstjens, HAM; Sibum, I; Sturkenboom, MGG, 2022
)
0.96
"An integrated evaluation of the tissue distribution and pharmacodynamic properties of a therapeutic is essential for successful translation to the clinic."( A multidimensional metabolomics workflow to image biodistribution and evaluate pharmacodynamics in adult zebrafish.
Chamberlain, CA; Doonan, SR; Jackstadt, MM; Patti, GJ; Shriver, LP, 2022
)
0.72
" There is a large degree of uncertainty in HCQ pharmacokinetic (PK) parameters which complicates dose selection when investigating its use in new disease states."( A linked physiologically based pharmacokinetic model for hydroxychloroquine and metabolite desethylhydroxychloroquine in SARS-CoV-2(-)/(+) populations.
Agrawal, V; Arnold, SLM; Barnabas, RV; Bershteyn, A; Chhonker, YS; Heller, KB; Johnston, C; Krows, ML; Landovitz, R; Laufer, M; Leingang, H; Murry, DJ; Paasche-Orlow, M; Stankiewicz Karita, HC; Steinbronn, C; Stewart, J; Wener, M, 2023
)
1.16

Compound-Compound Interactions

Many studies have found that glucocorticoid (GC) combined with hydroxychloroquine (HCQ) has a good clinical effect in the treatment of systemic lupus erythematosus (SLE) rash, but there is no relevant systematic evaluation at present. Nevertheless, the risk of QT prolongation due to drug-drug interactions (DDIs) between hydroxy chloroquine and concomitant medications has not yet been studied. We herein report the first case of hydroxyloroquine retinopathy combined with RPE detachment.

ExcerptReferenceRelevance
"To prospectively determine the efficacy and safety of etanercept in combination with sulfasalazine (SSZ), hydroxychloroquine (HCQ), and gold in the treatment of rheumatoid arthritis (RA)."( Etanercept in combination with sulfasalazine, hydroxychloroquine, or gold in the treatment of rheumatoid arthritis.
Blakely, K; Fernandez, A; Haire, C; Leff, R; O'Dell, JR; Palmer, W; Petersen, K; Schned, E, 2006
)
0.81
"This study is the first to prospectively evaluate the safety of etanercept in combination with SSZ, HCQ, and gold in patients with RA."( Etanercept in combination with sulfasalazine, hydroxychloroquine, or gold in the treatment of rheumatoid arthritis.
Blakely, K; Fernandez, A; Haire, C; Leff, R; O'Dell, JR; Palmer, W; Petersen, K; Schned, E, 2006
)
0.59
"  The present study investigates the change in clinical parameters of erythema, desquamation and edema, when calcineurin inhibitors are used as monotherapy or in combination with hydroxychloroquine in CLE for a period of 60 days."( Effectiveness of topical calcineurin inhibitors as monotherapy or in combination with hydroxychloroquine in cutaneous lupus erythematosus.
Arapaki, A; Avgerinou, G; Katsambas, A; Nasiopoulou, A; Papafragkaki, DK; Stavropoulos, PG, 2012
)
0.79
"  18 patients were treated with topical tacrolimus and 20 patients with topical pimecrolimus, as monotherapy or in combination with hydroxychloroquine."( Effectiveness of topical calcineurin inhibitors as monotherapy or in combination with hydroxychloroquine in cutaneous lupus erythematosus.
Arapaki, A; Avgerinou, G; Katsambas, A; Nasiopoulou, A; Papafragkaki, DK; Stavropoulos, PG, 2012
)
0.81
"To describe a case of hydroxychloroquine retinopathy combined with retinal pigment epithelium (RPE) detachment and evaluate possible causes of pigment epithelium detachment."( Hydroxychloroquine retinopathy combined with retinal pigment epithelium detachment.
Ko, MK; Lee, BR; Lee, WJ, 2012
)
2.14
"We herein report the first case of hydroxychloroquine retinopathy combined with RPE detachment."( Hydroxychloroquine retinopathy combined with retinal pigment epithelium detachment.
Ko, MK; Lee, BR; Lee, WJ, 2012
)
2.1
" Patients were treated orally with escalating doses of HCQ daily (QD) (d 2 to 21 of a 21-d cycle) in combination with 400 mg VOR QD (d one to 21)."( Combined autophagy and HDAC inhibition: a phase I safety, tolerability, pharmacokinetic, and pharmacodynamic analysis of hydroxychloroquine in combination with the HDAC inhibitor vorinostat in patients with advanced solid tumors.
Amaravadi, RK; Carew, JS; Curiel, TJ; Davis, LE; Espitia, CM; Giles, FJ; Mahalingam, D; Mita, AC; Mita, M; Nawrocki, ST; Sarantopoulos, J; Wood, L, 2014
)
0.61
" Murine studies have previously demonstrated that treatment with the late-autophagy inhibitor chloroquine in combination with chemotherapy limited tumor growth."( Safety and Biologic Response of Pre-operative Autophagy Inhibition in Combination with Gemcitabine in Patients with Pancreatic Adenocarcinoma.
Bahary, N; Bao, P; Bartlett, DL; Boone, BA; Espina, V; Liotta, LA; Lotze, MT; Loughran, P; Moser, AJ; Normolle, DP; Singhi, AD; Wu, WC; Zeh, HJ; Zureikat, AH, 2015
)
0.42
"To evaluate the efficacy and safety of orally administered once-daily peficitinib in combination with limited conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) in patients with moderate-to-severe rheumatoid arthritis (RA)."( Peficitinib, a JAK Inhibitor, in Combination With Limited Conventional Synthetic Disease-Modifying Antirheumatic Drugs in the Treatment of Moderate-to-Severe Rheumatoid Arthritis.
Cardiel, MH; Codding, C; Garg, JP; Genovese, MC; Greenwald, M; Kivitz, AJ; Shay, K; Wang, A; Wang, X; Zubrzycka-Sienkiewicz, A, 2017
)
0.46
"In patients with moderate-to-severe RA, orally administered once-daily peficitinib in combination with limited csDMARDs resulted in a dose-dependent ACR20 response rate over 12 weeks with satisfactory tolerability."( Peficitinib, a JAK Inhibitor, in Combination With Limited Conventional Synthetic Disease-Modifying Antirheumatic Drugs in the Treatment of Moderate-to-Severe Rheumatoid Arthritis.
Cardiel, MH; Codding, C; Garg, JP; Genovese, MC; Greenwald, M; Kivitz, AJ; Shay, K; Wang, A; Wang, X; Zubrzycka-Sienkiewicz, A, 2017
)
0.46
"The effect of additional treatments combined with conventional therapy on pregnancy outcomes was examined in high-risk primary antiphospholipid syndrome (PAPS) patients to identify the most effective treatment strategy."( Effect of Additional Treatments Combined with Conventional Therapies in Pregnant Patients with High-Risk Antiphospholipid Syndrome: A Multicentre Study.
Alijotas-Reig, J; Andreoli, L; Bertero, MT; Costedoat-Chalumeau, N; Cuadrado, MJ; De Carolis, S; Gerosa, M; Grandone, E; Haladyj, E; Hoxha, A; Khamashta, MA; Latino, JO; Maina, A; Marozio, L; Mayer-Pickel, K; Mekinian, A; Meroni, PL; Morel, N; Pengo, V; Ramoni, V; Reshetnyak, T; Ruffatti, A; Sciascia, S; Serrano, F; Simchen, MJ; Tenti, S; Tincani, A; Tonello, M; Udry, S, 2018
)
0.48
" Here we report a rare case of MP, which is the first report about treatment by hydroxychloroquine in combination with superficial X-ray."( Hydroxychloroquine combined with superficial X-ray-A new therapeutic method in the treatment of morphea profunda.
Chen, Y; Li, C; Wang, W; Zhang, J, 2019
)
2.18
"Management of drug-drug interactions between investigational anti-SARS-CoV-2 drugs and immunosuppressants is a complex task for the clinician."( Pharmacologic Treatment of Transplant Recipients Infected With SARS-CoV-2: Considerations Regarding Therapeutic Drug Monitoring and Drug-Drug Interactions.
Bergan, S; Elens, L; Hesselink, DA; Langman, LJ; Lemaitre, F; Moes, DJAR; Molinaro, M; Venkataramanan, R, 2020
)
0.56
" However, polypharmacy predisposes patients to increased risk of drug-drug interactions with hydroxychloroquine and may render many in this population ineligible to participate in trials."( COVID-SAFER: Deprescribing Guidance for Hydroxychloroquine Drug Interactions in Older Adults.
Battu, K; Bonnici, A; Downar, J; Elsayed, S; Huang, A; Lee, TC; McDonald, EG; Papillon-Ferland, L; Pilote, L; Porter, S; Rashidi, B; Ross, SB; Tamblyn, R; Wilson, MG; Wu, PE, 2020
)
1.05
" We first identified patients taking medications with potentially harmful drug-drug interactions with hydroxychloroquine that might exclude them from participation in a typical 2019 coronavirus disease (COVID-19) therapeutic trial."( COVID-SAFER: Deprescribing Guidance for Hydroxychloroquine Drug Interactions in Older Adults.
Battu, K; Bonnici, A; Downar, J; Elsayed, S; Huang, A; Lee, TC; McDonald, EG; Papillon-Ferland, L; Pilote, L; Porter, S; Rashidi, B; Ross, SB; Tamblyn, R; Wilson, MG; Wu, PE, 2020
)
1.04
"9%) were receiving one or more home medications that could potentially interact with hydroxychloroquine, and of these, 255 (43."( COVID-SAFER: Deprescribing Guidance for Hydroxychloroquine Drug Interactions in Older Adults.
Battu, K; Bonnici, A; Downar, J; Elsayed, S; Huang, A; Lee, TC; McDonald, EG; Papillon-Ferland, L; Pilote, L; Porter, S; Rashidi, B; Ross, SB; Tamblyn, R; Wilson, MG; Wu, PE, 2020
)
1.05
"The present study was undertaken to investigate the reality of this putative drug-drug interaction between hydroxychloroquine and metformin using pharmacovigilance data."( A New Drug-Drug Interaction Between Hydroxychloroquine and Metformin? A Signal Detection Study.
Montastruc, JL; Toutain, PL, 2020
)
1.05
" Introducing a treatment against COVID-19, either on an outpatient basis or during hospitalization for more severe cases, raises the question of potential drug-drug interactions."( Potential drug-drug interactions associated with drugs currently proposed for COVID-19 treatment in patients receiving other treatments.
Barin-Le Guellec, C; Elens, L; Grégoire, M; Lagarce, L; Lemaitre, F; Polard, E; Saint-Salvi, B; Solas, C; Sommet, A; Tod, M, 2020
)
0.56
" A randomized, double-blind clinical trial was performed to evaluate the efficacy and safety of low-dose oral GCs combined with methotrexate (MTX) and hydroxychloroquine (HCQ) in early RA (ERA)."( Efficacy and safety of low-dose glucocorticoids combined with methotrexate and hydroxychloroquine in the treatment of early rheumatoid arthritis: A single-center, randomized, double-blind clinical trial.
Du, H; Fan, J; Hua, L; Shi, X; Wu, H; Ying, M, 2020
)
0.98
"Low-dose GCs combined with MTX and HCQ significantly achieves disease remission indexed by ACR20 and DAS28-ESR, and improves clinical and radiological outcomes in ERA patients at the early stage, with superiority over placebo + MTX + HCQ, without enhancing adverse reactions."( Efficacy and safety of low-dose glucocorticoids combined with methotrexate and hydroxychloroquine in the treatment of early rheumatoid arthritis: A single-center, randomized, double-blind clinical trial.
Du, H; Fan, J; Hua, L; Shi, X; Wu, H; Ying, M, 2020
)
0.79
" Some studies have shown that COVID-19 combined with diabetes is an independent risk factor for death or other adverse outcomes."( Efficacy and safety of chloroquine and hydroxychloroquine in the treatment of patients with COVID-19 combined with diabetes mellitus: A protocol for systematic review and meta-analysis.
Fu, X; Liu, Y; Xie, C, 2020
)
0.83
"Patients hospitalised with severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2; coronavirus 2019 disease (COVID-19)] infection are frequently older with co-morbidities and receiving polypharmacy, all of which are known risk factors for drug-drug interactions (DDIs)."( Drug-Drug Interactions and Prescription Appropriateness in Patients with COVID-19: A Retrospective Analysis from a Reference Hospital in Northern Italy.
Antinori, S; Bradanini, L; Cattaneo, D; Covizzi, A; Gervasoni, C; Giacomelli, A; Maggioni, AP; Oreni, L; Pasina, L; Ridolfo, A; Schiuma, M, 2020
)
0.56
"To evaluate the therapeutic effectiveness of favipiravir combined with inhaled interferon beta-1b in adult patients hospitalized with moderate to severe COVID-19 pneumonia."( Randomized controlled open label trial on the use of favipiravir combined with inhaled interferon beta-1b in hospitalized patients with moderate to severe COVID-19 pneumonia.
Al Bahrani, M; Al Balushi, Z; Al Barwani, U; Al Lawati, A; Al Naabi, H; Al Salmi, I; Al Sharji, M; Al-Zakwani, I; Ambusaidi, Z; Khamis, F; Pandak, N, 2021
)
0.62
"Many recent studies have investigated the role of either Chloroquine (CQ) or Hydroxychloroquine (HCQ) alone or in combination with azithromycin (AZM) in the management of the emerging coronavirus."( A systematic review and meta-analysis on chloroquine and hydroxychloroquine as monotherapy or combined with azithromycin in COVID-19 treatment.
Almaghraby, A; Beshir, H; Ghazy, RM; Kamal, A; Moursi, A; Ramadan, A; Shaaban, R; Taha, SHN, 2020
)
1.03
" The objective of this study was to analyse the potential drug-drug interactions (pDDIs) derived from the medication used in COVID-19 patients in the first pandemic wave and to evaluate the real consequences of such interactions in clinical practice."( Real-world prevalence and consequences of potential drug-drug interactions in the first-wave COVID-19 treatments.
Álvarez-Payero, M; Casanova-Martínez, C; Castro-Núñez, I; García-Beloso, N; González-Costas, S; Inaraja-Bobo, MT; Leboreiro-Enríquez, B; López-López, A; Lorenzo-Lorenzo, K; Martínez-López-de-Castro, N; Martínez-Reglero, C; Otero-Millán, L; Paradela-Carreiro, A; Pérez-Landeiro, A; Piñeiro-Corrales, G; Regueira-Arcay, AM; Robles-Torres, D; Samartín-Ucha, M; Vázquez-López, C; Yaiza Romero-Ventosa, E, 2021
)
0.62
" The aim of this article is to share pharmacology considerations contributing to the rationale of this combination, and to provide safety information to prevent toxicity and drug-drug interactions, based on available evidence."( Combination of Hydroxychloroquine Plus Azithromycin As Potential Treatment for COVID-19 Patients: Safety Profile, Drug Interactions, and Management of Toxicity.
Brouqui, P; Deharo, JC; Gautret, P; Hache, G; Honoré, S; Raoult, D; Rolain, JM, 2021
)
0.97
" The goal of this study was to predict the potential of 25 small molecule drugs in clinical trials for COVID-19 to cause clinically relevant drug-drug interactions (DDIs), which could lead to potential adverse drug reactions (ADRs) with the use of concomitant medications."( Drugs in COVID-19 Clinical Trials: Predicting Transporter-Mediated Drug-Drug Interactions Using In Vitro Assays and Real-World Data.
Enogieru, OJ; Giacomini, KM; Jakobsen, S; Koleske, ML; Kosti, I; Oskotsky, T; Rödin, M; Sirota, M; Vora, B; Yee, SW; Zou, L, 2021
)
0.62
" Nevertheless, the risk of QT prolongation due to drug-drug interactions (DDIs) between hydroxychloroquine and concomitant medications has not yet been identified."( Risk of QT prolongation through drug interactions between hydroxychloroquine and concomitant drugs prescribed in real world practice.
Choi, BJ; Chung, WY; Jung, YJ; Kim, TY; Koo, Y; Lim, HS; Park, B; Park, JE; Yoon, D, 2021
)
1.09
" However, management of acute seizures in patients with COVID-19 as well as management of PWE and COVID-19 needs to consider potential drug-drug interactions between antiseizure drugs and candidate drugs currently assessed as therapeutic options for COVID-19."( Management of COVID-19 in patients with seizures: Mechanisms of action of potential COVID-19 drug treatments and consideration for potential drug-drug interactions with anti-seizure medications.
Chandra, PP; Jain, S; Potschka, H; Tripathi, M; Vohora, D, 2021
)
0.62
"Primary aim was to assess prevalence and severity of potential and real drug-drug interactions (DDIs) among therapies for COVID-19 and concomitant medications in hospitalized patients with confirmed SARS-CoV-2 infection."( Drug-drug interactions between treatment specific pharmacotherapy and concomitant medication in patients with COVID-19 in the first wave in Spain.
Cantudo-Cuenca, MD; Contreras-Macías, E; Fernández-Fuertes, M; Gutiérrez-Pizarraya, A; Lao-Domínguez, FA; Macías, J; Morillo-Verdugo, R; Pineda, JA; Pinilla-Fernández, A; Rincón, P, 2021
)
0.62
" It was aimed to identify potential clinically significant drug-drug interaction (DDI) pairs of HCQ."( Potential clinically significant drug-drug interactions of hydroxychloroquine used in the treatment of COVID-19.
Biswas, M; Roy, DN, 2021
)
0.86
" This study compare the clinical efficacy and safety of herbal decoction CheReCunJin alone and combined with hydroxychloroquine for the treatment of pSS."( Comparative analysis of the efficacy and safety of herbal decoction CheReCunJin alone and combined with hydroxychloroquine for treating primary Sjögren's syndrome: A randomized controlled trial.
Jin, L; Li, C; Shao, Q; Wang, J; Wang, M; Wang, Q; Wu, B,
)
0.56
"Seventy pSS patients without visceral involvement were randomly assigned in equal numbers to oral administration of CheReCunJin decoction only (group 1) or CheReCunJin decoction combined with hydroxychloroquine (group 2), Efficacy was evaluated after 3 months of treatment by the TCM syndrome and total effectiveness scores, European League Against Rheumatism (EULAR) Sjögren's Syndrome Patient Reported Index (ESSPRI), and Sjögren's Syndrome Disease Activity Index (ESSDAI), Schirmer's test, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and immunoglobulin G (IgG) levels."( Comparative analysis of the efficacy and safety of herbal decoction CheReCunJin alone and combined with hydroxychloroquine for treating primary Sjögren's syndrome: A randomized controlled trial.
Jin, L; Li, C; Shao, Q; Wang, J; Wang, M; Wang, Q; Wu, B,
)
0.54
"In this study, we aimed to explore the effects of iguratimod (IGU) combined with methotrexate (MTX) and hydroxychloroquine (HCQ) on bone mineral density (BMD) in patients with rheumatoid arthritis (RA)."( The effects of iguratimod combined with methotrexate and hydroxychloroquine on bone mineral density in patients with rheumatoid arthritis.
Ma, RR; Wu, F; Wu, TJ; Ying, ZH; Yu, JJ; Zhang, Y, 2021
)
1.08
"This study aimed to analyze the effect of hydroxychloroquine combined with Huangqi tablets in the treatment of diabetic nephropathy (DN)."( The Efficacy of Hydroxychloroquine Combined with Huangqi Tablets in the Treatment of Diabetic Nephropathy.
Chen, X; Kong, X; Sheng, D, 2021
)
1.23
"The aim of the study is to provide an overview of Drug-drug Interactions (DDIs) and adverse effects caused by drugs used in SARS-CoV-2 infection during the first epidemic wave."( [Treatments for SARS-CoV-2 infection: A retrospective study of drug-drug interactions and safety].
Benomar, A; Clou, E; Debrix, I; Dubois, A; Fansi Ndengoue, D; Féral, A; Michot, J; Pain, JB, 2022
)
0.72
" Collectively, these results indicated that the lysosome‑targeted drug combination induces multiple organelle dysfunction and exerts a marked cytotoxic effect in PDAC cells."( Lysosome‑targeted drug combination induces multiple organelle dysfunctions and non‑canonical death in pancreatic cancer cells.
Hiramoto, M; Hirota, A; Kazama, H; Miyazaki, M; Miyazawa, K; Ogawa, M; Ota, K; Suzuki, S; Takano, N, 2022
)
0.72
" This primary evidence may concern preventing potential or unintentional effects resulting from Drug-drug interaction, Improving patient quality of life."( Drug interaction risk between cardioprotective drugs and drugs used in treatment of COVID-19: A evidence-based review from six databases.
B, S; Kalala, KP; P A, A; Pm, A; S K, SR; Sabarathinam, S, 2022
)
0.72
"To observe the clinical efficacy of a multifunctional laser photoelectric platform combined with hydroxychloroquine in the treatment of l sensitive facia skin."( Effect of multifunctional laser photoelectricity platform combined with hydroxychloroquine treatment sensitive facial skin.
Fan, X; Wang, H; Wang, Z; Zhou, S, 2022
)
1.17
" This research explored the effects of hydroxychloroquine combined with low-dose aspirin on maternal and infant outcomes and cytokines of pregnant women with SLE."( Benefits of Hydroxychloroquine Combined with Low-Dose Aspirin on Pregnancy Outcomes and Serum Cytokines in Pregnant Women with Systemic Lupus Erythematosus.
Li, Y; Li, YW; Zhang, HX; Zhang, N, 2023
)
1.56
"Ninety pregnant women with SLE were divided into the hydroxychloroquine (HCQ) group (45 cases) and the hydroxychloroquine combined with low-dose aspirin (HCQASP) group (45 cases) by random number table."( Benefits of Hydroxychloroquine Combined with Low-Dose Aspirin on Pregnancy Outcomes and Serum Cytokines in Pregnant Women with Systemic Lupus Erythematosus.
Li, Y; Li, YW; Zhang, HX; Zhang, N, 2023
)
1.54
"Hydroxychloroquine combined with low-dose aspirin can effectively improve the pregnancy outcomes of pregnant women with SLE by affecting the levels of T helper (Th) 2 and Th1 cytokines."( Benefits of Hydroxychloroquine Combined with Low-Dose Aspirin on Pregnancy Outcomes and Serum Cytokines in Pregnant Women with Systemic Lupus Erythematosus.
Li, Y; Li, YW; Zhang, HX; Zhang, N, 2023
)
2.73
"Drugs that are used in COVID-19 infection, may interact with each other, as well as with the drugs for comorbidities, used concomitantly with COVID-19 treatment."( Evaluation of potential drug-drug interactions and polypharmacy in hospitalized COVID-19 patients.
Erarslan, S; Kilit, TP; Onbaşı, K; Özyiğit, F, 2022
)
0.72
"It is quite important to calculate and present the patients' exposure to clinically important potential drug-drug interactions (pDDIs)."( Evaluation of potential drug-drug interactions and polypharmacy in hospitalized COVID-19 patients.
Erarslan, S; Kilit, TP; Onbaşı, K; Özyiğit, F, 2022
)
0.72
"Many studies have found that glucocorticoid (GC) combined with hydroxychloroquine (HCQ) has a good clinical effect in the treatment of systemic lupus erythematosus (SLE) rash, but there is no relevant systematic evaluation at present."( Meta-analysis of effectiveness and safety of glucocorticoid combined with hydroxychloroquine in the treatment of systemic lupus erythematosus rash.
Fang, H; Guan, T; Liang, S; Wei, Z, 2023
)
1.38
"Randomized controlled trials of GC combined with HCQ in the treatment of SLE rash were collected through computer retrieval of Cochrane Library, PubMed, Embase, CNKI, China Science and Technology Journal Database (VIP), Wanfang Data Knowledge Service Platform (Wanfang), and China Biology Medicine disc (CBM) since the establishment of the database."( Meta-analysis of effectiveness and safety of glucocorticoid combined with hydroxychloroquine in the treatment of systemic lupus erythematosus rash.
Fang, H; Guan, T; Liang, S; Wei, Z, 2023
)
1.14
" The meta-analysis results showed that compared with the single use of GC, GC combined with HCQ could improve the clinical total effective rate in the treatment of SLE rash (odds ratio [OR] = 4."( Meta-analysis of effectiveness and safety of glucocorticoid combined with hydroxychloroquine in the treatment of systemic lupus erythematosus rash.
Fang, H; Guan, T; Liang, S; Wei, Z, 2023
)
1.14
"Compared with the use of GC alone, GC combined with HCQ can improve the clinical effectiveness of SLE rash treatment, with a low incidence of adverse reactions and good clinical safety."( Meta-analysis of effectiveness and safety of glucocorticoid combined with hydroxychloroquine in the treatment of systemic lupus erythematosus rash.
Fang, H; Guan, T; Liang, S; Wei, Z, 2023
)
1.14
" Trametinib in combination with hydroxychloroquine (HCQ) or CDK4/6 inhibitors for pancreatic adenocarcinoma showed promising efficacy in preclinical studies."( A real-world analysis of trametinib in combination with hydroxychloroquine or CDK4/6 inhibitor as third- or later-line therapy in metastatic pancreatic adenocarcinoma.
Bai, C; Cheng, Y; Ge, Y; Li, X; Tang, H; Wang, Y; You, T, 2023
)
1.44

Bioavailability

Hydroxychloroquine and chloroquine (CQ) are well absorbed. Combination treatment of rheumatoid arthritis with MTX and HCQ has been shown, clinically, to be more potent than MTX used alone.

ExcerptReferenceRelevance
"The dissolution procedure serves as a quality control test to assure batch-to-batch uniformity and bioequivalence of a product once the bioavailability of the product has been established."( Influence of higher rates of agitation on release patterns of immediate-release drug products.
Dighe, S; Gurbarg, M; Noory, A; Shah, VP; Skelly, JP, 1992
)
0.28
"Four deconvolution methods (staircase, delta function, and least squares methods using single and sequential first-order input functions) were used to assess the absolute bioavailability of hydroxychloroquine tablets in nine healthy fasting volunteers."( Bioavailability of hydroxychloroquine tablets assessed with deconvolution techniques.
Cutler, DJ; Day, RO; Tett, SE, 1992
)
0.8
" Five healthy volunteers received, in a randomised crossover design study, a 155 mg oral tablet and an intravenous infusion of 155 mg racemic hydroxychloroquine (200 mg hydroxychloroquine sulphate) to assess the bioavailability of the commercially available tablet (Plaquenil, Winthrop Laboratories, Australia)."( Bioavailability of hydroxychloroquine tablets in healthy volunteers.
Brown, KF; Cutler, DJ; Day, RO; Tett, SE, 1989
)
0.81
" Its bioavailability is variable and may decrease by as much as 70% in the presence of food, antacids and iron salts."( Clinical pharmacokinetics of slow-acting antirheumatic drugs.
Tett, SE, 1993
)
0.29
" Bioavailability was estimated using a sequential exponential least squares deconvolution method."( Bioavailability of hydroxychloroquine tablets in patients with rheumatoid arthritis.
Cutler, DJ; Day, RO; McLachlan, AJ; Tett, SE, 1994
)
0.62
"Hydroxychloroquine (HCQ) and chloroquine (CQ) are well absorbed (0."( Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases.
Furst, DE, 1996
)
2.06
" Bioavailability was not limited by tablet formulation."( Hydroxychloroquine relative bioavailability: within subject reproducibility.
Cutler, D; Day, R; Tett, S, 1996
)
1.74
"To examine the bioavailability of methotrexate (MTX) in the presence of hydroxychloroquine (HCQ), and vice versa, to determine a possible pharmacokinetic explanation for the observation that combination treatment of rheumatoid arthritis with MTX and HCQ has been shown, clinically, to be more potent than MTX used alone."( Combination therapy with methotrexate and hydroxychloroquine for rheumatoid arthritis increases exposure to methotrexate.
Beal, J; Carmichael, SJ; Day, RO; Tett, SE, 2002
)
0.81
" Four methods of deconvolution were used to assess the absolute bioavailability of the tablet and oral solution doses."( Absorption and in vivo dissolution of hydroxycholoroquine in fed subjects assessed using deconvolution techniques.
Cutler, DJ; Day, RO; McLachlan, AJ; Tett, SE, 1993
)
0.29
" This study aimed to develop a population PK model including an estimation of the oral bioavailability of HCQ."( Population pharmacokinetics of hydroxychloroquine in patients with rheumatoid arthritis.
Carmichael, SJ; Charles, B; Tett, SE, 2003
)
0.6
" While being relatively well absorbed orally and with good bioavailability, they have long and variable plasma terminal elimination half-lives (approximately 40-60 days)."( Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases.
Clifford-Rashotte, M; Kean, WF; Parke, AL; Rainsford, KD, 2015
)
0.68
" Methotrexate has better bioavailability as injection."( [Update on Current Care Guidelines. Rheumatoid Arthritis (RA)].
, 2015
)
0.42
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
"8% oral bioavailability in mice."( A Chemical Switch for Transforming a Purine Agonist for Toll-like Receptor 7 to a Clinically Relevant Antagonist.
Bandopadhyay, P; Ganguly, D; Kundu, B; Mitra, M; Mukherjee, A; Paul, B; Raychaudhuri, D; Sinha, BP; Talukdar, A, 2020
)
0.56
" Concretely, this relates to (a) the inconsistent individual bioavailability of these drugs at the alveolar target cells, depending on intestinal resorption, hepatic first-pass metabolism and accumulation in liver, spleen and lung, and (b) the need for a relatively high concentration of 1-5 µM at the alveolar surface."( Hydroxychloroquine as an aerosol might markedly reduce and even prevent severe clinical symptoms after SARS-CoV-2 infection.
Hefner, G; Klimke, A; Voss, U; Will, B, 2020
)
2
"7 L/h for the absorption rate constant, the central compartment volume, and the clearance, respectively."( Population Pharmacokinetics of Hydroxychloroquine in COVID-19 Patients: Implications for Dose Optimization.
Belkhir, L; Dauby, N; De Greef, J; Delongie, KA; Dogné, JM; Hamdani, J; Kiridis, S; Lescrainier, C; Musuamba, FT; Nasreddine, R; Thémans, P; Vandeputte, M; Verlinden, V; Wallemacq, P; Wittebole, X; Wuillaume, F; Yombi, JC, 2020
)
0.84
" The bioavailability of IBR was largely improved, and enhanced sensitivity of glioma to IBR was achieved due to inhibition effect of HCQ on IBR-induced pro-survival autophagy."( Co-delivery of ibrutinib and hydroxychloroquine by albumin nanoparticles for enhanced chemotherapy of glioma.
Du, Y; Gao, H; Lei, L; Li, Y; Tong, F; Wang, X; Xia, X; Yang, Z, 2023
)
1.2
" However, clinical evidence has suggested poor outcomes for HCQ due to various obstacles, including non-specific distribution, low aqueous solubility and low bioavailability at target sites, transport across tissue barriers, and retinal toxicity."( Hydroxychloroquine: Key therapeutic advances and emerging nanotechnological landscape for cancer mitigation.
Chang, SK; Chellappan, DK; Dua, K; Gan, SH; Goh, BH; Khaw, KY; Kong, CK; Lai-Foenander, AS; Lee, WL; Low, LE; Ming, LC; Ong, YS; Siew, WS; Singh, SK; Siva, SP; Tey, BT; Wu, Y; Yap, WH, 2023
)
2.35

Dosage Studied

The purpose of this study was to implement a clinical decision support tool (CDS) and assess its impact on adherence to 2016 American Academy of Ophthalmology (AAO) hydroxychloroquine dosing recommendations. Of the 13 institutions listed, 62% recommended maintenance dosing of 200 mg twice daily.

ExcerptRelevanceReference
" Prednisone in high dosage was associated in this series with 9 deaths and in 6 patients, with renal failure or an extra-renal complication."( [Lupus nephropathy. Treatment with the indomethacin-hydroxychloroquine combination and comparison with corticoids].
Conte, JJ; Fournie, GJ; Mignon-Conte, MA, 1975
)
0.51
" Risk factors of unknown degree may appear at this dosage level only when the duration of treatment exceeds 10 years or when chronic renal insufficiency is present."( Ocular safety of hydroxychloroquine sulfate (Plaquenil).
Bernstein, HN, 1992
)
0.62
" Small risk factors may appear at this dosage level only when the duration of treatment exceeds ten years and/or chronic renal insufficiency is present."( Ocular safety of hydroxychloroquine.
Bernstein, HN, 1991
)
0.62
" Taken together, these data suggest that more effective dosage regimens will be possible when therapeutic concentration ranges are properly established."( Antimalarials in rheumatic diseases.
Cutler, D; Day, R; Tett, S, 1990
)
0.28
" Among the steroid-dependent patients, cumulative mean monthly steroid dosage required decreased 50% from 383 mg at entry to 191 mg at week 28 (P less than ."( Open study of hydroxychloroquine in the treatment of severe symptomatic or corticosteroid-dependent asthma.
Charous, BL, 1990
)
0.64
" If response occurred, other medications were first tapered and then the hydroxychloroquine dosage was reduced or stopped."( Hydroxychloroquine is effective therapy for control of cutaneous sarcoidal granulomas.
Callen, JP; Jones, E, 1990
)
1.95
" These patients have their treatment dosage carefully monitored and have been receiving regular ophthalmic examinations."( Screening for hydroxychloroquine retinal toxicity: is it necessary?
Jessop, JD; Livesey, SJ; Mills, PV; Morsman, CD; Richards, IM, 1990
)
0.64
" A period of 6 months is required to achieve 96% of steady-state levels of hydroxychloroquine with the usual once daily, oral dosage regimen."( Bioavailability of hydroxychloroquine tablets in healthy volunteers.
Brown, KF; Cutler, DJ; Day, RO; Tett, SE, 1989
)
0.84
" No nonlinear elimination or distribution processes appeared to be operating at the doses of hydroxychloroquine used in this study, supporting the hypothesis that in the therapeutic dosing range the pharmacokinetics of hydroxychloroquine are linear."( A dose-ranging study of the pharmacokinetics of hydroxy-chloroquine following intravenous administration to healthy volunteers.
Brown, KF; Cutler, DJ; Day, RO; Tett, SE, 1988
)
0.49
"Chloroquine is two to three times as toxic in animals as hydroxychloroquine, even though various single and repeated oral dosage regimens in man have given nearly identical plasma level curves."( Animal toxicity and pharmacokinetics of hydroxychloroquine sulfate.
McChesney, EW, 1983
)
0.78
" Depression of extra-oculogram is an early sign of excessive dosage and can be used to measure potential toxicity during therapy with 4-aminoquinolines."( Pharmacologic actions of 4-aminoquinoline compounds.
Mackenzie, AH, 1983
)
0.27
" In two patients the corticosteroid dosage could be tapered."( Cutaneous lesions of dermatomyositis are improved by hydroxychloroquine.
Bickers, DR; Callen, JP; Hanno, R; Hawkins, C; Voorhees, JJ; Woo, TY, 1984
)
0.52
" Prednisone dosage was decreased or administration discontinued in nine of ten patients (5."( Intractable rheumatoid arthritis. Treatment with combined cyclophosphamide, azathioprine, and hydroxychloroquine.
Carrera, GF; McCarty, DJ, 1982
)
0.48
" I therefore consider these dosage rates safe, since they are below the threshold of retinal toxicity."( Dose refinements in long-term therapy of rheumatoid arthritis with antimalarials.
Mackenzie, AH, 1983
)
0.27
" Many of these reviews, while generally excellent, have propagated some apparent misconceptions by disregarding or de-emphasizing data suggesting that irreversible retinal toxicity due to antimalarials can be easily avoided by judicious daily dosage and regular ophthalmologic follow-up."( Antimalarials and ophthalmologic safety.
Olansky, AJ, 1982
)
0.26
" All patients received the medication for at least one year and most were treated with a daily dosage of 400 mg."( Hydroxychloroquine. Seven-year experience.
Krohel, G; Rynes, RI; Tobin, DR, 1982
)
1.71
" No correlation could be found between indices of visual field function and total drug usage, average daily dose, dosage in mg/kg body weight or duration of treatment."( Hydroxychloroquine, dosage parameters and retinopathy.
Hughes, GR; Spalton, DJ; Verdon Roe, GM, 1993
)
1.73
" The dosage recommended officially for this disease is vague."( Hydroxychloroquine.
Potter, B, 1993
)
1.73
"The risk of retinopathy associated with the use of hydroxychloroquine is said to be nullified if the dosage recommendations are followed strictly."( Hydroxychloroquine toxicity despite normal dose therapy.
Falcone, PM; Lou, PL; Paolini, L, 1993
)
1.98
" The dosage parameters associated with retinopathy are still uncertain as well as the best way to screen for it but the dosage/kg body weight appears to be important."( Retinopathy and antimalarial drugs--the British experience.
Spalton, DJ, 1996
)
0.29
" The significant variability in relative bioavailability between but not within individuals indicated that individualising dosing to target concentrations associated with optimal outcomes may minimise variability in response."( Hydroxychloroquine relative bioavailability: within subject reproducibility.
Cutler, D; Day, R; Tett, S, 1996
)
1.74
"In HCQ-treated patients whose renal function is normal, routine ophthalmic screening is not indicated if the daily dosage is <6."( Incidence of hydroxychloroquine retinopathy in 1,207 patients in a large multicenter outpatient practice.
Cohen, HB; Levy, GD; Munz, SJ; Paschal, J; Peterson, T; Pince, KJ, 1997
)
0.67
" Hydroxychloroquine, given at a dosage of 200-400 mg/day, led to a complete and long-lasting remission."( Chronic ulcerative stomatitis.
Kunzelmann, KH; Meurer, M; Plewig, G; Schaller, M; Wollenberg, A; Wörle, B, 1997
)
1.21
" The primary outcome was time to a major flare of SLE which resulted in either the institution of or an increase in the current dosage of prednisone of 10 mg/day or more, or institution of therapy with immunosuppressive agents."( A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group.
Choquette, D; Cividino, A; Danoff, D; Esdaile, JM; Joseph, L; Osterland, CK; Senécal, JL; Smith, CD; Tsakonas, E; Yeadon, C, 1998
)
0.62
" Patients should be dosed on the basis of ideal body weight (not actual body weight) to reduce the incidence of macular toxicity."( Detection and prevention of maculopathy associated with antimalarial agents.
Easterbrook, M, 1999
)
0.3
"To study the effect of hydroxychloroquine (HCQ) on glucose and insulin homeostasis, healthy rats were dosed with 160 mg x kg (-1) x day(-1) of HCQ orally, and streptozocin-induced diabetic rats received 80, 120, and 160 mg x kg(-1) x day(-1) of HCQ, while controls received normal saline."( Insulin-sparing effect of hydroxychloroquine in diabetic rats is concentration dependent.
Emami, J; Gerstein, HC; Jamali, F; Pasutto, FM, 1999
)
0.91
" Their clinical features illustrate that with normal renal function there is no threshold for total dosage for HCQ toxicity; that color vision testing is important; that almost all patients complain of altered central vision as their first symptom; and that a normal optic fundus does not exclude the diagnosis."( Hydroxychloroquine retinopathy despite regular ophthalmologic evaluation: a consecutive series.
Bienfang, D; Coblyn, JS; Corzillius, M; Liang, MH, 2000
)
1.75
"We report on a case of a 17-year-old female with systemic lupus erythematosus (SLE), with a clinical history of complex partial seizure, who developed a tonicoclonic crisis after receiving hydroxychloroquine for 2 weeks at a dosage of 200 mg/day (5 mg/kg)."( Hydroxychloroquine-induced seizure in a patient with systemic lupus erythematosus.
Cappelli, M; Danieli, MG; Fraticelli, P; Malcangi, G; Palmieri, C, 2000
)
1.94
" Comparing prednisone dosage change, we noted a decrease in the HCQ and an increase in the PL group."( Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study.
Albuquerque, EM; Cataldo, MJ; Duarte, JL; Jesús, NR; Levy, RA; Ramos, RC; Tura, BR; Vilela, VS, 2001
)
1.75
"This report describes the case of an appropriately dosed patient who developed maculopathy <8 years after starting hydroxychloroquine (HCQ) therapy for systemic lupus erythematosus."( Early hydroxychloroquine macular toxicity.
Warner, AE, 2001
)
1
" The primary end points of the study were 1) the percentage of patients with an American College of Rheumatology (ACR) 50% improvement (ACR50) response at 2 years, and 2) the dosage of prednisone at 2 years."( Treatment of early seropositive rheumatoid arthritis: a two-year, double-blind comparison of minocycline and hydroxychloroquine.
Blakely, KW; Eckhoff, PJ; Fernandez, AM; Haire, CE; Klassen, LW; Leff, RD; Mallek, JA; Moore, GF; O'Dell, JR; Palmer, WR; Paulsen, GA; Sems, KM; Wees, SJ, 2001
)
0.52
"All cases arose because of failure by physicians to avoid dosing above published safe levels."( Hydroxychloroquine and chloroquine retinopathy: screening for drug toxicity.
Browning, DJ, 2002
)
1.76
"A dose-response relationship for hydroxychloroquine (HCQ), in terms of the proportion of patients achieving the Paulus 20% criteria for improvement, had previously been observed in patients with rheumatoid arthritis (RA) receiving a 6-week loading regimen of 400, 800, or 1,200 mg HCQ daily."( Hydroxychloroquine concentration-response relationships in patients with rheumatoid arthritis.
Baethge, BA; Botstein, GR; Caldwell, J; Dietz, F; Ettlinger, R; Furst, DE; Gibbs, JP; Golden, HE; Lindsley, H; McLaughlin, GE; Moreland, LW; Munster, T; Roberts, WN; Rooney, TW; Rothschild, B; Sack, M; Sebba, AI; Shen, D; Weisman, M; Welch, KE; Yocum, D, 2002
)
2.04
" HCQ was given at a dosage of 200 mg twice a day."( Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial.
Blakely, K; Churchill, M; Eckhoff, PJ; Felt, J; Fernandez, A; Hadley, S; Haire, C; Klassen, L; Leff, R; Mallek, J; Moore, G; O'Dell, JR; Palmer, W; Paulsen, G; Stoner, J; Waytz, P; Wees, S, 2002
)
0.56
" Risk factors for the development of toxicity are daily dosage related to body weight, total drug dosage and the specific drug used."( (Hydroxy)-chloroquine retinal toxicity: two case reports and safety guidelines.
Herman, K; Leys, A; Spileers, W, 2002
)
0.31
"In a randomized crossover study, 10 healthy subjects received, on each of 5 dosing occasions, MTX alone as tablets or intravenous solution, HCQ alone as a tablet or oral solution, or a coadministered dose of MTX tablets with an HCQ tablet."( Combination therapy with methotrexate and hydroxychloroquine for rheumatoid arthritis increases exposure to methotrexate.
Beal, J; Carmichael, SJ; Day, RO; Tett, SE, 2002
)
0.58
"957) between any of the dosing occasions."( Combination therapy with methotrexate and hydroxychloroquine for rheumatoid arthritis increases exposure to methotrexate.
Beal, J; Carmichael, SJ; Day, RO; Tett, SE, 2002
)
0.58
"For the majority of chronic asthmatics, symptoms are best controlled using inhaled steroids, but for a small group of asthma sufferers, symptoms cannot be controlled using inhaled steroids and instead continuous use of high dosage oral steroids (corticosteroids) are required."( Chloroquine as a steroid sparing agent for asthma.
Bara, A; Dean, T; Dewey, A; Lasserson, TJ; Walters, EH, 2003
)
0.32
" Further trials should optimise oral steroid dosage before addition of the steroid-sparing agent."( Chloroquine as a steroid sparing agent for asthma.
Bara, A; Dean, T; Dewey, A; Lasserson, TJ; Walters, EH, 2003
)
0.32
" A one-compartment PK model was supported, rather than a three-compartment model as previously published, probably because of the clustering of concentrations taken at the end of a dosing interval."( Population pharmacokinetics of hydroxychloroquine in patients with rheumatoid arthritis.
Carmichael, SJ; Charles, B; Tett, SE, 2003
)
0.6
" Ideal agents would be efficacious, easily dosed and administered, inexpensive, and with few adverse effects."( Chloroquine and hydroxychloroquine as inhibitors of human immunodeficiency virus (HIV-1) activity.
Hoven, AD; Romanelli, F; Smith, KM, 2004
)
0.67
" Although its pathogenesis is unclear, risk factors include: daily dosage of hydroxychloroquine, cumulative dosage, duration of treatment, coexisting renal or liver disease, patient age, and concomitant retinal disease."( Ocular toxicity of hydroxychloroquine.
Kwok, AK; Yam, JC, 2006
)
0.89
" Dosage adjustments and additions of further DMARDs were contingent on response to therapy and tolerance."( Response-driven combination therapy with conventional disease-modifying antirheumatic drugs can achieve high response rates in early rheumatoid arthritis with minimal glucocorticoid and nonsteroidal anti-inflammatory drug use.
Ayres, OC; Caughey, GE; Cleland, LG; Goldblatt, F; Hill, CL; James, MJ; Keen, HI; Lee, AT; Proudman, SM; Rischmueller, M; Stamp, LK, 2007
)
0.34
"This implementation study demonstrates the feasibility, safety, and efficacy of combination therapy with inexpensive DMARDs, fish oil, and minimal glucocorticoid use, in routine clinical practice using predefined rules for dosage adjustment."( Response-driven combination therapy with conventional disease-modifying antirheumatic drugs can achieve high response rates in early rheumatoid arthritis with minimal glucocorticoid and nonsteroidal anti-inflammatory drug use.
Ayres, OC; Caughey, GE; Cleland, LG; Goldblatt, F; Hill, CL; James, MJ; Keen, HI; Lee, AT; Proudman, SM; Rischmueller, M; Stamp, LK, 2007
)
0.34
" A young patient presenting with toxic maculopathy after 57 g of hydroxychloroquine and a daily dosage of 2 mg/kg body weight prompted us to retrospectively look at our patients examined in this respect over about 1 year."( [Chloroquine/hydroxychloroquine: variability of retinotoxic cumulative doses].
Berndt, S; Foerster, J; Rüther, K; Schroeter, J, 2007
)
0.95
"Hydroxychloroquine was found to be significantly more effective than chloroquine in the treatment of polymorphic light eruption and can be used safely in the dosage studied in such patients with little risk of ocular toxicity."( Comparative study of efficacy and safety of hydroxychloroquine and chloroquine in polymorphic light eruption: a randomized, double-blind, multicentric study.
Chandurkar, N; Khopkar, U; Naik, GS; Pareek, A; Sacchidanand, S,
)
1.84
"5 months) were randomized to receive step-up therapy (sulfasalazine [SSZ] monotherapy, then after 3 months, methotrexate [MTX] was added, and when the maximum tolerated dosage of MTX was reached, hydroxychloroquine [HCQ] was added) or parallel triple therapy (SSZ/MTX/HCQ)."( Triple therapy in early active rheumatoid arthritis: a randomized, single-blind, controlled trial comparing step-up and parallel treatment strategies.
Capell, HA; Kincaid, W; McMahon, AD; Porter, DR; Saunders, SA; Stirling, A; Vallance, R, 2008
)
0.54
" Among patients who had taken a cumulative dose of less than 1,250 g, 7 of 67 eyes (10%) showed a characteristic mfERG defect, while in patients with a cumulative dosage of 1,250 g or more, 26 of 64 eyes (41%) showed one of these defects."( Using multifocal ERG ring ratios to detect and follow Plaquenil retinal toxicity: a review : Review of mfERG ring ratios in Plaquenil toxicity.
Lyons, JS; Severns, ML, 2009
)
0.35
" Subcutaneous administration of methotrexate was more effective than the oral administration at the same dosage in patients suffering from active rheumatoid arthritis."( [What's new in internal medicine?].
Francès, C, 2008
)
0.35
" A higher dosage per kg body mass, long therapy duration, presence of keratopathy and renal or hepatic dysfunction are probably associated with an increased risk to develop a maculopathy/retinopathy."( [Retinal damage by (hydroxy)chloroquine intake: published evidence for an efficient ophthalmological follow-up].
Pluta, JP; Rüther, K, 2009
)
0.35
" After two years, the choice and dosing of DMARDs and prednisolone were not restricted, but the treatment was still targeted to achieve or maintain remission."( Renal safety of initial combination versus single DMARD therapy in patients with early rheumatoid arthritis: an 11-year experience from the FIN-RACo Trial.
Hannonen, PJ; Kaipiainen-Seppänen, OA; Karjalainen, AH; Karstila, KL; Korpela, MM; Leirisalo-Repo, M; Möttönen, TT; Mustonen, JT; Rantalaiho, VM,
)
0.13
" While every patient received 400 mg of hydroxychloroquine per day, every patient exceeded the recommended daily dosage allowance (6."( Clinical characteristics of hydroxychloroquine retinopathy.
Aaberg, TM; Hubbard, GB; Payne, JF; Yan, J, 2011
)
0.93
" Individual and weight-adapted dosing is especially essential for chloroquine."( Evaluation of risk factors for retinal damage due to chloroquine and hydroxychloroquine.
Bergholz, R; Rüther, K; Schroeter, J, 2010
)
0.6
"In this retrospective study, patients with a diagnosis of perniosis treated with hydroxychloroquine were analyzed for dosage required, subjective improvement in signs and symptoms, and adverse drug reactions."( Successful treatment of perniosis with hydroxychloroquine.
English, JC; Perez, OA; Yang, X, 2010
)
0.86
"The prior recommendation emphasized dosing by weight."( Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy.
Kellner, U; Lai, TY; Lyons, JS; Marmor, MF; Mieler, WF, 2011
)
0.61
"In our patient, sarcoidosis developed after 3 years of continuous recombinant interferon-beta therapy, dosed 3 times a week."( Sarcoidosis triggered by interferon-Beta treatment of multiple sclerosis: a case report and focused literature review.
Chakravarty, SD; Crow, MK; Harris, ME; Schreiner, AM, 2012
)
0.38
" This prospective randomised, double-blind, placebo-controlled, multicentre study sought to compare standard and adjusted HCQ dosing schedules that target [HCQ] ≥1000 ng/ml to reduce SLE flares."( Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study).
Ackermann, F; Amoura, Z; Asli, B; Aumaître, O; Boutin, du LT; Cacoub, P; Cohen-Bittan, J; Costedoat-Chalumeau, N; Desmurs-Clavel, H; Fain, O; Francès, C; Galicier, L; Hulot, JS; Jallouli, M; Kahn, JE; Le Guern, V; Lechat, P; Leroux, G; Limal, N; Lioté, F; Musset, L; Papo, T; Perard, L; Piette, JC; Pourrat, J; Sacré, K; Sailler, L; Smail, A; Stirnemann, J; Tanguy, ML, 2013
)
1.83
" HCPs completed surveys before and after viewing the MBDA test result, recording dosage and frequency for all planned RA medications and physician global assessment of disease activity."( Impact of a multi-biomarker disease activity test on rheumatoid arthritis treatment decisions and therapy use.
Cavet, G; Emerling, D; Ford, K; Li, W; Sasso, EH, 2013
)
0.39
"Detection of toxic daily dosing is a cost-effective way to reduce hydroxychloroquine toxicity, but height, weight, and daily dose were commonly not checked."( Impact of the revised american academy of ophthalmology guidelines regarding hydroxychloroquine screening on actual practice.
Browning, DJ, 2013
)
0.86
" Twenty patients in Group C were treated with YFI and hydroxychloroquine sulfate tablet (with the same dose and dosage as Group A and B)."( [Analysis of the clinical efficacy of yiqi fumai injection combined hydroxychloroquine sulfate tablet for treating Sjogren's syndrome].
Chen, FY; Wang, H; Xue, B, 2012
)
0.86
" Studies included were trials in which: (1) the participants were classified as having GCA by the 1990 ACR criteria or biopsy proven disease; (2) parallel-group randomised control of at least 16 weeks duration had been conducted with at least 20 participants; (3) the design included either alternative adjunct immunosuppressant regimens, alternative GCs dosing or routes of administration; and (4) outcome data was included on either relapse rates or rates of infection."( Prednisolone combined with adjunctive immunosuppression is not superior to prednisolone alone in terms of efficacy and safety in giant cell arteritis: meta-analysis.
Loke, YK; MacGregor, AJ; Watts, RA; Yates, M, 2014
)
0.4
" We present data from the Amsterdam Lupus Cohort on use, reasons for non-use, and dosage related intolerance of AMs, as well as disease related variables associated with non-use."( Long-term evaluation of antimalarials in a Dutch SLE cohort: intolerance and other reasons for non-use.
Bultink, IE; Tsang-A-Sjoe, MW; Voskuyl, AE,
)
0.13
" Daily dosage of HCQ was 400 mg in 115/136 (84."( Long-term evaluation of antimalarials in a Dutch SLE cohort: intolerance and other reasons for non-use.
Bultink, IE; Tsang-A-Sjoe, MW; Voskuyl, AE,
)
0.13
" The effect of biologics was consistent across all multivariate stratified analyses and the association between biologics use and cancer risk was independent of dosage of concomitant nbDMARDs."( The risk of cancer in patients with rheumatoid arthritis taking tumor necrosis factor antagonists: a nationwide cohort study.
Chang, YT; Chen, CC; Chen, DY; Chen, YJ; Ho, HJ; Kuo, KN; Liu, HN; Shen, JL; Wu, CY, 2014
)
0.4
"To reassess the prevalence of and risk factors for hydroxychloroquine retinal toxicity and to determine dosage levels that facilitate safe use of the drug."( The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy.
Marmor, MF; Melles, RB, 2014
)
0.9
" The authors discuss the usefulness dosage of anti-cyclic citrullinated peptide antibodies for establishing the differential diagnosis between rheumatoid arthritis and hepatitis C-related arthropathy and the particularities of the specific treatment when there is a hepatitis C virus associated infection."( Differentiation of rheumatoid arthritis from hepatitis C-related arthropathy: case report.
Arhire, O; Dima-Cozma, C; Macovei, L; Mitu, F; Rezuş, E,
)
0.13
"Subgroup analyses for the response to antimalarials considering CLE subtypes, type, and dosage of antimalarials could not be performed because of the lack of available data."( Influence of smoking on the efficacy of antimalarials in cutaneous lupus: a meta-analysis of the literature.
Amoura, Z; Arnaud, L; Barete, S; Chasset, F; Francès, C, 2015
)
0.42
" A new study indicates that toxicity is not as rare as once believed, but depends critically on daily dosage and duration of use, as well as other risk factors."( A Critical Review of the Effects of Hydroxychloroquine and Chloroquine on the Eye.
Brézin, AP; Costedoat-Chalumeau, N; Dunogué, B; Jallouli, M; Le Guern, V; Leroux, G; Marmor, MF; Melles, RB; Morel, N; Piette, JC, 2015
)
0.69
" These agents are generally used in fixed, weight-based dosing regimens, and both incomplete response and adverse effects are common."( Optimizing the use of existing therapies in lupus.
Croyle, L; Morand, EF, 2015
)
0.42
" If the quinoline-based strategies should nevertheless be pursued in future studies, particular care must be devoted to the dosage selection, in order to maximize the chances to obtain effective in vivo drug concentrations."( Chloroquine and beyond: exploring anti-rheumatic drugs to reduce immune hyperactivation in HIV/AIDS.
Savarino, A; Shytaj, IL, 2015
)
0.42
" There is disagreement about dosing; rheumatologists recommend weight-based dosing while some other specialists advocate height-based "ideal body weight" dosing."( Hydroxychloroquine Blood Levels in Systemic Lupus Erythematosus: Clarifying Dosing Controversies and Improving Adherence.
Clarke, WA; Durcan, L; Magder, LS; Petri, M, 2015
)
1.86
" Renal failure dosing led to suboptimum levels."( Hydroxychloroquine Blood Levels in Systemic Lupus Erythematosus: Clarifying Dosing Controversies and Improving Adherence.
Clarke, WA; Durcan, L; Magder, LS; Petri, M, 2015
)
1.86
" Based on this study, the dosage regimens of HCQ sulfate for Japanese patients with CLE/SLE should be calculated using the individual ideal body weight."( Population Pharmacokinetics of Hydroxychloroquine in Japanese Patients With Cutaneous or Systemic Lupus Erythematosus.
Morita, S; Takahashi, T; Yokota, N; Yoshida, Y, 2016
)
0.72
" Median adjusted daily dosage was 11."( Retinal toxicity of high-dose hydroxychloroquine in patients with chronic graft-versus-host disease.
Boyd, S; Easterbrook, M; Hammoudi, DS; Krema, H; Lipton, JH; Navajas, EV; Simpson, ER, 2015
)
0.71
" After a 2-month course of treatment with hydroxychloroquine dosage of 200 mg per day and a break of 3 months between courses, we observed a complete remission."( Unilateral unique Lupus tumidus: pathogenetic mystery and diagnostic problem.
Bakardzhiev, I; Chokoeva, AA; Krasnaliev, I; Lotti, T; Tana, C; Tchernev, G; Wollina, U, 2016
)
0.7
"To determine dosing patterns and examine predictors of filled hydroxychloroquine (HCQ) prescriptions in patients with systemic lupus erythematosus (SLE) with end-stage renal disease (ESRD)."( Hydroxychloroquine in patients with systemic lupus erythematosus with end-stage renal disease.
Bethel, M; Carbone, LD; Li, S; Machua, W; Nahman, NS; Oliver, AM; Yang, FM, 2016
)
2.12
"In patients with SLE with ESRD, the dosing strategies for HCQ with regard to potential toxicity and disparities in prescribing patterns need further study."( Hydroxychloroquine in patients with systemic lupus erythematosus with end-stage renal disease.
Bethel, M; Carbone, LD; Li, S; Machua, W; Nahman, NS; Oliver, AM; Yang, FM, 2016
)
1.88
" Cases (1555 patients with SLE who developed HZ) and controls (3049 age- and sex-matched patients with SLE but without HZ) were analyzed for use of various immunosuppressive medications in the preceding 3-month period, and dose-response relationships were determined."( Immunosuppressive medication use and risk of herpes zoster (HZ) in patients with systemic lupus erythematosus (SLE): A nationwide case-control study.
Chen, GS; Hu, SC; Lin, CL; Lin, YC; Wang, TN; Yen, FL, 2016
)
0.43
"Current technology of siRNA delivery relies on pharmaceutical dosage forms to route maximal doses of siRNA to the tumor."( Hydroxychloroquine-conjugated gold nanoparticles for improved siRNA activity.
Cabral, H; Dirisala, A; Hespel, L; Kataoka, K; Mi, P; Miyata, K; Perche, F; Yi, Y, 2016
)
1.88
" While the mechanisms for the differential responses to drug therapy are unclear, variation in drug exposure with the same dosing protocol related to pharmacogenetic and pharmacokinetic factors may contribute."( Therapeutic monitoring of the immuno-modulating drugs in systemic lupus erythematosus.
Mok, CC, 2017
)
0.46
" HCQ may reduce the risk of flares, allow the reduction of the dosage of steroids, reduce organ damage, and prevent the thrombotic effects of anti-phospholipid antibodies."( Hydroxychloroquine in systemic lupus erythematosus (SLE).
Moroni, G; Ponticelli, C, 2017
)
1.9
"To study the adherence of rheumatologists to the hydroxychloroquine (HCQ) dosing guidelines established by the American Academy of Ophthalmology in 2011 and 2016."( Adherence to Hydroxychloroquine Dosing Guidelines by Rheumatologists: An Electronic Medical Record-Based Study in an Integrated Health Care System.
Braslow, RA; Macsai, MS; Shiloach, M, 2017
)
1.08
"Data on patient weights, height, gender, and HCQ dosage were extracted from the EMR."( Adherence to Hydroxychloroquine Dosing Guidelines by Rheumatologists: An Electronic Medical Record-Based Study in an Integrated Health Care System.
Braslow, RA; Macsai, MS; Shiloach, M, 2017
)
0.82
" A separate analysis of all patients currently receiving maintenance HCQ therapy demonstrated excess dosing in 297 of 527 (56%), according to the 2016 guidelines."( Adherence to Hydroxychloroquine Dosing Guidelines by Rheumatologists: An Electronic Medical Record-Based Study in an Integrated Health Care System.
Braslow, RA; Macsai, MS; Shiloach, M, 2017
)
0.82
" Our data suggest that the publication of the consensus guidelines in 2011 had no appreciable effect on HCQ dosing and that transitioning to the 2016 dosing modification is unlikely to change this outcome unless additional steps are taken to improve adherence."( Adherence to Hydroxychloroquine Dosing Guidelines by Rheumatologists: An Electronic Medical Record-Based Study in an Integrated Health Care System.
Braslow, RA; Macsai, MS; Shiloach, M, 2017
)
0.82
" HCQ is generally safe and effective for the treatment of systemic disease but because of the risk of HCQ retinal toxicity, modern screening methods and ideal dosing should be implemented."( Hydroxychloroquine retinopathy.
Downes, SM; Luqmani, R; Sharma, S; Yusuf, IH, 2017
)
1.9
" All patients completed a structured questionnaire to collect demographic data, dosage and treatment duration of hydroxychloroquine, other drug intake, hydroxychloroquine indication, and presence of pigmentary changes on the skin, nail, hair, and mucosa."( Hydroxychloroquine-induced hyperpigmentation in systemic diseases: prevalence, clinical features and risk factors: a cross-sectional study of 41 cases.
Bahloul, E; Bahloul, Z; Garbaa, S; Jallouli, M; Marzouk, S; Masmoudi, A; Turki, H, 2017
)
2.11
" Adhering to careful weight-based dosing can significantly reduce the risk of this adverse event and is recommended in recent guidelines."( Hydroxychloroquine dosing in immune-mediated diseases: implications for patient safety.
Gianfrancesco, MA; Haserodt, S; Izadi, Z; Jafri, K; Schmajuk, G; Shiboski, S; Sirota, M; Trupin, L; Yazdany, J, 2017
)
1.9
" Each patient was fasted overnight and had standardized meals and dosing schedule."( Steady-state pharmacokinetics of hydroxychloroquine in patients with cutaneous lupus erythematosus.
Al-Rawi, H; Meggitt, SJ; Wahie, S; Williams, FM, 2018
)
0.76
" Proper dosing of maximum 5 mg/kg and regular screening according to risk factors are important in HCQ use."( Risk of Retinal Toxicity in Longterm Users of Hydroxychloroquine.
Choe, JY; Kim, JW; Kim, SK; Kim, YY; Lee, H; Park, SH, 2017
)
0.71
" In patients with SDC measured, dosage was adjusted in 41% (n = 68), concerning an increase in 64 patients."( The effect of measuring serum doxycycline concentrations on clinical outcomes during treatment of chronic Q fever.
Bleeker-Rovers, CP; de Regt, MJA; Hoepelman, AIM; Kampschreur, LM; Oosterheert, JJ; van Roeden, SE; Vermeulen Windsant, A; Wever, PC, 2018
)
0.48
"SDC measurement decreases the risk for disease-related events, potentially through more optimal dosing or improved compliance."( The effect of measuring serum doxycycline concentrations on clinical outcomes during treatment of chronic Q fever.
Bleeker-Rovers, CP; de Regt, MJA; Hoepelman, AIM; Kampschreur, LM; Oosterheert, JJ; van Roeden, SE; Vermeulen Windsant, A; Wever, PC, 2018
)
0.48
"Hydroxychloroquine dosage restrictions may have reduced efficacy."( Hydroxychloroquine Effectiveness in Reducing Symptoms of Hand Osteoarthritis: A Randomized Trial.
Arden, NK; Arundel, C; Birrell, F; Conaghan, PG; Dickson, J; Doherty, M; Dziedzic, K; Garrood, T; Grainger, A; Green, M; Keding, A; Kingsbury, SR; Menon, A; O'Neill, TW; Ronaldson, SJ; Scott, DL; Sheeran, T; Tharmanathan, P; Torgerson, D; Vincent, T; Wakefield, RJ; Watt, FE, 2018
)
3.37
"Ninety patients with IgAN who received HCQ in addition to optimized dosage of renin-angiotensin-aldosterone system inhibitors (RAASi) were recruited for this study, and 90 matched historical controls who received RAASi alone were selected from our registry by the propensity score matching method."( Effects of Hydroxychloroquine on Proteinuria in Immunoglobulin A Nephropathy.
Chen, YQ; Liu, LJ; Lv, JC; Shi, SF; Wang, JW; Yang, YZ; Zhang, H, 2018
)
0.87
" We developed and validated a novel ion-pairing HPLC-FL method for the simultaneous dosage of HCQ, and its major metabolites desethylhydroxychloroquine, desethylchloroquine and bisdesethylchloroquine, after extraction from whole blood."( Development of a novel ion-pairing HPLC-FL method for the separation and quantification of hydroxychloroquine and its metabolites in whole blood.
Charlier, B; Conti, V; Dal Piaz, F; Filippelli, A; Izzo, V; Pingeon, M; Valentini, G, 2018
)
0.91
"We aimed to assess the impact of ophthalmology weight-based hydroxychloroquine (HCQ) dosing guidelines on prescribing patterns."( Sharp decline in hydroxychloroquine dosing-analysis of 17,797 initiators from 2007 to 2016.
Choi, HK; Jorge, AM; Marmor, MF; Melles, RB; Zhang, Y, 2018
)
1.06
"Two patients with dermatological conditions developed retinal toxicity after treatment with hydroxychloroquine that exceeded dosing recommendations."( Hydroxychloroquine retinal toxicity in two patients with dermatological conditions.
Baker, C; Kowalski, T; Mack, HG, 2018
)
2.14
" Appropriate dosing and recognition of early disease are important to minimize adverse visual sequelae."( Case Report: Hydroxychloroquine Retinopathy.
Chan, EW; Eldeeb, M; Omar, A, 2018
)
0.85
"The 2016 American Academy of Ophthalmology guidelines for hydroxychloroquine retinopathy were revised to reflect new dosing and care guidelines for early detection of retinal toxicity and to minimize the extent of irreversible vision loss."( Case Report: Hydroxychloroquine Retinopathy.
Chan, EW; Eldeeb, M; Omar, A, 2018
)
1.09
"Hydroxychloroquine (HCQ) retinopathy may be more common than previously recognized; recent ophthalmology guidelines have revised recommendations from ideal body weight (IBW)-based dosing to actual body weight (ABW)-based dosing."( Hydroxychloroquine prescription trends and predictors for excess dosing per recent ophthalmology guidelines.
Aranow, C; Askanase, A; Choi, H; Clarke, AE; Costenbader, KH; Esdaile, JM; Jorge, AM; Lim, SS; Lu, N; Melles, RB; Petri, M; Rai, SK; Ramsey-Goldman, R; Urowitz, MB; Young, LH; Zhang, Y, 2018
)
3.37
"We examined a UK general population database to investigate HCQ dosing between 2007 and 2016."( Hydroxychloroquine prescription trends and predictors for excess dosing per recent ophthalmology guidelines.
Aranow, C; Askanase, A; Choi, H; Clarke, AE; Costenbader, KH; Esdaile, JM; Jorge, AM; Lim, SS; Lu, N; Melles, RB; Petri, M; Rai, SK; Ramsey-Goldman, R; Urowitz, MB; Young, LH; Zhang, Y, 2018
)
1.92
"Among 20,933 new HCQ users (78% female), the proportions of initial HCQ excess dosing declined from 40% to 36% using IBW and 38% to 30% using ABW, between 2007 and 2016."( Hydroxychloroquine prescription trends and predictors for excess dosing per recent ophthalmology guidelines.
Aranow, C; Askanase, A; Choi, H; Clarke, AE; Costenbader, KH; Esdaile, JM; Jorge, AM; Lim, SS; Lu, N; Melles, RB; Petri, M; Rai, SK; Ramsey-Goldman, R; Urowitz, MB; Young, LH; Zhang, Y, 2018
)
1.92
"A substantial proportion of HCQ users in the UK, particularly women, may have excess HCQ dosing per the previous or recent weight-based guidelines despite a modest decline in recent years."( Hydroxychloroquine prescription trends and predictors for excess dosing per recent ophthalmology guidelines.
Aranow, C; Askanase, A; Choi, H; Clarke, AE; Costenbader, KH; Esdaile, JM; Jorge, AM; Lim, SS; Lu, N; Melles, RB; Petri, M; Rai, SK; Ramsey-Goldman, R; Urowitz, MB; Young, LH; Zhang, Y, 2018
)
1.92
" A distinguishing feature of CUS is the low response to conventional corticosteroid therapy and the good outcome with hydroxychloroquine at the dosage of 200 mg/day or higher dosages."( Chronic ulcerative stomatitis: A comprehensive review and proposal for diagnostic criteria.
Azzi, L; Cerati, M; Croveri, F; Lombardo, M; Maurino, V; Olszewska, M; Pellilli, M; Tagliabue, A; Tettamanti, L, 2019
)
0.72
" The relationships between the RNFL thicknesses and the duration or cumulative dosage of HCQ use were analyzed."( Peripapillary Retinal Nerve Fiber Layer Thicknesses Did Not Change in Long-term Hydroxychloroquine Users.
Cha, HS; Eo, DR; Ham, DI; Han, JC; Kang, SW; Kee, C; Kim, SJ; Koh, EM; Lee, EJ; Lee, J; Lee, MG, 2018
)
0.71
"01), particularly those using corticosteroids with a cumulative dosage >5g (cases/controls: n=17/5, AOR=2."( The influence of immunosuppressants on the non-melanoma skin cancer among patients with systemic lupus erythematosus and primary Sjögren's syndrome: a nationwide retrospective case-control study in Taiwan.
Huang, WC; Lu, LY; Tseng, HW,
)
0.13
" Although new recommendations exist for hydroxychloroquine dosing, there is still uncertainty about the dosage that will elicit a satisfactory response in CLE while limiting adverse effects, specifically retinopathy."( An update on the use of hydroxychloroquine in cutaneous lupus erythematosus: A systematic review.
Demetres, M; Jorizzo, JL; Shipman, WD; Vernice, NA, 2020
)
1.13
" These studies show that a hydroxychloroquine dosage up to 400 mg/d is effective for most CLE patients (range of effectiveness, 50%-97%), with few adverse effects."( An update on the use of hydroxychloroquine in cutaneous lupus erythematosus: A systematic review.
Demetres, M; Jorizzo, JL; Shipman, WD; Vernice, NA, 2020
)
1.16
"Daily dosing based on real and ideal weight was calculated."( The 2016 American Academy of Ophthalmology Hydroxychloroquine Dosing Guidelines For Short, Obese Patients.
Browning, DJ; Easterbrook, M; Lee, C, 2019
)
0.78
"Determine the number (and percentage) of patients given daily dosing according to real-weight and ideal-weight guidelines."( The 2016 American Academy of Ophthalmology Hydroxychloroquine Dosing Guidelines For Short, Obese Patients.
Browning, DJ; Easterbrook, M; Lee, C, 2019
)
0.78
"Twenty-seven percent of cases of hydroxychloroquine retinopathy in obese women had ostensibly safe dosing based on 2016 AAO guidelines."( The 2016 American Academy of Ophthalmology Hydroxychloroquine Dosing Guidelines For Short, Obese Patients.
Browning, DJ; Easterbrook, M; Lee, C, 2019
)
1.06
" We found that the sonodynamic therapy (SDT) in low dosage induced autophagy and might function as a survival pathway for breast cancer and exhibit resistance to SDT-mediated apoptosis."( Cancer Cell Membrane-Biomimetic Nanoplatform for Enhanced Sonodynamic Therapy on Breast Cancer via Autophagy Regulation Strategy.
Feng, Q; Feng, X; Hao, Y; Hou, L; Wang, N; Yang, X; Zhang, Z, 2019
)
0.51
" Embedding the taste-masking and suspension agents within the adult tablet formulation would remove the need for aqueous-based vehicles and simplify the creation of a water-based suspension formulation to support improved compliance, dosing accuracy, and health outcomes in pediatric patients who are weight-base dosed with HCQ."( Evaluation of an Immediate-Release Formulation of Hydroxychloroquine Sulfate With an Interwoven Pediatric Taste-Masking System.
Brackett, J; Joshi, H; Pauli, E; Towa, L; Vasavada, A, 2020
)
0.81
" The unknown dose-response relationships of these drugs and the lack of definitions of the minimum dose needed for clinical efficacy and what doses are toxic pose challenges to clinical practice."( Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology.
Dörner, T; Schrezenmeier, E, 2020
)
0.87
" Using the PBPK models, hydroxychloroquine concentrations in lung fluid were simulated under 5 different dosing regimens to explore the most effective regimen while considering the drug's safety profile."( In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Cui, C; Dong, E; Huang, B; Li, H; Liu, D; Liu, X; Lu, R; Niu, P; Song, C; Tan, W; Yao, X; Ye, F; Zhan, S; Zhang, M; Zhao, L, 2020
)
1.1
" The objectives of our study were (1) to characterize the frequency of inappropriate HCQ dosing and retinopathy screening, and (2) to improve guideline-based management by implementing quality improvement (QI) strategies."( Improving Hydroxychloroquine Dosing and Toxicity Screening at a Tertiary Care Ambulatory Center: A Quality Improvement Initiative.
Farrer, C; Gakhal, N; Gottheil, S; Koppikar, S, 2021
)
1.02
" The primary aim was to increase the percentage of patients appropriately dosed from 30% to 90% over a 10-month period."( Improving Hydroxychloroquine Dosing and Toxicity Screening at a Tertiary Care Ambulatory Center: A Quality Improvement Initiative.
Farrer, C; Gakhal, N; Gottheil, S; Koppikar, S, 2021
)
1.02
" Appropriate HCQ dosing improved from 30% to 89%."( Improving Hydroxychloroquine Dosing and Toxicity Screening at a Tertiary Care Ambulatory Center: A Quality Improvement Initiative.
Farrer, C; Gakhal, N; Gottheil, S; Koppikar, S, 2021
)
1.02
"Dosing charts in clinic rooms, addition of weight scales, and EMR force function autodosing prescriptions significantly improved appropriate HCQ dosing practices."( Improving Hydroxychloroquine Dosing and Toxicity Screening at a Tertiary Care Ambulatory Center: A Quality Improvement Initiative.
Farrer, C; Gakhal, N; Gottheil, S; Koppikar, S, 2021
)
1.02
" However, all ongoing clinical trials with HCQ use different dosing regimens, resulting in various concentrations."( Towards Optimization of Hydroxychloroquine Dosing in Intensive Care Unit COVID-19 Patients.
Botelho-Nevers, É; Delavenne, X; Diconne, É; Lachand, R; Launay, M; Louf-Durier, A; Murgier, M; Page, D; Perinel, S; Thierry, G; Vermesch, R, 2020
)
0.87
" The optimal dosing of HCQ is unknown."( Optimizing Hydroxychloroquine Dosing for Patients With COVID-19: An Integrative Modeling Approach for Effective Drug Repurposing.
Aweeka, F; Ernest, JP; Garcia-Cremades, M; Hughes, E; Luetkemeyer, AF; Savic, RM; Solans, BP; Wallender, E, 2020
)
0.95
"Different dosage regimens of hydroxychloroquine are used to manage coronavirus disease 2019 (COVID-19) patients, without information on the pharmacokinetics in this population."( Hydroxychloroquine in Coronavirus Disease 2019 Patients: What Still Needs to Be Known About the Kinetics.
Concordet, D; Conil, JM; Delavigne, K; Delobel, P; Duhalde, V; Eyvrard, F; Faguer, S; Gandia, P; Georges, B; Guimbaud, R; Izopet, J; Mansuy, JM; Martin-Blondel, G; Minville, V; Murris, M; Pugnet, G; Rolland, Y; Ruiz, S; Silva Sifontes, S, 2020
)
2.29
" Therefore, we propose in a first dose estimation the use of HCQ as an aerosol in a dosage of 2-4 mg per inhalation in order to reach sufficient therapeutic levels at the alveolar epithelial cells."( Hydroxychloroquine as an aerosol might markedly reduce and even prevent severe clinical symptoms after SARS-CoV-2 infection.
Hefner, G; Klimke, A; Voss, U; Will, B, 2020
)
2
" Although in some recent studies a clinical improvement in COVID-19 patients has been observed, the clinical efficacy of CQ and HCQ in COVID-19 has yet to be proven with randomized controlled studies, many of which are currently ongoing, also considering pharmacokinetics, optimal dosing regimen, therapeutic level and duration of treatment and taking into account patients with different severity degrees of disease."( The possible mechanisms of action of 4-aminoquinolines (chloroquine/hydroxychloroquine) against Sars-Cov-2 infection (COVID-19): A role for iron homeostasis?
Biasiotto, G; Magro, P; Quiros Roldan, E; Zanella, I, 2020
)
0.79
"Translation of in vitro antiviral activity to the in vivo setting is crucial to identify potentially effective dosing regimens of hydroxychloroquine."( Connecting Hydroxychloroquine In Vitro Antiviral Activity to In Vivo Concentration for Prediction of Antiviral Effect: A Critical Step in Treating Patients With Coronavirus Disease 2019.
Bergman, K; Fan, J; Huang, SM; Liu, J; Liu, Q; Reynolds, K; Wang, Y; Yang, Y; Zhang, X; Zheng, N; Zhu, H, 2020
)
1.15
" The dosage is two tablets daily, once a week for one to three months (based on the duration of the Coronavirus epidemic in Tehran)."( Effect of hydroxychloroquine on prevention of COVID-19 virus infection among healthcare professionals: a structured summary of a study protocol for a randomised controlled trial.
Dehpour, AR; Mohammad Jafari, R; Moini, A; Pirjani, R; Sepidarkish, M; Shizarpour, A; Soori, T, 2020
)
0.96
" To support pediatric clinical studies for investigational treatments of coronavirus disease 2019 (COVID-19), pediatric-specific dosing is required."( Simulated Assessment of Pharmacokinetically Guided Dosing for Investigational Treatments of Pediatric Patients With Coronavirus Disease 2019.
Balevic, SJ; Benjamin, DK; Cohen-Wolkowiez, M; Gonzalez, D; Hornik, CD; Hornik, CP; Maharaj, AR; Smith, PB; Wu, H; Zimmerman, KO, 2020
)
0.56
"To define pediatric-specific dosing regimens for hydroxychloroquine and remdesivir for COVID-19 treatment."( Simulated Assessment of Pharmacokinetically Guided Dosing for Investigational Treatments of Pediatric Patients With Coronavirus Disease 2019.
Balevic, SJ; Benjamin, DK; Cohen-Wolkowiez, M; Gonzalez, D; Hornik, CD; Hornik, CP; Maharaj, AR; Smith, PB; Wu, H; Zimmerman, KO, 2020
)
0.81
" Physiologically based pharmacokinetic modeling was used to inform pediatric dosing for hydroxychloroquine."( Simulated Assessment of Pharmacokinetically Guided Dosing for Investigational Treatments of Pediatric Patients With Coronavirus Disease 2019.
Balevic, SJ; Benjamin, DK; Cohen-Wolkowiez, M; Gonzalez, D; Hornik, CD; Hornik, CP; Maharaj, AR; Smith, PB; Wu, H; Zimmerman, KO, 2020
)
0.78
" A simulation-based dose-ranging study was conducted in simulated children exploring different absolute and weight-normalized dosing strategies."( Simulated Assessment of Pharmacokinetically Guided Dosing for Investigational Treatments of Pediatric Patients With Coronavirus Disease 2019.
Balevic, SJ; Benjamin, DK; Cohen-Wolkowiez, M; Gonzalez, D; Hornik, CD; Hornik, CP; Maharaj, AR; Smith, PB; Wu, H; Zimmerman, KO, 2020
)
0.56
"For hydroxychloroquine, the physiologically based pharmacokinetic model analysis included 500 and 600 simulated white adult and pediatric participants, respectively, and supported weight-normalized dosing for children weighing less than 50 kg."( Simulated Assessment of Pharmacokinetically Guided Dosing for Investigational Treatments of Pediatric Patients With Coronavirus Disease 2019.
Balevic, SJ; Benjamin, DK; Cohen-Wolkowiez, M; Gonzalez, D; Hornik, CD; Hornik, CP; Maharaj, AR; Smith, PB; Wu, H; Zimmerman, KO, 2020
)
1.12
"This analysis provides pediatric-specific dosing suggestions for hydroxychloroquine and remdesivir and raises concerns regarding hydroxychloroquine use for COVID-19 treatment because concentrations were less than those needed to mediate an antiviral effect."( Simulated Assessment of Pharmacokinetically Guided Dosing for Investigational Treatments of Pediatric Patients With Coronavirus Disease 2019.
Balevic, SJ; Benjamin, DK; Cohen-Wolkowiez, M; Gonzalez, D; Hornik, CD; Hornik, CP; Maharaj, AR; Smith, PB; Wu, H; Zimmerman, KO, 2020
)
0.8
"This paper reviews the mechanism, clinical efficacy and safety, pharmacokinetic characteristics, exposureresponse relationship and precautions and drug interactions of HCQ, and summarizes dosage recommendations for HCQ sulfate."( Review on the Clinical Pharmacology of Hydroxychloroquine Sulfate for the Treatment of COVID-19.
Cui, C; En, VSJ; Li, H; Li, X; Liu, D; Tu, S; Yao, X, 2020
)
0.83
" Although a number of different dosage regimens were assessed, the purpose of our study was not to provide recommendations for a dosing strategy, but to demonstrate the utility of a physiologically-based pharmacokinetic modeling approach to estimate lung concentrations."( Impact of Disease on Plasma and Lung Exposure of Chloroquine, Hydroxychloroquine and Azithromycin: Application of PBPK Modeling.
Almond, LM; Ban Ke, A; Jones, HM; Pan, X; Rowland Yeo, K; Wesche, D; Zhang, M, 2020
)
0.8
" Patients who received hydroxychloroquine (200 mg 3 times daily dosage for 10 days) on a compassionate basis in addition to standard of care (SOC) were compared with patients without contraindications to hydroxychloroquine who received SOC alone."( Compassionate Use of Hydroxychloroquine in Clinical Practice for Patients With Mild to Severe COVID-19 in a French University Hospital.
Baptiste, A; Bleibtreu, A; Boutolleau, D; Burrel, S; Calvez, V; Caumes, E; Faiçal, A; Godefroy, N; Hajage, D; Itani, O; Klement, E; Marcelin, AG; Monsel, G; Paccoud, O; Palich, R; Pourcher, V; Tebano, G; Tubach, F; Tubiana, R; Valantin, MA, 2021
)
1.25
"In the absence of a commonly agreed dosing protocol based on pharmacokinetic (PK) considerations, the dose and treatment duration for hydroxychloroquine (HCQ) in COVID-19 disease currently vary across national guidelines and clinical study protocols."( Model informed dosing of hydroxycholoroquine in COVID-19 patients: Learnings from the recent experience, remaining uncertainties and gaps.
Dauby, N; Delforge, M; Dogné, JM; Hamdani, J; Konopnicki, D; Lebout, F; Lescrainier, C; Libois, A; Musuamba, FT; Nasreddine, R; Payen, MC; Schrooyen, L; Thémans, P; Verlinden, V; Wuillaume, F, 2021
)
0.82
" Limited adverse drug reactions have been reported so far for this dosing regimen, most often confounded by co-medications, comorbidities or underlying COVID-19 disease effects."( Model informed dosing of hydroxycholoroquine in COVID-19 patients: Learnings from the recent experience, remaining uncertainties and gaps.
Dauby, N; Delforge, M; Dogné, JM; Hamdani, J; Konopnicki, D; Lebout, F; Lescrainier, C; Libois, A; Musuamba, FT; Nasreddine, R; Payen, MC; Schrooyen, L; Thémans, P; Verlinden, V; Wuillaume, F, 2021
)
0.62
"Our results were clear, indicating the unmet need for characterization of target PK exposures to inform HCQ dosing optimization in COVID-19."( Model informed dosing of hydroxycholoroquine in COVID-19 patients: Learnings from the recent experience, remaining uncertainties and gaps.
Dauby, N; Delforge, M; Dogné, JM; Hamdani, J; Konopnicki, D; Lebout, F; Lescrainier, C; Libois, A; Musuamba, FT; Nasreddine, R; Payen, MC; Schrooyen, L; Thémans, P; Verlinden, V; Wuillaume, F, 2021
)
0.62
" The suggested dose of chloroquine for COVID-19 infection is considerably higher than the usual dosage for malaria treatment; therefore, it is plausible that the ototoxic effects will be greater."( Clinical Implications of Chloroquine and Hydroxychloroquine Ototoxicity for COVID-19 Treatment: A Mini-Review.
Baguley, DM; Kasbekar, AV; Prayuenyong, P, 2020
)
0.82
"To describe the rationale for revising the hydroxychloroquine (HCQ) dosing and screening guidelines and to identify the barriers to more effective guidelines in the future."( Rethinking the Hydroxychloroquine Dosing and Retinopathy Screening Guidelines.
Browning, DJ; Greenberg, PB; Perlman, E; Yokogawa, N, 2020
)
1.17
"A PubMed query of studies on HCQ dosing and HCQ retinopathy (HCQR) screening was conducted with a selective review of the English language literature."( Rethinking the Hydroxychloroquine Dosing and Retinopathy Screening Guidelines.
Browning, DJ; Greenberg, PB; Perlman, E; Yokogawa, N, 2020
)
0.91
"Three iterations of the American Academy of Ophthalmology HCQ dosing and HCQR screening guidelines have been published without including prescribing physicians on the writing committees."( Rethinking the Hydroxychloroquine Dosing and Retinopathy Screening Guidelines.
Browning, DJ; Greenberg, PB; Perlman, E; Yokogawa, N, 2020
)
0.91
"The HCQ dosing and screening guidelines should be updated and a prospective study of HCQ dosing and HCQR should be initiated with the joint efforts of ophthalmologists and prescribing physicians."( Rethinking the Hydroxychloroquine Dosing and Retinopathy Screening Guidelines.
Browning, DJ; Greenberg, PB; Perlman, E; Yokogawa, N, 2020
)
0.91
" Median dosage of HCQ was 400 mg daily, and median (25th-75th percentile) duration of HCQ therapy was 1006 (471-2075) days."( Effects of hydroxychloroquine treatment on QT interval.
Adabag, S; Bart, B; Hooks, M; Vardeny, O; Westanmo, A, 2020
)
0.95
"1) To determine whether chemoprophylaxis with daily versus weekly dosing of hydroxychloroquine increases time to contracting COVID-19 disease in frontline healthcare workers."( ChemoPROphyLaxIs with hydroxychloroquine For covId-19 infeCtious disease (PROLIFIC) to prevent covid-19 infection in frontline healthcare workers: A structured summary of a study protocol for a randomised controlled trial.
Cheriyan, J; Fisk, M; Hubsch, A; Kaloyirou, F; McEniery, CM; Miles, K; Smith, J; Wilkinson, IB, 2020
)
1.1
" Hydroxychloroquine-identical matched placebo tablets will ensure that all participants are taking the same number and dosing regimen of tablets across the three trial arms."( ChemoPROphyLaxIs with hydroxychloroquine For covId-19 infeCtious disease (PROLIFIC) to prevent covid-19 infection in frontline healthcare workers: A structured summary of a study protocol for a randomised controlled trial.
Cheriyan, J; Fisk, M; Hubsch, A; Kaloyirou, F; McEniery, CM; Miles, K; Smith, J; Wilkinson, IB, 2020
)
1.78
"Time to diagnosis of positive COVID-19 disease (defined by record of date of symptoms onset and confirmed by laboratory test) RANDOMISATION: Participants will be randomised to either hydroxychloroquine dosed daily with weekly placebo, HCQ dosed weekly with daily placebo, or placebo dosed daily and weekly."( ChemoPROphyLaxIs with hydroxychloroquine For covId-19 infeCtious disease (PROLIFIC) to prevent covid-19 infection in frontline healthcare workers: A structured summary of a study protocol for a randomised controlled trial.
Cheriyan, J; Fisk, M; Hubsch, A; Kaloyirou, F; McEniery, CM; Miles, K; Smith, J; Wilkinson, IB, 2020
)
1.06
" The dosage is a critical factor in a clinical trial: too low and the drug will not have an effect, too high and the side effects may counteract any potential benefits."( Concentration-dependent mortality of chloroquine in overdose.
Baud, FJ; Clemessy, JL; Hoglund, RM; Megarbane, B; Tarning, J; Watson, JA; White, NJ, 2020
)
0.56
" In the hospitalized group, tacrolimus dosage was reduced in 46% of patients and mycophenolate mofetil (MMF) therapy was stopped in 61% of patients."( Kidney allograft recipients, immunosuppression, and coronavirus disease-2019: a report of consecutive cases from a New York City transplant center.
Aull, MJ; Craig-Schapiro, R; Dadhania, DM; Gingras, L; Hartono, C; Kapur, S; Kodiyanplakkal, RP; Lee, JB; Lee, JR; Lubetzky, M; Marku-Podvorica, J; Muthukumar, T; Saal, S; Salinas, T; Sultan, S; Suthanthiran, M, 2020
)
0.56
"7 percentage points, medication adherence of >90%, and a 75% relative increase in appropriate hydroxychloroquine dosing were recognized."( Multidisciplinary practice advancement: Role of a clinical pharmacy specialist in a pediatric specialty clinic.
Ferguson, PJ; Lynton, JJ; Mersch, A, 2020
)
0.78
" Surges in volume of patients requiring mechanical ventilation coupled with prolonged ventilator days and the high sedative dosing requirements observed quickly led to the depletion of "just-in-time" inventories typically maintained by institutions."( It Takes a Village…: Contending With Drug Shortages During Disasters.
Barletta, JF; Burry, LD; Christian, MD; Dichter, J; Erstad, BL; Geiling, J; Kanji, S; Maves, RC; Williamson, D, 2020
)
0.56
" This position statement recommends dosage adjustment for these drugs in the context of renal impairment."( Position statement from the Brazilian Society of Nephrology regarding chloroquine and hydroxychloroquine drug dose adjustment according to renal function.
Andreoli, MCC; Bastos, K; D'Avila, R; Kraychete, A; Misael, AM; Moura-Neto, JA; Nascimento, MMD; Silva, DRD, 2020
)
0.78
" However, a wide variety of dosing schemes has been applied in the clinical practice and tested in clinical studies."( Optimization of hydroxychloroquine dosing scheme based on COVID-19 patients' characteristics: a review of the literature and simulations.
Ismailos, G; Karalis, V; Karatza, E; Marangos, M, 2021
)
0.97
" The aim of this paper is to describe the pharmacokinetics of hydroxychloroquine in COVID-19 patients, considered to be a key step toward its dosing optimization."( Population Pharmacokinetics of Hydroxychloroquine in COVID-19 Patients: Implications for Dose Optimization.
Belkhir, L; Dauby, N; De Greef, J; Delongie, KA; Dogné, JM; Hamdani, J; Kiridis, S; Lescrainier, C; Musuamba, FT; Nasreddine, R; Thémans, P; Vandeputte, M; Verlinden, V; Wallemacq, P; Wittebole, X; Wuillaume, F; Yombi, JC, 2020
)
1.08
" Simulations were performed to compare the exposure obtained with alternative dosing regimens."( Population Pharmacokinetics of Hydroxychloroquine in COVID-19 Patients: Implications for Dose Optimization.
Belkhir, L; Dauby, N; De Greef, J; Delongie, KA; Dogné, JM; Hamdani, J; Kiridis, S; Lescrainier, C; Musuamba, FT; Nasreddine, R; Thémans, P; Vandeputte, M; Verlinden, V; Wallemacq, P; Wittebole, X; Wuillaume, F; Yombi, JC, 2020
)
0.84
"The developed models provide useful insight for the dosing optimization of hydroxychloroquine in COVID-19 patients."( Population Pharmacokinetics of Hydroxychloroquine in COVID-19 Patients: Implications for Dose Optimization.
Belkhir, L; Dauby, N; De Greef, J; Delongie, KA; Dogné, JM; Hamdani, J; Kiridis, S; Lescrainier, C; Musuamba, FT; Nasreddine, R; Thémans, P; Vandeputte, M; Verlinden, V; Wallemacq, P; Wittebole, X; Wuillaume, F; Yombi, JC, 2020
)
1.07
" The choice of (typically subtherapeutic) dosing regimens, influenced partly by "QT-phobia," varied widely and seems anecdotal without any pharmacologically reliable supporting clinical evidence."( Chloroquine and hydroxychloroquine for COVID-19: Perspectives on their failure in repurposing.
Shah, RR, 2021
)
0.97
" Further, almost all of the trials registered do not consider dosage adjustment in the elderly, a patient population most likely to require HCQ treatment."( Inhaled hydroxychloroquine to improve efficacy and reduce harm in the treatment of COVID-19.
Arthur, A; Dayton, F; Farragher, JP; Kavanagh, O; Mahoney, B; Marie Healy, A; O'Reilly, NJ; Robinson, S; Walker, G, 2020
)
0.99
" We envision that MAT can be used to optimize the dosing regimen of HCQ by maximizing its bioavailability, while simultaneously minimizing the cytotoxic damage."( A multiscale absorption and transit model for oral delivery of hydroxychloroquine: Pharmacokinetic modeling and intestinal concentration prediction to assess toxicity and drug-induced damage in healthy subjects.
Kannan, R; Przekwas, A, 2020
)
0.8
" Chloroquine (CQ) had a 100% discharge rate compared to 50% with lopinavir-ritonavir at day 14, however a trial has recommended against a high dosage due to cardiotoxic events."( Repurposing of drugs for COVID-19: a systematic review and meta-analysis.
Amparore, D; Checcucci, E; Dasgupta, P; Elhage, O; Fiori, C; Kotecha, P; Light, A; Porpiglia, F, 2022
)
0.72
"To evaluate the association and dose-response pattern between antimalarial drugs and overall and cause specific mortality in SLE patients."( Association of antimalarial drugs with decreased overall and cause specific mortality in systemic lupus erythematosus.
Da, Z; Ding, X; Feng, X; Hu, H; Jin, Z; Li, J; Liu, L; Pan, W; Qian, X; Sun, L; Tan, J; Tao, J; Wang, F; Wang, M; Wei, H; Wu, J; Wu, M; Zhang, M; Zou, Y, 2021
)
0.62
" Interestingly, both the time and the daily dosage of HCQ/CQ use were related to decreased mortality of SLE in a linear dose-response relationship."( Association of antimalarial drugs with decreased overall and cause specific mortality in systemic lupus erythematosus.
Da, Z; Ding, X; Feng, X; Hu, H; Jin, Z; Li, J; Liu, L; Pan, W; Qian, X; Sun, L; Tan, J; Tao, J; Wang, F; Wang, M; Wei, H; Wu, J; Wu, M; Zhang, M; Zou, Y, 2021
)
0.62
" The protective effects for survival might be augmented by adherence and full dosage of these drugs."( Association of antimalarial drugs with decreased overall and cause specific mortality in systemic lupus erythematosus.
Da, Z; Ding, X; Feng, X; Hu, H; Jin, Z; Li, J; Liu, L; Pan, W; Qian, X; Sun, L; Tan, J; Tao, J; Wang, F; Wang, M; Wei, H; Wu, J; Wu, M; Zhang, M; Zou, Y, 2021
)
0.62
" However, achievement of lung concentrations predicted to have in vivo antiviral efficacy might not be possible with the currently proposed oral dosing regimens."( A Strategy to Treat COVID-19 Disease With Targeted Delivery of Inhalable Liposomal Hydroxychloroquine: A Preclinical Pharmacokinetic Study.
Chen, YC; Shih, SF; Tai, TT; Tsai, YC; Wang, AM; Wang, HT; Wu, HD; Wu, TJ, 2021
)
0.85
" The revised 2016 American Academy of Ophthalmology (AAO) guidelines created controversy regarding the correct dosing and evaluation of HCQ toxicity."( Rheumatologists' perspective on hydroxychloroquine guidelines.
Askanase, AD; Gartshteyn, Y; Khalili, L; Park, L; Weiner, J; Winebrake, J, 2020
)
0.84
" Those aware of the guidelines cited limited dosing options (54."( Rheumatologists' perspective on hydroxychloroquine guidelines.
Askanase, AD; Gartshteyn, Y; Khalili, L; Park, L; Weiner, J; Winebrake, J, 2020
)
0.84
"7%)) and incorrect dosing (n=6 (10."( Prescribing practices of lopinavir/ritonavir, hydroxychloroquine and azithromycin during the COVID-19 epidemic crisis and pharmaceutical interventions in a French teaching hospital.
Belmas, AS; Danion, F; Fourtage, M; Gourieux, B; Michel, B; Nai, T; Nivoix, Y; Reisz, F; Reiter-Schatz, A; Ruch, Y; Walther, J, 2021
)
0.88
" For the lack of efficacy, we discuss the fundamental differences of treatment initiation between in vitro and in vivo studies, the pitfalls of the pharmacological calculations of effective blood drug concentrations and related dosing regimens, and the possible negative effect of HCQ on the antiviral type-I interferon response."( It is time to drop hydroxychloroquine from our COVID-19 armamentarium.
Kashour, T; Tleyjeh, IM, 2020
)
0.89
"Different dosage regimens of hydroxychloroquine (HCQ) have been used to manage COVID-19 (coronavirus disease 2019) patients, with no information on lung exposure in this population."( Hydroxychloroquine lung pharmacokinetics in critically ill patients with COVID-19.
Baklouti, S; Concordet, D; Conil, JM; Gandia, P; Georges, B; Goudy, P; Lanot, T; Lavit, M; Losha, E; Mané, C; Minville, V; Rousset, D; Ruiz, S; Vinour, H, 2021
)
2.36
" This review summarizes the current data for the most commonly used drugs for coronavirus disease 2019 and will cover the unique factors that may affect the dosing of these medications in patients with CKD."( Treatment Options for Coronavirus Disease 2019 in Patients With Reduced or Absent Kidney Function.
Govil, A; Luckett, K; Miller-Handley, H, 2020
)
0.56
" Recommendations were made based on available data, consideration of pharmacokinetic properties (including variability), the dosing and anticipated treatment duration of each regimen in COVID-19 and known toxicities."( Recommendations for Dosing of Repurposed COVID-19 Medications in Patients with Renal and Hepatic Impairment.
Back, D; Boyle, A; Burger, D; Davidson, K; El-Sherif, O; Gibbons, S; Khoo, S; Marra, F; Marzolini, C; Siccardi, M; Smolders, EJ; Sommerville, AJ, 2021
)
0.62
" Lower white blood cell count and lactate dehydrogenase at the time of drug administration as well as shorter time from supplemental oxygen initiation to dosing were significantly associated with clinical improvement in the univariate analysis."( Early clinical outcomes with tocilizumab for severe COVID-19: a two-centre retrospective study.
Daniel, NM; Hilden, P; Raja, K; Smoke, SM, 2021
)
0.62
" Additional liabilities of these medications include pharmacokinetic profiles that require extended dosing to achieve therapeutic tissue concentrations."( Nanomedicine Reformulation of Chloroquine and Hydroxychloroquine.
Crist, RM; Stern, ST; Stevens, DM, 2020
)
0.82
" Optimal weight-based dosing of HCQ is unknown."( Association of Higher Hydroxychloroquine Blood Levels With Reduced Thrombosis Risk in Systemic Lupus Erythematosus.
Goldman, DW; Konig, MF; Li, J; Petri, M, 2021
)
0.94
" Longitudinal measurement of HCQ levels may allow for personalized HCQ dosing strategies."( Association of Higher Hydroxychloroquine Blood Levels With Reduced Thrombosis Risk in Systemic Lupus Erythematosus.
Goldman, DW; Konig, MF; Li, J; Petri, M, 2021
)
0.94
" However, should some hospitalized patients have dosage escalation to intermediate dose? Should some be considered for full-dose anticoagulation without a measurable thromboembolic event and how should that anticoagulation be monitored? Should patients receive postdischarge anticoagulation and with what medication and for how long? What thrombotic issues are related to the various medications being used to treat this coagulopathy? Is antiphospholipid antibody part of this syndrome? What is the significance of isolated ischemic stroke and limb ischemia in this disorder and how does this interface with the rest of the clinical and laboratory features of this disorder? The aims of this article are to explore these questions and interpret the available data based on the current evidence."( COVID-19 and Its Implications for Thrombosis and Anticoagulation.
Berkman, SA; Tapson, VF, 2021
)
0.62
"Hydroxychloroquine (HCQ) dosage required to reach circulating levels that inhibit SARS-Cov-2 are extrapolated from pharmacokinetic data in non-COVID-19 patients."( Pharmacokinetics and pharmacodynamics of hydroxychloroquine in hospitalized patients with COVID-19.
Allenbach, Y; Benveniste, O; Bleibtreu, A; Cacoub, P; Combes, A; Funck-Brentano, C; Gandjbakhch, E; Hekimian, G; Llopis, B; Mayaux, J; Paccoud, O; Pinna, B; Pourcher, V; Saadoun, D; Salem, JE; Urien, S; Zahr, N,
)
1.84
" At a daily dosage of ≤5 mg/kg/day actual body weight, the risk of retinal toxicity from HCQ is <2% for usage up to 10 years."( American College of Rheumatology, American Academy of Dermatology, Rheumatologic Dermatology Society, and American Academy of Ophthalmology 2020 Joint Statement on Hydroxychloroquine Use With Respect to Retinal Toxicity.
Costenbader, KH; Desmarais, J; Fett, N; Ginzler, EM; Goodman, SM; Marmor, MF; Melles, RB; O'Dell, JR; Rosenbaum, JT; Schmajuk, G; Werth, VP, 2021
)
0.82
" The association was stronger among current-high daily dosage [15."( QTc-interval prolongation and increased risk of sudden cardiac death associated with hydroxychloroquine.
Ahmadizar, F; Ikram, MA; Kavousi, M; Kors, JA; Soroush, N; Stricker, BH, 2022
)
0.95
" Nine trials compared HCQ with standard care (7779 participants), and one compared HCQ with placebo (491 participants); dosing schedules varied."( Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19.
Chaplin, M; Fletcher, T; Kredo, T; Ryan, H; Singh, B, 2021
)
0.97
"001), and average oral dosage of >7."( Pneumocystis Jirovecii Pneumonia in Systemic Lupus Erythematosus: A Nationwide Cohort Study in Taiwan.
Chang, YS; Chen, WS; Huang, YF; Lai, CC; Li, TH; Tsao, YP; Wang, WH, 2022
)
0.72
" Authors discretion is to conduct more studies considering the optimal dosing regimen and pharmacokinetics assessment."( Exploring insights of hydroxychloroquine, a controversial drug in Covid-19: An update.
Joshi, G; Poduri, R; Thakur, S, 2021
)
0.94
"The dosage was consistent in both groups: 250 mg of chloroquine or 200 mg of hydroxychloroquine daily."( Chloroquine and hydroxychloroquine - safety profile of potential COVID-19 drugs from the rheumatologist's perspective.
Grygiel-Górniak, B; Majewska, KA; Majewski, D; Naskręcka, M, 2021
)
1.2
" Data from the literature show that high dosage as recommended in COVID-19 treatment may pose a risk of toxicity and require precise management, but prophylactic, long-term use of lower, safe doses might be a promising solution."( Chloroquine and hydroxychloroquine - safety profile of potential COVID-19 drugs from the rheumatologist's perspective.
Grygiel-Górniak, B; Majewska, KA; Majewski, D; Naskręcka, M, 2021
)
0.97
" Advances in our understanding of HCQ retinopathy have led to changes in the recommendations for HCQ dosing and retinopathy screening."( Hydroxychloroquine treatment in European patients with lupus erythematosus: dosing, retinopathy screening and adherence.
Andersen, J; Bultink, IEM; Cornet, A; Frankel, S; Osmani, Z; Schrama, TJ; van Vollenhoven, RF; Zacouris-Verweij, W, 2021
)
2.06
" Additionally, the data collected remotely in this trial will provide critical information regarding the accuracy of teleresearch in lupus, the impact of adherence to hydroxychloroquine on disease activity and a pharmacokinetic analysis to inform paediatric-specific dosing of hydroxychloroquine."( Delivering clinical trials at home: protocol, design and implementation of a direct-to-family paediatric lupus trial.
Balevic, SJ; Cohen-Wolkowiez, M; Cunningham, A; Hornik, CP; Randell, RL; Schanberg, LE; Singler, L, 2021
)
0.82
" Trough plasma concentrations of lopinavir and ritonavir were higher than those expected, while those of hydroxychloroquine were those expected with the dosing regimen."( An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19.
Ader, F; Alfaiate, T; Andrejak, C; Belhadi, D; Botelho-Nevers, E; Bouadma, L; Bouiller, K; Bouscambert-Duchamp, M; Burdet, C; Cabié, A; Clere-Jehl, R; Costagliola, D; Courjon, J; Danion, F; Dechanet, A; Delmas, C; Diallo, A; Dubost, C; Dupont, A; Epaulard, O; Faure, E; Gaci, R; Gagneux-Brunon, A; Gallien, S; Goehringer, F; Hites, M; Jaureguiberry, S; Kimmoun, A; Lacombe, K; Lanoix, JP; Launay, O; Lê, MP; Leroy, S; Lescure, FX; Lina, B; Makinson, A; Martin-Blondel, G; Mentré, F; Mercier, N; Mootien, J; Mourvillier, B; Navellou, JC; Noret, M; Nseir, S; Peiffer-Smadja, N; Peytavin, G; Piroth, L; Poissy, J; Pourcher, V; Raffi, F; Reignier, J; Reuter, J; Richard, JC; Saillard, J; Staub, T; Tolsma, V; Wallet, F; Yazdanpanah, Y, 2021
)
1.04
"03 per 100000 person-month for high and low dosage respectively."( Hydroxychloroquine might reduce risk of incident endometriosis in patients with systemic lupus erythematosus: A retrospective population-based cohort study.
Chen, FY; Chen, SW; Chen, X; Huang, JY; Wei, JC; Ye, Z, 2021
)
2.06
" Of the 13 institutions listing hydroxychloroquine dosing recommendations, 62% recommended maintenance dosing of 200 mg twice daily."( Open-source institutional guideline recommendations during the COVID-19 pandemic.
Collins, CD; Huang, J; Potoski, BA, 2020
)
0.84
" Meanwhile, it is kept in mind that due to safety concerns, changes have also been made in the dosage and combined use of frequently used drugs."( COVID-19: Are Experimental Drugs a Cure or Cause?
Elkama, A; Karahalil, B, 2022
)
0.72
" Here, pharmacokinetic (PK) assessment of HCQ in non-tumor-bearing mice after intraperitoneal dosing established 60 mg/kg as the human equivalent dose of HCQ in mice."( Pharmacokinetic and Pharmacodynamic Assessment of Hydroxychloroquine in Breast Cancer.
Gustafson, DL; Van Eaton, KM, 2021
)
0.87
" However, the hypothesis that Hydroxychloroquine might have a beneficial role in subgroups of patients at low risk and/or when used at low dosage (≤ 400 mg/day) deserves to be tested in large, well designed randomised clinical trials."( Hydroxichloroquine for COVID-19 infection: Do we have a final word after one year?
Costanzo, S; de Gaetano, G; Di Castelnuovo, A; Gialluisi, A; Iacoviello, L, 2021
)
0.91
" Dose-response curves in single-molecule assays with hydroxychloroquine were created for isolates with suspected reduced susceptibility."( Heterogeneity in susceptibility to hydroxychloroquine of SARS-CoV-2 isolates.
Aherfi, S; Andreani, J; Bideau, ML; Boschi, C; Colson, P; Delerce, J; Gendrot, M; Jardot, P; La Scola, B; Levasseur, A; Pradines, B, 2021
)
1.15
" The dose-response model showed a decrease in susceptibility of these three strains to hydroxychloroquine."( Heterogeneity in susceptibility to hydroxychloroquine of SARS-CoV-2 isolates.
Aherfi, S; Andreani, J; Bideau, ML; Boschi, C; Colson, P; Delerce, J; Gendrot, M; Jardot, P; La Scola, B; Levasseur, A; Pradines, B, 2021
)
1.12
" Using the PK model, we conducted dosing simulations and imputed 0%/20%/40%/60% non-adherence to evaluate the impact of adherence versus physiological changes on HCQ concentrations."( Hydroxychloroquine PK and exposure-response in pregnancies with lupus: the importance of adherence for neonatal outcomes.
Balevic, SJ; Clowse, MEB; Cohen-Wolkowiez, M; Eudy, AM; Gonzalez, D; Hornik, CP; Maharaj, AR; Weiner, D, 2022
)
2.16
" Accordingly, optimising adherence in pregnancy may be more clinically meaningful than adjusting HCQ dosage to account for physiological changes."( Hydroxychloroquine PK and exposure-response in pregnancies with lupus: the importance of adherence for neonatal outcomes.
Balevic, SJ; Clowse, MEB; Cohen-Wolkowiez, M; Eudy, AM; Gonzalez, D; Hornik, CP; Maharaj, AR; Weiner, D, 2022
)
2.16
" A physiologically based pharmacokinetic model with detailed respiratory physiology was used to predict regional airway exposure and optimize dosing regimens."( Translational Modeling of Chloroquine and Hydroxychloroquine Dosimetry in Human Airways for Treating Viral Respiratory Infections.
Calvino-Martin, F; Hoeng, J; Kolli, AR, 2022
)
0.99
"Our analysis provides a framework for extrapolating in vitro effective concentrations of chloroquine and hydroxychloroquine to in vivo dosing regimens for treating viral respiratory infections."( Translational Modeling of Chloroquine and Hydroxychloroquine Dosimetry in Human Airways for Treating Viral Respiratory Infections.
Calvino-Martin, F; Hoeng, J; Kolli, AR, 2022
)
1.2
" A positive correlation was found between HCQ dosage (ideal bodyweight) and WBHCQ (r = 0."( Correlation of whole blood hydroxychloroquine concentration with cutaneous lupus erythematosus and factors associated with it: First multicenter, cross-sectional analysis in Malaysia.
Beh, PJ; How, KN; Lim, AL; Peh, D; Stanslas, J; Tan, WC; Thevarajah, S; Wan Ahmad Kammal, WSL; Yong, ACH, 2022
)
1.02
"Potential interaction effects such as worsening glycemic control were prominent with lopinavir/ritonavir and the primarily used antidiabetic drugs, which needs dosage adjustment and close monitoring."( Drug interaction risk between cardioprotective drugs and drugs used in treatment of COVID-19: A evidence-based review from six databases.
B, S; Kalala, KP; P A, A; Pm, A; S K, SR; Sabarathinam, S, 2022
)
0.72
"9 years, and the mean drug dosage was 244 mg."( Oral pigmentation as an adverse effect of chloroquine and hydroxychloroquine use: A scoping review.
Blumenberg, C; Cardoso, SV; Franco, A; Oliveira, MB; Paranhos, LR; Silva, PUJ; Siqueira, WL; Vieira, W, 2022
)
0.97
"The outcomes of this study suggest that hyperpigmentation depend on drug dosage and treatment length."( Oral pigmentation as an adverse effect of chloroquine and hydroxychloroquine use: A scoping review.
Blumenberg, C; Cardoso, SV; Franco, A; Oliveira, MB; Paranhos, LR; Silva, PUJ; Siqueira, WL; Vieira, W, 2022
)
0.97
" The protective effect of HCQ was dosage related."( Low-dose glucocorticoids withdrawn in systemic lupus erythematosus: a desirable and attainable goal.
Deng, X; Gao, D; Geng, Y; Hao, Y; Huang, H; Ji, L; Wang, Y; Zhang, Z, 2022
)
0.72
"There is no clear correlation between weight-based dosing of hydroxychloroquine and the resulting blood levels of the medication."( Advances in the clinical use of hydroxychloroquine levels.
Chakrabarti, K; McCune, WJ, 2022
)
1.25
" In conclusion, the CQ dosage and regimen used to treat COVID-19 induced adverse effects in diabetic rats, suggesting the need to reevaluate the effective dose of CQ in humans."( Safety considerations of chloroquine in the treatment of patients with diabetes and COVID-19.
Gao, X; Guo, D; Ji, H; Jiang, S; Jing, X; Peng, L; Qiu, Y; Wang, J; Wu, W; Zheng, Y, 2022
)
0.72
" She did not have persistent good improvement despite treatment with 1 mg/kg oral prednisolone, along with successive trials with many steroid-sparing adjuvants in adequate dosage and duration, including hydroxychloroquine, methotrexate and cyclosporine, in the following 6 months."( B cell depletion therapy using rituximab to induce long-term remission of recalcitrant skin lesions of subacute cutaneous lupus erythematosus.
Arava, S; Baskaran, N; Gupta, S; Mehta, N, 2022
)
0.91
" A new weight-based dosage regimen was proposed to maintain the trough concentration above the EC50 threshold."( Population Pharmacokinetics of Hydroxychloroquine Sulfate in Healthcare Workers, Given for Prophylaxis Against Coronavirus Disease 2019 (COVID-19) in India.
Gogtay, NJ; Kakkar, AK; Kshirsagar, NA; Mallayasamy, S; Mekala, P; Pandey, A; Pingali, U; Raj, JP; Raju, AP; Shafiq, N, 2022
)
1.01
" However, local safety profile should also be evaluated depending on the new indication, administration route and dosage form."( Antivirals and the Potential Benefits of Orally Inhaled Drug Administration in COVID-19 Treatment.
Akbal-Dagistan, O; Basarir, NS; Culha, M; Erturk, A; Sahin, G; Sancar, S; Yildiz-Pekoz, A, 2022
)
0.72
"The purpose of this study was to implement a clinical decision support tool (CDS) and assess its impact on adherence to 2016 American Academy of Ophthalmology (AAO) hydroxychloroquine dosing recommendations."( Impact of an Electronic Decision Support Tool to Improve Ophthalmic Safety in Hydroxychloroquine Prescribing Practices.
Chen, RI; Deal, C; Kalur, A; Kuo, BL; Muste, JC; Singh, RP, 2022
)
1.14
" Prevalence of excessive dosing after CDS implementation was assessed."( Impact of an Electronic Decision Support Tool to Improve Ophthalmic Safety in Hydroxychloroquine Prescribing Practices.
Chen, RI; Deal, C; Kalur, A; Kuo, BL; Muste, JC; Singh, RP, 2022
)
0.95
" After intervention, prevalence of excessive dosing decreased from 27."( Impact of an Electronic Decision Support Tool to Improve Ophthalmic Safety in Hydroxychloroquine Prescribing Practices.
Chen, RI; Deal, C; Kalur, A; Kuo, BL; Muste, JC; Singh, RP, 2022
)
0.95
"This study highlights the efficacy of a CDS in reducing excessive hydroxychloroquine dosing and improving adherence to AAO ophthalmic safety guidelines."( Impact of an Electronic Decision Support Tool to Improve Ophthalmic Safety in Hydroxychloroquine Prescribing Practices.
Chen, RI; Deal, C; Kalur, A; Kuo, BL; Muste, JC; Singh, RP, 2022
)
1.19
" Furthermore, a systematic determination of the optimal dosage of combined LipSHK and LipHCQa suggested that autophagy inhibiting at an appropriate dosage level was beneficial for maximizing ICD-based antitumor immunity."( Autophagy inhibition recovers deficient ICD-based cancer immunotherapy.
Cai, W; He, Z; Li, J; Li, X; Liu, H; Ouyang, D; Wang, Y; Yu, J; Zhou, S, 2022
)
0.72
"Reduction of the hydroxychloroquine (HCQ) dosage is recommended in systemic lupus erythematosus (SLE) patients with renal impairment, but a pharmacokinetics (PK) study of patients with renal impairment has not yet been performed."( Pharmacokinetics of hydroxychloroquine in Japanese systemic lupus erythematosus patients with renal impairment.
Furudate, S; Hashiguchi, M; Nagai, Y; Ohshima, M; Setoguchi, K; Shimada, K; Shimizu, M; Yokogawa, N, 2023
)
1.57
"From the PK perspective, a dosage reduction is unnecessary in SLE patients with impaired renal function."( Pharmacokinetics of hydroxychloroquine in Japanese systemic lupus erythematosus patients with renal impairment.
Furudate, S; Hashiguchi, M; Nagai, Y; Ohshima, M; Setoguchi, K; Shimada, K; Shimizu, M; Yokogawa, N, 2023
)
1.23
" We observed high interindividual variability in HCQ PK and found that weight-based dosing for HCQ is poorly correlated with drug concentrations, suggesting the need to use therapeutic drug monitoring to individualise dosing."( Pharmacokinetics of hydroxychloroquine in paediatric lupus: data from a novel, direct-to-family clinical trial.
Balevic, SJ; Beard, C; Cohen-Wolkowiez, M; Gonzalez, D; Hornik, CP; Randell, R; Schanberg, LE; Weiner, D, 2022
)
1.04
"6% probability of improving 6-month survival across varying hydrocortisone dosing strategies."( Long-term (180-Day) Outcomes in Critically Ill Patients With COVID-19 in the REMAP-CAP Randomized Clinical Trial.
Al-Beidh, F; Angus, DC; Annane, D; Arabi, YM; Beane, A; Berry, LR; Berry, S; Bhimani, Z; Bonten, MJM; Bradbury, CA; Brunkhorst, FM; Burrell, A; Buxton, M; Buzgau, A; Charles, WN; Cove, M; Derde, LPG; Detry, MA; Estcourt, LJ; Fagbodun, EO; Fitzgerald, M; Girard, TD; Goligher, EC; Goossens, H; Gordon, AC; Green, C; Haniffa, R; Higgins, AM; Hills, T; Horvat, CM; Huang, DT; Ichihara, N; Lamontagne, F; Lawler, PR; Lewis, RJ; Lorenzi, E; Marshall, JC; McArthur, CJ; McAuley, DF; McGlothlin, A; McGuinness, SP; McQuilten, Z; McVerry, BJ; Mouncey, PR; Murthy, S; Neal, MD; Nichol, AD; Parke, RL; Parker, JC; Parry-Billings, K; Peters, SEC; Reyes, LF; Rowan, KM; Saito, H; Santos, MS; Saunders, CT; Serpa-Neto, A; Seymour, CW; Shankar-Hari, M; Stronach, LM; Turgeon, AF; Turner, AM; van Bentum-Puijk, W; van de Veerdonk, FL; Webb, SA; Zarychanski, R, 2023
)
0.91
" Based on its structure and riboswitch dose-response activity we identified that the antagonist activity of hydroxychloroquine is consistent with it being a conformationally restricted analog of the polyamine spermidine."( 4-Aminoquinolines modulate RNA structure and function: Pharmacophore implications of a conformationally restricted polyamine.
Aldhumani, AH; Boesger, H; Herath, D; Hines, JV; Hossain, MI; Myers, M, 2023
)
1.12
"Patients with low oral HCQ dosage tend to have more flares, although the difference was not statistically significant."( Hydroxychloroquine daily dose, hydroxychloroquine blood levels and the risk of flares in patients with systemic lupus erythematosus.
Ciccia, F; Coscia, MA; Fasano, S; Iudici, M; Messiniti, V, 2023
)
2.35
" The HCQ dosing included a loading dose of HCQ 600 mg twice on day 1, followed by 400 mg daily for 29 days."( Hydroxychloroquine for pre-exposure prophylaxis of COVID-19 in health care workers: a randomized, multicenter, placebo-controlled trial Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine (HERO-HCQ).
Anderson, DJ; Anstrom, KJ; Cahuayme-Zuniga, L; Castro, M; Cohen, LW; Collins, SP; Currier, J; Fraulo, E; Friedland, A; Garg, J; George, A; Hernandez, AF; Lakshmi, S; Milstone, A; Mulder, H; Naggie, S; O'Brien, EC; Olson, RE; Rothman, RL; Shenkman, E; Shostak, J; Turner, KB; Woods, CW, 2023
)
2.35
" Patients with low eGFR need to adjust the HCQ dosage according to the monitoring results of HCQ blood concentrations."( Low estimated glomerular filtration rate is an independent risk factor for higher hydroxychloroquine concentration.
He, J; Jin, YB; Liu, SL; Zhang, Q; Zhong, X, 2023
)
1.14
" A phase II selection design will be used to determine hdroxychloroquine's efficacy, using prednisolone dosage and Birmingham Vasculitis Activity Score as a measure of disease activity."( The HAVEN study-hydroxychloroquine in ANCA vasculitis evaluation-a multicentre, randomised, double-blind, placebo-controlled trial: study protocol and statistical analysis plan.
Arnold, L; Beckley-Hoelscher, N; Cape, A; Casian, A; D'Cruz, D; Douiri, A; Galloway, J; Jayne, D; John, S; Kim, S; Learoyd, AE; Luqmani, R; Morton, N; Nel, L; Reid, F; Sangle, S; Shivapatham, D, 2023
)
1.26
" Study results indicated that HCQ dosing management was adequate based on the revised guidelines."( Nationwide patterns of hydroxychloroquine dosing and monitoring of retinal toxicity in patients with systemic lupus erythematosus.
Jung, SY; Kim, YJ; Lee, JE; Nam, DR; Sung, YK, 2023
)
1.22
" Regions of decreased cone density and associations between age, rheumatic disease type, dosage for ideal body weight, and cone density were evaluated."( Cone Density Distribution and Related Factors in Patients Receiving Hydroxychloroquine Treatment.
Huang, H; Liu, H; Liu, X; Mo, S; Tang, J; Zhu, Z, 2023
)
1.15
" Cone density loss in the horizontal axis increases with age; further, hydroxychloroquine dosage is negatively correlated with cone density in the vertical axis and inferior quadrant."( Cone Density Distribution and Related Factors in Patients Receiving Hydroxychloroquine Treatment.
Huang, H; Liu, H; Liu, X; Mo, S; Tang, J; Zhu, Z, 2023
)
1.38
"This study aimed to understand the profile of hydroxychloroquine-treated patients, referral patterns, and dosing and to assess the adherence of eye care providers to the latest 2016 screening guidelines provided by the American Academy of Ophthalmology."( Trends and practices following the 2016 hydroxychloroquine screening guidelines.
Arnett, J; Baxter, SL; Borooah, S; Kalaw, FGP; Pedersen, B; Walker, E, 2023
)
1.44
"Our results suggest that the optimal blood concentration of HCQ measured approximately 12-18 hours after the last dosage may be between 500 and 600 ng/mL in Chinese patients with SLE."( Genotype-guided new approach for dose optimisation of hydroxychloroquine administration in Chinese patients with SLE.
Ge, W; Geng, L; Huang, X; Jin, Z; Shen, W; Shu, Q; Sun, L; Wang, D; Wang, Y; Wen, X; Xie, H; Zhu, Y, 2023
)
1.16
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (4)

RoleDescription
antimalarialA drug used in the treatment of malaria. Antimalarials are usually classified on the basis of their action against Plasmodia at different stages in their life cycle in the human.
antirheumatic drugA drug used to treat rheumatoid arthritis.
dermatologic drugA drug used to treat or prevent skin disorders or for the routine care of skin.
anticoronaviral agentAny antiviral agent which inhibits the activity of coronaviruses.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (5)

ClassDescription
aminoquinolineAny member of the class of quinolines in which the quinoline skeleton is substituted by one or more amino or substituted-amino groups.
organochlorine compoundAn organochlorine compound is a compound containing at least one carbon-chlorine bond.
primary alcoholA primary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has either three hydrogen atoms attached to it or only one other carbon atom and two hydrogen atoms attached to it.
secondary amino compoundA compound formally derived from ammonia by replacing two hydrogen atoms by organyl groups.
tertiary amino compoundA compound formally derived from ammonia by replacing three hydrogen atoms by organyl groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (28)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
EWS/FLI fusion proteinHomo sapiens (human)Potency24.31460.001310.157742.8575AID1259252; AID1259253; AID1259255; AID1259256
lamin isoform A-delta10Homo sapiens (human)Potency35.48130.891312.067628.1838AID1487
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Genome polyprotein Zika virusKi92.30000.80000.80000.8000AID1659175
Muscarinic acetylcholine receptor M2Homo sapiens (human)IC50 (µMol)2.95100.00001.23267.7930AID625152
Muscarinic acetylcholine receptor M2Homo sapiens (human)Ki3.08880.00000.690210.0000AID1409619; AID625152
Muscarinic acetylcholine receptor M4Homo sapiens (human)Ki5.49540.00000.79519.1201AID1409621
Muscarinic acetylcholine receptor M5Homo sapiens (human)Ki19.95260.00000.72926.9183AID1409622
Alpha-2A adrenergic receptorHomo sapiens (human)Ki6.45650.00010.807410.0000AID1409617
Replicase polyprotein 1abSevere acute respiratory syndrome-related coronavirusIC50 (µMol)3,584.00000.00402.92669.9600AID1805801
Replicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2IC50 (µMol)3,584.00000.00022.45859.9600AID1805801
Muscarinic acetylcholine receptor M1Homo sapiens (human)Ki15.48820.00000.59729.1201AID1409612
Alpha-2B adrenergic receptorHomo sapiens (human)Ki72.44360.00020.725710.0000AID1409618
Alpha-2C adrenergic receptorHomo sapiens (human)Ki15.84890.00030.483410.0000AID1409610
Muscarinic acetylcholine receptor M3Homo sapiens (human)Ki4.78630.00000.54057.7600AID1409620
Alpha-1D adrenergic receptorHomo sapiens (human)IC50 (µMol)4.77200.00020.75688.8970AID625200
Alpha-1D adrenergic receptorHomo sapiens (human)Ki2.34600.00000.360910.0000AID625200
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)Ki2.51190.00211.840710.0000AID1409624
Sigma intracellular receptor 2Homo sapiens (human)Ki1.00000.00010.83604.6005AID1409615
Cyclic GMP-AMP synthaseHomo sapiens (human)IC50 (µMol)23.00000.00403.51607.0000AID1854214
Sigma non-opioid intracellular receptor 1Homo sapiens (human)Ki0.12590.00000.490110.0000AID1409616
Toll-like receptor 9Homo sapiens (human)IC50 (µMol)0.11000.11000.11000.1100AID1422466
Toll-like receptor 7Homo sapiens (human)IC50 (µMol)3.40000.80003.40008.6000AID1422467; AID1607164; AID1755701
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Spike glycoproteinBetacoronavirus England 1EC50 (µMol)5.65670.00304.57559.8200AID1804127
Replicase polyprotein 1abBetacoronavirus England 1EC50 (µMol)5.65670.00304.57559.8200AID1804127
Transmembrane protease serine 2Homo sapiens (human)EC50 (µMol)5.65670.00304.51689.8200AID1804127
Procathepsin LHomo sapiens (human)EC50 (µMol)5.65670.00304.48749.8200AID1804127
Replicase polyprotein 1aSevere acute respiratory syndrome-related coronavirusEC50 (µMol)5.65670.00304.61369.8200AID1804127
Replicase polyprotein 1abHuman coronavirus 229EEC50 (µMol)5.65670.00304.61369.8200AID1804127
Replicase polyprotein 1abSevere acute respiratory syndrome-related coronavirusEC50 (µMol)5.65670.00304.45549.8200AID1804127
Replicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2EC50 (µMol)5.65670.00304.11059.8200AID1804127
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusEC50 (µMol)5.65670.00304.57559.8200AID1804127
Angiotensin-converting enzyme 2 Homo sapiens (human)EC50 (µMol)5.65670.00304.57559.8200AID1804127
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (238)

Processvia Protein(s)Taxonomy
viral translationTransmembrane protease serine 2Homo sapiens (human)
proteolysisTransmembrane protease serine 2Homo sapiens (human)
protein autoprocessingTransmembrane protease serine 2Homo sapiens (human)
positive regulation of viral entry into host cellTransmembrane protease serine 2Homo sapiens (human)
adaptive immune responseProcathepsin LHomo sapiens (human)
proteolysisProcathepsin LHomo sapiens (human)
protein autoprocessingProcathepsin LHomo sapiens (human)
fusion of virus membrane with host plasma membraneProcathepsin LHomo sapiens (human)
receptor-mediated endocytosis of virus by host cellProcathepsin LHomo sapiens (human)
antigen processing and presentationProcathepsin LHomo sapiens (human)
antigen processing and presentation of exogenous peptide antigen via MHC class IIProcathepsin LHomo sapiens (human)
collagen catabolic processProcathepsin LHomo sapiens (human)
zymogen activationProcathepsin LHomo sapiens (human)
enkephalin processingProcathepsin LHomo sapiens (human)
fusion of virus membrane with host endosome membraneProcathepsin LHomo sapiens (human)
CD4-positive, alpha-beta T cell lineage commitmentProcathepsin LHomo sapiens (human)
symbiont entry into host cellProcathepsin LHomo sapiens (human)
antigen processing and presentation of peptide antigenProcathepsin LHomo sapiens (human)
proteolysis involved in protein catabolic processProcathepsin LHomo sapiens (human)
elastin catabolic processProcathepsin LHomo sapiens (human)
macrophage apoptotic processProcathepsin LHomo sapiens (human)
cellular response to thyroid hormone stimulusProcathepsin LHomo sapiens (human)
positive regulation of apoptotic signaling pathwayProcathepsin LHomo sapiens (human)
positive regulation of peptidase activityProcathepsin LHomo sapiens (human)
immune responseProcathepsin LHomo sapiens (human)
G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M2Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M2Homo sapiens (human)
phospholipase C-activating G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M2Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M2Homo sapiens (human)
nervous system developmentMuscarinic acetylcholine receptor M2Homo sapiens (human)
regulation of heart contractionMuscarinic acetylcholine receptor M2Homo sapiens (human)
response to virusMuscarinic acetylcholine receptor M2Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayMuscarinic acetylcholine receptor M2Homo sapiens (human)
presynaptic modulation of chemical synaptic transmissionMuscarinic acetylcholine receptor M2Homo sapiens (human)
regulation of smooth muscle contractionMuscarinic acetylcholine receptor M2Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M2Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMuscarinic acetylcholine receptor M2Homo sapiens (human)
chemical synaptic transmissionMuscarinic acetylcholine receptor M2Homo sapiens (human)
signal transductionMuscarinic acetylcholine receptor M4Homo sapiens (human)
cell surface receptor signaling pathwayMuscarinic acetylcholine receptor M4Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M4Homo sapiens (human)
regulation of locomotionMuscarinic acetylcholine receptor M4Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayMuscarinic acetylcholine receptor M4Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M4Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMuscarinic acetylcholine receptor M4Homo sapiens (human)
chemical synaptic transmissionMuscarinic acetylcholine receptor M4Homo sapiens (human)
gastric acid secretionMuscarinic acetylcholine receptor M5Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M5Homo sapiens (human)
dopamine transportMuscarinic acetylcholine receptor M5Homo sapiens (human)
transmission of nerve impulseMuscarinic acetylcholine receptor M5Homo sapiens (human)
regulation of phosphatidylinositol dephosphorylationMuscarinic acetylcholine receptor M5Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayMuscarinic acetylcholine receptor M5Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMuscarinic acetylcholine receptor M5Homo sapiens (human)
chemical synaptic transmissionMuscarinic acetylcholine receptor M5Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M5Homo sapiens (human)
positive regulation of cytokine productionAlpha-2A adrenergic receptorHomo sapiens (human)
DNA replicationAlpha-2A adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
Ras protein signal transductionAlpha-2A adrenergic receptorHomo sapiens (human)
Rho protein signal transductionAlpha-2A adrenergic receptorHomo sapiens (human)
female pregnancyAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of cell population proliferationAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of norepinephrine secretionAlpha-2A adrenergic receptorHomo sapiens (human)
regulation of vasoconstrictionAlpha-2A adrenergic receptorHomo sapiens (human)
actin cytoskeleton organizationAlpha-2A adrenergic receptorHomo sapiens (human)
platelet activationAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of cell migrationAlpha-2A adrenergic receptorHomo sapiens (human)
activation of protein kinase activityAlpha-2A adrenergic receptorHomo sapiens (human)
activation of protein kinase B activityAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of epinephrine secretionAlpha-2A adrenergic receptorHomo sapiens (human)
cellular response to hormone stimulusAlpha-2A adrenergic receptorHomo sapiens (human)
receptor transactivationAlpha-2A adrenergic receptorHomo sapiens (human)
vasodilationAlpha-2A adrenergic receptorHomo sapiens (human)
glucose homeostasisAlpha-2A adrenergic receptorHomo sapiens (human)
fear responseAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of potassium ion transportAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of MAP kinase activityAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of epidermal growth factor receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of calcium ion-dependent exocytosisAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of insulin secretionAlpha-2A adrenergic receptorHomo sapiens (human)
intestinal absorptionAlpha-2A adrenergic receptorHomo sapiens (human)
thermoceptionAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of lipid catabolic processAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of membrane protein ectodomain proteolysisAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of calcium ion transportAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of insulin secretion involved in cellular response to glucose stimulusAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of uterine smooth muscle contractionAlpha-2A adrenergic receptorHomo sapiens (human)
adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-inhibiting adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
phospholipase C-activating adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of wound healingAlpha-2A adrenergic receptorHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of calcium ion transmembrane transporter activityAlpha-2A adrenergic receptorHomo sapiens (human)
symbiont-mediated perturbation of host ubiquitin-like protein modificationReplicase polyprotein 1aSevere acute respiratory syndrome-related coronavirus
symbiont-mediated perturbation of host ubiquitin-like protein modificationReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
positive regulation of monoatomic ion transportMuscarinic acetylcholine receptor M1Homo sapiens (human)
signal transductionMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
protein kinase C-activating G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
phospholipase C-activating G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
neuromuscular synaptic transmissionMuscarinic acetylcholine receptor M1Homo sapiens (human)
nervous system developmentMuscarinic acetylcholine receptor M1Homo sapiens (human)
regulation of locomotionMuscarinic acetylcholine receptor M1Homo sapiens (human)
saliva secretionMuscarinic acetylcholine receptor M1Homo sapiens (human)
cognitionMuscarinic acetylcholine receptor M1Homo sapiens (human)
regulation of postsynaptic membrane potentialMuscarinic acetylcholine receptor M1Homo sapiens (human)
regulation of glial cell proliferationMuscarinic acetylcholine receptor M1Homo sapiens (human)
positive regulation of intracellular protein transportMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
postsynaptic modulation of chemical synaptic transmissionMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMuscarinic acetylcholine receptor M1Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
chemical synaptic transmissionMuscarinic acetylcholine receptor M1Homo sapiens (human)
MAPK cascadeAlpha-2B adrenergic receptorHomo sapiens (human)
angiogenesisAlpha-2B adrenergic receptorHomo sapiens (human)
regulation of vascular associated smooth muscle contractionAlpha-2B adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-2B adrenergic receptorHomo sapiens (human)
cell-cell signalingAlpha-2B adrenergic receptorHomo sapiens (human)
female pregnancyAlpha-2B adrenergic receptorHomo sapiens (human)
negative regulation of norepinephrine secretionAlpha-2B adrenergic receptorHomo sapiens (human)
platelet activationAlpha-2B adrenergic receptorHomo sapiens (human)
activation of protein kinase B activityAlpha-2B adrenergic receptorHomo sapiens (human)
negative regulation of epinephrine secretionAlpha-2B adrenergic receptorHomo sapiens (human)
receptor transactivationAlpha-2B adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-2B adrenergic receptorHomo sapiens (human)
positive regulation of neuron differentiationAlpha-2B adrenergic receptorHomo sapiens (human)
positive regulation of blood pressureAlpha-2B adrenergic receptorHomo sapiens (human)
positive regulation of uterine smooth muscle contractionAlpha-2B adrenergic receptorHomo sapiens (human)
adrenergic receptor signaling pathwayAlpha-2B adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-2B adrenergic receptorHomo sapiens (human)
regulation of smooth muscle contractionAlpha-2C adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-2C adrenergic receptorHomo sapiens (human)
cell-cell signalingAlpha-2C adrenergic receptorHomo sapiens (human)
negative regulation of norepinephrine secretionAlpha-2C adrenergic receptorHomo sapiens (human)
regulation of vasoconstrictionAlpha-2C adrenergic receptorHomo sapiens (human)
platelet activationAlpha-2C adrenergic receptorHomo sapiens (human)
activation of protein kinase B activityAlpha-2C adrenergic receptorHomo sapiens (human)
negative regulation of epinephrine secretionAlpha-2C adrenergic receptorHomo sapiens (human)
receptor transactivationAlpha-2C adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-2C adrenergic receptorHomo sapiens (human)
positive regulation of neuron differentiationAlpha-2C adrenergic receptorHomo sapiens (human)
adrenergic receptor signaling pathwayAlpha-2C adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-2C adrenergic receptorHomo sapiens (human)
negative regulation of insulin secretionAlpha-2C adrenergic receptorHomo sapiens (human)
calcium-mediated signalingMuscarinic acetylcholine receptor M3Homo sapiens (human)
regulation of monoatomic ion transmembrane transporter activityMuscarinic acetylcholine receptor M3Homo sapiens (human)
smooth muscle contractionMuscarinic acetylcholine receptor M3Homo sapiens (human)
signal transductionMuscarinic acetylcholine receptor M3Homo sapiens (human)
G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
phospholipase C-activating G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
synaptic transmission, cholinergicMuscarinic acetylcholine receptor M3Homo sapiens (human)
nervous system developmentMuscarinic acetylcholine receptor M3Homo sapiens (human)
positive regulation of insulin secretionMuscarinic acetylcholine receptor M3Homo sapiens (human)
protein modification processMuscarinic acetylcholine receptor M3Homo sapiens (human)
positive regulation of smooth muscle contractionMuscarinic acetylcholine receptor M3Homo sapiens (human)
saliva secretionMuscarinic acetylcholine receptor M3Homo sapiens (human)
acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
ion channel modulating, G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
ligand-gated ion channel signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
regulation of smooth muscle contractionMuscarinic acetylcholine receptor M3Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMuscarinic acetylcholine receptor M3Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
chemical synaptic transmissionMuscarinic acetylcholine receptor M3Homo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-1D adrenergic receptorHomo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayAlpha-1D adrenergic receptorHomo sapiens (human)
positive regulation of cell population proliferationAlpha-1D adrenergic receptorHomo sapiens (human)
neuron-glial cell signalingAlpha-1D adrenergic receptorHomo sapiens (human)
cell-cell signalingAlpha-1D adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-1D adrenergic receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayAlpha-1D adrenergic receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationAlpha-1D adrenergic receptorHomo sapiens (human)
positive regulation of vasoconstrictionAlpha-1D adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-1D adrenergic receptorHomo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by hormonePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of DNA-templated transcriptionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion homeostasisPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cardiac muscle contractionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of ventricular cardiac muscle cell membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cellular response to xenobiotic stimulusPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane depolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion import across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of cell growthSigma intracellular receptor 2Homo sapiens (human)
regulation of intracellular lipid transportSigma intracellular receptor 2Homo sapiens (human)
regulation of intracellular cholesterol transportSigma intracellular receptor 2Homo sapiens (human)
cholesterol homeostasisSigma intracellular receptor 2Homo sapiens (human)
positive regulation of wound healingSigma intracellular receptor 2Homo sapiens (human)
positive regulation of lipoprotein transportSigma intracellular receptor 2Homo sapiens (human)
activation of innate immune responseCyclic GMP-AMP synthaseHomo sapiens (human)
pattern recognition receptor signaling pathwayCyclic GMP-AMP synthaseHomo sapiens (human)
positive regulation of defense response to virus by hostCyclic GMP-AMP synthaseHomo sapiens (human)
regulation of immunoglobulin productionCyclic GMP-AMP synthaseHomo sapiens (human)
cytoplasmic pattern recognition receptor signaling pathwayCyclic GMP-AMP synthaseHomo sapiens (human)
DNA repairCyclic GMP-AMP synthaseHomo sapiens (human)
DNA damage responseCyclic GMP-AMP synthaseHomo sapiens (human)
determination of adult lifespanCyclic GMP-AMP synthaseHomo sapiens (human)
cAMP-mediated signalingCyclic GMP-AMP synthaseHomo sapiens (human)
cGMP-mediated signalingCyclic GMP-AMP synthaseHomo sapiens (human)
positive regulation of type I interferon productionCyclic GMP-AMP synthaseHomo sapiens (human)
paracrine signalingCyclic GMP-AMP synthaseHomo sapiens (human)
innate immune responseCyclic GMP-AMP synthaseHomo sapiens (human)
regulation of T cell activationCyclic GMP-AMP synthaseHomo sapiens (human)
defense response to virusCyclic GMP-AMP synthaseHomo sapiens (human)
cGAS/STING signaling pathwayCyclic GMP-AMP synthaseHomo sapiens (human)
negative regulation of cGAS/STING signaling pathwayCyclic GMP-AMP synthaseHomo sapiens (human)
negative regulation of double-strand break repair via homologous recombinationCyclic GMP-AMP synthaseHomo sapiens (human)
positive regulation of cellular senescenceCyclic GMP-AMP synthaseHomo sapiens (human)
cellular response to exogenous dsRNACyclic GMP-AMP synthaseHomo sapiens (human)
lipid transportSigma non-opioid intracellular receptor 1Homo sapiens (human)
nervous system developmentSigma non-opioid intracellular receptor 1Homo sapiens (human)
G protein-coupled opioid receptor signaling pathwaySigma non-opioid intracellular receptor 1Homo sapiens (human)
regulation of neuron apoptotic processSigma non-opioid intracellular receptor 1Homo sapiens (human)
protein homotrimerizationSigma non-opioid intracellular receptor 1Homo sapiens (human)
negative regulation of signaling receptor activityAngiotensin-converting enzyme 2 Homo sapiens (human)
symbiont entry into host cellAngiotensin-converting enzyme 2 Homo sapiens (human)
regulation of cytokine productionAngiotensin-converting enzyme 2 Homo sapiens (human)
angiotensin maturationAngiotensin-converting enzyme 2 Homo sapiens (human)
angiotensin-mediated drinking behaviorAngiotensin-converting enzyme 2 Homo sapiens (human)
regulation of systemic arterial blood pressure by renin-angiotensinAngiotensin-converting enzyme 2 Homo sapiens (human)
tryptophan transportAngiotensin-converting enzyme 2 Homo sapiens (human)
viral life cycleAngiotensin-converting enzyme 2 Homo sapiens (human)
receptor-mediated endocytosis of virus by host cellAngiotensin-converting enzyme 2 Homo sapiens (human)
regulation of vasoconstrictionAngiotensin-converting enzyme 2 Homo sapiens (human)
regulation of transmembrane transporter activityAngiotensin-converting enzyme 2 Homo sapiens (human)
regulation of cell population proliferationAngiotensin-converting enzyme 2 Homo sapiens (human)
symbiont entry into host cellAngiotensin-converting enzyme 2 Homo sapiens (human)
receptor-mediated virion attachment to host cellAngiotensin-converting enzyme 2 Homo sapiens (human)
negative regulation of smooth muscle cell proliferationAngiotensin-converting enzyme 2 Homo sapiens (human)
regulation of inflammatory responseAngiotensin-converting enzyme 2 Homo sapiens (human)
positive regulation of amino acid transportAngiotensin-converting enzyme 2 Homo sapiens (human)
maternal process involved in female pregnancyAngiotensin-converting enzyme 2 Homo sapiens (human)
positive regulation of cardiac muscle contractionAngiotensin-converting enzyme 2 Homo sapiens (human)
membrane fusionAngiotensin-converting enzyme 2 Homo sapiens (human)
negative regulation of ERK1 and ERK2 cascadeAngiotensin-converting enzyme 2 Homo sapiens (human)
blood vessel diameter maintenanceAngiotensin-converting enzyme 2 Homo sapiens (human)
entry receptor-mediated virion attachment to host cellAngiotensin-converting enzyme 2 Homo sapiens (human)
positive regulation of gap junction assemblyAngiotensin-converting enzyme 2 Homo sapiens (human)
regulation of cardiac conductionAngiotensin-converting enzyme 2 Homo sapiens (human)
positive regulation of L-proline import across plasma membraneAngiotensin-converting enzyme 2 Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processAngiotensin-converting enzyme 2 Homo sapiens (human)
positive regulation of interleukin-8 productionToll-like receptor 9Homo sapiens (human)
microglial cell activationToll-like receptor 9Homo sapiens (human)
regulation of protein phosphorylationToll-like receptor 9Homo sapiens (human)
toll-like receptor signaling pathwayToll-like receptor 9Homo sapiens (human)
positive regulation of immunoglobulin productionToll-like receptor 9Homo sapiens (human)
regulation of dendritic cell cytokine productionToll-like receptor 9Homo sapiens (human)
MyD88-dependent toll-like receptor signaling pathwayToll-like receptor 9Homo sapiens (human)
male gonad developmentToll-like receptor 9Homo sapiens (human)
positive regulation of autophagyToll-like receptor 9Homo sapiens (human)
positive regulation of gene expressionToll-like receptor 9Homo sapiens (human)
maintenance of gastrointestinal epitheliumToll-like receptor 9Homo sapiens (human)
positive regulation of B cell proliferationToll-like receptor 9Homo sapiens (human)
detection of molecule of bacterial originToll-like receptor 9Homo sapiens (human)
positive regulation of chemokine productionToll-like receptor 9Homo sapiens (human)
positive regulation of granulocyte macrophage colony-stimulating factor productionToll-like receptor 9Homo sapiens (human)
positive regulation of interferon-alpha productionToll-like receptor 9Homo sapiens (human)
positive regulation of interferon-beta productionToll-like receptor 9Homo sapiens (human)
positive regulation of type II interferon productionToll-like receptor 9Homo sapiens (human)
positive regulation of interleukin-10 productionToll-like receptor 9Homo sapiens (human)
positive regulation of interleukin-12 productionToll-like receptor 9Homo sapiens (human)
positive regulation of interleukin-18 productionToll-like receptor 9Homo sapiens (human)
positive regulation of interleukin-6 productionToll-like receptor 9Homo sapiens (human)
positive regulation of interleukin-8 productionToll-like receptor 9Homo sapiens (human)
positive regulation of tumor necrosis factor productionToll-like receptor 9Homo sapiens (human)
toll-like receptor 9 signaling pathwayToll-like receptor 9Homo sapiens (human)
regulation of toll-like receptor 9 signaling pathwayToll-like receptor 9Homo sapiens (human)
positive regulation of toll-like receptor 9 signaling pathwayToll-like receptor 9Homo sapiens (human)
defense response to bacteriumToll-like receptor 9Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionToll-like receptor 9Homo sapiens (human)
positive regulation of MAPK cascadeToll-like receptor 9Homo sapiens (human)
innate immune responseToll-like receptor 9Homo sapiens (human)
regulation of B cell differentiationToll-like receptor 9Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIToll-like receptor 9Homo sapiens (human)
positive regulation of JNK cascadeToll-like receptor 9Homo sapiens (human)
positive regulation of inflammatory responseToll-like receptor 9Homo sapiens (human)
defense response to Gram-negative bacteriumToll-like receptor 9Homo sapiens (human)
positive regulation of B cell activationToll-like receptor 9Homo sapiens (human)
negative regulation of ERK1 and ERK2 cascadeToll-like receptor 9Homo sapiens (human)
cellular response to lipopolysaccharideToll-like receptor 9Homo sapiens (human)
cellular response to metal ionToll-like receptor 9Homo sapiens (human)
positive regulation of non-canonical NF-kappaB signal transductionToll-like receptor 9Homo sapiens (human)
negative regulation of ATPase-coupled calcium transmembrane transporter activityToll-like receptor 9Homo sapiens (human)
cellular response to chloroquineToll-like receptor 9Homo sapiens (human)
positive regulation of intestinal epithelial cell developmentToll-like receptor 9Homo sapiens (human)
defense response to virusToll-like receptor 9Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activityToll-like receptor 9Homo sapiens (human)
canonical NF-kappaB signal transductionToll-like receptor 9Homo sapiens (human)
regulation of protein phosphorylationToll-like receptor 7Homo sapiens (human)
inflammatory responseToll-like receptor 7Homo sapiens (human)
canonical NF-kappaB signal transductionToll-like receptor 7Homo sapiens (human)
I-kappaB phosphorylationToll-like receptor 7Homo sapiens (human)
JNK cascadeToll-like receptor 7Homo sapiens (human)
positive regulation of chemokine productionToll-like receptor 7Homo sapiens (human)
positive regulation of interferon-alpha productionToll-like receptor 7Homo sapiens (human)
positive regulation of interferon-beta productionToll-like receptor 7Homo sapiens (human)
positive regulation of type II interferon productionToll-like receptor 7Homo sapiens (human)
positive regulation of interleukin-8 productionToll-like receptor 7Homo sapiens (human)
toll-like receptor 7 signaling pathwayToll-like receptor 7Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionToll-like receptor 7Homo sapiens (human)
innate immune responseToll-like receptor 7Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIToll-like receptor 7Homo sapiens (human)
positive regulation of inflammatory responseToll-like receptor 7Homo sapiens (human)
defense response to virusToll-like receptor 7Homo sapiens (human)
positive regulation of macrophage cytokine productionToll-like receptor 7Homo sapiens (human)
response to cGMPToll-like receptor 7Homo sapiens (human)
cellular response to mechanical stimulusToll-like receptor 7Homo sapiens (human)
cellular response to virusToll-like receptor 7Homo sapiens (human)
positive regulation of non-canonical NF-kappaB signal transductionToll-like receptor 7Homo sapiens (human)
toll-like receptor signaling pathwayToll-like receptor 7Homo sapiens (human)
positive regulation of interleukin-6 productionToll-like receptor 7Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (78)

Processvia Protein(s)Taxonomy
serine-type endopeptidase activityTransmembrane protease serine 2Homo sapiens (human)
protein bindingTransmembrane protease serine 2Homo sapiens (human)
serine-type peptidase activityTransmembrane protease serine 2Homo sapiens (human)
fibronectin bindingProcathepsin LHomo sapiens (human)
cysteine-type endopeptidase activityProcathepsin LHomo sapiens (human)
protein bindingProcathepsin LHomo sapiens (human)
collagen bindingProcathepsin LHomo sapiens (human)
cysteine-type peptidase activityProcathepsin LHomo sapiens (human)
histone bindingProcathepsin LHomo sapiens (human)
proteoglycan bindingProcathepsin LHomo sapiens (human)
serpin family protein bindingProcathepsin LHomo sapiens (human)
cysteine-type endopeptidase activator activity involved in apoptotic processProcathepsin LHomo sapiens (human)
G protein-coupled acetylcholine receptor activityMuscarinic acetylcholine receptor M2Homo sapiens (human)
arrestin family protein bindingMuscarinic acetylcholine receptor M2Homo sapiens (human)
G protein-coupled serotonin receptor activityMuscarinic acetylcholine receptor M2Homo sapiens (human)
G protein-coupled serotonin receptor activityMuscarinic acetylcholine receptor M4Homo sapiens (human)
G protein-coupled acetylcholine receptor activityMuscarinic acetylcholine receptor M4Homo sapiens (human)
phosphatidylinositol phospholipase C activityMuscarinic acetylcholine receptor M5Homo sapiens (human)
protein bindingMuscarinic acetylcholine receptor M5Homo sapiens (human)
G protein-coupled acetylcholine receptor activityMuscarinic acetylcholine receptor M5Homo sapiens (human)
G protein-coupled serotonin receptor activityMuscarinic acetylcholine receptor M5Homo sapiens (human)
alpha2-adrenergic receptor activityAlpha-2A adrenergic receptorHomo sapiens (human)
protein bindingAlpha-2A adrenergic receptorHomo sapiens (human)
protein kinase bindingAlpha-2A adrenergic receptorHomo sapiens (human)
alpha-1B adrenergic receptor bindingAlpha-2A adrenergic receptorHomo sapiens (human)
alpha-2C adrenergic receptor bindingAlpha-2A adrenergic receptorHomo sapiens (human)
thioesterase bindingAlpha-2A adrenergic receptorHomo sapiens (human)
heterotrimeric G-protein bindingAlpha-2A adrenergic receptorHomo sapiens (human)
protein homodimerization activityAlpha-2A adrenergic receptorHomo sapiens (human)
protein heterodimerization activityAlpha-2A adrenergic receptorHomo sapiens (human)
epinephrine bindingAlpha-2A adrenergic receptorHomo sapiens (human)
norepinephrine bindingAlpha-2A adrenergic receptorHomo sapiens (human)
guanyl-nucleotide exchange factor activityAlpha-2A adrenergic receptorHomo sapiens (human)
RNA-dependent RNA polymerase activityReplicase polyprotein 1aSevere acute respiratory syndrome-related coronavirus
cysteine-type endopeptidase activityReplicase polyprotein 1aSevere acute respiratory syndrome-related coronavirus
K63-linked deubiquitinase activityReplicase polyprotein 1aSevere acute respiratory syndrome-related coronavirus
K48-linked deubiquitinase activityReplicase polyprotein 1aSevere acute respiratory syndrome-related coronavirus
3'-5'-RNA exonuclease activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
RNA-dependent RNA polymerase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
cysteine-type endopeptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
mRNA 5'-cap (guanine-N7-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
mRNA (nucleoside-2'-O-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
5'-3' RNA helicase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
K63-linked deubiquitinase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
K48-linked deubiquitinase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
3'-5'-RNA exonuclease activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
RNA-dependent RNA polymerase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
cysteine-type endopeptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA 5'-cap (guanine-N7-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA (nucleoside-2'-O-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA guanylyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
RNA endonuclease activity, producing 3'-phosphomonoestersReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
ISG15-specific peptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
5'-3' RNA helicase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
protein guanylyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
phosphatidylinositol phospholipase C activityMuscarinic acetylcholine receptor M1Homo sapiens (human)
protein bindingMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled acetylcholine receptor activityMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled serotonin receptor activityMuscarinic acetylcholine receptor M1Homo sapiens (human)
alpha2-adrenergic receptor activityAlpha-2B adrenergic receptorHomo sapiens (human)
protein bindingAlpha-2B adrenergic receptorHomo sapiens (human)
epinephrine bindingAlpha-2B adrenergic receptorHomo sapiens (human)
alpha2-adrenergic receptor activityAlpha-2C adrenergic receptorHomo sapiens (human)
protein bindingAlpha-2C adrenergic receptorHomo sapiens (human)
alpha-2A adrenergic receptor bindingAlpha-2C adrenergic receptorHomo sapiens (human)
protein homodimerization activityAlpha-2C adrenergic receptorHomo sapiens (human)
protein heterodimerization activityAlpha-2C adrenergic receptorHomo sapiens (human)
epinephrine bindingAlpha-2C adrenergic receptorHomo sapiens (human)
guanyl-nucleotide exchange factor activityAlpha-2C adrenergic receptorHomo sapiens (human)
phosphatidylinositol phospholipase C activityMuscarinic acetylcholine receptor M3Homo sapiens (human)
protein bindingMuscarinic acetylcholine receptor M3Homo sapiens (human)
G protein-coupled acetylcholine receptor activityMuscarinic acetylcholine receptor M3Homo sapiens (human)
signaling receptor activityMuscarinic acetylcholine receptor M3Homo sapiens (human)
acetylcholine bindingMuscarinic acetylcholine receptor M3Homo sapiens (human)
G protein-coupled serotonin receptor activityMuscarinic acetylcholine receptor M3Homo sapiens (human)
protein bindingAlpha-1D adrenergic receptorHomo sapiens (human)
identical protein bindingAlpha-1D adrenergic receptorHomo sapiens (human)
alpha1-adrenergic receptor activityAlpha-1D adrenergic receptorHomo sapiens (human)
transcription cis-regulatory region bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
delayed rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ubiquitin protein ligase bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
identical protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein homodimerization activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
C3HC4-type RING finger domain bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
scaffold protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein bindingSigma intracellular receptor 2Homo sapiens (human)
oxysterol bindingSigma intracellular receptor 2Homo sapiens (human)
cholesterol bindingSigma intracellular receptor 2Homo sapiens (human)
DNA bindingCyclic GMP-AMP synthaseHomo sapiens (human)
chromatin bindingCyclic GMP-AMP synthaseHomo sapiens (human)
double-stranded DNA bindingCyclic GMP-AMP synthaseHomo sapiens (human)
protein bindingCyclic GMP-AMP synthaseHomo sapiens (human)
ATP bindingCyclic GMP-AMP synthaseHomo sapiens (human)
GTP bindingCyclic GMP-AMP synthaseHomo sapiens (human)
phosphatidylinositol-4,5-bisphosphate bindingCyclic GMP-AMP synthaseHomo sapiens (human)
nucleosome bindingCyclic GMP-AMP synthaseHomo sapiens (human)
protein homodimerization activityCyclic GMP-AMP synthaseHomo sapiens (human)
metal ion bindingCyclic GMP-AMP synthaseHomo sapiens (human)
2',3'-cyclic GMP-AMP synthase activityCyclic GMP-AMP synthaseHomo sapiens (human)
molecular condensate scaffold activityCyclic GMP-AMP synthaseHomo sapiens (human)
poly-ADP-D-ribose modification-dependent protein bindingCyclic GMP-AMP synthaseHomo sapiens (human)
G protein-coupled opioid receptor activitySigma non-opioid intracellular receptor 1Homo sapiens (human)
protein bindingSigma non-opioid intracellular receptor 1Homo sapiens (human)
virus receptor activityAngiotensin-converting enzyme 2 Homo sapiens (human)
endopeptidase activityAngiotensin-converting enzyme 2 Homo sapiens (human)
carboxypeptidase activityAngiotensin-converting enzyme 2 Homo sapiens (human)
metallocarboxypeptidase activityAngiotensin-converting enzyme 2 Homo sapiens (human)
protein bindingAngiotensin-converting enzyme 2 Homo sapiens (human)
metallopeptidase activityAngiotensin-converting enzyme 2 Homo sapiens (human)
peptidyl-dipeptidase activityAngiotensin-converting enzyme 2 Homo sapiens (human)
zinc ion bindingAngiotensin-converting enzyme 2 Homo sapiens (human)
identical protein bindingAngiotensin-converting enzyme 2 Homo sapiens (human)
interleukin-1 receptor bindingToll-like receptor 9Homo sapiens (human)
siRNA bindingToll-like receptor 9Homo sapiens (human)
pattern recognition receptor activityToll-like receptor 9Homo sapiens (human)
protein homodimerization activityToll-like receptor 9Homo sapiens (human)
unmethylated CpG bindingToll-like receptor 9Homo sapiens (human)
double-stranded RNA bindingToll-like receptor 7Homo sapiens (human)
single-stranded RNA bindingToll-like receptor 7Homo sapiens (human)
protein bindingToll-like receptor 7Homo sapiens (human)
siRNA bindingToll-like receptor 7Homo sapiens (human)
pattern recognition receptor activityToll-like receptor 7Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (71)

Processvia Protein(s)Taxonomy
extracellular regionTransmembrane protease serine 2Homo sapiens (human)
nucleoplasmTransmembrane protease serine 2Homo sapiens (human)
plasma membraneTransmembrane protease serine 2Homo sapiens (human)
extracellular exosomeTransmembrane protease serine 2Homo sapiens (human)
extracellular regionProcathepsin LHomo sapiens (human)
extracellular spaceProcathepsin LHomo sapiens (human)
nucleusProcathepsin LHomo sapiens (human)
lysosomeProcathepsin LHomo sapiens (human)
multivesicular bodyProcathepsin LHomo sapiens (human)
Golgi apparatusProcathepsin LHomo sapiens (human)
plasma membraneProcathepsin LHomo sapiens (human)
apical plasma membraneProcathepsin LHomo sapiens (human)
endolysosome lumenProcathepsin LHomo sapiens (human)
chromaffin granuleProcathepsin LHomo sapiens (human)
lysosomal lumenProcathepsin LHomo sapiens (human)
intracellular membrane-bounded organelleProcathepsin LHomo sapiens (human)
collagen-containing extracellular matrixProcathepsin LHomo sapiens (human)
extracellular exosomeProcathepsin LHomo sapiens (human)
endocytic vesicle lumenProcathepsin LHomo sapiens (human)
extracellular spaceProcathepsin LHomo sapiens (human)
lysosomeProcathepsin LHomo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M2Homo sapiens (human)
membraneMuscarinic acetylcholine receptor M2Homo sapiens (human)
clathrin-coated endocytic vesicle membraneMuscarinic acetylcholine receptor M2Homo sapiens (human)
asymmetric synapseMuscarinic acetylcholine receptor M2Homo sapiens (human)
symmetric synapseMuscarinic acetylcholine receptor M2Homo sapiens (human)
presynaptic membraneMuscarinic acetylcholine receptor M2Homo sapiens (human)
neuronal cell bodyMuscarinic acetylcholine receptor M2Homo sapiens (human)
axon terminusMuscarinic acetylcholine receptor M2Homo sapiens (human)
postsynaptic membraneMuscarinic acetylcholine receptor M2Homo sapiens (human)
glutamatergic synapseMuscarinic acetylcholine receptor M2Homo sapiens (human)
cholinergic synapseMuscarinic acetylcholine receptor M2Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M2Homo sapiens (human)
synapseMuscarinic acetylcholine receptor M2Homo sapiens (human)
dendriteMuscarinic acetylcholine receptor M2Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M4Homo sapiens (human)
postsynaptic membraneMuscarinic acetylcholine receptor M4Homo sapiens (human)
dendriteMuscarinic acetylcholine receptor M4Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M4Homo sapiens (human)
synapseMuscarinic acetylcholine receptor M4Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M5Homo sapiens (human)
postsynaptic membraneMuscarinic acetylcholine receptor M5Homo sapiens (human)
dendriteMuscarinic acetylcholine receptor M5Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M5Homo sapiens (human)
synapseMuscarinic acetylcholine receptor M5Homo sapiens (human)
cytoplasmAlpha-2A adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2A adrenergic receptorHomo sapiens (human)
basolateral plasma membraneAlpha-2A adrenergic receptorHomo sapiens (human)
neuronal cell bodyAlpha-2A adrenergic receptorHomo sapiens (human)
axon terminusAlpha-2A adrenergic receptorHomo sapiens (human)
presynaptic active zone membraneAlpha-2A adrenergic receptorHomo sapiens (human)
dopaminergic synapseAlpha-2A adrenergic receptorHomo sapiens (human)
postsynaptic density membraneAlpha-2A adrenergic receptorHomo sapiens (human)
glutamatergic synapseAlpha-2A adrenergic receptorHomo sapiens (human)
GABA-ergic synapseAlpha-2A adrenergic receptorHomo sapiens (human)
receptor complexAlpha-2A adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2A adrenergic receptorHomo sapiens (human)
double membrane vesicle viral factory outer membraneReplicase polyprotein 1aSevere acute respiratory syndrome-related coronavirus
double membrane vesicle viral factory outer membraneReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
double membrane vesicle viral factory outer membraneReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
plasma membraneMuscarinic acetylcholine receptor M1Homo sapiens (human)
membraneMuscarinic acetylcholine receptor M1Homo sapiens (human)
presynaptic membraneMuscarinic acetylcholine receptor M1Homo sapiens (human)
axon terminusMuscarinic acetylcholine receptor M1Homo sapiens (human)
Schaffer collateral - CA1 synapseMuscarinic acetylcholine receptor M1Homo sapiens (human)
postsynaptic density membraneMuscarinic acetylcholine receptor M1Homo sapiens (human)
glutamatergic synapseMuscarinic acetylcholine receptor M1Homo sapiens (human)
cholinergic synapseMuscarinic acetylcholine receptor M1Homo sapiens (human)
synapseMuscarinic acetylcholine receptor M1Homo sapiens (human)
dendriteMuscarinic acetylcholine receptor M1Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M1Homo sapiens (human)
cytosolAlpha-2B adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2B adrenergic receptorHomo sapiens (human)
cell surfaceAlpha-2B adrenergic receptorHomo sapiens (human)
intracellular membrane-bounded organelleAlpha-2B adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2B adrenergic receptorHomo sapiens (human)
cytoplasmAlpha-2C adrenergic receptorHomo sapiens (human)
endosomeAlpha-2C adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2C adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2C adrenergic receptorHomo sapiens (human)
endoplasmic reticulum membraneMuscarinic acetylcholine receptor M3Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M3Homo sapiens (human)
basal plasma membraneMuscarinic acetylcholine receptor M3Homo sapiens (human)
basolateral plasma membraneMuscarinic acetylcholine receptor M3Homo sapiens (human)
postsynaptic membraneMuscarinic acetylcholine receptor M3Homo sapiens (human)
synapseMuscarinic acetylcholine receptor M3Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M3Homo sapiens (human)
dendriteMuscarinic acetylcholine receptor M3Homo sapiens (human)
plasma membraneAlpha-1D adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-1D adrenergic receptorHomo sapiens (human)
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cell surfacePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
perinuclear region of cytoplasmPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
endoplasmic reticulumSigma intracellular receptor 2Homo sapiens (human)
lysosomeSigma intracellular receptor 2Homo sapiens (human)
endoplasmic reticulumSigma intracellular receptor 2Homo sapiens (human)
rough endoplasmic reticulumSigma intracellular receptor 2Homo sapiens (human)
plasma membraneSigma intracellular receptor 2Homo sapiens (human)
rough endoplasmic reticulum membraneSigma intracellular receptor 2Homo sapiens (human)
nuclear membraneSigma intracellular receptor 2Homo sapiens (human)
cytoplasmCyclic GMP-AMP synthaseHomo sapiens (human)
cytosolCyclic GMP-AMP synthaseHomo sapiens (human)
nucleusCyclic GMP-AMP synthaseHomo sapiens (human)
nucleoplasmCyclic GMP-AMP synthaseHomo sapiens (human)
cytosolCyclic GMP-AMP synthaseHomo sapiens (human)
plasma membraneCyclic GMP-AMP synthaseHomo sapiens (human)
nuclear bodyCyclic GMP-AMP synthaseHomo sapiens (human)
site of double-strand breakCyclic GMP-AMP synthaseHomo sapiens (human)
nucleusCyclic GMP-AMP synthaseHomo sapiens (human)
site of double-strand breakCyclic GMP-AMP synthaseHomo sapiens (human)
nuclear envelopeSigma non-opioid intracellular receptor 1Homo sapiens (human)
nuclear inner membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
nuclear outer membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
endoplasmic reticulumSigma non-opioid intracellular receptor 1Homo sapiens (human)
endoplasmic reticulum membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
lipid dropletSigma non-opioid intracellular receptor 1Homo sapiens (human)
cytosolSigma non-opioid intracellular receptor 1Homo sapiens (human)
postsynaptic densitySigma non-opioid intracellular receptor 1Homo sapiens (human)
membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
growth coneSigma non-opioid intracellular receptor 1Homo sapiens (human)
cytoplasmic vesicleSigma non-opioid intracellular receptor 1Homo sapiens (human)
anchoring junctionSigma non-opioid intracellular receptor 1Homo sapiens (human)
postsynaptic density membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
endoplasmic reticulumSigma non-opioid intracellular receptor 1Homo sapiens (human)
plasma membraneAngiotensin-converting enzyme 2 Homo sapiens (human)
extracellular regionAngiotensin-converting enzyme 2 Homo sapiens (human)
extracellular spaceAngiotensin-converting enzyme 2 Homo sapiens (human)
endoplasmic reticulum lumenAngiotensin-converting enzyme 2 Homo sapiens (human)
plasma membraneAngiotensin-converting enzyme 2 Homo sapiens (human)
ciliumAngiotensin-converting enzyme 2 Homo sapiens (human)
cell surfaceAngiotensin-converting enzyme 2 Homo sapiens (human)
membraneAngiotensin-converting enzyme 2 Homo sapiens (human)
apical plasma membraneAngiotensin-converting enzyme 2 Homo sapiens (human)
endocytic vesicle membraneAngiotensin-converting enzyme 2 Homo sapiens (human)
brush border membraneAngiotensin-converting enzyme 2 Homo sapiens (human)
membrane raftAngiotensin-converting enzyme 2 Homo sapiens (human)
extracellular exosomeAngiotensin-converting enzyme 2 Homo sapiens (human)
extracellular spaceAngiotensin-converting enzyme 2 Homo sapiens (human)
endoplasmic reticulumToll-like receptor 9Homo sapiens (human)
early endosome membraneToll-like receptor 9Homo sapiens (human)
Golgi membraneToll-like receptor 9Homo sapiens (human)
extracellular regionToll-like receptor 9Homo sapiens (human)
cytoplasmToll-like receptor 9Homo sapiens (human)
lysosomeToll-like receptor 9Homo sapiens (human)
endosomeToll-like receptor 9Homo sapiens (human)
endoplasmic reticulumToll-like receptor 9Homo sapiens (human)
endoplasmic reticulum membraneToll-like receptor 9Homo sapiens (human)
plasma membraneToll-like receptor 9Homo sapiens (human)
endosome membraneToll-like receptor 9Homo sapiens (human)
basolateral plasma membraneToll-like receptor 9Homo sapiens (human)
apical plasma membraneToll-like receptor 9Homo sapiens (human)
early phagosomeToll-like receptor 9Homo sapiens (human)
endolysosomeToll-like receptor 9Homo sapiens (human)
endolysosome membraneToll-like receptor 9Homo sapiens (human)
plasma membraneToll-like receptor 9Homo sapiens (human)
Golgi membraneToll-like receptor 7Homo sapiens (human)
cytoplasmToll-like receptor 7Homo sapiens (human)
lysosomeToll-like receptor 7Homo sapiens (human)
endosomeToll-like receptor 7Homo sapiens (human)
endoplasmic reticulumToll-like receptor 7Homo sapiens (human)
endoplasmic reticulum membraneToll-like receptor 7Homo sapiens (human)
plasma membraneToll-like receptor 7Homo sapiens (human)
endosome membraneToll-like receptor 7Homo sapiens (human)
early phagosomeToll-like receptor 7Homo sapiens (human)
endolysosome membraneToll-like receptor 7Homo sapiens (human)
receptor complexToll-like receptor 7Homo sapiens (human)
plasma membraneToll-like receptor 7Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (173)

Assay IDTitleYearJournalArticle
AID1347112qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347125qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347119qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347110qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells)2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347114qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347118qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347109qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347115qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347117qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347123qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347126qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347127qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347116qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347121qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347122qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347111qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347113qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347128qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347129qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347124qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID557182AUC (last) in healthy human at 400 mg, po administered as single dose2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Pharmacokinetics of hydroxychloroquine and its clinical implications in chemoprophylaxis against malaria caused by Plasmodium vivax.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1684809Antiviral activity against SARS-CoV-2 UC-1074 infected in African green monkey Vero cells assessed as reduction in virus plaque formation measured on day 5 post-viral infection by microscopic analysis2021ACS medicinal chemistry letters, Jan-14, Volume: 12, Issue:1
Influence of 4'-Substitution on the Activity of Gemcitabine and Its ProTide Against VZV and SARS-CoV-2.
AID557190AUC (infinity) in healthy human assessed as desethylchloroquine level at 400 mg, po administered as single dose2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Pharmacokinetics of hydroxychloroquine and its clinical implications in chemoprophylaxis against malaria caused by Plasmodium vivax.
AID1684807Cytotoxicity against African green monkey Vero cells assessed as alteration in cell morphology by microscopic analysis2021ACS medicinal chemistry letters, Jan-14, Volume: 12, Issue:1
Influence of 4'-Substitution on the Activity of Gemcitabine and Its ProTide Against VZV and SARS-CoV-2.
AID557192Ratio of AUC for bisdesethylchloroquine level to AUC for compound in healthy human at 400 mg, po administered as single dose2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Pharmacokinetics of hydroxychloroquine and its clinical implications in chemoprophylaxis against malaria caused by Plasmodium vivax.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1422469Selectivity ratio of IC50 for human TLR7 expressed in HEK-Blue cells to IC50 for TLR9 expressed in HEK-Blue cells2018European journal of medicinal chemistry, Nov-05, Volume: 159Activity-guided development of potent and selective toll-like receptor 9 antagonists.
AID1409613Selectivity ratio: ratio of AUC (viral infection %) of SARS-CoV-2 in the Vero E6 cell line compared to AUC (cytotoxicity %) of compound against Vero E6 cells by MTT assay.2020Nature, 07, Volume: 583, Issue:7816
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
AID557183AUC (infinity) in healthy human at 400 mg, po administered as single dose2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Pharmacokinetics of hydroxychloroquine and its clinical implications in chemoprophylaxis against malaria caused by Plasmodium vivax.
AID1203048Inhibition of autophagy in human H460 cells assessed as increase in punctate LC3 level after 24 hrs by immunoblot analysis2015ACS medicinal chemistry letters, Feb-12, Volume: 6, Issue:2
Discovery of autophagy inhibitors with antiproliferative activity in lung and pancreatic cancer cells.
AID557197AUC (last) in healthy human assessed as bisdesethylchloroquine level at 400 mg, po administered as single dose2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Pharmacokinetics of hydroxychloroquine and its clinical implications in chemoprophylaxis against malaria caused by Plasmodium vivax.
AID1409622Activity of compound against Muscarinic acetylcholine receptor M5 (CHRM5) by displacement of 3H-QNB2020Nature, 07, Volume: 583, Issue:7816
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1684808Antiviral activity against SARS-CoV-2 UC-1075 infected in African green monkey Vero cells assessed as reduction in virus plaque formation measured on day 5 post-viral infection by microscopic analysis2021ACS medicinal chemistry letters, Jan-14, Volume: 12, Issue:1
Influence of 4'-Substitution on the Activity of Gemcitabine and Its ProTide Against VZV and SARS-CoV-2.
AID1409611AUC (cytotoxicity %) of compound against Vero E6 cells by MTT assay.2020Nature, 07, Volume: 583, Issue:7816
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
AID1400974Antiproliferative activity in human A549 cells at 25 ug/ml after 60 hrs by xCELLigence RTCA SP based cellular impedance analysis2017European journal of medicinal chemistry, Aug-18, Volume: 136Design, synthesis and biological evaluation of nitrogen-containing macrocyclic bisbibenzyl derivatives as potent anticancer agents by targeting the lysosome.
AID557194Tmax in healthy human assessed as bisdesethylchloroquine level at 400 mg, po administered as single dose2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Pharmacokinetics of hydroxychloroquine and its clinical implications in chemoprophylaxis against malaria caused by Plasmodium vivax.
AID1659175Inhibition of Zika virus NS2B-NS3 protease2020Bioorganic & medicinal chemistry letters, 03-01, Volume: 30, Issue:5
Inhibitors of the Zika virus protease NS2B-NS3.
AID1203041Antiproliferative activity against human H460 cells after 72 hrs by SRB method2015ACS medicinal chemistry letters, Feb-12, Volume: 6, Issue:2
Discovery of autophagy inhibitors with antiproliferative activity in lung and pancreatic cancer cells.
AID1684806Cytotoxicity against African green monkey Vero cells assessed as reduction in cell growth by coulter counter analysis2021ACS medicinal chemistry letters, Jan-14, Volume: 12, Issue:1
Influence of 4'-Substitution on the Activity of Gemcitabine and Its ProTide Against VZV and SARS-CoV-2.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1409608AUC (viral infection %) for SARS-CoV-2 in the Vero E6 cell line at 48 h by immunofluorescence-based assay (detecting the viral NP protein in the nucleus of the Vero E6 cells).2020Nature, 07, Volume: 583, Issue:7816
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
AID557185Apparent peripheral distribution volume in healthy human at 400 mg, po administered as single dose2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Pharmacokinetics of hydroxychloroquine and its clinical implications in chemoprophylaxis against malaria caused by Plasmodium vivax.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID557181Terminal half life in healthy human at 400 mg, po administered as single dose2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Pharmacokinetics of hydroxychloroquine and its clinical implications in chemoprophylaxis against malaria caused by Plasmodium vivax.
AID1400976Induction of apoptosis in human A549 cells assessed as late apoptotic cells at 50 ug/ml after 8 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 0.02%)2017European journal of medicinal chemistry, Aug-18, Volume: 136Design, synthesis and biological evaluation of nitrogen-containing macrocyclic bisbibenzyl derivatives as potent anticancer agents by targeting the lysosome.
AID557184Apparent oral clearance in healthy human at 400 mg, po administered as single dose2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Pharmacokinetics of hydroxychloroquine and its clinical implications in chemoprophylaxis against malaria caused by Plasmodium vivax.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1688328Antimalarial activity against chloroquine-resistant Plasmodium falciparum K1 infected in human erythrocytes assessed as inhibition of [G-3H]hypoxanthine uptake preincubated for 24 hrs followed by [G-3H]hypoxanthine addition and measured after 18 to 24 hrs2020European journal of medicinal chemistry, Feb-15, Volume: 188Current progress in antimalarial pharmacotherapy and multi-target drug discovery.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1409624hERG binding assays: Displacement of [3H]-Dofetilide (5 nM final) from hERG membranes obtained from HEK293 cells2020Nature, 07, Volume: 583, Issue:7816
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
AID1409619Activity of compound against Muscarinic acetylcholine receptor M2 (CHRM2) by displacement of 3H-QNB2020Nature, 07, Volume: 583, Issue:7816
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
AID1409609Cytotoxicity of compound against Vero E6 cells by MTT assay.2020Nature, 07, Volume: 583, Issue:7816
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1422466Antagonist activity at human TLR9 expressed in HEK-Blue cells assessed as reduction in CpGB-induced NF-kappaB levels after 24 hrs by spectrophotometric analysis2018European journal of medicinal chemistry, Nov-05, Volume: 159Activity-guided development of potent and selective toll-like receptor 9 antagonists.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1631456Antiviral activity against Dengue virus 2 PL046 infected in human Hepa1-6 cells by immunofluorescence analysis2016Journal of medicinal chemistry, 06-23, Volume: 59, Issue:12
The Medicinal Chemistry of Dengue Virus.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1422467Antagonist activity at human TLR7 expressed in HEK-Blue cells assessed as reduction in CL264-induced NF-kappaB levels after 24 hrs by spectrophotometric analysis2018European journal of medicinal chemistry, Nov-05, Volume: 159Activity-guided development of potent and selective toll-like receptor 9 antagonists.
AID1540910Inhibition of EED subunit of PRC2 complex in human MM1S cells assessed as reduction in H3K27me3 expression after 24 hrs by Western blot analysis2019European journal of medicinal chemistry, Dec-01, Volume: 183A drug repurposing screening reveals a novel epigenetic activity of hydroxychloroquine.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID557186Tmax in healthy human assessed as desethylchloroquine level at 400 mg, po administered as single dose2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Pharmacokinetics of hydroxychloroquine and its clinical implications in chemoprophylaxis against malaria caused by Plasmodium vivax.
AID557191Ratio of AUC for desethylchloroquine level to AUC for compound in healthy human at 400 mg, po administered as single dose2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Pharmacokinetics of hydroxychloroquine and its clinical implications in chemoprophylaxis against malaria caused by Plasmodium vivax.
AID1409621Activity of compound against Muscarinic acetylcholine receptor M4 (CHRM4) by displacement of 3H-QNB2020Nature, 07, Volume: 583, Issue:7816
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
AID1607164Antagonist activity at human TLR7 expressed in HEK-Blue cells assessed as inhibition of CL264-induced NFkappaB activation by measuring reduction in SEAP level after overnight incubation using qunati-blue reagent by SEAP reporter gene-based spectrophotomet2020Journal of medicinal chemistry, 05-14, Volume: 63, Issue:9
A Chemical Switch for Transforming a Purine Agonist for Toll-like Receptor 7 to a Clinically Relevant Antagonist.
AID1846469Antiviral activity against SARS CoV-2 (01/human/Jan2020/Thailand) infected in human Calu-3 cells for 2 hrs assessed as inhibition of viral replication measured after 48 hrs post infection by IFA assay
AID1854214Inhibition of cGAS in human THP-1 cells2022European journal of medicinal chemistry, Aug-05, Volume: 238Small molecules targeting cGAS-STING pathway for autoimmune disease.
AID1409620Activity of compound against Muscarinic acetylcholine receptor M3 (CHRM3) by displacement of 3H-QNB2020Nature, 07, Volume: 583, Issue:7816
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
AID1400977Induction of apoptosis in human A549 cells assessed as necrotic cells at 50 ug/ml after 8 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 0.06%)2017European journal of medicinal chemistry, Aug-18, Volume: 136Design, synthesis and biological evaluation of nitrogen-containing macrocyclic bisbibenzyl derivatives as potent anticancer agents by targeting the lysosome.
AID1631458Antiviral activity against Dengue virus 2 PL046 infected in mouse J774A.1 cells by immunofluorescence analysis2016Journal of medicinal chemistry, 06-23, Volume: 59, Issue:12
The Medicinal Chemistry of Dengue Virus.
AID557198AUC (infinity) in healthy human assessed as bisdesethylchloroquine level at 400 mg, po administered as single dose2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Pharmacokinetics of hydroxychloroquine and its clinical implications in chemoprophylaxis against malaria caused by Plasmodium vivax.
AID557187Cmax in healthy human plasma assessed as desethylchloroquine level at 400 mg, po administered as single dose2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Pharmacokinetics of hydroxychloroquine and its clinical implications in chemoprophylaxis against malaria caused by Plasmodium vivax.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1409612Activity of compound against Muscarinic acetylcholine receptor M1 (CHRM1) by displacement of 3H-QNB2020Nature, 07, Volume: 583, Issue:7816
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
AID1203049Inhibition of autophagy in human H460 cells assessed as increase in punctate LC3 level at 10 uM by immunoblot analysis2015ACS medicinal chemistry letters, Feb-12, Volume: 6, Issue:2
Discovery of autophagy inhibitors with antiproliferative activity in lung and pancreatic cancer cells.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1203050Inhibition of autophagy in human H460 cells assessed as increase in p62 level after 24 hrs by immunoblot analysis2015ACS medicinal chemistry letters, Feb-12, Volume: 6, Issue:2
Discovery of autophagy inhibitors with antiproliferative activity in lung and pancreatic cancer cells.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1400973Antiproliferative activity in human A549 cells at 25 ug/ml up to 20 hrs by xCELLigence RTCA SP based cellular impedance analysis2017European journal of medicinal chemistry, Aug-18, Volume: 136Design, synthesis and biological evaluation of nitrogen-containing macrocyclic bisbibenzyl derivatives as potent anticancer agents by targeting the lysosome.
AID1755701Antagonist activity at TLR7 (unknown origin)2021European journal of medicinal chemistry, Jan-15, Volume: 210Synthesis and characterization of new potent TLR7 antagonists based on analysis of the binding mode using biomolecular simulations.
AID1409610Activity of compound against Alpha 2C (ADRA2C) adrenergic receptor by displacement of [3H]-rauwolscine2020Nature, 07, Volume: 583, Issue:7816
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID318590Elevation in glycogen level in fasting BALB/c mouse at 5.70 mg/kg, ip after 3 hrs2008Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
Pharmacophore modeling, quantitative structure-activity relationship analysis, and in silico screening reveal potent glycogen synthase kinase-3beta inhibitory activities for cimetidine, hydroxychloroquine, and gemifloxacin.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1203040Cmax in human at 1200 mg2015ACS medicinal chemistry letters, Feb-12, Volume: 6, Issue:2
Discovery of autophagy inhibitors with antiproliferative activity in lung and pancreatic cancer cells.
AID1409607IC50 for antiviral activity against SARS-CoV-2 in the Vero E6 cell line at 48 h by immunofluorescence-based assay (detecting the viral NP protein in the nucleus of the Vero E6 cells).2020Nature, 07, Volume: 583, Issue:7816
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
AID557196Terminal half life in healthy human assessed as bisdesethylchloroquine level at 400 mg, po administered as single dose2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Pharmacokinetics of hydroxychloroquine and its clinical implications in chemoprophylaxis against malaria caused by Plasmodium vivax.
AID1203042Antiproliferative activity against human HCC827 cells after 72 hrs by SRB method2015ACS medicinal chemistry letters, Feb-12, Volume: 6, Issue:2
Discovery of autophagy inhibitors with antiproliferative activity in lung and pancreatic cancer cells.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1631455Antiviral activity against Dengue virus 2 PL046 infected in human A549 cells by immunofluorescence analysis2016Journal of medicinal chemistry, 06-23, Volume: 59, Issue:12
The Medicinal Chemistry of Dengue Virus.
AID1203046Induction of apoptosis in human H460 cells at 25 to 75 uM after 24 hrs by annexin-V staining-based flow cytometry2015ACS medicinal chemistry letters, Feb-12, Volume: 6, Issue:2
Discovery of autophagy inhibitors with antiproliferative activity in lung and pancreatic cancer cells.
AID1409618Activity of compound against Alpha 2B (ADRA2B) adrenergic receptor by displacement of [3H]-rauwolscine2020Nature, 07, Volume: 583, Issue:7816
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
AID1409615Displacement of [3H]-DTG from the Sigma2 receptor2020Nature, 07, Volume: 583, Issue:7816
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
AID1540911Inhibition of HA-tagged human EED subunit of PRC2 complex expressed in human MM1S cells assessed as reduction in transfected EED cDNA vector-induced H3K27me3 overexpression at 10 uM after 24 hrs by Western blot analysis2019European journal of medicinal chemistry, Dec-01, Volume: 183A drug repurposing screening reveals a novel epigenetic activity of hydroxychloroquine.
AID1203051Inhibition of autophagy in human H460 cells assessed as increase in LC3-2 level at IC50 after 24 hrs by immunoblot analysis2015ACS medicinal chemistry letters, Feb-12, Volume: 6, Issue:2
Discovery of autophagy inhibitors with antiproliferative activity in lung and pancreatic cancer cells.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID557179Tmax in healthy human at 400 mg, po administered as single dose2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Pharmacokinetics of hydroxychloroquine and its clinical implications in chemoprophylaxis against malaria caused by Plasmodium vivax.
AID557189AUC (last) in healthy human assessed as desethylchloroquine level at 400 mg, po administered as single dose2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Pharmacokinetics of hydroxychloroquine and its clinical implications in chemoprophylaxis against malaria caused by Plasmodium vivax.
AID1717755Antiviral activity against SARS-CoV-2 infected in African green monkey Vero cells incubated for 48 hrs by RT-PCR method2020Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22
Chinese Therapeutic Strategy for Fighting COVID-19 and Potential Small-Molecule Inhibitors against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1599409Antiviral activity against DENV2 infected in BHK-21 incubated for 2 hrs followed by compound washout and subsequent replating by plaque-forming assay2019European journal of medicinal chemistry, Aug-15, Volume: 176Recent update on anti-dengue drug discovery.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID557180Cmax in healthy human plasma at 400 mg, po administered as single dose2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Pharmacokinetics of hydroxychloroquine and its clinical implications in chemoprophylaxis against malaria caused by Plasmodium vivax.
AID1409625Selectivity index for SigmaR1/R2 on-target Kd values vs. hERG ion channel2020Nature, 07, Volume: 583, Issue:7816
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1409617Activity of compound against Alpha-2A (ADRA2A) adrenergic receptor by displacement of [3H]-rauwolscine2020Nature, 07, Volume: 583, Issue:7816
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
AID1409616Displacement of [3H]-pentazocin from the Sigma1 receptor2020Nature, 07, Volume: 583, Issue:7816
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
AID1409623IC90 for antiviral activity against SARS-CoV-2 in the Vero E6 cell line by measuring infectious viral titer of supernatent from compound-treated Vero E6 cells by Median Tissue Culture Infectious Dose (TCID)50 by the method of Reed and Muench2020Nature, 07, Volume: 583, Issue:7816
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID557188Terminal half life in healthy human assessed as desethylchloroquine level at 400 mg, po administered as single dose2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Pharmacokinetics of hydroxychloroquine and its clinical implications in chemoprophylaxis against malaria caused by Plasmodium vivax.
AID1203043Antiproliferative activity against human BxPC3 cells after 72 hrs by SRB method2015ACS medicinal chemistry letters, Feb-12, Volume: 6, Issue:2
Discovery of autophagy inhibitors with antiproliferative activity in lung and pancreatic cancer cells.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1203047Inhibition of autophagy in human NCI-H3122 cells assessed as increase in punctate LC3 expression at 25 to 50 uM after 6 hrs by fluorescence microscopic analysis2015ACS medicinal chemistry letters, Feb-12, Volume: 6, Issue:2
Discovery of autophagy inhibitors with antiproliferative activity in lung and pancreatic cancer cells.
AID1631457Antiviral activity against Dengue virus 2 PL046 infected in human WS1 cells by immunofluorescence analysis2016Journal of medicinal chemistry, 06-23, Volume: 59, Issue:12
The Medicinal Chemistry of Dengue Virus.
AID1688329Antimalarial activity against chloroquine-resistant Plasmodium falciparum T996 infected in human erythrocytes assessed as inhibition of [G-3H]hypoxanthine uptake preincubated for 24 hrs followed by [G-3H]hypoxanthine addition and measured after 18 to 24 h2020European journal of medicinal chemistry, Feb-15, Volume: 188Current progress in antimalarial pharmacotherapy and multi-target drug discovery.
AID557195Cmax in healthy human plasma assessed as bisdesethylchloroquine level at 400 mg, po administered as single dose2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Pharmacokinetics of hydroxychloroquine and its clinical implications in chemoprophylaxis against malaria caused by Plasmodium vivax.
AID1400975Induction of apoptosis in human A549 cells assessed as early apoptotic cells at 50 ug/ml after 8 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 0.03%)2017European journal of medicinal chemistry, Aug-18, Volume: 136Design, synthesis and biological evaluation of nitrogen-containing macrocyclic bisbibenzyl derivatives as potent anticancer agents by targeting the lysosome.
AID557193Antimalarial activity against Plasmodium vivax infected in patient assessed as prophylaxis at 800 mg, po followed by 400 mg administration at 6, 24 and 48 hrs afterwards2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Pharmacokinetics of hydroxychloroquine and its clinical implications in chemoprophylaxis against malaria caused by Plasmodium vivax.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1804127No assay is provided from Article 10.1002/med.21724: \\The recent outbreaks of human coronaviruses: A medicinal chemistry perspective.\\2021Medicinal research reviews, 01, Volume: 41, Issue:1
The recent outbreaks of human coronaviruses: A medicinal chemistry perspective.
AID1805801Various Assay from Article 10.1021/acs.jmedchem.1c00409: \\Perspectives on SARS-CoV-2 Main Protease Inhibitors.\\2021Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23
Perspectives on SARS-CoV-2 Main Protease Inhibitors.
AID1345471Human TLR7 (Toll-like receptor family)2014Molecular pharmacology, Mar, Volume: 85, Issue:3
Novel small molecule inhibitors of TLR7 and TLR9: mechanism of action and efficacy in vivo.
AID1345567Human TLR9 (Toll-like receptor family)2014Molecular pharmacology, Mar, Volume: 85, Issue:3
Novel small molecule inhibitors of TLR7 and TLR9: mechanism of action and efficacy in vivo.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5,496)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990481 (8.75)18.7374
1990's364 (6.62)18.2507
2000's528 (9.61)29.6817
2010's1445 (26.29)24.3611
2020's2678 (48.73)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 126.54

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index126.54 (24.57)
Research Supply Index8.76 (2.92)
Research Growth Index5.26 (4.65)
Search Engine Demand Index239.38 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (126.54)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials474 (8.05%)5.53%
Reviews953 (16.19%)6.00%
Case Studies1,278 (21.72%)4.05%
Observational165 (2.80%)0.25%
Other3,015 (51.23%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (433)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Hydroxychloroquine as a Steroid-sparing Agent in Extrapulmonary Sarcoidosis: Multicenter, Prospective, Placebo-controlled, Randomized Trial [NCT05841758]Phase 4140 participants (Anticipated)Interventional2023-09-01Not yet recruiting
A Pilot Study of Hydroxychloroquine for the Treatment of Muscle Cramps in Patients With Cirrhosis [NCT01495403]Early Phase 13 participants (Actual)Interventional2011-12-31Completed
The Immunological Impact of Adding Hydroxychloroquine in Patients With Discordant CD4+ Cell Responses to Suppressive HAART: A Phase I Pilot Study. [NCT01232660]Phase 112 participants (Anticipated)Interventional2010-10-31Recruiting
Autophagy Inhibition Using Hydrochloroquine in Breast Cancer Patients:a Pilot Study [NCT01292408]Phase 220 participants (Anticipated)Interventional2011-01-31Recruiting
A Phase I/II Pharmacodynamic Study of Hydroxychloroquine in Combination With FOLFOX Plus Bevacizumab to Inhibit Autophagy in Colorectal Cancer [NCT01206530]Phase 1/Phase 250 participants (Actual)Interventional2010-09-30Completed
Hydroxychloroquine Efficacy and Safety in Preventing SARS-CoV-2 Infection and COVID-19 Disease Severity During Pregnancy and Postpartum [NCT04410562]Phase 3129 participants (Actual)Interventional2020-05-13Completed
Hydroxychloroquine Administration for Reduction of Pexophagy [NCT03856866]Phase 23 participants (Actual)Interventional2019-01-11Completed
Post-exposure Prophylaxis or Preemptive Therapy for SARS-Coronavirus-2: A Pragmatic Randomized Clinical Trial [NCT04308668]Phase 31,312 participants (Actual)Interventional2020-03-17Completed
A Triple Combination Antiviral Coronavirus Therapy (TriACT) RCT Comparing Nitazoxanide, Ribavirin and Hydroxychloroquine vs. Placebo [NCT04605588]Phase 27 participants (Actual)Interventional2020-12-02Terminated(stopped due to Lack of participants willing to enroll)
A Phase II Randomized Double-Blind Placebo-Controlled Clinical Trial Of Hydroxychloroquine For Prophylaxis Against Covid-19 In Patients Receiving Radiotherapy (COVID) [NCT04381988]Phase 24 participants (Actual)Interventional2020-05-07Terminated(stopped due to The study was terminated based results of other studies and use of the new vaccine.)
Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine Trial (HERO-HCQ Trial) [NCT04334148]Phase 31,360 participants (Actual)Interventional2020-04-22Completed
Treating COVID-19 With Hydroxychloroquine: A Multicenter Randomized, Double-blind, Placebo-controlled Clinical Trial in Hospitalized Adults [NCT04369742]Phase 2128 participants (Actual)Interventional2020-04-15Terminated(stopped due to Investigator decision)
CHOICES: A Randomized Phase II Trial of Imatinib (IM) Versus Hydroxychloroquine (HCQ) and IM for Patients With Chronic Myeloid Leukemia (CML) in Major Cytogenetic Response (MCyR) With Residual Disease Detectable by Quantitative Polymerase Chain Reaction ( [NCT01227135]Phase 266 participants (Anticipated)Interventional2010-03-31Recruiting
A Phase I/II Study of CPI-613 and Hydroxychloroquine for Patients With High Risk MDS Who Have Failed Hypomethylating Therapy [NCT03929211]Phase 1/Phase 20 participants (Actual)Interventional2021-05-31Withdrawn(stopped due to Administrative withdrawal by IRB)
Pharmacological Treatment In Osteoarthritis [NCT01148043]Phase 3200 participants (Actual)Interventional2010-07-31Completed
A Phase I Trial of Sirolimus (mTOR Inhibitor) or Vorinostat (HDAC Inhibitor) in Combination With Hydroxychloroquine (Autophagy Inhibitor) in Patients With Advanced Malignancies [NCT01266057]Phase 1143 participants (Actual)Interventional2011-04-28Completed
The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine) [NCT04329923]Phase 2173 participants (Actual)Interventional2020-04-09Terminated(stopped due to Cohort 1: slow accrual Cohort 2: Other studies showed no benefit Cohort 3: Study met pre-specificied futility analysis at planned second interim analysis)
IL-7 and IL-7R Expression in Peripheral Blood Mononuclear Cells, Peripheral Blood Monocytes or Differentiated Macrophages of Rheumatoid Arthritis Patients With Active vs. Inactive Disease Treated With DMARD and/or CIMZIA [NCT02451748]Phase 432 participants (Actual)Interventional2015-08-31Completed
A Prospective, Single-centre, Randomised Study Evaluating the Clinical, Imaging and Immunological Depth of Remission Achieved by Very Early Versus Delayed Etanercept in Patients With Rheumatoid Arthritis [NCT02433184]Phase 4120 participants (Actual)Interventional2011-07-31Completed
Cytochrome P450 and ATP-Binding Cassette C C (ABCC) Variants in Egyptian Patients Receiving Hydroxychloroquine and Their Association With Efficacy and Toxicity [NCT03180190]50 participants (Anticipated)Observational [Patient Registry]2017-06-28Not yet recruiting
Comparison of Sulfasalazine Versus Leflunomide Based Combination Disease Modifying Anti-rheumatic Drug Therapy (DMARD) in Patients With Rheumatoid Arthritis Failing Methotrexate Monotherapy : A Randomized Control Trial [NCT02930343]Phase 3136 participants (Actual)Interventional2016-09-30Terminated(stopped due to Due to time constraints, the study was halted prematurely)
Phase Ib/II Study of Hydroxychloroquine in Metastatic ER-Positive Breast Cancer Progressing on Hormonal Therapy [NCT02414776]Phase 13 participants (Actual)Interventional2014-07-31Terminated(stopped due to PI Leaving Site)
A Three-arm, Multicenter, Open-label Randomized Controlled Trial of Hydroxychloroquine and Low-dose Prednisone on Recurrent Spontaneous Abortion With Undifferentiated Connective Tissue Diseases: Protocol for the Immunosuppressant Regimens for Living FEtus [NCT03671174]420 participants (Anticipated)Interventional2019-08-02Recruiting
A Randomized Phase 2/3 Trial of Hydroxychloroquine In Covid-19 Kinetics [NCT04353271]Phase 2/Phase 33 participants (Actual)Interventional2020-04-17Terminated(stopped due to FDA recommendations to not use outside of the hospital setting or in a clinical trial due to the risk of cardiac arrhythmias)
Chloroquine/ Hydroxychloroquine Prevention of Coronavirus Disease (COVID-19) in the Healthcare Setting; a Randomised, Placebo-controlled Prophylaxis Study (COPCOV) [NCT04303507]4,652 participants (Actual)Interventional2020-04-29Completed
Randomised Evaluation of COVID-19 Therapy [NCT04381936]Phase 2/Phase 350,000 participants (Anticipated)Interventional2020-03-19Recruiting
Renal Division, Peking University First Hospital, Institute of Nephrology, Peking University, Key Laboratory of Renal Disease [NCT02351752]Phase 420 participants (Actual)Interventional2015-01-31Completed
Treatment in Patients With Suspected or Confirmed COVID-19 With Early Moderate or Severe Disease: A Randomized Clinical Trial [NCT04344444]Phase 322 participants (Actual)Interventional2020-04-13Terminated(stopped due to Lack of efficacy data from other studies)
Phase II Open-Label Multi-Cohort Study Evaluating CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Patients With Advanced Chemorefractory Colorectal, Pancreatic, or Other Solid Cancers [NCT05733000]Phase 294 participants (Anticipated)Interventional2023-03-08Recruiting
Biological Effects of Maintenance Usage of Hydroxychloroquine on PAR-4 Levels in Patients With Resected Solid Tumors [NCT03015324]Phase 138 participants (Actual)Interventional2017-08-08Completed
Hydroxychloroquine Treatment for Severe COVID-19 Respiratory Disease: Randomised Clinical Trial (HYDRA Trial) [NCT04315896]Phase 3320 participants (Actual)Interventional2020-04-14Completed
Hydroxychloroquine in Pediatric ILD With Genetic Surfactant Dysfunction Disorders: Cross-control, Prospective Study [NCT03822780]25 participants (Anticipated)Interventional2017-07-01Recruiting
The Efficacy and Safety of Iguratimod (IGU) in the Treatment of Primary Sjögren's Syndrome: A Multi-center, Prospective, Open Study [NCT04981145]Phase 478 participants (Anticipated)Interventional2022-01-14Recruiting
Hydroxychloroquine for Prevention of Abnormal Glucose Tolerance and Diabetes in Individuals At-risk for Type 1 Diabetes Mellitus (T1D) [NCT03428945]Phase 2275 participants (Actual)Interventional2018-08-15Terminated(stopped due to This trial has undergone a prespecified interim analysis which determined that this treatment provides no statistically significant delay in the onset of abnormal glucose tolerance or Type 1 Diabetes.)
Targeted Treatment Early With Etanercept Plus Methotrexate Versus T2T Care for DMARD-naïve Early RA Patients. A Prospective, Longitudinal Cohort Study With Embedded Pilot Randomised Controlled Trial to Assess Treatment Rationalisation Based on naïve T-cel [NCT03813771]Phase 4106 participants (Anticipated)Interventional2019-03-31Not yet recruiting
The Effectiveness and Safety of Ivermectin as add-on Therapy in Severe COVID-19 Management [NCT04646109]Phase 366 participants (Actual)Interventional2020-05-11Completed
A lead-in Phase I Followed by a Phase II Clinical Trial on the Combination of Dabrafenib, Trametinib and the Autophagy Inhibitor Hydroxychloroquine in BRAF/MEK Inhibitor-pretreated Patients With Advanced BRAF V600 Mutant Melanoma [NCT03754179]Phase 1/Phase 263 participants (Anticipated)Interventional2018-01-23Recruiting
Feasibility, Safety and Early Efficacy Trial of Hydroxychloroquine as Primary Prevention of Corona Virus Disease 2019 in High Risk Health Care Providers [NCT04345653]Phase 248 participants (Actual)Interventional2020-04-14Completed
The Efficacy of Aspirin Combined With Hydroxychloroquine Treatment in High Risk Pregnancies for Preeclampsia: a Multicenter, Open-label, Single Arm Trial, Investigator Initiated Study [NCT05287321]Phase 358 participants (Anticipated)Interventional2022-05-31Recruiting
Hydroxychloroquine in Isolated Cutaneous Mastocytosis Patients or Indolent Systemic Mastocytosis With Associated Skin Involvement Patients: Proof of Concept Study [NCT05084872]Phase 2/Phase 330 participants (Anticipated)Interventional2021-10-31Not yet recruiting
Cyclophosphamide and Hydroxychloroquine for the Treatment of Severe Thrombocytopenia in Systemic Lupus Erythematosus [NCT02444728]Phase 350 participants (Actual)Interventional2015-07-31Terminated(stopped due to Because of insufficient enrollement)
A Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19 [NCT04358068]Phase 220 participants (Actual)Interventional2020-05-13Terminated(stopped due to Slow enrollment and lack of community enthusiasm)
CSP #551 - Rheumatoid Arthritis: Comparison of Active Therapies in Patients With Active Disease Despite Methotrexate Therapy [NCT00405275]353 participants (Actual)Interventional2007-07-31Completed
A Prospective Double Blind Placebo Controlled Trial of Combination Disease Modifying Antirheumatic Drugs (DMARDs) vs Monotherapy (Sulfasalazine) in Patients With Inflammatory Low Backache in Early Seronegative Spondylarthropathy [NCT01040195]Phase 333 participants (Actual)Interventional2009-06-30Completed
THREAD: A Phase I Trial of Trametinib and Hydroxychloroquine in Patients With Advanced Pancreatic Cancer [NCT03825289]Phase 139 participants (Anticipated)Interventional2019-01-18Recruiting
Effect of Sarilumab on Patient-reported Outcomes in Patients With Moderately to Severely Active Rheumatoid Arthritis and With Inadequate Response or Intolerance to Current Conventional Synthetic DMARDs or Tumor Necrosis Factor Inhibitors [NCT03449758]Phase 484 participants (Actual)Interventional2018-03-05Completed
Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma Through Image-guided Locoregional Therapy [NCT05842174]Phase 1/Phase 293 participants (Anticipated)Interventional2023-09-01Not yet recruiting
Open Label Non-comparative Trial of the Combination of Hydroxychloroquine and Azithromycin in the Treatment of Hospitalized Patients With Moderate or Severe COVID-19 Infection [NCT04458948]Phase 228 participants (Actual)Interventional2020-03-24Terminated(stopped due to The World Health Organization (WHO) paused Hydrochloroquinone from its Solidarity Trial in order to conduct a safety data review by the Data Safety Monitoring Board of the WHO to evaluate HCQ in its clinical trials.)
A Registry to Capture Patient Outcomes With KRAS G12R Altered Advanced Pancreatic Ductal Adenocarcinoma Treated With MEK Inhibitor-based Combination Therapy [NCT05630989]40 participants (Anticipated)Observational [Patient Registry]2023-02-07Recruiting
Binimetinib Plus Hydroxychloroquine in KRAS Mutant Metastatic Pancreatic Cancer [NCT04132505]Phase 139 participants (Anticipated)Interventional2019-10-22Recruiting
A Phase I/II Study of Hydroxychloroquine and Itraconazole as Therapy for Men With Androgen Normalised Prostate Cancer [NCT03513211]Phase 1/Phase 212 participants (Actual)Interventional2018-08-23Completed
Autophagy Inhibition to Augment Mammilian Target of Rapamycin (mTOR) Inhibition: A Phase I/II Trial of RAD001 and Hydroxychloroquine (HCQ) in Patients With Previously Treated Renal Cell Carcinoma [NCT01510119]Phase 1/Phase 240 participants (Actual)Interventional2011-09-30Completed
Comparative Study Between Chloroquine and Hydroxychloroquine as Therapeutic Modalities for Children and Adolescents With Proliferative Lupus Nephritis [NCT03687905]60 participants (Anticipated)Observational [Patient Registry]2018-09-18Recruiting
Worldwide Trends on COVID-19 Research After the Declaration of COVID-19 Pandemic: An Observational Study [NCT04460547]200 participants (Anticipated)Observational2020-07-25Not yet recruiting
Randomized, Double-Blind, Controlled Trial of Hydroxychloroquine vs Placebo as Post-Exposure Prophylaxis Against COVID-19 Infection [NCT04372017]Phase 31 participants (Actual)Interventional2020-05-14Terminated(stopped due to Unlikelihood of benefit based on other studies.)
A Phase I/IIA Study of ABC294640 Alone and in Combination With Hydroxychloroquine Sulfate in the Treatment of Patients With Advanced, Unresectable Intra-hepatic, Perihilar and Extra-Hepatic Cholangiocarcinoma [NCT03377179]Phase 265 participants (Actual)Interventional2018-03-07Completed
RCT Assessing Hydroxychloroquine for Unexplained Recurrent Pregnancy Loss [NCT02379650]Phase 20 participants (Actual)Interventional2016-07-31Withdrawn(stopped due to Testing required by FDA for IND approval was too expensive to move forward with conduct of the study.)
Efficacy of Hydroxychloroquine for Post-exposure Prophylaxis (PEP) to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection Among Adults Exposed to Coronavirus Disease (COVID-19): a Blinded, Randomized Study [NCT04328961]Phase 2/Phase 3943 participants (Actual)Interventional2020-03-31Completed
A Phase III, Randomized, Double-Blind Placebo-Controlled, Non-Inferiority, Multi-Center Study of the Effects of Stopping Hydroxychloroquine in Elderly Lupus Disease [NCT05799378]Phase 3330 participants (Anticipated)Interventional2023-10-31Not yet recruiting
The Therapeutic Potential of Convalescent Plasma Therapy on Treating Critically-ill COVID-19 Patients Residing in Respiratory Care Units in Hospitals in Baghdad, Iraq [NCT04441424]49 participants (Actual)Interventional2020-04-03Completed
Chemoprophylaxis With Hydroxychloroquine in Healthcare Personnel in Contact With COVID-19 Patients: A Randomized Controlled Trial (PHYDRA Trial) [NCT04318015]Phase 3289 participants (Actual)Interventional2020-04-14Completed
Hydroxychloroquine Versus Placebo: Impact on Thrombotic Relapse in Primary Antiphospholipid Syndrome [NCT03540810]Phase 3300 participants (Anticipated)Interventional2018-08-15Not yet recruiting
Efficacy and Safety of Hydroxychloroquine in Patients With X-linked Alport Syndrome in China (CHXLAS) [NCT04937907]Phase 250 participants (Anticipated)Interventional2021-09-08Recruiting
Hydroxychloroquine for Improvement of Pregnancy Outcome in Unexplained Recurrent Miscarriage [NCT04228263]156 participants (Actual)Interventional2020-01-01Completed
Hydroxychloroquine as Steroid-Sparing Agent in Pulmonary Sarcoidosis (HySSAS). A Multicenter, Prospective, Controlled, Randomized Trial. [NCT02200146]Phase 394 participants (Actual)Interventional2009-03-31Completed
Multi-centre, Adaptive, Randomized Trial of the Safety and Efficacy of Treatments of COVID-19 in Hospitalized Adults [NCT04315948]Phase 31,552 participants (Actual)Interventional2020-03-22Completed
Phase 1/2 Open-label Study of Combination Therapy With the MEK Inhibitor, Cobimetinib, Immune Checkpoint Blockade, Atezolizumab, and the AUTOphagy Inhibitor, Hydroxychloroquine in KRAS-mutated Advanced Malignancies [NCT04214418]Phase 1/Phase 2175 participants (Anticipated)Interventional2020-02-12Active, not recruiting
Combination of Autophagy Selective Therapeutics (COAST) in Advanced Solid Tumors or Relapsed Prostate Cancer, A Phase I/II Trial [NCT05036226]Phase 1/Phase 276 participants (Anticipated)Interventional2022-03-03Recruiting
Rediscovering Hydroxychloroquine as a Novel Insulin Sensitizer [NCT02124681]Phase 134 participants (Actual)Interventional2014-04-30Completed
A Randomized Open-label Prophylaxis Trial Among Migrant Workers at High-risk of COVID-19 (DORM Trial) [NCT04446104]Phase 34,257 participants (Actual)Interventional2020-05-13Completed
Off Label Study to Evaluate the Efficacy of Hydroxychloroquine as Prophylaxis to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection Among Health Care Workers at High Risk of Occupational Exposure to SARS-CoV-2 [NCT04435808]Phase 1/Phase 21 participants (Actual)Interventional2020-04-14Terminated(stopped due to Stopped for futility by DSMB)
Evaluation of the Pharmacokinetics and Pharmacodynamics of Hydroxychloroquine in COVID-19 Intensive Care Unit Patients [NCT04522466]Phase 37 participants (Actual)Interventional2020-04-03Terminated(stopped due to Stop of the study by competent authority (ANSM))
Treatment of Early Aggressive Rheumatoid Arthritis (TEAR) [NCT00259610]Phase 4755 participants (Actual)Interventional2004-05-31Completed
Modulation of Autophagy: A Clinical Study of Vorinostat Plus Hydroxychloroquine Versus Regorafenib in Refractory Metastatic Colorectal Cancer (mCRC) Patients (CTMS# 14-2015) [NCT02316340]Phase 244 participants (Actual)Interventional2015-02-11Completed
Safety and Efficacy of Hydroxychloroquine for the Treatment & Prevention of Coronavirus Disease 2019 (COVID-19) Caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) [NCT04590274]Phase 10 participants (Actual)Interventional2020-11-30Withdrawn(stopped due to Investigative Team no longer interested)
A Phase IIa Randomized, Controlled Study of Combination Therapies to Treat COVID-19 Infection [NCT04459702]Phase 20 participants (Actual)Interventional2020-07-31Withdrawn(stopped due to Was never started)
Randomized Phase II Trial of Pre-Operative Gemcitabine, Nab-Paclitaxel, and Hydroxychloroquine With or Without Avelumab (PGHA vs. PGH) [NCT03344172]Phase 232 participants (Actual)Interventional2017-12-13Terminated(stopped due to Suspected Serious Adverse Events related to treatment)
Persistent Lyme Empiric Antibiotic Study Europe. A Prospective, Randomised Study Comparing Two Prolonged Oral Antibiotic Strategies After Initial Intravenous Ceftriaxone Therapy for Patients With Symptoms of Proven or Possible Persistent Lyme Disease [NCT01207739]Phase 4280 participants (Actual)Interventional2010-09-30Completed
A Phase II Trial of Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast Cancer (PALAVY) [NCT04841148]Phase 296 participants (Anticipated)Interventional2021-06-01Recruiting
Modulation of Autophagy With Hydroxychloroquine in Patients With Advanced/Recurrent Non-small Cell Lung Cancer - a Phase II Study. A Study of The Cancer Institute of New Jersey Oncology Group (CINJOG) [NCT01649947]Phase 232 participants (Actual)Interventional2011-12-23Completed
Multicenter Registry of Pediatric Lupus Nephritis in China [NCT03791827]1,200 participants (Anticipated)Observational2018-12-01Recruiting
A Phase IB Study of Hydroxychloroquine Prior to Nephrectomy in Patients With Primary Renal Cell Carcinoma [NCT01144169]Phase 17 participants (Actual)Interventional2010-10-31Terminated(stopped due to barriers to accrual: delay until surgery and additional pre-operative visits)
NJ 1808: Autophagic Cell Death With Hydroxychloroquine in Patients With Hormone-Dependent Prostate-Specific Antigen Progression After Local Therapy For Prostate Cancer. [NCT00726596]Phase 264 participants (Actual)Interventional2008-08-31Completed
BRAF, Autophagy and MEK Inhibition in Metastatic Melanoma: A Phase I/II Open-Label Trial of Dabrafenib, Trametinib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma [NCT02257424]Phase 1/Phase 250 participants (Actual)Interventional2014-10-31Completed
Pre-exposure Prophylaxis for SARS-Coronavirus-2: A Pragmatic Randomized Clinical Trial [NCT04328467]Phase 31,483 participants (Actual)Interventional2020-04-06Completed
Hydroxychloroquine and Metabolic Outcomes in Patients Undergoing Total Pancreatectomy and Autologous Islet Transplantation: A Clinical, Molecular, and Genomic Study [NCT03283566]Phase 29 participants (Actual)Interventional2017-10-03Completed
Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response [NCT03414502]Phase 3400 participants (Anticipated)Interventional2007-12-10Recruiting
Proflaxis for Healthcare Professionals Using Hydroxychloroquine Plus Vitamin Combining Vitamins C, D and Zinc During COVID-19 Pandemia: An Observational Study [NCT04326725]80 participants (Anticipated)Observational2020-03-20Active, not recruiting
Mechanisms of Action of Hydroxychloroquine in Reducing Risk of Type 2 Diabetes [NCT01326533]Phase 432 participants (Actual)Interventional2011-03-31Completed
Phase 1B Study of Hepatic Chemoembolization Plus Axitinib and Hydroxychlorquine for Liver-Dominant Metastatic Adenocarcinoma Of The Colon And Rectum [NCT04873895]Phase 125 participants (Anticipated)Interventional2022-01-24Recruiting
Evaluation of the Safety and Clinical Efficacy of Hydroxychloroquine Associated With Azithromycin in Patients With Pneumonia Caused by Infection by the SARS-CoV2 Virus - Coalition COVID-19 Brasil II - SEVERE - Patients [NCT04321278]Phase 3440 participants (Actual)Interventional2020-03-28Completed
Hydroxychloroquine Assessment of Management Study in Coronary Artery Disease After Angiography. [NCT02874287]Phase 435 participants (Actual)Interventional2017-10-08Completed
A Phase I Trial of Hydroxychloroquine in Combination With Temsirolimus in Patients With Refractory Solid Tumors [NCT00909831]Phase 140 participants (Anticipated)Interventional2008-10-31Completed
A Phase I Study of Hydroxychloroquine in Combination With Temozolomide in Patients With Advanced Solid Tumors [NCT00714181]Phase 138 participants (Actual)Interventional2008-06-30Completed
Hydroxychloroquine (HCQ) in Combination With Abemaciclib and Endocrine Therapy in HR+/Her 2- Advanced Breast Cancer After a Lead in Dose Escalation Cohort of HCQ and Abemaciclib in Advanced Solid Tumors [NCT04316169]Phase 10 participants (Actual)Interventional2021-10-21Withdrawn(stopped due to Funding and PI leaving institution)
Autophagic Modulation With Anti-angiogenic Therapy in Patients With Advanced Malignancies: A Phase I Trial of Sunitinib and Hydroxychloroquine [NCT00813423]Phase 140 participants (Actual)Interventional2010-02-19Completed
Efficiency of Hydroxychloroquine on the Endothelial Dysfunction in Antiphospholipid Syndrome (APLAQUINE) [NCT02595346]Phase 230 participants (Anticipated)Interventional2016-06-30Recruiting
Effect of Hydroxychloroquine on Endothelial Function: a Clinical Trial [NCT04161339]Phase 450 participants (Anticipated)Interventional2019-07-01Recruiting
Clinical Trial to Evaluate Intermittent Screening and Treatment and Intermittent Preventive Treatment of Malaria in Asymptomatic Schoolchildren to Decrease P. Falciparum Infection and Transmission: Phase 2 Comparing Drug Regimens [NCT05980156]Phase 4646 participants (Actual)Interventional2023-02-13Completed
Evaluation and Prediction of Relapse Risk After Glucocorticoid Withdrawal in Patients With Stable Systemic Lupus Erythematosus: An Open-labeled Multi-centric Randomized Controlled Study From China [NCT02842814]333 participants (Actual)Interventional2016-10-31Completed
"Evaluation de l'efficacité et de la tolérance de Quinquina et d'un phytomédicament ACAR en Comparaison Avec l'Hydroxychloroquine Chez Des Adultes Malades de Covid-19 Sans symptômes" [NCT04501965]Phase 2231 participants (Actual)Interventional2020-06-01Enrolling by invitation
Treatment of Covid-19 With Favipiravir Versus Hydroxychloroquine: a Randomized Comparator Trial [NCT04387760]Phase 2150 participants (Actual)Interventional2020-08-11Completed
A Randomized Study to Compare the Efficacy of Vorinostat/Hydroxychloroquine/Maraviroc (VHM) in Controlling HIV After Treatment Interruption in Subjects Who Initiated ART During Acute HIV Infection [NCT02475915]Phase 1/Phase 215 participants (Actual)Interventional2015-01-31Completed
A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Inhaled TLC19 in Healthy Volunteers [NCT04697654]Phase 130 participants (Actual)Interventional2020-10-08Completed
An Adaptive, Multicenter, Randomized, Open-label, Comparative Clinical Study to Assess Efficacy and Safety of Favipiravir in Hospitalized Patients With COVID-19 [NCT04434248]Phase 2/Phase 3330 participants (Actual)Interventional2020-04-23Active, not recruiting
The Effect of Plaquenil on Serum Inflammatory Markers and Goiter in Euthyroid Young Women With Hashimoto's Thyroiditis [NCT02126683]60 participants (Anticipated)Interventional2014-04-30Active, not recruiting
Clinical Trial for the Prevention and Treatment With Hydroxychloroquine + Azithromycin of Acute Respiratory Syndrome Induced by COVID-19 [NCT04954040]Phase 2132 participants (Anticipated)Interventional2021-02-10Recruiting
A Phase I Trial of MK-2206 and Hydroxychloroquine in Solid Tumors, Melanoma, Renal and Prostate Cancer to Examine the Role of Autophagy in Tumorigenesis [NCT01480154]Phase 162 participants (Actual)Interventional2011-11-23Active, not recruiting
The Efficacy and Safety of Hydroxychloroquine for the Treatment Of Non-Severe COVID-19 in Adults in Uganda: A Randomized Open Label Phase II Clinical Trial [NCT04860284]Phase 2105 participants (Actual)Interventional2020-09-18Active, not recruiting
The Clinical Features and Pregnancy Outcomes of Patients With Connective Tissue Disease :a Prospective Cohort Study [NCT04918524]126 participants (Anticipated)Observational2018-09-11Recruiting
Prospective Clinical Study to Observe the Efficacy and Safety of Iguratimod in Rheumatoid Arthritis and Early Rheumatoid Arthritis Patients for 6 Months Treatment in China [NCT03855007]Phase 4400 participants (Actual)Interventional2016-01-01Completed
Phase I/II Safety and Efficacy Study of Autophagy Inhibition With Hydroxychloroquine to Augment the Antiproliferative and Biological Effects of Pre-Operative Palbociclib Plus Letrozole for Estrogen Receptor-Positive and HER2-Negative Breast Cancer [NCT03774472]Phase 1/Phase 215 participants (Actual)Interventional2018-08-20Active, not recruiting
Efficacy of Sofosbuvir Plus Ledipasvir in Egyptian Patients With COVID-19 Compared to Standard Treatment [NCT04530422]Phase 3250 participants (Actual)Interventional2020-04-15Completed
Bioavailability of Hydroxychloroquine Sulfate, 200 mg Tablets [NCT00946790]Phase 172 participants (Actual)Interventional1993-07-31Completed
Acute Rhabdomyolysis and Muscle Pain Associated With Mutations in the LPIN1 Gene - A Retrospective Study Describing the Safety and Efficacy of Hydroxychloroquine Sulfate Given on a Compassionate Basis to Patients Suffering From Lipin-1 Deficiency [NCT04007562]0 participants (Actual)Observational2019-07-31Withdrawn(stopped due to The study never started)
The Effect of Hydroxychloroquine Sulphate on Hedonic Food Intake, Appetite-related Sensations and Gastrointestinal Hormone Release in Healthy Female Subjects [NCT04005768]Phase 410 participants (Anticipated)Interventional2019-08-01Not yet recruiting
Window of Opportunity for Neoadjuvant Stroma Modification in Pancreatic Cancer [NCT05365893]Early Phase 120 participants (Anticipated)Interventional2021-10-20Recruiting
A Phase II With a Lead in Phase I Study to Examine the Tolerability, Safety Profile and Efficacy of Hydroxychloroquine and Gefitinib in Advanced Non-Small Cell Lung Cancer [NCT00809237]Phase 1/Phase 271 participants (Anticipated)Interventional2008-11-30Recruiting
A Phase I/II Trial of Hydroxychloroquine in Conjunction With Radiation Therapy and Concurrent and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme [NCT00486603]Phase 1/Phase 292 participants (Actual)Interventional2007-10-29Completed
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia [NCT02735707]Phase 310,000 participants (Anticipated)Interventional2016-04-11Recruiting
Hydroxychloroquine Efficacy in Chronic Urticaria [NCT01073852]0 participants (Actual)Interventional2011-06-30Withdrawn(stopped due to withdrawn, not funded)
Use of TNF-blocking Therapy in Combination With DMARDs in Patients With Early Rheumatoid Arthritis [NCT00908089]Phase 4100 participants (Actual)Interventional2003-03-31Active, not recruiting
Efficacy and Safety of Hydroxychloroquine for Treatment of COVID-19 [NCT04261517]Phase 330 participants (Actual)Interventional2020-02-06Completed
Hydroxychloroquine and Cognitive Function After Surgery [NCT03025087]Phase 430 participants (Anticipated)Interventional2017-06-19Suspended(stopped due to Interim analysis)
Hydroxychloroquine Sulfate Alleviates Persistent Proteinuria in IgA Nephropathy:a Single Center Prospective Randomized Controlled Study [NCT02765594]Phase 498 participants (Anticipated)Interventional2016-06-30Recruiting
Circulating MicroRNAs in Understanding Pathogenesis of Systemic Lupus Erythematosis [NCT02756546]Phase 1/Phase 2100 participants (Actual)Interventional2014-09-30Completed
An International Randomized Trial of Additional Treatments for COVID-19 in Hospitalized Patients Who Are All Receiving the Local Standard of Care Philippines [NCT05024006]1,314 participants (Actual)Interventional2020-04-23Completed
Low-dose Hydroxychloroquine for Primary Prophylaxis Against SARS-CoV-2 in Health-care Workers - a Randomized, Double-blind, Controlled Trial [NCT04336748]Phase 30 participants (Actual)Interventional2020-04-30Withdrawn(stopped due to Not feasible)
The Effect of Hydroxychloroquine Sulphate on Hedonic Food Intake, Appetite-related Sensations and Gastrointestinal Hormone Release in Overweight Female Subjects [NCT04005781]Phase 440 participants (Anticipated)Interventional2019-10-01Not yet recruiting
A Phase I Study of Combination Chemotherapy With Mitoxantrone and Etoposide (VP-16) Combined With an Autophagy Inhibitor, Hydroxychloroquine (HCQ), for the Treatment of Patients With Relapsed Acute Myelogenous Leukemia (AML) [NCT02631252]Phase 11 participants (Actual)Interventional2016-08-18Terminated(stopped due to Inability to accrue)
Hydroxychloroquine in ANCA Vasculitis Evaluation - A Multicentre, Randomised, Double-blind, Placebo-controlled Trial [NCT04316494]Phase 476 participants (Anticipated)Interventional2020-12-17Recruiting
A Prospective Comparison of Low Dose Hydroxychloroquine and Phlebotomy in the Treatment of Porphyria Cutanea Tarda. IRB 02-435 [NCT01573754]Phase 248 participants (Actual)Interventional2006-03-21Completed
Evaluation of the Efficacy of Hydroxychloroquine in Decreasing Immune Activation in Asymptomatic HIV-infected Patients [NCT01067417]Phase 283 participants (Actual)Interventional2008-06-30Active, not recruiting
Comparison of Combination Disease Modifying Antirheumatic Drugs (DMARDs) With Single Drug (Methotrexate) Therapy in Early Rheumatoid Arthritis [NCT02644499]Phase 4186 participants (Actual)Interventional2015-12-31Completed
CLEVER Pilot Trial: A Phase II Pilot Trial of HydroxyChLoroquine, EVErolimus or the Combination for Prevention of Recurrent Breast Cancer [NCT03032406]Phase 254 participants (Actual)Interventional2017-01-23Active, not recruiting
Treat-to-target Strategy in Ankylosing Spondylitis Using Etanercept and Conventional Synthetic DMARDs, a Prospective Randomized Controlled Study [NCT04077957]Phase 4100 participants (Anticipated)Interventional2019-10-07Not yet recruiting
Phase II Trial of Paricalcitol and Hydroxychloroquine (PH) Combination With Gemcitabine and Nab-Paclitaxel in Advanced or Metastatic Pancreatic Cancer [NCT04524702]Phase 221 participants (Anticipated)Interventional2020-09-14Recruiting
Hydroxychloroquine in SARS-CoV-2 (COVID-19) Pneumonia Trial [NCT04382625]Phase 40 participants (Actual)Interventional2020-10-31Withdrawn(stopped due to Secondary to other study results, suspended for a scientific review)
Triple III Comparison of Leflunomide Alone Versus Two DMARD Combinations (Leflunomide-Hydroxychloroquine-Sulfasalazine or Methotrexate-Hydroxychloroquine-Sulfasalazine) in the Treatment of Rheumatoid Arthritis [NCT00579878]Phase 369 participants (Actual)Interventional2001-03-27Completed
Effects of Hydroxychloroquine on Oral Complaints of Sjögren Patients: a Prospective Sample Study. [NCT00873496]30 participants (Actual)Observational2005-01-31Completed
Effect of Hydroxychloroquine on Thrombosis Prevention and Antiphospholipid Antibody Levels in Patients With Primary Antiphospholipid Syndrome: An Pilot Randomized Prospective Study. [NCT04153201]50 participants (Actual)Interventional2013-01-15Completed
A Randomized, Open-Label Study in the Asia-Pacific Region Comparing the Safety and Efficacy of Etanercept With Usual DMARD Therapy in Subjects With Rheumatoid Arthritis [NCT00422227]Phase 4300 participants (Actual)Interventional2007-06-30Completed
High-dose Hydroxychloroquine for the Treatment of Ambulatory Patients With Mild COVID-19 [NCT04351620]Phase 112 participants (Actual)Interventional2020-04-20Completed
Hydroxychloroquine vs. Azithromycin for Hospitalized Patients With Suspected or Confirmed COVID-19 (HAHPS): A Prospective Pragmatic Trial [NCT04329832]Phase 285 participants (Actual)Interventional2020-03-30Completed
A Comparative Observational Study on Ivermectin and Hydroxychloroquine on the COVID19 Patients in Bangladesh [NCT04434144]116 participants (Actual)Observational [Patient Registry]2020-05-02Completed
The Clinical Study to Observe the Efficacy and Safety of Immunomodulators in Rheumatoid Arthritis Patients for 6 Months Treatment in China [NCT05626348]Phase 4400 participants (Anticipated)Interventional2021-12-22Recruiting
Evaluation of the Benefit of Adjuvant Treatment With Hydroxychloroquine to the Usual Medical Management for Obtaining an Uncomplicated Term Pregnancy in Primary Obstetric Antiphospholipid Syndrome [NCT04275778]Phase 2110 participants (Anticipated)Interventional2021-07-09Recruiting
Randomized Controlled Clinical Trials of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19) [NCT04307693]Phase 265 participants (Actual)Interventional2020-03-11Terminated(stopped due to Terminated early because no patients were further enrolled since mid-Apr 2020.)
A Multicenter, Double-blind, Randomized and Parallel Controlled Study of Hydroxychloroquine Sulfate in the Treatment of Recurrent Miscarriage With Antiphospholipid Syndrome [NCT04624269]Phase 4384 participants (Anticipated)Interventional2020-12-01Not yet recruiting
A Pilot Study of Infusional Cyclophosphamide and Pulse Dexamethasone With Rapamycin or Hydroxychloroquine in Patients With Relapsed or Refractory Multiple Myeloma [NCT01396200]Early Phase 16 participants (Anticipated)Interventional2011-06-30Completed
Pragmatic, Double-blind, Placebo-controlled Randomized Clinical Trial, Evaluating Hydroxychloroquine for Prevention of Hospitalization and Respiratory Complications in Non-hospitalized Patients With Confirmed or Probable COVID-19 [NCT04466540]Phase 41,372 participants (Actual)Interventional2020-05-12Completed
A Multicenter, Open-label, ExploRatory Platform Trial to EValuate ImmunOtherapy Combinations With Chemotherapy for the Treatment of Patients With PreviousLy UnTreated MetastatIc Pancreatic AdenOcarciNoma (REVOLUTION) [NCT04787991]Phase 145 participants (Anticipated)Interventional2021-08-09Active, not recruiting
A Phase Ib/II Study Confirmed Inhibition of Autophagy Synergizes Anti-tumor Effect of High Dose CDK4/6i With Manageable Safety in HR+HER2-breast Cancer Patients [NCT05953350]Phase 1/Phase 229 participants (Anticipated)Interventional2023-06-12Recruiting
Preemptive Therapy for SARS-Coronavirus-2 (COVID-19 PEP Canada) [NCT04421664]Phase 370 participants (Actual)Interventional2020-03-25Terminated(stopped due to Request of Health Canada after publication of https://doi.org/10.7326/M20-4207)
Low Doses of Lung Radiation Therapy in Cases of COVID-19 Pneumonia: Prospective Multicentric Study in Radiation Oncology Centers [NCT04394182]15 participants (Anticipated)Interventional2020-04-21Suspended(stopped due to lack of recruitment)
Hydroxychloroquine in Pediatric ILD: START Randomized Controlled in Parallel-group, Then Switch Placebo to Active Drug, and STOP Randomized Controlled in Parallel-Group to Evaluate the Efficacy and Safety of Hydroxychloroquine (HCQ) [NCT02615938]Phase 280 participants (Anticipated)Interventional2015-04-30Suspended(stopped due to Correction of inspection findings)
MEK and Autophagy Inhibition in Metastatic/Locally Advanced, Unresectable Neuroblastoma RAS (NRAS) Melanoma: A Phase Ib/II Trial of Trametinib Plus Hydroxychloroquine in Patients With NRAS Melanoma [NCT03979651]29 participants (Anticipated)Interventional2019-10-15Recruiting
IMPact of Inflammatory Arthritis on COVID-19 sTudy of the RAPPORT-ONTRAAC and FORCAST Rheumatic Disease Registries [NCT04347798]773 participants (Actual)Observational [Patient Registry]2020-11-01Completed
Open-label, Single-center, Single-arm Futility Trial Evaluating Oral Hydroxychloroquine 200mg BID for Reducing Progression of Disability in Patients With Primary Progressive Multiple Sclerosis (PPMS) [NCT02913157]Phase 235 participants (Actual)Interventional2016-11-30Completed
Study of the Reduction of Systemic Lupus Erythematosus Flares Through Adaptation of the Dosage of Hydroxychloroquine to Its Whole-blood Concentration. National Multicenter Randomized Prospective Study [NCT00413361]Phase 4543 participants (Actual)Interventional2007-06-30Completed
Efficacy and Safety of Ivermectin for Treatment and Prophylaxis of COVID-19 Pandemic [NCT04668469]600 participants (Actual)Interventional2020-06-08Completed
Modulation of Sorafenib Induced Autophagy Using Hydroxychloroquine in Hepatocellular Cancer [NCT03037437]Phase 268 participants (Anticipated)Interventional2017-02-16Recruiting
The (Norwegian) NOR Solidarity Multicenter Trial on the Efficacy of Different Anti-viral Drugs in SARS-CoV-2 Infected Patients [NCT04321616]Phase 2/Phase 3700 participants (Anticipated)Interventional2020-03-28Recruiting
A Prospective, Randomized, Adaptive Phase II/III Clinical Trial, Controlled, Open-label, 3-arms, Parallel, Multi-centred, Chemoprevention of COVID-19: Hydroxychloroquine Post Exposure Prophylaxis For COVID-19 [NCT04597775]Phase 2/Phase 393 participants (Anticipated)Interventional2020-10-27Not yet recruiting
A Randomized, Multi-institutional, Phase 2 Study of Hydroxichloroquine Plus Azithromycin for High Risk SARS-CoV-2 Positive Patients (COVID-19) [NCT04575558]Phase 20 participants (Actual)Interventional2020-06-30Withdrawn(stopped due to Withdrawn due to lack of study centers interested in participating.)
A Phase I/II Trial of Hydroxychloroquine Added to Bortezomib for Relapsed/Refractory Myeloma [NCT00568880]Phase 125 participants (Actual)Interventional2010-09-08Completed
Local Tolerability and Pharmacokinetic Evaluation of Cyclops Dry Powder Hydroxychloroquine Inhalation in Healthy Volunteers; a Pilot Study [NCT04497519]Phase 112 participants (Actual)Interventional2020-09-15Completed
A Randomised Phase 2 Trial Investigating the Additional Benefit of Hydroxychloroquine(HCQ)to Short Course Radiotherapy (SCRT) in Patients Aged 70 Years and Older With High Grade Gliomas (HGG) [NCT01602588]Phase 254 participants (Actual)Interventional2013-05-31Completed
Preventive Approach to Congenital Heart Block With Hydroxychloroquine [NCT01379573]Phase 274 participants (Actual)Interventional2011-01-01Completed
Prévention Des Fausses Couches Spontanées Répétées Par Hydroxychloroquine. Essai thérapeutique Multicentrique, randomisé, en Double Insu, Contre Placebo [NCT03165136]Phase 3300 participants (Anticipated)Interventional2017-12-04Active, not recruiting
A Phase II, Blinded, Randomised, Placebo Controlled Clinical Trial to Determine the Safety and Effect on Pain and Function According to RAPID-3 of IHL-675A in Patients With Rheumatoid Arthritis [NCT05942911]Phase 2128 participants (Anticipated)Interventional2023-11-22Recruiting
A Phase II, Multicentre, Randomised Trial Comparing Combination Gemcitabine/Carboplatin and Hydroxychloroquine Versus Carboplatin/Etoposide Therapy Alone in Small Cell Lung Cancer (SCLC) [NCT02722369]Phase 272 participants (Actual)Interventional2017-03-14Terminated(stopped due to Low recruitment, lack of efficacy and increased adverse events in investigational arm.)
Randomized, Double-blind, Placebo-controlled Trial of Hydroxychloroquine in Primary Sjögren's Syndrome [NCT00632866]Phase 3120 participants (Actual)Interventional2008-03-31Completed
A Phase 1b, Randomized, Double-blinded, Placebo-controlled Study of Hydroxychloroquine in Outpatient Adults With COVID-19 [NCT04333654]Phase 18 participants (Actual)Interventional2020-04-12Terminated(stopped due to Rate of enrollment too slow to allow completion in a reasonable timeframe)
Hydroxychloroquine for the Prevention of Recurrent Cardiovascular Events in Myocardial Infarction Patients - a Safety Pilot Trial [NCT02648464]Phase 4125 participants (Actual)Interventional2016-02-01Completed
Hydroxychloroquine to Improve Insulin Sensitivity in Rheumatoid Arthritis [NCT01132118]Phase 330 participants (Actual)Interventional2010-06-30Completed
Phase II Study of Erlotinib With or Without Hydroxychloroquine in Patients With Previously Untreated Advanced NSCLC and EGFR Mutations [NCT00977470]Phase 276 participants (Actual)Interventional2009-10-31Active, not recruiting
Phase I/II Study of Preoperative Gemcitabine in Combination With Oral Hydroxychloroquine (GcHc) in Subjects With High Risk Stage IIb or III Adenocarcinoma of the Pancreas [NCT01128296]Phase 1/Phase 235 participants (Actual)Interventional2010-10-31Completed
A Phase 1 Study of Hydroxychloroquine in Patients With Solid Tumors Receiving Radiotherapy for Bone Metastases [NCT01417403]Phase 110 participants (Actual)Interventional2011-08-31Terminated(stopped due to Recently published data that has shown HCQ to be safe when combined with chemo and or radiation at even higher doses than what is used in this study.)
Phase I/II Trial of Dabrafenib, Trametinib, and Hydroxychloroquine (HCQ) for BRAF V600E-mutant or Trametinib and HCQ for BRAF Fusion/Duplication Positive or NF1-associated Recurrent or Progressive Gliomas in Children and Young Adults [NCT04201457]Phase 1/Phase 275 participants (Anticipated)Interventional2020-01-17Recruiting
Finding Treatments for COVID-19: A Phase 2 Multi-centre Adaptive Platform Trial to Assess Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV) [NCT05041907]Phase 23,000 participants (Anticipated)Interventional2021-09-30Recruiting
Open Label Study of Hydroxychloroquine for Alopecia Areata, Alopecia Totalis [NCT00176982]Phase 416 participants Interventional2002-04-30Completed
Metabolic Effects of Hydroxychloroquine [NCT02026232]21 participants (Actual)Interventional2012-03-31Terminated(stopped due to COVID-19 & loss of funding)
A Phase 2 Basket Trial of Ulixertinib (BVD-523) in Combination With Hydroxychloroquine in Patients With Advanced GI Malignancies Harboring Mitogen-activated Protein Kinase (MAPK) Pathway Mutations (BVD-523-HCQ) [NCT05221320]Phase 2215 participants (Anticipated)Interventional2022-05-26Recruiting
Comparison of Three Different Treatment Regimes in Early Rheumatoid Arthritis: A Randomized Open-labelled Trial [NCT01870128]Phase 360 participants (Actual)Interventional2009-08-31Completed
[NCT02942381]Phase 260 participants (Actual)Interventional2016-09-13Completed
Hydroxychloroquine for the Treatment of Patients With Mild to Moderate COVID-19 to Prevent Progression to Severe Infection or Death [NCT04323631]Early Phase 10 participants (Actual)Interventional2020-04-30Withdrawn(stopped due to Trial not started due to accumulating evidence against HCQ for COVID)
Will Hydroxychloroquine Impede or Prevent COVID-19: WHIP COVID-19 Study [NCT04341441]Phase 3624 participants (Actual)Interventional2020-04-07Terminated(stopped due to Interim analysis did not reveal any safety concerns by the DSMB, but unblinded data did not provide support to continue. Event rate did not meet projected magnitude; given low recruitment potential, it is unlikely that a positive result will occur.)
Prophylactic Hydroxychloroquine vs Vitamin C in Healthcare Workers at Risk of COVID-19: A RCT [NCT04347889]Phase 20 participants (Actual)Interventional2020-04-20Withdrawn(stopped due to Evidence that HCQ ineffective, loss of HCW interest,)
Efficacy and Safety of Mucoadhesive Sustained Release, Mucodentol, in Comparison With Hydroxychloroquine to Prevent COVID-19 Disease in Healthcare Providers at Baqiyatallah Hospital in Tehran [NCT04466280]0 participants (Actual)Interventional2020-08-12Withdrawn(stopped due to The financier of this research project died due to covid-19, Therefore, this project was stopped due to lack of funds)
Oxygen-Ozone as Adjuvant Treatment in Early Control of Disease Progression in Patients With COVID-19 Associated With Modulation of the Gut Microbial Flora [NCT04366089]Phase 2152 participants (Anticipated)Interventional2020-03-26Recruiting
Hydroxychloroquine in Combination With Sirolimus and Dexamethasone for Treating COVID-19 PatiEnts: A Pilot, Multicenter Randomized Open-Label Trial [NCT04374903]0 participants (Actual)Interventional2022-04-01Withdrawn(stopped due to study could not be implemented at the site)
Pragmatic Factorial Trial of Hydroxychloroquine, Azithromycin, or Both for Treatment of Severe SARS-CoV-2 Infection [NCT04335552]Phase 211 participants (Actual)Interventional2020-04-17Terminated(stopped due to Poor recruitment, strong evidence from larger trials of no therapeutic benefit)
Phase II Study of Neoadjuvant Accelerated Short Course Radiation Therapy With Proton or Photon RT Plus Capecitabine and Hydroxychloroquine for Resectable Pancreatic Cancer [NCT01494155]Phase 250 participants (Actual)Interventional2011-12-31Active, not recruiting
Effectiveness of Hydroxychloroquine in Covid-19 Patients: A Single Centred Single-blind RCT Study [NCT04328272]Phase 375 participants (Anticipated)Interventional2020-03-28Not yet recruiting
The Clinical Efficacy and Safety of Telitacicept Followed With Rituximab Therapy on APS Secondary to SLE ,a Multicentre Observational Study [NCT05644210]80 participants (Anticipated)Observational2022-10-01Recruiting
Safety and Efficacy of Post-exposure Prophylaxis With Hydroxychloroquine (HCQ) for the Prevention of COVID-19 in High-risk Older Individuals in Long-term and Specialized Care: A Double-blind Randomized Control Trial [NCT04397328]Phase 3336 participants (Anticipated)Interventional2020-05-19Not yet recruiting
Rapid Development and Implementation of a Remote ECG-monitored Prospective Randomized Clinical Trial During a Pandemic: Hydroxychloroquine Prophylaxis in COVID-19 Household Contacts [NCT04652648]Phase 454 participants (Actual)Interventional2020-05-27Completed
Hydroxychloroquine Post Exposure Prophylaxis (PEP) for Household Contacts of COVID-19 Patients: A NYC Community-Based Randomized Clinical Trial [NCT04318444]Phase 2/Phase 31,600 participants (Anticipated)Interventional2020-03-29Recruiting
Norwegian Coronavirus Disease 2019 Study: An Open Labeled Randomized Controlled Pragmatic Trial to Evaluate the Antiviral Effect of Chloroquine in Adult Patients With SARS-CoV-2 Infection [NCT04316377]Phase 453 participants (Actual)Interventional2020-03-25Active, not recruiting
An Open-label, Randomized Controlled Trial of Hydroxychloroquine and Azithromycin for COVID-19 Infection on Hospitalized, Noncritical Patients [NCT04322123]Phase 3667 participants (Actual)Interventional2020-04-01Completed
LIMIT Melanoma: (Lysosomal Inhibition + Melanoma ImmunoTherapy) A Phase 1/2 Open Label Trial of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Patients With Advanced Melanoma [NCT04464759]Phase 1/Phase 294 participants (Anticipated)Interventional2020-10-21Recruiting
The Efficacy of Levamisole and Isoprinosine in the Treatment of COVID19: A Proposed Therapeutic Trial [NCT04383717]Phase 360 participants (Anticipated)Interventional2020-05-05Not yet recruiting
Effect of Hydroxychloroquine on Atrial Fibrillation Recurrence After Radiofrequency Catheter Ablation in Patients With Atrial Fibrillation [NCT03592823]Phase 4240 participants (Anticipated)Interventional2018-08-01Recruiting
PROTECT: A Randomized Study With Hydroxychloroquine Versus Observational Support for Prevention or Early Phase Treatment of Coronavirus Disease (COVID-19) [NCT04363827]Phase 22,300 participants (Anticipated)Interventional2020-05-14Active, not recruiting
VA Remote and Equitable Access to COVID-19 Healthcare Delivery (VA-REACH TRIAL) [NCT04363203]Phase 3300 participants (Anticipated)Interventional2020-04-30Suspended(stopped due to concerns related to study drug)
Efficacy Evaluation of Hydroxychloroquine Azithromycin in the Treatment of COVID-19 in Pregnant Women: an Open-label Randomized Clinical Trial [NCT04365231]Phase 30 participants (Actual)Interventional2020-04-01Withdrawn(stopped due to no authorization obtained)
Evaluation of the Impact of Bacteriotherapy in the Treatment of COVID-19 [NCT04368351]70 participants (Actual)Observational2020-03-01Active, not recruiting
Efficacy and Safety of Favipiravir Compared to the Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized, Controlled, Double-Blind, Clinical Trial [NCT04359615]Phase 440 participants (Anticipated)Interventional2020-04-20Not yet recruiting
Comparative Efficacy of Various Doses of Hydroxychloroquine in Pre-Exposure Prophylaxis for COVID 19 in Healthcare Personnel [NCT04359537]Phase 2200 participants (Anticipated)Interventional2020-05-01Recruiting
"A Phase Ib/II Trial of Gedatolisib, Hydroxychloroquine or the Combination for Prevention of Recurrent Breast Cancer (GLACIER)" [NCT03400254]Phase 1/Phase 20 participants (Actual)Interventional2019-02-26Withdrawn(stopped due to due to business decision regarding the study drug.)
Hydroxychloroquine for the Management of CVD in CKD [NCT03636152]Phase 2100 participants (Anticipated)Interventional2018-12-14Recruiting
A Phase II Study of 5-FU, Irinotecan, Bevacizumab and Hydroxychloroquine in Drug-Tolerant Persister (DTP)-Selected Patients With Metastatic Colorectal Cancer [NCT05843188]Phase 2155 participants (Anticipated)Interventional2023-08-09Recruiting
Phase II Study of Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy Inhibitor) in Patients With KRAS Mutation Refractory Bile Tract Carcinoma (BTC). [NCT04566133]Phase 22 participants (Actual)Interventional2022-02-15Terminated(stopped due to Slow accrual)
Administration of Hydroxychloroquine (Plaquenil) to African Americans and Hispanics for the Treatment of Mild to Severe Ulcerative Colitis [NCT05119140]Phase 1/Phase 220 participants (Anticipated)Interventional2022-06-10Recruiting
A Study of Hydroxychloroquine and Chlorphenesin Carbamate in Combination With mFOLFIRINOX in Inoperable Locally Advanced or Metastatic Pancreatic Cancer [NCT05083780]Phase 140 participants (Actual)Interventional2021-11-30Active, not recruiting
Multicentric Double Blind Versus Placebo Randomised Study Evaluating the Corticosteroid Sparing Effect of Hydrocyschloroquine in Non Complicated Giant Cell Arteritis. [NCT00430807]Phase 375 participants (Actual)Interventional2002-01-31Completed
Hydroxychloroquine Versus Clobetasol 0.05% Rinse for the Treatment of Oral Lichen Planus [NCT00102557]Phase 274 participants Interventional2005-01-31Completed
Phase I/II Study of Neoadjuvant mFOLFIRINOX in Combination With Peri-operative Oral Hydroxychloroquine (FHQ) in Subjects With Resectable Adenocarcinoma of the Pancreas. [NCT04911816]Phase 1/Phase 240 participants (Anticipated)Interventional2021-07-16Recruiting
A Multi-center, Randomized, Open-label, Controlled Trial to Evaluate the Efficacy and Tolerability of Hydroxychloroquine (HCQ) in Adult Patients With Mild to Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment [NCT04384380]33 participants (Actual)Interventional2020-04-01Completed
Comparative Study of Hydroxychloroquine and Ivermectin in COVID-19 Prophylaxis [NCT04384458]400 participants (Anticipated)Interventional2020-07-20Recruiting
The Regimen of Favipiravir Plus Hydroxychloroquine Can Accelerate Recovery of the COVID-19 Patients With Moderate Severity in Comparison to Lopinavir/Ritonavir Plus Hydroxychloroquine Regimen: an Open-label, Non-randomized Clinical Trial Study [NCT04376814]40 participants (Actual)Interventional2020-03-29Completed
Protecting Frontline Health Care Workers From COVID-19 With Hydroxychloroquine Pre-exposure Prophylaxis: A Randomized, Placebo-controlled Multi-Site Trial in Toronto, Canada [NCT04374942]Phase 313 participants (Actual)Interventional2020-04-30Terminated(stopped due to Due to unproven issues associated with hydroxychloroquine use and safety, further complicated by media and political misinformation which in effect rendered all global studies on HCQ to stop enrolling participants.)
RCT in Asymptomatic Volunteers With COVID-19 Comparing Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone vs Standard of Care Without Antibiotics [NCT04374552]Phase 20 participants (Actual)Interventional2020-05-05Withdrawn(stopped due to The investigators have decided not to go forward with this protocol)
A Randomized Trial of Efficacy and Safety of an Early OUTpatient Treatment of COVID-19 in Patients With Risk Factor for Poor Outcome: a Strategy to Prevent Hospitalization [NCT04365582]Phase 30 participants (Actual)Interventional2020-05-07Withdrawn(stopped due to The PI decided.)
A Randomized-Control Pilot Study to Assess Hydroxychloroquine in Patients Infected With SARS-CoV-2 (COVID-19) [NCT04363866]Phase 20 participants (Actual)Interventional2020-08-31Withdrawn(stopped due to discontinued in favor of more promising directions that may benefit patients)
"An Open-Label Study to Compare the Efficacy, Safety, and Tolerability of Hydroxychloroquine Combined With Azithromycin Compared to Hydroxychloroquine Combined With Camostat Mesylate and to no Treatment in Hospitalized Patients Suffering From a Mild or Mo [NCT04355052]Phase 3250 participants (Anticipated)Interventional2020-04-11Recruiting
Clinical Study Evaluating the Efficacy of Chloroquine or Hydroxychloroquine in COVID-19 Treatment [NCT04353336]Phase 2/Phase 3194 participants (Actual)Interventional2020-03-23Completed
Protecting Health Care Workers From COVID-19 With Hydroxychloroquine Pre-exposure Prophylaxis: A Randomized, Placebo-controlled Trial [NCT04352946]Phase 3374 participants (Anticipated)Interventional2020-04-24Not yet recruiting
Efficacy and Safety of Umifenovir as an Adjuvant Therapy Compared to the Control Therapeutic Regiment of Interferon Beta 1a, Lopinavir / Ritonavir and a Single Dose of Hydroxychloroquine in Moderate to Severe COVID-19: A Randomized, Double-Blind, Placebo- [NCT04350684]Phase 440 participants (Anticipated)Interventional2020-04-15Enrolling by invitation
Hydroxychloroquine Treatment of Healthcare Workers With COVID19 Illness at Montefiore: a Review of Process Feasibility, Safety, and Clinical Outcomes [NCT04350450]Phase 20 participants (Actual)Interventional2020-04-30Withdrawn(stopped due to PI withdrew the submission to the IRB)
Randomized Placebo-controlled Trial of Hydroxychloroquine With or Without Azithromycin for Virologic Cure of COVID-19 [NCT04349592]456 participants (Actual)Interventional2020-04-14Completed
A Randomized, Controlled Clinical Trial of the Safety and Efficacy of Hydroxychloroquine for the Treatment of COVID-19 in Hospitalized Patients [NCT04345692]Phase 317 participants (Actual)Interventional2020-03-26Terminated(stopped due to RECOVERY Trial results - no efficacy)
Hydroxychloroquine for the Treatment of Mild COVID-19 Disease [NCT04340544]Phase 217 participants (Actual)Interventional2020-04-22Terminated(stopped due to It appeared to be impossible for the study centres to recruit the targeted number of patients, due to reduced incidence and reduced acceptance to IMP)
Evaluation of the Efficacy and Safety of Camostat Mesilate + Hydroxychloroquine Combination Therapy in Hospitalized Patients With Moderate COVID-19 Infection [NCT04338906]Phase 40 participants (Actual)Interventional2020-05-31Withdrawn(stopped due to lack of public funding; planned control arm with Hydroxychloroquine treatment showed out as not being standard of care anymore as time evolved.)
Prevention of SARS-CoV-2 (COVID-19) Through Pre-Exposure Prophylaxis With Tenofovir Disoproxil Fumarate/Emtricitabine and Hydroxychloroquine in Healthcare Personnel: Randomized Clinical Trial Controlled With Placebo [NCT04334928]Phase 31,002 participants (Actual)Interventional2020-04-15Completed
Hydroxychloroquine vs. Azithromycin for Outpatients in Utah With COVID-19 (HyAzOUT): A Prospective Pragmatic Trial [NCT04334382]Phase 31,550 participants (Anticipated)Interventional2020-04-02Recruiting
Efficacy of Sarilumab + Azithromycin + Hydroxychloroquine, and Sarilumab Alone, for Adult Patients Hospitalized With Moderate to Severe COVID-19: a Multicenter Open-label 1:1 Randomized Controlled Trial [NCT04341870]Phase 2/Phase 327 participants (Actual)Interventional2020-04-11Suspended(stopped due to DSMB recommendation (futility))
Lupus and Observance [NCT03019926]200 participants (Actual)Observational2017-01-19Completed
[NCT02910076]Phase 1/Phase 240 participants (Anticipated)Interventional2016-10-31Not yet recruiting
Strategy to Prevent the Onset of Clinically-Apparent Rheumatoid Arthritis [NCT02603146]Phase 2144 participants (Actual)Interventional2016-04-27Terminated(stopped due to Enrollment was closed before reaching the target. In the 1st interim analysis after enrollment closure, the follow up & treatment of active participants were stopped early due to evidence of futility.)
Open-label, Single-center, Single-arm Futility Trial Evaluating the Combination of Oral Hydroxychloroquine 200mg BID and Indapamide 2.5mg OD for Reducing Progression of Disability in People With Secondary Progressive Multiple Sclerosis (SPMS) [NCT05013463]Phase 235 participants (Anticipated)Interventional2021-10-01Recruiting
Hydroxychloroquine Versus Placebo in Patients Presenting COVID-19 Infection and at Risk of Secondary Complication: a Prospective, Multicentre, Randomised, Double-blind Study [NCT04325893]Phase 3259 participants (Actual)Interventional2020-04-01Terminated(stopped due to decrease in number of eligible patients)
A Randomized, Double Blind, Baseline Controlled Study Using Placebo as Reference for Assessing the Efficacy and Safety of Hydroxychloroquine Sulfate in Patients With Systemic Lupus Erythematosus or Cutaneous Lupus Erythematosus in the Presence of Active L [NCT01551069]Phase 3103 participants (Actual)Interventional2012-03-31Completed
Randomized, Controlled, Double-blind Clinical Trial Comparing the Efficacy and Safety of Chemoprophylaxis With Hydroxychloroquine in Patients Under Biological Treatment and / or JAK Inhibitors in the Prevention of SARS-CoV-2 Infection [NCT04330495]Phase 40 participants (Actual)Interventional2020-04-06Withdrawn(stopped due to "Care pressures on the investigator team during the COVID-19 pandemic.~Subsequent appearance of scientific evidence on the lack of efficacy of hydroxychloroquine in the treatment or prophylaxis of COVID-19 infection.")
A Randomized Controlled Trial on the Effect of Hydroxychloroquine in Mild Graves' Orbitopathy [NCT05126147]Phase 4108 participants (Anticipated)Interventional2022-03-21Recruiting
Phase III Trial of Hydroxychloroquine + Standard Therapy for Chronic Graft-Versus-Host Disease [NCT00031824]Phase 382 participants (Actual)Interventional2002-04-30Completed
High-Dose Ivermectin for Mild-to-Moderate COVID-19 - The (HD)IVACOV Trial [NCT04712279]Phase 2/Phase 3294 participants (Anticipated)Interventional2021-01-25Not yet recruiting
Combined Carfilzomib and Hydroxychloroquine in Patients With Relapsed/Refractory Multiple Myeloma - a Phase 1 Trial [NCT04163107]Phase 119 participants (Actual)Interventional2020-01-07Completed
Pakistan Randomized and Observational Trial to Evaluate Coronavirus Treatment [NCT04338698]Phase 3550 participants (Actual)Interventional2020-04-22Completed
Role of Hydroxychloroquine to Improve Endothelial Dysfunction in Patients With Rheumatoid Arthritis [NCT03085940]37 participants (Actual)Interventional2017-01-20Completed
Phase II Study of Hydroxychloroquine in Previously Treated Patients With Metastatic Pancreatic Cancer [NCT01273805]Phase 220 participants (Actual)Interventional2011-01-31Completed
Azithromycin Added to Hydrochloroquine in Patients Admitted to Intensive Care Due to Coronavirus Disease 2019 (COVID-19)- Randomised Controlled Trial [NCT04339816]Phase 33 participants (Actual)Interventional2020-05-13Terminated(stopped due to Steering Committee decision in accordance with stopping rule 1: Emergence of new data)
Evaluation of Safety and Efficacy of Monotherapy Versus Polytherapy of Enoxaparin and Hydroxychloroquine for the Treatment of Covid-19 [NCT05311813]200 participants (Actual)Interventional2021-06-01Completed
A Randomized, Double-Blind, Placebo-Controlled Phase IIa Study of Quintuple Therapy to Treat COVID-19 Infection [NCT04334512]Phase 2600 participants (Anticipated)Interventional2020-06-22Recruiting
Hydroxychloroquine Treatment During Pregnancy is Associated With Lower Risk of Preeclampsia in Patients With Recurrent Spontaneous Abortion of Unknown Aetiology [NCT06020378]359 participants (Anticipated)Observational2023-12-01Not yet recruiting
A Phase II Study of ABT-263/Abiraterone (Arm A) or ABT-263/Abiraterone and Hydroxychloroquine (Arm B) in Patients With Metastatic Castrate Refractory Prostate Cancer (CRPC) and Progression Following Chemotherapy and Abiraterone [NCT01828476]Phase 213 participants (Actual)Interventional2013-06-30Terminated(stopped due to The Investigator left the organization.)
A Phase II Trial of Combined Hydroxychloroquine and Sirolimus in Soft Tissue Sarcoma [NCT01842594]Phase 213 participants (Actual)Interventional2012-08-31Terminated(stopped due to Most patients completed only the primary objective (PET) and not went throught the secondary outcome (efficacy phase) of 8wks period.)
Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19 [NCT04336332]Phase 275 participants (Actual)Interventional2020-04-01Terminated(stopped due to Ineffectiveness of treatment)
Efficacy and Safety of Hydroxychloroquine in Colchicine-RESistant Glucocorticoid-DependenT IdiOpathic REcurrent Pericarditis: A Randomized Clinical Trial (The RESTORE Randomized Clinical Trial) [NCT05737680]Phase 330 participants (Anticipated)Interventional2023-02-28Not yet recruiting
Randomized Controlled Clinical Trial Evaluating Methotrexate or Leflunomide + Targeted Therapy Versus Methotrexate or Leflunomide + Sulfasalazine + Hydroxychloroquine in Patients With Rheumatoid Arthritis and Insufficient Response to Methotrexate or Leflu [NCT02714634]Phase 4286 participants (Anticipated)Interventional2016-03-30Recruiting
Preventing Malaria in School Children to Protect the Whole Community in Rural Blantyre District, Malawi [NCT06083688]Phase 41,000 participants (Anticipated)Interventional2024-10-31Not yet recruiting
A Multi Centre, Randomised, Controlled, Open-Label Phase 2/3 Study to Evaluate The Efficacy, Tolerability and Safety of Metabolic Cofactor Supplementation and Hydroxychloroquine Combination in Covid-19 Patients [NCT04573153]Phase 2/Phase 3400 participants (Anticipated)Interventional2020-09-21Recruiting
Corona Virus (COVID-19) Disease Duration and Gastrointestinal Tract (GIT) Manifestations; Can be New Disease Severity Classification. A Pilot Egyptian Single National Center Experience [NCT04554979]199 participants (Actual)Observational2020-06-01Completed
Phase 1 Study of Hydroxychloroquine in Cystic Fibrosis [NCT00311883]Phase 120 participants (Actual)Interventional2006-03-31Completed
Hydroxychloroquine as Primary Prophylaxis for COVID-19 in Healthcare Workers (HCQPreP) [NCT04363450]Phase 31,700 participants (Anticipated)Interventional2020-04-27Recruiting
The Clinical Features and Pregnancy Outcomes of Patients With Rheumatoid Arthritis :a Prospective Cohort Study [NCT05651373]100 participants (Anticipated)Observational2021-07-30Recruiting
A Phase I Study of Hydroxychloroquine With or Without Erlotinib in Advanced NSCLC [NCT01026844]Phase 127 participants (Actual)Interventional2007-07-31Terminated(stopped due to slow enrollment)
A Phase 1/2 Study of Gemcitabine and Docetaxel in Combination With Hydroxychloroquine (Autophagy Inhibitor) in Patients With Recurrent Osteosarcoma [NCT03598595]Phase 1/Phase 231 participants (Actual)Interventional2019-01-28Active, not recruiting
Open-label, Randomized Trial of the Safety and Efficacy of Doxycycline and Rivaroxaban Therapy Versus National Standard Therapy in Ambulatory Patients With Mild Symptomatic COVID-19 [NCT04715295]Phase 4200 participants (Anticipated)Interventional2020-10-05Recruiting
Low Dose Anti-inflammatory Radiotherapy for the Treatment of Pneumonia by COVID-19: Multi-central Prospective Study [NCT04380818]106 participants (Anticipated)Interventional2020-06-05Recruiting
A Phase I Dose-Escalation Trial of Oral Hydroxychloroquine Plus Oral Sorafenib to Treat Patients With Refractory or Relapsed Solid Tumors [NCT01634893]Phase 118 participants (Actual)Interventional2012-06-30Completed
#StayHome: Efficacy of Early Hydroxychloroquine in Outpatients to Reduce Secondary Hospitalisation and Household Transmission of COVID-19 in Switzerland: A Double-blind, Randomised, Placebo-controlled Trial [NCT04385264]Phase 2/Phase 3800 participants (Anticipated)Interventional2022-01-31Suspended(stopped due to Sufficient number of subjects would probably not reach)
Off Label Study to Evaluate the Efficacy of HCQ for Pre-exposure Prophylaxis (PrEP) to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection Among Health Care Workers (HCWs) Who Are at High Risk of Occupational Exposure to SARS-Co [NCT04354870]Phase 2130 participants (Actual)Interventional2020-04-03Completed
The Effect of Hydroxychloroquine Treatment in Hashimoto's Thyroiditis [NCT01760421]40 participants (Actual)Interventional2011-10-31Completed
A Pilot Randomised Study to Compare Combination Antibiotic Therapy (Ciprofloxacin, Doxycycline and Hydroxychloroquine) With Standard Therapy (Budesonide) in the Treatment of Active Crohn's Disease [NCT01783106]Phase 259 participants (Actual)Interventional2014-02-01Completed
COVID 19 - Epidemiology of SARS-CoV-2 and Mortality to Covid19 Disease Upon Hydroxychloroquine and Azithromycin Therapy in French Cancer Patients [NCT04341207]Phase 21,000 participants (Anticipated)Interventional2020-04-03Recruiting
Low-dose Hydroxychloroquine and Bromhexine: a Novel Regimen for COVID-19 Prophylaxis in Healthcare Professionals (ELEVATE Trial) [NCT04340349]Early Phase 1214 participants (Anticipated)Interventional2021-02-01Enrolling by invitation
A Multicenter, Randomized, Active Controlled, Open Label, Platform Trial on the Efficacy and Safety of Experimental Therapeutics for Patients With COVID-19 (Caused by Infection With Severe Acute Respiratory Syndrome Coronavirus-2) [NCT04351724]Phase 2/Phase 3500 participants (Anticipated)Interventional2020-04-16Recruiting
An Open-Label Study to Evaluate the Efficacy, Safety and Tolerability of Ribavirin Monotherapy Followed by Combined Treatment With Ribavirin and Hydroxychloroquine in Patients Infected With Hepatitis C [NCT01833845]Phase 1/Phase 24 participants (Actual)Interventional2013-04-30Terminated(stopped due to due to failure to recruit subjects)
Randomized Study to Evaluate the Safety and Antiviral Efficacy of Hydroxychloroquine in Patients With Newly Diagnosed COVID-19 Compared to Standard of Care Treatment [NCT04334967]Phase 413 participants (Actual)Interventional2020-03-30Suspended(stopped due to suspected unfavorable risk/benefit assessment)
An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial [NCT04350671]Phase 440 participants (Anticipated)Interventional2020-04-15Enrolling by invitation
An Open-label Randomized Controlled Trial on Interferon β-1b and Hydroxychloroquine Combination Versus Hydroxychloroquine Alone, as Treatment for COVID-19 Infection [NCT04350281]Phase 260 participants (Actual)Interventional2020-04-09Completed
A Randomized, Double-Blind, Double-Dummy Study Assessing The Safety and Tolerability of Sarilumab and Tocilizumab In Patients With Rheumatoid Arthritis Who Are Inadequate Responders to or Intolerant of TNF Antagonists [NCT01768572]Phase 3202 participants (Actual)Interventional2013-03-31Completed
Hydroxychloroquine/Atorvastatin in the Treatment of OA of the Knee [NCT01645176]Phase 221 participants (Actual)Interventional2012-05-31Completed
Using Hydroxychloroquine to Treat Nonalcoholic Steatohepatitis [NCT05733897]150 participants (Anticipated)Observational2022-06-10Recruiting
Oral Hydroxychloroquine for Retinitis Pigmentosa Caused by P23H-RHO (Substitution of Proline to Histidine at Codon 23 of the Rhodopsin Protein) [NCT04120883]Phase 1/Phase 212 participants (Anticipated)Interventional2020-02-25Recruiting
Open, Multicentric, Non Randomized, Exploratory Clinical Trial to Assess the Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Acute Respiratory Syndrome (COVID-19) Caused by SARS-CoV-2 Virus [NCT04329572]Early Phase 1400 participants (Anticipated)Interventional2020-04-23Suspended(stopped due to Azidus, the CRO hired for this study by Prevent Senior has lost the interest to conduct this study.)
The Efficacy and Mechanism of Hydroxychloroquine in Patients With Inflammatory Cardiomyopathy After Myocarditis [NCT05961202]Phase 2/Phase 3200 participants (Anticipated)Interventional2022-01-01Recruiting
Safety and Efficacy of Hydroxychloroquine in Children's Interstitial Lung Diseases With Genetic Causes: a Randomized Controlled Study [NCT04532346]Early Phase 160 participants (Anticipated)Interventional2024-03-31Not yet recruiting
The LIMIT KRAS Mutant NSCLC Trial: Lysosome Inhibition to Enhance MAPK Inhibition Targeting KRAS Mutant NSCLC: A Phase 2 Open Label Trial of Binimetinib and Hydroxychloroquine in Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer [NCT04735068]Phase 211 participants (Actual)Interventional2021-04-09Active, not recruiting
Efficacy and Safety of Hydroxychloroquine in Primary Prophylaxis of SARS-CoV-2 Infection in Healthcare Workers at Risk of Exposure: Randomised Control Trial [NCT04370015]374 participants (Anticipated)Interventional2020-05-15Not yet recruiting
Autophagy and Anti-Angiogenesis in Metastatic Colorectal Carcinoma: A Phase II Trial of Hydroxychloroquine to Augment Effectiveness of XELOX-Bevacizumab. A Study of the Cancer Institute of New Jersey Oncology Group (CINJOG) [NCT01006369]Phase 238 participants (Actual)Interventional2009-05-31Completed
Randomized Controlled Trial of Hydroxychloroquine Versus Placebo for the Treatment of Adult Patients With Acute Coronavirus Disease 2019 - COVID-19 [NCT04342221]Phase 330 participants (Actual)Interventional2020-03-29Terminated(stopped due to Reduced acceptance of IMP)
Dexamethasone Combined With Hydroxychloroquine Compared to Hydroxychloroquine Alone for Treatment of Severe Acute Respiratory Distress Syndrome Induced by Coronavirus Disease 19 (COVID-19): a Multicentre, Randomised Controlled Trial [NCT04347980]Phase 35 participants (Actual)Interventional2020-04-17Terminated(stopped due to ANSM RECOMMANDATION)
Pilot, Randomized, Multicenter, Open-label Clinical Trial of the Use of Tocilizumab for Treatment of SARS-CoV-2 Infection (COVID-19) [NCT04332094]Phase 2276 participants (Anticipated)Interventional2020-04-02Recruiting
Randomised, Double-blind, Placebo-controlled Phase 2 Study Evaluating the Efficacy of Hydroxychloroquine and Azithromycine in Patients With COVID-19 and Hematological Malignancies [NCT04392128]Phase 20 participants (Actual)Interventional2020-09-02Withdrawn(stopped due to competent authority decision)
"Development and Validation of Ready-to-Use Inhalable Forms of Hydroxychloroquine for Treatment of COVID-19" [NCT04477083]40 participants (Anticipated)Interventional2020-07-15Active, not recruiting
Evaluation of Efficacy of Pharmacotherapy Treatment of COVID- 19 Infection Using Oral Levamisole and Formoterol+Budesonide Inhaler and Comparison of This Treatment Protocol With Standard National Treatment of the Disease [NCT04331470]Phase 2/Phase 330 participants (Anticipated)Interventional2020-04-04Recruiting
A Phase 1 Randomized Double Blind Placebo Controlled, Single-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Orally Inhaled Aerosolized Hydroxychloroquine Sulfate in Healthy Adult Volunteers [NCT04461353]Phase 112 participants (Actual)Interventional2020-06-25Completed
ChemoPROphyLaxIs For covId-19 Infectious Disease (the PROLIFIC Trial) [NCT04352933]Phase 31,000 participants (Anticipated)Interventional2020-05-11Recruiting
A Study of Hydroxychloroquine as Post Exposure Prophylaxis for SARS-CoV-2(HOPE Trial) [NCT04330144]Phase 30 participants (Actual)Interventional2020-04-01Withdrawn(stopped due to No Participants Enrolled)
Antimalarial and Covid 19 in Rheumatoid Arthritis [NCT04389320]60 participants (Actual)Observational2020-03-15Completed
Limiting HIV Target Cells by Inducing Immune Quiescence in the Female Genital Tract [NCT02079077]91 participants (Actual)Interventional2014-04-30Completed
Ivermectin Role in Severe Covid-19 Treatment; a Double-blinded, Randomized Clinical Trial [NCT04746365]Phase 4300 participants (Actual)Interventional2020-12-06Completed
A Study to Evaluate the Efficacy and Safety Hydroxychloroquine in Immune Related Arthritis or Arthralgias [NCT04354649]Phase 246 participants (Anticipated)Interventional2021-09-16Recruiting
A Trial of Favipiravir and Hydroxychloroquine Combination in Adults Hospitalized With Moderate and Severe Covid-19 [NCT04392973]268 participants (Actual)Interventional2020-05-21Completed
A Phase I/II Open-Label Trial of CPI-613® (Devimistat) Plus Hydroxychloroquine to Evaluate Maximally Tolerated Dose (MTD), Safety and Efficacy in Patients With Relapsed or Refractory Clear Cell Sarcoma of Soft Tissue [NCT04593758]Phase 1/Phase 216 participants (Actual)Interventional2021-09-01Completed
Immune Monitoring of Prophylactic Effect of Hydroxychloroquine in Healthcare Providers Highly Exposed to SARS-Cov-2 [NCT04346329]Phase 30 participants (Actual)Interventional2020-03-30Withdrawn(stopped due to The study did not get financed. Never got started.)
A Phase 0 Trial of Hydroxychloroquine, an Inhibitor of Autophagy, in Patients With Stage III or IV Resectable Melanoma [NCT00962845]Early Phase 120 participants (Actual)Interventional2010-09-30Completed
Inhibiting the Systemic Autophagic Syndrome - A Phase I/II Study of Hydroxychloroquine and Aldesleukin in Renal Cell Carcinoma Patients (RCC). A Cytokine Working Group (CWG) Study [NCT01550367]Phase 1/Phase 230 participants (Actual)Interventional2012-03-31Completed
TOFAcitinib Plus Hydroxycloroquine vs Hydroxycloroquine in Patients With Early Onset SARS-CoV2 (COVID-19) Interstitial Pneumonia:a Multicenter Randomized Controlled Open Label Trial [NCT04390061]Phase 2116 participants (Anticipated)Interventional2020-06-30Not yet recruiting
PROphylaxis for paTiEnts at Risk of COVID-19 infecTion (PROTECT): a Basket Trial of Prophylactic Interventions Amongst At-risk Patients [NCT04389359]Phase 2/Phase 30 participants (Actual)Interventional2020-09-30Withdrawn(stopped due to Regulatory approvals not received)
Comparative Therapeutic Efficacy and Safety of Remdesivir Plus Lopinavir/ Ritonavir and Tocilizumab Versus Hydroxychloroquine Plus Ivermectin and Tocilizumab in COVID-19 Patients. [NCT04779047]Phase 4150 participants (Anticipated)Interventional2020-10-01Recruiting
Efficacy of Novel Agents for Treatment of SARS-CoV-2 Infection Among High-Risk Outpatient Adults: An Adaptive Randomized Platform Trial [NCT04354428]Phase 2/Phase 3289 participants (Actual)Interventional2020-04-16Terminated(stopped due to Low number of events contributing to primary outcome)
Use and Dosage of Hydroxychloroquine and Chloroquine to Convert Symptomatic RT-PCR Positive Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Coronavirus Infectious Disease 2019 (COVID-19) Patients to RT- PCR-Negative as a Means to Reduce Hospi [NCT04351191]Phase 4137 participants (Actual)Interventional2020-04-15Terminated(stopped due to Poor accrual)
Hydroxychloroquine is an Immunomodulator for Improvement of Pregnancy Outcomes in Preeclampsia [NCT04755322]50 participants (Actual)Interventional2021-03-01Completed
Targeting Autophagy for the Treatment of TSC and LAM: a Phase I Trial of Hydroxychloroquine and Sirolimus [NCT01687179]Phase 114 participants (Actual)Interventional2012-09-30Completed
Safety And Efficacy Of Hydroxychloroquine For At Risk Population (SHARP) Against COVID-19- A Cluster Randomized Controlled Trial (SHARP COVID-19 RCT) [NCT04342156]Phase 30 participants (Actual)Interventional2020-04-30Withdrawn(stopped due to The number of patients with COVID-19 in Singapore was coming down for the community and the concerns about the potential side effects particularly when the baseline ECG and serum electrolytes was not proposed.)
The Use of Ivermectin In the Treatment of COVID 19 Patients [NCT04425707]100 participants (Anticipated)Interventional2020-06-09Recruiting
Hydroxychloroquine Use in Hospitalized Patients With COVID-19: Impact on Progression to Severe or Critical Disease [NCT04429867]Phase 4700 participants (Anticipated)Interventional2020-05-07Active, not recruiting
Efficacy of Hydroxychloroquine (HCQ) as Post Exposure Prophylaxis (PEP) for Prevention of COVID-19 in Asymptomatic Individual at Risk for SARS-CoV-2 Infection-A Randomized Control Clinical Trial [NCT04858633]Phase 31,000 participants (Anticipated)Interventional2021-03-22Recruiting
Hydroxychloroquine and Apixaban: Analysis of Physiological Parameters for the Prevention of Complications in Patients With Infection With the New Coronavirus (Covid-19). A Randomized Clinical Trial [NCT04788355]Phase 3176 participants (Actual)Interventional2020-07-01Completed
Tacrolimus for Mild Thrombocytopenia in Sjogren's Syndrome [NCT05678335]Phase 2/Phase 354 participants (Anticipated)Interventional2023-02-28Not yet recruiting
"A Phase II Pilot Trial of ABemacicliB or Abemaciclib and HydroxYchloroquine to Target Minimal Residual Disease in Breast Cancer Patients (ABBY)" [NCT04523857]Phase 266 participants (Anticipated)Interventional2021-11-01Recruiting
Hydroxychloroquine to Prevent COVID-19 Disease Amongst Healthcare Workers (PROVIDE): A Parallel Randomized Controlled Trial [NCT04371523]Phase 30 participants (Actual)Interventional2020-05-01Withdrawn(stopped due to Study was not initiated due to evidence becoming available that did not support the use of hydroxychloroquine in this population, with potential risk of added harm)
Efficacy and Safety of Hydroxychloroquine for COVID-19 Post-Exposure Prophylaxis of Healthcare Workers in the Philippine General Hospital and UP Manila National Institutes of Health: A Randomized, Double-blind, Placebo-controlled Trial [NCT04364815]Phase 30 participants (Actual)Interventional2020-12-31Withdrawn(stopped due to Investigators opted to change the design of the study.)
"An Open Randomized Study of the Effectiveness of the Drug Mefloquine, Tablets 250 mg, Produced by FSUE SPC Farmzashita of the Federal Medical Biological Agency, FMBA of Russia (Russia) for the Treatment of Patients With COVID19" [NCT04347031]Phase 2/Phase 3320 participants (Actual)Interventional2020-04-08Completed
Randomized Trial Evaluating Effect of Outpatient Hydroxychloroquine on Reducing Hospital Admissions in Pregnant Women With SARS-CoV-2 Infection: HyPreC Trial [NCT04354441]Phase 20 participants (Actual)Interventional2020-05-31Withdrawn(stopped due to Not started)
Hydroxychloroquine or Hydroxychloroquine Associated With Azithromycin for Inpatients With Moderate or Severe Lung Disease Due to SARS-CoV-2 (COVID-19) [NCT04361461]Phase 30 participants (Actual)Interventional2020-04-30Withdrawn(stopped due to This study was canceled before enrollment due to a decision by the Sponsor)
Multi-centre Randomised Controlled Trial of Chloroquine/Hydroxychloroquine Versus Standard of Care for Treatment of Mild Covid-19 in HIV-positive Outpatients in South Africa [NCT04360759]Phase 30 participants (Actual)Interventional2020-05-01Withdrawn(stopped due to Equipoise for hydroxychloquine was lost)
Phase 3 Study of Hydroxychloroquine Treatment of Dry Eyes in Patients With Primary Sjögren's Syndrome [NCT01601028]Phase 339 participants (Actual)Interventional2011-07-31Completed
A Phase I/II Trial Investigating the Tolerability, Toxicity and Efficacy of Hydroxychloroquine and Itraconazole in Patients With Advanced Platinum-resistant Epithelial Ovarian Cancer (EOC) (HYDRA-1 Study) [NCT03081702]Phase 1/Phase 213 participants (Actual)Interventional2017-07-25Completed
Therapies to Prevent Progression of COVID-19, Including Hydroxychloroquine, Azithromycin, Zinc, Vitamin D, Vitamin B12 With or Without Vitamin C, a Multi-centre, International, Randomized Trial: The International ALLIANCE Study [NCT04395768]Phase 2200 participants (Anticipated)Interventional2020-09-09Recruiting
Use of Hydroxychloroquine in Patients With COVID-19: A Randomized Controlled Clinical Trial [NCT04394442]Phase 2200 participants (Anticipated)Interventional2020-03-21Recruiting
Safety and Efficacy of Intravenous Infusion of Wharton's Jelly Derived Mesenchymal Stem Cell Plus Standard Therapy for the Treatment of Patients With Acute Respiratory Distress Syndrome Diagnosis Due to COVID 19: A Randomized Controlled Trial [NCT04390152]Phase 1/Phase 240 participants (Anticipated)Interventional2020-01-13Recruiting
A Phase I Trial of Vemurafenib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma [NCT01897116]Phase 18 participants (Actual)Interventional2013-06-30Completed
Phase 2 Study of Hydroxychloroquine to Increase Tumor Suppressor PAR-4 Levels in Oligometastatic Prostate Cancer [NCT04011410]Phase 220 participants (Actual)Interventional2019-12-03Active, not recruiting
Using Montelukast to Treat the Patients Infected With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) [NCT04714515]150 participants (Actual)Observational2020-02-20Completed
Randomized Controlled Trial of Hydroxychloroquine Versus Placebo in Early Ambulatory Diagnosis and Treatment of Elderly COVID19 Patients [NCT04351516]Phase 2/Phase 30 participants (Actual)Interventional2020-04-21Withdrawn(stopped due to No Patients enrolled)
Sequential Application of Yisaipu® and Disease Modifying Anti-Rheumatic Drugs (DMARDs) in Treating Mild-to-Moderate Ankylosing Spondylitis: the Mid-term Follow-up Result [NCT03411798]Phase 476 participants (Actual)Interventional2017-12-15Completed
A Prospective Clinical Study of Hydroxychloroquine in the Prevention of SARS- CoV-2 (COVID-19) Infection in Healthcare Workers After High-risk Exposures [NCT04333225]Phase 2221 participants (Actual)Interventional2020-04-03Completed
Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease [NCT04332991]Phase 3479 participants (Actual)Interventional2020-04-02Completed
A Pilot Study to Determine the Biological Effects of Hydroxychloroquine on PAR-4 Levels in Patients With Resectable Solid Tumors [NCT02232243]Phase 110 participants (Actual)Interventional2015-07-31Completed
Study on the Treatment Strategy of Patients With Rheumatoid Arthritis During Pregnancy, a Randomized Control Trial in China [NCT04569890]100 participants (Anticipated)Interventional2020-12-01Not yet recruiting
Treatments Against RA and Effect on FDG-PET/CT (The TARGET Trial) [NCT02374021]Phase 4159 participants (Actual)Interventional2016-07-31Completed
A Multicenter, Randomized, Open-Label, Parallel-Group Usability Study Of The Sarilumab Auto-Injector Device And A Prefilled Syringe In Patients With Moderate To Severe Active Rheumatoid Arthritis Who Are Candidates For Anti-IL6R Therapy [NCT02057250]Phase 3217 participants (Actual)Interventional2014-03-31Completed
Chemoprophylaxis of SARS-CoV-2 Infection (COVID-19) in Exposed Healthcare Workers : A Randomized Double-blind Placebo-controlled Clinical Trial [NCT04328285]Phase 3118 participants (Actual)Interventional2020-04-14Terminated(stopped due to French authority's decision)
Comparing the Effects of Hydroxychloroquine (HCQ) to Pioglitazone in Type 2 Diabetic Patients Failing Maximal Doses of Metformin Plus a Sulfonylurea [NCT02303405]Phase 222 participants (Actual)Interventional2014-11-30Terminated(stopped due to Investigator decision)
A Multicenter, Randomized, Open-label, Blinded-assessor, Follow-up, Phase 4 Study in Patients With Rheumatoid Arthritis Who Have Completed the Initial Treatment Part in the NORD-STAR Study and Have Reached Stable Low Disease Activity [NCT02466581]Phase 425 participants (Actual)Interventional2015-02-03Active, not recruiting
Efficacy of Hydroxychloroquine, Telmisartan and Azithromycin on the Survival of Hospitalized Elderly Patients With COVID-19: a Randomized, Multicenter, Adaptative Study [NCT04359953]Phase 316 participants (Actual)Interventional2020-04-25Terminated(stopped due to difficulty in recruiting)
Assessment of the Efficacy and Safety of Hydroxychloroquine (HCQ) Administered as a Prophylaxis for Health Professionals Exposed to COVID19 and Working in Medical Intensive Care Units, in Tunisia. Multicentric Randomized Comparative Study [NCT04349228]Phase 30 participants (Actual)Interventional2020-04-28Withdrawn(stopped due to - Interest in the use of HCQ is controversial.)
A Phase II Study of Paclitaxel Protein Bound + Gemcitabine + Cisplatin+ Hydroxychlororoquine as Preoperative Treatment in Patients With Untreated Resectable, Borderline Resectable and Locally Advanced Adenocarcinoma of the Pancreas [NCT04669197]Phase 219 participants (Actual)Interventional2020-12-01Active, not recruiting
A Phase II Study of Docetaxel and Modulation of Autophagy With Hydroxychloroquine for Metastatic Hormone Refractory Prostate Cancer [NCT00786682]Phase 211 participants (Actual)Interventional2008-12-31Terminated(stopped due to Lack of improved efficacy compared to historical controls, competing studies)
An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to Interferon Beta 1b And The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized Clinical Trial [NCT04343768]Phase 260 participants (Actual)Interventional2020-04-09Completed
An Open-Label, Single-Arm, Phase II Study to Evaluate the Efficacy and Safety of Oral Hydroxychloroquine, Indomethacin and Zithromax in Subjects Positive With SARS-CoV-2 With Mild Symptoms [NCT04344457]Phase 1/Phase 280 participants (Anticipated)Interventional2020-04-16Recruiting
Randomized Multicenter Study Evaluating the Efficacy of Azithromycin and Hydroxychloroquine in the Prevention of SARS-CoV-2 Infection in the Hospital Population Exposed to Virus [NCT04344379]Phase 3122 participants (Actual)Interventional2020-04-17Completed
A Phase I Dose Escalation Study of Hydroxychloroquine With Infusional Cyclophosphamide, Pulse Dexamethasone and Rapamycin in Patients With Relapsed or Refractory Multiple Myeloma [NCT01689987]Phase 118 participants (Actual)Interventional2012-09-30Completed
Treatment With Hydroxychloroquine vs Nitazoxanide + Hydroxychloroquine in Patients With COVID-19 With Risk Factors for Poor Outcome [NCT04341493]Phase 444 participants (Actual)Interventional2020-04-06Terminated(stopped due to Concerns about safety of Hydroxychloroquine)
Randomized Controlled Trial Testing the Effect of Hydroxychloroquine Combined With Low-dose Corticosteroid Therapy in Pulmonary Sarcoidosis [NCT05247554]Phase 3200 participants (Anticipated)Interventional2022-03-01Not yet recruiting
WU 352: Open-label, Randomized Controlled Trial of Hydroxychloroquine Alone or Hydroxychloroquine Plus Azithromycin or Chloroquine Alone or Chloroquine Plus Azithromycin in the Treatment of SARS CoV-2 Infection [NCT04341727]Phase 331 participants (Actual)Interventional2020-04-04Terminated(stopped due to DSMB recommended study suspension slow accrual)
NEw Clinical Endpoints in Patients With Primary Sjögren's Syndrome (pSS): an Interventional Trial Based on stratifYing Patients [NCT05113004]Phase 2300 participants (Anticipated)Interventional2022-01-20Recruiting
Pilot Study of Hydroxychloroquine for the Treatment of Hidradenitis Suppurativa [NCT03275870]Phase 1/Phase 217 participants (Actual)Interventional2017-09-28Completed
Proactive Protection With Azithromycin and Hydroxychloroquine in Hospitalized Patients With COVID: A Randomized, Placebo-controlled Double-blinded Trial Evaluating Treatment With Azithromycin and Hydroxychloroquine to Patients With COVID-19 [NCT04322396]Phase 2117 participants (Actual)Interventional2020-04-06Terminated(stopped due to Recommended by the DSMB)
Pre-Exposure Prophylaxis With Hydroxychloroquine for High-Risk Healthcare Workers During the COVID-19 Pandemic: A Multicentre, Double-Blinded Randomized Controlled Trial [NCT04331834]Phase 3275 participants (Actual)Interventional2020-04-03Completed
Double-blind, Randomized, Prospective, Parallel Study to Demonstrate the Efficacy and Safety of Outpatient Treatment of the Fixed Combination of Hydroxychloroquine With Azithromycin Versus Hydroxychloroquine Treatment and Placebo Treatment in Patients Dia [NCT04964583]Phase 2/Phase 3105 participants (Anticipated)Interventional2021-01-20Recruiting
(NJ 1508) Modulation of Autophagy With Hydroxychloroquine in Combination With Carboplatin, Paclitaxel and Bevacizumab in Patients With Advanced/Recurrent Non-Small Cell Lung Cancer - A Phase I/II Study [NCT00728845]Phase 1/Phase 28 participants (Actual)Interventional2008-06-16Terminated(stopped due to Slow accrual)
Assessment of the Biological Effect of Autophagic Inhibition With Hydroxychloroquine in Prostate Cancer [NCT02421575]Early Phase 14 participants (Actual)Interventional2012-07-31Terminated(stopped due to slow accrual)
A Multi-center, Prospective, Open-label, Randomized Study to Explore Efficacy and Safety of Baricitinib in Active Primary Sjogren's Syndrome Patients [NCT05016297]Phase 287 participants (Anticipated)Interventional2022-07-14Recruiting
Hydroxychloroquine to Prevent SARS-CoV-2 Infection Among Healthcare Workers: Randomized Controlled, Open-label, Phase 3 Clinical Trial [NCT04414241]Phase 368 participants (Actual)Interventional2020-06-25Completed
Study of Anti-Malarials in Incomplete Lupus Erythematosus [NCT03030118]Phase 2187 participants (Actual)Interventional2017-12-28Active, not recruiting
Hydroxychloroquine Post-Exposure Prophylaxis for Coronavirus Disease (COVID-19) Among Health-Care Workers: A Randomized-Controlled Trial [NCT04438837]582 participants (Anticipated)Interventional2020-07-31Not yet recruiting
The BAMM2 (BRAF, Autophagy, MEK Inhibition in Melanoma) Study: A Randomized Double Blind Phase II Study of Dabrafenib and Trametinib With or Without Hydroxychloroquine in Advanced BRAF V600E/K Melanoma [NCT04527549]Phase 284 participants (Anticipated)Interventional2021-06-01Active, not recruiting
A Phase I Trial of Ulixertinib (BVD-523) and Hydroxychloroquine in Patients With Advanced MAPK-Mutated Gastrointestinal Adenocarcinomas [NCT04145297]Phase 117 participants (Actual)Interventional2020-03-17Active, not recruiting
A Randomized, Double-Blind, Placebo-Controlled Phase IIa Study of Hydroxychloroquine, Vitamin C, Vitamin D, and Zinc for the Prevention of COVID-19 Infection [NCT04335084]Phase 2600 participants (Anticipated)Interventional2020-06-22Recruiting
Phase I/II Trial of Regorafenib, Hydroxychloroquine, and Entinostat in Metastatic Colorectal Cancer [NCT03215264]Phase 120 participants (Actual)Interventional2017-10-02Completed
Single-center, Phase II, Randomized Double-blind, Placebo-controlled Study of Hydroxychloroquine Compared to Placebo as Treatment for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection [NCT04379492]Phase 20 participants (Actual)Interventional2020-05-05Withdrawn(stopped due to Emerging evidence does not support the use of HCQ for treatment or prevention of SARS -CoV2 infection. No pts have been enrolled.)
EVALUATION OF THE EFFICACY OF THE HYDROXYCHLOROQUINE-AZITHROMYCIN COMBINATION IN THE IN THE PREVENTION OF COVID-19 RELATED SDRA [NCT04347512]Phase 30 participants (Actual)Interventional2020-06-02Withdrawn(stopped due to In view of the notices concerning hydroxychloroquine issued by the regulatory authorities, we withdraw the protocol)
Efficacy of HYdroxychloroquine and DILtiazem-nIClosamide Combination for the Treatment of Non-severe Forms of SARS-CoV2 Infection in Patients With Co-morbidities: Multicenter, Randomized, Open-labeled Controlled Trial [NCT04372082]Phase 30 participants (Actual)Interventional2020-05-31Withdrawn(stopped due to evidence showed chloroquine is not effective against COVID-19)
Prophylactic Benefit of Hydroxychloroquine in COVID-19 Cases With Mild to Moderate Symptoms and in Healthcare Workers With High Exposure Risk (PREVENT) [NCT04371926]0 participants (Actual)Interventional2020-06-30Withdrawn(stopped due to Concerned about the adverse effects of HCQ)
An Open Label Cluster Randomized Controlled Trial of Chloroquine, Hydroxychloroquine or Only Supportive Care in Patients AdmItted With Moderate to Severe COVID-19 [NCT04362332]Phase 425 participants (Actual)Interventional2020-04-14Terminated(stopped due to Currently, almost no patients admitted to Dutch hospitals. If any effect of HCQ is to be expected we need more than 1000 inclusions)
Clinical Trial Evaluating Safety and Efficacy of Hydroxychloroquine and Nitazoxanide Combination as Adjuvant Therapy in Covid-19 Newly Diagnosed Egyptian Patients: A Tanta University Hope [NCT04361318]Phase 2/Phase 3100 participants (Anticipated)Interventional2020-05-31Not yet recruiting
A Phase 1, Open-Label Study to Investigate Drug-Drug Interaction (DDI) Potential of Nipocalimab With Coadministration of Etanercept or Hydroxychloroquine in Healthy Participants [NCT04973566]Phase 148 participants (Actual)Interventional2021-08-31Completed
Open Label, Multicentric, Non Randomized, Exploratory Clinical Trial to Assess the Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Mild Acute Respiratory Syndrome (COVID-19) Caused by SARS-CoV-2 Virus [NCT04348474]Early Phase 1200 participants (Anticipated)Interventional2020-04-20Suspended(stopped due to Azidus, the CRO hired for this study by Prevent Senior has lost the interest to conduct this study.)
Proteomics Combined With Metabolomics Studies on the Efficacy of Telitacicept in Chinese Patients of Systemic Lupus Erythematosus [NCT05666336]Phase 430 participants (Anticipated)Interventional2022-12-31Recruiting
The Efficacy of Hydroxychloroquine on Behcet's Disease Thrombotic Events Prevention [NCT04022421]50 participants (Anticipated)Interventional2018-10-01Recruiting
A Single-Arm, Phase II Study of Autophagy Modulation Using Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in Metastatic BRAF-mutated Colorectal Cancer Refractory to Standard Therapies [NCT05576896]Phase 243 participants (Anticipated)Interventional2022-10-10Recruiting
A Phase I/II, Open Clinical Trial to Assess the Safety, Tolerability and Efficacy of a Fixed Dose Combination Therapy of: Hydroxychloroquine (HCQ), Pegylated Interferon Alpha-2a (Peg-IFN Alpha-2a) and Ribavirin (RBV) in Chronic Hepatitis C Genotype 1 Infe [NCT01272310]Phase 1/Phase 236 participants (Anticipated)Interventional2011-01-31Not yet recruiting
Multicenter, Open Label, Phase IIIb Study to Evaluate the Safety and Tolerability of Subcutaneous Tocilizumab as Monotherapy and/or in Combination With Methotrexate or Other Non-Biologic Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Ar [NCT01941095]Phase 3100 participants (Actual)Interventional2013-11-20Completed
A Study of Hydroxychloroquine and Zinc in the Prevention of COVID-19 Infection in Military Healthcare Workers (COVID-Milit) [NCT04377646]Phase 3660 participants (Anticipated)Interventional2020-05-04Not yet recruiting
A Phase II Randomized Double-Blind Trial of Baricitinib or Placebo Combined With Antiviral Therapy in Patients With Moderate and Severe COVID-19 [NCT04373044]Phase 26 participants (Actual)Interventional2020-05-01Terminated(stopped due to The study was terminated after the release of results of ACTT-2 (NCT04401579).)
Efficacy of Azithromycin-associated Hydroxychloroquine Therapy Given in General Practice in Early-stage Disease in COVID-19 Patients: Randomized Controlled Trial: MG-COVID [NCT04371406]Phase 30 participants (Actual)Interventional2020-04-30Withdrawn(stopped due to Regulatory approvals have not been obtained)
A Randomized Study Evaluating the Safety and Efficacy of Hydroxychloroquine and Zinc in Combination With Either Azithromycin or Doxycycline for the Treatment of COVID-19 in the Outpatient Setting [NCT04370782]Phase 418 participants (Actual)Interventional2020-04-28Completed
Use of Bromhexine and Hydroxychloroquine for Treatment of COVID-19 Pneumonia [NCT04355026]Phase 490 participants (Anticipated)Interventional2020-04-10Recruiting
Efficacy and Safety of Azithromycin Compared to the Base Therapeutic Regiment of Hydroxychloroquine in Moderate to Severe COVID-19: A Randomized, Controlled, Double-Blind, Clinical Trial [NCT04359316]Phase 440 participants (Anticipated)Interventional2020-04-20Not yet recruiting
Prevention of COVID19 Infection by the Administration of Hydroxychloroquine to Institutionalized Older People and Nursing Home Staff. Controlled Clinical Trial, Randomized Triple Blind by Clusters (PREVICHARM Study) [NCT04400019]Phase 2/Phase 31,930 participants (Anticipated)Interventional2020-09-30Not yet recruiting
PaTcH Trial: A Phase 2 Study to Explore Primary and Emerging Resistance Mechanisms in Patients With Metastatic Refractory Pancreatic Cancer Treated With Trametinib and Hydroxychloroquine [NCT05518110]Phase 222 participants (Anticipated)Interventional2023-05-31Recruiting
Does Zinc Supplementation Enhance the Clinical Efficacy of Chloroquine/Hydroxychloroquine in Treatment of COVID-19? [NCT04447534]Phase 3191 participants (Actual)Interventional2020-06-23Completed
"Hydroxychloroquine and Lopinavir/ Ritonavir for Hospitalization and Mortality Reduction in Patients With COVID-19 and Mild Disease Symptoms: The Hope Coalition" [NCT04403100]Phase 31,968 participants (Anticipated)Interventional2020-06-03Recruiting
A Randomized, Double-blinded Phase 3 Multi-center Study of the Clinical and Microbiologic Efficacy of a Combination of Azithromycin and Hydroxychloroquine for Treatment of COVID-19 Infection [NCT05026801]Phase 30 participants (Actual)Interventional2021-02-08Withdrawn(stopped due to Inadequate support to carry out study)
Efficacy and Safety of the Use of Hydroxychloroquine, Favipiravir or Hydroxychloroquine + Favipiravir in Early SARS-CoV-2 (COVID-19) Treatment [NCT04981379]Phase 31,120 participants (Actual)Interventional2020-11-16Completed
Hydroxychloroquine for Outpatients With Confirmed COVID-19 [NCT04342169]Phase 2368 participants (Actual)Interventional2020-04-04Completed
The Danish Pre-HCQ Dialysis Study: Hydroxychloroquine for Prevention of COVID19 in Dialysis-treated Patients With End-stage Renal Disease - A Multicenter Parallel-group Open Randomized Clinical Trial [NCT05110651]Phase 40 participants (Actual)Interventional2020-04-10Withdrawn(stopped due to No funding)
A Phase I/II/Pharmacodynamic Study of Hydroxychloroquine in Combination With Gemcitabine/Abraxane to Inhibit Autophagy in Pancreatic Cancer [NCT01506973]Phase 1/Phase 2119 participants (Actual)Interventional2011-12-31Completed
Comparison of Infliximab With Sulfasalazine/Hydroxychloroquine Initiated After Methotrexate by Rheumatoid Arthritis Patients Treated in Clinical Practice (Real-World Emulation of SWEFOT Trial) [NCT05051137]509 participants (Actual)Observational2006-01-12Completed
A Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of Oral Hydroxychloroquine for the Treatment of SARS-CoV-2 Positive Patients for the Prevention of Severe COVID-19 Disease. [NCT04329611]Phase 3148 participants (Actual)Interventional2020-04-13Terminated(stopped due to Enrolment was suspended on 22may2020, after Mehra et al (Lancet 2020) then stopped due to lack of Covid19 cases.)
An Investigator-Initiated, Phase II, Randomized, Withdrawal Study of Mycophenolate Mofetil (MMF) in Patients With Stable, Quiescent Systemic Lupus Erythematosus (SLE) [NCT01946880]Phase 2102 participants (Actual)Interventional2013-11-20Terminated(stopped due to Slow enrollment.)
Hydroxychloroquine in Cardiovascular Disease in Patients With Chronic Kidney Disease: A Proof of Concept Study [NCT01537315]Phase 28 participants (Actual)Interventional2012-02-29Terminated(stopped due to lack of funding)
Assessment of Efficacy and Safety of HCQ and Antibiotics Administrated to Patients COVID19(+), inTunisia [NCT04351919]Phase 40 participants (Actual)Interventional2020-05-05Withdrawn(stopped due to - Interest in the use of HCQ is controversial.)
Phase II Study to Evaluate the Tolerability and Efficacy of Treatment of Previously Untreated B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients With Hydroxychloroquine. [NCT00771056]Phase 223 participants (Actual)Interventional2008-07-31Terminated(stopped due to study suspended while data is reviewed for safety and efficacy.)
A Prospective Randomized Controlled Trial of Hydroxychloroquine in the Primary Thrombosis Prophylaxis of aPL Positive But Thrombosis-free Patients. [NCT01784523]Phase 311 participants (Actual)Interventional2013-02-28Terminated(stopped due to low recruitment rate exacerbated by manufacturing shortage and price increase of hydroxychloroquine.)
Relevance of Monitoring Blood Levels Compared to Salivar Levels of Drugs Used in Rheumatic Autoimmune Diseases: Adherence and Understanding the Possible Underlying Mechanisms Involved in Effectiveness and in Adverse Effects [NCT03122431]Phase 493 participants (Actual)Interventional2017-06-05Completed
Use and Dosage of Hydroxychloroquine and Chloroquine to Convert Real Time Polymerase Chain Reaction (RT-PCR) Positive Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Coronavirus Infectious Disease 2019 (COVID-19) Patients to RT- PCR-Negative [NCT04346667]Phase 4125 participants (Actual)Interventional2020-04-14Terminated(stopped due to Poor accrual.)
Efficacy and Safety of Hydroxychloroquine and Ivermectin in Hospitalized no Critical Patients Secondary to COVID-19 Infection: Randomized Controlled Trial [NCT04391127]Phase 3108 participants (Actual)Interventional2020-05-04Completed
The Fleming [FMTVDM] Directed CoVid-19 Treatment Protocol [NCT04349410]Phase 2/Phase 31,800 participants (Actual)Interventional2020-04-11Completed
Hydroxychloroquine, Azithromycin in the Treatment of Covid-19 Pneumonia: A Randomized,Open-label,Controlled Clinical Trial [NCT04405921]Phase 3200 participants (Anticipated)Interventional2020-07-31Not yet recruiting
Phase I/II Study of Ixabepilone in Combination With the Autophagy Inhibitor Hydroxychloroquine for the Treatment of Patients With Metastatic Breast Cancer [NCT00765765]Phase 1/Phase 26 participants (Actual)Interventional2009-02-28Terminated(stopped due to Slow accrual)
Phase II Clinical Study of Hydroxychloroquine Combined With Gemcitabine in the Treatment of Advanced Non-small Cell Lung Cancer [NCT05647330]Phase 255 participants (Anticipated)Interventional2022-12-15Not yet recruiting
Inhibition of Autophagy in Solid Tumors: A Phase I Pharmacokinetic and Pharmacodynamic Study of Hydroxychloroquine in Combination With the HDAC Inhibitor Vorinostat for the Treatment of Patients With Advanced Solid Tumors With an Expansion Study in Advanc [NCT01023737]Phase 172 participants (Actual)Interventional2009-11-30Completed
Randomized Trial Assessing Efficacy and Safety of Hydroxychloroquine Plus Azithromycin Versus Hydroxychloroquine for Hospitalized Adults With COVID-19 Pneumonia [NCT04345861]Phase 2/Phase 37 participants (Actual)Interventional2020-04-11Terminated(stopped due to halted prematurely.)
Post Exposure Prophylaxis (PEP) in Healthcare Workers Exposed to COVID-19 Patients: A Double-blind Randomized Clinical Trial [NCT04437693]Phase 2/Phase 3500 participants (Anticipated)Interventional2020-08-31Not yet recruiting
Hydroxychloroquine in Unexplained Recurrent Pregnancy Loss ,Double Blinded Randomized Controlled Trial . [NCT05237843]Phase 170 participants (Anticipated)Interventional2022-03-01Not yet recruiting
Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines- Methotrexate vs Hydroxychloroquine [NCT04691505]133,553 participants (Actual)Observational2020-12-23Completed
Comparative Efficacy of Ivermectin Versus Combination of Hydroxychloroquine Plus Darunavir/ Ritonavir for Shortening Duration of SARS-CoV2 Detection From Respiratory Secretion Among Asymptomatic or Afebrile COVID-19 Infection [NCT04435587]Phase 480 participants (Anticipated)Interventional2020-07-13Recruiting
Phase 2, Single Center, Single Arm Study to Evaluate the Decrease in CIPN With the Addition of Hydroxychloroquine to Chemotherapy in Patients With Early Stage (1-3) Breast Cancer and Gynecological Cancers Treated With Curative Intent [NCT05689359]Phase 224 participants (Anticipated)Interventional2024-01-31Not yet recruiting
Phase II Trial of ERK Inhibition Alone and in Combination With Autophagy Inhibition in Patients With Metastatic Pancreatic Cancer [NCT04386057]Phase 252 participants (Actual)Interventional2020-05-27Active, not recruiting
Randomized Phase II Trial of Pre-Operative Gemcitabine and Nab Paclitacel With or With Out Hydroxychloroquine [NCT01978184]Phase 2104 participants (Actual)Interventional2013-11-30Completed
An Open-Label, Multicenter, Parallel-Group, Randomized, Phase III Study to Evaluate the Efficacy and Safety of Hydroxychloroquine and Favipiravir in the Treatment of Mild to Moderate COVID-19 [NCT04411433]Phase 31,008 participants (Actual)Interventional2020-05-08Active, not recruiting
Hydroxycloroquin (Plaquenil) Behandling af Gentagne Graviditetstab (Abortus Habitualis) - et Randomiseret, Dobbeltblindet, Placebo Kontrolleret Studium [NCT03305263]Phase 3186 participants (Anticipated)Interventional2018-01-25Recruiting
Efficacy and Safety of Anti-hepatitis C Drugs in the Treatment of COVID-19 [NCT04443725]Phase 2/Phase 3100 participants (Anticipated)Interventional2020-07-31Not yet recruiting
Reposition of Second Line Treatment in Chronic Immune Thrombocytopenia [NCT03229746]Phase 440 participants (Actual)Interventional2017-08-01Completed
Multicentric Pragmatic Randomized Controled Trial to Evaluate the Efficacy Chloroquine or Hydroxychloroquine for Five Days in Treating Pneumonia Caused by SARS-Cov-2 - COVID-19 [NCT04420247]Phase 3142 participants (Actual)Interventional2020-04-16Completed
A Randomized, Double-blind, Parallel, Placebo-controlled Study Assessing the Efficacy and Safety of Sarilumab Added to Non-biologic DMARD Therapy in Patients With Rheumatoid Arthritis Who Are Inadequate Responders to or Intolerant of TNF-α Antagonists [NCT01709578]Phase 3546 participants (Actual)Interventional2012-10-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00259610 (2) [back to overview]Radiographic Disease Progression Between Baseline and Week 102 as Assessed by Van Der Heijde Modified Sharp Scores.
NCT00259610 (2) [back to overview]Disease Activity Score Erythrocyte Sedimentation Rate(DAS28-ESR)
NCT00405275 (1) [back to overview]Mean 48-week Change in DAS28
NCT00422227 (10) [back to overview]Percent Change From Baseline in DAS28 at Week 16
NCT00422227 (10) [back to overview]Change From Baseline in Adjusted Mean of American College of Rheumatology Response (ACR-N) Area Under Curve (AUC) Over 16 Weeks
NCT00422227 (10) [back to overview]Percentage of Participants Achieving European League Against Rheumatism (EULAR) Moderate or Good Response
NCT00422227 (10) [back to overview]Percent Change From Baseline in Duration (Minutes) of Morning Stiffness
NCT00422227 (10) [back to overview]Percent Change From Baseline in General Health, Pain, and Fatigue, Visual Analog Scales
NCT00422227 (10) [back to overview]Percent Change From Baseline in Painful and Swollen Joint Counts
NCT00422227 (10) [back to overview]Percent Change From Baseline in Physician And Subject Global Assessments
NCT00422227 (10) [back to overview]Percentage of Participants Achieving ACR 20, 50, and 70 Responses
NCT00422227 (10) [back to overview]Percentage of Participants Achieving DAS28 <3.2 (Low Disease Activity) and <2.6 (Remission)
NCT00422227 (10) [back to overview]Percentage of Participants With DAS28 Improvement of ≥0.6 and ≥1.2
NCT00486603 (10) [back to overview](Phase II) Number of Participants With Grade 3 and 4 Toxicity
NCT00486603 (10) [back to overview]Pharmocodynamics as Determined by Number of Participants With Autophagy Inhibition in Relation to Maximal Concentration (Cmax) of HCQ
NCT00486603 (10) [back to overview](Phase I) Maximum Tolerated Dose (MTD) of Hydroxychloroquine (HCQ)
NCT00486603 (10) [back to overview]PK of Hydroxychloroquine as Measured by Volume of Distribution of Central Compartment (V/F)
NCT00486603 (10) [back to overview]PK of Hydroxychloroquine as Measured by Oral Clearance (Liters/Hour) From Central Compartment (CL/F)
NCT00486603 (10) [back to overview]PK of Hydroxychloroquine as Measured by First-order Absorption Rate Constant (Ka)
NCT00486603 (10) [back to overview](Phase I) Number of Participants Who Experienced Dose Limiting Toxicity (DLT)
NCT00486603 (10) [back to overview]PK of Hydroxychloroquine as Measured by Distribution Volume of Peripheral Compartment (V2/F)
NCT00486603 (10) [back to overview]Pharmacokinetics (PK) of Hydroxychloroquine as Measured by Lag Time (Tlag)
NCT00486603 (10) [back to overview](Phase II) Overall Survival
NCT00579878 (1) [back to overview]Measuring the Safety and Efficacy of a New DMARD, Leflunomide Alone or in Combination With Traditional DMARD's. Participants Reaching ACR 20 Response. at 48 Weeks
NCT00726596 (2) [back to overview]Prostate-specific Antigen (PSA) Response
NCT00726596 (2) [back to overview]Feasibility and Safety of Administering Hydroxychloroquine in This Population of Patients. Rate of Adverse Events
NCT00771056 (2) [back to overview]Time to Next Treatment
NCT00771056 (2) [back to overview]Percentage of Participants With Response
NCT00977470 (5) [back to overview]Percent of Participants in Which FMISO-PET ([18F]-Fluoromisonidazole-positron Emission Tomography) is Able to Detect and Quantify Changes in Tumor Hypoxia After Erlotinib.
NCT00977470 (5) [back to overview]Nine-month Progression-free Survival Rate
NCT00977470 (5) [back to overview]Median Progression Free Survival
NCT00977470 (5) [back to overview]Treatment Related Toxicity, > 10% Frequency, Any Grade
NCT00977470 (5) [back to overview]Objective Tumor Response Rate Following Treatment With Erlotinib and With Erlotinib/HCQ.
NCT01006369 (3) [back to overview]Progression-free Survival
NCT01006369 (3) [back to overview]Overall Response Rate
NCT01006369 (3) [back to overview]Overall Survival
NCT01026844 (3) [back to overview]Determine the Pharmacokinetic (PK) Parameters of Hydroxychloroquine (HCQ) Plus Erlotinib.
NCT01026844 (3) [back to overview]Describe the Number and Type of Observed Dose Limiting Toxcities
NCT01026844 (3) [back to overview]Objective Tumor Response Rate
NCT01128296 (10) [back to overview]Overall Survival (OS) by Response to HCQ Treatment
NCT01128296 (10) [back to overview]Disease-free Survival (DFS) by Response to HCQ Treatment
NCT01128296 (10) [back to overview]Overall Survival (OS) by CA 19-9 Response
NCT01128296 (10) [back to overview]Overall Survival (OS) by p53 Mutant Status
NCT01128296 (10) [back to overview]Disease-free Survival by p53 Genetic Status
NCT01128296 (10) [back to overview]Disease-free Survival (DFS) by CA 19-9 Response
NCT01128296 (10) [back to overview]R0 Resection Rate
NCT01128296 (10) [back to overview]Overall Survival (OS)
NCT01128296 (10) [back to overview]Number of Participants That Experienced a Dose Limiting Toxicity (DLT)
NCT01128296 (10) [back to overview]Disease-free Survival (DFS)
NCT01132118 (7) [back to overview]HOMA-IR
NCT01132118 (7) [back to overview]Total Cholesterol
NCT01132118 (7) [back to overview]LDL Cholesterol
NCT01132118 (7) [back to overview]Insulin Sensitivity Index
NCT01132118 (7) [back to overview]HOMA-B
NCT01132118 (7) [back to overview]HDL Cholesterol
NCT01132118 (7) [back to overview]Triglycerides
NCT01273805 (5) [back to overview]2-month Progression-Free Survival Rate
NCT01273805 (5) [back to overview]Tumor Response Rate
NCT01273805 (5) [back to overview]Progression-Free Survival
NCT01273805 (5) [back to overview]Overall Survival
NCT01273805 (5) [back to overview]Grade 4-5 Treatment-Related Toxicity
NCT01326533 (2) [back to overview]Insulin Sensitivity
NCT01326533 (2) [back to overview]Beta Cell Function
NCT01379573 (9) [back to overview]Fetal Death Not Related to Cardiac Dysfunction
NCT01379573 (9) [back to overview]Recurrence of Advanced Heart Block
NCT01379573 (9) [back to overview]Prolonged PR Interval (>150msec)
NCT01379573 (9) [back to overview]Prematurity
NCT01379573 (9) [back to overview]Echocardiographic Densities Consistent With EFE Confirmed Postnatally
NCT01379573 (9) [back to overview]Cutaneous Neonatal Lupus
NCT01379573 (9) [back to overview]Birth Weight <10% in the Context of Gestational Age
NCT01379573 (9) [back to overview]Any Sign of Myocardial Injury, Without Change in Cardiac Rate or Rhythm
NCT01379573 (9) [back to overview]Abnormal Fluid Collection
NCT01537315 (1) [back to overview]Change From Baseline in Inflammatory Marker, Hs-C Reactive Protein, at 6 Months
NCT01550367 (18) [back to overview]Worst Grade of Adverse Event At Least Possibly Related to Treatment Experienced
NCT01550367 (18) [back to overview]Serum Lactate Dehydrogenase
NCT01550367 (18) [back to overview]Serum Calcium Levels (Corrected)
NCT01550367 (18) [back to overview]Hemoglobin Levels
NCT01550367 (18) [back to overview]Number of Participants With Low Karnofsky Performance Status
NCT01550367 (18) [back to overview]Conventional Dendritic Cells (cDC)
NCT01550367 (18) [back to overview]Myeloid Derived Suppressor Cell (MDSC)
NCT01550367 (18) [back to overview]Number of Doses of IL-2 + HCQ
NCT01550367 (18) [back to overview]Frequency of Grade III and Grade IV Toxicities
NCT01550367 (18) [back to overview]T-cell Lymphocytes
NCT01550367 (18) [back to overview]Regulatory T Cells (Treg)
NCT01550367 (18) [back to overview]Prior Nephrectomy
NCT01550367 (18) [back to overview]Plasmacytoid Dendritic Cells (pDC)
NCT01550367 (18) [back to overview]Natural Killer (NK) Cells
NCT01550367 (18) [back to overview]Overall Survival (OS)
NCT01550367 (18) [back to overview]Worst Grade of Adverse Event Experienced
NCT01550367 (18) [back to overview]Worst Grade of Adverse Event At Least Probably Related to Treatment Experienced
NCT01550367 (18) [back to overview]Progression-free Survival (PFS)
NCT01573754 (4) [back to overview]Number of Days With Normal Urinary Porphyrin Levels
NCT01573754 (4) [back to overview]50% Reduction in Plasma Porphyrin Level
NCT01573754 (4) [back to overview]75% Reduction in Plasma Porphyrin Level
NCT01573754 (4) [back to overview]Remission
NCT01645176 (1) [back to overview]Change in Synovitis
NCT01649947 (2) [back to overview]Progression Free Survival (PFS)
NCT01649947 (2) [back to overview]Antitumor Activity, as Measured by Tumor Response Rate of Hydroxychloroquine, Paclitaxel, Carboplatin, and Bevacizumab (for Eligible Patients) in Patients With Advanced or Recurrent NSCLC Cancer
NCT01687179 (1) [back to overview]Safety of Combination Therapy With Sirolimus and Hydroxychloroquine in LAM Patients
NCT01709578 (41) [back to overview]Change From Baseline in WPS-RA at Week 12: RA Interference With Household Work Productivity
NCT01709578 (41) [back to overview]Change From Baseline in WPS-RA at Week 12: House Work Days Missed Due to RA
NCT01709578 (41) [back to overview]Change From Baseline in WPS-RA at Week 12: Days With Work Productivity Reduced by ≥ 50% Due to RA
NCT01709578 (41) [back to overview]Change From Baseline in WPS-RA at Week 12: Days With Outside Help Hired Due to RA
NCT01709578 (41) [back to overview]Change From Baseline in WPS-RA at Week 12: Days With Household Work Productivity Reduced by ≥ 50% Due to RA
NCT01709578 (41) [back to overview]Change From Baseline in WPS-RA at Week 12: Days With Family/Social/Leisure Activities Missed Due to RA
NCT01709578 (41) [back to overview]Change From Baseline in Work Productivity Survey - Rheumatoid Arthritis (WPS-RA) at Week 24: Work Days Missed Due to RA
NCT01709578 (41) [back to overview]Change From Baseline in the Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 12
NCT01709578 (41) [back to overview]Change From Baseline in the Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-fatigue) Score at Week 24
NCT01709578 (41) [back to overview]Change From Baseline in the FACIT-fatigue at Week 12
NCT01709578 (41) [back to overview]Change From Baseline in SF-36 MCS at Week 24
NCT01709578 (41) [back to overview]Change From Baseline in Rheumatoid Arthritis Impact of Disease (RAID) Scores at Week 24
NCT01709578 (41) [back to overview]Change From Baseline in RAID Scores at Week 12
NCT01709578 (41) [back to overview]Change From Baseline in Morning Stiffness VAS at Week 24
NCT01709578 (41) [back to overview]Change From Baseline in HAQ-DI at Week 24
NCT01709578 (41) [back to overview]Change From Baseline in European Quality of Life-5 Dimension 3 Level (EQ-5D-3L) VAS Scores at Week 24
NCT01709578 (41) [back to overview]Change From Baseline in EQ-5D-3L VAS Scores at Week 12
NCT01709578 (41) [back to overview]Change From Baseline in Disease Activity Score for 28 Joints -C-Reactive Protein (DAS28--CRP) Score at Week 24
NCT01709578 (41) [back to overview]Change From Baseline in DAS28-CRP at Week 12
NCT01709578 (41) [back to overview]Change From Baseline in Clinical Disease Activity Index (CDAI) at Week 24
NCT01709578 (41) [back to overview]Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Physical Component Summary Scores (PCS) at Week 24
NCT01709578 (41) [back to overview]Percentage of Participants Achieving ACR20, ACR50 and ACR70 Criteria at Week 12
NCT01709578 (41) [back to overview]Change From Baseline in SF-36 at Week 12
NCT01709578 (41) [back to overview]Change From Baseline in Individual ACR Component - CRP Level at Week 12 and Week 24
NCT01709578 (41) [back to overview]Percentage of Participants Who Achieved at Least 20% Improvement in the American College of Rheumatology (ACR20) Criteria at Week 24
NCT01709578 (41) [back to overview]Percentage of Participants Achieving Clinical Remission Score (DAS28-CRP) <2.6 at Week 24
NCT01709578 (41) [back to overview]Percentage of Participants Achieving Clinical Remission Score (DAS28--CRP <2.6) at Week 12
NCT01709578 (41) [back to overview]Percentage of Participants Achieving ACR70 Criteria at Week 24
NCT01709578 (41) [back to overview]Percentage of Participants Achieving ACR50 Criteria at Week 24
NCT01709578 (41) [back to overview]Change From Baseline in WPS-RA at Week 24: RA Interference With Work Productivity
NCT01709578 (41) [back to overview]Change From Baseline in WPS-RA at Week 24: RA Interference With Household Work Productivity
NCT01709578 (41) [back to overview]Change From Baseline in WPS-RA at Week 24: House Work Days Missed Due to RA
NCT01709578 (41) [back to overview]Change From Baseline in WPS-RA at Week 24: Days With Work Productivity Reduced by ≥ 50% Due to RA
NCT01709578 (41) [back to overview]Change From Baseline in WPS-RA at Week 24: Days With Outside Help Hired Due to RA
NCT01709578 (41) [back to overview]Change From Baseline in WPS-RA at Week 24: Days With Household Work Productivity Reduced by ≥ 50% Due to RA
NCT01709578 (41) [back to overview]Change From Baseline in WPS-RA at Week 24: Days With Family/Social/Leisure Activities Missed Due to RA
NCT01709578 (41) [back to overview]Change From Baseline in WPS-RA at Week 12: Work Days Missed Due to RA
NCT01709578 (41) [back to overview]Change From Baseline in WPS-RA at Week 12: RA Interference With Work Productivity
NCT01709578 (41) [back to overview]Change From Baseline in Individual ACR Component - HAQ-DI at Week 12 and Week 24
NCT01709578 (41) [back to overview]Change From Baseline in Individual ACR Component - Physician Global VAS, Participant Global VAS and Pain VAS at Week 12 and Week 24
NCT01709578 (41) [back to overview]Change From Baseline in Individual ACR Components - TJC and SJC at Week 12 and Week 24
NCT01768572 (1) [back to overview]Number of Participants With Treatment Emergent Adverse Events (TEAEs)
NCT01784523 (1) [back to overview]Number of Participants With an Acute Thrombosis Event
NCT01828476 (8) [back to overview]Circulating Tumor Cells Pre-enrollment and During Therapy
NCT01828476 (8) [back to overview]Time to PSA Progression
NCT01828476 (8) [back to overview]Progression Free Survival
NCT01828476 (8) [back to overview]Overall Survival
NCT01828476 (8) [back to overview]Measurable Tumor Response in Patients With Measurable Disease
NCT01828476 (8) [back to overview]Biomarkers of Autophagy Modulation by EM; and LC3, and/or p62 by Immunoblotting in PBMC and Tumor Tissue When Available
NCT01828476 (8) [back to overview]Biochemical Response to ABT-263 and Abiraterone and to ABT-263 in Combination With Hydroxychloroquine and Abiraterone in Patients That Are Progressing on Abiraterone
NCT01828476 (8) [back to overview]Bcl-2 Family Protein Expression (Bcl-2, Bcl-XL, MCL-1) in Paraffin Blocks When Available by Immunohistochemistry
NCT01833845 (1) [back to overview]Safety: Number of Participants With Adverse Events
NCT01842594 (2) [back to overview]The Toxicity
NCT01842594 (2) [back to overview]The Maximum Standardized Uptake Values (SUVmax) Change on PET/CT Scan
NCT01941095 (19) [back to overview]Number of Participants With Anti-Tocilizumab Antibodies (ATA)
NCT01941095 (19) [back to overview]Percentage of Participants Who Achieved Disease Activity Score Based on 28 Joint Count and Erythrocyte Sedimentation Rate (DAS28-ESR) Remission at Week 24
NCT01941095 (19) [back to overview]Percentage of Participants With Corticosteroid Dose Reduction or Discontinuation
NCT01941095 (19) [back to overview]Change From Baseline in DAS28-ESR up to Week 52
NCT01941095 (19) [back to overview]Change From Baseline in Simplified Disease Activity Index (SDAI) Score up to Week 52
NCT01941095 (19) [back to overview]Change From Baseline in SJC28 up to Week 52
NCT01941095 (19) [back to overview]Change From Baseline in TJC28 up to Week 52
NCT01941095 (19) [back to overview]Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Total Score
NCT01941095 (19) [back to overview]HAQ-DI Score
NCT01941095 (19) [back to overview]Number of Participants by Reasons (Categories) for Corticosteroid Dose Reduction or Discontinuation
NCT01941095 (19) [back to overview]Number of Participants With American College of Rheumatology 20 (ACR20) Response
NCT01941095 (19) [back to overview]Patient Assessment of Pain, Using VAS Score
NCT01941095 (19) [back to overview]Percentage of Participants Who Achieved DAS28-ESR Remission/Low Disease Activity (LDA) From Week 28 up to Week 52 Among Participants With Intensification of Methotrexate/Other Non-Biologic DMARDs in Combination With Tocilizumab Since Week 24
NCT01941095 (19) [back to overview]Percentage of Participants Who Maintained DAS28-ESR Remission From Week 24 up to Week 52 Among Participants on Tocilizumab Monotherapy Since Week 24
NCT01941095 (19) [back to overview]Percentage of Participants With Good, Moderate, or No Response According to European League Against Rheumatism (EULAR) Response Criteria
NCT01941095 (19) [back to overview]PGA, Using VAS Score
NCT01941095 (19) [back to overview]Soluble Interleukin-6 Receptor (sIL-6R) Levels
NCT01941095 (19) [back to overview]Tocilizumab Serum Levels
NCT01941095 (19) [back to overview]Percentage of Participants Who Received All Planned Study Medication (Compliance)
NCT01946880 (36) [back to overview]Number of Participants Experiencing a Severe Safety of Estrogens in Lupus Erythematosus National Assessment-Systemic Lupus Erythematosus-Disease Activity Index (SELENA-SLEDAI) Flare by Week 60
NCT01946880 (36) [back to overview]Number of Participants Experiencing a Severe Safety of Estrogens in Lupus Erythematosus National Assessment-Systemic Lupus Erythematosus-Disease Activity Index (SELENA-SLEDAI) Flare by Week 60 Within the Lupus Nephritis Subgroup
NCT01946880 (36) [back to overview]Number of Participants Experiencing a Severe Safety of Estrogens in Lupus Erythematosus National Assessment-Systemic Lupus Erythematosus-Disease Activity Index (SELENA-SLEDAI) Flare by Week 60 Within the Non-Lupus Nephritis Subgroup
NCT01946880 (36) [back to overview]Number of Participants Experiencing Any British Isles Lupus Assessment Group (BILAG) A Flare by Week 60
NCT01946880 (36) [back to overview]Number of Participants Experiencing Clinically Significant Disease Reactivation by Week 60
NCT01946880 (36) [back to overview]Number of Participants Experiencing Severe Safety of Estrogens in Lupus Erythematosus National Assessment-Systemic Lupus Erythematosus-Disease Activity Index (SELENA-SLEDAI) Flare by Week 60 in the Baseline MMF <2000 mg/Day Subgroup
NCT01946880 (36) [back to overview]Number of Participants Experiencing Severe Safety of Estrogens in Lupus Erythematosus National Assessment-Systemic Lupus Erythematosus-Disease Activity Index (SELENA-SLEDAI) Flare by Week 60 in the Baseline MMF ≥ 2000 mg/Day Subgroup
NCT01946880 (36) [back to overview]Number of Participants in the Lupus Nephritis Subgroup Experiencing a British Isles Lupus Assessment Group (BILAG) A Renal Flare by Week 60
NCT01946880 (36) [back to overview]Number of Serious Adverse Events (SAEs).
NCT01946880 (36) [back to overview]The Addition of Aggressive Adjunctive Therapy to Mycophenolate Mofetil (MMF) or Change in MMF Therapy to Cytotoxic Drug Due to Flare by Week 60
NCT01946880 (36) [back to overview]Time From Clinically Significant Disease Reactivation to Improvement in British Isles Lupus Assessment Group (BILAG) From Maximum Level During Flare
NCT01946880 (36) [back to overview]Time From Clinically Significant Disease Reactivation to Recovery to Baseline British Isles Lupus Assessment Group (BILAG) Score or BILAG C
NCT01946880 (36) [back to overview]Time From Clinically Significant Disease Reactivation to Return to Pre-Flare Steroid Dose
NCT01946880 (36) [back to overview]Time to Clinically Significant Disease Reactivation
NCT01946880 (36) [back to overview]Number of Grade 3, 4, or 5 Adverse Events (AEs)
NCT01946880 (36) [back to overview]Time to First Mild/Moderate or Severe Safety of Estrogens in Lupus Erythematosus National Assessment-Systemic Lupus Erythematosus-Disease Activity Index (SELENA-SLEDAI) Flare
NCT01946880 (36) [back to overview]Time to First Severe Safety of Estrogens in Lupus Erythematosus National Assessment-Systemic Lupus Erythematosus-Disease Activity Index (SELENA-SLEDAI) Flare
NCT01946880 (36) [back to overview]Change From Baseline in the Functional Assessment of Chronic Illness Therapy (FACIT-F) Fatigue Scale (FS): Total Score
NCT01946880 (36) [back to overview]Change From Baseline in the Lupus Quality of Life (QoL)Score
NCT01946880 (36) [back to overview]Change From Baseline in the Short Form Health Survey (SF-36) Physical Component Summary (PCS) Score
NCT01946880 (36) [back to overview]Change From Baseline in the Short Form Health Survey (SF-36) Physical Functioning (PF) Score
NCT01946880 (36) [back to overview]Change From Baseline in the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Disease Damage Index for Systemic Lupus Erythematosus (SLICC/DI): Total Score
NCT01946880 (36) [back to overview]Number of Grade 3, 4, or 5 Adverse Events (AEs) Related to Mycophenolate Mofetil (MMF)
NCT01946880 (36) [back to overview]Number of Grade 3, 4, or 5 Adverse Events (AEs) Related to Systemic Lupus Erythematosus (SLE)
NCT01946880 (36) [back to overview]Number of Grade 3, 4, or 5 Hematological Adverse Events (AEs).
NCT01946880 (36) [back to overview]Number of Infection-Related Adverse Events (AEs)
NCT01946880 (36) [back to overview]All-Cause Mortality
NCT01946880 (36) [back to overview]Cumulative Excess Systemic Steroid Dose From Time of Clinically Significant Disease Reactivation to Return to Pre-Flare Dose or End of Trial Participation
NCT01946880 (36) [back to overview]Cumulative Systemic Steroid Dose by Week 60
NCT01946880 (36) [back to overview]Mortality Related to Systemic Lupus Erythematosus (SLE)
NCT01946880 (36) [back to overview]Number of Malignancies Reported as Adverse Events (AEs).
NCT01946880 (36) [back to overview]Number of Participants Experiencing a Mild/Moderate or Severe Safety of Estrogens in Lupus Erythematosus National Assessment-Systemic Lupus Erythematosus-Disease Activity Index (SELENA-SLEDAI) Flare by Week 60
NCT01946880 (36) [back to overview]Number of Participants Experiencing a Mild/Moderate or Severe Safety of Estrogens in Lupus Erythematosus National Assessment-Systemic Lupus Erythematosus-Disease Activity Index (SELENA-SLEDAI) Flare by Week 60 in the Baseline MMF ≥ 2000 mg/Day Subgroup
NCT01946880 (36) [back to overview]Number of Participants Experiencing a Mild/Moderate or Severe Safety of Estrogens in Lupus Erythematosus National Assessment-Systemic Lupus Erythematosus-Disease Activity Index (SELENA-SLEDAI) Flare by Week 60 in the Baseline MMF<2000 mg/Day Subgroup
NCT01946880 (36) [back to overview]Number of Participants Experiencing a Mild/Moderate or Severe Safety of Estrogens in Lupus Erythematosus National Assessment-Systemic Lupus Erythematosus-Disease Activity Index (SELENA-SLEDAI) Flare by Week 60 Within the Lupus Nephritis Subgroup
NCT01946880 (36) [back to overview]Number of Participants Experiencing a Mild/Moderate or Severe Safety of Estrogens in Lupus Erythematosus National Assessment-Systemic Lupus Erythematosus-Disease Activity Index (SELENA-SLEDAI) Flare by Week 60 Within the Non-Lupus Nephritis Subgroup
NCT01978184 (11) [back to overview]Type of Surgical Procedure (Operation)
NCT01978184 (11) [back to overview]Age-Adjusted Charlson Comorbidity Index
NCT01978184 (11) [back to overview]Age at Diagnosis
NCT01978184 (11) [back to overview]Cancer Diagnosis Stage
NCT01978184 (11) [back to overview]Evans Grade Histopathologic Response
NCT01978184 (11) [back to overview]Robotic Resection Surgery
NCT01978184 (11) [back to overview]Carbohydrate Antigen 19-9 (CA19-9) Response
NCT01978184 (11) [back to overview]Carbohydrate Antigen 19-9 (CA19-9) Response
NCT01978184 (11) [back to overview]CT Tumor Size
NCT01978184 (11) [back to overview]Positive Lymph Node Involvement
NCT01978184 (11) [back to overview]Rate of R0 Resection
NCT02026232 (2) [back to overview]Effect of HCQ on Fasting Low Density Lipoprotein
NCT02026232 (2) [back to overview]Effect of HCQ on Fasting Blood Glucose
NCT02057250 (2) [back to overview]Area Under the Serum Concentration Versus Time Curve Calculated Using the Trapezoidal Method During a Dose Interval (AUC[0-tau]) for Sarilumab
NCT02057250 (2) [back to overview]Number of Validated AID Associated Product Technical Failures (PTFs)
NCT02079077 (2) [back to overview]Change in Number of CCR5+CD4+ T Cell Population at the Female Genital Tract.
NCT02079077 (2) [back to overview]Changes in Systemic Immune Activation From Baseline Observed by the CD69 Expression on CD4 T Cells
NCT02232243 (2) [back to overview]Patients With Elevated Par-4 Levels
NCT02232243 (2) [back to overview]Optimal Biologic Dose of Hydroxychloroquine
NCT02303405 (11) [back to overview]Weight
NCT02303405 (11) [back to overview]Adverse Events
NCT02303405 (11) [back to overview]Body Mass Index
NCT02303405 (11) [back to overview]Fasting Plasma Glucose
NCT02303405 (11) [back to overview]Hemoglobin A1c
NCT02303405 (11) [back to overview]HOMA-IR
NCT02303405 (11) [back to overview]Hs-CRP
NCT02303405 (11) [back to overview]Hypoglycemic Events
NCT02303405 (11) [back to overview]Leucocyte Count
NCT02303405 (11) [back to overview]Percent of Subjects Achieving HbA1c < 7.5%
NCT02303405 (11) [back to overview]QUICKI
NCT02374021 (5) [back to overview]Change From Baseline in the MDS of the Aorta
NCT02374021 (5) [back to overview]Change From Baseline in the Average TBR of the Index Vessel
NCT02374021 (5) [back to overview]Change From Baseline in the Average TBR of the Bilateral Carotids
NCT02374021 (5) [back to overview]Change From Baseline in the Average TBR of the Aorta
NCT02374021 (5) [back to overview]Change From Baseline in Vascular Inflammation as Measured by FDG-PET/CT at 6 Months
NCT02603146 (15) [back to overview]Percent of Participants Experiencing Grade 3 or Higher Adverse Events (AEs)
NCT02603146 (15) [back to overview]Time to Development of Clinically-Apparent Rheumatoid Arthritis (CL - RA) By Treatment Arm
NCT02603146 (15) [back to overview]Level of Anti-Cyclic Citrullinated Peptide-3 (Anti-CCP3) By Treatment Arm
NCT02603146 (15) [back to overview]Level of High-Sensitivity C-Reactive Protein (hsCRP) Treatment Arm
NCT02603146 (15) [back to overview]Level of Immunoglobulin M - Rheumatoid Factor (IgM-RF) By Treatment Arm
NCT02603146 (15) [back to overview]Number of Participant Self-Reported Painful Joints By Treatment Arm
NCT02603146 (15) [back to overview]Number of Participant Self-Reported Painful Joints in the Hands, Wrists and Feet By Treatment Arm
NCT02603146 (15) [back to overview]Number of Participant Self-Reported Stiff Joints By Treatment Arm
NCT02603146 (15) [back to overview]Number of Participant Self-Reported Stiff Joints in the Hands, Wrists and Feet By Treatment Arm
NCT02603146 (15) [back to overview]Number of Participant Self-Reported Swollen Joints By Treatment Arm
NCT02603146 (15) [back to overview]Number of Participant Self-Reported Swollen Joints in the Hands, Wrists and Feet By Treatment Arm
NCT02603146 (15) [back to overview]Number of Participants Who Developed Clinically-Apparent Rheumatoid Arthritis (CL - RA) From Treatment Initiation to Month 36 By Treatment Arm
NCT02603146 (15) [back to overview]Number of Participants Who Developed Clinically-Apparent Rheumatoid Arthritis (CL-RA) From Treatment Initiation to Month 12 By Treatment Arm
NCT02603146 (15) [back to overview]Number of Participants Who Developed Inflammatory Arthritis (IA) From Treatment Initiation to Month 12.
NCT02603146 (15) [back to overview]Number of Participants Who Developed Inflammatory Arthritis (IA) From Treatment Initiation to Month 36
NCT02930343 (4) [back to overview]Disease Activity as Per Ultrasound-7 (US-7) Score
NCT02930343 (4) [back to overview]Indian Health Assessment Questionnaire (iHAQ)
NCT02930343 (4) [back to overview]Number of Patients Achieving Good EULAR Response at the End of 12 Weeks
NCT02930343 (4) [back to overview]Number of Participants With Adverse Drug Reactions
NCT03122431 (2) [back to overview]Serum Levels of Hydroxycloroquine
NCT03122431 (2) [back to overview]Serum Levels of Thalidomide
NCT03215264 (1) [back to overview]Maximum Tolerated Dose (MTD) of Hydroxychloroquine and Entinostat in Combination With Regorafenib
NCT03275870 (2) [back to overview]Change in Disease Severity
NCT03275870 (2) [back to overview]Change in Quality of Life
NCT03283566 (3) [back to overview]Quotient of Stimulated C-peptide/Glucose Level Normalized for IEQ/Kg Infused in Response to MMTT
NCT03283566 (3) [back to overview]C-peptide AUC Response to MMTT
NCT03283566 (3) [back to overview]Ratio of C-peptide AUC to Glucose AUC in Response to MMTT Adjusted for Infused Islet Cell Mass
NCT03344172 (4) [back to overview]Worst Grade of Adverse Event Experienced At Least Probably Related to Treatment
NCT03344172 (4) [back to overview]Worst Grade of Adverse Event Experienced At Least Possibly Related to Treatment
NCT03344172 (4) [back to overview]Proportion of Grade IIb or Higher Histolopathologic Responses
NCT03344172 (4) [back to overview]Change in CA19-9 Levels
NCT03449758 (30) [back to overview]Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
NCT03449758 (30) [back to overview]Number of Participants Achieving Low Disease Activity (DAS28 ESR Score <=3.2) and Remission (DAS28 ESR Score <2.6) at Weeks 12, and 24
NCT03449758 (30) [back to overview]Rheumatoid Arthritis Impact of Disease Total Score at Baseline, Weeks 4, 12 and 24
NCT03449758 (30) [back to overview]Change From Baseline in Disease Activity Score-28 for Rheumatoid Arthritis With Erythrocyte Sedimentation Rate at Weeks 4, 12, and 24
NCT03449758 (30) [back to overview]Change From Baseline in Duration of Morning Stiffness at Weeks 4, 12, and 24
NCT03449758 (30) [back to overview]Change From Baseline in Erythrocyte Sedimentation Rate at Weeks 4, 12, and 24
NCT03449758 (30) [back to overview]Change From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue Total Scores at Weeks 4, 12 and 24
NCT03449758 (30) [back to overview]Change From Baseline in Hospital Anxiety and Depression Scale: Anxiety (HADS-A) and Depression (HADS-D) Subscale Scores at Weeks 4, 12 and 24
NCT03449758 (30) [back to overview]Number of Participants Achieving Clinical Disease Activity Index: Low Disease Activity (CDAI Score <=10.0) and Remission (CDAI Score <=2.8) Weeks 12, and 24
NCT03449758 (30) [back to overview]Multidimensional Assessment of Thymic States (MAThyS) Scale Total Score at Baseline, Weeks 4, 12 and 24
NCT03449758 (30) [back to overview]International Physical Activity Questionnaire (IPAQ) Total Score at Baseline, Weeks 4, 12 and 24
NCT03449758 (30) [back to overview]Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) Total Scores at Baseline, Weeks 4, 12 and 24
NCT03449758 (30) [back to overview]Erythrocyte Sedimentation Rate (ESR) at Baseline, Weeks 4, 12, and 24
NCT03449758 (30) [back to overview]Change From Baseline in International Physical Activity Questionnaire Total Score at Weeks 4, 12 and 24
NCT03449758 (30) [back to overview]Duration of Morning Stiffness at Baseline, Weeks 4, 12, and 24
NCT03449758 (30) [back to overview]Disease Activity Score-28 for Rheumatoid Arthritis With Erythrocyte Sedimentation Rate (DAS28-ESR) at Baseline, Weeks 4, 12, and 24
NCT03449758 (30) [back to overview]Clinical Disease Activity Index (CDAI) Total Score at Baseline, Weeks 4, 12, and 24
NCT03449758 (30) [back to overview]Change From Baseline in Stanford Health Assessment Questionnaire Disability Index Total Score at Weeks 4, 12 and 24
NCT03449758 (30) [back to overview]Number of Swollen Joints at Baseline, Weeks 4, 12, and 24
NCT03449758 (30) [back to overview]Change From Baseline in Rheumatoid Arthritis Impact of Disease Total Score at Weeks 4 and 12
NCT03449758 (30) [back to overview]Change From Baseline in Patient Global Assessment of Disease Activity Score by Visual Analog Scale at Weeks 4, 12, and 24
NCT03449758 (30) [back to overview]Change From Baseline in Multidimensional Assessment of Thymic States Scale Total Score at Weeks 4, 12 and 24
NCT03449758 (30) [back to overview]Change From Baseline in Number of Tender Joints at Weeks 4, 12, and 24
NCT03449758 (30) [back to overview]Stanford Health Assessment Questionnaire Disability Index (HAQ-DI) Total Score at Baseline, Weeks 4, 12 and 24
NCT03449758 (30) [back to overview]Change From Baseline in Rheumatoid Arthritis Impact of Disease Total Score at Week 24
NCT03449758 (30) [back to overview]Change From Baseline in Number of Swelling Joints at Weeks 4, 12, and 24
NCT03449758 (30) [back to overview]Patient Global Assessment (PtGA) of Disease Activity Score by Visual Analog Scale (VAS) at Baseline, Weeks 4, 12 and 24
NCT03449758 (30) [back to overview]Number of Tender Joints at Baseline, Weeks 4, 12, and 24
NCT03449758 (30) [back to overview]Hospital Anxiety and Depression Scale (HADS): Anxiety (HADS-A) and Depression (HADS-D) Subscale Scores at Baseline, Weeks 4, 12, and 24
NCT03449758 (30) [back to overview]Change From Baseline in Clinical Disease Activity Index Total Score at Weeks 4, 12, and 24
NCT04308668 (9) [back to overview]Number of Participants With Active COVID-19 Disease at Day 14 Among Those Who Were Asymptomatic at Baseline
NCT04308668 (9) [back to overview]Number of Participants With Severe COVID-19 Disease at 14 Days Among Those Who Are Symptomatic at Trial Entry
NCT04308668 (9) [back to overview]Occurrence of Symptoms Compatible With COVID-19 (Possible Disease)
NCT04308668 (9) [back to overview]Rate of All-Cause Study Medicine Discontinuation or Withdrawal
NCT04308668 (9) [back to overview]Rate of Confirmed SARS-CoV-2 Detection
NCT04308668 (9) [back to overview]Rate of Death
NCT04308668 (9) [back to overview]Rate of Hospitalization
NCT04308668 (9) [back to overview]Change in Disease Severity Over 14 Days Among Those Who Are Symptomatic at Baseline
NCT04308668 (9) [back to overview]Overall Symptom Severity at 5 and 14 Days
NCT04322396 (12) [back to overview]"Time for no Oxygen Supplement (or Regular Oxygen Supplement LTOT)"
NCT04322396 (12) [back to overview]Length of Hospitalization
NCT04322396 (12) [back to overview]Length of Stay in ICU
NCT04322396 (12) [back to overview]Mortality
NCT04322396 (12) [back to overview]Number of Days Using Non-invasive Ventilation (NIV)
NCT04322396 (12) [back to overview]Number of Days Alive and Discharged From Hospital Within 14 Days
NCT04322396 (12) [back to overview]Number of Participants on Non-invasive Ventilation (NIV) During Hospitalization
NCT04322396 (12) [back to overview]Number of Readmissions (All Causes)
NCT04322396 (12) [back to overview]Change in Patient's Oxygen Partial Pressure
NCT04322396 (12) [back to overview]Change of pH in Blood
NCT04322396 (12) [back to overview]Days Alive and Discharged From Hospital
NCT04322396 (12) [back to overview]Change in Patient's Carbondioxide Partial Pressure
NCT04328467 (7) [back to overview]Incidence of Possible COVID-19 Symptoms
NCT04328467 (7) [back to overview]Ordinal Scale of COVID-19 Disease Maximum Severity if COVID-19 Diagnosed at Study End
NCT04328467 (7) [back to overview]COVID-19-free Survival
NCT04328467 (7) [back to overview]Incidence of All-cause Study Medicine Discontinuation
NCT04328467 (7) [back to overview]Incidence of Hospitalization for COVID-19 or Death
NCT04328467 (7) [back to overview]Number of Confirmed SARS-CoV-2 Detection
NCT04328467 (7) [back to overview]Incidence of Possible Study Medication-related Side Effects
NCT04328961 (4) [back to overview]Rate of Participant-reported Adverse Events
NCT04328961 (4) [back to overview]Number of Participants Who Had Polymerase Chain Reaction (PCR) Confirmed SARS-CoV-2 Infection
NCT04328961 (4) [back to overview]Number of Participants Who Had COVID-19 Disease
NCT04328961 (4) [back to overview]The Number of Participants Who Had Polymerase Chain Reaction (PCR) Confirmed SARS-CoV-2 Infection
NCT04329832 (5) [back to overview]Ventilator-free Days at 28 Days (Number of Days Patient Not on a Ventilator)
NCT04329832 (5) [back to overview]Time to a 1-point Decrease in the WHO Ordinal Recovery Score
NCT04329832 (5) [back to overview]Hospital-free Days at 28 Days
NCT04329832 (5) [back to overview]COVID Ordinal Outcomes Scale at 14 Days
NCT04329832 (5) [back to overview]ICU-free Days at 28 Days
NCT04329923 (5) [back to overview]Number of Health Care Workers Who Developed SARS-COV-2 Infection
NCT04329923 (5) [back to overview]Rate of Hospitalization
NCT04329923 (5) [back to overview]Rate of Housemate Infection
NCT04329923 (5) [back to overview]Time to Hospital Discharge
NCT04329923 (5) [back to overview]Time to Release From Quarantine Time
NCT04332991 (27) [back to overview]Ventilator-free Days Through Day 28
NCT04332991 (27) [back to overview]Hospital-free Days to Day 28
NCT04332991 (27) [back to overview]All-location, All-cause Mortality Assessed on Study Day 15 (14 Days After Randomization)
NCT04332991 (27) [back to overview]All-location, All-cause Mortality Assessed on Study Day 29 (28 Days After Randomization)
NCT04332991 (27) [back to overview]COVID Ordinal Outcomes Scale on Study Day 29 (28 Days After Randomization)
NCT04332991 (27) [back to overview]COVID Ordinal Outcomes Scale on Study Day 3 (2 Days After Randomization)
NCT04332991 (27) [back to overview]COVID Ordinal Outcomes Scale on Study Day 8 (7 Days After Randomization)
NCT04332991 (27) [back to overview]COVID Outcomes Scale Score on Study Day 15 (14 Days After Randomization)
NCT04332991 (27) [back to overview]ICU-free Days to Day 28
NCT04332991 (27) [back to overview]Number of Patients Dead or With Receipt of ECMO Between Enrollment and Day 28
NCT04332991 (27) [back to overview]Number of Patients With Acute Kidney Injury to day28
NCT04332991 (27) [back to overview]Number of Patients With Acute Pancreatitis Arrest to Day 28
NCT04332991 (27) [back to overview]Number of Patients With Anemia to Day 28
NCT04332991 (27) [back to overview]Number of Patients With Atrial Arrhythmia to Day 28
NCT04332991 (27) [back to overview]Number of Patients With Cardiac Arrest to Day 28
NCT04332991 (27) [back to overview]Number of Patients With Elevation in Aspartate Aminotransferase or Alanine Aminotransferase to Twice the Local Upper Limit of Normal to Day 28
NCT04332991 (27) [back to overview]Number of Patients With Lymphopenia to Day 28
NCT04332991 (27) [back to overview]Number of Patients With Neutropenia to Day 28
NCT04332991 (27) [back to overview]Number of Patients With Receipt of Renal Replacement Therapy to Day 28
NCT04332991 (27) [back to overview]Number of Patients With Seizures to Day 28
NCT04332991 (27) [back to overview]Number of Patients With Severe Dermatologic Reaction to Day 28
NCT04332991 (27) [back to overview]Number of Patients With Symptomatic Hypoglycemia to Day 28
NCT04332991 (27) [back to overview]Number of Patients With Thrombocytopenia to Day 28
NCT04332991 (27) [back to overview]Number of Patients With Ventricular Arrhythmia to Day 28
NCT04332991 (27) [back to overview]Oxygen-free Days Through Day 28
NCT04332991 (27) [back to overview]Time to Recovery, Defined as Time to Reaching Level 5, 6, or 7 on the COVID Outcomes Scale, Which is the Time to the Earlier of Final Liberation From Supplemental Oxygen or Hospital Discharge
NCT04332991 (27) [back to overview]Vasopressor-free Days Through Day 28
NCT04333225 (2) [back to overview]Time From Study Initiation Until the Occurrence of COVID-19 or COVID-19 Like Illness or Being Censored
NCT04333225 (2) [back to overview]Number of Participants Infected With COVID-19 or COVID-19 Like Illness During the Trial
NCT04334148 (3) [back to overview]Number of Participants With COVID-19 Viral Shedding
NCT04334148 (3) [back to overview]Number of Participants With Serious Adverse Events (SAEs) or Hydroxychloroquine-Associated Events of Special Interest (EOSIs)
NCT04334148 (3) [back to overview]Number of Participants With Clinical Infection With COVID-19 Infection
NCT04335552 (8) [back to overview]World Health Organization (WHO) Ordinal Scale Measured at 14 Days After Enrollment
NCT04335552 (8) [back to overview]WHO Ordinal Scale Measured at 28 Days After Enrollment
NCT04335552 (8) [back to overview]Hospital Length of Stay in Days for the Index Hospitalization
NCT04335552 (8) [back to overview]Number of Days on Mechanical Ventilation
NCT04335552 (8) [back to overview]Number of Participants Who Died During the Index Hospitalization
NCT04335552 (8) [back to overview]Number of Participants With All-cause Study Medication Discontinuation
NCT04335552 (8) [back to overview]Number of Participants With Severe Adverse Events
NCT04335552 (8) [back to overview]Number of Patients Not Receiving Mechanical Ventilation at Baseline Who Progress to Requiring Mechanical Ventilation During the Index Hospitalization
NCT04341441 (11) [back to overview]Identify Immunologic, Serological and Inflammatory Markers Associated With Acquisition and Response to COVID-19 in Both HCQ and Placebo Participants Developing Laboratory or Clinical Confirmed Disease.
NCT04341441 (11) [back to overview]Examine the Correlation Between HCQ Drug Levels and Development of COVID-19 Symptoms or Positive COVID-19 Test Results.
NCT04341441 (11) [back to overview]Determine the Safety and Tolerability of HCQ Dosing for Preventive Strategy Against COVID-19 as Measured by Adverse Events and Serious Adverse Events.
NCT04341441 (11) [back to overview]Determine the Effect of Hydroxychloroquine Dose in the Prevention of COVID-19 Viremia and Disease.
NCT04341441 (11) [back to overview]Comparison of the Rate of SARS-CoV 2 Infections as Measured by IgM/IgG Seroconversion in Study Participants Receiving Randomized HCQ Versus Placebo.
NCT04341441 (11) [back to overview]To Determine if the Use of Hydroxychloroquine as Preventive Therapy Decreases the Rate of Acquisition of SARS-CoV 2 Infections With Clinical COVID-19 Disease in Study Participants for Each Randomized Treatment Arm as Compared to Placebo.
NCT04341441 (11) [back to overview]Comparison of the Emergence of Clinical Symptoms or COVID-19 Diagnosis in Participants Presenting Asymptomatically at Study Entry But Identified as Seropositive by Serology at Entry Between the Randomized Treatment Arms and Comparator Arm.
NCT04341441 (11) [back to overview]Compare the Seroprevalence of SARS-CoV 2 IgM and/or IgG Positive Samples at Study Entry and Study Conclusion in All Participants Receiving HCQ Compared to Those Receiving Placebo.
NCT04341441 (11) [back to overview]To Examine the Level of Care Needed by Participants in Each Arm Developing COVID19 as Measured as Requiring Emergency Room Visit, Hospitalization or Able to Stay Home Without Hospital Care.
NCT04341441 (11) [back to overview]To Examine Other Clinical Factors Contributing to the Risk of SARS-CoV 2 Infection in Healthcare Workers and First Responders.
NCT04341441 (11) [back to overview]Assess the Impact of Chronic Weight-based Dosing of HCQ for COVID-19 Prevention.
NCT04342169 (5) [back to overview]Adult Household Contact Viral Acquisition
NCT04342169 (5) [back to overview]Duration of COVID-19-attributable Symptoms
NCT04342169 (5) [back to overview]Duration of Viral Shedding
NCT04342169 (5) [back to overview]Hospitalization
NCT04342169 (5) [back to overview]Number of Participants With Viral Shedding on Day 28
NCT04345653 (4) [back to overview]Recruitment Feasibility
NCT04345653 (4) [back to overview]Early Feasibility as Reflected on the Number of Participants Contracting COVID-19 (10% or Less) in Comparison to the Expected 30% as Per CDC.
NCT04345653 (4) [back to overview]Resource Utilization
NCT04345653 (4) [back to overview]Safety as Reflected on the Number and Severity of Adverse Events and Serious Adverse Events
NCT04353271 (5) [back to overview]Number of Participants Who Are Virus Free
NCT04353271 (5) [back to overview]Number of Participants Who Die Secondary to Covid 19 Infection
NCT04353271 (5) [back to overview]Number of Participants Who Discontinue or Withdraw Medication Use for Any Reason
NCT04353271 (5) [back to overview]Number of Participants Who Have Confirmed Covid 19 Infection
NCT04353271 (5) [back to overview]Number of Participants Who Are Hospitalized for Covid 19 Infection
NCT04354428 (6) [back to overview]Number of Participants With Serious Adverse Events and Adverse Events Resulting in Treatment Discontinuation
NCT04354428 (6) [back to overview]Number of Persons With Lower Respiratory Tract Infection (LRTI), Defined as Resting Blood Oxygen Saturation (SpO2<93%) Level Sustained for 2 Readings 2 Hours Apart and Presence of Subjective Dyspnea or Cough
NCT04354428 (6) [back to overview]Time to Clearance of Nasal SARS-CoV-2
NCT04354428 (6) [back to overview]Time to Resolution of COVID-19 Symptom Resolution in Days
NCT04354428 (6) [back to overview]COVID-19-related Hospitalization Days
NCT04354428 (6) [back to overview]Number of Participants With Hospitalization or Mortality
NCT04354870 (3) [back to overview]Change From Baseline in the Number of Participants With Seroconversion to SARS-CoV-2 at 1 Month
NCT04354870 (3) [back to overview]Number of Participants With of AEs or SAEs Possibly, Probably, or Definitely Related to HCQ Upon Study Termination Time
NCT04354870 (3) [back to overview]Number of Participants With Symptomatic vs. Asymptomatic Seroconversion
NCT04358068 (10) [back to overview]Duration of Fever
NCT04358068 (10) [back to overview]Number of Participants With an Occurrence of Fainting
NCT04358068 (10) [back to overview]Time to Self-reported Return to Usual (Pre-COVID) Health.
NCT04358068 (10) [back to overview]Participant-specific Area Under the Curve (AUC) of the Symptom Score Associated With COVID-19 Disease Over Time
NCT04358068 (10) [back to overview]Number of Participants Who Prematurely Discontinue Study Treatment Due to an Adverse Event
NCT04358068 (10) [back to overview]Number of Participants Who Had Any Cardiac Adverse Events
NCT04358068 (10) [back to overview]Number of Participants Who Died From Any Cause, or Were Hospitalized, or Had an Urgent Visit to Emergency Room or Clinic
NCT04358068 (10) [back to overview]Number of Participants Who Died From Any Cause or Were Hospitalized
NCT04358068 (10) [back to overview]Number of Participants Who Died From Any Cause
NCT04358068 (10) [back to overview]Duration of Symptoms Associated With COVID-19 Disease
NCT04369742 (26) [back to overview]Percent of Participants Who Required Extracorporeal Membrane Oxygenation (ECMO)
NCT04369742 (26) [back to overview]Percent of Participants Showing a Severe Disease Progression Composite Outcome
NCT04369742 (26) [back to overview]Hospital Length of Stay
NCT04369742 (26) [back to overview]Days of Non-rebreather Mask Oxygen Supplementation
NCT04369742 (26) [back to overview]Days of Non-invasive Ventilator Use
NCT04369742 (26) [back to overview]Change in White Blood Cell (WBC) Count
NCT04369742 (26) [back to overview]Change in Total Bilirubin Levels
NCT04369742 (26) [back to overview]Change in Hemoglobin Levels
NCT04369742 (26) [back to overview]Change in Platelet Count
NCT04369742 (26) [back to overview]Change in Lactate Dehydrogenase (LDH) Levels
NCT04369742 (26) [back to overview]Change in Interleukin 6 (IL-6) Levels
NCT04369742 (26) [back to overview]Change in Glucose Levels
NCT04369742 (26) [back to overview]Change in Creatinine Levels
NCT04369742 (26) [back to overview]Change in C-Reactive Protein (CRP) Levels
NCT04369742 (26) [back to overview]Change in Aspartate Aminotransferase (AST) Levels
NCT04369742 (26) [back to overview]Change in Alanine Aminotransferase (ALT) Levels
NCT04369742 (26) [back to overview]Days of Fever
NCT04369742 (26) [back to overview]Percent of Subjects With Q-T Interval, Corrected (qTC) Prolongation at End of Treatment (EOT)
NCT04369742 (26) [back to overview]Percent of Patients Who Resulted in Mortality
NCT04369742 (26) [back to overview]Percent of Participants With SARS-CoV-2 Viral Eradication From Nasopharyngeal Specimens at EOT
NCT04369742 (26) [back to overview]Percent of Participants With SAE Through Day 30
NCT04369742 (26) [back to overview]Percent of Participants With Hypotension Requiring Vasopressor Support
NCT04369742 (26) [back to overview]Percent of Participants With Grade 3 or 4 AEs Through Day 30
NCT04369742 (26) [back to overview]Percent of Participants With Discontinuation of Therapy (for Any Reason)
NCT04369742 (26) [back to overview]Percent of Participants Who Required Invasive Mechanical Ventilation
NCT04369742 (26) [back to overview]Percent of Participants Who Required ICU Admission
NCT04458948 (1) [back to overview]Number of Participants That Had Viral Shedding as Determined by RT-PCR.
NCT04566133 (6) [back to overview]Median Progression Free Survival (PFS)
NCT04566133 (6) [back to overview]Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0)
NCT04566133 (6) [back to overview]Proportion of Participants With a Response (Complete Response (CR) + Partial Response (PR) Reported With an 95% Confidence Interval
NCT04566133 (6) [back to overview]Proportion of Participants With a Response (Complete Response (CR) + Partial Response (PR) Reported With an 80% Confidence Interval
NCT04566133 (6) [back to overview]Serious Adverse Events Possibly, Probably, and/or Definitely Related to Treatment
NCT04566133 (6) [back to overview]Overall Survival
NCT04646109 (27) [back to overview]Rate of COVID-19 Polymerase Chain Reaction (PCR) Test Negativity
NCT04646109 (27) [back to overview]Respiratory Rate Means of the Patients
NCT04646109 (27) [back to overview]Treatment-Related Adverse Events as Assessed by CTCAE v4.0
NCT04646109 (27) [back to overview]Changes in Oxygen Saturation (SpO2) Values
NCT04646109 (27) [back to overview]Changes in Serum D-dimer Levels
NCT04646109 (27) [back to overview]Changes in Serum D-dimer Levels
NCT04646109 (27) [back to overview]Changes in Serum Ferritin Levels
NCT04646109 (27) [back to overview]Changes in Serum Ferritin Levels
NCT04646109 (27) [back to overview]Changes in Serum Lymphocyte Counts
NCT04646109 (27) [back to overview]Changes in the Ratio of Partial Pressure of Oxygen (PaO2) to Fraction of Inspired Oxygen (FiO2) (PaO2/FiO2)
NCT04646109 (27) [back to overview]Changes in the Ratio of Partial Pressure of Oxygen (PaO2) to Fraction of Inspired Oxygen (FiO2) (PaO2/FiO2)
NCT04646109 (27) [back to overview]Changes in the Ratio of Polymorphonuclear Leukocyte Count to Lymphocyte Count (PNL/L)
NCT04646109 (27) [back to overview]Changes in Serum Lymphocyte Counts
NCT04646109 (27) [back to overview]Changes in the Ratio of Polymorphonuclear Leukocyte Count to Lymphocyte Count (PNL/L)
NCT04646109 (27) [back to overview]Gender Distribution of the Patients
NCT04646109 (27) [back to overview]Genetic Examination of Haplotypes and Mutations That Cause Function Losing for Ivermectin Metabolism
NCT04646109 (27) [back to overview]Percentage of Patients With Accompanying Diseases
NCT04646109 (27) [back to overview]Percentage of Patients With Baseline Clinical Symptoms
NCT04646109 (27) [back to overview]Systolic and Diastolic Pressure Means of the Patients
NCT04646109 (27) [back to overview]Number of Participants With Clinical Response
NCT04646109 (27) [back to overview]Changes in Oxygen Saturation (SpO2) Values
NCT04646109 (27) [back to overview]Age Distribution of the Patients
NCT04646109 (27) [back to overview]Body Temperature Means of the Patients
NCT04646109 (27) [back to overview]Heart Rate Means of the Patients
NCT04646109 (27) [back to overview]Mortality
NCT04646109 (27) [back to overview]Number of Participants With Clinical Response
NCT04646109 (27) [back to overview]Treatment-Related Adverse Events as Assessed by CTCAE v4.0

Radiographic Disease Progression Between Baseline and Week 102 as Assessed by Van Der Heijde Modified Sharp Scores.

Changes in disease progression between treatment groups will be described by the mean score at two years as assessed after adjustment for the baseline radiographic score. Radiographs were observed of hands, wrists, and feet. The range of scores available for the modified Sharp Score is 0 to 448. The erosion score per joint of the hands can range from 0 to 5. The maximal erosion score for each hand is thus 80, considering the 16 areas for erosions per hand. Joint space narrowing and joint subluxation or luxation are combined in a single score with a range of 0 to 4 with a max score of 60. The erosion score per joint can range from 0 to 10, with each side of the joint independently scored from 0 to 5. The maximal erosion score per foot is thus 60. The joint space narrowing and joint (sub)luxation are combined in a single score with a range of 0 to 4. The maximal narrowing/(sub)luxation score per foot is thus 24. (NCT00259610)
Timeframe: Year 2, Week 102

InterventionScores on a scale (Mean)
MTX + Immediate Etanercept7.0
MTX+ Immediate SSZ +HCQ7.3
MTX + Step-up Etanercept4.8
MTX + Step-up SSZ + HCQ(ST)6.2

[back to top]

Disease Activity Score Erythrocyte Sedimentation Rate(DAS28-ESR)

"Outcome measured was the observed-group analysis of the DAS28-ESR between weeks 48 and 102. DAS28 is a calculated scale using a formula that includes the number of tender joints and swollen joints (28 joints maximum). The following is the calculation: DAS28 = 0.56 * sqrt(tender28) + 0.28 * sqrt(swollen28) + 0.70 * ln(ESR) + 0.014 * GH. The ESR is the rate at which red blood cells sediment in a period of one hour.~The total range for the DAS28ESR goes from 0.0 to 9.2; this indicates the current activity of the rheumatoid arthritis of a subject. A DAS28 above 5.1 means high disease activity whereas a DAS28 below 3.2 indicates low disease activity." (NCT00259610)
Timeframe: Change of the Mean of DAS28-ESR between weeks 48 - 102.

InterventionScores on a scale (Mean)
MTX + Immediate Etanercept3.0
MTX+ Immediate SSZ +HCQ2.9
MTX + Step-up Etanercept3.1
MTX + Step-up SSZ + HCQ(ST)2.8

[back to top]

Mean 48-week Change in DAS28

"Average difference between 48-week and Baseline DAS28.~The Disease Activity Score for 28 Joints (DAS28) is a well-validated composite outcome measure ranging from 2-10 (higher scores indicating more disease) that incorporates a tender and swollen joint count of 28 joints, a laboratory measure of systemic inflammation (ESR) and a patient-reported general assessment of health on a visual analog scale (ranging from 0-10cm) all into one measure.~Low disease activity is defined as DAS28 ≤ 3.2 units." (NCT00405275)
Timeframe: 48 weeks after baseline assessment

Interventionunits on a scale (Mean)
Triple-2.12
Etanercept-2.29

[back to top]

Percent Change From Baseline in DAS28 at Week 16

Disease Activity Score 28 based on 28 Joints (DAS28) is the calculation of DAS28: DAS28 = 0.56 sqrt (28 painful joint count) + 0.28 sqrt (28 swollen joint count) + 0.70 (ln erythrocyte sedimentation rate (ESR)) + 0.014 (General Health) (GH). GH = Subject general health visual analog scale (0-10 mm). (NCT00422227)
Timeframe: Week 16

InterventionPercent change (Number)
ETN/MTX38.32
DMARD/MTX27.46

[back to top]

Change From Baseline in Adjusted Mean of American College of Rheumatology Response (ACR-N) Area Under Curve (AUC) Over 16 Weeks

"ACR-N = the lowest of 3 values (percent change in the number of swollen joints, percent change in the number of tender joints, and median of the other 5 measures in the ACR core data set). Negative numbers indicate worsening.~The ACR-N AUC was calculated using the trapezoidal rule as the ACR-N multiplied by the duration of the assessment period (in weeks) and was presented as %-weeks." (NCT00422227)
Timeframe: 16 weeks

InterventionUnits on a scale (Mean)
ETN/MTX434.83
DMARD/MTX289.54

[back to top]

Percentage of Participants Achieving European League Against Rheumatism (EULAR) Moderate or Good Response

EULAR Response Criteria DAS28) improvement at week 16. Good response was defined as >1.2 improvement in DAS from Baseline and DAS attained during follow-up of ≤2.4. Non-responders were participants with improvement of ≤0.6 or participants with improvement of >0.6 but ≤1.2 and DAS attained during follow-up of >3.7. Remaining participants were classified as moderate. Scores of good and moderate were considered to have therapeutic response. (NCT00422227)
Timeframe: Week 16

InterventionPercentage of Participants (Number)
ETN/MTX87.82
DMARD/MTX73.79

[back to top]

Percent Change From Baseline in Duration (Minutes) of Morning Stiffness

The duration of morning stiffness on the day of examination should be determined by asking the following two questions: When did you awaken this morning? When were you able to resume your normal activities without stiffness? Duration of morning stiffness is equal to the time elapsed between the above two times in minutes; If none is present enter 0, If morning stiffness is still continuing, please indicate average of duration of stiffness over the past 3 days. If stiffness persists the entire day 1440 minutes (24h x 60 minutes) should be recorded. (NCT00422227)
Timeframe: Week 2, 4, 8, 12, 16

,
InterventionPercent change (Number)
Week 2Week 4Week 8Week 12Week 16
DMARD/MTX16.4333.2237.3552.7646.77
ETN/MTX54.9263.8573.4179.7680.55

[back to top]

Percent Change From Baseline in General Health, Pain, and Fatigue, Visual Analog Scales

"VAS, participant indicates by marking a vertical line at an appropriate position through a horizontal line. The length of the line measures from left (in mm) and the value (in mm) is recorded. General Health VAS, in general how would you rate your heath over the last 2-3 weeks, 0mm equals very well and 100mm equals extremely bad. Pain VAS: indicate the amount of pain experienced during the last 2-3 days, 0 mm equals no pain and 100 mm equals pain as bad as it can be. Fatigue VAS: how fatigued or tired have you been over the last week, range =No Fatigue - Extremely Fatigued." (NCT00422227)
Timeframe: Week 2, 4, 8, 12, 16

,
InterventionPercent change (Number)
General Health - Week 2General Health - Week 4General Health - Week 8General Health - Week 12General Health - Week 16Pain - Week 2Pain - Week 4Pain - Week 8Pain - Week 12Pain - Week 16Fatigue - Week 2Fatigue - Week 4Fatigue - Week 8Fatigue - Week 12Fatigue - Week 16
DMARD/MTX8.8822.7827.8630.2633.899.9922.9829.1433.9736.456.6319.0021.8228.6530.04
ETN/MTX21.1430.6138.5742.1050.4927.5934.7342.9748.4654.4220.9030.8735.9239.6546.92

[back to top]

Percent Change From Baseline in Painful and Swollen Joint Counts

Participant's assessment of pain - A horizontal pain visual analog scale (VAS) (0-100 mm) is used to assess the participants current level of pain; 0 = no pain and 100 = worst pain. Swollen joint count - ACR swollen joint count, an assessment of 28 joints. Joints are classified as either swollen or not swollen. (NCT00422227)
Timeframe: Week 2, 4, 8, 12, 16

,
InterventionPercent change (Number)
Painful Joints - Week 2Painful Joints - Week 4Painful Joints - Week 8Painful Joints - Week 12Painful Joints - Week 16Swollen Joints - Week 2Swollen Joints - Week 4Swollen Joints - Week 8Swollen Joints - Week 12Swollen Joints - Week 16
DMARD/MTX27.6836.7149.7155.5557.3121.3227.7244.1950.4856.32
ETN/MTX34.1746.1155.4865.6568.9938.5949.3359.9167.9773.83

[back to top]

Percent Change From Baseline in Physician And Subject Global Assessments

The Physician Global Assessment of Disease Activity: The participant's disease activity is estimated over the last two - three days by the physician; A zero (0) means no disease activity and a ten (10) means extreme disease activity. The Subject Global Assessment of Disease Activity: The participant assesses overall arthritis activity. A zero (0) means no disease activity and a ten (10) means extreme disease activity. (NCT00422227)
Timeframe: Week 2, 4, 8, 12, 16

,
InterventionPercent change (Number)
Physician Global Assessment - Week 2Physician Global Assessment - Week 4Physician Global Assessment - Week 8Physician Global Assessment - Week 12Physician Global Assessment - Week 16Subject Global Assessment - Week 2Subject Global Assessment - Week 4Subject Global Assessment - Week 8Subject Global Assessment - Week 12Subject Global Assessment - Week 16
DMARD/MTX11.8322.8135.4138.6745.047.2419.2226.0830.1030.55
ETN/MTX30.4039.5845.8655.0062.0521.8428.9434.9243.1850.76

[back to top]

Percentage of Participants Achieving ACR 20, 50, and 70 Responses

Response includes improvement in tender or swollen joints as well as 20 percent improvement in three of the other five criteria. Required: ≥ 20%, 50% or 70% improvement in tender joint count ≥ 20% , 50% or 70% improvement in swollen joint count and at least 20%, 50%, 70% improvement in 3 of the following 5:Patient pain assessment , Patient global assessment ,Physician global assessment, Patient self-assessed disability. (NCT00422227)
Timeframe: Week 16

,
InterventionPercentage of Participants (Number)
ACR 20ACR 50ACR 70
DMARD/MTX58.1634.697.14
ETN/MTX78.8756.7019.07

[back to top]

Percentage of Participants Achieving DAS28 <3.2 (Low Disease Activity) and <2.6 (Remission)

Disease Activity Score 28 based on 28 Joints (DAS28) is the calculation of DAS28: DAS28 = 0.56 sqrt (28 painful joint count) + 0.28 sqrt (28 swollen joint count) + 0.70 (ln erythrocyte sedimentation rate (ESR)) + 0.014 (General Health) (GH). GH = Subject general health visual analog scale (0-10 mm). (NCT00422227)
Timeframe: Week 16

,
InterventionPercentage of Participants (Number)
Low Disease (DAS28 <3.2)Remission (DAS28 <2.6)
DMARD/MTX18.457.77
ETN/MTX39.0915.74

[back to top]

Percentage of Participants With DAS28 Improvement of ≥0.6 and ≥1.2

Disease Activity Score 28 based on 28 Joints (DAS28) is the calculation of DAS28: DAS28 = 0.56 sqrt (28 painful joint count) + 0.28 sqrt (28 swollen joint count) + 0.70 (ln erythrocyte sedimentation rate (ESR) + 0.014 (General Health) (GH). GH = Subject general health visual analog scale (0-10 mm). (NCT00422227)
Timeframe: Week 16

,
InterventionPercentage of Participants (Number)
≥0.6≥1.2
DMARD/MTX78.6466.02
ETN/MTX91.3782.74

[back to top]

(Phase II) Number of Participants With Grade 3 and 4 Toxicity

Number of participants experiencing Grade 3 and 4 toxicity, as defined by CTCAE v3.0, with a possible, probable or definite relationship to HCQ, TMZ or both (NCT00486603)
Timeframe: up to 2 years

InterventionParticipants (Count of Participants)
Phase 2: RT + TMZ + HCQ22

[back to top]

Pharmocodynamics as Determined by Number of Participants With Autophagy Inhibition in Relation to Maximal Concentration (Cmax) of HCQ

Autophagy inhibition is represented by an increase in autophagic vacuoles (AV) in participants with at least 2 peripheral blood mononuclear cell samples that were amenable to EM. (NCT00486603)
Timeframe: up to 9 weeks

,
InterventionParticipants (Count of Participants)
AV IncreaseNo AV Increase
HCQ Cmax <= 1785 ng/mL1012
HCQ Cmax>1785 ng/mL126

[back to top]

(Phase I) Maximum Tolerated Dose (MTD) of Hydroxychloroquine (HCQ)

Number of participants who tolerated doses of HCQ without dose limiting toxicity. The highest dose at which participants did not experience dose limiting toxicity was determined as the MTD. (NCT00486603)
Timeframe: 10 weeks

InterventionParticipants (Count of Participants)
200mg400mg600mg800mg
Phase 1 - Dose Finding3730

[back to top]

PK of Hydroxychloroquine as Measured by Volume of Distribution of Central Compartment (V/F)

The population model PK parameters do not specifically represent steady-state values, as they were determined from multiple repeated single doses taken from multiple repeated doses taken by the individual patient during their period on the study. To obtain steady state PK parameters, individual estimates were simulated from the population model. (NCT00486603)
Timeframe: up to 276 days

InterventionLiters (Mean)
Phase 2: RT + TMZ + HCQ483.96

[back to top]

PK of Hydroxychloroquine as Measured by Oral Clearance (Liters/Hour) From Central Compartment (CL/F)

The population model PK parameters do not specifically represent steady-state values, as they were determined from multiple repeated single doses taken from multiple repeated doses taken by the individual patient during their period on the study. To obtain steady state PK parameters, individual estimates were simulated from the population model. (NCT00486603)
Timeframe: up to 276 days

InterventionL/hr (Mean)
Phase 2: RT + TMZ + HCQ11.85

[back to top]

PK of Hydroxychloroquine as Measured by First-order Absorption Rate Constant (Ka)

The population model PK parameters do not specifically represent steady-state values, as they were determined from multiple repeated single doses taken from multiple repeated doses taken by the individual patient during their period on the study. To obtain steady state PK parameters, individual estimates were simulated from the population model. (NCT00486603)
Timeframe: up to 276 days

Interventionhours (Mean)
Phase 2: RT + TMZ + HCQ0.51

[back to top]

(Phase I) Number of Participants Who Experienced Dose Limiting Toxicity (DLT)

Dose limiting toxicity defined as: Any DLT must be a toxicity considered at least possibly related to HCQ. DLTs will include any possibly, probably, or definitely HCQ-related Grade 3 or 4 toxicity. Known or reasonably suspected TMZ hematological toxicities will not be considered dose limiting unless the treating physician considers the toxicity to be exacerbated by HCQ. Nonhematological toxicities: Any Grades 3-4 severity (except nausea and vomiting without sufficient antiemetic prophylaxis) (NCT00486603)
Timeframe: 10 weeks

InterventionParticipants (Count of Participants)
Phase 1: RT+TMZ+HCQ - 200mg0
Phase 1: RT+TMZ+HCQ - 400mg0
Phase 1: RT+TMZ+HCQ - 600mg0
Phase 1: RT+TMZ+HCQ - 800mg3

[back to top]

PK of Hydroxychloroquine as Measured by Distribution Volume of Peripheral Compartment (V2/F)

The population model PK parameters do not specifically represent steady-state values, as they were determined from multiple repeated single doses taken from multiple repeated doses taken by the individual patient during their period on the study. To obtain steady state PK parameters, individual estimates were simulated from the population model. (NCT00486603)
Timeframe: up to 276 days

InterventionLiters (Mean)
Phase 2: RT + TMZ + HCQ963

[back to top]

Pharmacokinetics (PK) of Hydroxychloroquine as Measured by Lag Time (Tlag)

The population model PK parameters do not specifically represent steady-state values, as they were determined from multiple repeated single doses taken from multiple repeated doses taken by the individual patient during their period on the study. To obtain steady state PK parameters, individual estimates were simulated from the population model. (NCT00486603)
Timeframe: up to 276 days

Interventionhour (Mean)
Phase 2: RT + TMZ + HCQ1.06

[back to top]

(Phase II) Overall Survival

Number of months alive after end of study participation (NCT00486603)
Timeframe: 2 years

Interventionmonths (Median)
Phase 2: RT + TMZ + HCQ15.6

[back to top]

Measuring the Safety and Efficacy of a New DMARD, Leflunomide Alone or in Combination With Traditional DMARD's. Participants Reaching ACR 20 Response. at 48 Weeks

"The combination of Methotrexate-Sulfasalazine-Hydroxychloroquine has been shown to be more effective than Methotrexate alone or the double combination of Methotrexate-Hydroxychloroquine. Primary outcome is ACR 20 response at 48 weeks.~An ACR 20 Response is a measure of at least 20% improvement in the number of tender and swollen joints. and a 20% improvement in at least 3 of the following:~the patient's global assessment of disease status; the patient's assessment of pain; the patient's assessment of function; the physician's global assessment of disease status; serum C-reactive protein levels." (NCT00579878)
Timeframe: 48 weeks

InterventionParticipants (Count of Participants)
1 Leflunomide Alone vs Combination Therapy8
Methotrexate-Sulfasalazine-Hydroxychloroquine20
Leflunomide-Sulfasalazine-Hydroxychloroquine12

[back to top]

Prostate-specific Antigen (PSA) Response

PSA response will be defined as a change in slope of at least 25%, when log (PSA) is plotted vs. time (NCT00726596)
Timeframe: 6 years

Interventionpercentage of participants (Number)
Cohort A. Hydroxychloroquine (200mg Bid)48
Cohort B. Hydroxychloroquine (200mg Tid)48

[back to top]

Feasibility and Safety of Administering Hydroxychloroquine in This Population of Patients. Rate of Adverse Events

Rate of adverse events were captured utilizing the CTCAE version3.0. (NCT00726596)
Timeframe: 6 years

InterventionParticipants (Count of Participants)
Cohort A. Hydroxychloroquine (200mg Bid)30
Cohort B. Hydroxychloroquine (200mg Tid)22

[back to top] [back to top]

Percentage of Participants With Response

Percentage of participants with a reduction of the absolute lymphocytic count- ALC (NCT00771056)
Timeframe: 1 yr

Interventionpercentage of participants (Number)
Hydroxychloroquine54.4

[back to top]

Percent of Participants in Which FMISO-PET ([18F]-Fluoromisonidazole-positron Emission Tomography) is Able to Detect and Quantify Changes in Tumor Hypoxia After Erlotinib.

[18F]-FMISO-PET/CT was performed on a 64-slice PET/CT scanner and tracer uptake was assessed using SUV (standardized uptake value), normalizing the radioactivity measured in tissue by the injected dose and the body weight of the patient. Mean and maximum SUV and threshold volume of FMISO uptake were measured to quantify the extent of hypoxia in the primary tumor. Imaging was performed before and after initiation of therapy with erlotinib. (NCT00977470)
Timeframe: 12 weeks

InterventionParticipants (Count of Participants)
Erlotinib2
Erlotinib and Hydroxychloroquine0

[back to top]

Nine-month Progression-free Survival Rate

This trial can detect a difference in proportions alive without progression at 9 months from 50% in the erlotinib arm to 77% in the erlotinib plus hydroxychloroquine (HCQ) arm, using an alpha of 0.15 and power of 85%, using the two-sided Likelihood Ratio test. Progression is defined as at least a 20% increase in the size of existing lesions or the appearance of one or more new lesions. (NCT00977470)
Timeframe: Nine months

Interventionpercentage of participants (Number)
Erlotinib71
Erlotinib and Hydroxychloroquine52

[back to top]

Median Progression Free Survival

A measure of progression-free survival in patients with advanced non small-cell lung cancer (NSCLC) and EGFR mutations treated with erlotinib as compared with patients treated with erlotinib plus hydroxychloroquine (HCQ). Disease progression is defined as at least a 20% increase in the sum of the longest diameter of target lesions, as seen on CT scan, or the appearance of one or more new lesions on CT scan. (NCT00977470)
Timeframe: From start of treatment until report of disease progression, assessed up to 10 years.

Interventionmonths (Median)
Erlotinib10.8
Erlotinib and Hydroxychloroquine10.8

[back to top] [back to top]

Objective Tumor Response Rate Following Treatment With Erlotinib and With Erlotinib/HCQ.

"Response is assessed via spiral CT scan, done at baseline and after every 2 cycles of study treatment. Standard RECIST (Response Evaluation Criteria in Solid Tumors) was used. Complete Response (CR) = disappearance of all target lesions; Partial Response (PR) = at least a 30% decrease in the size of target lesions, as compared to baseline; Progressive Disease (PD) = at least at 20% increase in the size of target lesions, or the appearance of one or more new lesions; Stable Disease (SD) = neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease.~Response rate = CR + PR. Disease control rate = CR + PR + SD" (NCT00977470)
Timeframe: 2 years

,
InterventionParticipants (Count of Participants)
Complete ResponsePartial ResponseStable DiseaseProgressive DiseaseResponse RateDisease Control Rate
Erlotinib1231032434
Erlotinib and Hydroxychloroquine2191062131

[back to top]

Progression-free Survival

Computed Kaplan-Meier survival curve estimates for progression free survival (PFS) and compared to historical controls of median PFS of 240 days. Evaluated response using RECIST criteria every 12 weeks. (NCT01006369)
Timeframe: 6 years

Interventiondays (Median)
FOLFOX6 + Bevacizumab + Hydroxychloroquine424

[back to top]

Overall Response Rate

Response rate was evaluated every 12 weeks using RECIST criteria. CR+PR+Stable= overall response (NCT01006369)
Timeframe: 6 years

Interventionpercentage of participants responding (Number)
FOLFOX6 + Bevacizumab + Hydroxychloroquine75

[back to top]

Overall Survival

Computed using Kaplan-Meier survival curve estimates which were compared to historical controls (median overall survival) was 21.3 months (596). (NCT01006369)
Timeframe: 6 years

Interventiondays (Median)
FOLFOX6 + Bevacizumab + Hydroxychloroquine788

[back to top]

Determine the Pharmacokinetic (PK) Parameters of Hydroxychloroquine (HCQ) Plus Erlotinib.

PK parameter tested was dose normalized minimum steady state concentration (Cmin SS) of HCQ in micromolar per gram. Note this outcome was only analyzed for the first 21 patients enrolled, 13 on erlotinib/HCQ and 8 on HCQ arm. (NCT01026844)
Timeframe: 2 years

Interventionmicromolar per gram (Mean)
Erlotinib Plus HCQ (Hydroxychloroquine)5.93
HCQ (Hydroxychloroquine)9.40

[back to top]

Describe the Number and Type of Observed Dose Limiting Toxcities

HCQ doses tested included 400mg, 600mg, 800mg, and 1000mg. Dose-limiting toxicities (DLTs) were defined as CTC of grade 2 or higher retinopathy or keratitis, or CTC of grade 3 or higher hematologic, skin, CNS, neuropathic, cardiac, respiratory, gastrointestinal, or renal AEs in the first cycle considered at least possibly related to HCQ. If a DLT was observed, an additional three patients were enrolled at that dose level. The maximum tolerated dose for HCQ in each arm would be defined as one dose level below that at which two or more of 6 patients experienced a DLT, or if no DLTs were observed, the highest tested dose. (NCT01026844)
Timeframe: 2 years

Interventionparticipants (Number)
Erlotinib Plus HCQ (Hydroxychloroquine)0
HCQ (Hydroxychloroquine)0

[back to top]

Objective Tumor Response Rate

Number of Response Evaluation Criteria in Solid Tumors (RECIST) responses divided by number of patients treated. Per RECIST version 1.0 complete response (CR) is defined as disappearance of all target lesions; Partial Response (PR) is defined as >=30% decrease in the sum of the longest diameter of target lesions. The objective tumor response rate is the CR + PR divided by the total number of patients (NCT01026844)
Timeframe: 2 years

Interventionpercentage of patients (Number)
Erlotinib Plus HCQ (Hydroxychloroquine)5
HCQ (Hydroxychloroquine)0

[back to top]

Overall Survival (OS) by Response to HCQ Treatment

Median number of months of overall survival in participants who did and did not experience response to HCQ treatment. Patients who had >51 % increase in their LC3-II staining were classified as having a response to HCQ. (NCT01128296)
Timeframe: Up to 35 months

Interventionmonths (Median)
Response to HQC treatmentNo response to HQC treatment
Preoperative Gemcitabine (1500 mg/m^2) + HCQ (≤1200 mg/Day)34.8310.83

[back to top]

Disease-free Survival (DFS) by Response to HCQ Treatment

Median number of months of disease-free survival in participants who did and did not experience response to HCQ treatment. Patients who had >51 % increase in their LC3-II staining were classified as having a response to HCQ. (NCT01128296)
Timeframe: Up to 30 months

Interventionmonths (Median)
Response to HQC treatmentNo response to HQC treatment
Preoperative Gemcitabine (1500 mg/m^2) + HCQ (≤1200 mg/Day)15.036.9

[back to top]

Overall Survival (OS) by CA 19-9 Response

Median number of months of overall survival for participants who experienced Ca 19-9 (surrogate biomarker) response (either an increase or decrease in Ca 19-9), or, no Ca 19-9 response. Per participant increases in Ca 19-9 ranged from >0 to 225%. Per participant decreases in Ca 19-9 ranged from >0 to 100%. (NCT01128296)
Timeframe: Up to 35 months

Interventionmonths (Median)
Ca 19-9 Response (increase or decrease)No Ca 19-9 Response
Preoperative Gemcitabine (1500 mg/m^2) + HCQ (≤1200 mg/Day)34.88.8

[back to top]

Overall Survival (OS) by p53 Mutant Status

(NCT01128296)
Timeframe: Up to 35 months

Interventionmonths (Median)
p53 WTp53 Mutant
Preoperative Gemcitabine (1500 mg/m^2) + HCQ (≤1200 mg/Day)NA26.1

[back to top]

Disease-free Survival by p53 Genetic Status

(NCT01128296)
Timeframe: Up to 35 months

Interventionmonths (Median)
p53 WTp53 Mutant
Preoperative Gemcitabine (1500 mg/m^2) + HCQ (≤1200 mg/Day)21.411.8

[back to top]

Disease-free Survival (DFS) by CA 19-9 Response

Median number of months of disease-free survival for participants who experienced Ca 19-9 (surrogate biomarker) response (either an increase or decrease in Ca 19-9), or no Ca 19-9 response. Per participant increases in Ca 19-9 ranged from >0 to 225%. Per participant decreases in Ca 19-9 ranged from >0 to 100%. (NCT01128296)
Timeframe: Up to 30 months

Interventionmonths (Median)
Ca 19-9 ResponseNo Ca 19-9 Response
Preoperative Gemcitabine (1500 mg/m^2) + HCQ (≤1200 mg/Day)21.46.9

[back to top]

R0 Resection Rate

Number of participants that underwent a resection with microscopically margin-negative resection in which no gross or microscopic tumor remains in the primary tumor bed (24) / number of that completed treatment (31) (NCT01128296)
Timeframe: Up to 30 months

Interventionpercentage of participants (Number)
Preoperative Gemcitabine (1500 mg/m^2) + HCQ (≤1200 mg/Day)77

[back to top]

Overall Survival (OS)

Median number of months of overall survival for participants receiving study treatment. (NCT01128296)
Timeframe: Up to 35 months

Interventionmonths (Median)
Preoperative Gemcitabine (1500 mg/m^2) + HCQ (≤1200 mg/Day)34.83

[back to top]

Number of Participants That Experienced a Dose Limiting Toxicity (DLT)

Number of Participants at each dose level of HCQ that experienced a Dose Limiting Toxicity (DLT). (NCT01128296)
Timeframe: Up to 31 days

Interventionparticipants (Number)
Preoperative Gemcitabine (1500 mg/m^2) + HCQ (200 mg/Day)0
Preoperative Gemcitabine (1500 mg/m^2) + HCQ (400 mg/Day)0
Preoperative Gemcitabine (1500 mg/m^2) + HCQ (600 mg/Day)0
Preoperative Gemcitabine (1500 mg/m^2) + HCQ (800 mg/Day)0
Preoperative Gemcitabine (1500 mg/m^2) + HCQ (1000 mg/Day)0
Preoperative Gemcitabine (1500 mg/m^2) + HCQ (1200 mg/Day)0

[back to top]

Disease-free Survival (DFS)

Median number of months of disease-free survival for participants receiving study treatment. (NCT01128296)
Timeframe: Up to 30 months

Interventionmonths (Median)
Preoperative Gemcitabine (1500 mg/m^2) + HCQ (1200 mg/Day)11.97

[back to top]

HOMA-IR

"We will examine the effect of HCQ on HOMA-IR during the active treatment phase compared with placebo phase.~HOMA-IR = (Glucose x insulin)/405" (NCT01132118)
Timeframe: Baseline and Week 8

,
Intervention(mg x mIU)/(dL*L) (Mean)
BaselinePeriodChange
Hydroxychloroquine2.01.7-0.3
Placebo2.01.6-0.42

[back to top]

Total Cholesterol

mg/dL (NCT01132118)
Timeframe: Baseline and Week 8

,
Interventionmg/dL (Mean)
BaselinePeriodChange
Hydroxychloroquine192.4179.7-12.7
Placebo192.4189.4-3.0

[back to top]

LDL Cholesterol

mg/dL (NCT01132118)
Timeframe: Baseline and Week 8

,
Interventionmg/dL (Mean)
BaselinePeriodChange
Hydroxychloroquine114.1101.7-12.4
Placebo114.1109.9-4.2

[back to top]

Insulin Sensitivity Index

"We will examine the effect of HCQ on the Matsuda Insulin Sensitivity Index (ISI) during the active treatment phase compared with placebo phase.~ISI is based on insulin and glucose levels in a fasting state during an oral glucose tolerance test (OGTT) and is calculated as follows:~ISI (Matsuda) = 10000/√ G0 X I0 X Gmean X Imean~G0 - fasting plasma glucose (mg/dL) I0 - fasting plasma insulin (mIU/L) Gmean - mean plasma glucose during OGTT (mg/dL) Imean - mean plasma insulin during OGTT (mIU/L)" (NCT01132118)
Timeframe: Baseline and Week 8

,
Intervention(dL x L)/(mg x mIU) (Mean)
BaselinePeriod ValueChange
Hydroxychloroquine7.78.10.4
Placebo7.77.80.14

[back to top]

HOMA-B

HOMA-B = (360 x Insulin)/(Glucose - 63) (NCT01132118)
Timeframe: Baseline and Week 8

,
Intervention(mIU x dL)/(L x mg) (Mean)
BaselinePeriodChange
Hydroxychloroquine116.5110.8-5.8
Placebo116.5109.7-6.8

[back to top]

HDL Cholesterol

mg/dL (NCT01132118)
Timeframe: Baseline and Week 8

,
Interventionmg/dL (Mean)
BaselinePeriodChange
Hydroxychloroquine58.159.41.3
Placebo58.160.32.2

[back to top]

Triglycerides

mg/dL (NCT01132118)
Timeframe: Baseline and Week 8

,
Interventionmg/dL (Mean)
BaselinePeriodChange
Hydroxychloroquine100.692.4-8.2
Placebo100.695.6-5.0

[back to top]

2-month Progression-Free Survival Rate

2-month progression-free survival rate was defined as the percentage of patients absent progression (PD) or death before 2 months. Patients were considered to have experienced PD if they demonstrated either clinical deterioration resulting in withdrawal or PD per RECIST 1.0 criteria: At least a 20% increase in the sum of longest diameter (LD) of target lesions taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions. PD for the evaluation of non-target lesions is the appearance of one or more new lesions and/or unequivocal progression of non-target lesions. (NCT01273805)
Timeframe: Disease was evaluated radiologically at baseline and at the first restaging at 2 months.

Interventionpercentage of patients (Number)
Hydroxychloroquine 400 mg b.i.d.10
Hydroxychloroquine 600 mg b.i.d.10

[back to top]

Tumor Response Rate

Tumor response rate is the percentage of patients achieving complete or partial response on treatment based on RECIST 1.0 criteria. For target lesions, complete response (CR) is disappearance of all target lesions and partial response (PR) is at least a 30% decrease in the sum of longest diameter (LD) of target lesions, taking as reference baseline sum LD. CR for the evaluation of non-target lesions is the disappearance of non-target lesions and normalization of tumor marker level. Appearance of one or more new lesions is classified as progression of non-target lesions. CR or PR confirmation is required >/= 4 weeks. (NCT01273805)
Timeframe: Disease was evaluated radiologically at baseline and every 2 months on treatment. Median duration of treatment for this study cohort was 34 days.

Interventionpercentage of patients (Number)
Hydroxychloroquine 400 mg b.i.d.0
Hydroxychloroquine 600 mg b.i.d.0

[back to top]

Progression-Free Survival

Progression-free survival based on the Kaplan-Meier method is defined as the duration of time from study entry to time of objective progression on CT scan or the time of death for patients with clinical deterioration resulting in withdrawal from the trial. Per RECIST 1.0 criteria: progressive disease (PD) is at least a 20% increase in the sum of longest diameter (LD) of target lesions taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions. PD for the evaluation of non-target lesions is the appearance of one or more new lesions and/or unequivocal progression of non-target lesions. Patients without an event were censored at date of last disease evaluation. (NCT01273805)
Timeframe: Disease was evaluated radiologically at baseline and every 2 months on treatment. Median PFS follow-up in this study cohort was 46.5 days (95% CI 33-61).

Interventiondays (Median)
Hydroxychloroquine 400 mg b.i.d.51.5
Hydroxychloroquine 600 mg b.i.d.44.5

[back to top]

Overall Survival

Overall survival estimated using Kaplan-Meier (KM) methods is defined as the time from study entry to death or date last known alive. (NCT01273805)
Timeframe: All patients were followed until death. Median survival follow-up in this study cohort was 60 days (95% CI: 40-184).

Interventiondays (Median)
Hydroxychloroquine 400 mg b.i.d.51.5
Hydroxychloroquine 600 mg b.i.d.83

[back to top] [back to top]

Insulin Sensitivity

Change from baseline in the insulin sensitivity index (Si) (NCT01326533)
Timeframe: 13 weeks after baseline measurement

Intervention10^-4/pmol*l/min (Mean)
Hydroxychloroquine0.08
Placebo-0.11

[back to top]

Beta Cell Function

Change from baseline in the disposition index (DI) (NCT01326533)
Timeframe: 13 weeks after baseline measurement

Interventionarbitrary units (Mean)
Hydroxychloroquine352
Placebo-218

[back to top] [back to top]

Recurrence of Advanced Heart Block

Echocardiogram reveals 2nd or 3rd degree AV block (NCT01379573)
Timeframe: After enrollment at 16-18 weeks gestation, then weekly until 26 weeks, biweekly to 34 weeks, at birth (approximately 9 months), and at one year follow up (approximately 21 months from enrollment)

InterventionParticipants (Count of Participants)
Pregnant Women With Previous Child With Cardiac Neonatal Lupus5

[back to top]

Prolonged PR Interval (>150msec)

EKG at birth must confirm 1st degree AV block. It is also possible that a fetus developing 1st degree block on study medication might have developed more advanced block in the absence of study medication. (NCT01379573)
Timeframe: After enrollment at 16-18 weeks gestation, then weekly until 26 weeks, biweekly to 34 weeks, at birth (approximately 9 months), and at one year follow up (approximately 21 months from enrollment)

InterventionParticipants (Count of Participants)
Pregnant Women With Previous Child With Cardiac Neonatal Lupus0

[back to top]

Prematurity

(gestational age <37 weeks at birth) (NCT01379573)
Timeframe: At birth (approximately 9 months)

InterventionParticipants (Count of Participants)
Pregnant Women With Previous Child With Cardiac Neonatal Lupus9

[back to top]

Echocardiographic Densities Consistent With EFE Confirmed Postnatally

(see title) (NCT01379573)
Timeframe: After enrollment at 16-18 weeks gestation, then weekly until 26 weeks, biweekly to 34 weeks, at birth (approximately 9 months), and at one year follow up (approximately 21 months from enrollment)

InterventionParticipants (Count of Participants)
Pregnant Women With Previous Child With Cardiac Neonatal Lupus0

[back to top]

Cutaneous Neonatal Lupus

(NCT01379573)
Timeframe: Up to 15 months (at birth - 9 months, and 6 months thereafter)

InterventionParticipants (Count of Participants)
Pregnant Women With Previous Child With Cardiac Neonatal Lupus4

[back to top]

Birth Weight <10% in the Context of Gestational Age

(NCT01379573)
Timeframe: At birth (approximately 9 months)

InterventionParticipants (Count of Participants)
Pregnant Women With Previous Child With Cardiac Neonatal Lupus1

[back to top]

Any Sign of Myocardial Injury, Without Change in Cardiac Rate or Rhythm

a) shortening fraction <28% = 2 SD below normal mean or qualitatively reduced systolic function; b) cardio-thoracic ratio >0.33; c) hydropic changes; d) moderate/severe tricuspid regurgitation. (NCT01379573)
Timeframe: After enrollment at 16-18 weeks gestation, then weekly until 26 weeks, biweekly to 34 weeks, at birth (approximately 9 months), and at one year follow up (approximately 21 months from enrollment)

InterventionParticipants (Count of Participants)
Pregnant Women With Previous Child With Cardiac Neonatal Lupus0

[back to top]

Abnormal Fluid Collection

(NCT01379573)
Timeframe: At birth (approximately 9 months)

InterventionParticipants (Count of Participants)
Pregnant Women With Previous Child With Cardiac Neonatal Lupus0

[back to top]

Change From Baseline in Inflammatory Marker, Hs-C Reactive Protein, at 6 Months

Hs-CRP will be measured at baseline (before study drug) and at end of study (6 months). This marker is measured by ELISA assay from serum. (NCT01537315)
Timeframe: Baseline and 6 months

Interventionng/ml (Mean)
Matching Placebo18653.6
Hydroxychloroquine14825.8

[back to top] [back to top]

Serum Lactate Dehydrogenase

Number of participants with either high serum lactate dehydrogenase (> 1.5 times upper limit of normal) or normal lactate dehydrogenase. (NCT01550367)
Timeframe: Up to 2 years

InterventionParticipants (Count of Participants)
Normal LDH72075282High LDH72075282
1200 mg/d HCQ600 mg/d HCQ
Hydroxychloroquine (HCQ) (1,200 mg/d or 600 mg/d) + IL-211
Hydroxychloroquine (HCQ) (1,200 mg/d or 600 mg/d) + IL-217
Hydroxychloroquine (HCQ) (1,200 mg/d or 600 mg/d) + IL-22
Hydroxychloroquine (HCQ) (1,200 mg/d or 600 mg/d) + IL-20

[back to top]

Serum Calcium Levels (Corrected)

Number of patients with either normal or high serum calcium levels. High serum calcium levels are considered to be clinically unfavorable. (NCT01550367)
Timeframe: Up to 3 years

InterventionParticipants (Count of Participants)
Normal Calcium72075283High Calcium72075283
1200 mg/d HCQ600 mg/d HCQ
Hydroxychloroquine (HCQ) (1,200 mg/d or 600 mg/d) + IL-213
Hydroxychloroquine (HCQ) (1,200 mg/d or 600 mg/d) + IL-214
Hydroxychloroquine (HCQ) (1,200 mg/d or 600 mg/d) + IL-20
Hydroxychloroquine (HCQ) (1,200 mg/d or 600 mg/d) + IL-23

[back to top]

Hemoglobin Levels

Low hemoglobin levels (less than the lower limit of normal (13.2 g/dL)) are considered to be unfavorable. (NCT01550367)
Timeframe: Up to 3 years

InterventionParticipants (Count of Participants)
Low hemoglobin level72075283Normal hemoglobin level72075283
1200 mg/d HCQ600 mg/d HCQ
Hydroxychloroquine (HCQ) (1,200 mg/d or 600 mg/d) + IL-26
Hydroxychloroquine (HCQ) (1,200 mg/d or 600 mg/d) + IL-23
Hydroxychloroquine (HCQ) (1,200 mg/d or 600 mg/d) + IL-27
Hydroxychloroquine (HCQ) (1,200 mg/d or 600 mg/d) + IL-214

[back to top]

Number of Participants With Low Karnofsky Performance Status

Karnofsky performance status is a standard way of measuring the ability of cancer patients to perform ordinary tasks. The Karnofsky Performance Status scores range from 0 to 100. A higher score means the patient is better able to carry out daily activities. Karnofsky Performance Status may be used to determine a patient's prognosis, to measure changes in a patient's ability to function, or to decide if a patient should be included in the trial. A low Karnofsky performance status (<80%) is considered to be unfavorable. (NCT01550367)
Timeframe: Up to 3 years

InterventionParticipants (Count of Participants)
1200 mg/d HCQ600 mg/d HCQ
Hydroxychloroquine (HCQ) (1,200 mg/d or 600 mg/d) + IL-200

[back to top]

Conventional Dendritic Cells (cDC)

Percentage of Conventional Dendritic Cells (cDC) per ml of blood. cDC reside in tissues and once activated, migrate to draining lymph nodes to promote adaptive immune responses. (NCT01550367)
Timeframe: Up to 3 years

Interventionpercentage of cells/mL (Mean)
Hydroxychloroquine (HCQ) (1,200 mg/d or 600 mg/d) + IL-20.6

[back to top]

Myeloid Derived Suppressor Cell (MDSC)

Percentage of Myeloid Derived Suppressor Cell per ml of blood. MDSC immune cells originate from bone marrow stem cells and strongly expand in cancer. (NCT01550367)
Timeframe: Up to 3 years

Interventionpercentage of cells/mL (Mean)
Hydroxychloroquine (HCQ) (1,200 mg/d or 600 mg/d) + IL-211.3

[back to top]

Number of Doses of IL-2 + HCQ

Number of doses of IL-2 administered during the first course of therapy. (NCT01550367)
Timeframe: Up to 3 years

Interventiondoses (Mean)
1200 mg/d HCQ600 mg/d HCQ
Hydroxychloroquine (HCQ) (1,200 mg/d or 600 mg/d) + IL-212.813.2

[back to top]

Frequency of Grade III and Grade IV Toxicities

Number of specified categories of grade III and IV or unexpected or rare toxicities occurring during the first course (up until the end of cycle 1) of IL-2 treatment. (NCT01550367)
Timeframe: Up to 3 years

Interventionevents (Number)
HypotensionGastrointestinalHematologicPulmonaryRenal/electrolytesPsychiatric
Hydroxychloroquine (HCQ) (1,200 mg/d or 600 mg/d) + IL-2511143

[back to top]

T-cell Lymphocytes

Percentage of T-cell lymphocytes in blood as cells per ml. T-cells are a subtype of white blood cells which play a key role in the immune system and fighting cancer. (NCT01550367)
Timeframe: Up to 3 years

Interventionpercentage of cells/mL (Mean)
Hydroxychloroquine (HCQ) (1,200 mg/d or 600 mg/d) + IL-263.9

[back to top]

Regulatory T Cells (Treg)

Percentage of Regulatory T cells per ml of blood. High levels of Tregs in the tumor microenvironment are associated with poor prognosis in many cancers by suppressing the body's anti-tumor immune response. (NCT01550367)
Timeframe: Up to 3 years

Interventionpercentage of cells/mL (Mean)
Hydroxychloroquine (HCQ) (1,200 mg/d or 600 mg/d) + IL-210.5

[back to top]

Prior Nephrectomy

Number of patients with history of a prior nephrectomy (surgical removal of a kidney) or no history of a prior nephrectomy. (NCT01550367)
Timeframe: Up to 3 years

InterventionParticipants (Count of Participants)
No Prior Nephrectomy72075283Prior Nephrectomy72075283
1200 mg/d HCQ600 mg/d HCQ
Hydroxychloroquine (HCQ) (1,200 mg/d or 600 mg/d) + IL-23
Hydroxychloroquine (HCQ) (1,200 mg/d or 600 mg/d) + IL-20
Hydroxychloroquine (HCQ) (1,200 mg/d or 600 mg/d) + IL-214
Hydroxychloroquine (HCQ) (1,200 mg/d or 600 mg/d) + IL-213

[back to top]

Plasmacytoid Dendritic Cells (pDC)

Percentage of Plasmacytoid dendritic cells per ml of blood. In cancer, pDC are malignant immune cells that demonstrate an impaired response that can contribute to the establishment of an immunosuppressive tumor microenvironment. (NCT01550367)
Timeframe: Up to 3 years

Interventionpercentage of cells/mL (Mean)
Hydroxychloroquine (HCQ) (1,200 mg/d or 600 mg/d) + IL-20.3

[back to top]

Natural Killer (NK) Cells

Percentage of Natural Killer (NK) cells per ml of blood. NK cells are lymphocytes with the ability to kill tumor cells without deliberate immunization or activation. (NCT01550367)
Timeframe: Up to 3 years

Interventionpercentage of cells (Mean)
Hydroxychloroquine (HCQ) (1,200 mg/d or 600 mg/d) + IL-238.4

[back to top]

Overall Survival (OS)

Time from date of first protocol treatment until the date of death, or censored at date of last contact. (NCT01550367)
Timeframe: Up to 3 years

Interventionmonths (Median)
Hydroxychloroquine (HCQ) (1,200 mg/d or 600 mg/d) + IL-2NA

[back to top]

Worst Grade of Adverse Event Experienced

Number of participants who experienced Grade 2-5 adverse events. (NCT01550367)
Timeframe: Up to 3 years

InterventionParticipants (Count of Participants)
1200 mg/d HCQ72075282600 mg/d HCQ72075282
Grade 2 adverse eventGrade 4 adverse eventGrade 5 adverse eventGrade 3 adverse event
Hydroxychloroquine (HCQ) (1,200 mg/d or 600 mg/d) + IL-21
Hydroxychloroquine (HCQ) (1,200 mg/d or 600 mg/d) + IL-27
Hydroxychloroquine (HCQ) (1,200 mg/d or 600 mg/d) + IL-20
Hydroxychloroquine (HCQ) (1,200 mg/d or 600 mg/d) + IL-24
Hydroxychloroquine (HCQ) (1,200 mg/d or 600 mg/d) + IL-213

[back to top] [back to top]

Progression-free Survival (PFS)

Time from the date of first protocol treatment until the date disease progression criteria are met (in responding patients progression criteria uses the reference of the smallest measurements recorded since the treatment started) or is censored at date of last disease assessment for those who have not progressed. Per RECIST 1.1, Progressive Disease (PD) is defined as ≥20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). The sum must also demonstrate an absolute increase of ≥5 mm. The appearance ≥1 new lesion(s) is considered progression. (NCT01550367)
Timeframe: Up to 3 years

Interventionmonths (Median)
Hydroxychloroquine (HCQ) (1,200 mg/d or 600 mg/d) + IL-25.5

[back to top]

Number of Days With Normal Urinary Porphyrin Levels

Number of days to normal urinary porphyrin levels for participants treated for Porphyria Cutanea Tarda (PCT). Days are summed together for all participants for a single value in each Arm. (NCT01573754)
Timeframe: To end of study, an average of 3 years

Interventiondays (Number)
Hydroxychloroquine175
Phlebotomy265

[back to top]

50% Reduction in Plasma Porphyrin Level

50% reduction in plasma porphyrin level during treatment (NCT01573754)
Timeframe: To end of study, an average of 3 years

Interventiondays (Median)
Hydroxychloroquine44
Phlebotomy65

[back to top]

75% Reduction in Plasma Porphyrin Level

Time to 75% reduction in plasma porphyrin level during treatment (NCT01573754)
Timeframe: To end of study, an average of 3 years

Interventiondays (Median)
Hydroxychloroquine73
Phlebotomy44

[back to top]

Remission

Time to a decrease in plasma porphyrin concentration to less than 0.9 mcg/dL (NCT01573754)
Timeframe: To end of study, an average of 3 years

Interventionmonths (Median)
Hydroxychloroquine6.1
Phlebotomy6.9

[back to top]

Change in Synovitis

"MRI readings performed independently by two musculoskeletal radiologists, using a semi-quantitative scoring system based on MRI assessment of knee OASynovitis scored using axial & sagittal CE-MRI sequence, while effusion & bone marrow lesions were scored using non-CE-MRI sequences of parent study.~Synovitis defined as enhancing thickened synovium (>2 mm) & was evaluated at nine sites of joint-medial & lateral parapatellar recess, suprapateller, infrapatellar, intercondylar, medial & lateral perimeniscal, & adjacent to anterior & posterior cruciate ligaments (ACL/PCL) in all subjects. Synovial thickness was scored semi-quantitatively based on maximal thickness in any slice at each site as follows: grade 0 if <2mm, grade 1 if 2-4 mm & grade 2 if >4mm. For assessment of whole knee synovitis scores of all sites were summed and categorized: 0-4 normal or equivocal synovitis; 5-8 mild synovitis; 9-12 moderate synovitis & >/= 13 severe synovitis." (NCT01645176)
Timeframe: baseline and 16 weeks

Interventionunits on a scale (Mean)
Osteoarthritis of Knee9.8

[back to top]

Progression Free Survival (PFS)

Kaplan-Meier estimates of survival were calculated. The median survival times and 95% confidence intervals are presented. (NCT01649947)
Timeframe: 6 years

Interventionmonths (Median)
Cohort 2: Bevacizumab Ineligible Patients4.2
Cohort 1: Bevacizumab Eligible Patients2.9

[back to top]

Antitumor Activity, as Measured by Tumor Response Rate of Hydroxychloroquine, Paclitaxel, Carboplatin, and Bevacizumab (for Eligible Patients) in Patients With Advanced or Recurrent NSCLC Cancer

Assessed using RECIST criteria. Determined using a Simon's two-stage minimax design with a 5% significance level and 80% power. (NCT01649947)
Timeframe: 6 years

Interventionpercentage of participants (Number)
Cohort 2: Bevacizumab Ineligible Patients55
Cohort 1: Bevacizumab Eligible Patients27

[back to top]

Safety of Combination Therapy With Sirolimus and Hydroxychloroquine in LAM Patients

"The Primary endpoint of this study was safety. Safety was assessed based on the adverse events and serious adverse events that occurred in these patients when they were on this combination therapy. Percentage of adverse events in each system at a dose was calculated from the total adverse events at that dose. Subjects were closely monitored and adverse events were classified and graded according to the Common Terminology Criteria for Adverse Events, (CTCAE) Version 4.0." (NCT01687179)
Timeframe: 48 weeks

,
InterventionPercentage of adverse events (Number)
Cardiac DisordersEye DisordersGI DisordersGeneral Disorders, Administration site condistionsImmune System disordersInfections and infestationsInjury, poisoning, procedural complicationsInvestigationsMetabolism and nutrition disordersMusculoskeletal, connective tissue disordersNervous system disordersPsychiatric disordersRenal and urinary disordersReproductive system and breast disorderRespiratory, thoracic, mediastinal disordersSkin and Subcutaneous disordersVascular disorders
Sirolimus and Hydroxychloroquine 200 mg2.27018.1818.18015.9106.82004.55006.822.2725.00
Sirolimus and Hydroxychloroquine 400 mg1.111.1122.226.670.568.330.56203.334.445.000.567.781.119.446.111.67

[back to top]

Change From Baseline in WPS-RA at Week 12: RA Interference With Household Work Productivity

The WPS-RA is a validated questionnaire that evaluates productivity limitations within work and within home associated with RA over the previous month. The questionnaire was interviewer-administered and was based on participant self-report. It contains 9 questions addressing employment status (1 item), productivity at work (3 items), and within and outside the home (5 items). The RA interference in the last month with household work productivity was measured on a scale that ranges from 0 (no interference) to 10 (complete interference). LS mean and SE at Week 12 were obtained from a MMRM with treatment, region, number of previous anti-TNFs, visit, and treatment-by-visit interaction as fixed effects and baseline WPS-RA as a covariate. (NCT01709578)
Timeframe: Baseline, Week 12

Interventionunits on a scale (Least Squares Mean)
Placebo q2w-1.210
Sarilumab 150 mg q2w-2.772
Sarilumab 200 mg q2w-2.404

[back to top]

Change From Baseline in WPS-RA at Week 12: House Work Days Missed Due to RA

The WPS-RA is a validated questionnaire that evaluates productivity limitations within work and within home associated with RA over the previous month. The questionnaire was interviewer-administered and was based on participant self-report. It contains 9 questions addressing employment status (1 item), productivity at work (3 items), and within and outside the home (5 items). Number of days with no household work in the last month by the participant was reported. LS mean and SE at Week 12 were obtained from a MMRM with treatment, region, number of previous anti-TNFs, visit, and treatment-by-visit interaction as fixed effects and baseline WPS-RA as a covariate. (NCT01709578)
Timeframe: Baseline, Week 12

InterventionDays (Least Squares Mean)
Placebo q2w-2.10
Sarilumab 150 mg q2w-5.52
Sarilumab 200 mg q2w-5.54

[back to top]

Change From Baseline in WPS-RA at Week 12: Days With Work Productivity Reduced by ≥ 50% Due to RA

The WPS-RA is a validated questionnaire that evaluates productivity limitations within work and within home associated with RA over the previous month. The questionnaire was interviewer-administered and was based on participant self-report. It contains 9 questions addressing employment status (1 item), productivity at work (3 items), and within and outside the home (5 items). Number of work days with reduced productivity by ≥ 50% in the last month by the participant was reported. LS mean and SE at Week 12 were obtained from a MMRM with treatment, region, number of previous anti-TNFs, visit, and treatment-by-visit interaction as fixed effects and baseline WPS-RA as a covariate. (NCT01709578)
Timeframe: Baseline, Week 12

InterventionDays (Least Squares Mean)
Placebo q2w-1.69
Sarilumab 150 mg q2w-4.24
Sarilumab 200 mg q2w-3.20

[back to top]

Change From Baseline in WPS-RA at Week 12: Days With Outside Help Hired Due to RA

The WPS-RA is a validated questionnaire that evaluates productivity limitations within work and within home associated with RA over the previous month. The questionnaire was interviewer-administered and was based on participant self-report. It contains 9 questions addressing employment status (1 item), productivity at work (3 items), and within and outside the home (5 items). Number of days with outside help hired in the last month by the participant was reported. LS mean and SE at Week 12 were obtained from a MMRM with treatment, region, number of previous anti-TNFs, visit, and treatment-by-visit interaction as fixed effects and baseline WPS-RA as a covariate. (NCT01709578)
Timeframe: Baseline, Week 12

InterventionDays (Least Squares Mean)
Placebo q2w-0.77
Sarilumab 150 mg q2w-3.07
Sarilumab 200 mg q2w-2.94

[back to top]

Change From Baseline in WPS-RA at Week 12: Days With Household Work Productivity Reduced by ≥ 50% Due to RA

The WPS-RA is a validated questionnaire that evaluates productivity limitations within work and within home associated with RA over the previous month. The questionnaire was interviewer-administered and was based on participant self-report. It contains 9 questions addressing employment status (1 item), productivity at work (3 items), and within and outside the home (5 items). Number of days with reduced household work productivity by ≥ 50% in the last month by the participant was reported. LS mean and SE at Week 12 were obtained from a MMRM with treatment, region, number of previous anti-TNFs, visit, and treatment-by-visit interaction as fixed effects and baseline WPS-RA as a covariate. (NCT01709578)
Timeframe: Baseline, Week 12

InterventionDays (Least Squares Mean)
Placebo q2w-2.60
Sarilumab 150 mg q2w-3.97
Sarilumab 200 mg q2w-3.98

[back to top]

Change From Baseline in WPS-RA at Week 12: Days With Family/Social/Leisure Activities Missed Due to RA

The WPS-RA is a validated questionnaire that evaluates productivity limitations within work and within home associated with RA over the previous month. The questionnaire was interviewer-administered and was based on participant self-report. It contains 9 questions addressing employment status (1 item), productivity at work (3 items), and within and outside the home (5 items). Number of days missed of family/social/leisure activities in the last month by the participant was reported. LS mean and SE at Week 12 were obtained from a MMRM with treatment, region, number of previous anti-TNFs, visit, and treatment-by-visit interaction as fixed effects and baseline WPS-RA as a covariate. (NCT01709578)
Timeframe: Baseline, Week 12

InterventionDays (Least Squares Mean)
Placebo q2w-2.23
Sarilumab 150 mg q2w-2.53
Sarilumab 200 mg q2w-3.26

[back to top]

Change From Baseline in Work Productivity Survey - Rheumatoid Arthritis (WPS-RA) at Week 24: Work Days Missed Due to RA

The WPS-RA is a validated questionnaire that evaluates productivity limitations within work and within home associated with RA over the previous month. The questionnaire was interviewer-administered and was based on participant self-report. It contains 9 questions addressing employment status (1 item), productivity at work (3 items), and within and outside the home (5 items). Number of work days missed in the last month by the participant was reported. LS mean and SE at Week 24 were obtained from a MMRM with treatment, region, number of previous anti-TNFs, visit, and treatment-by-visit interaction as fixed effects and baseline WPS-RA as a covariate. (NCT01709578)
Timeframe: Baseline, Week 24

InterventionDays (Least Squares Mean)
Placebo q2w-2.01
Sarilumab 150 mg q2w-2.87
Sarilumab 200 mg q2w-3.19

[back to top]

Change From Baseline in the Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 12

Physical function was assessed by HAQ-DI. It consisted of at least 2 questions per category, participant reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week rated on a 4-point scale where 0 = no difficulty; 1 = some difficulty; 2 = much difficulty; 3 = unable to do. Overall score was computed as the sum of category scores and divided by the number of categories answered, ranging from 0 to 3, where 0 = no disability and 3 = unable to do, high-dependency disability. Least-squares (LS) means and standard errors (SE) at Week 12 were obtained from a mixed-effect model with repeated measures (MMRM) with treatment, region, number of previous anti-TNFs, visit, and treatment-by-visit interaction as fixed effects and baseline HAQ-DI as a covariate. (NCT01709578)
Timeframe: Baseline, Week 12

Interventionunits on a scale (Least Squares Mean)
Placebo q2w-0.26
Sarilumab 150 mg q2w-0.46
Sarilumab 200 mg q2w-0.47

[back to top]

Change From Baseline in the Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-fatigue) Score at Week 24

The FACIT-Fatigue is a 13-item questionnaire assessing fatigue where participants scored each item on a 5-point scale (0-4): 0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, 4=very much. A total score ranging from 0 to 52. A higher score corresponded to a lower level of fatigue. A positive change from baseline score indicates an improvement. LS mean and SE at Week 24 were obtained from a MMRM with treatment, region, number of previous anti-TNFs, visit, and treatment-by-visit interaction as fixed effects and baseline FACIT-fatigue as a covariate. (NCT01709578)
Timeframe: Baseline, Week 24

Interventionunits on a scale (Least Squares Mean)
Placebo q2w6.82
Sarilumab 150 mg q2w9.86
Sarilumab 200 mg q2w10.06

[back to top]

Change From Baseline in the FACIT-fatigue at Week 12

The FACIT-Fatigue is a 13-item questionnaire assessing fatigue where participants scored each item on a 5-point scale (0-4): 0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, 4=very much. A total score ranging from 0 to 52. A higher score corresponded to a lower level of fatigue. A positive change from baseline score indicates an improvement. LS mean and SE at Week 12 were obtained from a MMRM with treatment, region, number of previous anti-TNFs, visit, and treatment-by-visit interaction as fixed effects and baseline FACIT-fatigue as a covariate. (NCT01709578)
Timeframe: Baseline, Week 12

Interventionunits on a scale (Least Squares Mean)
Placebo q2w5.56
Sarilumab 150 mg q2w8.02
Sarilumab 200 mg q2w9.45

[back to top]

Change From Baseline in SF-36 MCS at Week 24

SF-36 is a generic 36-item questionnaire measuring HRQL covering 2 summary measures: PCS and MCS. The SF-36 consists of 8 subscales. The PCS is represented by 4 subscales: physical function, role limitations due to physical problems, pain, and general health perception. The MCS is represented by 4 subscales: vitality, social function, role limitations due to emotional problems, and mental health. Participants self-report on items in a subscale that have between 2-6 choices per item using Likert-type responses (e.g. none of the time, some of the time, etc.). Summations of item scores of the same subscale give the subscale scores, which are transformed into a range from 0 to 100; 0= worst HRQL, 100=best HRQL. Higher scores indicate better health and well-being. LS mean and SE at Week 24 were obtained from a MMRM with treatment, region, number of previous anti-TNFs, visit, and treatment-by-visit interaction as fixed effects and baseline SF-36 MCS as a covariate. (NCT01709578)
Timeframe: Baseline, Week 24

Interventionunits on a scale (Least Squares Mean)
Placebo q2w4.74
Sarilumab 150 mg q2w6.26
Sarilumab 200 mg q2w6.76

[back to top]

Change From Baseline in Rheumatoid Arthritis Impact of Disease (RAID) Scores at Week 24

RAID is a composite measure of the impact of RA on participants that takes into account 7 domains: pain, functional disability, fatigue, physical and emotional well being, quality of sleep, and coping. The RAID is calculated based on 7 numerical rating scales (NRS) questions. Range of the final RAID value is 0-10 where 0= not affected, very good and 10 = most affected weighted and calculated with a total score range of 0 (not affected, very good) to 10 (most affected). A higher RAID value indicate worse status and lower indicate not affected. LS mean and SE at Week 24 were obtained from a MMRM with treatment, region, number of previous anti-TNFs, visit, and treatment-by-visit interaction as fixed effects and baseline RAID as a covariate. (NCT01709578)
Timeframe: Baseline, Week 24

Interventionunits on a scale (Least Squares Mean)
Placebo q2w-1.80
Sarilumab 150 mg q2w-2.55
Sarilumab 200 mg q2w-2.80

[back to top]

Change From Baseline in RAID Scores at Week 12

RAID score is a composite measure of the impact of RA on participants that takes into account 7 domains: pain, functional disability, fatigue, physical and emotional well being, quality of sleep, and coping. The RAID is calculated based on 7 NRS questions. Range of the final RAID value is 0-10 where 0= not affected, very good and 10 = most affected weighted and calculated with a total score range of 0 (not affected, very good) to 10 (most affected). A higher RAID value indicates worse status and lower indicates not affected. LS mean and SE at Week 12 were obtained from a MMRM with treatment, region, number of previous anti-TNFs, visit, and treatment-by-visit interaction as fixed effects and baseline RAID scores as a covariate. (NCT01709578)
Timeframe: Baseline, Week 12

Interventionunits on a scale (Mean)
Placebo q2w-1.34
Sarilumab 150 mg q2w-2.27
Sarilumab 200 mg q2w-2.47

[back to top]

Change From Baseline in Morning Stiffness VAS at Week 24

RA is associated with stiffness of joints, especially in the morning after prolonged stationery state. The degree of stiffness can be an indicator of disease severity. The severity of morning stiffness was assessed on a VAS scale from 0 mm (no problem) to 100 mm (major problem). LS mean and SE at Week 24 were obtained from a MMRM with treatment, region, number of previous anti-TNFs, visit, and treatment-by-visit interaction as fixed effects and baseline Morning Stiffness as a covariate. (NCT01709578)
Timeframe: Baseline, Week 24

Interventionmm (Least Squares Mean)
Placebo q2w-21.66
Sarilumab 150 mg q2w-32.30
Sarilumab 200 mg q2w-33.79

[back to top]

Change From Baseline in HAQ-DI at Week 24

Physical function was assessed by HAQ-DI. It consisted of at least 2 questions per category, participant reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week rated on a 4-point scale where 0 = no difficulty; 1 = some difficulty; 2 = much difficulty; 3 = unable to do. Overall score was computed as the sum of category scores and divided by the number of categories answered, ranging from 0 to 3, where 0 = no disability and 3 = unable to do, high-dependency disability. LS means and SE at Week 24 were obtained from a MMRM with treatment, region, number of previous anti-TNFs, visit, and treatment-by-visit interaction as fixed effects and baseline HAQ-DI as a covariate. (NCT01709578)
Timeframe: Baseline, Week 24

Interventionunits on a scale (Least Squares Mean)
Placebo q2w-0.34
Sarilumab 150 mg q2w-0.52
Sarilumab 200 mg q2w-0.58

[back to top]

Change From Baseline in European Quality of Life-5 Dimension 3 Level (EQ-5D-3L) VAS Scores at Week 24

The EQ-5D-3L is a standardized, generic measure of health outcome. It was designed for self-completion by participants. It was specifically included to address concerns regarding the health economic impact of RA. The EQ-5D-3L comprises 5 questions on mobility, self-care, pain, usual activities, and psychological status with 3 possible answers for each item (1=no problem, 2=moderate problems, 3=severe problems) and a vertical VAS that allows the participants to indicate their health state today that can range from 0 (worst imaginable) to 100 (best imaginable). LS mean and SE at Week 24 were obtained from a MMRM with treatment, region, number of previous anti-TNFs, visit, and treatment-by-visit interaction as fixed effects and baseline EQ-5D-3L Scores as a covariate. (NCT01709578)
Timeframe: Baseline, Week 24

Interventionunits on a scale (Least Squares Mean)
Placebo q2w14.85
Sarilumab 150 mg q2w20.06
Sarilumab 200 mg q2w18.40

[back to top]

Change From Baseline in EQ-5D-3L VAS Scores at Week 12

The EQ-5D-3L is a standardized, generic measure of health outcome. EQ-5D was designed for self-completion by participants. The EQ-5D was specifically included to address concerns regarding the health economic impact of RA. The EQ-5D-3L comprises 5 questions on mobility, self-care, pain, usual activities, and psychological status with 3 possible answers for each item (1=no problem, 2=moderate problems, 3=severe problems) and a vertical VAS that allows the participants to indicate their health state today that can range from 0 (worst imaginable) to 100 (best imaginable). LS mean and SE at Week 12 were obtained from a MMRM with treatment, region, number of previous anti-TNFs, visit, and treatment-by-visit interaction as fixed effects and baseline EQ-5D-3L scores as a covariate. (NCT01709578)
Timeframe: Baseline, Week 12

Interventionunits on a scale (Least Squares Mean)
Placebo q2w8.39
Sarilumab 150 mg q2w17.16
Sarilumab 200 mg q2w15.23

[back to top]

Change From Baseline in Disease Activity Score for 28 Joints -C-Reactive Protein (DAS28--CRP) Score at Week 24

DAS28 is a composite score that includes 4 variables: TJC (based on 28 joints); SJC (based on 28 joints); General health (GH) assessment by the participant assessed from the ACR rheumatoid arthritis (RA) core set questionnaire (participant global assessment) in 100 mm visual analog scale (VAS). Marker of inflammation assessed by the high sensitivity C-reactive protein (hs-CRP) in mg/L. The DAS28 score provides a number indicating the current disease activity of the RA. DAS28 total score ranges from 2-10. A DAS28 score above 5.1 means high disease activity, whereas a DAS28 score below 3.2 indicates low disease activity and a DAS28 score below 2.6 means disease remission. LS means and SE at Week 24 were obtained from a MMRM with treatment, region, number of previous anti-TNFs, visit, and treatment-by-visit interaction as fixed effects and baseline DAS28-CRP score as a covariate. (NCT01709578)
Timeframe: Baseline, Week 24

Interventionunits on a scale (Least Squares Mean)
Placebo q2w-1.38
Sarilumab 150 mg q2w-2.35
Sarilumab 200 mg q2w-2.82

[back to top]

Change From Baseline in DAS28-CRP at Week 12

DAS28 is a composite score that includes 4 variables: TJC (based on 28 joints); SJC (based on 28 joints); GH by the participant assessed from the ACR rheumatoid arthritis core set questionnaire (participant global assessment) in 100 mm VAS; marker of inflammation assessed by hs-CRP in mg/L. The DAS28 provides a number indicating the current activity of the RA. DAS28 total score ranges from 2-10. A DAS28 score above 5.1 means high disease activity, whereas a DAS28 score below 3.2 indicates low disease activity and a DAS28 score below 2.6 means disease remission. LS mean and SE at Week 12 were obtained from a MMRM with treatment, region, number of previous anti-TNFs, visit, and treatment-by-visit interaction as fixed effects and baseline DAS score as a covariate. (NCT01709578)
Timeframe: Baseline, Week 12

Interventionunits on a scale (Least Squares Mean)
Placebo q2w-0.97
Sarilumab 150 mg q2w-2.13
Sarilumab 200 mg q2w-2.45

[back to top]

Change From Baseline in Clinical Disease Activity Index (CDAI) at Week 24

CDAI is a composite index constructed to measure clinical remission in RA that does not include a laboratory test, and is a numerical summation of 4 components: TJC (28 joints), SJC (28 joints), Participant's Global Assessment of Disease Activity VAS (in cm), and Physician's Global Assessment of Disease VAS (in cm). Total scores ranges from 0 to 76 with a negative change in CDAI score indicating an improvement in disease activity and a positive change in score indicating a worsening of disease activity. LS means and SE at Week 24 were obtained from a MMRM with treatment, region, number of previous anti-TNFs, visit, and treatment-by-visit interaction as fixed effects and baseline CDAI as a covariate. (NCT01709578)
Timeframe: Baseline, Week 24

Interventionunits on a scale (Least Squares Mean)
Placebo q2w-16.35
Sarilumab 150 mg q2w-23.65
Sarilumab 200 mg q2w-26.08

[back to top]

Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Physical Component Summary Scores (PCS) at Week 24

SF-36 is a generic 36-item questionnaire measuring health-related quality of life (HRQL) covering 2 summary measures: PCS and mental component summary (MCS). The SF-36 consists of 8 subscales. The PCS had 4 subscales: physical function, role limitations due to physical problems, pain, and general health perception. The MCS had 4 subscales: vitality, social function, role limitations due to emotional problems, and mental health. Participants self-report on items in a subscale that have between 2-6 choices per item using Likert-type responses (e.g. none of the time, some of the time, etc.). Summations of item scores of the same subscale give the subscale scores, which are transformed into a range from 0 to 100; 0= worst HRQL, 100=best HRQL. Higher scores indicate better health and well-being. LS mean and SE at Week 24 by MMRM with treatment,region,number of previous anti TNFs,visit,and treatment-by-visit interaction as fixed effects and baseline SF-36 (PCS) as a covariate. (NCT01709578)
Timeframe: Baseline, Week 24

Interventionunits on a scale (Least Squares Mean)
Placebo q2w4.40
Sarilumab 150 mg q2w7.65
Sarilumab 200 mg q2w8.48

[back to top]

Percentage of Participants Achieving ACR20, ACR50 and ACR70 Criteria at Week 12

ACR responses are assessed with a composite rating scale of the American College of Rheumatology that includes 7 variables: TJC; SJC; levels of an acute phase reactant (CRP level); participant's assessment of pain; participant's global assessment of disease activity; physician's global assessment of disease activity; participant's assessment of physical function by HAQ--DI. ACR20 is defined as achieving at least 20% improvement in both TJC and SJC, and at least 20% improvement in at least 3 of the 5 other assessments of the ACR. ACR50 is defined as achieving at least 50% improvement in both TJC and SJC, and at least 50% improvement in at least 3 of the 5 other assessments of the ACR. ACR70 is defined as achieving at least 70% improvement in both TJC and SJC, and at least 70% improvement in at least 3 of the 5 other assessments of the ACR. (NCT01709578)
Timeframe: Week 12

,,
InterventionPercentage of participants (Number)
ACR20ACR50ACR70
Placebo q2w37.613.32.2
Sarilumab 150 mg q2w54.130.413.8
Sarilumab 200 mg q2w62.533.214.7

[back to top]

Change From Baseline in SF-36 at Week 12

SF-36 is a generic 36-item questionnaire measuring HRQL covering 2 summary measures: PCS and MCS. The SF-36 consists of 8 subscales. The PCS is represented by 4 subscales: physical function, role limitations due to physical problems, pain, and general health perception. The MCS is represented by 4 subscales: vitality, social function, role limitations due to emotional problems, and mental health. Participants self-report on items in a subscale that have between 2-6 choices per item using Likert-type responses (e.g. none of the time, some of the time, etc.). Summations of item scores of the same subscale give the subscale scores, which are transformed into a range from 0 to 100; 0= worst HRQL, 100=best HRQL. Higher scores indicate better health and well-being. LS mean and SE at Week 12 were obtained from a MMRM with treatment, region, number of previous anti-TNFs, visit, and treatment-by-visit interaction as fixed effects and baseline SF-36 as a covariate. (NCT01709578)
Timeframe: Baseline, Week 12

,,
Interventionunits on a scale (Least Squares Mean)
Physical Component Summary Score at Week 12Mental Component Summary Score at Week 12
Placebo q2w3.743.50
Sarilumab 150 mg q2w6.935.14
Sarilumab 200 mg q2w6.846.47

[back to top]

Change From Baseline in Individual ACR Component - CRP Level at Week 12 and Week 24

"ACR components were: TJC, SJC, physician global VAS, participant global VAS, pain VAS, HAQ-DI & CRP. An elevated CRP level was considered a non-specific marker for RA. A reduction level indicates improvement. LS mean and SE at Week 12 & 24 by MMRM with treatment, region, number of previous anti-TNFs, visit, and treatment-by-visit interaction as fixed effects and baseline ACR components as a covariate." (NCT01709578)
Timeframe: Baseline, Week 12 and Week 24

,,
Interventionmg/L (Least Squares Mean)
CRP at week 12CRP at week 24
Placebo q2w-3.63-3.60
Sarilumab 150 mg q2w-15.08-15.24
Sarilumab 200 mg q2w-22.98-23.27

[back to top]

Percentage of Participants Who Achieved at Least 20% Improvement in the American College of Rheumatology (ACR20) Criteria at Week 24

ACR responses are assessed with a composite rating scale of the American College of Rheumatology that includes 7 variables: tender joint count (TJC); swollen joint count (SJC); levels of an acute phase reactant (C-reactive Protein levels [CRP]); participant's assessment of pain; participant's global assessment of disease activity; physician's global assessment of disease activity; participant's assessment of physical function by (health assessment questionnaire disability index [HAQ-DI]). ACR20 is defined as achieving at least 20% improvement in both TJC and SJC, and at least 20% improvement in at least 3 of the 5 other assessments of the ACR. (NCT01709578)
Timeframe: Week 24

Interventionpercentage of participants (Number)
Placebo q2w33.7
Sarilumab 150 mg q2w55.8
Sarilumab 200 mg q2w60.9

[back to top]

Percentage of Participants Achieving Clinical Remission Score (DAS28-CRP) <2.6 at Week 24

DAS28 is a composite score that includes 4 variables: TJC (based on 28 joints); SJC (based on 28 joints); GH by the participant assessed from the ACR rheumatoid arthritis core set questionnaire (participant global assessment) in 100 mm VAS; marker of inflammation assessed by hs-CRP in mg/L. The DAS28 provides a number indicating the current activity of the RA. DAS28 total score ranges from 2-10. A DAS28 score above 5.1 means high disease activity, whereas a DAS28 score below 3.2 indicates low disease activity and a DAS28 score below 2.6 means disease remission. (NCT01709578)
Timeframe: Week 24

InterventionPercentage of participants (Number)
Placebo q2w7.2
Sarilumab 150 mg q2w24.9
Sarilumab 200 mg q2w28.8

[back to top]

Percentage of Participants Achieving Clinical Remission Score (DAS28--CRP <2.6) at Week 12

DAS28 is a composite score that includes 4 variables: TJC (based on 28 joints); SJC (based on 28 joints); GH by the participant assessed from the ACR RA core set questionnaire (participant global assessment) in 100 mm VAS; marker of inflammation assessed by hs-CRP in mg/L. The DAS28 provides a number indicating the current activity of the RA. DAS28 total score ranges from 2-10. A DAS28 score above 5.1 means high disease activity, whereas a DAS28 score below 3.2 indicates low disease activity and a DAS28 score below 2.6 means disease remission. (NCT01709578)
Timeframe: Week 12

InterventionPercentage of participants (Number)
Placebo q2w3.9
Sarilumab 150 mg q2w17.1
Sarilumab 200 mg q2w17.9

[back to top]

Percentage of Participants Achieving ACR70 Criteria at Week 24

ACR responses are assessed with a composite rating scale of the American College of Rheumatology that includes 7 variables: TJC; SJC; levels of an acute phase reactant (CRP level); participant's assessment of pain; participant's global assessment of disease activity; physician's global assessment of disease activity; participant's assessment of physical function by HAQ--DI. ACR70 is defined as achieving at least 70% improvement in both TJC and SJC, and at least 70% improvement in at least 3 of the 5 other assessments of the ACR. (NCT01709578)
Timeframe: Week 24

InterventionPercentage of participants (Number)
Placebo q2w7.2
Sarilumab 150 mg q2w19.9
Sarilumab 200 mg q2w16.3

[back to top]

Percentage of Participants Achieving ACR50 Criteria at Week 24

ACR responses are assessed with a composite rating scale that includes 7 variables: TJC; SJC; levels of an acute phase reactant (CRP level); participant's assessment of pain; participant's global assessment of disease activity; physician's global assessment of disease activity; participant's assessment of physical function by HAQ--DI. ACR50 is defined as achieving at least 50% improvement in both TJC and SJC, and at least 50% improvement in at least 3 of the 5 other assessments of the ACR. (NCT01709578)
Timeframe: Week 24

InterventionPercentage of participants (Number)
Placebo q2w18.2
Sarilumab 150 mg q2w37.0
Sarilumab 200 mg q2w40.8

[back to top]

Change From Baseline in WPS-RA at Week 24: RA Interference With Work Productivity

The WPS-RA is a validated questionnaire that evaluates productivity limitations within work and within home associated with RA over the previous month. The questionnaire was interviewer-administered and was based on participant self-report. It contains 9 questions addressing employment status (1 item), productivity at work (3 items), and within and outside the home (5 items). Interference in the last month with work productivity is measured on a scale that ranges from 0 (no interference) to 10 (complete interference). LS mean and SE at Week 24 were obtained from a MMRM with treatment, region, number of previous anti-TNFs, visit, and treatment-by-visit interaction as fixed effects and baseline WPS-RA as a covariate. (NCT01709578)
Timeframe: Baseline, Week 24

Interventionunits on a scale (Least Squares Mean)
Placebo q2w-1.632
Sarilumab 150 mg q2w-2.422
Sarilumab 200 mg q2w-2.727

[back to top]

Change From Baseline in WPS-RA at Week 24: RA Interference With Household Work Productivity

The WPS-RA is a validated questionnaire that evaluates productivity limitations within work and within home associated with RA over the previous month. The questionnaire was interviewer-administered and was based on participant self-report. It contains 9 questions addressing employment status (1 item), productivity at work (3 items), and within and outside the home (5 items). The RA interference in the last month with household work productivity was measured on a scale that ranges from 0 (no interference) to 10 (complete interference). LS mean and SE at Week 24 were obtained from a MMRM with treatment, region, number of previous anti-TNFs, visit, and treatment-by-visit interaction as fixed effects and baseline WPS-RA as a covariate. (NCT01709578)
Timeframe: Baseline, Week 24

Interventionunits on a scale (Least Squares Mean)
Placebo q2w-1.970
Sarilumab 150 mg q2w-3.096
Sarilumab 200 mg q2w-3.269

[back to top]

Change From Baseline in WPS-RA at Week 24: House Work Days Missed Due to RA

The WPS-RA is a validated questionnaire that evaluates productivity limitations within work and within home associated with RA over the previous month. The questionnaire was interviewer-administered and was based on participant self-report. It contains 9 questions addressing employment status (1 item), productivity at work (3 items), and within and outside the home (5 items). Number of days with no household work in the last month by the participant was reported. LS mean and SE at Week 24 were obtained from a MMRM with treatment, region, number of previous anti-TNFs, visit, and treatment-by-visit interaction as fixed effects and baseline WPS-RA as a covariate. (NCT01709578)
Timeframe: Baseline, Week 24

InterventionDays (Least Squares Mean)
Placebo q2w-3.50
Sarilumab 150 mg q2w-6.13
Sarilumab 200 mg q2w-6.18

[back to top]

Change From Baseline in WPS-RA at Week 24: Days With Work Productivity Reduced by ≥ 50% Due to RA

The WPS-RA is a validated questionnaire that evaluates productivity limitations within work and within home associated with RA over the previous month. The questionnaire was interviewer-administered and was based on participant self-report. It contains 9 questions addressing employment status (1 item), productivity at work (3 items), and within and outside the home (5 items). Number of work days with reduced productivity by ≥ 50% in the last month by the participant was reported. LS mean and SE at Week 24 were obtained from a MMRM with treatment, region, number of previous anti-TNFs, visit, and treatment-by-visit interaction as fixed effects and baseline WPS-RA as a covariate. (NCT01709578)
Timeframe: Baseline, Week 24

InterventionDays (Least Squares Mean)
Placebo q2w-3.64
Sarilumab 150 mg q2w-4.26
Sarilumab 200 mg q2w-4.34

[back to top]

Change From Baseline in WPS-RA at Week 24: Days With Outside Help Hired Due to RA

The WPS-RA is a validated questionnaire that evaluates productivity limitations within work and within home associated with RA over the previous month. The questionnaire was interviewer-administered and was based on participant self-report. It contains 9 questions addressing employment status (1 item), productivity at work (3 items), and within and outside the home (5 items). Number of days with outside help hired in the last month by the participant was reported. LS mean and SE at Week 24 were obtained from a MMRM with treatment, region, number of previous anti-TNFs, visit, and treatment-by-visit interaction as fixed effects and baseline WPS-RA as a covariate. (NCT01709578)
Timeframe: Baseline, Week 24

InterventionDays (Least Squares Mean)
Placebo q2w-1.60
Sarilumab 150 mg q2w-3.87
Sarilumab 200 mg q2w-3.86

[back to top]

Change From Baseline in WPS-RA at Week 24: Days With Household Work Productivity Reduced by ≥ 50% Due to RA

The WPS-RA is a validated questionnaire that evaluates productivity limitations within work and within home associated with RA over the previous month. The questionnaire was interviewer-administered and was based on participant self-report. It contains 9 questions addressing employment status (1 item), productivity at work (3 items), and within and outside the home (5 items). Number of days with reduced household work productivity by ≥ 50% in the last month by the participant was reported. LS mean and SE at Week 24 were obtained from a MMRM with treatment, region, number of previous anti-TNFs, visit, and treatment-by-visit interaction as fixed effects and baseline WPS-RA as a covariate. (NCT01709578)
Timeframe: Baseline, Week 24

InterventionDays (Least Squares Mean)
Placebo q2w-3.36
Sarilumab 150 mg q2w-4.60
Sarilumab 200 mg q2w-4.88

[back to top]

Change From Baseline in WPS-RA at Week 24: Days With Family/Social/Leisure Activities Missed Due to RA

The WPS-RA is a validated questionnaire that evaluates productivity limitations within work and within home associated with RA over the previous month. The questionnaire was interviewer-administered and was based on participant self-report. It contains 9 questions addressing employment status (1 item), productivity at work (3 items), and within and outside the home (5 items). Number of days missed of family/social/leisure activities in the last month by the participant was reported. LS mean and SE at Week 24 were obtained from a MMRM with treatment, region, number of previous anti-TNFs, visit, and treatment-by-visit interaction as fixed effects and baseline WPS-RA as a covariate. (NCT01709578)
Timeframe: Baseline, Week 24

InterventionDays (Least Squares Mean)
Placebo q2w-1.97
Sarilumab 150 mg q2w-3.51
Sarilumab 200 mg q2w-4.12

[back to top]

Change From Baseline in WPS-RA at Week 12: Work Days Missed Due to RA

The WPS-RA is a validated questionnaire that evaluates productivity limitations within work and within home associated with RA over the previous month. The questionnaire was interviewer-administered and was based on participant self-report. It contains 9 questions addressing employment status (1 item), productivity at work (3 items), and within and outside the home (5 items). Number of work days missed in the last month by the participant was reported. LS mean and SE at Week 12 were obtained from a MMRM with treatment, region, number of previous anti-TNFs, visit, and treatment-by-visit interaction as fixed effects and baseline WPS-RA as a covariate. (NCT01709578)
Timeframe: Baseline, Week 12

InterventionDays (Least Squares Mean)
Placebo q2w-1.20
Sarilumab 150 mg q2w-1.97
Sarilumab 200 mg q2w-2.98

[back to top]

Change From Baseline in WPS-RA at Week 12: RA Interference With Work Productivity

The WPS-RA is a validated questionnaire that evaluates productivity limitations within work and within home associated with RA over the previous month. The questionnaire was interviewer-administered and was based on participant self-report. It contains 9 questions addressing employment status (1 item), productivity at work (3 items), and within and outside the home (5 items). Interference in the last month with work productivity was measured on a scale that ranges from 0 (no interference) to 10 (complete interference). LS mean and SE at Week 12 were obtained from a MMRM with treatment, region, number of previous anti-TNFs, visit, and treatment-by-visit interaction as fixed effects and baseline WPS-RA as a covariate. (NCT01709578)
Timeframe: Baseline, Week 12

Interventionunits on a scale (Least Squares Mean)
Placebo q2w-1.043
Sarilumab 150 mg q2w-1.924
Sarilumab 200 mg q2w-1.873

[back to top]

Change From Baseline in Individual ACR Component - HAQ-DI at Week 12 and Week 24

ACR components were: TJC, SJC, physician global VAS, participant global VAS, pain VAS,HAQ-DI & CRP. HAQ-DI consisted of at least 2 questions per category, participant reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week rated on a 4-point scale where 0 = no difficulty; 1 = some difficulty; 2 = much difficulty; 3 = unable to do. Overall score was computed as the sum of category scores and divided by the number of categories answered, ranging from 0 to 3, where 0 = no disability and 3 = unable to do, high-dependency disability. LS mean and SE at Week 12 & 24 by MMRM with treatment, region, number of previous anti-TNFs, visit, and treatment-by-visit interaction as fixed effects and baseline ACR components as a covariate. (NCT01709578)
Timeframe: Baseline, Week 12 and Week 24

,,
Interventionunits on a scale (Least Squares Mean)
HAQ-DI at week 12HAQ-DI at week 24
Placebo q2w-0.26-0.34
Sarilumab 150 mg q2w-0.46-0.52
Sarilumab 200 mg q2w-0.47-0.58

[back to top]

Change From Baseline in Individual ACR Component - Physician Global VAS, Participant Global VAS and Pain VAS at Week 12 and Week 24

"ACR components were: TJC, SJC, physician global VAS, participant global VAS, pain VAS, HAQ-DI & CRP. Physician global VAS & participant global VAS was done by 100 mm non-anchored VAS, from no arthritis (0) activity to maximal arthritis (100) activity. Pain VAS by 100 mm VAS ranging from 0 no pain to 100 worst pain. LS mean and SE at Week 12 & 24 by MMRM with treatment, region, number of previous anti-TNFs, visit, and treatment-by-visit interaction as fixed effects and baseline ACR components as a covariate." (NCT01709578)
Timeframe: Baseline, Week 12 and Week 24

,,
Interventionmm (Least Squares Mean)
Physician global VAS at week 12Participant global VAS at week 12Pain VAS at week 12Physician global VAS at week 24Participant global VAS at week 24Pain VAS at week 24
Placebo q2w-22.74-13.75-15.13-28.55-19.76-21.27
Sarilumab 150 mg q2w-33.64-25.28-26.93-40.65-29.59-31.90
Sarilumab 200 mg q2w-35.44-27.38-30.56-43.22-31.28-33.65

[back to top]

Change From Baseline in Individual ACR Components - TJC and SJC at Week 12 and Week 24

ACR components were: TJC, SJC, physician global VAS, participant global VAS, pain VAS,HAQ-DI & CRP. 68 joints were assessed for tenderness (TJC scoring 0-68) and 66 joints for swelling (SJC scoring 0-66). The 66 SJC evaluated the following joints: temporomandibular, sternoclavicular, acromioclavicular, shoulder, elbow, wrist, metacarpophalangeal, interphalangeal of thumb, distal interphalangeal, proximal interphalangeal, knee, ankle mortise, ankle tarsus, metatarsophalangeal, interphalangeal of great toe, and proximal/distal interphalangeal of the toes. The TJC examined hip joints, in addition to the joints assessed for SJC. Increase in number of tender joints/swollen joints indicated severity. LS mean and SE at Week 12 & 24 by MMRM with treatment, region, number of previous anti-TNFs, visit, and treatment-by-visit interaction as fixed effects and baseline ACR components as a covariate. (NCT01709578)
Timeframe: Baseline, Week 12 and Week 24

,,
Interventionjoints (Least Squares Mean)
TJC at week 12SJC at week 12TJC at week 24SJC at week 24
Placebo q2w-8.55-6.75-10.55-8.19
Sarilumab 150 mg q2w-13.74-10.54-14.44-11.56
Sarilumab 200 mg q2w-14.87-10.59-16.95-11.94

[back to top]

Number of Participants With Treatment Emergent Adverse Events (TEAEs)

Adverse event (AE) was defined as any untoward medical occurrence in a participant who received study drug and does not necessary have to have a causal relationship with treatment. All adverse events that occurred from the first dose of the study drug administration up to 60 days after the end of treatment visit were considered as TEAEs. Serious AE (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly or a medically important event. A summary of SAEs, all other non-serious AEs, regardless of causality, are reported in AE section. (NCT01768572)
Timeframe: Up to 211 days

,,
Interventionparticipants (Number)
Any TEAEAny treatment-emergent SAEAny TEAE leading to deathAny TEAE leading to discontinuation
Sarilumab 150 mg q2w33106
Sarilumab 200 mg q2w36308
Tocilizumab q4w68714

[back to top]

Number of Participants With an Acute Thrombosis Event

To determine the efficacy of Hydroxychloroquine in the primary thrombosis prevention of persistently aPL-positive but thrombosis free patients with no other systemic autoimmune diseases over the five year study period. (NCT01784523)
Timeframe: 2 years

InterventionParticipants (Count of Participants)
Standard Treatment0
Hydroxychloroquine0

[back to top]

Circulating Tumor Cells Pre-enrollment and During Therapy

(NCT01828476)
Timeframe: 5 years

Intervention ()
ARM A0
ARM B0

[back to top]

Time to PSA Progression

(NCT01828476)
Timeframe: 5 years

Intervention ()
ARM A0
ARM B0

[back to top]

Progression Free Survival

(NCT01828476)
Timeframe: 5 years

Intervention ()
ARM A - Dose Escalation0
ARM B - Dose Escalation0

[back to top]

Overall Survival

(NCT01828476)
Timeframe: 5 years

Intervention ()
ARM A0
ARM B0

[back to top]

Measurable Tumor Response in Patients With Measurable Disease

(NCT01828476)
Timeframe: 5 years

Intervention ()
ARM A0
ARM B0

[back to top]

Biomarkers of Autophagy Modulation by EM; and LC3, and/or p62 by Immunoblotting in PBMC and Tumor Tissue When Available

(NCT01828476)
Timeframe: 5 years

Intervention ()
ARM A0
ARM B0

[back to top]

Biochemical Response to ABT-263 and Abiraterone and to ABT-263 in Combination With Hydroxychloroquine and Abiraterone in Patients That Are Progressing on Abiraterone

"Characterize biochemical response to ABT-263 and Abiraterone and to ABT-263 in combination with hydroxychloroquine and Abiraterone by looking at PSA levels." (NCT01828476)
Timeframe: 5 years

InterventionParticipants (Count of Participants)
ARM A0

[back to top]

Bcl-2 Family Protein Expression (Bcl-2, Bcl-XL, MCL-1) in Paraffin Blocks When Available by Immunohistochemistry

(NCT01828476)
Timeframe: 5 years

Intervention ()
ARM A0
ARM B0

[back to top]

Safety: Number of Participants With Adverse Events

Safety was assessed throughout study by collection of adverse event and concomitant medication data, and routine monitoring of lab safety tests, physical exams, ophthalmic examination, vital signs and 12 lead electrocardiograms. (NCT01833845)
Timeframe: all 24 weeks

Interventionparticipants (Number)
Ribavirin+HCQ4

[back to top]

The Toxicity

Number of Participants with Adverse Events. Toxicities parameters are according to the Nation Cancer Institute Common Terminology Criteria for Adverse Event, version 3.0. (NCT01842594)
Timeframe: 2 Weeks

Interventionparticipants (Number)
Sirolimus and Hydroxychloroquine3

[back to top]

The Maximum Standardized Uptake Values (SUVmax) Change on PET/CT Scan

A baseline whole-body [18F]-fluorodeoxyglucose(FDG) PET was performed before therapy initiation. Patients received 1 mg of Rapa and 200 mg of HCQ twice a day before a meal for 2 weeks. A second [18F]-FDG PET was performed after treatment completion. SUVs were calculated for all lesions. Regions of interest (ROI) were contoured to represent tumors (>2 cm) and organs (lungs, spleen, and liver) on all transaxial and coronal slices. ROIs were normalized for injection dose and body weight, and the maximum voxel value was recorded for each region or organ. The highest SUV measured with increased uptake was considered the SUVmax. Correlative diagnostic CT examinations were used for accurate localization of the lesions. The most intense uptake at baseline was identified as the index lesion and evaluated for treatment response. (NCT01842594)
Timeframe: 2 Weeks

Interventionpercentage of the SUVmax Change (Mean)
Sirolimus and Hydroxychloroquine-19.6

[back to top]

Number of Participants With Anti-Tocilizumab Antibodies (ATA)

All samples were tested using a screening assay and, if positive, by a confirmation assay to determine specificity and a neutralizing assay to test for the ability to inhibit the activity of tocilizumab. Number of participants with a positive assay result for screening assay (ATA - Screen), confirmatory assay (ATA - Confirmatory), and neutralizing assay (ATA - Neutralizing) was reported separately. (NCT01941095)
Timeframe: Baseline (Week 1), Weeks 12, 24, 36, 52, and 8 weeks after Week 52 dose (Week 60)

Interventionparticipants (Number)
Week 1: ATA - ScreenWeek 1: ATA - ConfirmatoryWeek 1: ATA - NeutralizingWeek 12: ATA - ScreenWeek 12: ATA - ConfirmatoryWeek 12: ATA - NeutralizingWeek 24: ATA - ScreenWeek 24: ATA - ConfirmatoryWeek 24: ATA - NeutralizingWeek 36: ATA - ScreenWeek 36: ATA - ConfirmatoryWeek 36: ATA - NeutralizingWeek 52: ATA - ScreenWeek 52: ATA - ConfirmatoryWeek 52: ATA - NeutralizingWeek 60: ATA - ScreenWeek 60: ATA - ConfirmatoryWeek 60: ATA - Neutralizing
Tocilizumab740300311200200110

[back to top]

Percentage of Participants Who Achieved Disease Activity Score Based on 28 Joint Count and Erythrocyte Sedimentation Rate (DAS28-ESR) Remission at Week 24

DAS28-ESR score is a measure of participant's disease activity calculated using tender joint count in 28 joints (TJC28), swollen joint count in 28 joints (SJC28), patient global assessment of disease activity (PGA) (general health [GH]) using visual analog scale (VAS): 0 millimeter (mm)=no disease activity to 100 mm=maximum disease activity, displayed on the 100 mm horizontal VAS, and acute phase response (ESR in millimeters per hour [mm/hr]). The score is calculated using the following formula: DAS28-ESR = [0.56 multiplied by (*) square root (√) of TJC28] plus (+) [0.28*√SJC28]+[0.70*the natural logarithm (ln) ESR]+[0.014*GH]. DAS28-ESR score varies from 0 to 10, where higher scores represent greater disease activity. DAS28-ESR score of less than (<) 2.6 represents DAS28-ESR remission. (NCT01941095)
Timeframe: Week 24

Interventionpercentage of participants (Number)
Tocilizumab40

[back to top]

Percentage of Participants With Corticosteroid Dose Reduction or Discontinuation

(NCT01941095)
Timeframe: From Baseline up to Week 52

Interventionpercentage of participants (Number)
Tocilizumab48.6

[back to top]

Change From Baseline in DAS28-ESR up to Week 52

DAS28-ESR score is a measure of participant's disease activity calculated using TJC28, SJC28, PGA using VAS 0 mm=no disease activity to 100 mm=maximum disease activity, displayed on the 100 mm horizontal VAS, and acute phase response (ESR in mm/hr) for a total possible score of 0 to 10. The score is calculated using the following formula: DAS28-ESR = [0.56 * √TJC28 + [0.28*√SJC28]+[0.70*ln ESR]+[0.014*GH]. DAS28-ESR score varies from 0 to 10, where higher scores represent greater disease activity. A negative change from baseline indicates an improvement. (NCT01941095)
Timeframe: Baseline (Week 1), Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52

Interventionunits on a scale (Mean)
Change at Week 2Change at Week 4Change at Week 8Change at Week 12Change at Week 16Change at Week 20Change at Week 24Change at Week 28Change at Week 32Change at Week 36Change at Week 40Change at Week 44Change at Week 48Change at Week 52
Tocilizumab-0.99-1.70-2.20-2.56-2.59-2.93-3.14-3.22-3.34-3.32-3.40-3.45-3.42-3.40

[back to top]

Change From Baseline in Simplified Disease Activity Index (SDAI) Score up to Week 52

SDAI is an index for measuring disease activity. SDAI is the numerical sum of five outcome parameters: TJC28 and SJC28, PGA and physician global assessment of disease activity assessed on VAS (0 centimeter [cm]-10 cm); 0 cm= no disease activity and 10 cm= worst disease activity, and CRP (in milligrams per deciliter [mg/dL]). SDAI total score ranges from 0 to 86, with higher scores indicating increased (or severe) disease activity. SDAI score 3.4 to 11 = low disease activity, >11 to 26 = moderate disease activity, and >26 = high (or severe) disease activity. (NCT01941095)
Timeframe: Baseline (Week 1), Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52

Interventionunits on a scale (Mean)
Change at Week 2Change at Week 4Change at Week 8Change at Week 12Change at Week 16Change at Week 20Change at Week 24Change at Week 28Change at Week 32Change at Week 36Change at Week 40Change at Week 44Change at Week 48Change at Week 52
Tocilizumab-3.41-6.54-8.72-11.07-13.47-13.88-14.08-15.37-16.09-15.61-14.86-16.31-16.47-17.35

[back to top]

Change From Baseline in SJC28 up to Week 52

28 joints were assessed for swelling and joints were classified as swollen/not swollen giving a total possible swollen joint count score of 0 to 28. A negative change from baseline indicated improvement. (NCT01941095)
Timeframe: Baseline (Week 1), Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52

Interventionswollen joints (Mean)
Change at Week 2Change at Week 4Change at Week 8Change at Week 12Change at Week 16Change at Week 20Change at Week 24Change at Week 28Change at Week 32Change at Week 36Change at Week 40Change at Week 44Change at Week 48Change at Week 52
Tocilizumab-1.82-3.08-4.71-5.24-5.79-6.06-6.60-6.65-6.73-6.76-6.91-6.82-6.63-6.98

[back to top]

Change From Baseline in TJC28 up to Week 52

28 joints were assessed for tenderness and joints were classified as tender/not tender giving a total possible tender joint count score of 0 to 28. A negative change from baseline indicated improvement. (NCT01941095)
Timeframe: Baseline (Week 1), Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52

Interventiontender joints (Mean)
Change at Week 2Change at Week 4Change at Week 8Change at Week 12Change at Week 16Change at Week 20Change at Week 24Change at Week 28Change at Week 32Change at Week 36Change at Week 40Change at Week 44Change at Week 48Change at Week 52
Tocilizumab-1.30-3.26-4.97-5.82-6.39-7.03-7.72-7.91-8.38-8.28-8.22-8.63-8.26-8.75

[back to top]

Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Total Score

FACIT-Fatigue total score is sum of FACIT-General subscale score and FACIT-Fatigue (additional concerns) subscale score. FACT-General consists of 27 questions grouped in 4 domains of general health-related quality of life: physical well-being, social/family well-being, emotional well-being, and functional well-being; each item ranges from 0 (not at all) to 4 (very much). FACT-General score ranges between 0-108. FACIT-Fatigue subscale is a 13-item questionnaire that evaluates self-reported fatigue and its impact upon daily activities. Each item ranges from 0 (Not at all) to 4 (Very much). For all items, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as 4 minus the participant's response. The sum of all responses resulted in the FACIT-Fatigue subscale score for a total possible score of 0 (worse score) to 52 (better score). FACIT-Fatigue total score (FACT-G plus FACT-F subscale scores) ranges from 0 (better score) to 160 (worse score). (NCT01941095)
Timeframe: Baseline (Week 1), Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52

Interventionunits on a scale (Mean)
Week 1Week 2Week 4Week 8Week 12Week 16Week 20Week 24Week 28Week 32Week 36Week 40Week 44Week 48Week 52
Tocilizumab89.6891.83100.38103.16106.39110.17112.60114.21114.85117.01116.50116.59119.67119.83121.82

[back to top]

HAQ-DI Score

"The Stanford HAQ-DI is a patient-reported questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to 8 component sets: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. Responses in each component set were scored from 0 (without any difficulty) to 3 (unable to do). The highest score recorded for any question in a category determines the score for the category, unless aids, devices, or help from another person was required. The HAQ-DI score was calculated as the sum of the category scores divided by the number of categories scored, giving a possible range of scores from 0 to 3. Scores of 0 to 1 are generally considered to represent mild to moderate difficulty, 1 to 2 as moderate to severe disability, and 2 to 3 as severe to very severe disability." (NCT01941095)
Timeframe: Baseline (Week 1), Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52

Interventionunits on a scale (Mean)
Week 1Week 2Week 4Week 8Week 12Week 16Week 20Week 24Week 28Week 32Week 36Week 40Week 44Week 48Week 52
Tocilizumab1.311.221.090.910.820.720.680.660.660.590.630.600.590.560.54

[back to top]

Number of Participants by Reasons (Categories) for Corticosteroid Dose Reduction or Discontinuation

Reasons for corticosteroid dose reduction included: Safety Reasons (including elevated liver function test results, respiratory infections, infections and infestations, gastrointestinal disorders etc.); Other Reasons (disease remission, improvement etc.); and Unknown Reasons (including no reason). Number of participants by reasons (Safety, Other, Unknown) for corticosteroid dose reduction or discontinuation were reported. (NCT01941095)
Timeframe: From Baseline up to Week 52

Interventionparticipants (Number)
SafetyOtherUnknown
Tocilizumab6102

[back to top]

Number of Participants With American College of Rheumatology 20 (ACR20) Response

ACR20 response was defined as >/=20% improvement from baseline in both TJC28 and SJC28 as well as in 3 out of 5 additional parameters: Separate patient and physician's global assessment of disease activity on VAS (0 mm=no disease activity to 100 mm=maximum disease activity, displayed on the 100 mm horizontal VAS), patient's assessment of pain on VAS (0 mm=no pain to 100 mm=unbearable pain, displayed on the 100 mm horizontal VAS), Health Assessment Questionnaire - Disability Index (HAQ-DI) (20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities, 0=without any difficulty to 3=unable to do), and acute phase response (ESR in mm/hr, for a total possible score of 0 to 10). (NCT01941095)
Timeframe: Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52

Interventionparticipants (Number)
Week 2Week 4Week 8Week 12Week 16Week 20Week 24Week 28Week 32Week 36Week 40Week 44Week 48Week 52
Tocilizumab19192391316913101110121315

[back to top]

Patient Assessment of Pain, Using VAS Score

"The participant's level of pain was assessed on a 0 to 100 mm horizontal VAS. The extreme left end of the line = 0 mm, and was described as no pain and the extreme right end = 100 mm, and was described as unbearable pain. Higher values correspond to worst state of participant (higher level of pain)." (NCT01941095)
Timeframe: Baseline (Week 1), Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52

Interventionmm (Mean)
Week 1Week 2Week 4Week 8Week 12Week 16Week 20Week 24Week 28Week 32Week 36Week 40Week 44Week 48Week 52
Tocilizumab46.4052.0449.8742.7237.2134.2431.0029.5729.6325.5026.7827.5026.8823.6123.98

[back to top]

Percentage of Participants Who Achieved DAS28-ESR Remission/Low Disease Activity (LDA) From Week 28 up to Week 52 Among Participants With Intensification of Methotrexate/Other Non-Biologic DMARDs in Combination With Tocilizumab Since Week 24

DAS28-ESR score is a measure of participant's disease activity calculated using TJC28, SJC28, PGA using VAS 0 mm=no disease activity to 100 mm=maximum disease activity, displayed on the 100 mm horizontal VAS, and acute phase response (ESR in mm/hr) for a total possible score of 0 to 10. The score is calculated using the following formula: DAS28-ESR = [0.56 * √TJC28 + [0.28*√SJC28]+[0.70*ln ESR]+[0.014*GH]. DAS28-ESR score varies from 0 to 10, where higher scores represent greater disease activity. DAS28-ESR score <2.6 represents DAS28-ESR remission. DAS28-ESR score greater than or equal to (>/=) 2.6 and <3.2 represents LDA. (NCT01941095)
Timeframe: Weeks 28, 32, 36, 40, 44, 48, 52

Interventionpercentage of participants (Number)
Week 28: RemissionWeek 32: RemissionWeek 36: RemissionWeek 40: RemissionWeek 44: RemissionWeek 48: RemissionWeek 52: RemissionWeek 28: LDAWeek 32: LDAWeek 36: LDAWeek 40: LDAWeek 44: LDAWeek 48: LDAWeek 52: LDA
Tocilizumab5.18.14.19.56.98.567.61.46.86.86.94.29

[back to top]

Percentage of Participants Who Maintained DAS28-ESR Remission From Week 24 up to Week 52 Among Participants on Tocilizumab Monotherapy Since Week 24

DAS28-ESR score is a measure of participant's disease activity calculated using TJC28, SJC28, PGA using VAS 0 mm=no disease activity to 100 mm=maximum disease activity, displayed on the 100 mm horizontal VAS, and acute phase response (ESR in mm/hr) for a total possible score of 0 to 10. The score is calculated using the following formula: DAS28-ESR = [0.56 * √TJC28 + [0.28*√SJC28]+[0.70*ln ESR]+[0.014*GH]. DAS28-ESR score varies from 0 to 10, where higher scores represent greater disease activity. DAS28-ESR score <2.6 represents DAS28-ESR remission. The percentage reported for Week 24 is based on confirmation on switching to SC tocilizumab monotherapy. (NCT01941095)
Timeframe: Weeks 24, 28, 32, 36, 40, 44, 48, 52

Interventionpercentage of participants (Number)
Week 24Week 28Week 32Week 36Week 40Week 44Week 48Week 52
Tocilizumab38.734.236.536.536.535.235.738.8

[back to top]

Percentage of Participants With Good, Moderate, or No Response According to European League Against Rheumatism (EULAR) Response Criteria

Response to treatment was determined using EULAR criteria based upon DAS28 absolute scores at the assessment visit and the DAS28 reduction from the baseline visit. Participants with a score lesser than or equal to () 1.2 points were assessed as having a 'good' response. Participants with a score >3.2 with reduction of >1.2 points, or a score 0.6 to 5.1 with reduction of >0.6 to NCT01941095)
Timeframe: Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52

Interventionpercentage of participants (Number)
Week 2: Good responseWeek 2: Moderate responseWeek 2: No responseWeek 4: Good responseWeek 4: Moderate responseWeek 4: No responseWeek 8: Good responseWeek 8: Moderate responseWeek 8: No responseWeek 12: Good responseWeek 12: Moderate responseWeek 12: No responseWeek 16: Good responseWeek 16: Moderate responseWeek 16: No responseWeek 20: Good responseWeek 20: Moderate responseWeek 20: No responseWeek 24: Good responseWeek 24: Moderate responseWeek 24: No responseWeek 28: Good responseWeek 28: Moderate responseWeek 28: No responseWeek 32: Good responseWeek 32: Moderate responseWeek 32: No responseWeek 36: Good responseWeek 36: Moderate responseWeek 36: No responseWeek 40: Good responseWeek 40: Moderate responseWeek 40: No responseWeek 44: Good responseWeek 44: Moderate responseWeek 44: No responseWeek 48: Good responseWeek 48: Moderate responseWeek 48: No responseWeek 52: Good responseWeek 52: Moderate responseWeek 52: No response
Tocilizumab9.444.845.89.538.951.610.823.665.69.220.770.15.915.378.86.126.867.16.221.272.66.311.482.3018.981.11.314.983.85.417.6772.813.983.35.711.482.99460

[back to top]

PGA, Using VAS Score

"PGA was assessed on a 0 to 100 mm horizontal VAS. The extreme left end of the line = 0 mm, and was described as no disease activity (symptom-free and no arthritis symptoms) and the extreme right end = 100 mm, and was described as maximum disease activity (maximum arthritis disease activity). Higher values correspond to worst state of participant (high disease activity)." (NCT01941095)
Timeframe: Baseline (Week 1), Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52

Interventionmm (Mean)
Week 1Week 2Week 4Week 8Week 12Week 16Week 20Week 24Week 28Week 32Week 36Week 40Week 44Week 48Week 52
Tocilizumab28.2627.5728.3632.2828.7324.4028.1532.6326.0227.0830.7930.5025.7923.8623.08

[back to top]

Soluble Interleukin-6 Receptor (sIL-6R) Levels

(NCT01941095)
Timeframe: Baseline (Week 1), Weeks 12, 24, 36, 52, and 8 weeks after Week 52 dose (Week 60)

Interventionnanograms per milliliter (ng/mL) (Mean)
Week 1Week 12Week 24Week 36Week 52Week 60
Tocilizumab39450553.43572.03570.78537.7342850

[back to top]

Tocilizumab Serum Levels

(NCT01941095)
Timeframe: Baseline (Week 1), Weeks 12, 24, 36, 52, and 8 weeks after Week 52 dose (Week 60)

Interventionmicrogrms per milliliter (mcg/mL) (Mean)
Week 1Week 12Week 24Week 36Week 52Week 60
Tocilizumab0.3841.9844.6747.9045.376.46

[back to top]

Percentage of Participants Who Received All Planned Study Medication (Compliance)

Compliance (in terms of percentage of participants who received all planned study medication) was assessed on the basis of participant diary cards and return records. (NCT01941095)
Timeframe: Baseline (Week 1), Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52

Interventionpercentage of participants (Number)
Week 1Week 2Week 4Week 8Week 12Week 16Week 20Week 24Week 28Week 32Week 36Week 40Week 44Week 48Week 52
Tocilizumab6697.910010098.997.698.8100100100100100100100100

[back to top]

Number of Participants Experiencing a Severe Safety of Estrogens in Lupus Erythematosus National Assessment-Systemic Lupus Erythematosus-Disease Activity Index (SELENA-SLEDAI) Flare by Week 60

The SELENA-SLEDAI assesses systemic lupus erythematosus (SLE) disease activity and categorizes severe flares based on changes in the SLEDAI score, the Physician's Global Assessment (PGA), medication use (prednisone, Nonsteroidal anti-inflammatory drugs, Plaquenil, major immunosuppressives), other disease activity criteria, and hospitalization due to SLE. An estimate of the risk difference ((i.e. risk(MMF Withdrawal) - risk(MMF Maintenance) and its corresponding 95% confidence interval (CI) were also included. (NCT01946880)
Timeframe: Baseline (Treatment Randomization) to Week 60

InterventionParticipants (Count of Participants)
MMF Maintenance4
MMF Withdrawal8

[back to top]

Number of Participants Experiencing a Severe Safety of Estrogens in Lupus Erythematosus National Assessment-Systemic Lupus Erythematosus-Disease Activity Index (SELENA-SLEDAI) Flare by Week 60 Within the Lupus Nephritis Subgroup

The SELENA-SLEDAI assesses systemic lupus erythematosus (SLE) disease activity and categorizes severe flares based on changes in the SLEDAI score, the Physician's Global Assessment (PGA), medication use (prednisone, Nonsteroidal anti-inflammatory drugs, Plaquenil, major immunosuppressives), other disease activity criteria, and hospitalization due to SLE. An estimate of the risk difference ((i.e. risk(MMF Withdrawal) - risk(MMF Maintenance) and its corresponding 95% confidence interval (CI) were also included. (NCT01946880)
Timeframe: Baseline (Treatment Randomization) to Week 60

InterventionParticipants (Count of Participants)
MMF Maintenance3
MMF Withdrawal7

[back to top]

Number of Participants Experiencing a Severe Safety of Estrogens in Lupus Erythematosus National Assessment-Systemic Lupus Erythematosus-Disease Activity Index (SELENA-SLEDAI) Flare by Week 60 Within the Non-Lupus Nephritis Subgroup

The SELENA-SLEDAI assesses systemic lupus erythematosus (SLE) disease activity and categorizes severe flares based on changes in the SLEDAI score, the Physician's Global Assessment (PGA), medication use (prednisone, Nonsteroidal anti-inflammatory drugs, Plaquenil, major immunosuppressives), other disease activity criteria, and hospitalization due to SLE. An estimate of the risk difference ((i.e. risk(MMF Withdrawal) - risk(MMF Maintenance) and its corresponding 95% confidence interval (CI) were also included. (NCT01946880)
Timeframe: Baseline (Treatment Randomization) to Week 60

InterventionParticipants (Count of Participants)
MMF Maintenance1
MMF Withdrawal1

[back to top]

Number of Participants Experiencing Any British Isles Lupus Assessment Group (BILAG) A Flare by Week 60

The BILAG assesses participants on a variety of disease activity criteria in nine body system categories (constitutional, mucocutaneous, neuropsychiatric, musculoskeletal, cardiorespiratory, gastrointestinal, ophthalmic, renal, and hematological). Each category is scored as an A, B, C, or D/E, where A indicates most severe disease activity and D/E indicates inactive/no disease activity. An estimate of the risk difference ((i.e. risk(MMF Withdrawal) - risk(MMF Maintenance) and its corresponding 95% confidence interval (CI) were also included. (NCT01946880)
Timeframe: Baseline (Treatment Randomization) to Week 60

InterventionParticipants (Count of Participants)
MMF Maintenance1
MMF Withdrawal4

[back to top]

Number of Participants Experiencing Clinically Significant Disease Reactivation by Week 60

Disease reactivation requires:1) SELENA-SLEDAI mild/moderate or severe flare,and 2) Increased immunosuppressive therapy on a sustained basis,defined by one of the following criteria:a) Sustained activity:Significant prolonged SLE flare requiring steroid increase/burst to ≥15 mg/day prednisone (or equivalent) for >4 weeks.b) Frequent relapsing/remitting:Participant flares requiring an increase/burst of steroids and is successfully tapered to <15 mg/day within 4 weeks, but this occurs on >2 occasions, or IA, IM or IV steroids on more than1 occasion.c)Clinical activity of sufficient severity to warrant resumption of/increased dose of MMF or addition of other major immunosuppressive including AZA or MTX.Regardless of steroid use, if the investigator observes disease activity of sufficient severity to warrant resumption, addition or increase in dosage of major immunosuppressant in the setting of a SELENA-SLEDAI flare, participant has met the primary endpoint.Risk difference also included (NCT01946880)
Timeframe: Baseline (Treatment Randomization) to Week 60

InterventionParticipants (Count of Participants)
MMF Maintenance5
MMF Withdrawal9

[back to top]

Number of Participants Experiencing Severe Safety of Estrogens in Lupus Erythematosus National Assessment-Systemic Lupus Erythematosus-Disease Activity Index (SELENA-SLEDAI) Flare by Week 60 in the Baseline MMF <2000 mg/Day Subgroup

"The SELENA-SLEDAI assesses systemic lupus erythematosus (SLE) disease activity and categorizes severe flares based on changes in the SLEDAI score, the Physician's Global Assessment (PGA), medication use (prednisone, Nonsteroidal anti-inflammatory drugs, Plaquenil, major immunosuppressives), other disease activity criteria, and hospitalization due to SLE. An estimate of the risk difference ((i.e. risk(MMF Withdrawal) - risk(MMF Maintenance) and its corresponding 95% confidence interval (CI) were also included.~MMF: mycophenolate mofetil" (NCT01946880)
Timeframe: Baseline (Treatment Randomization) to Week 60

InterventionParticipants (Count of Participants)
MMF Maintenance3
MMF Withdrawal6

[back to top]

Number of Participants Experiencing Severe Safety of Estrogens in Lupus Erythematosus National Assessment-Systemic Lupus Erythematosus-Disease Activity Index (SELENA-SLEDAI) Flare by Week 60 in the Baseline MMF ≥ 2000 mg/Day Subgroup

"The SELENA-SLEDAI assesses systemic lupus erythematosus (SLE) disease activity and categorizes severe flares based on changes in the SLEDAI score, the Physician's Global Assessment (PGA), medication use (prednisone, Nonsteroidal anti-inflammatory drugs, Plaquenil, major immunosuppressives), other disease activity criteria, and hospitalization due to SLE. An estimate of the risk difference ((i.e. risk(MMF Withdrawal) - risk(MMF Maintenance) and its corresponding 95% confidence interval (CI) were also included.~MMF: mycophenolate mofetil" (NCT01946880)
Timeframe: Baseline (Treatment Randomization) to Week 60

InterventionParticipants (Count of Participants)
MMF Maintenance1
MMF Withdrawal2

[back to top]

Number of Participants in the Lupus Nephritis Subgroup Experiencing a British Isles Lupus Assessment Group (BILAG) A Renal Flare by Week 60

The BILAG assesses participants on a variety of disease activity criteria in nine body system categories (constitutional, mucocutaneous, neuropsychiatric, musculoskeletal, cardiorespiratory, gastrointestinal, ophthalmic, renal, and hematological). Each category is scored as an A, B, C, or D/E, where A indicates most severe disease activity and D/E indicates inactive/no disease activity. An estimate of the risk difference ((i.e. risk(MMF Withdrawal) - risk(MMF Maintenance) and its corresponding 95% confidence interval (CI) were also included. (NCT01946880)
Timeframe: Baseline (Treatment Randomization) to Week 60

InterventionParticipants (Count of Participants)
MMF Maintenance0
MMF Withdrawal2

[back to top]

Number of Serious Adverse Events (SAEs).

The number of SAEs. The severity of AEs was classified using the National Cancer Institute's Common Toxicity Criteria for Adverse Events (NCI-CTCAE), Version 4.0. (NCT01946880)
Timeframe: Baseline (Treatment Randomization) to Week 60

InterventionSerious Adverse Events (Number)
MMF Maintenance12
MMF Withdrawal6

[back to top]

The Addition of Aggressive Adjunctive Therapy to Mycophenolate Mofetil (MMF) or Change in MMF Therapy to Cytotoxic Drug Due to Flare by Week 60

The addition of aggressive adjunctive therapy could include intravenous (IV) immunoglobulin or rituximab at any point during the participant's study participation. A change in therapy to cytotoxic drug due to flare could include drugs such as cyclophosphamide, etc. A blinded list of study medications was reviewed to identify the addition of aggressive adjunctive therapy or cytotoxic drugs. (NCT01946880)
Timeframe: Baseline (Treatment Randomization) to Week 60

InterventionParticipants (Count of Participants)
MMF Maintenance0
MMF Withdrawal1

[back to top]

Time From Clinically Significant Disease Reactivation to Improvement in British Isles Lupus Assessment Group (BILAG) From Maximum Level During Flare

For each participant who experienced disease reactivation, time from clinically significant disease reactivation to improvement in BILAG from maximum level (at least an A or B) during the flare was calculated in study days as: date of clinically significant disease reactivation minus (-) date of BILAG improvement. If multiple body systems had a BILAG flare at the visit, then the body system with the most severe score was tracked for improvement; if multiple body systems had the same score (at least an A or B), then just one needed to show improvement. (NCT01946880)
Timeframe: Baseline (Treatment Randomization) to Week 60

InterventionDays (Mean)
MMF Maintenance114.5
MMF Withdrawal40.5

[back to top]

Time From Clinically Significant Disease Reactivation to Recovery to Baseline British Isles Lupus Assessment Group (BILAG) Score or BILAG C

For each participant who experienced disease reactivation, time from clinically significant disease reactivation to recovery to baseline BILAG scores or BILAG C, whichever is worse, was calculated in study days as: date of clinically significant disease reactivation minus (-) date of BILAG recovery. (NCT01946880)
Timeframe: Baseline (Treatment Randomization) to Week 60

InterventionDays (Mean)
MMF Maintenance114.5
MMF Withdrawal77.7

[back to top]

Time From Clinically Significant Disease Reactivation to Return to Pre-Flare Steroid Dose

For each participant who experienced disease reactivation, time from clinically significant disease reactivation to recovery to pre-flare steroid dose was calculated in study days as: date of clinically significant disease reactivation minus (-) date of return to pre-flare steroid dose. (NCT01946880)
Timeframe: Baseline (Treatment Randomization) to Week 60

InterventionDays (Mean)
MMF MaintenanceNA
MMF Withdrawal37

[back to top]

Time to Clinically Significant Disease Reactivation

The time to clinically significant disease reactivation was defined as the time from Baseline/Day 0 to the date of the first Severe Safety of Estrogens in Lupus Erythematosus National Assessment-Systemic Lupus Erythematosus-Disease Activity Index (SELENA-SLEDAI) assessment that met (or went on to meet) the criteria for clinically significant disease reactivation. Time to clinically significant disease reactivation was defined in study weeks as: date of SELENA-SLEDAI assessment that met reactivation criteria minus (-) baseline date. (NCT01946880)
Timeframe: Baseline (Treatment Randomization) to Week 60

InterventionWeeks (Mean)
MMF Maintenance38.0
MMF Withdrawal38.5

[back to top]

Number of Grade 3, 4, or 5 Adverse Events (AEs)

The number of Grade 3, 4, or 5 AEs. The severity of AEs was classified using the National Cancer Institute's Common Toxicity Criteria for Adverse Events (NCI-CTCAE), Version 4.0. (NCT01946880)
Timeframe: Baseline (Treatment Randomization) to Week 60

,
InterventionAdverse Events (Number)
Grade 3Grade 4Grade 5
MMF Maintenance1820
MMF Withdrawal1500

[back to top]

Time to First Mild/Moderate or Severe Safety of Estrogens in Lupus Erythematosus National Assessment-Systemic Lupus Erythematosus-Disease Activity Index (SELENA-SLEDAI) Flare

The time to first mild/moderate or severe SELENA-SLEDAI flare was defined as the time from Baseline/Day 0 to the date of the first mild/moderate or severe SELENA-SLEDAI flare. Time to SELENA-SLEDAI flare was defined in study weeks as: date of SELENA-SLEDAI flare minus (-) baseline date. The SELENA-SLEDAI assesses systemic lupus erythematosus (SLE) disease activity and categorizes mild/moderate or severe flares based on changes in the SLEDAI score, the Physician's Global Assessment (PGA), medication use (prednisone, Nonsteroidal anti-inflammatory drugs, Plaquenil, major immunosuppressives), other disease activity criteria, and hospitalization due to SLE. (NCT01946880)
Timeframe: Baseline (Treatment Randomization) to Week 60

InterventionWeeks (Mean)
MMF Maintenance20.5
MMF Withdrawal27.5

[back to top]

Time to First Severe Safety of Estrogens in Lupus Erythematosus National Assessment-Systemic Lupus Erythematosus-Disease Activity Index (SELENA-SLEDAI) Flare

The time to first severe SELENA-SLEDAI flare was defined as the time from Baseline/Day 0 to the date of the first severe SELENA-SLEDAI flare. Time to severe SELENA-SLEDAI flare was defined in study weeks as: date of SELENA-SLEDAI flare minus (-) baseline date. The SELENA-SLEDAI assesses systemic lupus erythematosus (SLE) disease activity and categorizes mild/moderate or severe flares based on changes in the SLEDAI score, the Physician's Global Assessment (PGA), medication use (prednisone, Nonsteroidal anti-inflammatory drugs, Plaquenil, major immunosuppressives), other disease activity criteria, and hospitalization due to SLE. (NCT01946880)
Timeframe: Baseline (Treatment Randomization) to Week 60

InterventionWeeks (Mean)
MMF Maintenance43.5
MMF Withdrawal41.5

[back to top]

Change From Baseline in the Functional Assessment of Chronic Illness Therapy (FACIT-F) Fatigue Scale (FS): Total Score

FACIT-Fatigue scale (FS) is a 13-item questionnaire completed by the patient (participant), that provides a measure of fatigue/quality of life, with a 7-day recall period. The participant scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The larger the participant's response to the questions (with the exception of 2 negatively stated), the greater the fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as 4 minus the participant's response. The sum of all responses resulted in the FACIT-FS score for a total possible score of 0 (worse score) to 52 (better score). A higher score reflected an improvement in the participant's health status. A decrease in the FACIT-FS score reflects worse fatigue/quality of life. (NCT01946880)
Timeframe: Baseline (Treatment Randomization) to Week 24, Week 48, and Week 60

,
Interventionunits on a scale (Mean)
Week 24Week 48Week 60
MMF Maintenance-2.41-3.39-3.13
MMF Withdrawal-0.81-0.850.42

[back to top]

Change From Baseline in the Lupus Quality of Life (QoL)Score

The Lupus QoL assessment is a 34 item questionnaire across 8 domains that is designed to find out how systemic lupus erythematosus (SLE) affects a participant's life over the preceding 4 weeks. Scores range from 0 (worst QoL) to 100 (best QoL). Domains include physical health, pain, planning, intimate relationships, burden to others, emotional health, body image, and fatigue. (NCT01946880)
Timeframe: Baseline (Treatment Randomization) to Week 24, Week 48, and Week 60

,
InterventionScores on a Scale (Mean)
Change in Physical Health at Week 24Change in Physical Health at Week 48Change in Physical Health at Week 60Change in Pain at Week 24Change in Pain at Week 48Change in Pain at Week 60Change in Planning at Week 24Change in Planning at Week 48Change in Planning at Week 60Change in Intimate Relationships at Week 24Change in Intimate Relationships at Week 48Change in Intimate Relationships at Week 60Change in Burden to Others at Week 24Change in Burden to Others at Week 48Change in Burden to Others at Week 60Change in Emotional Health at Week 24Change in Emotional Health at Week 48Change in Emotional Health at Week 60Change in Body Image at Week 24Change in Body Image at Week 48Change in Body Image at Week 60Change in Fatigue at Week 24Change in Fatigue at Week 48Change in Fatigue at Week 60
MMF Maintenance-1.11-2.830.00-0.17-3.10-0.190.35-5.43-3.03-1.47-0.81-2.081.56-0.58-1.33-0.87-2.03-1.522.94-0.173.223.78-2.18-0.57
MMF Withdrawal1.040.461.561.771.601.423.90-0.180.184.29-1.102.860.18-4.43-3.550.09-1.22-0.87-1.09-0.56-4.45-1.17-1.56-1.95

[back to top]

Change From Baseline in the Short Form Health Survey (SF-36) Physical Component Summary (PCS) Score

The SF-36 is a 36-item, patient-reported survey of patient health. Higher scores indicate better outcomes while lower scores indicate more disability. The Physical Component Score is comprised of the Physical Functioning Scale, the Role-Physical Scale, the Bodily Pain Scale, and the General Health Scale. It is scaled from 0 to 100 with a score of 0 equivalent to maximum disability and a score of 100 equivalent to no disability. (NCT01946880)
Timeframe: Baseline (Treatment Randomization) to Week 24, Week 48, and Week 60

,
InterventionScores on a Scale (Mean)
Week 24Week 48Week 60
MMF Maintenance-0.75-1.92-1.51
MMF Withdrawal0.900.251.51

[back to top]

Change From Baseline in the Short Form Health Survey (SF-36) Physical Functioning (PF) Score

The SF-36 is a 36-item, patient-reported survey of patient health. Higher scores indicate better outcomes while lower scores indicate more disability. The PF score is used to assess changes in physical functioning. It is scaled from 0 to 100 with a score of 0 equivalent to maximum disability and a score of 100 equivalent to no disability. (NCT01946880)
Timeframe: Baseline (Treatment Randomization) to Week 24, Week 48, and Week 60

,
InterventionScores on a Scale (Mean)
Week 24Week 48Week 60
MMF Maintenance-0.33-0.49-0.19
MMF Withdrawal0.220.951.79

[back to top]

Change From Baseline in the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Disease Damage Index for Systemic Lupus Erythematosus (SLICC/DI): Total Score

The SLICC/DI measures accumulated damage that has occurred since the onset of systemic lupus erythematosus (SLE), regardless of cause, in 12 organ systems. SLE damage is defined as an irreversible change in an organ or system that has been present for at least 6 months. The SLICC/DI includes 39 areas of damage in 12 domains, where each item is rated as present or absent; if evidence of damage is present for a particular item, it is given a score of 1. Some items are scored with 2 or 3 points in the case of recurring events or end stage renal disease. The SLICC/DI total score will be computed as the sum of all scores for items indicated as present; scores can range from 0 to 45. Higher scores indicate more damage. (NCT01946880)
Timeframe: Baseline (Treatment Randomization) to Week 24, Week 48, and Week 60

,
InterventionScores on a Scale (Mean)
Week 24Week 48Week 60
MMF Maintenance0.00.00.0
MMF Withdrawal0.00.00.0

[back to top] [back to top] [back to top]

Number of Grade 3, 4, or 5 Hematological Adverse Events (AEs).

The number of Grade 3, 4, or 5 hematological AEs. The severity of AEs was classified using the National Cancer Institute's Common Toxicity Criteria for Adverse Events (NCI-CTCAE), Version 4.0. (NCT01946880)
Timeframe: Baseline (Treatment Randomization) to Week 60

,
InterventionAdverse Events (Number)
Grade 3Grade 4Grade 5
MMF Maintenance300
MMF Withdrawal000

[back to top] [back to top]

All-Cause Mortality

All-cause mortality is defined as death from any cause occurring after randomization. The severity of AEs was classified using the National Cancer Institute's Common Toxicity Criteria for Adverse Events (NCI-CTCAE), Version 4.0. (NCT01946880)
Timeframe: Baseline (Treatment Randomization) to Week 60

InterventionParticipants (Count of Participants)
MMF Maintenance0
MMF Withdrawal0

[back to top]

Cumulative Excess Systemic Steroid Dose From Time of Clinically Significant Disease Reactivation to Return to Pre-Flare Dose or End of Trial Participation

"For each participant who experienced disease reactivation, excess systemic steroid dose was summed from the time of clinically significant disease reactivation until the dose returns to pre-flare levels or the end of study participation, whichever occurred first. Excess systemic steroid dose was defined as the total dose given for the flare minus (-) a participant's pre-flare steroid dose. Participants who do not have an increase in their steroid use due to the flare had their excess dose set to zero. Steroids include medications that code to a medication class which includes the terms glucocorticoid or corticosteroid. Systemic steroids will include any of these steroids that are taken by mouth (PO), intravenous (IV), or intramuscular (IM)." (NCT01946880)
Timeframe: Baseline (Treatment Randomization) to Week 60

InterventionSteroid dose (mg) (Mean)
MMF Maintenance812.8
MMF Withdrawal1750.7

[back to top]

Cumulative Systemic Steroid Dose by Week 60

"Steroids include medications that code to a medication class which includes the terms glucocorticoid or corticosteroid. Systemic steroids will include any of these steroids that are taken by mouth (PO), intravenous (IV), or intramuscular (IM). Total cumulative systemic steroid dose, in milligrams, was summarized over the 60 week study period, or until early study termination, for each participant." (NCT01946880)
Timeframe: Baseline (Treatment Randomization) to Week 60

Interventionsteroid dose (mg) (Mean)
MMF Maintenance851
MMF Withdrawal912

[back to top] [back to top]

Number of Malignancies Reported as Adverse Events (AEs).

The number of malignancies reported as AEs. The severity of AEs was classified using the National Cancer Institute's Common Toxicity Criteria for Adverse Events (NCI-CTCAE), Version 4.0. (NCT01946880)
Timeframe: Baseline (Treatment Randomization) to Week 60

InterventionAdverse Events (Number)
MMF Maintenance2
MMF Withdrawal3

[back to top]

Number of Participants Experiencing a Mild/Moderate or Severe Safety of Estrogens in Lupus Erythematosus National Assessment-Systemic Lupus Erythematosus-Disease Activity Index (SELENA-SLEDAI) Flare by Week 60

The SELENA-SLEDAI assesses systemic lupus erythematosus (SLE) disease activity and categorizes mild/moderate or severe flares based on changes in the SLEDAI score, the Physician's Global Assessment (PGA), medication use (prednisone, Nonsteroidal anti-inflammatory drugs, Plaquenil, major immunosuppressives), other disease activity criteria, and hospitalization due to SLE. An estimate of the risk difference ((i.e. risk(MMF Withdrawal) - risk(MMF Maintenance) and its corresponding 95% confidence interval (CI) were also included. (NCT01946880)
Timeframe: Baseline (Treatment Randomization) to Week 60

InterventionParticipants (Count of Participants)
MMF Maintenance20
MMF Withdrawal25

[back to top]

Number of Participants Experiencing a Mild/Moderate or Severe Safety of Estrogens in Lupus Erythematosus National Assessment-Systemic Lupus Erythematosus-Disease Activity Index (SELENA-SLEDAI) Flare by Week 60 in the Baseline MMF ≥ 2000 mg/Day Subgroup

"The SELENA-SLEDAI assesses systemic lupus erythematosus (SLE) disease activity and categorizes severe flares based on changes in the SLEDAI score, the Physician's Global Assessment (PGA), medication use (prednisone, Nonsteroidal anti-inflammatory drugs, Plaquenil, major immunosuppressives), other disease activity criteria, and hospitalization due to SLE. An estimate of the risk difference ((i.e. risk(MMF Withdrawal) - risk(MMF Maintenance) and its corresponding 95% confidence interval (CI) were also included.~MMF: mycophenolate mofetil" (NCT01946880)
Timeframe: Baseline (Treatment Randomization) to Week 60

InterventionParticipants (Count of Participants)
MMF Maintenance9
MMF Withdrawal12

[back to top]

Number of Participants Experiencing a Mild/Moderate or Severe Safety of Estrogens in Lupus Erythematosus National Assessment-Systemic Lupus Erythematosus-Disease Activity Index (SELENA-SLEDAI) Flare by Week 60 in the Baseline MMF<2000 mg/Day Subgroup

"The SELENA-SLEDAI assesses systemic lupus erythematosus (SLE) disease activity and categorizes severe flares based on changes in the SLEDAI score, the Physician's Global Assessment (PGA), medication use (prednisone, Nonsteroidal anti-inflammatory drugs, Plaquenil, major immunosuppressives), other disease activity criteria, and hospitalization due to SLE. An estimate of the risk difference ((i.e. risk(MMF Withdrawal) - risk(MMF Maintenance) and its corresponding 95% confidence interval (CI) were also included.~MMF: mycophenolate mofetil" (NCT01946880)
Timeframe: Baseline (Treatment Randomization) to Week 60

InterventionParticipants (Count of Participants)
MMF Maintenance11
MMF Withdrawal13

[back to top]

Number of Participants Experiencing a Mild/Moderate or Severe Safety of Estrogens in Lupus Erythematosus National Assessment-Systemic Lupus Erythematosus-Disease Activity Index (SELENA-SLEDAI) Flare by Week 60 Within the Lupus Nephritis Subgroup

The SELENA-SLEDAI assesses systemic lupus erythematosus (SLE) disease activity and categorizes severe flares based on changes in the SLEDAI score, the Physician's Global Assessment (PGA), medication use (prednisone, Nonsteroidal anti-inflammatory drugs, Plaquenil, major immunosuppressives), other disease activity criteria, and hospitalization due to SLE. An estimate of the risk difference ((i.e. risk(MMF Withdrawal) - risk(MMF Maintenance) and its corresponding 95% confidence interval (CI) were also included. (NCT01946880)
Timeframe: Baseline (Treatment Randomization) to Week 60

InterventionParticipants (Count of Participants)
MMF Maintenance15
MMF Withdrawal19

[back to top]

Number of Participants Experiencing a Mild/Moderate or Severe Safety of Estrogens in Lupus Erythematosus National Assessment-Systemic Lupus Erythematosus-Disease Activity Index (SELENA-SLEDAI) Flare by Week 60 Within the Non-Lupus Nephritis Subgroup

The SELENA-SLEDAI assesses systemic lupus erythematosus (SLE) disease activity and categorizes severe flares based on changes in the SLEDAI score, the Physician's Global Assessment (PGA), medication use (prednisone, Nonsteroidal anti-inflammatory drugs, Plaquenil, major immunosuppressives), other disease activity criteria, and hospitalization due to SLE. An estimate of the risk difference ((i.e. risk(MMF Withdrawal) - risk(MMF Maintenance) and its corresponding 95% confidence interval (CI) were also included. (NCT01946880)
Timeframe: Baseline (Treatment Randomization) to Week 60

InterventionParticipants (Count of Participants)
MMF Maintenance5
MMF Withdrawal6

[back to top]

Type of Surgical Procedure (Operation)

The number of participants in having each type of surgical resection procedure: Celiac Axis Resection With Distal Pancreatectomy (DPCAR) (Modified Appleby), Distal Pancreatectomy, Total Pancreatectomy, or Whipple. (Operation variable used in the proportional odds logistic regression, secondary analysis of Evans Grade). (NCT01978184)
Timeframe: At the time of surgery (≥2 weeks and ≤6 weeks post chemotherapy)

,
InterventionParticipants (Count of Participants)
DPCARDistal PancreatectomyTotal PancreatectomyWhipple
Gemcitabine + Abraxane23124
Gemcitabine + Abraxane and Hydroxychloroquine05036

[back to top]

Age-Adjusted Charlson Comorbidity Index

The Charlson Comorbidity Index is a method of categorizing comorbidities of patients based on the International Classification of Diseases (ICD) diagnosis codes found in administrative data, such as hospital abstracts data. Each comorbidity category has an associated weight (from 1 to 6), based on the adjusted risk of mortality or resource use, and the sum of all the weights results in a single comorbidity score for a patient. A score of zero indicates that no comorbidities were found. The higher the score, the more likely the predicted outcome will result in mortality or higher resource use. Up to 12 comorbidities with various weightings can result in a maximum score of 24. The minimum score is zero. (NCT01978184)
Timeframe: Prior to treatment

,
InterventionParticipants (Count of Participants)
Age-Adjusted CCI=2Age-Adjusted CCI=3Age-Adjusted CCI=4Age-Adjusted CCI=5Age-Adjusted CCI=6Age-Adjusted CCI=7Age-Adjusted CCI=8
Gemcitabine + Abraxane3578520
Gemcitabine + Abraxane and Hydroxychloroquine121115822

[back to top]

Age at Diagnosis

The mean age of patients at the time of diagnosis of disease (as a variable in the proportional odds logistic regression, secondary analysis of Evans Grade). (NCT01978184)
Timeframe: Baseline - At the time of diagnosis, prior to treatment

Interventionyears (Mean)
Gemcitabine + Abraxane63.6
Gemcitabine + Abraxane and Hydroxychloroquine66.1

[back to top]

Cancer Diagnosis Stage

"The number of participants in cancer diagnosis stage groups. Stage 0: cancer hasn't spread to nearby tissues/located in the same of origin.Stage I: cancers hasn't grown deeply into nearby tissues or spread to lymph nodes or other parts of the body. Stage II and III: cancers have grown more deeply into nearby tissues (may have metastasized to lymph nodes but not other parts of the body). Stage IV: most advanced stage (metastatic cancer) ; cancer has spread to other parts of the body. Stages subdivided further into the categories A (less agressive disease) and B (more advanced cancer). Example: stage IIA is less aggressive than stage IIB, but stage IIIA is more aggressive than stage IIB. (Stage variable used in the proportional odds logistic regression, secondary analysis of Evans Grade)." (NCT01978184)
Timeframe: Baseline - At the time of diagnosis, prior to treatment

,
InterventionParticipants (Count of Participants)
IAIBIIAIIBNot Available
Gemcitabine + Abraxane056190
Gemcitabine + Abraxane and Hydroxychloroquine2111207

[back to top]

Evans Grade Histopathologic Response

The number of patients who exhibited an Evans grade Histologic response (I, IIA, IIB, or III) to pre-operative gemcitabine / nab-paclitaxel. Histological response validated scoring system by Evans is as follows: Grade I: 1-9% tumor destruction, Grade II: 10 - 90%, Grade III: >90% tumor destruction (Grade IIA = 10-50% of tumor cells destroyed; Grade IIB = 50-90% of tumor cells destroyed), Grade IV: Absence of viable tumor cells. (NCT01978184)
Timeframe: Up to 4 years

,
Interventionnumber of participants (Number)
Evans grade - IEvans grade - IIAEvans grade - IIBEvans grade - III
Gemcitabine + Abraxane101730
Gemcitabine + Abraxane and Hydroxychloroquine712139

[back to top]

Robotic Resection Surgery

The number of participants who had robotic resection surgery. (Robotic surgery variable used in the proportional odds logistic regression, secondary analysis of Evans Grade). (NCT01978184)
Timeframe: At the time of surgery (≥2 weeks and ≤6 weeks post chemotherapy)

,
InterventionParticipants (Count of Participants)
Yes - robotic surgical resection procedureNo - not robotic surgical resection procedure
Gemcitabine + Abraxane822
Gemcitabine + Abraxane and Hydroxychloroquine1031

[back to top]

Carbohydrate Antigen 19-9 (CA19-9) Response

Levels of Carbohydrate antigen 19-9 (CA19-9) response to pre-operative gemcitabine/ nab-paclitaxel measured in the serum (original scale) (NCT01978184)
Timeframe: Prior to treatment (average 73.3 +/- 9.9 days prior to surgery)

Interventionunits per milliliter (U/mL) (Mean)
Gemcitabine + Abraxane351.820
Gemcitabine + Abraxane and Hydroxychloroquine1534.633

[back to top]

Carbohydrate Antigen 19-9 (CA19-9) Response

Levels of Carbohydrate antigen 19-9 (CA19-9) response to pre-operative gemcitabine/ nab-paclitaxel measured in the serum (original scale). (NCT01978184)
Timeframe: After treatment (50-67 days post treatment/surgery)

Interventionunits per milliliter (U/mL) (Mean)
Gemcitabine + Abraxane319.079
Gemcitabine + Abraxane and Hydroxychloroquine1696.710

[back to top]

CT Tumor Size

Tumor size as measured via computerized tomography (CT) scan (as a variable in the proportional odds logistic regression, secondary analysis of Evans Grade). (NCT01978184)
Timeframe: Baseline - At the time of diagnosis, prior to treatment

Interventioncentimeters (Mean)
Gemcitabine + Abraxane2.562069
Gemcitabine + Abraxane and Hydroxychloroquine2.543056

[back to top]

Positive Lymph Node Involvement

The proportion of participants with positive (disease) lymph nodes involvement. (NCT01978184)
Timeframe: At the time of surgery (≥2 weeks and ≤6 weeks post chemotherapy)

Interventionproportion of participants (Number)
Gemcitabine + Abraxane0.8
Gemcitabine + Abraxane and Hydroxychloroquine0.561

[back to top]

Rate of R0 Resection

The proportion of participants having resection for cure or complete remission, in which the surgical margins are negative for tumor cells. R0 resection indicates a microscopically margin-negative resection, in which no gross or microscopic tumor remains in the primary tumor bed. (NCT01978184)
Timeframe: At the time of surgery (≥2 weeks and ≤6 weeks post chemotherapy)

Interventionproportion of participants (Mean)
Gemcitabine + Abraxane0.7
Gemcitabine + Abraxane and Hydroxychloroquine0.829

[back to top]

Effect of HCQ on Fasting Low Density Lipoprotein

determined by lipid profile with calculated LDL performed at baseline and follow-up (NCT02026232)
Timeframe: 4 weeks

,
Interventionmg/dL (Mean)
Baseline - LDL (mg/dL)Follow-up - LDL (mg/dL)
Hydroxychloroquine90.472.4
Placebo92.887.7

[back to top]

Effect of HCQ on Fasting Blood Glucose

determined by fasting blood glucose performed at baseline and follow-up (NCT02026232)
Timeframe: 4 weeks

,
Interventionmg/dL (Mean)
Baseline Glucose (mg/dL)Follow-up Glucose (mg/dL)
Hydroxychloroquine186.9165.9
Placebo163.1158.8

[back to top]

Area Under the Serum Concentration Versus Time Curve Calculated Using the Trapezoidal Method During a Dose Interval (AUC[0-tau]) for Sarilumab

AUC(0-tau) is defined as area under the serum concentration versus time curve calculated using the trapezoidal method during a dose interval, where dose interval was 2 weeks. Serum concentrations of sarilumab were analyzed using validated enzyme linked immunosorbent assay (ELISA). (NCT02057250)
Timeframe: Week 0-2: pre-dose on Day 1, anytime post-dose on Day 3, Day 5, Day 8, Day 12, Day 15; Week 10-12: pre-dose on Day 71, anytime post-dose on Day 73, Day 75, Day 78, Day 82, Day 85

,,,
Interventionmg*day/L (Mean)
Week 0-2Week 10-12
Sarilumab 150 mg by AID (AID Assessment Phase)131205
Sarilumab 150 mg by PFS (AID Assessment Phase)152220
Sarilumab 200 mg by AID (AID Assessment Phase)235455
Sarilumab 200 mg by PFS (AID Assessment Phase)227405

[back to top]

Number of Validated AID Associated Product Technical Failures (PTFs)

"A PTF was defined as any product technical complaint (PTC) related to the use of the AID that had a validated technical cause. Each participant was given a diary having questions related to participant's ability to remove the cap, to start the injection, to complete the injection and regarding confirmation of completing the injection. Participants were asked to answer the questions each time they self-inject the sarilumab. If the response was no to any of the first 3 questions, this was considered as a PTC. The used AID, for which PTC was reported, was sent to sponsor, examined and evaluated for the occurrence of a PTF." (NCT02057250)
Timeframe: Baseline up to Week 12

InterventionPTFs (Number)
Sarilumab 150 mg by AID (AID Assessment Phase)0
Sarilumab 200 mg by AID (AID Assessment Phase)0

[back to top]

Change in Number of CCR5+CD4+ T Cell Population at the Female Genital Tract.

We will measure changes in the number of CD4+T cells expressing CCR5 at the female genital tract before and at the end of the study. (NCT02079077)
Timeframe: baseline and 8 weeks

Interventionpercentage of cells (Median)
Acetylsalicylic Acid (ASA)17.60
Hydroxychloroquine (HCQ)22.10

[back to top]

Changes in Systemic Immune Activation From Baseline Observed by the CD69 Expression on CD4 T Cells

We will analyse reduce of immune activation by measuring change in T cell activation (CD69) between baseline and every month during drug administration phase (8 weeks). (NCT02079077)
Timeframe: Baseline and 8 weeks

,
Interventionpercentage of cells (Mean)
Average of CD4+CD69+ at baselineAverage of CD4+CD69+ T cells cells after treatment
Acetylsalicylic Acid (ASA)4.044.9
Hydroxychloroquine (HCQ)5.554.99

[back to top]

Patients With Elevated Par-4 Levels

Number of patients with 2-fold change in Par-4 levels from baseline to day 14 (NCT02232243)
Timeframe: Baseline and day 14

InterventionParticipants (Count of Participants)
Initial: Hydroxychloroquine 400mg HCQ3
Secondary: Hydroxychloroquine 800mg HCQ2
Tertiary: Hydroxychloroquine 400mg HCQ1

[back to top]

Optimal Biologic Dose of Hydroxychloroquine

Dose (mg twice daily) wherein 70% of patients exhibit a 2-fold increase in Par-4 levels with a dose-limiting toxicity of no more than 30%. (NCT02232243)
Timeframe: Day 14

Interventionmg twice daily (Number)
All Patients200

[back to top]

Weight

Body weight (NCT02303405)
Timeframe: 4 months

Interventionkilograms (Mean)
Hydroxychloroquine85.4
Pioglitazone87.0

[back to top]

Adverse Events

All other adverse events other than hypoglycemia (NCT02303405)
Timeframe: 4 months

InterventionEvents (Number)
Hydroxychloroquine0
Pioglitazone1.0

[back to top]

Body Mass Index

Body mass index (BMI) (NCT02303405)
Timeframe: 4 months

Interventionkg per square meter (Mean)
Hydroxychloroquine35.2
Pioglitazone35.5

[back to top]

Fasting Plasma Glucose

Fasting glucose level (NCT02303405)
Timeframe: 4 months

Interventionmg/dL (Mean)
Hydroxychloroquine147
Pioglitazone105

[back to top]

Hemoglobin A1c

Glycemic control (NCT02303405)
Timeframe: 4 months

Intervention% of hemoglobin (Mean)
Hydroxychloroquine7.4
Pioglitazone6.3

[back to top]

HOMA-IR

Insulin resistance by the HOMA model (NCT02303405)
Timeframe: 4 months

InterventionuU/mL*mg/dL (Mean)
Hydroxychloroquine3.91
Pioglitazone1.48

[back to top]

Hs-CRP

Highly-sensitive C-reactive protein (inflammatory marker) (NCT02303405)
Timeframe: 4 months

Interventionmg/L (Mean)
Hydroxychloroquine4.2
Pioglitazone3.3

[back to top]

Hypoglycemic Events

Number of hypoglycemic events (NCT02303405)
Timeframe: 4 months

InterventionEvents (Number)
Hydroxychloroquine0
Pioglitazone6.0

[back to top]

Leucocyte Count

White cell count (surrogate marker of inflammation) (NCT02303405)
Timeframe: 4 months

Interventionx 10^9 cells/ L (Mean)
Hydroxychloroquine7.7
Pioglitazone6.8

[back to top]

Percent of Subjects Achieving HbA1c < 7.5%

Percent of subjects achieving a HbA1c level < 7.5% (NCT02303405)
Timeframe: 4 months

InterventionParticipants (Count of Participants)
Hydroxychloroquine10
Pioglitazone7

[back to top]

QUICKI

Insulin resistance by the QUICKI model (NCT02303405)
Timeframe: 4 months

Intervention(Log(uU/dL)+Log(mg/dL))^-1 (Mean)
Hydroxychloroquine0.32
Pioglitazone0.38

[back to top]

Change From Baseline in the MDS of the Aorta

"The outcome was the change in the mean of the maximum of the target to background ratio (TBR) in the most diseased segment (MDS) of the aorta as measured by FDG-PET/CT scans conducted at baseline and after 24 weeks of randomized treatment allocation (MDS meanmaxTBR). Higher values indicate greater vascular inflammation.~FDG uptake measurement: PET-CT images were batch-analyzed by an investigator blinded to the patients' clinical information. FDG uptake was evaluated within the wall of the ascending aorta and bilateral carotid arteries (as maximum and mean standardized FDG uptake value [SUVmax and SUVmean, respectively]) approximately every 5 mm on axial images. Subsequently, the target-to-background ratio (TBR) was reported (ratio of the average arterial to blood axial slice SUVmax) to correct for the blood compartment contribution." (NCT02374021)
Timeframe: 0, 6 months

InterventionRatio (Mean)
Triple Therapy (MTX+SSZ+HCQ)-0.17
TNF Inhibitor (Etanercept or Adalimumab)-0.17

[back to top]

Change From Baseline in the Average TBR of the Index Vessel

"The outcome was the change in the target to background ratio (TBR) in the index vessel as measured by FDG-PET/CT scans conducted at baseline and after 24 weeks of randomized treatment allocation (MDS meanmaxTBR). Higher values indicate greater vascular inflammation.~FDG uptake measurement: PET-CT images were batch-analyzed by an investigator blinded to the patients' clinical information. FDG uptake was evaluated within the wall of the ascending aorta and bilateral carotid arteries (as maximum and mean standardized FDG uptake value [SUVmax and SUVmean, respectively]) approximately every 5 mm on axial images. Subsequently, the target-to-background ratio (TBR) was reported (ratio of the average arterial to blood axial slice SUVmax) to correct for the blood compartment contribution." (NCT02374021)
Timeframe: 0, 6 months

InterventionRatio (Mean)
Triple Therapy (MTX+SSZ+HCQ)-0.07
TNF Inhibitor (Etanercept or Adalimumab)-0.09

[back to top]

Change From Baseline in the Average TBR of the Bilateral Carotids

"The outcome was the change in the target to background ratio (TBR) of the average of the left and right carotids as measured by FDG-PET/CT scans conducted at baseline and after 24 weeks of randomized treatment allocation (MDS meanmaxTBR). The baseline values of the left and right carotids were averaged and then the follow-up values of the left and right carotids were averaged resulting in one value at each time point. Higher values indicate greater vascular inflammation.~FDG uptake measurement: PET-CT images were batch-analyzed by an investigator blinded to the patients' clinical information. FDG uptake was evaluated within the wall of the ascending aorta and bilateral carotid arteries (as maximum and mean standardized FDG uptake value [SUVmax and SUVmean, respectively]) approximately every 5 mm on axial images. Subsequently, the target-to-background ratio (TBR) was reported (ratio of the average arterial to blood axial slice SUVmax) to correct for the blood compartment contribution. (NCT02374021)
Timeframe: 0, 6 months

InterventionRatio (Mean)
Triple Therapy (MTX+SSZ+HCQ)-0.10
TNF Inhibitor (Etanercept or Adalimumab)-0.06

[back to top]

Change From Baseline in the Average TBR of the Aorta

"The outcome was the change in the target to background ratio (TBR) of the aorta as measured by FDG-PET/CT scans conducted at baseline and after 24 weeks of randomized treatment allocation (MDS meanmaxTBR). Higher values indicate greater vascular inflammation.~FDG uptake measurement: PET-CT images were batch-analyzed by an investigator blinded to the patients' clinical information. FDG uptake was evaluated within the wall of the ascending aorta and bilateral carotid arteries (as maximum and mean standardized FDG uptake value [SUVmax and SUVmean, respectively]) approximately every 5 mm on axial images. Subsequently, the target-to-background ratio (TBR) was reported (ratio of the average arterial to blood axial slice SUVmax) to correct for the blood compartment contribution." (NCT02374021)
Timeframe: 0, 6 months

InterventionRatio (Mean)
Triple Therapy (MTX+SSZ+HCQ)-0.06
TNF Inhibitor (Etanercept or Adalimumab)-0.02

[back to top]

Change From Baseline in Vascular Inflammation as Measured by FDG-PET/CT at 6 Months

"The primary outcome was the change in the mean of the maximum of the target to background ratio (TBR) in the most diseased segment (MDS) of of the index vessel as measured by FDG-PET/CT scans conducted at baseline and after 24 weeks of randomized treatment allocation (MDS meanmaxTBR). The index vessel is the vessel (either aorta, left carotid, or right carotid) with the highest meanmaxTBR at baseline. Higher values indicate greater vascular inflammation.~FDG uptake measurement: PET-CT images were batch-analyzed by an investigator blinded to the patients' clinical information. FDG uptake was evaluated within the wall of the ascending aorta and bilateral carotid arteries (as maximum and mean standardized FDG uptake value [SUVmax and SUVmean, respectively]) approximately every 5 mm on axial images. Subsequently, the target-to-background ratio (TBR) was reported (ratio of the average arterial to blood axial slice SUVmax) to correct for the blood compartment contribution." (NCT02374021)
Timeframe: 0, 6 months

Interventionratio (Mean)
Triple Therapy (MTX+SSZ+HCQ)-0.19
TNF Inhibitor (Etanercept or Adalimumab)-0.24

[back to top]

Percent of Participants Experiencing Grade 3 or Higher Adverse Events (AEs)

Adverse Events (AEs) grading will be defined by the National Cancer Institute (NCI) - Common Terminology Criteria for Adverse Events (CTCAE), version 4.0. The number of AEs will be identified by monitoring participant-reported AEs, vital signs, medical history, physical exams and blood safety tests. (NCT02603146)
Timeframe: Non-serious AEs were collected from treatment initiation through month 18. Serious AEs were collected from screening through month 36.

InterventionPercent of Participants (Number)
Hydroxychloroquine14.1
Placebo12.3

[back to top]

Time to Development of Clinically-Apparent Rheumatoid Arthritis (CL - RA) By Treatment Arm

"Mean Time from treatment initiation until development of CL-RA. CL- RA is defined by the 2010 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) Classification Criteria as either: 1.) a score of ≥ 6 defining definite RA or 2.) a joint examination consistent with IA with ≥ 1 erosion confirmed by x-ray imaging of the hands, wrists, and feet." (NCT02603146)
Timeframe: Baseline to Month 36

Interventionmonths (Mean)
Hydroxychloroquine29.02
Placebo28.49

[back to top]

Level of Anti-Cyclic Citrullinated Peptide-3 (Anti-CCP3) By Treatment Arm

Anti-CCP3 is a laboratory test for the presence of antibodies to citrullinated protein antigens (ACPAs) in serum. ACPA positivity assists with the classification/diagnosis of Rheumatoid Arthritis (RA) of a patient with Inflammatory Arthritis (IA). In addition, determining autoantibody positivity helps with the prediction of RA disease severity. Anti-CCP3 positivity at any level, and in particular anti-CCP3 levels of ≥2 times the normal cut-off level (or ≥ 40 units) are highly predictive of future RA development. (NCT02603146)
Timeframe: Baseline, Week 52 (End of Treatment), Month 36/End of Study

,
Interventionunits (Median)
BaselineWeek 52Month 36
Hydroxychloroquine184.20105.65154.75
Placebo125.5594.485.20

[back to top]

Level of High-Sensitivity C-Reactive Protein (hsCRP) Treatment Arm

HsCRP is used to detect systemic inflammation in the body, assists with the classification/diagnosis of Rheumatoid Arthritis (RA), and elevations of hsCRP in patients with RA have been associated with poor disease outcomes. (NCT02603146)
Timeframe: Baseline, Week 52 (End of Treatment), Month 36/End of Study

,
Interventionmg/L (Median)
BaselineWeek 52Month 36
Hydroxychloroquine2.0302.3002.075
Placebo3.0431.4301.645

[back to top]

Level of Immunoglobulin M - Rheumatoid Factor (IgM-RF) By Treatment Arm

IgM-RF is a laboratory test for the presence of antibodies to RF in serum. IgM-RF positivity assists with the classification/diagnosis of Rheumatoid Arthritis (RA) of a patient with Inflammatory Arthritis (IA). In addition, determining autoantibody positivity helps with the prediction of RA disease severity. Higher levels of antibodies (e.g. >2-3 times the normal cut-off values) have greater specificity for RA disease. (NCT02603146)
Timeframe: Baseline, Week 52 (End of Treatment), Month 36/End of Study

,
InterventionU/mL (Median)
BaselineWeek 52Month 36
Hydroxychloroquine13.1003.6005.730
Placebo5.3502.0250.250

[back to top]

Number of Participant Self-Reported Painful Joints By Treatment Arm

The Participant Self-Reported Joint Symptoms assessment was used by participants to indicate which joints were painful on the day of the visit or in the past week. The Participant Self-Reported Joint Symptoms assessment contained a diagram of the body joints which participants used to mark their painful joints. (NCT02603146)
Timeframe: At Week 52 and Month 36/End of Study

,
Interventionjoints (Median)
Week 52Month 36
Hydroxychloroquine1.01.0
Placebo1.02.0

[back to top]

Number of Participant Self-Reported Painful Joints in the Hands, Wrists and Feet By Treatment Arm

The Participant Self-Reported Joint Symptoms assessment was used by participants to indicate which joints were painful on the day of the visit or in the past week. The Participant Self-Reported Joint Symptoms assessment contained a diagram of the body joints which participants used to mark their painful joints. (NCT02603146)
Timeframe: At Week 52 and Month 36/End of Study

,
InterventionJoints (Median)
Week 52Month 36
Hydroxychloroquine0.00.0
Placebo0.00.0

[back to top]

Number of Participant Self-Reported Stiff Joints By Treatment Arm

The Participant Self-Reported Joint Symptoms assessment was used by participants to indicate which joints were stiff on the day of the visit or in the past week. The Participant Self-Reported Joint Symptoms assessment contained a diagram of the body joints which participants used to mark their stiff joints. (NCT02603146)
Timeframe: At Week 52 and Month 36/End of Study

,
InterventionJoints (Median)
Week 52Month 36
Hydroxychloroquine1.00.0
Placebo1.01.0

[back to top]

Number of Participant Self-Reported Stiff Joints in the Hands, Wrists and Feet By Treatment Arm

The Participant Self-Reported Joint Symptoms assessment was used by participants to indicate which joints were stiff on the day of the visit or in the past week. The Participant Self-Reported Joint Symptoms assessment contained a diagram of the body joints which participants used to mark their stiff joints. (NCT02603146)
Timeframe: At Week 52 and Month 36/End of Study

,
InterventionJoints (Median)
Week 52 resultsMonth 36 results
Hydroxychloroquine0.00.0
Placebo0.012

[back to top]

Number of Participant Self-Reported Swollen Joints By Treatment Arm

The Participant Self-Reported Joint Symptoms assessment was used by participants to indicate which joints were swollen on the day of the visit or in the past week. The Participant Self-Reported Joint Symptoms assessment contained a diagram of the body joints which participants used to mark their swollen joints. (NCT02603146)
Timeframe: At Week 52 and Month 36/End of Study

,
InterventionJoints (Median)
Week 52Month 36
Hydroxychloroquine0.00.0
Placebo0.00.0

[back to top]

Number of Participant Self-Reported Swollen Joints in the Hands, Wrists and Feet By Treatment Arm

The Participant Self-Reported Joint Symptoms assessment was used by participants to indicate which joints were swollen on the day of the visit or in the past week. The Participant Self-Reported Joint Symptoms assessment contained a diagram of the body joints which participants used to mark their swollen joints. (NCT02603146)
Timeframe: At Week 52 and Month 36/End of Study

,
InterventionJoints (Median)
Week 52Month 36
Hydroxychloroquine0.00.0
Placebo0.00.0

[back to top]

Number of Participants Who Developed Clinically-Apparent Rheumatoid Arthritis (CL - RA) From Treatment Initiation to Month 36 By Treatment Arm

"Clinically-Apparent RA is defined by the 2010 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) Classification Criteria as either: 1.) a score of ≥ 6 defining definite RA or 2.) a joint examination consistent with Inflammatory Arthritis (IA) with ≥ 1 erosion confirmed by x-ray imaging of the hands, wrists, and feet." (NCT02603146)
Timeframe: Baseline to Month 36

InterventionParticipants (Count of Participants)
Hydroxychloroquine20
Placebo24

[back to top]

Number of Participants Who Developed Clinically-Apparent Rheumatoid Arthritis (CL-RA) From Treatment Initiation to Month 12 By Treatment Arm

"Clinically-Apparent RA is defined by the 2010 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) Classification Criteria as either: 1.) a score of ≥ 6 defining definite RA or 2.) a joint examination consistent with IA with ≥ 1 erosion confirmed by x-ray imaging of the hands, wrists, and feet." (NCT02603146)
Timeframe: Baseline to Month 12

InterventionParticipants (Count of Participants)
Hydroxychloroquine11
Placebo13

[back to top]

Number of Participants Who Developed Inflammatory Arthritis (IA) From Treatment Initiation to Month 12.

IA is defined as the development of at least one swollen joint consistent with rheumatoid arthritis-like (RA-like) synovitis. The joint exams conducted by a physician at each clinic visit were used to identify the presence of swollen joints due to IA. (NCT02603146)
Timeframe: Baseline to Month 12

InterventionParticipants (Count of Participants)
Hydroxychloroquine12
Placebo13

[back to top]

Number of Participants Who Developed Inflammatory Arthritis (IA) From Treatment Initiation to Month 36

IA is defined as the development of at least one swollen joint consistent with rheumatoid arthritis-like (RA-like) synovitis. The joint exams conducted by a physician at each clinic visit were used to identify the presence of swollen joints due to IA. (NCT02603146)
Timeframe: Baseline to Month 36

InterventionParticipants (Count of Participants)
Hydroxychloroquine21
Placebo27

[back to top]

Disease Activity as Per Ultrasound-7 (US-7) Score

Ultrasound 7 score (US-7) Calculates ultrasound score in 7 joints using greyscale and power doppler to evaluate for disease activity (synovitis, tenosynovitis) and damage (erosions) Score minimum value= 0 Maximum value = 108 Higher score indicates worse disease (NCT02930343)
Timeframe: 12 weeks

Interventionunits on a scale (Median)
Group 1- MTX+LEF+HCQ3.5
Group 2- MTX+SSZ+HCQ4

[back to top]

Indian Health Assessment Questionnaire (iHAQ)

Indian version of Health assessment Questionnaire (iHAQ) Comprises of 12 questions relating to functional activity iHAQ score ranges from 0 to 3 (minimum 0, maximum 3) Higher scores indicate more disability (NCT02930343)
Timeframe: 12 weeks

Interventionscore on a scale (Median)
Group 1- MTX+LEF+HCQ0.7
Group 2- MTX+SSZ+HCQ0.5

[back to top]

Number of Patients Achieving Good EULAR Response at the End of 12 Weeks

"EULAR response criteria for Rheumatoid arthritis includes- estimation of DAS 28 ESR, that includes-~Tender joint count 28~Swollen joint count 28~ESR~Patient global assessment of health" (NCT02930343)
Timeframe: 12 weeks

Interventionparticipants (Number)
Group 1- MTX+LEF+HCQ40
Group 2- MTX+SSZ+HCQ37

[back to top]

Number of Participants With Adverse Drug Reactions

Infections, transaminitis, nausea, vomiting, derranged renal function tests etc (NCT02930343)
Timeframe: 24 weeks

,
InterventionParticipants (Count of Participants)
Total number of any adverse eventsSerious adverse eventsAny gastrointestinal adverse reactionNauseaDiarrheaSwitch to parenteral MethotrexateRaised liver enzymes > 2 times upper limit normalHerpes labialisupper respiratory tract infectionurinary tract infectionHypertensionhairfallCytopenia
Group 1- MTX+LEF+HCQ150114151051120
Group 2- MTX+SSZ+HCQ2101661141250020

[back to top]

Serum Levels of Hydroxycloroquine

Serum levels of hydroxycloroquine by LCMS (NCT03122431)
Timeframe: 12 months

Interventionng/mL (Mean)
Inactive SLE With Standard Dose of HCQ991.6
Inactive SLE With Reduced Dose of HCQ569.0

[back to top]

Serum Levels of Thalidomide

Serum levels of thalidomide by liquid chromatography and tandem mass spectrometry (HPLC-MS/MS) (NCT03122431)
Timeframe: 12 months

Interventionng/mL (Mean)
SLE/Cutaneous Lupus With Thalidomide415.1

[back to top]

Maximum Tolerated Dose (MTD) of Hydroxychloroquine and Entinostat in Combination With Regorafenib

Participants were evaluable for toxicity if they have taken one dose of HCQ and one dose of entinostat. To be considered for evaluability in a Phase I cohort in the absence of dose-limiting toxicity, patients should have completed > 85% of HCQ doses, and at least 3 of 4 entinostat doses. The MTD will be defined as a) the dose producing DLT in 1 out of 6 patients, or b) the dose level below the dose which produced DLT in ≥ 2 out of 3 patients, or in ≥ 2 out of 6 patients. DLTs will be defined by toxicity occurring during the first 4 weeks of this study. (NCT03215264)
Timeframe: 18 months

Interventionmg (Number)
Hydroxychloroquine DailyEntinostat weekly
All Participants12005

[back to top]

Change in Disease Severity

Comparison of baseline and post-treatment Sartorius severity scoring Sartorius scoring: minimum 0, no maximum, higher scores mean a worse outcome (NCT03275870)
Timeframe: 6 months

Interventionscore on a scale (Mean)
Baseline sartorius score6 month sartorius score
Hydroxychloroquine Treatment23.317.7

[back to top]

Change in Quality of Life

Comparison of baseline and post-treatment self-reported quality of life Dermatology Life Quality Index score: minimum 0, maximum 30. higher scores mean worse outcome. (NCT03275870)
Timeframe: 6 months

Interventionscore on a scale (Mean)
Baseline DLQI score6 month DLQI score
Hydroxychloroquine Treatment14.76

[back to top]

Quotient of Stimulated C-peptide/Glucose Level Normalized for IEQ/Kg Infused in Response to MMTT

HCQ-treated compared to placebo arm. This outcome measure was reported in Mean and Standard deviation looking at C peptide/glucose secretion at 90 mins during mixed meal test adjusted for IEG/Kg (islet cell equivalency) infused to the patient. (NCT03283566)
Timeframe: 12 months

Interventionng/mg glucose/IEQ/kg (Mean)
Hydroxychloroquine.000000077
Placebo0.000000079

[back to top]

C-peptide AUC Response to MMTT

HCQ-treated compared to placebo arm. We used a standard, 5 hour Mixed meal tolerance test (MMT). Blood draws were taken every 15 mins for the first hours, then every 30 mins the second hour, then hourly until completion. (NCT03283566)
Timeframe: 12 months

Interventionng/mL/min (Mean)
Hydroxychloroquine813
Placebo588

[back to top]

Ratio of C-peptide AUC to Glucose AUC in Response to MMTT Adjusted for Infused Islet Cell Mass

C-peptide, ng/mL/min/IEQ/kg iAUC post-MMTT. Our measurement can be reported in area under the curve for C-peptide normalized for glucose values as well as Islet cell mass infused to the patient in order to compare placebo vs intervention arms. (NCT03283566)
Timeframe: 12 months

Interventionng/mL/min/IEQ/kg iAUC post-MMT (Mean)
Hydroxychloroquine0.00091
Placebo0.00222

[back to top] [back to top] [back to top]

Proportion of Grade IIb or Higher Histolopathologic Responses

Number of grade IIb+lll+lllm+IV+lVm responses / total number of all grade histolopathologic responses. Histoligic appearance will be assess per the Grading System for Pathological Response: Grade I - Characteristic cytologic changes of malignancy present, but little (< 10%) or no tumor cell destruction is evident; Grade II - Characteristic cytologic changes of malignancy; 10% to 90% of tumor cells are destroyed; Grade IIa - Destruction of 10% to 50% of tumor cells; Grade IIb - Destruction of 51% to 90% of tumor cells; Grade III - Few (< 10%) viable-appearing tumor cells are present; Grade IIIm - Sizable pools of mucin present; Grade IV - No viable tumor cells present; Grade IVm - Acellular pools of mucin present. (NCT03344172)
Timeframe: up to 3 years

Interventionpercentage of participants (Number)
PGHA: Gemcitabine, Nab-Paclitaxel, Hydroxychloroquine+Avelumab33.3
PGH: Gemcitabine, Nab-Paclitaxel, and Hydroxychloroquine50.0

[back to top]

Change in CA19-9 Levels

Levels of CA19-9 (tumor marker) in preoperative and postoperative tissues will be determined. Higher levels of CA19-9 are associated with progressive disease. (NCT03344172)
Timeframe: Up to 3 years

Interventionunits per milliliter (U/mL) (Mean)
PGHA: Gemcitabine, Nab-Paclitaxel, Hydroxychloroquine+Avelumab-0.37
PGH: Gemcitabine, Nab-Paclitaxel, and Hydroxychloroquine-0.88

[back to top]

Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

An adverse event (AE) was defined as any untoward medical occurrence in a participant who received study drug and did not necessarily had a causal relationship with the study treatment. SAE: Any untoward medical occurrence that resulted in any of the following outcomes: death, life-threatening, required initial or prolonged in-patient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. TEAEs were defined as AEs that occurred in the time from the first injection of study drug up to 39.7 weeks. (NCT03449758)
Timeframe: Baseline up to end of study (up to 39.7 weeks)

InterventionParticipants (Count of Participants)
SAETEAEAE leading to death
Sarilumab10760

[back to top]

Number of Participants Achieving Low Disease Activity (DAS28 ESR Score <=3.2) and Remission (DAS28 ESR Score <2.6) at Weeks 12, and 24

DAS28-ESR was a composite score that included 4 variables: TJC (based on 28 joints); SJC (based on 28 joints); participant's global assessment of health activity using 100 mm VAS: range 0 (no pain) to 100 (maximum pain imaginable) marker of inflammation assessed by ESR in mm/h. DAS28-ESR total score ranged from 0-10, higher score indicated more disease activity. The DAS28-ESR score provided a number indicating the current disease activity of the RA. A DAS28-ESR score above 5.1 indicated high disease activity, DAS28-ESR score <= 3.2 indicated LDA, > 3.2 to <=5.1 implied moderate disease activity and DAS28-ESR score below 2.6 indicated disease remission. (NCT03449758)
Timeframe: Weeks 12 and 24

InterventionParticipants (Count of Participants)
LDA: Week 12LDA: Week 24Remission: Week 12Remission: Week 24
Sarilumab1244045

[back to top]

Rheumatoid Arthritis Impact of Disease Total Score at Baseline, Weeks 4, 12 and 24

RAID was a participant reported outcome measure used to evaluate the impact of RA on participant's quality of life which comprised 7 domains: • pain, • function, • fatigue, • physical and psychological well-being, • sleep disturbances, and • coping. Each domain was a single question scored on a 0 to 10 continuous NRS. The values for each of these domains were weighed by participant assessment of relative importance and combined in a single value. Total RAID score range was 0 (not affected, very good) to 10 (most affected), where higher value indicated worse status. (NCT03449758)
Timeframe: Baseline, Weeks 4, 12 and 24

Interventionscore on a scale (Mean)
Week 4Week 12Week 24
Sarilumab4.63.93.3

[back to top]

Change From Baseline in Disease Activity Score-28 for Rheumatoid Arthritis With Erythrocyte Sedimentation Rate at Weeks 4, 12, and 24

DAS28-ESR was a composite score that included 4 variables: TJC (based on 28 joints); SJC (based on 28 joints); participant's global assessment of health activity using 100 mm VAS: range 0 (no pain) to 100 (maximum pain imaginable); marker of inflammation assessed by ESR in mm/h. DAS28-ESR total score ranged from 0-10, higher score indicated more disease activity. The DAS28-ESR score provided a number indicating the current disease activity of the RA. A DAS28-ESR score above 5.1 indicated high disease activity, DAS28-ESR score <= 3.2 indicated LDA, > 3.2 to <=5.1 implied moderate disease activity and DAS28-ESR score below 2.6 indicated disease remission. (NCT03449758)
Timeframe: Baseline, Weeks 4, 12 and 24

Interventionscore on a scale (Mean)
Week 4Week 12Week 24
Sarilumab-1.8-2.3-2.7

[back to top]

Change From Baseline in Duration of Morning Stiffness at Weeks 4, 12, and 24

Duration of morning stiffness was defined as the time elapsed (in minutes) between the time of usual awakening (even if not in the morning) and the time the participant was able to resume normal activities without stiffness. At each specified time point, duration of morning stiffness was reported by the participant during the visit. (NCT03449758)
Timeframe: Baseline, Weeks 4, 12 and 24

Interventionminutes (Mean)
Week 4Week 12Week 24
Sarilumab-39.9-47.9-52.8

[back to top]

Change From Baseline in Erythrocyte Sedimentation Rate at Weeks 4, 12, and 24

ESR was a laboratory test to provide non-specific measure of inflammation in the body. The test assessed the rate at which red blood cells fell in a test tube and was measured in mm/h. (NCT03449758)
Timeframe: Baseline, Weeks 4, 12 and 24

Interventionmm/h (Mean)
Week 4Week 12Week 24
Sarilumab-18.1-19.5-22.0

[back to top]

Change From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue Total Scores at Weeks 4, 12 and 24

FACIT-F was a 13-item questionnaire that assess fatigue in participants under chronic illness therapy. Participants scored each item on a 5-point Likert scale ranged from 0 to 4 (0 = not at all; 1 = a little bit; 2 = somewhat; 3 = quite a bit; 4 = very much). The scores of each item were reversed during score calculations, so that higher score values indicated more favorable conditions. Total score was the sum of score from each item and resulted in a score range from 0 to 52, with higher score indicated better participant health status (lower level of fatigue). (NCT03449758)
Timeframe: Baseline, Weeks 4, 12 and 24

Interventionscore on a scale (Mean)
Week 4Week 12Week 24
Sarilumab-4.8-6.4-7.6

[back to top]

Change From Baseline in Hospital Anxiety and Depression Scale: Anxiety (HADS-A) and Depression (HADS-D) Subscale Scores at Weeks 4, 12 and 24

HADS questionnaire measures the presence and severity of anxiety and depression in both hospital and community settings. The questionnaire comprised of 14 items divided into 2 subscales: 7 items for anxiety subscale (HADS-A) and 7 items for depression subscale (HADS-D). Each item was scored on a 0 to 3 rating scale. The anxiety and depression subscales each ranged from 0 to 21 (0-7: normal, 8-10: borderline abnormal and 11-21: abnormal), where higher scores indicated greater severity of anxiety/depression. The subscales were independent for each result of depression and anxiety. (NCT03449758)
Timeframe: Baseline, Weeks 4, 12 and 24

Interventionscore on a scale (Mean)
HADS-A: Week 4HADS-A: Week 12HADS-A: Week 24HADS-D: Week 4HADS-D: Week 12HADS-D: Week 24
Sarilumab-1.0-2.1-1.9-0.4-1.2-1.7

[back to top]

Number of Participants Achieving Clinical Disease Activity Index: Low Disease Activity (CDAI Score <=10.0) and Remission (CDAI Score <=2.8) Weeks 12, and 24

CDAI was a composite index constructed to measure clinical remission in RA that does not included a laboratory test, and is a numerical summation of 4 components: SJC (28 joints), TJC (28 joints), participant's global disease activity (in cm), and physician's global assessment (in cm). Total score ranged from 0 to 76 with a lower score indicated less disease activity. A CDAI score of <=2.8 represents clinical remission and a score of <=10.0 represents LDA. (NCT03449758)
Timeframe: Weeks 12 and 24

InterventionParticipants (Count of Participants)
LDA: Week 12LDA: Week 24Remission: Week 12Remission: Week 24
Sarilumab29291820

[back to top]

Multidimensional Assessment of Thymic States (MAThyS) Scale Total Score at Baseline, Weeks 4, 12 and 24

MAThyS was a multi-dimensional self-administered questionnaire comprised of five dimensions (emotional reactivity, cognition speed, psychomotor function, motivation and sensory perception) divided into 20 items relating to individual states as perceived by participants for the preceding week (at each specified Week). Each item was measured on a visual analog scale (VAS; in centimeters [cm]) ranged from 0 (inhibition of the state evaluated by the item) to 10 (excitation for the evaluated state). Total MAThyS score was sum of the 20 items and that might vary from score range 0 to 200 with lower scores indicated general inhibition and higher scores indicated general excitation. (NCT03449758)
Timeframe: Baseline, Weeks 4, 12 and 24

Interventioncm (Mean)
BaselineWeek 4Week 12Week 24
Sarilumab88.489.694.890.9

[back to top]

International Physical Activity Questionnaire (IPAQ) Total Score at Baseline, Weeks 4, 12 and 24

IPAQ was a 27-item self-reported questionnaire designed to measure physical activity of participant. The score was reported in metabolic equivalent (MET)-minutes per week. MET minutes represented the amount of energy expended to carry out physical activity. For IPAQ total score, the minimum value is zero and there is no maximum. Higher scores mean better levels of physical activity. (NCT03449758)
Timeframe: Baseline, Weeks 4, 12 and 24

InterventionMET minutes per week (Mean)
BaselineWeek 4Week 12Week 24
Sarilumab1759.91881.12061.02089.5

[back to top]

Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) Total Scores at Baseline, Weeks 4, 12 and 24

FACIT-F was a 13-item questionnaire that assess fatigue in participants under chronic illness therapy. Participants scored each item on a 5-point Likert scale ranged from 0 to 4 (0 = not at all; 1 = a little bit; 2 = somewhat; 3 = quite a bit; 4 = very much). The scores of each item were reversed during score calculations, so that higher score values indicated more favorable conditions. Total score was the sum of score from each item and resulted in a score range from 0 to 52, with higher score indicated better participant health status (lower level of fatigue). (NCT03449758)
Timeframe: Baseline, Weeks 4, 12 and 24

Interventionscore on a scale (Mean)
BaselineWeek 4Week 12Week 24
Sarilumab25.521.018.817.9

[back to top]

Erythrocyte Sedimentation Rate (ESR) at Baseline, Weeks 4, 12, and 24

ESR was a laboratory test to provide non-specific measure of inflammation in the body. The test assessed the rate at which red blood cells fell in a test tube and was measured in millimeter per hour (mm/h). (NCT03449758)
Timeframe: Baseline, Weeks 4, 12 and 24

Interventionmm/h (Mean)
BaselineWeek 4Week 12Week 24
Sarilumab28.810.59.28.4

[back to top]

Change From Baseline in International Physical Activity Questionnaire Total Score at Weeks 4, 12 and 24

IPAQ was a 27-item self-reported questionnaire designed to measure physical activity of participant. The score was reported in MET minutes per week. MET minutes represented the amount of energy expended to carry out physical activity. For IPAQ total score, the minimum value is zero and there is no maximum. Higher scores mean better levels of physical activity. (NCT03449758)
Timeframe: Baseline, Weeks 4, 12 and 24

InterventionMET minutes per week (Mean)
Week 4Week 12Week 24
Sarilumab175.6533.4382.0

[back to top]

Duration of Morning Stiffness at Baseline, Weeks 4, 12, and 24

Duration of morning stiffness was defined as the time elapsed (in minutes) between the time of usual awakening (even if not in the morning) and the time the participant was able to resume normal activities without stiffness. At each specified time point, duration of morning stiffness was reported by the participant during the visit. (NCT03449758)
Timeframe: Baseline, Weeks 4, 12 and 24

Interventionminutes (Mean)
BaselineWeek 4Week 12Week 24
Sarilumab72.334.728.921.3

[back to top]

Disease Activity Score-28 for Rheumatoid Arthritis With Erythrocyte Sedimentation Rate (DAS28-ESR) at Baseline, Weeks 4, 12, and 24

DAS28-ESR was a composite score that included 4 variables: tender joint count (TJC) (based on 28 joints); swollen joint count (SJC) (based on 28 joints); participant's global assessment of health activity using 100 mm VAS: range 0 (no pain) to 100 (maximum pain imaginable); marker of inflammation assessed by ESR in mm/h. DAS28-ESR total score ranged from 0-10, higher score indicated more disease activity. The DAS28-ESR score provided a number indicating the current disease activity of the RA. A DAS28-ESR score above 5.1 indicated high disease activity, DAS28-ESR score less than or equal to (<=) 3.2 indicated low disease activity (LDA), greater than (>) 3.2 to <=5.1 implied moderate disease activity and DAS28-ESR score below 2.6 indicated disease remission. (NCT03449758)
Timeframe: Baseline, Weeks 4, 12 and 24

Interventionscore on a scale (Mean)
BaselineWeek 4Week 12Week 24
Sarilumab5.03.12.62.3

[back to top]

Clinical Disease Activity Index (CDAI) Total Score at Baseline, Weeks 4, 12, and 24

CDAI was a composite index constructed to measure clinical remission in RA that does not include a laboratory test, and is a numerical summation of 4 components: SJC (28 joints), TJC (28 joints), participant's global disease activity (in cm), and physician's global assessment of disease (in cm). CDAI total score ranges from 0 to 76 with a lower score indicating less disease activity. A CDAI score of <=2.8 represents clinical remission and a score of <=10.0 represents LDA. (NCT03449758)
Timeframe: Baseline, Weeks 4, 12 and 24

Interventionscore on a scale (Mean)
BaselineWeek 4Week 12Week 24
Sarilumab22.512.69.98.1

[back to top]

Change From Baseline in Stanford Health Assessment Questionnaire Disability Index Total Score at Weeks 4, 12 and 24

HAQ-DI was a participant-oriented questionnaire developed specifically to assess the extent of a RA participant's functional ability. It consisted of at least 2 or 3 questions per category, participant reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week (at each specified visit) rated on a 4-point scale where 0 = no difficulty; 1 = some difficulty; 2 = much difficulty; 3 = unable to do. Overall score was computed as the sum of category scores and divided by the number of categories answered, and ranged from 0 to 3, where 0 = no disability and 3 = completely disabled, higher score indicated more disability. (NCT03449758)
Timeframe: Baseline, Weeks 4, 12 and 24

Interventionscore on a scale (Mean)
Week 4Week 12Week 24
Sarilumab-0.2-0.4-0.5

[back to top]

Number of Swollen Joints at Baseline, Weeks 4, 12, and 24

Number of joints with swelling are reported. Joints which were assessed included 28 joints (which included shoulders, elbows, wrists, knees and 2 joints in each finger and thumb). (NCT03449758)
Timeframe: Baseline, Weeks 4, 12 and 24

Interventionjoints (Mean)
BaselineWeek 4Week 12Week 24
Sarilumab6.32.51.91.6

[back to top]

Change From Baseline in Rheumatoid Arthritis Impact of Disease Total Score at Weeks 4 and 12

RAID was a participant reported outcome measure used to evaluate the impact of RA on participant's quality of life which comprised 7 domains: • pain, • function, • fatigue, • physical and psychological wellbeing, • sleep disturbance, and • coping. Each domain was a single question scored on a 0 to 10 continuous NRS. The values for each of these domains were weighed by participant assessment of relative importance and combined in a single value. Total RAID score range was 0 (not affected, very good) to 10 (most affected), where higher value indicated worse status. (NCT03449758)
Timeframe: Baseline, Weeks 4 and 12

Interventionscore on a scale (Mean)
Week 4Week 12
Sarilumab-1.2-1.8

[back to top]

Change From Baseline in Patient Global Assessment of Disease Activity Score by Visual Analog Scale at Weeks 4, 12, and 24

PtGA of disease activity was measured using a 100 mm horizontal VAS ranged from 0=no pain to 100=maximum pain imaginable, where higher score indicated more disease activity. (NCT03449758)
Timeframe: Baseline, Weeks 4, 12 and 24

Interventionmm (Mean)
Week 4Week 12Week 24
Sarilumab-17.2-24.3-26.7

[back to top]

Change From Baseline in Multidimensional Assessment of Thymic States Scale Total Score at Weeks 4, 12 and 24

MAThyS was a multi-dimensional self-administered questionnaire comprised of five dimensions (emotional reactivity, cognition speed, psychomotor function, motivation and sensory perception) divided into 20 items relating to individual states as perceived by participants for the preceding week (at each specified Week). Each item was measured on a VAS (in cm) ranging from 0 (inhibition of the state evaluated by the item) to 10 (excitation for the evaluated state). Total MAThyS score was sum of the 20 items and that might vary from score range 0 to 200 with lower scores indicated general inhibition and higher scores indicated general excitation. (NCT03449758)
Timeframe: Baseline, Weeks 4, 12 and 24

Interventioncm (Mean)
Week 4Week 12Week 24
Sarilumab-0.22.9-1.1

[back to top]

Change From Baseline in Number of Tender Joints at Weeks 4, 12, and 24

Number of joints with tenderness are reported. Joints which were assessed included 28 joints (which included shoulders, elbows, wrists, knees and 2 joints in each finger and thumb). (NCT03449758)
Timeframe: Baseline, Weeks 4, 12 and 24

Interventionjoints (Mean)
Week 4Week 12Week 24
Sarilumab-2.5-3.7-4.8

[back to top]

Stanford Health Assessment Questionnaire Disability Index (HAQ-DI) Total Score at Baseline, Weeks 4, 12 and 24

HAQ-DI was a participant-oriented questionnaire developed specifically to assess the extent of a RA participant's functional ability. It consisted of at least 2 or 3 questions per category, participant reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week (at each specified visit) rated on a 4-point scale where 0 = no difficulty; 1 = some difficulty; 2 = much difficulty; 3 = unable to do. Overall score was computed as the sum of category scores and divided by the number of categories answered, and ranged from 0 to 3, where 0 = no disability and 3 = completely disabled, higher score indicated more disability. (NCT03449758)
Timeframe: Baseline, Weeks 4, 12 and 24

Interventionscore on a scale (Mean)
BaselineWeek 4Week 12Week 24
Sarilumab1.31.10.80.8

[back to top]

Change From Baseline in Rheumatoid Arthritis Impact of Disease Total Score at Week 24

RAID was a participant reported outcome measure used to evaluate the impact of RA on participant's quality of life which comprised 7 domains: • pain, • function, • fatigue, • physical and psychological well-being, • sleep disturbance, and • coping. Each domain was a single question scored on a 0 to 10 continuous NRS. The values for each of these domains were weighed by participant assessment of relative importance and combined in a single value. Total RAID score range was 0 (not affected, very good) to 10 (most affected), where higher value indicated worse status. (NCT03449758)
Timeframe: Baseline, Week 24

Interventionscore on a scale (Mean)
Sarilumab-2.4

[back to top]

Change From Baseline in Number of Swelling Joints at Weeks 4, 12, and 24

Number of joints with swelling are reported. Joints which were assessed included 28 joints (which included shoulders, elbows, wrists, knees and 2 joints in each finger and thumb). (NCT03449758)
Timeframe: Baseline, Weeks 4, 12 and 24

Interventionjoints (Mean)
Week 4Week 12Week 24
Sarilumab-3.9-4.1-4.7

[back to top]

Patient Global Assessment (PtGA) of Disease Activity Score by Visual Analog Scale (VAS) at Baseline, Weeks 4, 12 and 24

PtGA of disease activity was measured using a 100 millimeters (mm) horizontal VAS ranged from 0=no pain to 100=maximum pain imaginable, where higher score indicated more disease activity. (NCT03449758)
Timeframe: Baseline, Weeks 4, 12 and 24

Interventionmm (Mean)
BaselineWeek 4Week 12Week 24
Sarilumab61.144.136.634.6

[back to top]

Number of Tender Joints at Baseline, Weeks 4, 12, and 24

Number of joints with tenderness are reported. Joints which were assessed included 28 joints (which included shoulders, elbows, wrists, knees and 2 joints in each finger and thumb). (NCT03449758)
Timeframe: Baseline, Weeks 4, 12 and 24

Interventionjoints (Mean)
BaselineWeek 4Week 12Week 24
Sarilumab7.34.73.52.5

[back to top]

Hospital Anxiety and Depression Scale (HADS): Anxiety (HADS-A) and Depression (HADS-D) Subscale Scores at Baseline, Weeks 4, 12, and 24

HADS questionnaire measures the presence and severity of anxiety and depression in both hospital and community settings. The questionnaire comprised of 14 items divided into 2 subscales: 7 items for anxiety subscale (HADS-A) and 7 items for depression subscale (HADS-D). Each item was scored on a 0 to 3 rating scale. The anxiety and depression subscales each ranged from 0 to 21 (0-7: normal, 8-10: borderline abnormal and 11-21: abnormal), where higher scores indicated greater severity of anxiety/depression. The subscales were independent for each result of depression and anxiety. (NCT03449758)
Timeframe: Baseline, Weeks 4, 12 and 24

Interventionscore on a scale (Mean)
HADS-A: BaselineHADS-A: Week 4HADS-A: Week 12HADS-A: Week 24HADS-D: BaselineHADS-D: Week 4HADS-D: Week 12HADS-D: Week 24
Sarilumab8.17.26.16.67.06.65.75.5

[back to top]

Change From Baseline in Clinical Disease Activity Index Total Score at Weeks 4, 12, and 24

CDAI was a composite index constructed to measure clinical remission in RA that does not include a laboratory test, and is a numerical summation of 4 components: SJC (28 joints), TJC (28 joints), participant's global disease activity (in cm), and physician's global assessment of disease (in cm). CDAI total score ranges from 0 to 76 with a lower score indicating less disease activity. A CDAI score of <=2.8 represents clinical remission and a score of <=10.0 represents LDA. (NCT03449758)
Timeframe: Baseline, Weeks 4, 12 and 24

Interventionscore on a scale (Mean)
Week 4Week 12Week 24
Sarilumab-9.8-12.2-14.6

[back to top]

Number of Participants With Active COVID-19 Disease at Day 14 Among Those Who Were Asymptomatic at Baseline

Number of participants at 14 days post enrollment with active COVID19 disease among those who were asymptomatic at baseline. (NCT04308668)
Timeframe: 14 days

InterventionParticipants (Count of Participants)
Treatment49
Placebo58

[back to top]

Number of Participants With Severe COVID-19 Disease at 14 Days Among Those Who Are Symptomatic at Trial Entry

Participants will self-report disease severity status as one of the following 3 options; no COVID19 illness (score of 1), COVID19 illness with no hospitalization (score of 2), or COVID19 illness with hospitalization or death (score of 3). Increased scale score indicates greater disease severity. Outcome is reported as the number of participants who report a score of 3. (NCT04308668)
Timeframe: 14 days

InterventionParticipants (Count of Participants)
Treatment5
Placebo8

[back to top]

Occurrence of Symptoms Compatible With COVID-19 (Possible Disease)

Outcome reported as the number of participants in each arm who self-report symptoms compatible with COVID-19 infection. (NCT04308668)
Timeframe: 14 days

InterventionParticipants (Count of Participants)
Treatment48
Placebo55

[back to top]

Rate of All-Cause Study Medicine Discontinuation or Withdrawal

Outcome reported as the number of participants in each arm who discontinue or withdraw medication use for any reason. (NCT04308668)
Timeframe: 14 days

InterventionParticipants (Count of Participants)
Treatment97
Placebo63

[back to top]

Rate of Confirmed SARS-CoV-2 Detection

Outcome reported as the number of participants in each arm who have confirmed SARS-CoV-2 infection. (NCT04308668)
Timeframe: 14 days

InterventionParticipants (Count of Participants)
Treatment11
Placebo9

[back to top]

Rate of Death

Outcome reported as the number of participants in each arm who expire due to COVID-19-related disease through study completion of 14 days. For those hospitalized within the 14-day study period, the protocol specified follow up would occur for up to 90 days to capture the final outcome of participants' hospitalization. Approximately 30-days was the maximal follow up for hospitalization outcome needed in the trial. (NCT04308668)
Timeframe: Approximately 30 days

InterventionParticipants (Count of Participants)
Treatment1
Placebo1

[back to top]

Rate of Hospitalization

Outcome reported as the number of participants in each arm who require hospitalization for COVID19-related disease. (NCT04308668)
Timeframe: 14 days

InterventionParticipants (Count of Participants)
Treatment5
Placebo9

[back to top]

Change in Disease Severity Over 14 Days Among Those Who Are Symptomatic at Baseline

Visual Analog Scale 0-10 score of rating overall symptom severity (0 = no symptoms; 10 = most severe) (NCT04308668)
Timeframe: baseline and 14 days

Interventionscore on a scale (Mean)
Treatment-2.6
Placebo-2.33

[back to top]

Overall Symptom Severity at 5 and 14 Days

Visual Analog Scale 0-10 score of rating overall symptom severity (0 = no symptoms; 10 = most severe) (NCT04308668)
Timeframe: 5 and 14 days

,
Interventionscore on a scale (Mean)
Day 5Day 14
Placebo-2.05-3.08
Treatment-2.22-3.36

[back to top]

"Time for no Oxygen Supplement (or Regular Oxygen Supplement LTOT)"

"Time for no oxygen supplement (or regular oxygen supplement LTOT) if on oxygen during admission." (NCT04322396)
Timeframe: 14 days

Interventionhours (Median)
Control72
Intervention72

[back to top]

Length of Hospitalization

(NCT04322396)
Timeframe: 14 days

Interventiondays (Median)
Control4
Intervention4

[back to top]

Length of Stay in ICU

Length of stay in intensive care unit. (NCT04322396)
Timeframe: 14 days

Interventiondays (Median)
Control11
Intervention14

[back to top]

Mortality

(NCT04322396)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Control2
Intervention1

[back to top]

Number of Days Using Non-invasive Ventilation (NIV)

Number of days using non-invasive ventilation (NIV) if on NIV during hospitalization. (NCT04322396)
Timeframe: 14 days

Interventiondays (Mean)
Control9.0
Intervention6.7

[back to top]

Number of Days Alive and Discharged From Hospital Within 14 Days

(NCT04322396)
Timeframe: 14 days

Interventiondays (Median)
Control9
Intervention9

[back to top]

Number of Participants on Non-invasive Ventilation (NIV) During Hospitalization

(NCT04322396)
Timeframe: 14 days

InterventionParticipants (Count of Participants)
Control1
Intervention3

[back to top]

Number of Readmissions (All Causes)

(NCT04322396)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Control6
Intervention9

[back to top]

Change in Patient's Oxygen Partial Pressure

PaO2 measured in arterial puncture at baseline and 4 days. (NCT04322396)
Timeframe: 4 days

InterventionmmHg (Mean)
Control-0.2
Intervention-3.0

[back to top]

Change of pH in Blood

pH measured in arterial puncture at baseline and 4 days. (NCT04322396)
Timeframe: 4 days

InterventionpH (Mean)
Control0.0
Intervention0.0

[back to top]

Days Alive and Discharged From Hospital

(NCT04322396)
Timeframe: 30 days

Interventiondays (Median)
Control26
Intervention26

[back to top]

Change in Patient's Carbondioxide Partial Pressure

PaCO2 measured in arterial puncture at baseline and 4 days. (NCT04322396)
Timeframe: 4 days

InterventionmmHg (Mean)
Control1.4
Intervention-3.0

[back to top]

Incidence of Possible COVID-19 Symptoms

Outcome reported as the count of participants in each arm who report COVID-19-related symptoms during study treatment. (NCT04328467)
Timeframe: up to 12 weeks

InterventionParticipants (Count of Participants)
Intervention Once Weekly29
Intervention Twice Weekly28
Control Group38

[back to top]

Ordinal Scale of COVID-19 Disease Maximum Severity if COVID-19 Diagnosed at Study End

Participants will self-report COVID-19 status on an ordinal scale as follows: No illness (score=1), Illness with outpatient observation (score=2), Hospitalization (or post-hospital discharge) (score=3), or Hospitalization with ICU stay or death (score=4). Possible scores range from 1-4 with higher scores indicating greater disease severity. (NCT04328467)
Timeframe: up to 12 weeks

Interventionscore on a scale (Mean)
Intervention Twice Weekly1
Control Group1

[back to top]

COVID-19-free Survival

Outcome reported as the number of participants in each arm who are COVID-19-free at the end of study treatment. (NCT04328467)
Timeframe: up to 12 weeks

InterventionParticipants (Count of Participants)
Intervention Once Weekly464
Intervention Twice Weekly468
Control Group454

[back to top]

Incidence of All-cause Study Medicine Discontinuation

Outcome reported as the count of participants in each arm who discontinue study medication use for any reason during treatment. (NCT04328467)
Timeframe: up to 12 weeks

InterventionParticipants (Count of Participants)
Intervention Once Weekly119
Intervention Twice Weekly158
Control Group133

[back to top]

Incidence of Hospitalization for COVID-19 or Death

Outcome reported as the number of participants in each arm who are hospitalized or expire due to COVID-19 during study treatment. (NCT04328467)
Timeframe: up to 12 weeks

InterventionParticipants (Count of Participants)
Intervention Once Weekly3
Intervention Twice Weekly8
Control Group9

[back to top]

Number of Confirmed SARS-CoV-2 Detection

Outcome reported as the number of participants in each arm who have a confirmed SARS-CoV-2 infection during study treatment. (NCT04328467)
Timeframe: up to 12 weeks

InterventionParticipants (Count of Participants)
Intervention Once Weekly29
Intervention Twice Weekly29
Control Group39

[back to top] [back to top]

Rate of Participant-reported Adverse Events

Safety and tolerability of Hydroxychloroquine as SARS-CoV-2 PEP in adults (NCT04328961)
Timeframe: 28 days from start of Hydroxychloroquine therapy

InterventionParticipants (Count of Participants)
Ascorbic Acid46
Hydroxychloroquine66

[back to top]

Number of Participants Who Had Polymerase Chain Reaction (PCR) Confirmed SARS-CoV-2 Infection

Polymerase chain reaction (PCR) confirmed severe acute respiratory syndrome coronavirus 2 of the genus Betacoronavirus (SARS-CoV-2) infection from self-collected samples collected daily for 14 days (NCT04328961)
Timeframe: Day 1 through Day 14 after enrolment

InterventionParticipants (Count of Participants)
Ascorbic Acid45
Hydroxychloroquine53

[back to top]

Number of Participants Who Had COVID-19 Disease

Participants who had a PCR-confirmed SARS-CoV-2 infection and met the Center for Disease Control (CDC) defined criteria for symptomatic COVID-19 disease. (NCT04328961)
Timeframe: 28 days from enrolment

InterventionParticipants (Count of Participants)
Ascorbic Acid26
Hydroxychloroquine37

[back to top]

The Number of Participants Who Had Polymerase Chain Reaction (PCR) Confirmed SARS-CoV-2 Infection

Polymerase chain reaction (PCR) confirmed SARS-CoV-2 infection from self-collected samples collected at study exit (NCT04328961)
Timeframe: Day 28 after enrolment

InterventionParticipants (Count of Participants)
Ascorbic Acid48
Hydroxychloroquine58

[back to top]

Ventilator-free Days at 28 Days (Number of Days Patient Not on a Ventilator)

Calculated as number of days that patient is not on a ventilator up to day 28 days after admission (NCT04329832)
Timeframe: Admission (day 1) to 28 days after admission (day 28)

Interventiondays (Median)
Ventilator-Free Days at Day 28 for Hydroxychloroquine Arm18
Ventilator-Free Days at Day 28 for Azithromycin Arm18

[back to top]

Time to a 1-point Decrease in the WHO Ordinal Recovery Score

"Time to 1-point decrease in the WHO ordinal recovery score is defined as the number of days until the ordinal outcome score drops by 1 relative to baseline on the 8-point WHO COVID Ordinal Outcomes scale, which reflects a range from uninfected to dead, where 0 is no clinical or virological evidence of infection, 1 is no limitation of activities, 2 is limitation of activities, 3 is hospitalized, no oxygen therapy, 4 is oxygen by mask or nasal prongs, 5 is non-invasive ventilation or high-flow oxygen, 6 is intubation and mechanical ventilation, 7 is ventilation + additional organ support - pressors, RRT (renal replacement therapy), ECMO (extracorporeal membrane oxygenation), and 8 is death." (NCT04329832)
Timeframe: Admission (day 1) to 14 days after admission (day 14)

InterventionDays (Median)
Days to a 1-point Decrease in WHO COVID Scale in Hydroxychloroquine Arm7
Days to a 1-point Decrease in WHO COVID Scale in Azithromycin Arm6

[back to top]

Hospital-free Days at 28 Days

Calculated as number of days patient not in hospital (NCT04329832)
Timeframe: Admission (day 1) to 28 days after admission (day 28)

InterventionDays (Median)
Hydroxychloroquine18.5
Azithromycin21

[back to top]

COVID Ordinal Outcomes Scale at 14 Days

"Improvement of clinical condition of the patient defined by the COVID-19 WHO ordinal Outcomes score. This scale reflects a range from uninfected to dead, where 0 is no clinical or virological evidence of infection, 1 is no limitation of activities, 2 is limitation of activities, 3 is hospitalized, no oxygen therapy, 4 is oxygen by mask or nasal prongs, 5 is non-invasive ventilation or high-flow oxygen, 6 is intubation and mechanical ventilation, 7 is ventilation + additional organ support - pressors, RRT (renal replacement therapy), ECMO (extracorporeal membrane oxygenation), and 8 is death." (NCT04329832)
Timeframe: Assessed once on day 14 after enrollment (enrollment is day 0)

Interventionscore on a scale (Median)
Day 14 WHO COVID Score: Hydroxychloroquine2.0
Day 14 WHO COVID Score: Azithromycin2.0

[back to top]

ICU-free Days at 28 Days

Calculated as number of days patient not in an ICU (NCT04329832)
Timeframe: Admission (day 1) to 28 days after admission (day 28)

InterventionDays (Median)
Hydroxychloroquine18
Azithromycin19

[back to top]

Number of Health Care Workers Who Developed SARS-COV-2 Infection

Cohort 3 Physicians and nurse prophylaxis: Rate of COVID-19 infection at 2 months (NCT04329923)
Timeframe: 2 months

InterventionParticipants (Count of Participants)
Cohort 3 HCQ4
Cohort 3 Placebo4

[back to top]

Rate of Hospitalization

Cohort 1 rate of hospitalization (NCT04329923)
Timeframe: until quarantine release

InterventionParticipants (Count of Participants)
Cohort 1 HCQ1
Cohort 1 Placebo0

[back to top]

Rate of Housemate Infection

Cohort 1 rate of participant-reported secondary infection of housemates (NCT04329923)
Timeframe: until quarantine release, or approximately <20 days

InterventionParticipants (Count of Participants)
Cohort 1 HCQ2
Cohort 1 Placebo2

[back to top]

Time to Hospital Discharge

Cohort 2 (hospitalized COVID-19 patients): median number of days until hospital discharge (NCT04329923)
Timeframe: until hospital discharge

Interventiondays (Median)
Cohort 2 HCQ High Dose5.5
Cohort 2 HCQ Low Dose4

[back to top]

Time to Release From Quarantine Time

Cohort 1 (home quarantined COVID-19 patients): Median time to release from quarantine by meeting the following criteria: 1) No fever for 72 hours 2) improvement in other symptoms and 3) 7 or 10 days (depending on CDC guidance at the time) have elapsed since the beginning of symptom onset. (NCT04329923)
Timeframe: until quarantine release or hospitalization

Interventiondays (Median)
Cohort 1 HCQ8
Cohort 1 Placebo11

[back to top]

Ventilator-free Days Through Day 28

Ventilator-free days is defined to be 28 days minus the duration of mechanical ventilation through day 28. Participants who do not survive to day 28 are assigned zero ventilator-free days. (NCT04332991)
Timeframe: 28 days after randomization

Interventiondays (Median)
Hydroxychloroquine28
Placebo28

[back to top]

Hospital-free Days to Day 28

Defined as 28 days minus the number of days from randomization to discharge home.If a patient has not been discharged home prior to day 28 or dies prior to day 28, hospital free days will be zero. (NCT04332991)
Timeframe: 28 days after randomization

Interventiondays (Median)
Hydroxychloroquine21
Placebo20

[back to top]

All-location, All-cause Mortality Assessed on Study Day 15 (14 Days After Randomization)

"Vital status of the patient on day 15 will be determined using any of the following methods: medical record review, phone calls to patient or proxy.~There were two patients for whom we were unable to collect their vital status." (NCT04332991)
Timeframe: assessed on study day 15

InterventionParticipants (Count of Participants)
Hydroxychloroquine18
Placebo14

[back to top]

All-location, All-cause Mortality Assessed on Study Day 29 (28 Days After Randomization)

"Vital status of the patient at day 28 will be determined using any of the following methods: medical record review, phone calls to patient or proxy.~There were two patients for whom we were unable to collect their vital status." (NCT04332991)
Timeframe: assessed on study day 29

InterventionParticipants (Count of Participants)
Hydroxychloroquine25
Placebo25

[back to top]

COVID Ordinal Outcomes Scale on Study Day 29 (28 Days After Randomization)

"We will determine the COVID Ordinal Scale on study day 29~COVID Ordinal Scale defined as:~Death~Hospitalized on invasive mechanical ventilation or ECMO ( extracorporeal membrane oxygenation)~Hospitalized on non-invasive ventilation or high flow nasal cannula~Hospitalized on supplemental oxygen~Hospitalized not on supplemental oxygen~Not hospitalized with limitation in activity (continued symptoms)~Not hospitalized without limitation in activity (no symptoms)" (NCT04332991)
Timeframe: assessed on study day 29

Interventionscore on a scale (Median)
Hydroxychloroquine6
Placebo6

[back to top]

COVID Ordinal Outcomes Scale on Study Day 3 (2 Days After Randomization)

"We will determine the COVID Ordinal Scale for all patients on study day 3~COVID Ordinal Scale defined as:~Death~Hospitalized on invasive mechanical ventilation or ECMO ( extracorporeal membrane oxygenation)~Hospitalized on non-invasive ventilation or high flow nasal cannula~Hospitalized on supplemental oxygen~Hospitalized not on supplemental oxygen~Not hospitalized with limitation in activity (continued symptoms)~Not hospitalized without limitation in activity (no symptoms)" (NCT04332991)
Timeframe: assessed on study day 3

Interventionscore on a scale (Median)
Hydroxychloroquine4
Placebo4

[back to top]

COVID Ordinal Outcomes Scale on Study Day 8 (7 Days After Randomization)

"We will determine the COVID Ordinal Scale on study day 8~COVID Ordinal Scale defined as:~Death~Hospitalized on invasive mechanical ventilation or ECMO ( extracorporeal membrane oxygenation)~Hospitalized on non-invasive ventilation or high flow nasal cannula~Hospitalized on supplemental oxygen~Hospitalized not on supplemental oxygen~Not hospitalized with limitation in activity (continued symptoms)~Not hospitalized without limitation in activity (no symptoms)" (NCT04332991)
Timeframe: assessed on study day 8

Interventionscore on a scale (Median)
Hydroxychloroquine5
Placebo6

[back to top]

COVID Outcomes Scale Score on Study Day 15 (14 Days After Randomization)

"We will determine the COVID Ordinal Scale for all patients on study day 15~COVID Ordinal Scale defined as:~Death~Hospitalized on invasive mechanical ventilation or ECMO ( extracorporeal membrane oxygenation)~Hospitalized on non-invasive ventilation or high flow nasal cannula~Hospitalized on supplemental oxygen~Hospitalized not on supplemental oxygen~Not hospitalized with limitation in activity (continued symptoms)~Not hospitalized without limitation in activity (no symptoms)" (NCT04332991)
Timeframe: Assessed on study day 15

Interventionscore on a scale (Median)
Hydroxychloroquine6
Placebo6

[back to top]

ICU-free Days to Day 28

The number of days spent out of the ICU to day 28. Patients who die prior to day 28 are assigned zero ICU free days. (NCT04332991)
Timeframe: 28 days after randomization

Interventiondays (Median)
Hydroxychloroquine28
Placebo28

[back to top]

Number of Patients Dead or With Receipt of ECMO Between Enrollment and Day 28

We will determine the number of patients who are either dead or on ECMO ( extracorporeal membrane oxygenation) between enrollment and day 28 (NCT04332991)
Timeframe: Enrollment to Day 28

InterventionParticipants (Count of Participants)
Hydroxychloroquine29
Placebo28

[back to top]

Number of Patients With Acute Kidney Injury to day28

We will determine the number of patients that experience acute kidney injury between randomization and day 28 (NCT04332991)
Timeframe: 28 days after randomization

InterventionParticipants (Count of Participants)
Hydroxychloroquine37
Placebo37

[back to top]

Number of Patients With Acute Pancreatitis Arrest to Day 28

We will determine the number of patients that experience acute pancreatitis between randomization and day 28 (NCT04332991)
Timeframe: 28 days after randomization

InterventionParticipants (Count of Participants)
Hydroxychloroquine5
Placebo6

[back to top]

Number of Patients With Anemia to Day 28

We will determine the number of patients that experience anemia between randomization and day 28 (NCT04332991)
Timeframe: 28 days after randomization

InterventionParticipants (Count of Participants)
Hydroxychloroquine139
Placebo120

[back to top]

Number of Patients With Atrial Arrhythmia to Day 28

We will determine the number of patients that experience atrial arrhythmia between randomization and day 28 (NCT04332991)
Timeframe: 28 days after randomization

InterventionParticipants (Count of Participants)
Hydroxychloroquine15
Placebo11

[back to top]

Number of Patients With Cardiac Arrest to Day 28

We will determine the number of patients that experience cardiac arrest between randomization and day 28 (NCT04332991)
Timeframe: 28 days after randomization

InterventionParticipants (Count of Participants)
Hydroxychloroquine10
Placebo4

[back to top]

Number of Patients With Elevation in Aspartate Aminotransferase or Alanine Aminotransferase to Twice the Local Upper Limit of Normal to Day 28

We will determine the number of patients that experience elevation in aspartate aminotransferase or alanine aminotransferase to twice the local upper limit of normal between randomization and day 28 (NCT04332991)
Timeframe: 28 days after randomization

InterventionParticipants (Count of Participants)
Hydroxychloroquine50
Placebo65

[back to top]

Number of Patients With Lymphopenia to Day 28

We will determine the number of patients that experience lymphopenia between randomization and day 28 (NCT04332991)
Timeframe: 28 days after randomization

InterventionParticipants (Count of Participants)
Hydroxychloroquine92
Placebo87

[back to top]

Number of Patients With Neutropenia to Day 28

We will determine the number of patients that experience neutropenia between randomization and day 28 (NCT04332991)
Timeframe: 28 days after randomization

InterventionParticipants (Count of Participants)
Hydroxychloroquine4
Placebo4

[back to top]

Number of Patients With Receipt of Renal Replacement Therapy to Day 28

We will determine the number of patients that experience renal replacement therapy between randomization and day 28 (NCT04332991)
Timeframe: 28 days after randomization

InterventionParticipants (Count of Participants)
Hydroxychloroquine10
Placebo14

[back to top]

Number of Patients With Seizures to Day 28

We will determine the number of patients that experience seizure between randomization and day 28 (NCT04332991)
Timeframe: 28 days after randomization

InterventionParticipants (Count of Participants)
Hydroxychloroquine1
Placebo0

[back to top]

Number of Patients With Severe Dermatologic Reaction to Day 28

We will determine the number of patients that experience severe dermatologic reaction between randomization and day 28 (NCT04332991)
Timeframe: 28 days after randomization

InterventionParticipants (Count of Participants)
Hydroxychloroquine1
Placebo1

[back to top]

Number of Patients With Symptomatic Hypoglycemia to Day 28

We will determine the number of patients that experience symptomatic hypoglycemia between randomization and day 28 (NCT04332991)
Timeframe: 28 days after randomization

InterventionParticipants (Count of Participants)
Hydroxychloroquine10
Placebo8

[back to top]

Number of Patients With Thrombocytopenia to Day 28

We will determine the number of patients that experience thrombocytopenia between randomization and day 28 (NCT04332991)
Timeframe: 28 days after randomization

InterventionParticipants (Count of Participants)
Hydroxychloroquine4
Placebo5

[back to top]

Number of Patients With Ventricular Arrhythmia to Day 28

We will determine the number of patients that experience ventricular arrhythmia between randomization and day 28 (NCT04332991)
Timeframe: 28 days after randomization

InterventionParticipants (Count of Participants)
Hydroxychloroquine5
Placebo6

[back to top]

Oxygen-free Days Through Day 28

The number of calendar days between randomization and 28 days later that the patient is alive and without the use of oxygen therapy. Patients who die prior to day 28 are assigned zero oxygen free days. (NCT04332991)
Timeframe: 28 days after randomization

Interventiondays (Median)
Hydroxychloroquine21
Placebo20

[back to top]

Time to Recovery, Defined as Time to Reaching Level 5, 6, or 7 on the COVID Outcomes Scale, Which is the Time to the Earlier of Final Liberation From Supplemental Oxygen or Hospital Discharge

Time to recovery, defined as time to reaching level 5, 6, or 7 on the COVID Outcomes Scale, which is the time to the earlier of final liberation from supplemental oxygen or hospital discharge. Patients who die prior to day 28 are assigned 28 days for time to recovery. (NCT04332991)
Timeframe: 28 days after randomization

Interventiondays (Median)
Hydroxychloroquine5
Placebo6

[back to top]

Vasopressor-free Days Through Day 28

The number of calendar days between randomization and 28 days later that the patient is alive and without the use of vasopressor therapy. Patients who die prior to day 28 are assigned zero vasopressor free days. (NCT04332991)
Timeframe: 28 days after randomization

Interventiondays (Median)
Hydroxychloroquine28
Placebo28

[back to top]

Time From Study Initiation Until the Occurrence of COVID-19 or COVID-19 Like Illness or Being Censored

"Time-to-first clinical event consisting of a persistent change for any of the following:~diagnosis of COVID-19~clinical characteristics of COVID-19 like illness~being censored" (NCT04333225)
Timeframe: Up to 7 weeks after study initiation

InterventionDays (Mean)
Hydroxychloroquine43.17
Control39.25

[back to top]

Number of Participants Infected With COVID-19 or COVID-19 Like Illness During the Trial

Number of participants infected with COVID-19 or identified as having COVID-19 like illness during the trial (NCT04333225)
Timeframe: Up to 7 weeks after study initiation

InterventionParticipants (Count of Participants)
Hydroxychloroquine13
Control32

[back to top]

Number of Participants With COVID-19 Viral Shedding

Number of participants with COVID-19 infection shedding via Covance swab PCR testing (NCT04334148)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Hydroxychloroquine2
Placebo2

[back to top]

Number of Participants With Serious Adverse Events (SAEs) or Hydroxychloroquine-Associated Events of Special Interest (EOSIs)

Safety and Tolerability as determined by subject reported serious adverse events (SAEs) and hydroxychloroquine-associated events of special interest. EOSIs include: arrhythmias (ventricular), hepatic failure, bone marrow failure, aplastic anemia, prolonged QT interval, angioedema, dermatitis exfoliative, acute generalized exanthematous pustulosis, psychosis, suicidal ideation, seizure, methemoglobinemia. (NCT04334148)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Hydroxychloroquine7
Placebo8

[back to top]

Number of Participants With Clinical Infection With COVID-19 Infection

This measure was a combination of confirmed infection and suspected infection. Confirmed clinical infection was defined as new-onset of fever or cough or dyspnea AND confirmed COVID-19 positive test result via local PCRI testing. Suspected infection was defined as new-onset fever or cough or dyspnea without local PCR testing due to local restrictions and/or testing policies. (NCT04334148)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Hydroxychloroquine41
Placebo53

[back to top]

World Health Organization (WHO) Ordinal Scale Measured at 14 Days After Enrollment

The ordinal scale is an assessment of the clinical status at the first assessment of a given study day. The scale is as follows: 1) Death; 2) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 4) Hospitalized, requiring supplemental oxygen; 5) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7) Not hospitalized, limitation on activities and/or requiring home oxygen; 8) Not hospitalized, no limitations on activities. (NCT04335552)
Timeframe: Day 14

Interventionunits on a scale (Mean)
Standard of Care1
Standard of Care Plus Hydroxychloroquine2.5
Standard of Care Plus Azithromycin5.3
Standard of Care Plus Hydroxychloroquine Plus Azithromycin4.5

[back to top]

WHO Ordinal Scale Measured at 28 Days After Enrollment

The ordinal scale is an assessment of the clinical status at the first assessment of a given study day. The scale is as follows: 1) Death; 2) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 4) Hospitalized, requiring supplemental oxygen; 5) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7) Not hospitalized, limitation on activities and/or requiring home oxygen; 8) Not hospitalized, no limitations on activities. (NCT04335552)
Timeframe: Day 28

Interventionscore on a scale (Mean)
Standard of Care1
Standard of Care Plus Hydroxychloroquine2.8
Standard of Care Plus Azithromycin5.3
Standard of Care Plus Hydroxychloroquine Plus Azithromycin4.5

[back to top]

Hospital Length of Stay in Days for the Index Hospitalization

(NCT04335552)
Timeframe: Index hospitalization, up to 46 days

Interventiondays (Mean)
Standard of Care6
Standard of Care Plus Hydroxychloroquine9
Standard of Care Plus Azithromycin14.7
Standard of Care Plus Hydroxychloroquine Plus Azithromycin2.5

[back to top]

Number of Days on Mechanical Ventilation

(NCT04335552)
Timeframe: Baseline

Interventiondays (Mean)
Standard of Care0
Standard of Care Plus Hydroxychloroquine5.5
Standard of Care Plus Azithromycin8.67
Standard of Care Plus Hydroxychloroquine Plus Azithromycin0

[back to top]

Number of Participants Who Died During the Index Hospitalization

(NCT04335552)
Timeframe: Index hospitalization, up to 46 days

InterventionParticipants (Count of Participants)
Standard of Care0
Standard of Care Plus Hydroxychloroquine1
Standard of Care Plus Azithromycin2
Standard of Care Plus Hydroxychloroquine Plus Azithromycin1

[back to top]

Number of Participants With All-cause Study Medication Discontinuation

Number of participants who discontinued study medication for any reason (NCT04335552)
Timeframe: Index hospitalization, up to 46 days

InterventionParticipants (Count of Participants)
Standard of Care0
Standard of Care Plus Hydroxychloroquine0
Standard of Care Plus Azithromycin0
Standard of Care Plus Hydroxychloroquine Plus Azithromycin0

[back to top]

Number of Participants With Severe Adverse Events

(NCT04335552)
Timeframe: Day 14

InterventionParticipants (Count of Participants)
Standard of Care0
Standard of Care Plus Hydroxychloroquine1
Standard of Care Plus Azithromycin1
Standard of Care Plus Hydroxychloroquine Plus Azithromycin0

[back to top]

Number of Patients Not Receiving Mechanical Ventilation at Baseline Who Progress to Requiring Mechanical Ventilation During the Index Hospitalization

(NCT04335552)
Timeframe: Index hospitalization, up to 46 days

InterventionParticipants (Count of Participants)
Standard of Care0
Standard of Care Plus Hydroxychloroquine1
Standard of Care Plus Azithromycin1
Standard of Care Plus Hydroxychloroquine Plus Azithromycin0

[back to top]

Identify Immunologic, Serological and Inflammatory Markers Associated With Acquisition and Response to COVID-19 in Both HCQ and Placebo Participants Developing Laboratory or Clinical Confirmed Disease.

Identification of immunologic, serological and inflammatory markers associated with acquisition and response to COVID-19 in both HCQ and placebo Participants developing laboratory or clinical confirmed disease via study visits, weekly questionnaire, and blood samples. (NCT04341441)
Timeframe: 8 weeks

InterventionInflammatory markers (Number)
Study Drug - Daily DoseNA
Study Drug - Weekly DoseNA
PlaceboNA
Non-Randomized Active ComparatorNA

[back to top]

Examine the Correlation Between HCQ Drug Levels and Development of COVID-19 Symptoms or Positive COVID-19 Test Results.

Examination of the correlation between HCQ drug levels and development of COVID-19 clinical symptoms and/or positive COVID-19 test results via weekly subject questionnaire and/or blood samples. (NCT04341441)
Timeframe: 8 Weeks

InterventionCorrelation coefficient (Number)
Study Drug - Daily DoseNA
Study Drug - Weekly DoseNA
PlaceboNA
Non-Randomized Active ComparatorNA

[back to top]

Determine the Safety and Tolerability of HCQ Dosing for Preventive Strategy Against COVID-19 as Measured by Adverse Events and Serious Adverse Events.

Measurement of the safety and tolerability of HCQ dosing for preventive strategy against COVID-19 as measured by adverse events and serious adverse events reported via weekly questionnaire. (NCT04341441)
Timeframe: 8 Weeks

,,,
InterventionNumber of adverse events. (Number)
Adverse events (only Level 1 and 2) observed in the study.Serious adverse events (Level 3 or 4).
Non-Randomized Active Comparator20
Placebo1880
Study Drug - Daily Dose2060
Study Drug - Weekly Dose1930

[back to top]

Determine the Effect of Hydroxychloroquine Dose in the Prevention of COVID-19 Viremia and Disease.

Compare the rates of SARS-CoV 2 symptomatic infections (number of events with both symptoms and positive test for COVID-19) between the randomized hydroxychloroquine treatment arms and the placebo control arm to determine the effect of HCQ dose in the prevention of COVID-19 viremia and disease. This analysis only includes only the randomized arms in the study (Study Drug - Daily Dose, Study Drug - Weekly Dose, and Placebo). (NCT04341441)
Timeframe: 8 Weeks

InterventionParticipants (Count of Participants)
Study Drug - Daily Dose1
Study Drug - Weekly Dose1
Placebo1

[back to top]

Comparison of the Rate of SARS-CoV 2 Infections as Measured by IgM/IgG Seroconversion in Study Participants Receiving Randomized HCQ Versus Placebo.

Measurement of the rate of SARS-CoV 2 infections as measured by IgM/IgG seroconversion in study participants receiving randomized HCQ versus placebo via blood samples in the randomized arms of the study (Study Drug - Daily Dose, Study Drug - Weekly Dose, and Placebo). (NCT04341441)
Timeframe: 8 Weeks

InterventionParticipants (Count of Participants)
Study Drug - Daily Dose1
Study Drug - Weekly Dose1
Placebo2

[back to top]

To Determine if the Use of Hydroxychloroquine as Preventive Therapy Decreases the Rate of Acquisition of SARS-CoV 2 Infections With Clinical COVID-19 Disease in Study Participants for Each Randomized Treatment Arm as Compared to Placebo.

The rate of acquisition of SARS-CoV 2 infections and clinical COVID-19 disease (number of events) in study participants for each randomized hydroxychloroquine treatment arm was compared to the placebo treatment arm. This included both symptomatic and asymptomatic patients. (NCT04341441)
Timeframe: 8 Weeks

InterventionParticipants (Count of Participants)
Study Drug - Daily Dose1
Study Drug - Weekly Dose1
Placebo1
Non-Randomized Active Comparator0

[back to top]

Comparison of the Emergence of Clinical Symptoms or COVID-19 Diagnosis in Participants Presenting Asymptomatically at Study Entry But Identified as Seropositive by Serology at Entry Between the Randomized Treatment Arms and Comparator Arm.

Measurement of the emergence of clinical symptoms or COVID-19 diagnosis in participants presenting asymptomatically at study entry but identified as seropositive by serology at entry between the randomized treatment arms and comparator arm and via weekly questionnaire and/or blood samples. (NCT04341441)
Timeframe: 8 Weeks

InterventionParticipants (Count of Participants)
Study Drug - Daily Dose1
Study Drug - Weekly Dose0
Placebo0
Non-Randomized Active Comparator0

[back to top]

Compare the Seroprevalence of SARS-CoV 2 IgM and/or IgG Positive Samples at Study Entry and Study Conclusion in All Participants Receiving HCQ Compared to Those Receiving Placebo.

Measurement of the seroprevalence of SARS-CoV 2 IgM and/or IgG positive samples in all arms of the study, randomized and non-randomized (Study Drug - Daily Dose, Study Drug - Weekly Dose, Placebo, and Non-Randomized Active Comparator). (NCT04341441)
Timeframe: 8 Weeks

InterventionParticipants (Count of Participants)
Study Drug - Daily Dose1
Study Drug - Weekly Dose1
Placebo2
Non-Randomized Active Comparator0

[back to top]

To Examine the Level of Care Needed by Participants in Each Arm Developing COVID19 as Measured as Requiring Emergency Room Visit, Hospitalization or Able to Stay Home Without Hospital Care.

Review of the level of care needed by participants in each arm developing COVID19 as measured as requiring emergency room visit, hospitalization or able to stay home without hospital care via weekly questionnaire. (NCT04341441)
Timeframe: 8 Weeks

InterventionParticipants (Count of Participants)
Study Drug - Daily Dose0
Study Drug - Weekly Dose0
Placebo0
Non-Randomized Active Comparator0

[back to top]

To Examine Other Clinical Factors Contributing to the Risk of SARS-CoV 2 Infection in Healthcare Workers and First Responders.

Examination of other clinical factors contributing to the risk of SARS-CoV 2 infection including demographics, work type and location, positive COVID-19 partners, possible exposures and clinical symptoms via study visits and weekly questionnaire. (NCT04341441)
Timeframe: 8 Weeks

InterventionClinical factors (Number)
Study Drug - Daily DoseNA
Study Drug - Weekly DoseNA
PlaceboNA
Non-Randomized Active ComparatorNA

[back to top]

Assess the Impact of Chronic Weight-based Dosing of HCQ for COVID-19 Prevention.

Compare the rates of SARS-CoV 2 infections (number of events of symptomatic patients with a positive COVID-19 test) in the non-randomized comparator arm to the randomized hydroxychloroquine and placebo arms to assess the impact of chronic weight-based dosing of HCQ for COVID-19 prevention via weekly questionnaire and/or blood samples. This analysis includes all randomized and non-randomized groups in the study. (NCT04341441)
Timeframe: 8 Weeks

InterventionParticipants (Count of Participants)
Study Drug - Daily Dose1
Study Drug - Weekly Dose1
Placebo1
Non-Randomized Active Comparator0

[back to top]

Adult Household Contact Viral Acquisition

"This outcome will be analyzed for households with at least two adults for which no other adult besides the index study subject is positive for COVID-19 at baseline and for which the index study subject is in the ITT population. This binary outcome will be at the household level and will be a yes if there is a positive swab by one or more adult household contacts for any of the study-administered swabs from days DayR + 1 to DayR + 14, inclusive. If there are no positive swabs but at least one negative swab, the outcome will be a no; otherwise it will be missing." (NCT04342169)
Timeframe: Days 1-14

Interventionhouseholds with at least two adults for (Count of Units)
Hydroxychloroquine16
Placebo19

[back to top]

Duration of COVID-19-attributable Symptoms

"Duration of COVID-19 symptoms (through DayA15):~this is an integer-valued outcome which is defined as date of first asymptomatic date through the start date.~To determine the end date, first each symptom assessment from baseline through DayA15, inclusive, will be classified as symptomatic, asymptomatic, or unknown.~A symptomatic day is one in which at least one of the core symptoms is observed to exceed the permissible threshold: not experiencing for fever and chills; extremely mild for shortness of breath, diarrhea, and muscle aches; mild for cough and tiredness. If at most one symptom level is missing on a given day and all observed core symptoms' levels are at or below the permissible threshold, the day will be classified as asymptomatic. Otherwise (i.e. if at most five of the core symptoms have a reported symptom level and none of the reported symptom levels exceeded the threshold), the day will be considered unknown." (NCT04342169)
Timeframe: Days 1-15

InterventionDays (Median)
Hydroxychloroquine6
Placebo6

[back to top]

Duration of Viral Shedding

Duration of viral shedding, as defined by time from randomization to the first of two consecutive negative swabs, measured on days 1 - 14. (NCT04342169)
Timeframe: Days

InterventionDays (Mean)
Hydroxychloroquine9.532447
Placebo10.39556

[back to top]

Hospitalization

Outcome is summarized by treatment received; all other summaries show treatment assigned (NCT04342169)
Timeframe: within 14 days of enrollment

InterventionParticipants (Count of Participants)
Hydroxychloroquine7
Placebo4

[back to top]

Number of Participants With Viral Shedding on Day 28

"The definition of the persistence of viral shedding on Day 28 outcome relies heavily on the Day 28 swab and is limited to those who have a test result for the Day 28 swab or who are not known to have died on or before DayR + 30 (there is a 2 day window for collecting the Day 28 swab). If the Day 28 swab result is known, the result will be used to define the outcome (yes if positive, no if negative). Otherwise, subjects with a confirmed cessation of viral shedding when considering daily swab results from DayR + 1 to DayR + 25, inclusive (with the requirement for confirmation waived if the latest available daily result in this interval is negative), and a missing Day 28 value will be assumed to be negative on Day 28; otherwise subjects hospitalized on any of the days DayR + 26{DayR + 30 with a missing Day 28 value will be assumed to be positive on Day 28; otherwise, multiple imputation will be performed." (NCT04342169)
Timeframe: Day 28

InterventionParticipants (Count of Participants)
Hydroxychloroquine30
Placebo30

[back to top]

Recruitment Feasibility

To evaluate the feasibility of this protocol including participants' recruitment within the estimated time frame, i.e. understand the ability of the team to identify eligible participants, enroll them, retain them and follow them up until study completion. (NCT04345653)
Timeframe: Study period, up to two months from the day the first participant was screened

InterventionParticipants (Count of Participants)
Study Arm46

[back to top]

Early Feasibility as Reflected on the Number of Participants Contracting COVID-19 (10% or Less) in Comparison to the Expected 30% as Per CDC.

To evaluate the early efficacy of HCQ in high-risk, healthy volunteers in the prevention of acquiring COVID-19 while continuing to follow standard precautions that meet or exceed Centers of Disease Control (CDC) guidelines. (NCT04345653)
Timeframe: 28 day post enrollment

Interventionparticipants (Number)
Study Arm - Hydroxychloroquine Sulfate (HCQ)0

[back to top]

Resource Utilization

To evaluate the utilization of tests and drug for this study in consideration with the limited availability of both for research purposes as reflected on the number of participants that got tested and received at least one dose of the drug. (NCT04345653)
Timeframe: Study period, up to two months from the day the first participant was screened

InterventionParticipants (Count of Participants)
Study Arm - Hydroxychloroquine Sulfate (HCQ)46

[back to top]

Safety as Reflected on the Number and Severity of Adverse Events and Serious Adverse Events

To Determine the Safety profile for a previously well studied drug in this select group of HCP. Incidence of well described side effects would be studied over the course of the study and will be compared with the side effects and their prevalence as described in the Pharmacy manual for HCQ. (NCT04345653)
Timeframe: 28 day post enrollment

InterventionAdverse Events (Number)
Serious Adverse eventsAdverse events
Study Arm - Hydroxychloroquine Sulfate (HCQ)024

[back to top]

Number of Participants Who Are Virus Free

Nasopharyngeal swab PCR measurement of viral load expressed as the % of negative PCR swabs (NCT04353271)
Timeframe: 7 days after initiation of trial

Interventionparticipants (Number)
Treatment0
Control0

[back to top]

Number of Participants Who Die Secondary to Covid 19 Infection

Number of subjects in each arm who die secondary to Covid-19 infection (NCT04353271)
Timeframe: 70 Days (10 weeks)

InterventionParticipants (Count of Participants)
Treatment0
Control0

[back to top]

Number of Participants Who Discontinue or Withdraw Medication Use for Any Reason

Number of subjects in each arm who discontinue or withdraw medication use for any reason (NCT04353271)
Timeframe: 14 days

InterventionParticipants (Count of Participants)
Treatment0
Control1

[back to top]

Number of Participants Who Have Confirmed Covid 19 Infection

Number of subjects in each arm who have confirmed Covid-19 infection (NCT04353271)
Timeframe: 14 days

InterventionParticipants (Count of Participants)
Treatment1
Control2

[back to top]

Number of Participants Who Are Hospitalized for Covid 19 Infection

Number of subjects in each arm who are hospitalized for Covid 19 infection (NCT04353271)
Timeframe: 14 days

InterventionParticipants (Count of Participants)
Treatment0
Control0

[back to top]

Number of Participants With Serious Adverse Events and Adverse Events Resulting in Treatment Discontinuation

Serious adverse events (including death and hospitalization) and adverse events resulting in treatment discontinuation (NCT04354428)
Timeframe: 28 days from enrolment

InterventionParticipants (Count of Participants)
Ascorbic Acid and Folic Acid6
Hydroxychloroquine and Folic Acid6
Hydroxychloroquine and Azithromycin8
Lopinavir-ritonavir9
Ascorbic Acid1

[back to top]

Number of Persons With Lower Respiratory Tract Infection (LRTI), Defined as Resting Blood Oxygen Saturation (SpO2<93%) Level Sustained for 2 Readings 2 Hours Apart and Presence of Subjective Dyspnea or Cough

Resting blood oxygen saturation (SpO2<93%) level sustained for 2 readings 2 hours apart and presence of subjective dyspnea or cough (NCT04354428)
Timeframe: 28 days from enrolment

InterventionParticipants (Count of Participants)
Ascorbic Acid and Folic Acid2
Hydroxychloroquine and Folic Acid0
Hydroxychloroquine and Azithromycin4
Lopinavir-ritonavir2
Ascorbic Acid1

[back to top]

Time to Clearance of Nasal SARS-CoV-2

Time to clearance of nasal SARS-CoV-2, defined as 2 consecutive negative swabs (NCT04354428)
Timeframe: Day 1 through Day 14 after enrolment

InterventionDays (Median)
Ascorbic Acid and Folic Acid7
Hydroxychloroquine and Folic Acid5
Hydroxychloroquine and Azithromycin6
Lopinavir-ritonavir4
Ascorbic Acid5

[back to top]

Time to Resolution of COVID-19 Symptom Resolution in Days

"COVID-19 symptoms are based on the following criteria:~At least TWO of the following symptoms: Fever (≥ 38ºC), chills, rigors, myalgia, headache, sore throat, new olfactory and taste disorder(s), OR~At least ONE of the following symptoms: cough, shortness of breath or difficulty breathing, OR~Severe respiratory illness with at least 1 of the following:~Clinical or radiological evidence of pneumonia, OR~Acute respiratory distress syndrome (ARDS), OR~LRTI, defined by resting SpO2<93% sustained for 2 readings 2 hours apart AND presence of subjective dyspnea or cough Death or COVID-19-related hospitalizations will count as a failure to resolve symptoms." (NCT04354428)
Timeframe: Day 1 through Day 14 after enrolment

InterventionDays (Median)
Ascorbic Acid and Folic Acid11.5
Hydroxychloroquine and Folic Acid10.5
Hydroxychloroquine and AzithromycinNA
Lopinavir-ritonavirNA
Ascorbic AcidNA

[back to top] [back to top]

Number of Participants With Hospitalization or Mortality

Number of participants with hospitalization or mortality (NCT04354428)
Timeframe: Day 28 after enrolment

InterventionParticipants (Count of Participants)
Ascorbic Acid and Folic Acid4
Hydroxychloroquine and Folic Acid2
Hydroxychloroquine and Azithromycin3
Lopinavir-ritonavir0
Ascorbic Acid1

[back to top]

Change From Baseline in the Number of Participants With Seroconversion to SARS-CoV-2 at 1 Month

Antibody titers will be measured to determine seroconversion, a binomial endpoint defined by a four-fold increase in antibody titers compared to baseline. (NCT04354870)
Timeframe: Baseline to 1 month post-baseline

InterventionParticipants (Count of Participants)
HCQ Group4
Control Group2

[back to top] [back to top]

Number of Participants With Symptomatic vs. Asymptomatic Seroconversion

To characterize whether high-risk HCW who seroconvert to SARS-CoV-2 have asymptomatic infection or report symptoms of COVID-19 in the 4 weeks preceding seroconversion (assessed by symptom questionnaire). (NCT04354870)
Timeframe: 4 Weeks Prior to Baseline

,
InterventionParticipants (Count of Participants)
Symptomatic SeroconversionAsymptomatic Seroconversion
Control Group20
HCQ Group13

[back to top]

Duration of Fever

Defined as the time from study treatment initiation to the last day in the participant's daily diary card on which a temperature greater than 100.4°F was recorded or a potentially antipyretic drug, such as acetaminophen or ibuprofen, was taken. Participants with at least one temperature who never reported fever or use of anti-pyretic medications were assigned a duration of zero days (NCT04358068)
Timeframe: Day 0 to Day 20, 21 days total

Interventiondays (Median)
Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro)0
Arm B: Placebo for Hydroxychloroquine and Azithromycin0

[back to top]

Number of Participants With an Occurrence of Fainting

Fainting was self-reported on the study diary card as absent (score 0), mild (1), moderate (2), or severe (3); scores of > 0 are defined as an occurrence of fainting (NCT04358068)
Timeframe: From start of study treatment through Day 20

InterventionParticipants (Count of Participants)
Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro)1
Arm B: Placebo for Hydroxychloroquine and Azithromycin1

[back to top]

Time to Self-reported Return to Usual (Pre-COVID) Health.

"Time to self-reported return to (pre-COVID) usual health was defined as the time from the start of study treatment to the first day in the participant's daily diary card on which they responded 'Yes' with no subsequent reports of 'No' to the question Have you returned to your usual (pre-COVID) health today? Participants who never reported a 'Yes' response were assigned a duration of 22 days." (NCT04358068)
Timeframe: Day 0 to Day 20, 21 days total

Interventiondays (Median)
Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro)17.0
Arm B: Placebo for Hydroxychloroquine and Azithromycin10.0

[back to top]

Participant-specific Area Under the Curve (AUC) of the Symptom Score Associated With COVID-19 Disease Over Time

Defined as the sum of scores for the targeted symptoms (defined in the protocol) in the participant's daily diary record (each symptom was scored from 0-best to 3-worst). Participant-specific areas under the curve (AUC) over time were calculated using the trapezoidal rule and defined as the area below the line formed by joining total symptom scores on each daily diary card from the pre-treatment score on Day 0 through to Day 20. AUCs were rescaled by time by dividing by 21 (corresponding to the number of daily diary cards during follow-up between pre-treatment Day 0 and Day 20), in order to provide results on a symptom scale from 0-best to 42-worst (for non-hospitalized participants). Participants who were hospitalized were assigned a value equal to the sum of the maximum possible scaled AUC (42) and the duration of hospitalization, and thus values >42 were possible. Missing scores between pre-treatment and Day 20 were linearly interpolated. Higher AUCs indicate worse outcomes. (NCT04358068)
Timeframe: Day 0 to Day 20, 21 days total

Interventionscore on a scale (Median)
Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro)4.0
Arm B: Placebo for Hydroxychloroquine and Azithromycin2.8

[back to top]

Number of Participants Who Prematurely Discontinue Study Treatment Due to an Adverse Event

Premature discontinuation of study treatment is defined as a permanent discontinuation of either study treatment (HCQ/Placebo and/or Azithro/Placebo) (NCT04358068)
Timeframe: From start of study treatment through Day 7

InterventionParticipants (Count of Participants)
Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro)0
Arm B: Placebo for Hydroxychloroquine and Azithromycin1

[back to top]

Number of Participants Who Had Any Cardiac Adverse Events

Cardiac adverse events included in the analysis were chosen a priori by the study chairs (NCT04358068)
Timeframe: From start of study treatment through Day 20

InterventionParticipants (Count of Participants)
Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro)0
Arm B: Placebo for Hydroxychloroquine and Azithromycin0

[back to top]

Number of Participants Who Died From Any Cause, or Were Hospitalized, or Had an Urgent Visit to Emergency Room or Clinic

Hospitalization was defined as requiring at least 24 hours of acute care in a hospital or similar acute care facility, including Emergency Rooms or temporary facilities instituted to address needs during the COVID-19 pandemic. Evaluation at a hospital or similar facility with less than 24 hours of acute care was not considered a hospitalization, but was included for this outcome measure. (NCT04358068)
Timeframe: The 20-day period from and including the day of the first dose of study treatment

InterventionParticipants (Count of Participants)
Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro)1
Arm B: Placebo for Hydroxychloroquine and Azithromycin1

[back to top]

Number of Participants Who Died From Any Cause or Were Hospitalized

Hospitalization was defined as requiring at least 24 hours of acute care in a hospital or similar acute care facility, including Emergency Rooms or temporary facilities instituted to address needs during the COVID-19 pandemic. Evaluation at a hospital or similar facility with less than 24 hours of acute care was not considered a hospitalization. Formal statistical testing was not conducted due to the small number of participants and events. (NCT04358068)
Timeframe: The 20-day period from and including the day of the first dose of study treatment

InterventionParticipants (Count of Participants)
Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro)0
Arm B: Placebo for Hydroxychloroquine and Azithromycin1

[back to top]

Number of Participants Who Died From Any Cause

Deaths reported due to any cause (COVID-related or not) (NCT04358068)
Timeframe: The 20-day period from and including the day of the first dose of study treatment

InterventionParticipants (Count of Participants)
Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro)0
Arm B: Placebo for Hydroxychloroquine and Azithromycin0

[back to top]

Duration of Symptoms Associated With COVID-19 Disease

Defined as the time from start of study treatment to the last day in the participant's daily diary card on which a moderate or worse targeted symptom was recorded. The set of target symptoms were cough, shortness of breath, feeling feverish, fatigue, muscle aches, diarrhea, vomiting, nausea, headache, sore throat, nasal obstruction (stuffy nose), nasal discharge (runny nose), loss of smell, and loss of taste. Participants who had missing diary records due to hospitalization were assumed to have moderate symptoms during the period of hospitalization in the analysis. Missing diary card records not due to hospitalization were assumed to have absent symptoms. (NCT04358068)
Timeframe: Day 0 to Day 20, 21 days total

Interventiondays (Median)
Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro)11.0
Arm B: Placebo for Hydroxychloroquine and Azithromycin10.0

[back to top]

Percent of Participants Who Required Extracorporeal Membrane Oxygenation (ECMO)

Individual component of severe disease progression composite endpoint evaluated. The measure value is reported as a percentage (# of patients with outcome/ # of patients * 100). (NCT04369742)
Timeframe: 30 Days

Interventionpercentage of participants (Number)
Hydroxychloroquine0
Placebo0

[back to top]

Percent of Participants Showing a Severe Disease Progression Composite Outcome

Including any of the following: mortality, ICU admission, invasive mechanical ventilation, ECMO, and/or hypotension requiring vasopressor support by the 14-day post-treatment evaluation (PTE). The measure value is reported as a percentage (# of patients with outcome/ # of patients * 100). (NCT04369742)
Timeframe: 14 days

Interventionpercentage of participants (Number)
Hydroxychloroquine18.30
Placebo10.50

[back to top]

Hospital Length of Stay

LOS is defined as the interval (in days) that the patient was admitted to a non-rehabilitation floor, categorized as short (<7 days), moderate (7-10 days), or extended (>10 days) (NCT04369742)
Timeframe: 30 days

Interventiondays (Mean)
Hydroxychloroquine9.75
Placebo6.8

[back to top]

Days of Non-rebreather Mask Oxygen Supplementation

Defined as the number of days the subject was on a non-rebreather mask. (NCT04369742)
Timeframe: 14 days

Interventiondays (Median)
Hydroxychloroquine0
Placebo0

[back to top]

Days of Non-invasive Ventilator Use

Defined as days the patient is placed on non-invasive ventilator support (CPAP or BiPAP), excluding routine CPAP use for sleep apnea. (NCT04369742)
Timeframe: 14 days

Interventiondays (Median)
Hydroxychloroquine0
Placebo0

[back to top]

Change in White Blood Cell (WBC) Count

Hematology lab-work will be completed to obtain WBC count (if not obtained as part of routine clinical care, the research team will order for clinical lab to add onto remnant specimens, if available). (NCT04369742)
Timeframe: Baseline, 6 days

Interventioncells per 10^6 L (Mean)
Hydroxychloroquine-0.0868
Placebo-0.0839

[back to top]

Change in Total Bilirubin Levels

Biochemistry lab-work will be completed to obtain bilirubin levels (if not obtained as part of routine clinical care, the research team will order for clinical lab to add onto remnant specimens, if available). (NCT04369742)
Timeframe: Baseline, 6 days

Interventionmg/dL (Mean)
Hydroxychloroquine-0.183
Placebo-0.0509

[back to top]

Change in Hemoglobin Levels

Hematology lab-work will be completed to obtain hemoglobin levels (if not obtained as part of routine clinical care, the research team will order for clinical lab to add onto remnant specimens, if available). (NCT04369742)
Timeframe: Baseline, 6 days

Interventiongm/dL (Mean)
Hydroxychloroquine-0.5
Placebo-0.443

[back to top]

Change in Platelet Count

Hematology lab-work will be completed to obtain platelet count (if not obtained as part of routine clinical care, the research team will order for clinical lab to add onto remnant specimens, if available). (NCT04369742)
Timeframe: Baseline, 6 days

Interventionplatelets per 10^6 L (Mean)
Hydroxychloroquine63.4
Placebo65.8

[back to top]

Change in Lactate Dehydrogenase (LDH) Levels

Biochemistry lab-work will be completed to obtain LDH levels (if not obtained as part of routine clinical care, the research team will order for clinical lab to add onto remnant specimens, if available). (NCT04369742)
Timeframe: Baseline, 6 days

InterventionU/L (Mean)
Hydroxychloroquine-2.65
Placebo-45.1

[back to top]

Change in Interleukin 6 (IL-6) Levels

Biochemistry lab-work will be completed to obtain IL-6 levels (if not obtained as part of routine clinical care, the research team will order for clinical lab to add onto remnant specimens, if available). (NCT04369742)
Timeframe: Baseline, 6 days

Interventionpg/ml (Mean)
Hydroxychloroquine85.6
Placebo19.3

[back to top]

Change in Glucose Levels

Biochemistry lab-work will be completed to obtain Glucose levels (if not obtained as part of routine clinical care, the research team will order for clinical lab to add onto remnant specimens, if available). (NCT04369742)
Timeframe: Baseline, 6 days

Interventionmg/dL (Mean)
Hydroxychloroquine2.69
Placebo-15.7

[back to top]

Change in Creatinine Levels

Biochemistry lab-work will be completed to obtain Creatinine levels (if not obtained as part of routine clinical care, the research team will order for clinical lab to add onto remnant specimens, if available). (NCT04369742)
Timeframe: Baseline, 6 days

Interventionmg/dL (Mean)
Hydroxychloroquine0.0198
Placebo-0.169

[back to top]

Change in C-Reactive Protein (CRP) Levels

Biochemistry lab-work will be completed to obtain CRP levels (if not obtained as part of routine clinical care, the research team will order for clinical lab to add onto remnant specimens, if available). (NCT04369742)
Timeframe: Baseline, 6 days

Interventionmg/L (Mean)
Hydroxychloroquine-21.8
Placebo-23.8

[back to top]

Change in Aspartate Aminotransferase (AST) Levels

Biochemistry lab-work will be completed to obtain AST levels (if not obtained as part of routine clinical care, the research team will order for clinical lab to add onto remnant specimens, if available). (NCT04369742)
Timeframe: Baseline, 6 days

InterventionU/L (Mean)
Hydroxychloroquine-1.52
Placebo3.66

[back to top]

Change in Alanine Aminotransferase (ALT) Levels

Biochemistry lab-work will be completed to obtain ALT levels (if not obtained as part of routine clinical care, the research team will order for clinical lab to add onto remnant specimens, if available). (NCT04369742)
Timeframe: Baseline, 6 days

InterventionU/L (Mean)
Hydroxychloroquine19.3
Placebo8.3

[back to top]

Days of Fever

Defined as number of days with temperature >100.4 degrees Fahrenheit. (NCT04369742)
Timeframe: 14 days

Interventiondays (Median)
Hydroxychloroquine0
Placebo0

[back to top]

Percent of Subjects With Q-T Interval, Corrected (qTC) Prolongation at End of Treatment (EOT)

(≥470 milliseconds in men; ≥480 milliseconds in women) on electrocardiogram at EOT (Day 6) (NCT04369742)
Timeframe: 6 Days

Interventionpercentage of participants (Number)
Hydroxychloroquine24.4
Placebo12.8

[back to top]

Percent of Patients Who Resulted in Mortality

Individual component of severe disease progression composite endpoint evaluated. The measure value is reported as a percentage (# of patients with outcome/ # of patients * 100). (NCT04369742)
Timeframe: 30 days

Interventionpercentage of participants (Number)
Hydroxychloroquine13.2
Placebo12

[back to top]

Percent of Participants With SARS-CoV-2 Viral Eradication From Nasopharyngeal Specimens at EOT

Laboratory endpoint, measured by RT-PCR, reported as the percentage of negative results at day 6 (NCT04369742)
Timeframe: 6 days

Interventionpercentage of participants (Number)
Hydroxychloroquine21.60
Placebo33.30

[back to top]

Percent of Participants With SAE Through Day 30

The measure value is reported as a percentage (# of patients with outcome/ # of patients * 100) (NCT04369742)
Timeframe: 30 days

Interventionpercentage of participants (Number)
Hydroxychloroquine14.90
Placebo16.40

[back to top]

Percent of Participants With Hypotension Requiring Vasopressor Support

Individual component of severe disease progression composite endpoint evaluated. For incidence, the measure value is reported as a percentage (# of patients with outcome/ # of patients * 100) (NCT04369742)
Timeframe: 30 Days

Interventionpercentage of participants (Number)
Hydroxychloroquine3.77
Placebo4

[back to top]

Percent of Participants With Grade 3 or 4 AEs Through Day 30

The measure value is reported as a percentage (# of patients with outcome/ # of patients * 100) (NCT04369742)
Timeframe: 30 days

Interventionpercentage of participants (Number)
Hydroxychloroquine13.40
Placebo13.10

[back to top]

Percent of Participants With Discontinuation of Therapy (for Any Reason)

The measure value is reported as a percentage (# of patients with outcome/ # of patients * 100) (NCT04369742)
Timeframe: 30 days

Interventionpercentage of participants (Number)
Hydroxychloroquine23.90
Placebo24.6

[back to top]

Percent of Participants Who Required Invasive Mechanical Ventilation

Individual component of severe disease progression composite endpoint evaluated. The measure value is reported as a percentage (# of patients with outcome/ # of patients * 100). (NCT04369742)
Timeframe: 30 Days

Interventionpercentage of participants (Number)
Hydroxychloroquine9
Placebo6

[back to top]

Percent of Participants Who Required ICU Admission

Individual component of severe disease progression composite endpoint evaluated. The measure value is reported as a percentage (# of patients with outcome/ # of patients * 100). (NCT04369742)
Timeframe: 30 Days

Interventionpercentage of participants (Number)
Hydroxychloroquine17
Placebo6

[back to top]

Number of Participants That Had Viral Shedding as Determined by RT-PCR.

To measure the duration of viral shedding in respiratory secretions of patients with moderate to severe COVID-19 infection treated with the combination of Hydroxychloroquine and azithromycin. (NCT04458948)
Timeframe: 14 to 28 days.

InterventionParticipants (Count of Participants)
Hydroxychloroquine and Azithromycin6

[back to top]

Median Progression Free Survival (PFS)

Participants with refractory bile tract carcinoma (BTC) with KRAS mutation that exceed 25% who receive trametinib plus hydroxychloroquine (HCQ) combination who are able to not have progressive disease at 5 months will be reported along with a 95% confidence interval. Progression was evaluated by the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 and is at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). The appearance of one or more new lesions is also considered progression). (NCT04566133)
Timeframe: 3 months

InterventionMonths (Median)
Cohort 1/Arm 1: Trametinib + Hydroxychloroquine (HCQ)2.48

[back to top]

Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0)

Here is the number of participants with serious and/or non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. (NCT04566133)
Timeframe: Date treatment consent signed to date off study, assessed for approximately 3 months and 25 days

InterventionParticipants (Count of Participants)
Cohort 1/Arm 1: Trametinib + Hydroxychloroquine (HCQ)2

[back to top]

Proportion of Participants With a Response (Complete Response (CR) + Partial Response (PR) Reported With an 95% Confidence Interval

Response is defined as a Complete Response (CR) + Partial Response (PR) in participants with refractory BTC with KRAS mutation treated with the combination of trametinib plus HCQ. Response was evaluated using the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Complete Response (CR) is disappearance of all target lesions, determined by two separate observations conducted not less than 4 weeks apart. Any pathological lymph nodes must have reduction in short axis to <10 mm. Partial Response (PR) is at least a 30% decrease in the sum of target lesions, taking as reference the baseline sum diameters. (NCT04566133)
Timeframe: Every 2 months up to approximately 10 months

Interventionproportion of participants (Number)
Complete ResponsePartial Response
Cohort 1/Arm 1: Trametinib + Hydroxychloroquine (HCQ)00

[back to top]

Proportion of Participants With a Response (Complete Response (CR) + Partial Response (PR) Reported With an 80% Confidence Interval

Response is defined as a Complete Response (CR) + Partial Response (PR) in participants with refractory BTC with KRAS mutation treated with the combination of trametinib plus HCQ. Response was evaluated using the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Complete Response (CR) is disappearance of all target lesions, determined by two separate observations conducted not less than 4 weeks apart. Any pathological lymph nodes must have reduction in short axis to <10 mm. Partial Response (PR) is at least a 30% decrease in the sum of target lesions, taking as reference the baseline sum diameters. (NCT04566133)
Timeframe: Every 2 months up to approximately 10 months

InterventionProportion of participants (Number)
Complete ResponsePartial Response
Cohort 1/Arm 1: Trametinib + Hydroxychloroquine (HCQ)00

[back to top] [back to top]

Overall Survival

Overall survival is defined as the duration of time from start of treatment to death from any cause. (NCT04566133)
Timeframe: duration of time from the start of treatment to death from any cause, approximately 10 months

InterventionMonths (Median)
Cohort 1/Arm 1: Trametinib + Hydroxychloroquine (HCQ)3.1

[back to top]

Rate of COVID-19 Polymerase Chain Reaction (PCR) Test Negativity

At the end of the follow-up period (10th day), patients in the study and control group were investigated by PCR test for SARS-CoV-2 and the negative results were recorded as percentage for both groups. (NCT04646109)
Timeframe: At the end of 10th day

InterventionParticipants (Count of Participants)
Control Group3
Study Group14

[back to top]

Respiratory Rate Means of the Patients

At the beginning of the study, the respiratory rates (as per minute) of the patients were measured and the mean respiratory rate values of both groups were recorded. (NCT04646109)
Timeframe: At the first day of the study

Interventionbreaths per minute (Mean)
Control Group24.7
Study Group24

[back to top] [back to top]

Changes in Oxygen Saturation (SpO2) Values

In both groups, after the treatment period was completed (first 5 days, primary endpoint), patients were followed up for 5 more days (follow-up period). SpO2 values at the end of 6th (FD1), 8th (FD3) and 10th day (FD5) were also recorded. The end of the 10th day was accepted as the secondary endpoint. While the change in SpO2 values on the 6th, 8th and 10th days was calculated graphically, the change in the SpO2 value at the end of the 10th day (secondary endpoint) with the baseline value was compared statistically (the results were given as p value). (NCT04646109)
Timeframe: From 6th to the end of 10th day

,
Interventionpercentage of peripheral capillary O2 (Mean)
BaselineFD1FD3FD5
Control Group89.6792.4392.9193.00
Study Group89.9394.5494.2495.35

[back to top]

Changes in Serum D-dimer Levels

Baseline serum D-dimer levels (mg/L) of the patients were recorded in both groups. Then, their treatments were started and serum D-dimer levels at the end of the 1st (TD1), 3rd (TD3) and 5th days (TD5) were also recorded. The end of the 5th day was accepted as the primary endpoint. While the change in serum D-dimer levels on the 1st, 3rd and 5th days after the basal level was calculated graphically, the change in the serum D-dimer level at the end of the 5th day (primary endpoint) with the baseline level was compared statistically (the results were given as p value). (NCT04646109)
Timeframe: From starting to the end of ivermectin therapy (0 to the end of 5th day)

,
Interventionmg/L (Mean)
BaselineTD1TD3TD5
Control Group1.322.804.143.58
Study Group1.251.403.245.85

[back to top]

Changes in Serum D-dimer Levels

In both groups, after the treatment period was completed (first 5 days, primary endpoint), patients were followed up for 5 more days (follow-up period). Serum D-dimer levels (mg/L) at the end of 6th (FD1), 8th (FD3) and 10th day (FD5) were also recorded. The end of the 10th day was accepted as the secondary endpoint. While the change in Serum D-dimer levels on the 6th, 8th and 10th days was calculated graphically, the change in the serum D-dimer level at the end of the 10th day (secondary endpoint) with the baseline value was compared statistically (the results were given as p value). (NCT04646109)
Timeframe: From 6th to the end of 10th day

,
Interventionmg/L (Mean)
BaselineFD1FD3FD5
Control Group1.323.451.631.49
Study Group1.251.370.890.71

[back to top]

Changes in Serum Ferritin Levels

In both groups, after the treatment period was completed (first 5 days, primary endpoint), patients were followed up for 5 more days (follow-up period). Serum ferritin levels (mg/dL) at the end of 6th (FD1), 8th (FD3) and 10th day (FD5) were also recorded. The end of the 10th day was accepted as the secondary endpoint. While the change in serum ferritin levels on the 6th, 8th and 10th days was calculated graphically, the change in the serum ferritin level at the end of the 10th day (secondary endpoint) with the baseline value was compared statistically (the results were given as p value). (NCT04646109)
Timeframe: From 6th to the end of 10th day

,
Interventionmg/dL (Mean)
BaselineFD1FD3FD5
Control Group747.051076.881097.571206.90
Study Group682.75628.45433.48494.71

[back to top]

Changes in Serum Ferritin Levels

Baseline serum ferritin levels (mg/dL) of the patients were recorded in both groups. Then, their treatments were started and serum ferritin levels at the end of the 1st (TD1), 3rd (TD3) and 5th days (TD5) were also recorded. The end of the 5th day was accepted as the primary endpoint. While the change in serum ferritin levels on the 1st, 3rd and 5th days after the basal level was calculated graphically, the change in the serum ferritin level at the end of the 5th day (primary endpoint) with the baseline level was compared statistically (the results were given as p value). (NCT04646109)
Timeframe: From starting to the end of ivermectin therapy (0 to the end of 5th day)

,
Interventionmg/dL (Mean)
BaselineTD1TD3TD5
Control Group747.05783.03881.171028.24
Study Group682.75834.94875.90875.12

[back to top]

Changes in Serum Lymphocyte Counts

Baseline Serum Lymphocyte counts (cell/mm^3) of the patients were recorded in both groups. Then, their treatments were started and Serum Lymphocyte counts at the end of the 1st (TD1), 3rd (TD3) and 5th days (TD5) were also recorded. The end of the 5th day was accepted as the primary endpoint. While the change in Serum Lymphocyte counts on the 1st, 3rd and 5th days after the basal level was calculated graphically, the change in the Serum Lymphocyte count at the end of the 5th day (primary endpoint) with the baseline count was compared statistically (the results were given as p value). (NCT04646109)
Timeframe: From starting to the end of ivermectin therapy (0 to the end of 5th day)

,
Interventioncell/mm^3 (Mean)
BaselineTD1TD3TD5
Control Group10101034977968
Study Group93292810211273

[back to top]

Changes in the Ratio of Partial Pressure of Oxygen (PaO2) to Fraction of Inspired Oxygen (FiO2) (PaO2/FiO2)

Baseline PaO2/FiO2 ratios of the patients were recorded in both groups. Then, their treatments were started and PaO2/FiO2 ratios at the end of the 1st (TD1), 3rd (TD3) and 5th days (TD5) were also recorded. The end of the 5th day was accepted as the primary endpoint. While the change in PaO2/FiO2 ratios on the 1st, 3rd and 5th days after the basal ratio was calculated graphically, the change in the PaO2/FiO2 ratio at the end of the 5th day (primary endpoint) with the baseline value was compared statistically (the results were given as p value). (NCT04646109)
Timeframe: From starting to the end of ivermectin therapy (0 to the end of 5th day)

,
InterventionRatio (Mean)
BaselineTD1TD3TD5
Control Group197.44181.83174.77180.13
Study Group158.83147.31147.74178.94

[back to top]

Changes in the Ratio of Partial Pressure of Oxygen (PaO2) to Fraction of Inspired Oxygen (FiO2) (PaO2/FiO2)

In both groups, after the treatment period was completed (first 5 days, primary endpoint), patients were followed up for 5 more days (follow-up period). PaO2/FiO2 ratios at the end of 6th (FD1), 8th (FD3) and 10th day (FD5) were also recorded. The end of the 10th day was accepted as the secondary endpoint. While the change in PaO2/FiO2 ratios on the 6th, 8th and 10th days was calculated graphically, the change in the PaO2/FiO2 ratio at the end of the 10th day (secondary endpoint) with the baseline ratio was compared statistically (the results were given as p value). (NCT04646109)
Timeframe: From 6th to the end of 10th day

,
InterventionRatio (Mean)
BaselineFD1FD3FD5
Control Group197.44204.28211.75220.78
Study Group158.83199.83227.43236.33

[back to top]

Changes in the Ratio of Polymorphonuclear Leukocyte Count to Lymphocyte Count (PNL/L)

Baseline PNL/L ratio of the patients were recorded in both groups. Then, their treatments were started and PNL/L ratios at the end of the 1st (TD1), 3rd (TD3) and 5th days (TD5) were also recorded. The end of the 5th day was accepted as the primary endpoint. While the change in PNL/L ratios on the 1st, 3rd and 5th days after the basal level was calculated graphically, the change in the PNL/L ratio at the end of the 5th day (primary endpoint) with the baseline ratio was compared statistically (the results were given as p value). (NCT04646109)
Timeframe: From starting to the end of ivermectin therapy (0 to the end of 5th day)

,
InterventionRatio (Mean)
BaselineTD1TD3TD5
Control Group7.487.749.269.88
Study Group8.7710.829.027.16

[back to top]

Changes in Serum Lymphocyte Counts

In both groups, after the treatment period was completed (first 5 days, primary endpoint), patients were followed up for 5 more days (follow-up period). Serum lymphocyte counts (cell/mm^3) at the end of 6th (FD1), 8th (FD3) and 10th day (FD5) were also recorded. The end of the 10th day was accepted as the secondary endpoint. While the change in serum lymphocyte counts on the 6th, 8th and 10th days was calculated graphically, the change in the serum lymphocyte count at the end of the 10th day (secondary endpoint) with the baseline value was compared statistically (the results were given as p value). (NCT04646109)
Timeframe: From 6th to the end of 10th day

,
Interventioncell/mm^3 (Mean)
BaselineFD1FD3FD5
Control Group101091610861256
Study Group932140316681698

[back to top]

Changes in the Ratio of Polymorphonuclear Leukocyte Count to Lymphocyte Count (PNL/L)

In both groups, after the treatment period was completed (first 5 days, primary endpoint), patients were followed up for 5 more days (follow-up period). PNL/L ratios at the end of 6th (FD1), 8th (FD3) and 10th day (FD5) were also recorded. The end of the 10th day was accepted as the secondary endpoint. While the change in PNL/L ratios on the 6th, 8th and 10th days was calculated graphically, the change in the PNL/L ratio at the end of the 10th day (secondary endpoint) with the baseline value was compared statistically (the results were given as p value). (NCT04646109)
Timeframe: From 6th to the end of 10th day

,
InterventionRatio (Mean)
BaselineFD1FD3FD5
Control Group7.4810.499.666.19
Study Group8.776.905.817.34

[back to top]

Gender Distribution of the Patients

The gender of patients (Male/female) in both groups were recorded at the time of inclusion. (NCT04646109)
Timeframe: At the first day of the study

,
InterventionParticipants (Count of Participants)
MaleFemale
Control Group1911
Study Group219

[back to top]

Genetic Examination of Haplotypes and Mutations That Cause Function Losing for Ivermectin Metabolism

A blood sample was taken from the patients included in the study group, after taking or during the first dose of ivermectin. From the blood samples, haplotypes and mutations that cause the function losing were investigated by performing sequence analysis of multidrug resistance 1 (MDR1)/ABCB1 and CYP3A4 genes with Sanger method. In case of detection of mutation, the patient were excluded from the study and if observed, side effects of ivermectin were noted. (NCT04646109)
Timeframe: At the first day of ivermectin therapy (1st day)

,
InterventionParticipants (Count of Participants)
Mutation positiveMutation negative
Control Group00
Study Group630

[back to top]

Percentage of Patients With Accompanying Diseases

"At the beginning of the study, the patients were asked whether there were any of the following accompanying diseases and the percentage of patients with accompanying disease in both groups were recorded:~Diabetes mellitus~Hypertension~Coronary artery disease~Cardiac failure~Chronic obstructive pulmonary disease~Malignancy~Immunodeficiency" (NCT04646109)
Timeframe: At the first day of the study

,
InterventionParticipants (Count of Participants)
Diabetes MellitusHypertensionCoronary artery diseaseCardiac failureChronic obstructive pulmonary diseaseMalignancyImmunodeficiency
Control Group101281311
Study Group91550600

[back to top]

Percentage of Patients With Baseline Clinical Symptoms

"At the beginning of the study, the patients were asked whether there were any of the following clinical symptoms and the percentage of patients with any of the clinical symptoms in both groups were recorded:~Fever~Cough~Sore throat~Dispnea~Headache~Weakness~Myalgia~Diarrhea~Nausea or vomiting" (NCT04646109)
Timeframe: At the first day of the study

,
InterventionParticipants (Count of Participants)
FeverCoughSore throatdyspneaHeadacheWeaknessMyalgiaDiarrheaNausea or vomiting
Control Group1314119211700
Study Group1516323513911

[back to top]

Systolic and Diastolic Pressure Means of the Patients

At the beginning of the study, the systolic and diastolic pressures (as mmHg) of the patients were measured and the mean systolic and diastolic pressure values of both groups were recorded. (NCT04646109)
Timeframe: At the first day of the study

,
InterventionmmHg (Mean)
Systolic pressureDiastolic pressure
Control Group124.6173.43
Study Group124.3975.64

[back to top]

Number of Participants With Clinical Response

"The presence of at least two of the following criteria in patients on the 10th day were accepted as clinical response: Respiration rate between 22-24/min, SpO2 level in room air >95%, absence of oxygen requirement, observation of radiological improvement in control lung tomography and no need for intensive care." (NCT04646109)
Timeframe: 10 days (5 days ivermectin therapy plus 5 days follow-up)

InterventionParticipants (Count of Participants)
Control Group16
Study Group22

[back to top]

Changes in Oxygen Saturation (SpO2) Values

Baseline SpO2 values of the patients were recorded in both groups. Then, their treatments were started and SpO2 values at the end of the 1st (TD1), 3rd (TD3) and 5th days (TD5) were also recorded. The end of the 5th day was accepted as the primary endpoint. While the change in SpO2 values on the 1st, 3rd and 5th days after the basal value calculated graphically, the change in the SpO2 value at the end of the 5th day (primary endpoint) with the baseline value was compared statistically (the results were given as p value). (NCT04646109)
Timeframe: From starting to the end of ivermectin therapy (0 to the end of 5th day)

,
Interventionpercentage of peripheral capillary O2 (Mean)
BaselineTD1TD3TD5
Control Group89.6790.5091.9093.00
Study Group89.9392.8593.0793.52

[back to top]

Age Distribution of the Patients

The age of the patients (years) in both groups were recorded at the time of inclusion. (NCT04646109)
Timeframe: At the first day of the study

InterventionYears (Mean)
Control Group66.23
Study Group58.17

[back to top]

Body Temperature Means of the Patients

At the beginning of the study, the body temperatures (as degree celcius) of the patients were measured and the mean body temperature values of both groups were recorded. (NCT04646109)
Timeframe: At the first day of the study

InterventionDegree celcius (Mean)
Control Group36.8
Study Group36.9

[back to top]

Heart Rate Means of the Patients

At the beginning of the study, the heart rates (as per minute) of the patients were measured and the mean heart rate values of both groups were recorded. (NCT04646109)
Timeframe: At the first day of the study

Interventionbeats per minute (Mean)
Control Group92
Study Group88

[back to top]

Mortality

The number of died patients were evaluated in study and control groups (NCT04646109)
Timeframe: Through study completion, an average of 3 months

InterventionParticipants (Count of Participants)
Control Group9
Study Group6

[back to top]

Number of Participants With Clinical Response

"The presence of at least two of the following criteria in patients at the end of 5th day were accepted as clinical response: Extubation in mechanically ventilated patients, respiratory rate <26/min, SpO2 level in room air >90%, PaO2/FiO2 >300 in patients receiving oxygen, presence of at least two of the 2-point reduction criteria in Sequential Organ Failure Assessment (SOFA) score." (NCT04646109)
Timeframe: From starting to the end of ivermectin therapy (0 to the end of 5th day)

InterventionParticipants (Count of Participants)
Control Group11
Study Group14

[back to top] [back to top]